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Gestational diabetes mellitus is defined as hyperglycemia with onset or first 
recognition during pregnancy. The incidence of gestational diabetes is still 
increasing and this pathological condition has strong association with adverse 
pregnancy outcomes. Since gestational diabetes can have long-term pathological 
consequences for both mother and the child, it is important that it is promptly 
recognized and adequately managed. Treatment of gestational diabetes is aimed 
to maintain euglycemia and it should involve regular glucose monitoring, dietary 
modifications, life style changes, appropriate physical activity, and when necessary, 
pharmacotherapy. Adequate glycemic control throughout the pregnancy can notably 
reduce the occurrence of specific adverse perinatal and maternal outcomes. In a long-
term prospect, in order to prevent development of diabetes later in life, as well to avoid 
associated complications, an adequate education on lifestyle modifications should start 
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Preface 
Gestational diabetes mellitus is generally defined as hyperglycemia with onset or first 
recognition during pregnancy. The incidence of gestational diabetes is still increasing
and this pathological condition has strong association with adverse pregnancy
outcomes. Given that gestational diabetes may have long-term pathological
consequences for both mother and the child, it is important that it is promptly 
recognized and adequately managed. Preconceptional screening and medical
informing of women with pre-existing diabetes, older age, family history of gestational 
diabetes, metabolic syndrome, obesity, polycystic ovary syndrome or hypertension 
would be significant in order to reduce the risk to the fetus and mother connected to 
gestational diabetes. Treatment of gestational diabetes is aimed to maintain 
euglycemia and it should involve regular glucose monitoring, dietary modifications, 
life style changes, exercise program, and when necessary, pharmacotherapy. In a long-
term view, in order to prevent development of diabetes later in life, as well to avoid
associated complications, an adequate education on lifestyle modifications should start
in pregnancy and continue postpartum.
This book brings together 21 chapters of up-to-date information on gestational 
diabetes. The idea of this book is to direct the reader to comprehensively explore 
etiology and different aspects of prevention, screening, diagnosis, treatment, and 
postpartum follow-up in consideration to gestational diabetes. Furthermore, the
presented facts provide a useful framework for both clinicians and basic investigators
to further explore and update existing knowledge on diabetes related to pregnancy. 
We hope that this book will be used as a reference textbook for researchers, medical
specialists, teachers and students.
We express sincere appreciation to all the authors of the chapters for their enthusiasm 
and expertise.
Miroslav Radenković, MD, PhD
Associate Professor
Department of Pharmacology, Clinical Pharmacology and Toxicology 
School of Medicine, University of Belgrade 
Serbia
Preface 
Gestational diabetes mellitus is generally defined as hyperglycemia with onset or first 
recognition during pregnancy. The incidence of gestational diabetes is still increasing 
and this pathological condition has strong association with adverse pregnancy 
outcomes. Given that gestational diabetes may have long-term pathological 
consequences for both mother and the child, it is important that it is promptly 
recognized and adequately managed. Preconceptional screening and medical 
informing of women with pre-existing diabetes, older age, family history of gestational 
diabetes, metabolic syndrome, obesity, polycystic ovary syndrome or hypertension 
would be significant in order to reduce the risk to the fetus and mother connected to 
gestational diabetes. Treatment of gestational diabetes is aimed to maintain 
euglycemia and it should involve regular glucose monitoring, dietary modifications, 
life style changes, exercise program, and when necessary, pharmacotherapy. In a long-
term view, in order to prevent development of diabetes later in life, as well to avoid 
associated complications, an adequate education on lifestyle modifications should start 
in pregnancy and continue postpartum. 
This book brings together 21 chapters of up-to-date information on gestational 
diabetes. The idea of this book is to direct the reader to comprehensively explore 
etiology and different aspects of prevention, screening, diagnosis, treatment, and 
postpartum follow-up in consideration to gestational diabetes. Furthermore, the 
presented facts provide a useful framework for both clinicians and basic investigators 
to further explore and update existing knowledge on diabetes related to pregnancy. 
We hope that this book will be used as a reference textbook for researchers, medical 
specialists, teachers and students. 
We express sincere appreciation to all the authors of the chapters for their enthusiasm 
and expertise. 
Miroslav Radenković, MD, PhD 
Associate Professor 
Department of Pharmacology, Clinical Pharmacology and Toxicology 
School of Medicine, University of Belgrade 
Serbia 
1 
Novel Screening Approaches for the  
Early Detection of Gestational Diabetes Mellitus 
Harry M. Georgiou1, Sebastián Illanes López2 and Gregory E. Rice3 
1Department of Obstetrics & Gynaecology, University of Melbourne, Victoria 
2Departamento de Obstetricia & Ginecología y laboratorio de Biología de la  
Reproducción, Universidad de los Andes, Santiago 




1.1 Complications of pregnancy 
Within the discipline of clinical obstetrics, our understanding of the aetiology of 
complications of pregnancy is lacking. This lack of understanding limits our ability to 
identify and implement efficacious management and intervention strategies to ameliorate 
any adverse effects on both the mother and her baby. This situation is further confounded 
by the lack of reliable screening test(s) to identify pre-symptomatic women who 
subsequently develop complications of pregnancy. Gestational diabetes mellitus (GDM), 
extremes of birth weight (intrauterine growth restriction (IUGR) and fetal macrosomia 
(FM)), preeclampsia toxaemia (PET) and preterm labour ((PTL), including preterm rupture 
of membranes) are the most important complications of pregnancy that have no effective 
antenatal preventative treatment.  
With an incidence each of about 5-10% of all pregnancies, these complications are common, 
responsible for the majority of obstetric and paediatric morbidity and mortality, and can 
permanently impact on lifelong health. For example, extreme preterm birth, whether 
spontaneous, or iatrogenic to protect the mother or fetus from progressive disease, can 
result in perinatal death or serious permanent disability such as blindness, deafness or 
neurological injury (Chandiramani, et al., 2007). Very low birth weight is not only an 
immediate threat to the fetus, but can programme adult onset hypertension, stroke and 
diabetes (Barker, 2006). Gestational diabetes is associated with a range of perinatal 
morbidities including fetal macrosomia, hyperinsulinaemia and hypoglycaemia, but may 
also programme childhood obesity and adult onset cardiovascular disease and diabetes 
(Moore, 2010, Nolan, 2011); diseases with the greatest impact on health economics. 
Moreover, women who develop gestational diabetes are at greatly increased risk of 
developing type 2 diabetes in later life (Henry and Beischer, 1991, Lee, et al., 2007).  
Early detection of disease risk and onset is the first step in implementing efficacious 
treatment. If such early detection tests were available they would represent a major advance 
and contribution to the discipline and afford the opportunity to evaluate alternate treatment 
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and clinical management strategies to improve health outcomes for both mother and baby. 
Based upon recent technological developments and studies, it is now realistic that clinically 
useful antenatal screening test(s) can be developed. Unlike diseases such as cancer where 
biomarkers need to be exquisitely specific, a useful antenatal screening test would ideally be 
highly sensitive, but not necessarily highly specific. The consequence of a false positive 
would be no worse than an erroneous triage to high-risk care. 
1.2 The future of diagnostics 
In the context of antenatal screening, the objective of proteomic approaches is to identify 
proteins or peptides that are informative of the risk of pre-symptomatic early pregnant 
women who subsequently develop complications of pregnancy. That is, how the 
antecedents of complications of pregnancy alter the expression of the genome and how this 
is manifested as altered protein and peptide expression. Informative proteins and peptides 
identified may be used to develop classification models (e.g. multiple biomarker diagnostic 
or prognostic tests) that assign the likelihood that an individual test sample came from a 
normal or “at-risk” group. Such tests (as with all in vitro diagnostic medical devices) inform 
clinical decision-making and provide an opportunity for timely and appropriate 
intervention. The performance of the test (i.e. its diagnostic efficiency) determines the 
quality of the information provided and ultimately patient management. The application of 
proteomics, thus, extends beyond mapping and comparing the protein complement of 
healthy and at-risk individuals and needs to be considered in the context of its contribution 
to the healthcare system. 
Global health care is rapidly evolving, being driven by two processes - technological 
development and information management systems. Technological developments now 
provide opportunity to acquire complex information about patients. For example, rather 
than relying on a single measurement (e.g. a single biomarker diagnostic blood test) to detect 
disease, multiple disease markers may be simultaneously measured and combined to 
provide earlier and more accurate diagnosis. Information management systems are allowing 
such complex data to be ascribed to the individual over the course of their lifetime. The 
anticipated outcome of these forces is a move from the episodic, reactionary medicine of 
today to personalised medicine where pharmacogenetics and molecular medicine will 
afford the opportunity to identify predisposition to disease, risk assessment, and assign 
individuals to personalised, efficacious treatment/intervention groups. Both genomics and 
proteomics will be useful contributors to the evolving healthcare system by providing a 
better understanding of physiology, by defining disease risk, by enabling earlier diagnosis 
and by monitoring treatment responses (Figure 1). 
It is now widely acknowledged that single biomarkers are unlikely to deliver the significant 
incremental gain in sensitivity and specificity required for the development of effective 
screening and classification tests requisite for the implementation of personalised medicine. 
New approaches based upon the measurement of multiple biomarkers of disease risk afford 
opportunity to increase diagnostic test sensitivity and specificity. Over the past decade, the 
advent and optimisation of new proteomic technologies has paved the way for new 
strategies for the development of such multiple biomarker diagnostic tests. Our research 
team has applied both candidate-based and discovery-based proteomic approaches to 
identify biomarkers that are informative of disease risk. The ultimate objective of these 
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collective efforts is the generation of multivariate, classification models that, at the very 
least, will allow the triage of early pregnant, asymptomatic women into low- and high-risk 
cohorts (Figure 2). 
 
 
Fig. 1. The evolving healthcare system. The role of proteomics in the evolution of the 
healthcare system  may be in the provision of multiple analyte protein and peptide profiles 
that facilitate risk assessment, earlier diagnosis and more effective treatment response 
monitoring. (Modified from “Personalised Healthcare 2010”, IBM Business Consulting Services) 
 
 
Fig. 2. Rationale for antenatal screening. The objective of implementing an antenatal 
screening test is to identify pre-symptomatic women who will subsequently develop 
complications of pregnancy and implement efficacious treatment to reduce morbidity and 
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2. Gestational diabetes mellitus 
2.1 Current screening 
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance of varying 
severity with onset or first recognition during pregnancy (Metzger and Coustan, 1998). 
GDM usually manifests in the latter half of pregnancy and is typically diagnosed by an oral 
glucose tolerance test. If GDM is diagnosed, women will usually be counselled and advised 
to adopt a healthy lifestyle for the duration of their pregnancy and where it is deemed 
appropriate, women may also be required to undergo pharmacologic or insulin therapy. 
During this time, increased surveillance of the pregnancy is undertaken to help ameliorate 
the consequent maternal and fetal morbidity associated with GDM. The clinical importance 
of this surveillance is highlighted by recent published findings that demonstrate that even 
mild hyperglycaemia over a prolonged period is associated with numerous adverse 
perinatal outcomes (Schafer-Graf, 2009) and that intensive intervention therapy can 
significantly reduce maternal and fetal morbidity (Crowther, et al., 2005, Landon, et al., 
2009). The effects of hyperglycaemia on pregnancy outcome are underpinned by 
experimental studies that identify putative effector pathways by which exposure to glucose 
concentrations may alter placental and maternal adipose tissue phenotype and 
responsiveness (Coughlan, et al., 2001, Coughlan, et al., 2004, Coughlan, et al., 2004, Lappas, 
et al., 2004). 
The current ‘gold standard’ for the diagnosis of GDM is the oral glucose tolerance test (OGTT) 
and although there is no international consensus on the diagnostic methods or the blood 
glucose thresholds, it has become more widely accepted that the OGTT should be performed 
between 24-28 weeks’ gestation using a 75 g glucose load with fasting, one-hour and two-hour 
venous glucose determinations (Coustan, et al., 2010, Metzger, et al., 2010). Universal screening 
and blood glucose thresholds remain contentious and may sometimes be based on resource 
availability and economic factors rather than clinical factors. Often, the more ‘restrictive’ blood 
glucose limits, leading to the diagnosis of the more severe hyperglycaemic patients, is all that 
can be provided in some instances. By contrast, professional associations advocate more 
‘inclusive’ diagnostic criteria, and consequently more patients being diagnosed with less 
severe hyperglycaemia (Agarwal, et al., 2005, Lindsay, 2011, Metzger, et al., 2010, Ryan, 2011). 
With the obesity epidemic well entrenched in the Western world and with more women 
delaying pregnancy and the associated increase in pre-pregnancy body mass index (BMI), the 
incidence of GDM is increasing irrespective of the diagnostic criteria used (Kerrigan and 
Kingdon, 2010, Wein and Beischer, 2000). 
2.2 The problem with current tests 
It is important to recognise that by the time GDM is diagnosed in the late second or early 
third trimester of pregnancy, the ‘pathology’ is probably established and that reversal of the 
potential adverse perinatal outcomes may be limited. Many health professionals advocate 
the need for an earlier diagnostic/predictive test for GDM while at the same time 
acknowledging that avenues for preventative treatment may be limited (Guedj, 2010). In 
fact, it is the lack of a reliable early test for GDM that has hampered the development of 
useful intervention therapies. Although a direct clinical benefit of the early diagnosis of 
GDM remains to be established conclusively, identification of women at greatest risk would 
allow triage of patients to an appropriate model of care and identify those who are at 
greatest need of glucose tolerance assessment (Caliskan, et al., 2004, Shirazian, et al., 2009). 
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Numerous GDM risk-factor assessments have been attempted during first trimester 
pregnancy and include, but not limited to, family history of GDM and/or diabetes 
(Savvidou, et al., 2010), maternal demographics (Alanis, et al., 2010, Phaloprakarn, et al., 
2009, Shirazian, et al., 2009, Wein, et al., 1995), maternal pregnancy weight gain (Morisset, et 
al., 2011), fasting plasma glucose (Riskin-Mashiah, et al., 2009, Riskin-Mashiah, et al., 2010), 
one-hour glucose challenge test (Maegawa, et al., 2003, Nahum, et al., 2002, Punthumapol 
and Tekasakul, 2008), oral glucose tolerance test (Bhattacharya, 2004, Phaloprakarn and 
Tangjitgamol, 2008, Sacks, et al., 2003) and haemoglobin A1c levels (Maegawa, et al., 2003). 
Although some tests have provided a good negative predictive measure for subsequent 
GDM, most tests suffer from poor positive predictive values and therefore are of limited 
efficacy. It is evident that other metabolic markers that precede hyperglycaemia would need 
to be identified if GDM were to be predicted from a test in early pregnancy. 
3. Early screening of impending GDM 
3.1 Single biomarker investigations 
Recently, a number of first trimester studies have identified various biomarkers associated 
with subsequent development of GDM. In some cases these can be regarded as surrogate 
markers of inflammation such as C-reactive protein (Wolf, et al., 2003), of oxidative stress 
such as 8-isoPGF2α (Rogers, et al., 2006) or of obesity such as serum triglycerides (Nolan, et 
al., 1995, Son, et al., 2010) and may not necessarily be specific for impending GDM. Perhaps 
the more exciting studies are those that have investigated serum or plasma protein 
biomarkers associated with early pregnancy placental function and carbohydrate/lipid 
metabolism. For example, it has been shown that lower sex hormone-binding globulin 
(Thadhani, et al., 2003), increased placental growth factor (Ong, et al., 2004), elevated leptin 
concentrations (Qiu, et al., 2004), reduced plasma adiponectin concentrations (Retnakaran, et 
al., 2004, Williams, et al., 2004) and lower follistatin-like-3 levels (Thadhani, et al., 2010) are 
all risk factors for subsequent development GDM. Although the associations are compelling 
further investigations are warranted as it appears that none of these markers alone provide 
adequate positive predictive values for subsequent GDM. 
3.2 Multiple biomarker investigations 
More recent studies have focused on multiple candidate-based profiling of blood-borne 
biomarkers to identify lead candidates for developing early pregnancy screening tests for 
gestational diabetes. For example, we measured multiple plasma biomarkers at 11 weeks’ 
gestation in women who subsequently experienced a normal pregnancy outcome (n=14) and 
women who subsequently developed gestational diabetes (n=14) (Georgiou, et al., 2008). Of 
the biomarkers considered (insulin, adiponectin, leptin, resistin and glucose), receiver 
operator characteristic (ROC) curves for three biomarkers (adiponectin, insulin and random 
blood glucose) are presented together with a ROC curve based on the predicted posterior 
probability values (ppv) generated by a classification model that combined information 
from all three biomarkers (Figure 3). The combined model out performed individual 
biomarkers based upon the area under the ROC curve (combined model = 0.94; adiponectin 
= 0.867; insulin = 0.872 and glucose = 0.827). This simple example demonstrates the putative 
benefit of a multimarker approach for improving diagnostic efficiency. Similar multiple 
biomarker investigations in association with GDM early (Nanda, et al., 2011) or late (Bomba-





2. Gestational diabetes mellitus 
2.1 Current screening 
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance of varying 
severity with onset or first recognition during pregnancy (Metzger and Coustan, 1998). 
GDM usually manifests in the latter half of pregnancy and is typically diagnosed by an oral 
glucose tolerance test. If GDM is diagnosed, women will usually be counselled and advised 
to adopt a healthy lifestyle for the duration of their pregnancy and where it is deemed 
appropriate, women may also be required to undergo pharmacologic or insulin therapy. 
During this time, increased surveillance of the pregnancy is undertaken to help ameliorate 
the consequent maternal and fetal morbidity associated with GDM. The clinical importance 
of this surveillance is highlighted by recent published findings that demonstrate that even 
mild hyperglycaemia over a prolonged period is associated with numerous adverse 
perinatal outcomes (Schafer-Graf, 2009) and that intensive intervention therapy can 
significantly reduce maternal and fetal morbidity (Crowther, et al., 2005, Landon, et al., 
2009). The effects of hyperglycaemia on pregnancy outcome are underpinned by 
experimental studies that identify putative effector pathways by which exposure to glucose 
concentrations may alter placental and maternal adipose tissue phenotype and 
responsiveness (Coughlan, et al., 2001, Coughlan, et al., 2004, Coughlan, et al., 2004, Lappas, 
et al., 2004). 
The current ‘gold standard’ for the diagnosis of GDM is the oral glucose tolerance test (OGTT) 
and although there is no international consensus on the diagnostic methods or the blood 
glucose thresholds, it has become more widely accepted that the OGTT should be performed 
between 24-28 weeks’ gestation using a 75 g glucose load with fasting, one-hour and two-hour 
venous glucose determinations (Coustan, et al., 2010, Metzger, et al., 2010). Universal screening 
and blood glucose thresholds remain contentious and may sometimes be based on resource 
availability and economic factors rather than clinical factors. Often, the more ‘restrictive’ blood 
glucose limits, leading to the diagnosis of the more severe hyperglycaemic patients, is all that 
can be provided in some instances. By contrast, professional associations advocate more 
‘inclusive’ diagnostic criteria, and consequently more patients being diagnosed with less 
severe hyperglycaemia (Agarwal, et al., 2005, Lindsay, 2011, Metzger, et al., 2010, Ryan, 2011). 
With the obesity epidemic well entrenched in the Western world and with more women 
delaying pregnancy and the associated increase in pre-pregnancy body mass index (BMI), the 
incidence of GDM is increasing irrespective of the diagnostic criteria used (Kerrigan and 
Kingdon, 2010, Wein and Beischer, 2000). 
2.2 The problem with current tests 
It is important to recognise that by the time GDM is diagnosed in the late second or early 
third trimester of pregnancy, the ‘pathology’ is probably established and that reversal of the 
potential adverse perinatal outcomes may be limited. Many health professionals advocate 
the need for an earlier diagnostic/predictive test for GDM while at the same time 
acknowledging that avenues for preventative treatment may be limited (Guedj, 2010). In 
fact, it is the lack of a reliable early test for GDM that has hampered the development of 
useful intervention therapies. Although a direct clinical benefit of the early diagnosis of 
GDM remains to be established conclusively, identification of women at greatest risk would 
allow triage of patients to an appropriate model of care and identify those who are at 
greatest need of glucose tolerance assessment (Caliskan, et al., 2004, Shirazian, et al., 2009). 
 
Novel Screening Approaches for the Early Detection of Gestational Diabetes Mellitus 
 
5 
Numerous GDM risk-factor assessments have been attempted during first trimester 
pregnancy and include, but not limited to, family history of GDM and/or diabetes 
(Savvidou, et al., 2010), maternal demographics (Alanis, et al., 2010, Phaloprakarn, et al., 
2009, Shirazian, et al., 2009, Wein, et al., 1995), maternal pregnancy weight gain (Morisset, et 
al., 2011), fasting plasma glucose (Riskin-Mashiah, et al., 2009, Riskin-Mashiah, et al., 2010), 
one-hour glucose challenge test (Maegawa, et al., 2003, Nahum, et al., 2002, Punthumapol 
and Tekasakul, 2008), oral glucose tolerance test (Bhattacharya, 2004, Phaloprakarn and 
Tangjitgamol, 2008, Sacks, et al., 2003) and haemoglobin A1c levels (Maegawa, et al., 2003). 
Although some tests have provided a good negative predictive measure for subsequent 
GDM, most tests suffer from poor positive predictive values and therefore are of limited 
efficacy. It is evident that other metabolic markers that precede hyperglycaemia would need 
to be identified if GDM were to be predicted from a test in early pregnancy. 
3. Early screening of impending GDM 
3.1 Single biomarker investigations 
Recently, a number of first trimester studies have identified various biomarkers associated 
with subsequent development of GDM. In some cases these can be regarded as surrogate 
markers of inflammation such as C-reactive protein (Wolf, et al., 2003), of oxidative stress 
such as 8-isoPGF2α (Rogers, et al., 2006) or of obesity such as serum triglycerides (Nolan, et 
al., 1995, Son, et al., 2010) and may not necessarily be specific for impending GDM. Perhaps 
the more exciting studies are those that have investigated serum or plasma protein 
biomarkers associated with early pregnancy placental function and carbohydrate/lipid 
metabolism. For example, it has been shown that lower sex hormone-binding globulin 
(Thadhani, et al., 2003), increased placental growth factor (Ong, et al., 2004), elevated leptin 
concentrations (Qiu, et al., 2004), reduced plasma adiponectin concentrations (Retnakaran, et 
al., 2004, Williams, et al., 2004) and lower follistatin-like-3 levels (Thadhani, et al., 2010) are 
all risk factors for subsequent development GDM. Although the associations are compelling 
further investigations are warranted as it appears that none of these markers alone provide 
adequate positive predictive values for subsequent GDM. 
3.2 Multiple biomarker investigations 
More recent studies have focused on multiple candidate-based profiling of blood-borne 
biomarkers to identify lead candidates for developing early pregnancy screening tests for 
gestational diabetes. For example, we measured multiple plasma biomarkers at 11 weeks’ 
gestation in women who subsequently experienced a normal pregnancy outcome (n=14) and 
women who subsequently developed gestational diabetes (n=14) (Georgiou, et al., 2008). Of 
the biomarkers considered (insulin, adiponectin, leptin, resistin and glucose), receiver 
operator characteristic (ROC) curves for three biomarkers (adiponectin, insulin and random 
blood glucose) are presented together with a ROC curve based on the predicted posterior 
probability values (ppv) generated by a classification model that combined information 
from all three biomarkers (Figure 3). The combined model out performed individual 
biomarkers based upon the area under the ROC curve (combined model = 0.94; adiponectin 
= 0.867; insulin = 0.872 and glucose = 0.827). This simple example demonstrates the putative 
benefit of a multimarker approach for improving diagnostic efficiency. Similar multiple 
biomarker investigations in association with GDM early (Nanda, et al., 2011) or late (Bomba-









Fig. 3. The advantage of multiple biomarker screening. A comparison of ROC curves of the 
performance of individual biomarkers (adiponectin, insulin and glucose) and a combined 
model (ppv) to correctly classify women who subsequently developed gestational diabetes. 
4. Proteomic approaches for early detection of GDM 
4.1 Sample selection and processing 
As with all analytical techniques, sample heterogeneity (e.g. variation from individual 
patients, sample collection and processing) needs to be minimised for proteomic analysis. 
This is particularly relevant to the collection of blood, where both the method of collection 
and processing may dramatically alter the peptide profile (e.g. clotting, temperature and 
time taken to process samples). For example, while the collection of serum may be suitable 
for some candidate-based approaches (e.g. protein solution array and immunoassay), the 
peptides generated during coagulation confound peptidomic analysis. 
The impact of the method used to collect blood is demonstrated in Figure 4, in which paired 
plasma and serum samples were collected from pregnant women. Blood was either 
collected into EDTA or Serum Clot Activator tubes. The former was immediately 
centrifuged for 15 min at room temperature, while the latter was allowed to clot at room 
temperature for 60 min and then centrifuged for 15 min at room temperature. Following 
 
Novel Screening Approaches for the Early Detection of Gestational Diabetes Mellitus 
 
7 
centrifugation, the resultant plasma or serum was stored at -80o C for mass spectrometry 
peptide profiling. Both plasma and serum samples were subjected to protein dye binding 
depletion (Affi-gel Blue™) as previously described (Ahmed, et al., 2003) followed by solid 
phase peptide enrichment using hydrophilic-lipophilic balanced solid phase extraction 
sorbent in 96-well micro-elution plates, eluted and analysed using matrix assisted laser 
desorption ionisation – time-of-flight (MALDI-ToF) mass spectrometry (AutoFlex II, Bruker 
Daltonics). The resultant peptide profiles of plasma and serum while showing some 
concordance at m/z >4000, exhibited dramatically different peptide ion profiles at m/z < 
2000 (Figure 4). It is likely that these ions represent peptides generated during the 
coagulation process and/or by the action of peptidases during the 60 min incubation at 
room temperature. Thus, for the purpose of primary peptidomic profiling of blood peptides, 
serum presents significant methodological challenges. Indeed, even different anticoagulant 
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4.2 Consideration of gestational change 
Of particular relevance to any discussion of biomarkers for the development of antenatal 
screening tests is gestational variation. To be of clinical utility, any early pregnancy 
screening test would need to be independent of or well outside the normal early gestational 
changes in the subset of the proteome being interrogated. For example, in seeking to identify 
plasma protein biomarkers that may be of utility in identifying women at risk of developing 
a complication of pregnancy, it is critical to first establish the variation (both gestational and 
inter-patient) that occurs within the temporal window in which the test is to be applied. 
That is, if the objective is to identify plasma protein biomarkers using two-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE) for a test that will be applied between 6-12 
weeks of gestation then the variation that occurs in the subset of proteins being screened 
must be established. 
To assess the early-pregnancy variation that plasma proteins display by 2D electrophoresis, 
we completed an initial study that begins to define the gestational variation in a subset of 
plasma proteins. Weekly peripheral blood samples were collected from women from 6-12 
weeks of pregnancy. Plasma samples were immuno-depleted of high-abundance proteins 
(IgY14 column, Sigma) and then labelled with fluorescent CyDyes (Cy3, Cy5) for pair-wise 
comparison (GE Healthcare). A pooled plasma sample was labelled with Cy2 for 
normalisation across gels. Labelled proteins were pooled and then separated in the first 
dimension (24 cm Immobiline™ Dry- Strips, pH 3-11NL) and then in the second dimension 
(12.5% 24 cm hand-cast acrylamide gels with low fluorescent glass). Gel were imaged using 
a Typhoon Trio 9100 (GE Healthcare) and then analysed using Progenesis SameSpots 
software (v3.2.3107.24565, Nonlinear Dynamics). The analysis focussed on spots with a 
greater than 1.5 fold difference. Protein spots that were common to all gels (n=89) were 
further investigated. Figure 5 presents a box-plot summary of the gestational variation in 
these proteins for one patient. To identify protein spots that varied significantly across 
gestation and accounting for ‘false discovery rates’, the combined data set was subjected to 
nonparametric analysis methodology using Significance of Microarray (SAM) analysis. 
Using a false discovery rate of 1%, 5 protein spots were identified that varied significantly 
during 6-12 weeks of pregnancy (Figure 6). 
4.3 Candidate-based profiling approaches (solution array workflow) 
Protein and antibody arrays and multiple immunoassay methodologies represent examples 
of candidate or targeted proteomic approaches. The advantages of these approaches include: 
rapid, high throughput screening of known targets and quantitative endpoints. Multiplex 
protein solution array is one application that represents a generation of antibody-based 
detection technology that allows the simultaneous quantification of multiple analytes in a 
single, small volume sample. Multiplex protein solution array has a number of advantages 
over current analyte quantification technologies, including: measurement of many 
biomarkers (up to 100 different analytes) in a single sample; wider operational dynamic 
range; and increased sensitivity and specificity derived from multivariate modelling of 
combinations of biomarker analytes. This system utilises a sandwich ELISA-like protocol, in 
which capture antibodies are coupled to spectrally distinct polystyrene or metal beads (5-6 
μm diameter). Biotinylated sandwich antibody and streptavidin-phycoerytherin (PE) 
fluorophore are used as a reporter complex. Assays are conducted in 96-well filter-bottom 
 
 




Fig. 5. Variation in plasma proteins displayed during early pregnancy (6-12 weeks of 
gestation). Serial peripheral blood samples were collected from women and displayed using 
2D-DIGE. The data presented represent normalised spot volumes for 89 protein spot that 
were common to all gels. 
 
Fig. 6. Non-parametric, significance of microarray (SAM) analysis of the variation in 
normalised protein spot volumes during early pregnancy. Five protein spot (shown in 
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plates and beads are washed by vacuum filtration. Bead identity and analyte-specific 
fluorescence are assessed using a flow cytometre (Luminex) fitted with dual lasers. Solution 
array offers excellent reproducibility (CV <10%) and analyte quantification and has the 
capacity to multiplex up to 100 different analytes in small sample volumes (e.g. 50-100 μl 
plasma).  
Various manufacturers have now produced a myriad of multiplex assay kits consisting of 
premixed panels of biologically related biomarkers (e.g. cytokines/chemokines, endocrine 
hormones, matrix metalloproteinases, phosphoproteins etc) or disease-related panels (e.g. 
cancer markers, autoimmunity biomarkers and more recently, diabetes biomarkers). All 
suppliers also offer single-plex biomarkers that can be custom mixed to produce any panel 
of choice. We have previously used cytokine/chemokine multiplex panels to investigate 
pregnancy related complications such as GDM (Georgiou, et al., 2008), intrauterine growth 
restriction (Georgiou, et al., 2011) and preterm prelabour rupture of membranes (Hodges, et 
al., 2010) as well as ovarian cancer (Edgell, et al., 2010). Although the differentially 
expressed biomarkers may only be associative rather than causative of disease, these and 
other similar studies highlight the advantages of multiple biomarker screening for improved 
diagnostic/predictive modelling. An important consideration for any method that utilises 
multiple analyte determination is the appropriate control for the false discovery rate when 
multiple comparisons (hypotheses) are being tested. 
4.4 Gel-based profiling approaches 
Gel-based platforms such as 1-dimensional and 2-dimensional polyacrylamide gel 
electrophoresis (1D or 2D-PAGE) and fluorescence 2D difference gel electrophoresis (2D-
DIGE) have been used in both expression and comparative studies to define plasma protein 
abundance and disease-associated or treatment-induced changes. The advantage of these 
approaches resides in their ability to identify post-translational modified protein isoforms. The 
limitation of gel-based systems is their relatively low throughput, the necessity for sample 
processing and fractionation prior to display and limited mass range (~10-200 kDa). In 
addition, procedural protein losses and the overall experimental variation in estimating 
endpoints by 2D-PAGE may be considerable. Procedural losses of proteins during 2D-PAGE 
display have been reported to be as high as 80% but this can vary depending on the starting 
protein load (Zhou, et al., 2005). As with any other technique, variation is apportioned 
between technical replication, both within assay and between assay, and biologic variation (i.e. 
sample-to-sample). Estimates of the variation attributable to technical replication average 25-
40%. Biological variation has been estimated to be between 24 and 70% (Molloy, et al., 2003). 
4.4.1 2-Dimensional Polyacrylamide Gel Electrophoresis (2D-PAGE) 
Using a traditional 2D-PAGE approach, we analysed the maternal plasma proteome from 
women with a normal pregnancy and compared this with women who subsequently 
developed GDM. Plasma samples were obtained at approximately 12 weeks’ (pre-GDM) 
and 28 weeks’ gestation (overt GDM) and gestation-matched with an equal number of 
normal controls. Individual plasma samples were depleted of high abundance proteins 
(albumin and immunoglobulins) by matrix binding centrifugation (Affi-gel Blue and Affi-
gel Protein A respectively), solubilised in a multiple chaotrope buffer and focused on 11 cm, 
pH4-7 immobilised pH gradient strips. Second dimension electrophoresis was performed on 
10% polyacrylamide gels and proteins visualised with Sypro Ruby staining. Protein spots 
were matched and relative abundance was determined using PD-Quest software (v7.3.1, 
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Bio-Rad Laboratories). Using this approach more than 600 protein spots were visualised. Of 
these up to 20 proteins were significantly differentially expressed in pre-symptomatic 
women. Some of these protein spots are unique to pre-GDM (12 weeks’ gestation) while 
others are also differentially expressed during overt disease (28 weeks’ gestation). In some 
cases only specific isomers of a particular protein were differentially expressed (Figure 7). 
The limitations of this methodology include (i) time consuming and sometimes unreliable 
matching of hundreds of spots in multiple gels, (ii) problems associated with spot 
normalisation, (iii) limited in-built statistical capacity of software to compare protein 
abundance, (iv) difficulty with excision of spots especially in small gel formats, and (v) the 
failure to reliably characterise proteins by MALDI-ToF mass spectrometry due to low 
protein abundance. This necessitates the need to scale-up methods for protein 
characterisation (orthogonal identification). 
 
 
Fig. 7. 2D-PAGE Gaussian image of human plasma taken at approximately 12 weeks’ 
gestation. Boxes indicate protein spots that were significantly differentially expressed in 
women who subsequently developed GDM compared to gestation-matched women who 
had a normal pregnancy. 
4.4.2 2-Difference Gel Electrophoresis (2D-DIGE) 
Some of the limitations of gel-based approaches have been overcome with the development 
of difference gel electrophoresis. This minimal labelling approach using fluorescent cyanine 
dyes increases throughput by reducing sample processing and both gel-to-gel and analytical 
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gestation. Boxes indicate protein spots that were significantly differentially expressed in 
women who subsequently developed GDM compared to gestation-matched women who 
had a normal pregnancy. 
4.4.2 2-Difference Gel Electrophoresis (2D-DIGE) 
Some of the limitations of gel-based approaches have been overcome with the development 
of difference gel electrophoresis. This minimal labelling approach using fluorescent cyanine 
dyes increases throughput by reducing sample processing and both gel-to-gel and analytical 





use of an internal standard for normalisation of data across gels (as described in 4.2 above). 
2D-DIGE also delivers useful relative quantification of protein expression profiles where the 
dyes are purported to have sub-nanogram sensitivity and a linear response to protein 
concentrations of over five orders of magnitude. The dyes are also compatible with mass 
spectrometric analysis. With respect to analysing the plasma proteome, 2D-DIGE is still 
limited by the compositional complexity of plasma and similarly benefits from sample 
fractionation and the removal of high-abundance proteins. 
In these experiments, we collected plasma from asymptomatic pregnant women at 12-18 
weeks’ gestation. Pregnancies were retrospectively classified as normal (n = 10), GDM (n=5), 
small-for-gestational age (n=5) and large-for-gestational age (n=5). Plasma was pooled for 
each group and depleted of high abundance proteins (top 14) using the IgY14/Supermix 
system (Sigma). Samples were then concentrated and labelled with Cy2, Cy3 and Cy5 
CyDye DIGE fluors (GE Healthcare) and subjected to 2D-PAGE using 13 cm, pH4-11 
immobilised pH gradient strips (1st dimension) followed by 12.5% gel electrophoresis (2nd 
dimension) as described in section 4.2 above. The analysis focused on spots with a greater 
than 2-fold difference in expression. Comparison between GDM and normal yielded 10 
proteins that were down-regulated and 4 proteins that were up-regulated (some being 
different isoforms of the same protein). Proteins associated with small or large for gestation 
fetal complications were also identified long before disease onset. 
4.5 Mass-spectrometry based quantitative profiling approaches 
There are now a number of mass spectrometry (MS)-based, relative quantification 
approaches currently available including: (i) Multidimensional Chromatography (e.g. 
MudPIT); (ii) Stable Isotope Labelling (e.g. metabolic-SILAC, enzymatic-18O labelling, 
chemical ICPL and iTRAQ labelling); (iii) MALDI-ToF Profiling (e.g. SELDI™ and 
ClinProt™) and (iv) Label Free Quantification (e.g. spectral counting). Of these, stable 
isotope labelling is becoming the method of choice for quantitative proteomics. Stable 
isotope labelling has the advantages of being more sensitive and reproducible than gel-
based methods. These approaches utilise either a mass tag coding strategy (e.g. ICPL - 
Isotope Coded Protein Labelling, ICAT - Isotope Coded Affinity Tag or iTRAQ - isobaric 
Tags for Relative and Absolute Quantification) that allow pooling of samples to reduce 
technical variation. Label-free quantification is an approach that holds the promise of true 
MudPIT-type ‘shotgun’ quantification but has some disadvantages in sample preparation, 
cost and the challenge of normalizing the data so that accurate quantification can be done 
across multiple samples and multiple analyses. Comparison of protein expression profiles 
between samples is based upon two metrics: ion peak intensities of extracted peptide signals 
from LC/MS profiles or spectral counting (number of times peptide precursor is selected for 
fragmentation) of identified proteins after MS/MS analysis (Zhu, et al., 2010). 
In addition to its analytical applications, mass spectrometry affords opportunities to identify 
signature profiles contained within biological samples for the purpose of classification. The 
application of mass spectrometry is a burgeoning area within the domain of diagnostic and 
predictive medicine. This approach now affords the opportunity to develop disease-specific 
patterns or profiles based upon the presence of specific peptides in a patient sample. MS-
based protein profiling relies on the presence and spatial relationships between peptide 
peaks to facilitate the classification of biological samples into different categories (e.g. 
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normal and disease). Based upon the analysis of a training sample set (e.g. disease-free 
patients), pattern recognition software and multivariate modelling are employed to build 
peptide profiles or motifs that characterise a disease-free condition. Once established, such 
reference profiles may be used as a template to detect variance and thus deliver a diagnosis 
or predictive capacity. Two of the mass spectrometry-based profiling approaches we have 
utilised to identify peptides that may be informative of disease risk are described. 
4.5.1 MALDI-ToF peptide profiling (ClinProt™ workflow) 
Matrix-affinity peptide capture coupled with mass spectrometry is a discovery-based tool 
for comparing peptide mass fingerprints between individual or groups of samples. 
Numerous ‘magnetic bead capture’ chemistries are available including metal affinity  
(Cu, Fe), cationic exchange and hydrophobic reverse phase. In a prospective study of GDM, 
plasma samples were collected from pregnant women at 10-14 weeks’ and 26-30 weeks’ 
gestation and retrospectively allocated to gestation-matched GDM and normal groups. 
Samples were analysed after removal of high abundance proteins (Affi-gel Blue/Affi-gel 
Protein A) following a single fractionation process. Processing of samples with magnetic 
beads was performed in quadruplicate using a robotic workstation. Samples were mixed 
with Copper Immobilised Metal Affinity Chromatography beads (IMAC-Cu, Bruker 
Daltonics) in 96-well plates. Unbound peptides in the supernatant were aspirated and 
discarded while magnetic beads were washed and bound peptides eluded. Extracted 
samples were then processed by traditional MALD-ToF methods and raw spectral files were 
analysed with ClinProTools software (v2.2, Bruker Daltonics). Based upon the analysis of 
peptide profiles, we were able to identify disease-specific differentially-detected peptide ion 
peaks (Figure 8) and to develop multivariate classification models (Support Vector Machine 
and Genetic Mutation Models) using ClinProtTools software that discriminated between 
women who subsequently experienced a normal or GDM pregnancy. For example, using a 
genetic mutation classification model, 5 peptides were selected that had the ability to 
correctly classify 100% of women to a low risk group (i.e. those women who subsequently 
experienced a normal pregnancy). Furthermore, the model correctly classified greater than 
93% of those women who subsequently experienced a GDM pregnancy. An independent 
and larger cohort is now required to validate these observations.  
4.5.2 Stable isotope labelling (iTRAQ workflow) 
The other mass-spectrometry based approach we have used to identify disease-specific 
proteins is iTRAQ. This labelling method is arguably the benchmark for relative protein 
quantification. One significant benefit is that it allows sample multiplexing and hence the 
ability to perform comparative analyses of up to eight different samples. For example, seven 
disease conditions or treatment groups and a pooled internal control could be processed in 
tandem, allowing identification and quantification relative to control.  
The same plasma samples described in section 4.4.2 above were subjected to iTRAQ analysis. 
Each pooled sample group was initially depleted of high abundance plasma proteins using 
the IgY14/Supermix system (Sigma). Depleted samples were digested with trypsin and each 
was labelled with one of four different iTRAQ reagents (ABSciex, normal - 114, IUGR - 116, 
GDM - 118 and FM - 121). After labelling, all 4 labelled reaction mixtures were  
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Fig. 8. MALDI-ToF peptide profile comparisons. Top. Example of the average peptide 
profiles over a limited spectral range (2300-2800 m/z) is presented to illustrate identified 
differences in peptide profiles between women with a normal pregnancy (red, n=19, 12 
weeks) and women who subsequently developed GDM (green, n=16, 12 weeks). Bottom. A 
peptide peak cluster plot highlighting the potential for using differentially-expressed 
peptides to classify women into low- and high-risk groups for subsequent GDM. The plot 
presents the data (integrated area) of two peptide peaks (1669 vs 2021 m/z) observed in 
plasma obtained from women (12 weeks’ gestation) who subsequently experienced a 
normal (red) or GDM pregnancy (green). Standard deviation envelopes are presented. 
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was eluted, collected, acidified and analysed by LC-MS/MS (QSTAR Elite, ABSciex) for 
simultaneous protein identification and peptide quantification (ProteinPilot ABSciex). 
Relative abundance of proteins in depleted plasma was determined by comparing the peak 
heights of reporter ions for each sample (m/z at 116, 118, 121) with those from the normal 
pregnancy (m/z at 114) pool. Using iTRAQ reagents and high resolution mass spectrometry, 
eight proteins that were differentially expressed (greater than 2-fold) in maternal plasma in 
association with GDM were unambiguously identified. Three of these proteins were up-
regulated while five proteins were down-regulated. It is important to note that there was 
partial concordance between the identified proteins using iTRAQ and 2D-DIGE methods.  
5. Conclusion 
The methods we have described in this brief chapter provide proof-of-principle both 
technically and conceptually that biomarkers associated with disease can be reliably 
identified before the onset of overt disease. The challenge now remains to validate these 
findings in large independent cohorts to determine the predictive efficacy of these 
biomarkers. These emerging technologies and sophisticated modelling approaches now 
afford a realistic opportunity to develop and robustly evaluate the risk of asymptomatic 
early pregnant women developing complications of pregnancy such as GDM, IUGR, FM, 
PET and PTL. The development of such test(s) will provide data that better informs clinical 
decision-making and patient management that will not only directly benefit the immediate 
pregnancy, but will also help mitigate the longer-term ramifications of these conditions for 
both mother and baby. 
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1. Introduction 
The prevalence of diabetes is increasing globally and the total number of people with this 
condition is projected to rise from 171 million in 2000 to 366 million in 2030 (Wild et al, 
2004). India is no exception, with projected rates of 79.4 million in 2030—a 151% increase 
from 31.7 million in 2000 (Wild et al, 2004). The increased prevalence is attributed to the 
aging population structure, urbanization, the obesity epidemic, and physical inactivity 
(Hunt & Schuller, 2007). While all these factors contribute to the epidemic of diabetes, 
intrauterine exposures are emerging as potential risk factors (Barker, 1995). The “fetal origin 
of adult disease” hypothesis proposes that gestational programming may critically influence 
adult health and disease (Barker, 1995). Gestational programming is a process whereby 
stimuli or stresses occurring at critical or sensitive periods of fetal development, 
permanently change structure, physiology, and metabolism, which predisposes individuals 
to disease in adult life (Lucas, 1991). If the stimulus happens to be glucose intolerance in 
pregnancy, it predisposes the offspring to an increased risk of developing glucose 
intolerance in the future. This vicious cycle is likely to influence and perpetuate the 
incidence and prevalence of glucose intolerance in any population (Seshiah et al., 2004). 
Therefore, preventive measures against type 2 diabetes should start during the intrauterine 
period and continue from early childhood throughout life (Tuomilehto, 2005). In this 
respect, detection of gestational diabetes mellitus (GDM), defined as carbohydrate 
intolerance of variable severity with onset or first recognition during the present pregnancy 
(Metzger, 1991), becomes an important public health issue. The etiopathogenesis of glucose 
intolerance that develops in women with GDM could be the result of their inability to 
increase insulin secretion enough to overcome insulin resistance that occurs even in non 
diabetic pregnancy (Kuhl et al., 1985). The present concept is that GDM represents, detection 
of chronic β cell dysfunction, rather than development of relative insulin deficiency as 
insulin resistance increases during pregnancy (Buchanan et al., 2007).  
2. Implications 
The usual recommendation of lifestyle modifications or drug intervention for prevention of 
diabetes is likely to delay or postpone the development of overt diabetes in persons 
diagnosed with abnormal glucose tolerance. These measures essentially target only the post 
primary prevention of diabetes whereas the aim should be primary prevention of diabetes 
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insulin resistance increases during pregnancy (Buchanan et al., 2007).  
2. Implications 
The usual recommendation of lifestyle modifications or drug intervention for prevention of 
diabetes is likely to delay or postpone the development of overt diabetes in persons 
diagnosed with abnormal glucose tolerance. These measures essentially target only the post 
primary prevention of diabetes whereas the aim should be primary prevention of diabetes 
by keeping the genetically or otherwise susceptible individuals normoglycemic, apart from 
preventing them from developing type 2 DM (Tuomilehto, 2005).  In this context, women 
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with GDM become the ideal group for primary prevention of diabetes (Girling & Dornhorst, 
2003), as women with GDM are at increased risk of developing diabetes predominantly type 
2 DM as are their children (Dornhorst & Rossi, 1998). The diagnosis of GDM offers a unique 
opportunity in identifying individuals who will be benefited by early therapeutic 
intervention with diet and exercise, thus normalizing the weight to delay or even possibly 
prevent the onset of diabetes.    
3. Prevalence  
The epidemiology of GDM is subject to various factors such as the population to be screened, 
the screening methods, the gestational weeks for screening and the glycemic criteria for 
diagnosis. Screening recommendations range from inclusion of all pregnant women 
(universal) to the exclusion of all other women except those with very specific risk factors 
(selective): (e.g., age > 25 years, obesity: BMI > 30, ethnicity: Hispanic, Native American, 
Asian-American, African-American, family history: first degree relative, and previous GDM or 
large for gestational age infant) (Mazze, 2006). Different ethnic groups when exposed to the 
same environmental setting, experienced a widely variable risk. Among ethnic groups in 
South Asian countries, Indian women have the highest frequency of GDM (15%), followed by 
Chinese (13.9%), Vietnam-born (7.8%) and Australian-born (4.3%)  (King, 1998).  
For a given population and ethnicity, the risk of diabetes in pregnancy, mirrors that of the 
underlying frequency of type 2 DM in that population (King, 1998). Impaired Glucose 
Tolerance (IGT) is generally much more prevalent than diabetes in women of child bearing 
age (King, 1998). Among Indians, the prevalence of IGT in the age group of 20 to 29 years 
and 30 to 39 years was found to be 12.2% and 15.3% respectively. No gender difference was 
seen in the prevalence of IGT (Ramachandran et al., 2001). It was observed in a national 
survey performed in 2002, the frequency of the occurrence of GDM was 16.55% by the 
World Health Organization (WHO) criteria (Seshiah et al., 2004) which was closer to the 
prevalence of IGT in the child-bearing age group of women in India (Ramachandran et al., 
2001). Parallel to the increased prevalence of IGT in the general population, the frequency of 
GDM had also increased. The prevalence of GDM was 2% in 1982 (Agarwal & Gupta, 1982) 
[IGT - 2% (Ramachandran et al., 1988)] which increased to 7.62% in 1991 (Narendra et al., 
1991) [IGT – 8.2% (Ramachandran et al., 1992)], and doubled to 16.55% in 2002 (Seshiah et 
al., 2004) [IGT – 14.5% (Ramachandran et al., 2001)]. The prevalence data published (Seshiah 
et al., 2004) included pregnant women attending different health care providing centres 
spread in different parts of the country (Table – 1).  
This phenomenal increase in the prevalence of GDM prompted the authors to initiate a 
project on ‘Diabetes In Pregnancy Awareness and Prevention (DIPAP)’, funded by the 
World Diabetes Foundation and supported by the government of Tamil Nadu, India. To 
have a community based prevalence data under the DIPAP project, the author’s group 
screened a total of 4151, 3960 and 3945 pregnant women in the urban, semi urban and rural 
areas of Tamil Nadu, respectively (Seshiah et al., 2008a). This was the largest prospective 
study (N=12,056) other than Hyperglycemia and Adverse Pregnancy Outcome (HAPO) 
study. GDM diagnosis was based on the WHO criterion of 2-h plasma glucose (PG) ≥ 7.8 
mmol/L with 75g oral glucose. WHO recommendation serves both as one step screening 
and diagnostic procedure, and is easy to perform besides being economical (Seshiah et al., 
2004, 2005). WHO criterion of 2-h PG ≥ 7.8 mmol/L identifying a large number of cases may 
have a greater potential for prevention (Schmidt et al., 2001). In addition, a study performed by  
 
 






Dr. Balaji et al North Chennai, Tamil Nadu 891 16.2% 
Dr. Anjalakshi et al South Chennai, Tamil Nadu 1002 15% 
Dr. K. P. Paulose Trivandrum, Kerala 750 15% 
Dr. Mary John Ludhiana, Punjab 220 17.5% 
Dr. Prasanna Kumar Bangalore, Karnataka 49 12% 
Dr. Shyam Mukundan Alwaye, Kerala 200 21% 
Dr. Aruyerchelvan Erode, Tamil Nadu 562 18.8% 
 TOTAL 3674 16.55% 
Table 1. Prevalence of GDM in different parts of India – 2002 
Crowther et al found that treatment of GDM diagnosed by WHO criterion reduces serious 
perinatal morbidity and may also improve the women’s health-related quality of life 
(Crowther at al., 2005). Similarly a long term outcome study conducted by Franks et al 
documented that when maternal 2-h PG was ≥ 7.8 mmol/L, the cumulative risk of offspring 
developing type 2 DM was 30% at the age 24 yrs (Franks et al., 2006). Both these short term 
and long term outcome studies validate the WHO criterion and hence the authors chose this 
criterion for the DIPAP project. In this project GDM was detected in 739 (17.8%) women in 
urban, 548 (13.8%) in semi urban and 392(9.9%) in rural areas. In this community based study, 
the overall prevalence of GDM was 13.9% (Seshiah et al., 2008a). The prevalence of GDM had 
increased from 16.55% to 17.8% in the urban areas in two years (Seshiah et al., 2004, 2008a). 
There is a definite divide between the rural and urban areas in the prevalence of GDM. The 
possible cause for the low prevalence in the rural settings may be due to the less mechanized, 
agriculture based lifestyle. In this population the risk factors for the development of GDM 
were: age ≥ 25 years, BMI ≥ 25 and family history of diabetes (Figure 1).    
 
 
Fig. 1. Risk factors for the development of GDM 
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3.1 Geographical variations in the prevalence of GDM 
Prevalence varies between 1% to 16% depending on the geographical variation and ethnicity 
and from one region to another in the same country (Yogev et al., 2003). The prevalence of 
GDM corresponds to the prevalence of IGT within a given population (King, 1998). The 
prevalence of GDM in India was 16.55% in the urban area and the frequency varied from 12% 
to 21% in different parts of the country (Seshiah et al., 2004) (Table 1). A low prevalence of 
GDM was observed in Kashmir (Zargar et al., 2004) (northern tip of India) 4.4% and a high 
prevalence of 16.55% in the southern part of India (Seshiah et al., 2004). The prevalence of 
GDM in other developing countries also showed regional variations. In Mexico, the prevalence 
of GDM varied from 4.3% to 11% when screening was done in different parts of the country 
(Forsbach et al., 1998).  The rate of abnormal screening test results ranged from 8.0% to 20.7% 
for different regions of Poland (Wojcikowski et al, 2002). Among Pan Arab countries, Saudi 
Arabia (12.5%) and Bahrain (13.5%) had the highest prevalence of GDM (Al Mahroos et al, 
2005; Ardawi et al, 2000). The frequency of GDM in Argentina was between 2% and 12% 
depending upon the population studied and geographical variations (Liliana et al, 2003).  
4. Rationale for universal screening 
Selective screening based on risk factors scored poorly in predicting GDM (Shamsuddin et 
al, 2001). If selective screening is employed, it is likely that 27% of GDM women will go 
undetected (Shamsuddin et al, 2001). GDM diagnosis is overlooked in about 1/3rd of the 
women, where selective rather than Universal screening is performed (Cosson et al., 2004a). 
Further selective screening recommended by American Diabetes Association (ADA) may be 
applicable for women belonging to the ethnic group with low prevalence of GDM.  Risk 
factor screening does not take into account the inevitable difficulties in implementation, 
including the potential for substantial under-diagnosis of GDM (Simmons et al., 2009). 
Among ethnic groups in South Asian countries, Indian women have the highest frequency 
of GDM necessitating Universal Screening (Beischer et al., 1991). The recognition of glucose 
intolerance during pregnancy is more relevant as Indian women have 11 fold increased risk 
of developing GDM compared to Caucasians (Dornhorst et al., 1992).  
Compared to selective screening, Universal screening for GDM detects more cases and 
improves maternal and offspring prognosis (Cosson, 2004b). Thus Universal screening 
appears to be the most reliable and desired method for the detection of GDM (Shamsuddin et 
al., 2001). For universal screening the test should be simple and cost effective. The two step 
procedure of screening with 50g Glucose challenge test (GCT) and then diagnosing GDM 
based on 75g OGTT is not feasible in a country like India, because the pregnant women may 
have to visit the antenatal clinic twice and at least 3 to 5 blood samples have to be drawn, 
which they resent. The scenario is likely to be the same in most of the developing countries.  
5. Diagnosis of GDM 
5.1 A single step procedure to diagnose GDM 
All the diagnostic criteria require women to be in fasting, but most of the time pregnant 
women do not come in the fasting state because of commutation and belief not to fast for 
long hours. Attending the first prenatal visit in the fasting state is impractical in many 
settings (Metzger et al., 2010). The dropout rate is very high when a pregnant woman is 
asked to come again for the glucose tolerance test (Seshiah et al., 2004; Magee et al., 2001).  
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For the successful implementation of universal screening, a test has to be casual and reliable. 
A procedure that does not impose any restriction would be ideal for universal screening. 
The test performed should be able to diagnose GDM, as they walk into the prenatal clinic or 
clinical laboratory irrespective of their last meal timings. Hence the authors undertook a 
study to evaluate, whether a 2-h 75g oral glucose test performed in a non-fasting state, 
irrespective of last meal timing, is as efficacious as 2-h 75g oral glucose test done in the 
fasting state recommended by WHO in detecting GDM (Anjalakshi et al., 2009). A total of 
862 consecutive pregnant women were subjected to 75g oral glucose test irrespective of time 
of the last meal. Venous samples were collected at 2-h after oral glucose administration. 
They were advised to follow a diet containing atleast 150g carbohydrate daily and usual 
activity for atleast 3 days and come to the prenatal clinic after an overnight fasting of 10-12 
h. At the second visit 800 of them responded and underwent 2-h 75g oral glucose test in the 
fasting state recommended by WHO. The observation in this study was, all women 
diagnosed as GDM (N=87) by 75g glucose test irrespective of the last meal timings also 
satisfied the diagnostic criteria of 75-g oral glucose test performed in the fasting state 
recommended by WHO. It was also found that there was no statistically significant 
difference (P > 0.05) between the PG levels of the 75g glucose test in fasting and non fasting 
state, irrespective of last meal timing, performed in the GDM and in NGT pregnant women. 
The rationale behind this study outcome is that, a normal glucose tolerant woman would be 
able to maintain euglycemia despite glucose challenge due to adequate insulin response, 
whereas in a woman with GDM who has impaired insulin secretion (Kuhl, 1991), her 
glycemic level increases with a meal and with glucose challenge, the glycemic excursion is 
expected to exaggerate. This cascading effect is advantageous as this would not result in 
false positive diagnosis of GDM. Performing this test procedure in the non-fasting state,  
irrespective of last meal timing, is prudent as glucose concentrations during the glucose 
tolerance are affected little by the time since the last meal (Gough et al., 1970). 
Pettitt et al. observed that WHO criteria based on the glucose concentration 2-h after 75g 
oral glucose administered to non-fasting women correctly identified subjects with GDM 
(Pettitt et al., 1994). The non-fasting 2-h post 75g glucose concentration strongly predicts 
adverse outcome for the mother and her offspring (Pettitt et al., 1991). Philips et al also 
observed that plasma glucose value with a glucose challenge test was unaffected by the time 
after a meal or time of the day in Normal Glucose Tolerant non pregnant subjects (Philips et 
al., 2009). Thus, this single test procedure performed irrespective of the last meal timing is 
rational and a patient friendly approach, which causes least disturbance in her routine 
activities. This procedure is a modified version of WHO criteria in that, only 2-h PG is taken 
into consideration for the diagnosis of GDM and is being followed by the Diabetes In 
Pregnancy Study Group India (DIPSI) (Seshiah et al., 2009) 
5.2 Comparison of WHO and IADPSG criteria 
All the diagnostic criteria, except the existing diagnostic criterion of WHO 2-h plasma 
glucose (PG) ≥ 7.8 mmol/L with 75g oral glucose load (King, 1998), are country specific or 
recommended by various associations. Recently, based on the HAPO study, the 
International Association of Diabetes and Pregnancy Study Groups (IADPSG) consensus 
panel recommended that GDM can be diagnosed, if any one value of fasting plasma glucose 
(FPG), 1-h and 2-h PG concentrations meet or exceed 5.1 mmol/L, 10.0 mmol/L and 8.5 
mmol/L respectively, with 75g oral glucose tolerance test (OGTT) (Metzger et al., 2010).  
India one of the most populous countries in the world was not part of the HAPO study. 
Hence the authors group undertook a prospective, collaborative study to ascertain whether 
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the present practice of diagnosing GDM by the guidelines recommended by Diabetes In 
Pregnancy Study Group India (DIPSI) (Seshiah et al., 2009) based on WHO criterion of 2-h 
PG ≥ 7.8 mmol/L can still be followed in India or adopt IADPSG recommendations. A total 
of 1,463 consecutive pregnant women with no previous history of GDM/pre GDM 
underwent a 75g OGTT and fasting, 1-h and 2-h PG were measured. Using the DIPSI 
criterion, 196 (13.4%) women were diagnosed as GDM. By applying IADPSG 
recommendation the cumulative prevalence of GDM was 14.6% (n=214). There was no 
significant difference (P > 0.05) in the discordant pair of diagnosing GDM by the two criteria 
which in turn implies, that the disagreement in diagnosing GDM by both criteria was not 
significant (P = 0.21, by Mc Nemar test). The difference in the diagnostic capability between 
IADPSG and DIPSI was 1.2% which was not significant (P>0.02) (Seshiah et al., 2011). IADPSG 
recommendation necessarily requires estimation of PG in three blood samples after 
administrating 75g oral glucose load. Pregnant women despise this procedure, as venous 
blood is drawn three times and they feel too much of blood is drained. Whereas, DIPSI 
criterion requires one blood sample drawn at 2-h following a 75g glucose load for estimating 
the PG. The cost involved in performing IADPSG recommended procedure is high, as this 
procedure requires three blood tests compared to one blood test of DIPSI. The cost will 
escalate further, if IADPSG diagnostic procedure is performed in each trimester in high risk 
population in whom GDM manifests in all trimesters of pregnancy (Seshiah et al., 2007). 
Among women with normal OGTT results in the first visit when tested in the subsequent 
visits, 28% of them were detected to have GDM (Seshiah et al., 2007). Hence, DIPSI procedure 
based on WHO criterion is feasible, sustainable, cost-effective and best buy to diagnose GDM 
in any country and particularly in less resource nations. IADPSG recommendations are 
suitable in clinical settings where financial and technical supports are available. The 
performance of both IADPSG and WHO criteria are similar as per GRADE ratings. 
5.3 Inadequacy of fasting plasma glucose to diagnose GDM 
The IADPSG criteria suggests FPG ≥ 5.1 mmol/L but ≤ 7.0 mmol/L to diagnose GDM in the 
first prenatal visit (Metzger et al., 2010) whereas the authors observed in their study that by 
applying this criterion of FPG ≥ 5. 1 mmol/L, only 24% (3.2% of the total population) of 
those diagnosed as GDM using WHO criterion 2-h PG ≥ 7.8 mmol/L would have been 
classified as GDM (Balaji et al., 2011a). Further, FPG of 5.1 mmol/L was not able to diagnose 
GDM in comparison to 2-h PG ≥ 7.8 mmol/L (Table 2). This is due to the ethnicity of Asian 
Indians who have high insulin resistance (IR) and as a consequence, their postprandial 
plasma glucose is higher compared to Caucasians (Mohan et al., 2007; Snehalatha et al., 
2009). Asian and South Asian ethnicity are both independently associated with increased IR 
in late pregnancy (Retnakaran et al., 2006). Siddhartha Das et al documented an increased IR 
during pregnancy in Asian Indian Women and IR escalates further in GDM (Das et al., 
2010). These studies provide evidence that FPG may not be an appropriate option to 
diagnose GDM in Asian Indian women.  Further, in all GDM, the FPG values do not reflect 
the postprandial hyperglycemia (Valensi et al., 2009), which is the hallmark of GDM (Weiss 
et al., 2000). In addition, there is a paucity of data regarding the reproducibility of the FPG 
test (Sacks et al., 2010). Hence, administering 75g oral glucose load and measuring 2-h PG 
serves as a one-step definitive procedure to diagnose GDM in less serviced regions. 
Perucchini et al also suggest one-step diagnostic procedure, though their observation was 
based on different ethnic population (Perucchini et al., 1999).  
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Table 2. Performance of FPG test for the predictor of gestational diabetes and macrosomia 
5.4 The validation of WHO criterion (DIPSI criterion) based on the fetal outcome 
The authors investigated whether the diagnosis of GDM by WHO criterion is rational based on 
the fetal outcome (N = 1463). Macrosomia was the end point of this study as this is the most 
common morbidity of GDM (Jovanovic, 2001). They observed that there was no statistically 
significant difference in the mean birth weight of neonates born to women in the normal 
glucose tolerance (NGT) and with intervention in GDM groups (P=0.705) (Balaji et al., 2011b). 
This was due to the medical nutrition therapy (MNT) and/or insulin in maintaining FPG ~ 5.0 
mmol/L and 2-h post meal ~ 6.7 mmol/L in GDM women. Intervention helped in maintaining 
the pregnancy outcome in GDM women equivalent to that of NGT women. Gayle et al also 
observed that diagnosis of GDM with OGTT 2-h PG ≥ 7.8 mmol/L and treatment in a 
combined diabetes antenatal clinic is worthwhile with a decreased macrosomia rate and fewer 
emergency cesarean sections (Gayle et al., 2010). The distribution of birth weight of neonates 
born to GDM and NGT women were similar (Figure 2) in the study conducted by the authors, 
indicating that the intervention given to pregnant women with 2-h PG ≥ 7.8 mmol/L had a 
significant effect in obtaining neonatal birth weight appropriate for gestational age. The level 
of association between macrosomia and GDM status after controlling the factors: maternal age, 
gestational age, family history of diabetes and BMI was elucidated. It was found that, the 
GDM status (2-h PG ≥ 7.8 mmol/L) of the pregnant women after intervention was not 
associated with macrosomia (adjusted OR = 0.752; 95% CI (0.406-1.390); P=0.363). There are 
publications confirming that treatment of GDM women as defined by WHO criterion was 
associated with a reduced risk of pregnancy outcome (Crowther et al., 2005; Gayle et al., 2010). 
In pregnancy, the decision to perform a placebo controlled trial requires clinical equipoise 
(Gifford et al., 2001). Hence, in this study, the authors did not have a control group of 
untreated pregnant women with 2-h PG ≥ 7.8 mmol/L, as there are evidences confirming that 
the treatment of GDM women as defined by WHO criterion was associated with a reduced 
risk of pregnancy outcome (Crowther et al., 2005; Gayle et al., 2010). The policy of not treating 
women with 2-h PG ≥ 7.8 mmol/L amounts to deliberately exposing the pregnant mothers to 
unphysiological glycemic level despite our extensive knowledge of the benefits of treatment of 
mild hyperglycemia during pregnancy (Seshiah et al., 2008a; Landon et al., 2009; Bevier et al., 
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the present practice of diagnosing GDM by the guidelines recommended by Diabetes In 
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1999; Negrato et al., 2008). Wahi et al observed in their prospective study, the advantage of 
adhering to a cut-off level of 2-h PG ≥ 7.8 mmol/L in diagnosis and management of GDM for a 
significantly positive effect on pregnancy outcomes  (Wahi et al., 2011). Fetal exposure to high 
maternal glucose (1-h PG > 7.2 mmol/L with 50g GCT) in the absence of preexisting 
diabetes/GDM may contribute to the development of overweight/obesity in the offspring, 
independent of maternal pre-pregnancy BMI (Deierlein et al., 2011). All these studies validate 
WHO/DIPSI criterion for the diagnosis of GDM 
 
 
Fig. 2. Neonate Birth weight distribution of women with NGT and GDM 
6. Gestational weeks for screening 
The current recommendation is to perform screening test between 24 - 28 weeks of gestation, 
though there are reports that claim, about 40% to 66% of women with GDM can be detected 
early during pregnancy (Super et al., 1991; Nahum et al., 2002). Nahum et al also suggest 
that the ideal period to screen for GDM is around 16 weeks of gestation and even earlier in 
high-risk groups with a history of fetal wastage (Nahum et al., 2002). This is due to the 
embryological development of fetal β cells. Each islet cell functions as an endocrine organ 
and differentiates between 10th and 12th weeks of gestation. They recognize and respond to 
maternal glycemia before 15 weeks of gestation, suggesting that metabolic perturbations are 
underway before diagnosis and that earlier screening and intervention may be warranted 
(Tisi et al., 2011). The study performed by the present authors group in the DIPAP project 
revealed that, 16.3% had glucose intolerance within 16 weeks, 22.4% between 17 - 23 weeks 
and remaining 61.3% more than 24 weeks of gestation (Seshiah et., 2007). If a pregnant 
woman has an A1c level > 6%, she is more likely to be an overt diabetic (Balaji et al., 2007). 
These studies stress the need for screening for GDM during the early weeks of gestation. If 
the test is normal in the first visit, the test has to be repeated in the subsequent visits. GDM 
diagnosis may not be missed by screening around 24 -28 weeks of gestation, but a 
substantial number of pregnant women who develop GDM in the earlier weeks of 
 
Gestational Diabetes Mellitus - A Perspective 29 
pregnancy are likely to have delayed diagnosis and may not receive appropriate medical 
care. Further, early screening for glucose intolerance and care could avoid some diabetes 
related complications in women with gestational diabetes (Bartha et al., 2003). To 
substantiate the above observation the present author’s group screened 207 pregnant women 
attending their referral centre for diabetes and pregnancy with a 75g OGTT (Seshiah et al., 
2006). Among them, 87 (42.03%) were diagnosed with GDM. Women in whom GDM was 
detected between 0 - 23 weeks of gestation were classified as Group 1 [54 (62.7%)] and beyond 
24 weeks of gestation as Group 2 [33 (37.93%)]. All of them were treated and followed till 
confinement. There was no statistically significant difference (P < 0.05) between the birth 
weight of the neonates born to Normal Glucose Tolerance (NGT) women (3.28  0.50 kg) and 
GDM women in group 1 (3.13 ± 0.55 kg). In group 2, the neonatal birth weight was 3.42 ± 0.58 
kg which is the upper limit of the normal range in Indian new born babies. In India, the 
normal birth weight varies between 2.5 to 3.5 kg (Paul et al., 2002). The observation of this 
study was that, by early detection of glucose intolerance during pregnancy and by giving 
adequate care to the antenatal women, a good fetal outcome can be achieved similar to that of 
NGT pregnant women (Seshiah et al., 2006, 2008b).  
7. Management  
The goal in the management is to avoid both low birth weight and macrosomic babies, as 
they are prone to develop diabetes in their adolescent and adult life (Jovanovic, 1998). In 
India, both under nutrition and over nutrition exists during pregnancy. There are two 
reported studies in India that relates size at birth to future risk of type 2 DM. In Mysore, low 
birth weight did not increase the risk of diabetes but babies who were short and fat at birth 
(higher BMI) were at increased risk (Fall et al., 1998). Fall et al speculate that the rise in type 
2 DM in Indian urban populations would have been triggered by mild obesity in mothers, 
leading to glucose intolerance during pregnancy, macrosomic changes in the fetus and 
insulin deficiency in adult life (Fall et al., 1998). Yet another study attributes high prevalence 
of type 2 DM and IGT in Indian people linked to poor fetal growth (Yajnik et al., 1995) 
which is at variant to Fall et al observation (Fall et al., 1998).   
7.1 Medical Nutrition Therapy (MNT)  
The meal pattern should provide adequate calories and nutrients to meet the needs of 
pregnancy metabolism. The meal plan advised has to be simple and easy to practice. The 
MNT recommended is based on their routine diet habit and glycemic excursions that occur 
with the meal. In a normal person, the peaking of the plasma glucose is high after breakfast 
(due to ‘Dawn phenomenon’) than after lunch and dinner, and the insulin secretion also 
matches the glycemic excursions that occur with these three meals (Polonsky et al., 1988). 
Since GDM mothers have deficiency in first phase insulin secretion, the quantity of food at 
one time should also be less, to overcome this insulin deficiency, particularly after breakfast. 
To avoid the post prandial plasma glucose peaking with breakfast, the authors guide their 
women with GDM to distribute calorie consumption especially the breakfast into two 
portions ‘Split Breakfast’. This implies splitting the usual breakfast into two halves and 
consuming these portions with a two-hour gap in between. By this, the undue peak in 
plasma glucose levels after ingestion of the total quantity of breakfast at one time is avoided.  
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7.2 Insulin therapy  
7.2.1 Human insulin  
The policy followed in India is to advise human insulin in women with GDM who failed to 
achieve FPG of ≤ 5.0 mmol/L and 2-h post meal plasma glucose level of ≤ 6.7 mmol/L with 
MNT. The aim is to maintain post meal peak plasma glucose level of ≤ 6.7 mmol/L. This 
time point is suggested as the diagnosis of GDM is made with 2-h PG and it is easy to 
remember the same timing. A number of studies have established the benefits of 
maintaining the plasma glucose at this level (Franks et al., 2006; de Sereday et al., 2003; Ben-
Haroush et al., 2004). However whichever time is targeted for monitoring glycemic control 
and adjusting the insulin dose, the blood tests have to be done at the same time at each visit.  
GDM women usually have high post breakfast plasma glucose level compared to post lunch 
and post dinner. The period between breakfast and lunch are often problematical because of 
the physiological tendency to hyperglycemia at this time and may necessitate substantial 
increases in the morning dose of short acting insulin, together with careful adjustment of 
meal timing and snacks to avoid pre-lunch hypoglycemia (Langer et al., 2000).  
7.2.2 Insulin analogues  
Due to the pharmacokinetic action of human regular insulin, a considerable segment of 
pregnant women with GDM, fail to achieve optimum glycemic control, mostly the post 
prandial plasma glucose. In them, the best option is to administer ultra short acting 
analogues, insulin lispro (Humalog) or insulin aspart (Novo rapid). These analogues 
improve the post prandial glucose control in pregnant women with type 1, type 2 DM and 
GDM, and are also safe and effective (Hermansen et al., 2002; Jovanovic et al., 1999). 
The authors group conducted an open label trial using a large independent cohort of GDM 
patients to evaluate the efficacy, safety and foetal outcome for Biphasic Insulin aspart (BIAsp 
30) compared with biphasic human insulin (BHI 30) in the management of GDM (Balaji et al., 
2010). GDM women (N = 323) who remained unable to maintain a FPG ≤ 5.0 mmol/L and 2-h 
PG ≤ 6.7 mmol/L with MNT were randomly allocated in a 1:1 ratio to receive either BIAsp 30 
(Group A) or BHI 30 (Group B). There was no statistical significance in the levels of glycaemic 
control achieved by the groups by labour onset. However, the mean total insulin dose 
administered by the last visit was significantly lower for Group A [19.83±15.75 U compared 
with 26.34±23.15 U for Group B (p=0.006)], implying that those receiving BHI 30 required a 
higher dose to achieve a similar degree of glycaemic control. The frequency of macrosomia 
was 6.3% in Group A and 6.9% in Group B. Although the proportion of macrosomia was 
numerically higher for Group B than Group A, the difference was not statistically significant 
(p=0.819). It was found that BIAsp 30 was non-inferior to BHI 30 and was well tolerated during 
pregnancy. Yet in another study, the authors observed that pregnant women found BIAsp 
convenient as this preparation allows flexibility in the meal time insulin dosing and did not 
disturb their routine life pattern. Most importantly, BIAsp was found to be safe during 
pregnancy (Balaji et al., 2010). 
7.3 Oral hypoglycemic agents  
7.3.1 Glibenclamide 
Glibenclamide (Glyburide) may be an alternative safe therapy for many GDM women who 
are hesitant to take insulin. This drug decreases the insulin resistance and improves insulin 
secretion, the pathogenic factors in the causation of hyperglycemia in GDM (Groop et al., 
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1991; Rossetti et al., 1990). Another advantage is that, the human placental transfer of 
glibenclamide is negligible. Maternally administered glibenclamide in pharmacologic doses, 
and even doses greatly exceeding therapeutic levels, may not reach the fetus (Elliott et al., 
1991). The landmark study of Langer et al concluded that glyburide was as effective as 
insulin in maintaining the desired glycemic levels and resulted in a comparable outcome 
(Langer et al., 2000). The author’s group undertook a prospective study comparing insulin 
and glibenclamide in GDM. In this study, both Glibenclamide and insulin treatment 
achieved equally good glycemic control and the perinatal outcome was not different 
(Anjalakshi et al., 2007). The observation of this study was that the mean dose of 
glibenclamide required at term was 1.45 ± 0.57 mg/day and mean insulin requirement at 
term was 21.7 ± 13.55 units/day to achieve the same glycemic level (Anjalakshi et al., 2007). 
It is noteworthy that Glibenclamide is very much economical and cost effective compared to 
insulin, which is not only expensive but also inconvenient as it has to be taken parenterally. 
Yet an another observation was that in Indian population, the dose of glibenclamide 
required is very much less compared to the other published studies (Langer et al., 2005).   
7.3.2 Metformin 
Women with polycystic ovary syndrome (PCOS) are advised metformin to induce 
ovulation. The drug is not withdrawn if a woman conceives while on metformin therapy 
and the maximum dose prescribed in the author’s clinical practice is 1500 mg.  If the plasma 
glucose is not under control with metformin, insulin is always added. No adverse 
pregnancy outcome with metformin therapy was observed. A preliminary study showed 
that metformin was safe in pregnant, glucose intolerant women either as an adjunct to 
insulin treatment or even as a monotherapy (Ramachandran et al., 2005). A prospective 
study found no adverse influence on the pregnancy outcome in PCOS women treated 
throughout pregnancy with Metformin (Glueck et al., 2004).  
Metformin in gestational diabetes (MiG) trial found that in women with gestational diabetes 
mellitus, metformin (alone or with supplemental insulin) was not associated with increased 
perinatal complications as compared with insulin (Rowan et al., 2008).  
8. Monitoring glycemic control 
The success of the treatment for a woman with GDM depends on the glycemic control 
maintained with meal plan or pharmacological intervention. To know the effectiveness of 
treatment, monitoring of glycemic control is essential.  
 Once diagnosis is made, medical nutritional therapy (MNT) is advised initially for two 
weeks. If MNT fails to achieve control i.e., FPG ≥ 5.0 mmol/L and/or 2-h PG ≥ 6.7 
mmol/L, insulin may be initiated. 
 Once target blood glucose is achieved, woman with GDM till the 28th week of gestation 
require laboratory monitoring of both fasting and 2-h post breakfast once a month and 
at other time of the day as the clinician decides. 
 After the 28th week of gestation, the laboratory monitoring should be more frequent 
atleast once in 2 weeks, if need be more frequently. 
 After 32 weeks of gestation, laboratory monitoring should be done once a week till 
delivery 
 In high risk pregnancies, frequency of monitoring may be intensified with self 
monitoring of blood glucose (SMBG). 
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7.2 Insulin therapy  
7.2.1 Human insulin  
The policy followed in India is to advise human insulin in women with GDM who failed to 
achieve FPG of ≤ 5.0 mmol/L and 2-h post meal plasma glucose level of ≤ 6.7 mmol/L with 
MNT. The aim is to maintain post meal peak plasma glucose level of ≤ 6.7 mmol/L. This 
time point is suggested as the diagnosis of GDM is made with 2-h PG and it is easy to 
remember the same timing. A number of studies have established the benefits of 
maintaining the plasma glucose at this level (Franks et al., 2006; de Sereday et al., 2003; Ben-
Haroush et al., 2004). However whichever time is targeted for monitoring glycemic control 
and adjusting the insulin dose, the blood tests have to be done at the same time at each visit.  
GDM women usually have high post breakfast plasma glucose level compared to post lunch 
and post dinner. The period between breakfast and lunch are often problematical because of 
the physiological tendency to hyperglycemia at this time and may necessitate substantial 
increases in the morning dose of short acting insulin, together with careful adjustment of 
meal timing and snacks to avoid pre-lunch hypoglycemia (Langer et al., 2000).  
7.2.2 Insulin analogues  
Due to the pharmacokinetic action of human regular insulin, a considerable segment of 
pregnant women with GDM, fail to achieve optimum glycemic control, mostly the post 
prandial plasma glucose. In them, the best option is to administer ultra short acting 
analogues, insulin lispro (Humalog) or insulin aspart (Novo rapid). These analogues 
improve the post prandial glucose control in pregnant women with type 1, type 2 DM and 
GDM, and are also safe and effective (Hermansen et al., 2002; Jovanovic et al., 1999). 
The authors group conducted an open label trial using a large independent cohort of GDM 
patients to evaluate the efficacy, safety and foetal outcome for Biphasic Insulin aspart (BIAsp 
30) compared with biphasic human insulin (BHI 30) in the management of GDM (Balaji et al., 
2010). GDM women (N = 323) who remained unable to maintain a FPG ≤ 5.0 mmol/L and 2-h 
PG ≤ 6.7 mmol/L with MNT were randomly allocated in a 1:1 ratio to receive either BIAsp 30 
(Group A) or BHI 30 (Group B). There was no statistical significance in the levels of glycaemic 
control achieved by the groups by labour onset. However, the mean total insulin dose 
administered by the last visit was significantly lower for Group A [19.83±15.75 U compared 
with 26.34±23.15 U for Group B (p=0.006)], implying that those receiving BHI 30 required a 
higher dose to achieve a similar degree of glycaemic control. The frequency of macrosomia 
was 6.3% in Group A and 6.9% in Group B. Although the proportion of macrosomia was 
numerically higher for Group B than Group A, the difference was not statistically significant 
(p=0.819). It was found that BIAsp 30 was non-inferior to BHI 30 and was well tolerated during 
pregnancy. Yet in another study, the authors observed that pregnant women found BIAsp 
convenient as this preparation allows flexibility in the meal time insulin dosing and did not 
disturb their routine life pattern. Most importantly, BIAsp was found to be safe during 
pregnancy (Balaji et al., 2010). 
7.3 Oral hypoglycemic agents  
7.3.1 Glibenclamide 
Glibenclamide (Glyburide) may be an alternative safe therapy for many GDM women who 
are hesitant to take insulin. This drug decreases the insulin resistance and improves insulin 
secretion, the pathogenic factors in the causation of hyperglycemia in GDM (Groop et al., 
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1991; Rossetti et al., 1990). Another advantage is that, the human placental transfer of 
glibenclamide is negligible. Maternally administered glibenclamide in pharmacologic doses, 
and even doses greatly exceeding therapeutic levels, may not reach the fetus (Elliott et al., 
1991). The landmark study of Langer et al concluded that glyburide was as effective as 
insulin in maintaining the desired glycemic levels and resulted in a comparable outcome 
(Langer et al., 2000). The author’s group undertook a prospective study comparing insulin 
and glibenclamide in GDM. In this study, both Glibenclamide and insulin treatment 
achieved equally good glycemic control and the perinatal outcome was not different 
(Anjalakshi et al., 2007). The observation of this study was that the mean dose of 
glibenclamide required at term was 1.45 ± 0.57 mg/day and mean insulin requirement at 
term was 21.7 ± 13.55 units/day to achieve the same glycemic level (Anjalakshi et al., 2007). 
It is noteworthy that Glibenclamide is very much economical and cost effective compared to 
insulin, which is not only expensive but also inconvenient as it has to be taken parenterally. 
Yet an another observation was that in Indian population, the dose of glibenclamide 
required is very much less compared to the other published studies (Langer et al., 2005).   
7.3.2 Metformin 
Women with polycystic ovary syndrome (PCOS) are advised metformin to induce 
ovulation. The drug is not withdrawn if a woman conceives while on metformin therapy 
and the maximum dose prescribed in the author’s clinical practice is 1500 mg.  If the plasma 
glucose is not under control with metformin, insulin is always added. No adverse 
pregnancy outcome with metformin therapy was observed. A preliminary study showed 
that metformin was safe in pregnant, glucose intolerant women either as an adjunct to 
insulin treatment or even as a monotherapy (Ramachandran et al., 2005). A prospective 
study found no adverse influence on the pregnancy outcome in PCOS women treated 
throughout pregnancy with Metformin (Glueck et al., 2004).  
Metformin in gestational diabetes (MiG) trial found that in women with gestational diabetes 
mellitus, metformin (alone or with supplemental insulin) was not associated with increased 
perinatal complications as compared with insulin (Rowan et al., 2008).  
8. Monitoring glycemic control 
The success of the treatment for a woman with GDM depends on the glycemic control 
maintained with meal plan or pharmacological intervention. To know the effectiveness of 
treatment, monitoring of glycemic control is essential.  
 Once diagnosis is made, medical nutritional therapy (MNT) is advised initially for two 
weeks. If MNT fails to achieve control i.e., FPG ≥ 5.0 mmol/L and/or 2-h PG ≥ 6.7 
mmol/L, insulin may be initiated. 
 Once target blood glucose is achieved, woman with GDM till the 28th week of gestation 
require laboratory monitoring of both fasting and 2-h post breakfast once a month and 
at other time of the day as the clinician decides. 
 After the 28th week of gestation, the laboratory monitoring should be more frequent 
atleast once in 2 weeks, if need be more frequently. 
 After 32 weeks of gestation, laboratory monitoring should be done once a week till 
delivery 
 In high risk pregnancies, frequency of monitoring may be intensified with self 
monitoring of blood glucose (SMBG). 
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 Continuous glucose monitoring devices are available but these equipments need special 
training and are expensive. These devices may be useful in high risk pregnancies to 
know the glycemic fluctuations and to plan proper insulin dosage. 
8.1 Glycosylated haemoglobin – A1c levels  
If the glucose intolerance is detected in the early pregnancy, A1c level will be helpful to 
differentiate between a pre gestational diabetic and GDM. If A1c level is more than 6% 
(Balaji et al., 2007), the chances are that she may be a pre GDM or GDM, in whom the 
glucose intolerance was detected in the early weeks of pregnancy; all the more validating 
that the screening needs to be performed in the early weeks of gestation. The estimation of 
A1c may help in distinguishing a pre GDM from an early onset GDM, but not essential, as 
this differentiation is of no consequence in clinical practice, as the treatment approach is 
going to be the same (Seshiah et al., 2007). Further, A1c is not estimated in the community 
health centres, barring a few tertiary care hospitals due to the difficulty in standardization, 
inadequate technical support and the cost.  
8.2 Measuring other parameters 
The blood pressure has to be monitored during every visit. Examination of the fundus and 
estimation of microalbuminuria, every trimester is recommended. 
8.3 Ultrasound fetal measurement  
The management of gestational diabetes, based on the foetal growth by ultrasonogram 
demands that the fetus at risk must first manifest overgrowth before treatment decisions are 
made. Further, the cost of performing a number of ultrasonograms to monitor the foetal 
growth and recommending therapy has to be kept in mind. Until there is evidence to 
absolutely prove that ignoring maternal hyperglycemia when the fetal growth patterns 
appear normal on the ultrasonogram, it is prudent to achieve and maintain normoglycemia 
in every pregnancy complicated by gestational diabetes.  
9. Target glycemic level 
Increased birth weight of neonates occurred even when the mother’s glucose tolerance was 
less than the glycemic criteria recommended by WHO (2-h PG > 7.8 mmol/L) for diagnosis 
of GDM. Increasing carbohydrate intolerance in women without overt GDM was associated 
with graded increase in the incidence of macrosomia (Sermer et al., 1998). The author’s 
group documented that the occurrence of macrosomia was continuum as the FPG increased 
> 5.0 mmol/L (Seshiah et al., 2008c) and the 2-h PG > 6.7 mmol/L (Balaji et al., 2006). Thus 
maintenance of mean plasma glucose level ~ 5.8 to 6.1 mmol/L is desirable for a good fetal 
outcome (Langer et al., 1989). This is possible if FPG and peak postprandial glucose levels 
are maintained ~ 5.0 mmol/L (4.4-5.0 mmol/L) and ~ 6.7 mmol/L (6.1 – 6.7 mmol/L, 
respectively) 
10. Prevention of type 2 dm 
The screening for glucose intolerance during pregnancy is not done routinely and probably 
the undiagnosed glucose intolerance that has been occurring in the past has resulted in the 
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increased prevalence of diabetes in India. This is likely to be true as GDM has a far reaching 
consequence in predisposing their offsprings to glucose intolerance. This observation was 
substantiated and documented in Pima Indians (Dabelea et al., 2000). The children born in 
1965 to women with GDM were followed up till 2000. By the time they reached 35 years, 
more than half of the group had diabetes (Dabelea et al., 2000). Hence as a policy to identify 
GDM and its consequences on the infant, a 75 g OGTT has been recommended to all women 
in the population during the third trimester of pregnancy (Dabelea et al., 2000). Now it is 
obvious that taking care of women with GDM is the first step in the primary prevention of 
diabetes.  
The important aspect of diabetes and pregnancy is that, the intrauterine millieu interieur, 
whether one of nutritional deprivation or one of nutritional plenty, results in changes in 
fetal pancreatic development and peripheral response to insulin that may lead to adult-
onset GDM and type 2 DM (Savona-Ventura & Chircop, 2003). Thus, the timely action taken 
now in screening all pregnant women for glucose intolerance, achieving euglycemia in them 
and ensuring adequate nutrition may prevent in all probability, the vicious cycle of 
transmitting glucose intolerance from one generation to another (Aerts, 2004). GDM offers 
an important opportunity for the development, testing and implementation of clinical 
strategies for diabetes prevention (Buchanan et al., 2007). 
‘No single period in human development provides a greater potential than pregnancy for a 
long range pay off via relatively short range period of enlightened metabolic manipulation’ - 
Norbert Frienkel.  
11. Summary  
 GDM women are at increased risk of future diabetes as are their children and following 
generations.  
 Prevalence of GDM varies from one region to another region in the same country. 
 Compared with selective screening, Universal screening for GDM detects more cases 
and improves maternal and offspring prognosis.  
 Asian women are ethnically more prone to develop glucose intolerance compared to 
other ethnic groups. 
 GDM based on 2-h 75g OGTT defined by WHO predicts adverse pregnancy outcome 
and warrants treatment. 
 A 2-h 75g post plasma glucose ≥ 7.8 mmol/L serves both as screening and diagnostic 
criteria which is a technically simple economical and evidence based one step 
procedure.   
 IADPSG recommendations are suitable in clinical settings where technical and financial 
supports are available.  
 Early screening for glucose intolerance and care could avoid some diabetes related 
complications in women with gestational diabetes 
 Women with NGT in the first visit are advised to undergo glucose tolerance test in the 
subsequent trimesters. 
 The meal pattern advised has to be simple, and easy to understand and follow. 
 The goal is to maintain mean plasma glucose of 5.8 to 6.1 mmol/L 
 Occurrence of macrosomia was continuum as the FPG increased from 5.0 mmol/L and 
2-h PG increased from 6.7 mmol/L. 
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 Continuous glucose monitoring devices are available but these equipments need special 
training and are expensive. These devices may be useful in high risk pregnancies to 
know the glycemic fluctuations and to plan proper insulin dosage. 
8.1 Glycosylated haemoglobin – A1c levels  
If the glucose intolerance is detected in the early pregnancy, A1c level will be helpful to 
differentiate between a pre gestational diabetic and GDM. If A1c level is more than 6% 
(Balaji et al., 2007), the chances are that she may be a pre GDM or GDM, in whom the 
glucose intolerance was detected in the early weeks of pregnancy; all the more validating 
that the screening needs to be performed in the early weeks of gestation. The estimation of 
A1c may help in distinguishing a pre GDM from an early onset GDM, but not essential, as 
this differentiation is of no consequence in clinical practice, as the treatment approach is 
going to be the same (Seshiah et al., 2007). Further, A1c is not estimated in the community 
health centres, barring a few tertiary care hospitals due to the difficulty in standardization, 
inadequate technical support and the cost.  
8.2 Measuring other parameters 
The blood pressure has to be monitored during every visit. Examination of the fundus and 
estimation of microalbuminuria, every trimester is recommended. 
8.3 Ultrasound fetal measurement  
The management of gestational diabetes, based on the foetal growth by ultrasonogram 
demands that the fetus at risk must first manifest overgrowth before treatment decisions are 
made. Further, the cost of performing a number of ultrasonograms to monitor the foetal 
growth and recommending therapy has to be kept in mind. Until there is evidence to 
absolutely prove that ignoring maternal hyperglycemia when the fetal growth patterns 
appear normal on the ultrasonogram, it is prudent to achieve and maintain normoglycemia 
in every pregnancy complicated by gestational diabetes.  
9. Target glycemic level 
Increased birth weight of neonates occurred even when the mother’s glucose tolerance was 
less than the glycemic criteria recommended by WHO (2-h PG > 7.8 mmol/L) for diagnosis 
of GDM. Increasing carbohydrate intolerance in women without overt GDM was associated 
with graded increase in the incidence of macrosomia (Sermer et al., 1998). The author’s 
group documented that the occurrence of macrosomia was continuum as the FPG increased 
> 5.0 mmol/L (Seshiah et al., 2008c) and the 2-h PG > 6.7 mmol/L (Balaji et al., 2006). Thus 
maintenance of mean plasma glucose level ~ 5.8 to 6.1 mmol/L is desirable for a good fetal 
outcome (Langer et al., 1989). This is possible if FPG and peak postprandial glucose levels 
are maintained ~ 5.0 mmol/L (4.4-5.0 mmol/L) and ~ 6.7 mmol/L (6.1 – 6.7 mmol/L, 
respectively) 
10. Prevention of type 2 dm 
The screening for glucose intolerance during pregnancy is not done routinely and probably 
the undiagnosed glucose intolerance that has been occurring in the past has resulted in the 
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increased prevalence of diabetes in India. This is likely to be true as GDM has a far reaching 
consequence in predisposing their offsprings to glucose intolerance. This observation was 
substantiated and documented in Pima Indians (Dabelea et al., 2000). The children born in 
1965 to women with GDM were followed up till 2000. By the time they reached 35 years, 
more than half of the group had diabetes (Dabelea et al., 2000). Hence as a policy to identify 
GDM and its consequences on the infant, a 75 g OGTT has been recommended to all women 
in the population during the third trimester of pregnancy (Dabelea et al., 2000). Now it is 
obvious that taking care of women with GDM is the first step in the primary prevention of 
diabetes.  
The important aspect of diabetes and pregnancy is that, the intrauterine millieu interieur, 
whether one of nutritional deprivation or one of nutritional plenty, results in changes in 
fetal pancreatic development and peripheral response to insulin that may lead to adult-
onset GDM and type 2 DM (Savona-Ventura & Chircop, 2003). Thus, the timely action taken 
now in screening all pregnant women for glucose intolerance, achieving euglycemia in them 
and ensuring adequate nutrition may prevent in all probability, the vicious cycle of 
transmitting glucose intolerance from one generation to another (Aerts, 2004). GDM offers 
an important opportunity for the development, testing and implementation of clinical 
strategies for diabetes prevention (Buchanan et al., 2007). 
‘No single period in human development provides a greater potential than pregnancy for a 
long range pay off via relatively short range period of enlightened metabolic manipulation’ - 
Norbert Frienkel.  
11. Summary  
 GDM women are at increased risk of future diabetes as are their children and following 
generations.  
 Prevalence of GDM varies from one region to another region in the same country. 
 Compared with selective screening, Universal screening for GDM detects more cases 
and improves maternal and offspring prognosis.  
 Asian women are ethnically more prone to develop glucose intolerance compared to 
other ethnic groups. 
 GDM based on 2-h 75g OGTT defined by WHO predicts adverse pregnancy outcome 
and warrants treatment. 
 A 2-h 75g post plasma glucose ≥ 7.8 mmol/L serves both as screening and diagnostic 
criteria which is a technically simple economical and evidence based one step 
procedure.   
 IADPSG recommendations are suitable in clinical settings where technical and financial 
supports are available.  
 Early screening for glucose intolerance and care could avoid some diabetes related 
complications in women with gestational diabetes 
 Women with NGT in the first visit are advised to undergo glucose tolerance test in the 
subsequent trimesters. 
 The meal pattern advised has to be simple, and easy to understand and follow. 
 The goal is to maintain mean plasma glucose of 5.8 to 6.1 mmol/L 
 Occurrence of macrosomia was continuum as the FPG increased from 5.0 mmol/L and 
2-h PG increased from 6.7 mmol/L. 
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 At least one point testing in the third trimester of measuring haemoglobin, blood 
pressure and plasma glucose in pregnant women will go a long way in achieving safe 
maternal and fetal outcome.  
 Taking care of women with gestational diabetes is envisaged as the first step in the 
primary prevention of diabetes. 
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1. Introduction  
Gestational diabetes (GD) is defined as carbohydrate intolerance that begins or is first 
diagnosed during pregnancy. Hyperglycemia is found only during pregnancy and 
diagnosis is confirmed when glucose tolerance test results return to normal levels in the 
postpartum (Metzger et al., 2007). GD occurs in around 4-10% of pregnancies; however, its 
incidence varies as a function of nutritional habits and differences in genetic patterns 
between populations (Metzger et al., 2007). 
The importance of GD was first described around forty years ago when it was noticed that 
women with this disorder were more likely to develop diabetes mellitus later on in their 
lives. The original diagnostic criteria proposed by O’Sullivan and Mahan were in fact never 
validated for the development of gestational complications or adverse perinatal outcomes 
(O’Sullivan and Mahan, 1964). Throughout all this time, the importance of this diagnosis for 
the prognosis of the pregnancy has been the subject of debate (Holt et al., 2011). Whereas 
some specialists feared that even mild levels of hyperglycemia would negatively affect 
pregnancy outcome, others have questioned the very existence of GD as a disease 
(Buchanan and Kjos, 1999). 
Recently, however, the harmful effects of hyperglycemia during pregnancy have been 
demonstrated (HAPO, 2008) and evidence is mounting on the risks of hyperglycemia during 
pregnancy, not only in terms of adverse perinatal outcome, but also for the future of the infant 
in adult life (Catalano, 2010; Chandler-Laney et al., 2011; Fall, 2010; Lawlor et al., 2011). 
In this chapter, the rationale and current recommendations for the diagnosis and treatment of 
gestational diabetes will be evaluated based on the best scientific evidence currently available. 
The MEDLINE, EMBASE, SCOPUS and SciELO databases and the systematic reviews of the 
Cochrane Library were reassessed using the key words: gestational diabetes, screening, 
diagnosis and therapy. Preference was given to randomized clinical trials and meta-analyses, 
with observational studies and review articles being included only when studies with a better 
level of evidence were unavailable. Guidelines and recommendations established by medical 
societies for the screening, diagnosis and treatment of gestational diabetes were also consulted. 
2. Physiopathology 
As any carbohydrate metabolism disorder, GD is characterized by insufficient insulin levels 
for insulin demand (Metzger et al., 2007). The cause of this insulin insufficiency in 
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2. Physiopathology 
As any carbohydrate metabolism disorder, GD is characterized by insufficient insulin levels 





pregnancy remains to be fully established; however, it is believed that the occurrence of this 
event during pregnancy reveals underlying maternal pancreatic disorders that would 
otherwise only become apparent later on in the woman’s life (Metzger et al., 2007). 
In a normal pregnancy, fetal and placental growth increases cortisol, growth hormone, 
human placental lactogen, progesterone, estrogen and prolactin levels. The presence of these 
stimuli triggers hyperinsulinemia, insulin resistance, fasting hypoglycemia and postprandial 
hyperglycemia. Consequently, there is a reduction in peripheral sensitivity to insulin and an 
increase in demand. As a compensatory mechanism, an increase occurs in pancreatic 
function at the cost of both hypertrophy and hyperplasia. Furthermore, in response to the 
high insulin levels, peripheral utilization of glucose by the muscles and peripheral glycogen 
storage increase in an attempt to maintain balance (Metzger et al., 2007; Pridjian and 
Benjamin, 2010). 
As pregnancy advances, these compensatory mechanisms may be insufficient in susceptible 
women, resulting in an imbalance between insulin production and insulin requirements in 
pregnancy. Compared to a normal pregnant woman, a woman with GD has pancreatic β-
cell dysfunction and a reduction in adaptive β-cell capacity. This results in insufficient 
insulin secretion and consequent hyperglycemia (Metzger et al., 2007; Pridjian and 
Benjamin, 2010). 
3. Consequences for the mother and child   
The consequences of gestational diabetes for the mother and child are summarized in Table 1. 
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• Fractures 
• Brachial plexus lesion 
Hypocalcemia Metabolic 
syndrome 
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Modified from Pridjian and Benjamin, 2010  
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4. Screening and diagnosis of gestational diabetes 
The screening and diagnosis of GD is the subject of intense debate and controversy 
worldwide (Holt et al., 2011; Leary et al., 2010). All aspects of diagnosis (who should be 
investigated, using which tests and what values are considered diagnostic) have been 
widely discussed over the past two decades (Holt et al., 2011). Consequently, the guidelines 
published by the major societies differ with respect to these aspects with the result that the 
practices of physicians worldwide differ to the same extent (Leary et al., 2010). 
The World Health Organization (WHO) recommends screening high-risk women with a 75-
gram oral glucose tolerance test in the first trimester of pregnancy and all other women at 
24-28 weeks, with fasting glucose measurements of 126 mg/dl and two-hour glucose levels 
of 140 mg/dl being considered abnormal (WHO, 1999). However, until recently (up to 
autumn 2010), the American Diabetes Association (ADA) recommended screening only 
women with risk factors and advocated an oral load of 100 grams of anhydrous glucose 
(ADA, 2004). The values adopted in each one of the guidelines also differed greatly. 
Recently, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) 
assembled the evidence accumulated over recent years and published new criteria for the 
screening and diagnosis of GD (IADPSG, Metzger et al., 2010). 
4.1 Screening 
Screening is performed to select individuals to be investigated. Since 1999, the World Health 
Organization (WHO) has recommended the screening of all women or all women except 
those considered low-risk (WHO, 1999). 
In 2003, a US taskforce was formed to evaluate screening for gestational diabetes. The 
authors’ conclusion was that better-quality evidence was required to determine whether the 
benefits of screening are greater than the risks. They recommended that until such evidence 
was available, to screen or not to screen should be left to the discretion of each individual 
physician according to his/her own clinical judgment and that both options are reasonable 
(The US Preventive Services Task-Force – USPSTF, Brody et al., 2003-A). 
The same taskforce evaluated the risk factors for gestational diabetes and found a strong 
association with: maternal obesity (body mass index > 25), age > 25 years, personal or family 
history of a carbohydrate metabolism disorder or a history of gestational diabetes in a 
previous pregnancy. Some ethnic groups such as Hispanics, Blacks, native American 
Indians and Asians are also at an increased risk of developing gestational diabetes. If all 
these criteria are taken into consideration, 90% of all women at risk of developing 
gestational diabetes will be identified (Brody et al., 2003-A). 
A systematic review was conducted of observational studies published in the past thirty 
years to evaluate the presence and strength of the association between pre-gestational body 
mass index (BMI) and the presence of gestational diabetes. Seventy studies were included 
involving 671,945 women (59 cohort studies and 11 case-control studies). Compared to 
women with normal pregestational BMI, in accordance with the odds ratio (OR) the 
estimated risk of developing gestational diabetes was 1.97 [95% confidence interval (95%CI) 
1.77 – 2.19], 3.01 [95%CI: 2.34 – 3.87] and 5.55 [95%CI: 4.27 – 7.21] for overweight, moderate 
obesity and severe obesity, respectively (Torloni et al., 2009). 
In addition to the principal risk factors, Table 2 provides a detailed list of risk factors from 
previous pregnancies as well as risk factors that may appear during the course of pregnancy 
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previous pregnancies as well as risk factors that may appear during the course of pregnancy 






Age > 35 years 
Obesity (BMI > 25) 
Arterial hypertension 
Family history of diabetes 
Obstetric history: 





Fetal death, principally in the final weeks of pregnancy  
Neonatal morbidity and mortality: 
- Hypoglycemia  




Complications in current pregnancy: 
Excessive weight gain 




Use of hyperglycemic drugs (betamimetics, corticoids) 
Amorim and Katz, 2011 
Table 2. Risk factors for gestational diabetes 
More recently, another systematic review evaluated the available literature, searching for 
further evidence on screening for gestational diabetes (Tieu et al.,2011). The  authors searched 
for articles which evaluated any individual screening tool or screening program, protocol or 
guideline for gestational diabetes compared with the absence of screening; or any individual 
screening tool or screening program, protocol or guideline for gestational diabetes with 
another. Thirty-one trials were considered for inclusion into the review but after application of 
eligibility criteria, only four of these trials were included. After analysis the authors found that 
there was insufficient evidence to determine the effects of screening for gestational diabetes 
and its subsequent management, or the comparative effects of different protocols for 
screening. Although women who were routinely screened by 50 g glucose challenge testing 
were more likely to be diagnosed with gestational diabetes than those screened by their risk 
factors, effects of subsequent management on health outcome are unclear. 
IADPSG recommends investigating “all women or all high-risk women” at their first 
prenatal consultation (IADPSG, Metzger et al., 2010). Universal investigation is justified by 
the increase in the prevalence of undiagnosed type 2 diabetes in young women (Leary et al., 
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2010) and in the risk factors for the occurrence of GD such as, for example, obesity 
(Catalano, 2010). In addition, it ensures that cases of early-onset GD will be identified (Leary 
et al., 2010). Early screening reflects the preference for universal investigation. 
In addition, IADPSG recommends universal investigation at 24-28 weeks of all women not 
previously diagnosed as having clinical or gestational diabetes (IADPSG et al., 2010). 
The argument used by those who support universal screening is based on the randomized 
clinical trial entitled the Australian Carbohydrate Intolerance Study in Pregnant Women 
(ACHOIS) trial group (Crowther et al., 2005), which showed a reduction in healthcare costs 
with universal screening. Nevertheless, criticism to the use of these results for 
recommending IADPSG’s proposal is based on the fact that the ACHOIS study used an oral 
glucose tolerance test of 75 grams, measuring fasting glucose levels and two-hour glucose 
levels alone, whereas the IADPSG recommendations also include measurement of glucose 
levels one hour after overload (Leary et al., 2010). Further studies should be conducted to 
evaluate the costs and benefits associated with this form of management. 
4.2 Diagnosis 
The origin of all this controversy surrounding the diagnosis of GD lies in the form in which 
testing was initially developed. The first authors to develop a diagnostic test for GD were 
John O’Sullivan and Clare Mahan in 1964 (O’Sullivan and Mahan, 1964). The test was 
developed to predict the risk of developing diabetes mellitus years after the pregnancy 
rather than the risk of an adverse perinatal outcome. 
Although it constituted a watershed in the diagnosis of GD, faults were found in the study 
conducted by O’Sullivan and Mahan when analyzed from a methodological point of view, 
particularly with respect to the conclusions drawn and the validation of the test as a 
diagnostic technique, which was clearly demonstrated by Naylor in a study published in 
1989 (Naylor, 1989). One of the questions raised was that gestational diabetes is more 
important as a predictor of a pregnancy with a higher maternal-fetal risk, whereas the end-
point initially evaluated was the presence of carbohydrate intolerance after the end of 
pregnancy. Since the investigators’ objective was to predict the development of diabetes 
mellitus over the long-term, this characteristic was taken into consideration to select the cut-
off points. It was later shown that when pregnant women considered to be diabetic in 
accordance with the values selected were treated with insulin, the rate of macrosomia 
decreased when glucose levels returned to normal (O’Sullivan, 1996 and 1973). This is an 
indirect way of reaching conclusions that is, nonetheless, far from ideal and does not allow 
the diagnostic technique to be adequately validated. According to Naylor, it would have 
been more appropriate to try to record the immediate and long-term neonatal complications 
and test their association using an oral glucose tolerance test. 
In the following years, changes were made to the diagnostic techniques used and glucose 
levels were no longer measured in full blood but rather in venous plasma. Furthermore, 
enzymatic methods began to be used to measure plasma glucose levels instead of the 
Somogyi-Nelson technique. These technical modifications led to the mathematical correction 
of the values initially proposed by O’Sullivan and Mahan with the appearance of different 
sets of values adopted by different organizations involved in the study of GD (National 
Diabetes Data Group [NDDG], 1979; Carpenter and Coustan, 1982). 
Later, an intense debate ensued among investigators regarding the best form of diagnosing 
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reduction in blood glucose levels or the adoption of fewer points on the curve as being 
sufficient for diagnosis. It was even proposed that the presence of hyperglycemia below the 
levels established for diagnosis could be sufficient to lead to adverse maternal and perinatal 
outcomes, or that the hyperglycemia occurring irrespective of an overload should be taken 
into consideration (Aberg et al., 2001; Jensen et al., 2001; Langer et al., 1987; Rudge et al., 
1990; Sermer et al., 1995). 
If on the one hand evidence was accumulating to the effect that milder degrees of 
hyperglycemia, albeit below the levels established for a diagnosis of GD, could lead to 
unfavorable perinatal outcomes, on the other hand some authors questioned the very 
existence of this diagnosis as a valid entity and called attention to the possible negative 
effects of this diagnosis (Buchanan, 1999; Lucas et al., 1993). A diagnosis of GD may result in 
excessive medicalization of pregnancy, which in itself would be negative. Furthermore, this 
diagnosis may result in an increase in the number of interventions performed, including 
even Cesarean sections, in situations in which the need for this type of delivery is 
questionable, due to the mere presence of a diagnosis of diabetes. In addition, it is important 
to remember the psychological burden caused by a label of diabetes. 
In 2005, an Australian group (ACHOIS) published the findings of a randomized clinical trial 
in which mild hyperglycemia was treated in women who did not fulfill the diagnostic 
criteria for GD, but who had measurements of 140 to 199 mg/dl in a 75-gram oral glucose 
tolerance test (OGTT) and were consequently considered to be carbohydrate intolerant 
(Crowther et al., 2005). These investigators found a reduction in composite final outcome 
(perinatal death, shoulder dystocia, fractures and brachial plexus palsy) compared with 
women managed in the usual manner. 
In 2009, a clinical trial was conducted to treat women who were found not to fulfill the 
diagnostic criteria for GD after being submitted to an oral glucose tolerance test with 100 
grams of carbohydrate, but whose glucose levels were not completely normal. Likewise, 
when this group was treated, a reduction was found in macrosomia, shoulder dystocia, 
Cesarean section and hypertensive diseases (Landon et al., 2009). 
Finally, the HAPO (Hyperglycemia and Adverse Pregnancy Outcome) study was conducted 
to evaluate the risks of hyperglycemia during pregnancy for the mother, the fetus and the 
newborn infant (HAPO, 2008). A total of 25,505 women were included and followed up 
prospectively to evaluate a possible association between glucose levels and maternal and 
perinatal outcome. The women were submitted to an OGTT using 75 grams of anhydrous 
glucose. 
The HAPO results were conclusive with respect to the existence of a linear association 
between elevated glucose levels in the pregnant woman and the rates of large-for-
gestational-age infants, preeclampsia and Cesarean sections. Moreover, an association was 
found between maternal hyperglycemia and neonatal hypoglycemia, C-peptide in umbilical 
cord blood, premature delivery, admission to the neonatal intensive care unit (ICU) and 
hyperbilirubinemia. No association was found between maternal hyperglycemia and 
neonatal death; however, the sample size may have been insufficient to evaluate this 
particular outcome. 
One of the most important findings of HAPO was the demonstration of an association that 
is continuous; hence no clear cut-off point can be defined above which adverse events occur 
(Leary et al., 2010). 
The choice of the 75-gram curve to investigate these women has never been validated 
scientifically. The first glucose overload to be described in pregnancy was performed using 
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100 grams of anhydrous glucose (O’Sullivan and Mahan, 1964), a procedure that was also 
recommended by the American Diabetes Association in 2004 (ADA, 2004). Nonetheless, 
since the WHO proposal in 1980 to use a 75-gram overload, as used in non-pregnant 
women, this practice became more and more common and even the HAPO study used the 
75-gram glucose overload. With the power obtained in the HAPO study showing the 
adverse perinatal effects of hyperglycemia associated with the levels obtained following a 
75-gram overload of anhydrous glucose, this test will probably increase in popularity 
compared to the 100-gram overload (Leary et al., 2010). 
Another interesting outcome of the HAPO study was the recommendation that a finding of 
only one abnormal value on the glucose curve should also be considered abnormal and 
diagnostic. This recommendation was made with the aim of increasing the likelihood of 
identifying milder degrees of hyperglycemia that had been associated with poorer maternal 
and perinatal prognosis in previous studies. 
The cut-off points recommended by IADPSG are arbitrarily defined based on an odds ratio 
of 1.75 relative to the mean glucose levels at each time-point, i.e. those measurements that 
result in a 75% greater likelihood of adverse perinatal outcomes. The selection had to be 
made in this way, since, as previously mentioned, the association between glucose levels 
and adverse outcome is continuous. These values, however, are subject to criticism and the 
occurrence of adverse outcomes with glucose levels below the proposed values is to be 
expected. Nevertheless, use of a lower cut-off point would certainly result in a greater 
percentage of diagnosed cases and the impact of this excess number of diagnoses on 
perinatal outcomes has yet to be established (Leary et al., 2010). 
The absence of any IADPSG recommendations regarding a category referred to as 
“carbohydrate intolerance” is noteworthy. According to current criteria, either a woman has 
normal glucose levels or she has gestational diabetes. However, cases need to be taken into 
consideration in which women have glucose levels outside the limits considered normal yet 
without reaching levels that would be considered diagnostic. The adoption of the term 
“carbohydrate intolerance” is suggested for such cases (Leary et al., 2010). 
The findings of the HAPO study appear to indicate that only normal glucose levels would 
eliminate the risk of adverse perinatal outcome; therefore, it could be argued that any 
deviation above normal levels should be considered abnormal (Leary et al., 2010). However, 
the economic and even the psychological impact of so many diagnoses of an “abnormal 
pregnancy” needs to be taken into consideration and may be immense. 
To determine the ideal cut-off point, a cost-benefit analysis has to be performed of different 
cut-off points. In addition to the cost of the diagnostic test itself, the financial burden caused 
by the additional cases diagnosed in terms of follow-up and treatment has to be taken into 
consideration. In addition, it has to be confirmed that treating these diagnosed cases will 
indeed lead to a reduction in the number of adverse outcomes (Leary et al., 2010) and, 
furthermore, that this reduction will cause a positive impact that will compensate for the 
costs of diagnosis and follow-up.  
The change in the diagnostic criteria defined by IADPSG will certainly have significant clinical 
implications for women and for the healthcare system. The number of women diagnosed as 
having gestational diabetes will rise. This increase in the prevalence of GD may cause a 
significant impact on all the additional women who will be diagnosed (Holt et al., 2011). In 
addition to the greater volume of resources required to follow-up and treat these women, the 
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Therefore, this change needs to be supported with convincing data showing beyond doubt 
that its adoption will improve pregnancy outcome. Since the HAPO study was merely 
observational, it is limited to associating adverse perinatal outcomes with higher glucose 
levels; however, it does not prove that normalizing glucose levels will necessarily result in 
any improvement in prognosis (Holt et al., 2011). 
Two studies evaluated the benefits of treating milder degrees of hyperglycemia in 
pregnancy: the ACHOIS study (Crowther, 2005) and the US Multicenter Randomized Trial 
for Treatment of Mild GMD (Landon, 2009). Despite promising results, it should be 
remembered that these studies differed in relation to the glucose levels considered treatable 
and in the number of glucose measurements performed for diagnosis. This hampers 
extrapolation of these results to the findings of the IADPSG study (Holt et al., 2011). 
4.3 Investigation 
The IADPSG proposal for the screening and diagnosis of GD is shown in Table 3: 
 
First prenatal consultation  
Fasting glucose level or hemoglobin A1 (HgA1) or random measurement in women 
• If clinical diabetes => treatment and follow-up for preexisting diabetes.  
• If results are non-diagnostic for clinical diabetes: 
• and fasting glucose level is > 92 and < 126 => diagnosis of GD 
• and fasting glucose level is < 92 => test at 24-28 weeks with OGTT, 75 grams. 
24 - 28 weeks of pregnancy  
OGTT, 75 grams: fasting glucose measurement/1 hour/2 hours 
• Consider clinical diabetes if fasting glucose > 126 
•  Consider GD if ONE or more measurements are above the cut-off points. 
• Consider normal if all the values are below the cut-off points. 
 
For a diagnosis of GD  (OGTT, 75g) 
Fasting glucose  > 92 mg/dl 
Glucose level at 1 hour after 
overload  
>180 mg/dl 
Glucose level at 2 hours after 
overload 
>153 mg/dl 
For a diagnosis of clinical diabetes during pregnancy (any one of these tests)  
Fasting glucose  > 126 mg/dl 
Hemoglobin A1  > 6.5% 
Random plasma glucose 
measurement 
> 200 mg/dl 
Table 3. Screening and diagnosis of GD according to the IADPSG 
It is important, however, to call attention to the fact that controversies persist, despite the 
enormous number of studies conducted in this field. Analyzing the guidelines drawn up by 
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the different organizations, it is clear that there is no consensus with respect to the quantity 
of glucose that should be used in the oral glucose tolerance test (OGTT), to the glucose levels 
that should be considered abnormal, or to the number of abnormal measurements on the 
curve that would permit a diagnosis of GD to be made (Holt et al., 2011). 
Table 4 shows the different criteria currently adopted for a diagnosis of gestational diabetes. 
 


















WHO 75g > 1 7.0mmol/l 126mg/dl  
7.8mmol/l 
140mg/dl 





ADIPS 75g > 1 5.5mmol/l 100mg/dl  
8.0mmol/l 
144mg/dl 





EASD 75g > 1 6.0mmol/l 108mg/dl  
9.0mmol/l 
162mg/dl 
NZSSD 75g > 1 5.5mmol/l 100mg/dl  
9.0mmol/l 
162mg/dl 
ADA: American Diabetes Association (until autumn 2010); ADIPS: Australasian Diabetes 
in Pregnancy Society; CDA: Canadian Diabetes Association; EASD: European Association 
for the Study of Diabetes; IADPSG: International Association of Diabetes and Pregnancy 
Study Groups; NZSSD: New Zealand Society for the Study of Diabetes; WHO: World 
Health Organization. *The ADA adopted the IAPDSG criteria in the autumn of 2010. 
Holt et al, 2011 
Table 4. Comparison of diagnostic criteria for gestational diabetes 
Until randomized clinical trials are conducted to compare the different strategies for 
screening and diagnosis and to define possible differences in maternal and perinatal 
outcome, the ideal test and the ideal criteria remain to be defined. The characteristics of each 
population should be evaluated, principally with respect to the frequency of gestational 
diabetes and macrosomia. In populations with a high risk for diabetes, we suggest that the 
IADPSG criteria be used; however, in low-risk populations in which there is no significant 
association between macrosomia and gestational diabetes, these criteria may not be 
applicable (Leary et al., 2010). 
5. Treatment of gestational diabetes 
5.1 Rationale for treatment 
Normally, the proposal of any strategy for screening and diagnosis of gestational diabetes is 
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Study Groups; NZSSD: New Zealand Society for the Study of Diabetes; WHO: World 
Health Organization. *The ADA adopted the IAPDSG criteria in the autumn of 2010. 
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Table 4. Comparison of diagnostic criteria for gestational diabetes 
Until randomized clinical trials are conducted to compare the different strategies for 
screening and diagnosis and to define possible differences in maternal and perinatal 
outcome, the ideal test and the ideal criteria remain to be defined. The characteristics of each 
population should be evaluated, principally with respect to the frequency of gestational 
diabetes and macrosomia. In populations with a high risk for diabetes, we suggest that the 
IADPSG criteria be used; however, in low-risk populations in which there is no significant 
association between macrosomia and gestational diabetes, these criteria may not be 
applicable (Leary et al., 2010). 
5. Treatment of gestational diabetes 
5.1 Rationale for treatment 
Normally, the proposal of any strategy for screening and diagnosis of gestational diabetes is 





suggests that adequate treatment successfully reduces maternal and fetal morbidity, 
particularly macrosomia (Crowther et al., 2005; Langer et al., 2005; Landon et al., 2009). 
Various therapeutic options are available such as diet, physical exercise, blood glucose 
monitoring and insulin therapy in cases in which diet alone fails to maintain adequate 
glucose levels (Pridjian and Benjamin, 2010). This chapter does not explore the details of 
each individual treatment, but simply reviews the available evidence regarding the need for 
treatment and its effectiveness. 
A systematic review in the Cochrane Library specifically deals with the various alternative 
therapeutic options for gestational diabetes (Alwan et al., 2011). Eight randomized clinical 
trials involving a total of 1,418 women were included in which any form of treatment was 
compared with routine prenatal care or different treatments were compared with each 
other. Except for one large Australian study published in 2005 that included 1,000 women 
(ACHOIS trial) (Crowther et al., 2005), the sample sizes were small in all the other studies. 
When the treatment of mild hyperglycemia was compared with routine prenatal care, a 
significant reduction was found in the risk of preeclampsia and an increase in the risk of 
induced labor in the group that received treatment. There were no differences in Cesarean 
section rates, rates of hospital admission, instrumental delivery or postpartum hemorrhage 
or in the duration of hospital stay. With respect to perinatal outcome, the treatment of 
diabetes resulted in a significant reduction in composite perinatal morbidity (death, 
shoulder dystocia, bone fracture and nerve palsy), as well as in the frequency of macrosomia 
(birthweight > 4000 grams) and shoulder dystocia. Although in the ACHOIS study the rate 
of admittance to a neonatal intensive care unit was higher for the infants of mothers who 
received treatment for hyperglycemia, in the meta-analysis this difference was not found to 
be statistically significant. There were no significant differences between the two groups 
with respect to gestational age at delivery, incidence of bone fracture in newborn infants, 
incidence of nerve palsy in the newborn, perinatal death, neonatal hypoglycemia, incidence 
of respiratory distress syndrome in the newborn infant or in the need for mechanical 
ventilation. The conclusion reached by these reviewers was that specific treatment for mild 
gestational diabetes, including diet and insulin, reduces the risk of maternal and perinatal 
morbidity; however, the risk of labor induction increases. Further studies need to be 
conducted to evaluate the effect of the different therapeutic modalities, including oral 
hypoglycemic drugs and insulin, on infant short and long-term outcomes. 
Specific analysis of the findings of the ACHOIS trial reveals a frequency of severe neonatal 
morbidity of 1% in the treated group compared to 4% in the group that received routine 
care. The incidence of neonatal admission to hospital was 71% versus 61%, respectively, 
whereas rates of labor induction were 39% in the treatment group versus 29% in the group 
receiving routine care. The rate of Cesarean sections was similar in both groups, 31% versus 
32%. In addition, lower rates of depression and better quality of life scores were found in the 
treated women in the ACHOIS trial at three months postpartum (Crowther et al., 2005). 
Another large randomized clinical trial conducted in the United States was published in 
2009 and has yet to be included in the Cochrane systematic review (Landon et al., 2009). The 
study included 958 women. There was no statistically significant difference in composite 
outcome (32.4% in the treated group and 37% in the control group) and no perinatal deaths 
occurred in either group. Nevertheless, birthweight was significantly lower in the treated 
group (3302 grams versus 3408 grams), as was the frequency of large-for-gestational-age 
infants (7.1% versus 14.5%), fetal macrosomia (5.9% versus 4.0%), shoulder dystocia (1.5% 
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versus 4.0%) and Cesarean sections (26.9% versus 33.8%). The rates of preeclampsia and 
gestational hypertension were also lower in the treated group (8.6% versus 13.6%). 
A more recent systematic review on the treatment of gestational diabetes included 18 
studies, five of which compared the specific treatment of diabetes with routine treatment 
(including the 2009 US trial). Modest effects of treatment were found, including a reduction 
in the risk of fetal macrosomia and shoulder dystocia and a trend, albeit non-significant, 
towards a reduction in the rate of Cesarean sections. Different levels and intensity of 
treatment were compared in 13 trials, with findings showing a significant reduction in risk 
only with respect to shoulder dystocia in the group receiving intensive treatment (Horvath 
et al., 2010). 
Based on the results of these more recent studies, we believe that it is important to diagnose 
and treat gestational diabetes in order to reduce maternal and neonatal morbidity. Data 
from the Hyperglycemia and Adverse Pregnancy Outcomes study (HAPO, 2008) reinforce 
this recommendation, since findings showed a significant association between increasing 
glucose levels and maternal complications such as preeclampsia, and neonatal 
complications such as macrosomia and metabolic alterations (Leary et al., 2010), leading, as 
previously discussed, to changes in the diagnostic criteria for gestational diabetes, as 
defined by the International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) (Metzger et al., 2010). Nonetheless, some criticism remains with respect to the 
comparability of the HAPO study with the more recent clinical trials, since different 
screening strategies were used (Horvath et al., 2010). 
5.2 Treatment strategies 
5.2.1 Diet 
The universal recommendation has been that all women with a confirmed diagnosis of 
gestational diabetes should receive dietary counseling and initiate an appropriate diet with 
the aim of normalizing glucose levels, preventing ketosis, ensuring adequate weight gain 
and contributing towards fetal well-being. The number of calories will depend on the 
woman’s current weight, with an allowance of 30 kcal/kg of current weight for women with 
a normal body mass index (BMI), 24 kcal/kg for overweight women and 12-15 kcal/kg for 
obese women. Carbohydrates (preferably complex carbohydrates) should correspond to 33-
40% of the total number of calories, with protein corresponding to 20% and fat to 40%, 
provided in the form of three main meals and three snacks. Moderate use of sweeteners 
such as aspartame is permitted. Following these dietary guidelines, glucose levels will 
normalize in around 75-80% of women with gestational diabetes (ADA, 2004). 
Nevertheless, the most adequate strategy for the control of gestational diabetes still remains 
to be defined, since diet alone may fail to prevent macrosomia. A systematic review 
available in the Cochrane Library included four studies with 612 women with gestational 
diabetes and failed to find any differences in the rates of macrosomia (OR = 0.78; 95%CI: 
0.45 – 1.35) or Cesarean section (Walkinshaw, 2011). However, the clinical trials included in 
this review were all small and old, with variations in quality and very wide confidence 
intervals that did not permit evaluation of the validity of dietetic therapy. The reviewers 
concluded that there is insufficient evidence to evaluate the use of primary dietetic therapy 
for women with impaired glucose metabolism in pregnancy. They recommended that larger 
studies should be conducted to evaluate the effects of diet on maternal outcome 
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Compliance with treatment and weight gain constitute factors capable of modifying 
response to dietetic treatment. One large retrospective study including more than 30,000 
women with gestational diabetes showed that in the women in whom weight gain was 
adequate maternal and perinatal outcomes were favorable, whereas those in whom weight 
gain was excessive had a higher risk of large-for-gestational-age infants, premature delivery 
and Cesarean sections (Cheng et al., 2008). 
5.2.2 Physical exercise 
Physical exercise has been proposed as part of the treatment for gestational diabetes based 
on the fact that, in adults, an improvement in physical fitness increases insulin sensitivity, 
improves glucose control and reduces the need for insulin (Colberg et al., 2010). 
A systematic review available in the Cochrane Library evaluated the effects of exercise 
programs alone or in association with other therapies on maternal and perinatal morbidity 
in pregnant women with diabetes. The review included four small, randomized clinical 
trials involving 114 women with gestational diabetes recruited during the third trimester of 
pregnancy. The intervention (exercise) was performed over six weeks. There were no 
statistically significant differences between the group that performed exercise and the 
controls for any one of the endpoints evaluated. The authors’ conclusion was that the 
evidence was insufficient to either recommend or contraindicate exercise for pregnant 
women with diabetes and that larger randomized clinical trials should be conducted to 
further evaluate this form of intervention (Ceysens et al., 2011). 
Despite the consistent lack of evidence on the effects of exercise on maternal and perinatal 
prognosis in women with gestational diabetes, the American Association of Diabetes (ADA) 
suggests a program of moderate exercise as part of the therapeutic management of women 
with gestational diabetes as long as there are no medical or obstetrical contraindications to 
this level of physical activity (ADA, 2004). 
5.2.3 Monitoring glucose levels 
Monitoring glucose levels may also alter the progression of the condition in women with 
gestational diabetes. One study showed that daily monitoring of pregnant women treated 
with diet allows identification of those who could benefit from treatment with an anti-
hyperglycemic agent, which may lead to a reduction in the rates of macrosomia (Hawkins et 
al., 2009; Hawkins, 2010). Nevertheless, the ideal frequency of self-monitoring in women 
with diet controlled gestational diabetes remains to be established and there is insufficient 
evidence regarding the ideal glucose levels and the duration of control that would allow 
longer intervals between capillary glucose measurements (Metzger, 2007). 
With respect to the timing and frequency of capillary glucose monitoring, although there are 
still some controversies between investigators, most of them currently recommend 
measuring fasting levels immediately after waking and one hour after meals. The proposal 
for self-monitoring made by some specialists is to test capillary glucose levels four times a 
day in cases of diet controlled gestational diabetes (fasting and one hour after each meal) 
and six times a day in gestational diabetes requiring the use of insulin (fasting, one hour 
prior to and one hour after each meal) (Jovanovic, 2008). 
A clinical trial comparing monitoring with schedules that involve either the measurement of 
pre-prandial glucose levels or fasting glucose and postprandial levels (one hour after meals) 
in patients with gestational diabetes using insulin therapy showed a better control of 
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glucose levels, a lower rate of large-for-gestational-age infants and a lower rate of Cesarean 
sections with the latter protocol (deVeciana et al., 1995). Comparing monitoring one hour 
postprandial with two hours postprandial, a prospective, observational study found less 
need for insulin therapy and a trend towards lower rates of fetal macrosomia and Cesarean 
sections with one-hour postprandial glucose measurements (Weisz et al., 2005). There is 
insufficient evidence to determine the role of continuous glucose monitoring in patients 
with gestational diabetes, although this may be useful in women who require insulin and 
who have difficulty in achieving adequate control of glucose levels (Hawkins, 2010). 
5.2.4 Pharmacological treatment 
5.2.4.1 Insulin therapy 
With respect to insulin therapy, there is no consensus on the glucose levels that would 
indicate that insulin should be initiated after the implementation of dietetic therapy. The 
American College of Obstetricians and Gynecologists (ACOG) suggests that insulin should 
be administered to reduce the risk of macrosomia with fasting glucose levels ≥ 95 mg% OR 
one-hour postprandial glucose levels > 130-140 mg% OR two-hour postprandial glucose 
levels ≥ 120 mg% (ACOG, 2001). There are no randomized clinical trials available in which 
different glucose levels were compared with the objective of determining the cut-off point 
for the implementation of insulin therapy. Three randomized clinical trials suggest initiating 
insulin therapy irrespective of glucose levels if ultrasonographic measurement of fetal 
abdominal circumference exceeds the 75th percentile (Bonomo et al., 2004; Kjos et al., 2001; 
Rossi et al., 2000). The doses and types of insulin will not be discussed in this chapter. 
5.2.4.2 Antihyperglycemic drugs 
Oral hypoglycemic drugs are classically contraindicated in pregnancy. First generation 
drugs such as chlorpropamide and tolbutamide cross the placental barrier and may 
potentially cause prolonged and profound states of hypoglycemia, leading to fetal 
malformation. Nevertheless, the newer hypoglycemic drugs such as glibenclamide do not 
enter fetal circulation (Langer, 2007). 
Furthermore, considering that in patients with gestational diabetes, the need for treatment 
initiates after embryogenesis (Langer, 2007), the newer oral hypoglycemic drugs were seen 
as a practical therapeutic option for this group of patients. Patient satisfaction with this 
route of administration may result in better compliance with treatment. Interest in 
evaluating these drugs as an option for the control of gestational diabetes has been intense 
and various randomized clinical trials using these agents have been published over the past 
ten years (Langer et al., 2000; Moore et al., 2010; Rowan et al., 2008). 
In 2008, a systematic review was published that included a meta-analysis of all the clinical 
trials in which the use of insulin was compared with glibenclamide in women with gestational 
diabetes. Nine clinical trials were included involving 1,382 women with gestational diabetes. 
The use of glibenclamide was not found to be associated with any increased risk of 
macrosomia nor with differences in relation to fetal weight or the frequency of large-for-
gestational-age infants, admission to the neonatal ICU or an increased risk of neonatal 
hypoglycemia. These findings suggest that there is no increased perinatal risk with the use of 
this drug; however, the effectiveness and safety of its use still need to be confirmed, since the 
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Another systematic review published by the Johns Hopkins University Evidence-Based 
Practice Center for the Agency for Healthcare Research and Quality evaluated oral 
hypoglycemic drugs in women with gestational diabetes. Nine studies were selected, four of 
which consisted of randomized clinical trials involving 1,229 participants, while five were 
observational studies involving 831 participants. Two clinical trials compared insulin with 
glibenclamide, while one compared glibenclamide with acarbose and another compared 
insulin with metformin. No statistically significant differences were found with respect to 
glycemic control, the weight of the newborn infant or in the rate of Cesarean sections when 
insulin was compared with glibenclamide. There was a greater proportion of newborn infants 
with hypoglycemia in the group that used insulin (8.1% versus 3.3%; p = 0.008). No statistically 
significant difference was found in the rate of congenital malformations when the pregnancies 
treated with insulin were compared with those treated with oral hypoglycemic drugs. The 
authors concluded that there are no substantial differences in maternal and neonatal outcomes 
between women with gestational diabetes using insulin and those using oral hypoglycemic 
drugs (glibenclamide and metformin) (Nicholson et al., 2009). 
The most recent systematic review on oral hypoglycemic drugs for the treatment of 
gestational diabetes showed no difference either in glycemic control or in the outcome of 
pregnancy when insulin was compared with hypoglycemic drugs in six randomized clinical 
trials involving a total of 1,388 pregnant women. There was no increased risk of neonatal 
hypoglycemia, macrosomia or Cesarean section, and maternal glucose levels were similar 
(Dhulkotia et al., 2010). 
Results with the use of glibenclamide for the treatment of gestational diabetes are 
encouraging and although the ADA and ACOG consensuses recommend not prescribing 
glibenclamide for women with gestational diabetes (ACOG, 2001; ADA 2004), it would 
appear that there is already sufficient and consistent evidence confirming its safety and 
effectiveness in this condition. Another issue to be evaluated with respect to glibenclamide 
is its cost, which is significantly lower compared to treatment with insulin (Melamed and 
Yogev, 2009). Nevertheless, the United States Food and Drug Administration (FDA) has not 
approved these drugs for this purpose. 
5.2.5 Obstetric treatment 
5.2.5.1 Evaluation of fetal vitality 
Randomized clinical trials have yet to be conducted to evaluate the need for antenatal 
testing or the type of antenatal tests for the assessment of fetal well-being. Nonetheless, the 
fetuses of women with gestational diabetes, depending on glycemic control, may be at an 
increased risk of macrosomia (Durnwald et al., 2011) and intrauterine death (Yogev and 
Visser, 2009), and some observational studies have reported a reduction in the risk of fetal 
loss with various protocols for evaluating vitality (Graves, 2007; Kjos et al., 2005). 
In 2001, the ACOG concluded that there is insufficient evidence to determine the ideal scheme 
for monitoring antepartum fetal vitality in women with gestational diabetes controlled by diet 
and in whom there are no additional perinatal risks (ACOG, 2001). The evaluation of fetal 
vitality in cases of gestational diabetes may include fetal biophysical profile and antepartum 
cardiotocography. Doppler blood flow measurement is not useful for evaluating fetal vitality 
in this context (Graves, 2007). The frequency with which these tests should be performed 
depends on the classification of diabetes and is not routinely recommended in cases controlled 
with diet (ACOG, 2001; Conway, 2007). In women who require insulin or antihyperglycemic 
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drugs, it has been suggested that monitoring should be performed twice weekly beginning at 
32 weeks (ACOG, 2001). The method of evaluating vitality and the periodicity of this 
evaluation, however, remains to be determined and varies in accordance with the protocol 
implemented in the service and the clinical situation (Conway, 2007). 
5.2.5.2 Screening for fetal macrosomia 
Macrosomia may be investigated by performing a single ultrasonography scan in the 36th 
week of pregnancy or by serial scans from 28 weeks onwards (Ben-Haroush et al., 2007). 
Nevertheless, the poor accuracy of ultrasonography for the prediction of fetal weight limits its 
use for this purpose (Wong et al., 2001). Based on specialist opinion, it has been suggested that 
fetal growth monitoring and the investigation of macrosomia is unnecessary in cases of 
gestational diabetes controlled by diet, principally because false-positive results may lead to 
unnecessary Cesarean sections (Melamed et al., 2010). Fetal weight estimated by 
ultrasonography would have to be ≥ 4,800 grams to have at least a 50% chance of predicting an 
infant being born with a birthweight of 4,500 kg or more (McLaren et al., 1995). 
5.2.5.3 Anticipating delivery 
Treatment of gestational diabetes may include anticipating delivery through induction or by 
elective Cesarean section. In a systematic review of the Cochrane Library, the policy of 
electively interrupting pregnancy by inducing labor in full-term diabetic women was 
evaluated (Boulvain et al., 2011). Only one study involving 200 women was included. 
Results showed that induction at 38 weeks reduced the frequency of newborn infants 
weighing > 4000 grams and above the 90th percentile, which is not surprising, since 
gestational age at delivery was lower in the induction group. This intervention, however, 
failed to reduce the risk of Cesarean section or of neonatal morbidities. Therefore, the 
authors concluded that further studies involving larger sample sizes are required in order to 
confirm the advantages of this intervention. Up to the present moment, there is insufficient 
evidence to enable this practice to be recommended. 
More recently, a systematic review including five studies (the same clinical trial included in 
the Cochrane review plus four observational studies) compared active management at term 
(induction or Cesarean section) with expectant management. The results of the randomized 
clinical trial were similar to the findings of the previous systematic review. When the four 
observational studies were analyzed, however, a potential reduction was found in the rate of 
macrosomia, of shoulder dystocia in induced deliveries and in Cesarean sections indicated 
because of fetal macrosomia. The authors concluded that active management appears to 
reduce the rates of macrosomia and its complications; however, further clinical trials are 
clearly necessary to strengthen the evidence and support clinical practice (Witkop et al., 2009). 
The ACOG suggests performing elective Cesarean sections as a means of reducing the risk of 
shoulder dystocia in cases of gestational diabetes when estimated fetal weight is ≥ 4,500 grams 
(ACOG, 2001). In diabetic pregnant women in whom estimated fetal weight is below 4,000 
grams, Cesarean section is unjustified on the basis of fetal weight alone (Hawkins and Casey, 
2007). On the other hand, the management of cases in which estimated fetal weight is between 
4,000 and 4,500 grams remains controversial. In addition to estimated fetal weight, the size of 
the mother’s pelvis and the progression of labor should also be taken into consideration when 
deciding on the type of delivery (Hawkins and Casey, 2007). It should also be noted that the 
limited accuracy of ultrasonography for adequately estimating fetal weight leads to 
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insulin with metformin. No statistically significant differences were found with respect to 
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Gestational Diabetes: Evidence-Based Screening, Diagnosis and Treatment 
 
55 
drugs, it has been suggested that monitoring should be performed twice weekly beginning at 
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weighing > 4000 grams and above the 90th percentile, which is not surprising, since 
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failed to reduce the risk of Cesarean section or of neonatal morbidities. Therefore, the 
authors concluded that further studies involving larger sample sizes are required in order to 
confirm the advantages of this intervention. Up to the present moment, there is insufficient 
evidence to enable this practice to be recommended. 
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clinical trial were similar to the findings of the previous systematic review. When the four 
observational studies were analyzed, however, a potential reduction was found in the rate of 
macrosomia, of shoulder dystocia in induced deliveries and in Cesarean sections indicated 
because of fetal macrosomia. The authors concluded that active management appears to 
reduce the rates of macrosomia and its complications; however, further clinical trials are 
clearly necessary to strengthen the evidence and support clinical practice (Witkop et al., 2009). 
The ACOG suggests performing elective Cesarean sections as a means of reducing the risk of 
shoulder dystocia in cases of gestational diabetes when estimated fetal weight is ≥ 4,500 grams 
(ACOG, 2001). In diabetic pregnant women in whom estimated fetal weight is below 4,000 
grams, Cesarean section is unjustified on the basis of fetal weight alone (Hawkins and Casey, 
2007). On the other hand, the management of cases in which estimated fetal weight is between 
4,000 and 4,500 grams remains controversial. In addition to estimated fetal weight, the size of 
the mother’s pelvis and the progression of labor should also be taken into consideration when 
deciding on the type of delivery (Hawkins and Casey, 2007). It should also be noted that the 
limited accuracy of ultrasonography for adequately estimating fetal weight leads to 





In the absence of macrosomia, specialists suggest that patients with gestational diabetes 
controlled by diet may be able to reach 40/41 weeks and recommend induction at this 
gestational age. In patients in use of insulin or oral antihyperglycemic drugs, labor should 
be induced at 39 weeks. In diabetic patients in use of insulin or those in whom glycemic 
control is poor, labor should be induced at 38 weeks and even prior to this gestational age if 
there are associated conditions such as severe preeclampsia, for example, or if fetal well-
being is compromised. There is no need for amniocentesis to evaluate fetal lung maturity in 
patients after 38 weeks of pregnancy when gestational age is well documented (Conway et 
al., 2007; Nicholson et al., 2008). 
6. Conclusions 
The most recent evidence suggests that screening for gestational diabetes is beneficial; 
however, the best screening strategy remains to be defined. Clinical trials also need to be 
conducted to compare various diagnostic tests and glucose levels; however, until these studies 
are performed, clinicians and societies have to define their own protocols for screening and 
diagnosis taking the characteristics of the population to be screened into consideration. In 
populations with a high risk for diabetes and consequently for macrosomia, a universal 
screening policy leads to a significant reduction in perinatal morbidity.  
With respect to treatment, although the Cochrane systematic review found only modest 
benefits with treatment, more recent randomized clinical trials suggest an improvement in 
perinatal outcome. Based on specialist opinion, initial dietetic therapy is recommended, 
with pharmacological treatment indicated when diet alone fails to control glucose levels. 
Despite recent evidence that treatment with antihyperglycemic drugs may represent a safe, 
reliable alternative for the pharmacological treatment of diabetes in pregnancy, the ADA 
and other guidelines continue recommending insulin therapy as standard treatment. There 
is insufficient evidence either to indicate or contraindicate exercise in women with 
gestational diabetes. 
The types of tests and the ideal frequency at which fetal well-being should be monitored are 
factors that are yet to be determined; however, they are unnecessary in cases in which 
glucose levels are controlled by diet. In addition, there is insufficient evidence to 
recommend ultrasonography for the prediction of macrosomia and scans should not be 
performed routinely for this purpose in pregnant women on dietetic therapy in whom 
glucose levels are under control. 
With respect to delivery, elective Cesarean sections are recommended by ACOG in the case 
of fetuses over 4,500 grams. In cases of gestational diabetes controlled by diet, it is possible 
to wait for spontaneous labor to occur up to a limit of 40/41 weeks. In patients in use of 
insulin or oral hypoglycemic drugs, labor should be induced at 39 weeks. In cases in which 
glucose control is poor, delivery should be anticipated at 38 weeks or earlier if fetal well-
being is compromised or there are other associated morbid conditions. 
7. References 
Aberg, A., Rydhstroem, H., Frid, A. Impaired glucose tolerance associated with adverse 
pregnancy outcome: a population-based study in southern Sweden. Am J Obstet 
Gynecol. 2001 Jan; 184:77-83. 
Alwan, N., Tuffnell, D.J., West, J. Treatments for gestational diabetes. Cochrane Database of 
Systematic Reviews. In: The Cochrane Library, Issue 04, 2011, Art. No. CD003395. 
DOI: 10.1002/14651858.CD003395.pub3 
 
Gestational Diabetes: Evidence-Based Screening, Diagnosis and Treatment 
 
57 
American College of Obstetricians and Gynecologists Committee on Practice Bulletins—
Obstetrics. ACOG Practice Bulletin. Clinical management guidelines for 
obstetrician-gynecologists. Number 30, September 2001. Gestational diabetes. 
Obstet Gynecol 2001; 98: 525-38. 
American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004 Jan; 27 
Suppl 1: S88-90. 
Ben-Haroush, A., Chen, R., Hadar, E., Hod, M., Yogev, Y. Accuracy of a single fetal weight 
estimation at 29-34 weeks in diabetic pregnancies: can it predict large-for-
gestational-age infants at term? Am J Obstet Gynecol 2007 Nov; 197:497.e1-6. 
Bonomo, M., Cetin, I., Pisoni, M.P., Faden, D., Mion, E., Taricco, E., et al. Flexible treatment 
of gestational diabetes modulated on ultrasound evaluation of intrauterine growth: 
a controlled randomized clinical trial. Diabetes Metab 2004 Jun; 30: 237-44. 
Boulvain, M., Stan, C.M., Irion, O. Elective delivery in diabetic pregnant women. Cochrane 
Database of Systematic Reviews. In: The Cochrane Library, Issue 04, 2011, Art. No. 
CD001997. DOI: 10.1002/14651858.CD001997.pub1 
Brody, S.C., Harris, R., Lohr, K. Screening for gestational diabetes: a summary of the 
evidence for the U.S. Preventive Services Task Force. Obstet Gynecol. 2003 Feb; 
101:380-92 
Buchanan, A.T., Kjos, L.S.: Gestational diabetes: Risk or myth? J Clin Endocrinol Metab 1999 
Jun; 84: 854-7. 
Carpenter, M.W., Coustan, D.R.B. Criteria for screening tests for gestational diabetes. Am J 
Obstet Gynecol 1982 Jun; 144:768-73 
Catalano, P.M. Obesity, insulin resistance, and pregnancy outcome. Reproduction. 2010 May; 
140: 365-71.  
Ceysens, G., Rouiller, D., Boulvain, M. Exercise for diabetic pregnant women. Cochrane 
Database of Systematic Reviews. In: The Cochrane Library, Issue 04, 2011, Art. No. 
CD004225. DOI: 10.1002/14651858.CD004225.pub3 
Chandler-Laney, P.C., Bush, N.C., Rouse, D.J., Mancuso, M.S., Gower, B.A. Maternal glucose 
concentration during pregnancy predicts fat and lean mass of prepubertal 
offspring. Diabetes Care. 2011 Mar; 34:741-5.  
Chauhan, S.P., Grobman, W.A., Gherman, R.A., Chauhan, V.B., Chang, G., Magann, E.F., 
Hendrix, N.W. Suspicion and treatment of the macrosomic fetus: a review. Am J 
Obstet Gynecol 2005 Aug; 193: 332-46. 
Cheng, Y.W., Chung, J.H., Kurbisch-Block, I., Inturrisi, M., Shafer, S., Caughey, A.B. 
Gestational weight gain and gestational diabetes mellitus: perinatal outcomes. 
Obstet Gynecol 2008 Nov; 112: 1015-22. 
Colberg, S.R., Sigal, R.J., Fernhall, B., Regensteiner, J.G., Blissmer, B.J., Rubin, R.R., Chasan-
Taber, L., Albright, A.L., Braun, B.; American College of Sports Medicine; American 
Diabetes Association. Exercise and type 2 diabetes: the American College of Sports 
Medicine and the American Diabetes Association: Joint Position Statement. Diabetes 
Care 2010 Dec; 33: e147-67. 
Conway, D.L. Obstetric management in gestational diabetes. Diabetes Care 2007 Jul; 30 Suppl 
2: S175-9. 
Crowther, C.A., Hiller, J.E., Moss , J.R., McPhee, A.J., Jeffries, W.S., Robinson, J.S.; Australian 
Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect 
of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 





In the absence of macrosomia, specialists suggest that patients with gestational diabetes 
controlled by diet may be able to reach 40/41 weeks and recommend induction at this 
gestational age. In patients in use of insulin or oral antihyperglycemic drugs, labor should 
be induced at 39 weeks. In diabetic patients in use of insulin or those in whom glycemic 
control is poor, labor should be induced at 38 weeks and even prior to this gestational age if 
there are associated conditions such as severe preeclampsia, for example, or if fetal well-
being is compromised. There is no need for amniocentesis to evaluate fetal lung maturity in 
patients after 38 weeks of pregnancy when gestational age is well documented (Conway et 
al., 2007; Nicholson et al., 2008). 
6. Conclusions 
The most recent evidence suggests that screening for gestational diabetes is beneficial; 
however, the best screening strategy remains to be defined. Clinical trials also need to be 
conducted to compare various diagnostic tests and glucose levels; however, until these studies 
are performed, clinicians and societies have to define their own protocols for screening and 
diagnosis taking the characteristics of the population to be screened into consideration. In 
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1. Introduction 
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance of varying 
degrees of severity with onset or first recognition during pregnancy (Metzer & Coustan, 
1998). Glucose tolerance deteriorates in human pregnancy, but about 97% to 98% of all 
pregnant women retain a normal glucose tolerance and only 2% to 3% develops GDM 
(Kuhl, 1991). However, failure to diagnose and treat GDM will result in increased morbidity 
in some pregnancies, while an aggressive approach to diagnosis and treatment may result in 
unnecessary intervention in others (Kjos & Buchanan, 1999). 
The prevalence of GDM ranges from 1% to 14% of all pregnancies, depending on the 
population studied and the diagnostic tests and criteria employed (World Health 
Organization [WHO], 1985). In a recent study by Al-Rowaily and Abolfotouh  in Riyadh, 
Saudi Arabia, the prevalence of GDM was 12.5% and 3.8% by the WHO and American 
Diabetes Association criteria respectively (Al-Rowaily & Abolfotouh, 2010). The 
appropriateness of these different diagnostic criteria has been debated (Gabir et al., 2000); 
nevertheless women meeting the definition for GDM by either set of criteria are at greater 
risk of complications than women without the diagnosis.  
The 75-g glucose load has been the international standard for the diagnosis of diabetes in 
nonpregnant adults for several decades. This oral glucose tolerance test (OGTT) identifies 
pregnant women who are at risk of pre-eclampsia and whose babies are at risk of 
macrosomia and perinatal mortality (Schmidt et al., 2001). Although the American Diabetes 
Association (ADA) still recommends a 3-h 100-g OGTT for the diagnosis of GDM, it has 
recently included in its recommendations the use of a 2-h 75-g OGTT (American Diabetes 
Association [ADA], 2000; Metzger & Coustan, 1998). 
A recent WHO panel, although in general maintaining previous diagnostic 
recommendations, now characterizes GDM as the joint category of diabetes and impaired 
glucose tolerance (fasting glucose ≥ 7.0 mmol/L or 2-h glucose ≥ 7.8mmol/L (WHO, 1999). 
At present, screening for gestational diabetes appears to be hampered by the lack of a clear 
definition, agreed diagnostic criteria and evidence to show that intervention and treatment 
for this condition leads to improved outcomes for the mother and fetus. Although fasting 
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recently included in its recommendations the use of a 2-h 75-g OGTT (American Diabetes 
Association [ADA], 2000; Metzger & Coustan, 1998). 
A recent WHO panel, although in general maintaining previous diagnostic 
recommendations, now characterizes GDM as the joint category of diabetes and impaired 
glucose tolerance (fasting glucose ≥ 7.0 mmol/L or 2-h glucose ≥ 7.8mmol/L (WHO, 1999). 
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and specificities in the literature, there also exists considerable debate about which screening 
test should be used if there is to be screening. A continuum of risk for GDM should be 
researched and risk of adverse pregnancy outcomes clarified on such a continuum. This 
would help to form the basis for diagnosis. The most appropriate strategies for screening, 
diagnosing and managing asymptomatic GDM remain controversial (Moody, 2003). 
The pregnant females who attend the antenatal clinic of King Abdulaziz Medical City at the 
National Guard Health Affairs (usually between 24-28 weeks of gestation) are prepared for 
the test by fasting for a minimum of 8 hrs. After that, a fasting sample is analyzed for 
glucose. Then, every pregnant female is subjected to the Glucose Challenge Test (GCT) by 
being given 75-g Glucose solution [named Glucola which is a chilled glucose syrup with 75-g 
of glucose  with orange flavor], and another blood sample is collected 2 hours after the drink 
(Berger et al., 2002). The diagnosis of GDM is based upon the results of both the fasting 
sample and the 2hr-glucose challenge test. 
Although GCT showed good sensitivity and specificity in a previous study (79% and 87% 
respectively), yet it has been observed that with Glucola drink, there is always a tendency for 
the pregnant female to vomit (O’Sullivan et al., 1973). This usually leads to non-compliance 
with the glucose challenge test by most of the pregnant females. Thus, the aim of the present 
study was to determine the threshold value of fasting blood sugar that suggests the pre-
diabetes status that needs further investigations including the GCT. 
2. Methods 
All pregnant females who attended the antenatal clinic of King Fahd Hospital at Riyadh 
National Guard Health Affairs during the period from July, 2005 to July, 2006 for the first 
time (n=769) constituted the target of the present study. For all respondents to the GCT 
(n=408,53.1%), all values of the fasting blood sugar were cross classified according to their 
status by the GCT, and by various cut-off points along the range of FBS values above which 
subjects may be considered having Impaired Glucose Tolerance (IGT) by the GCT(≥ 
7.8mmol/L) result. From these tabulations, the sensitivity, specificity and positive predictive 
value were computed for Fasting Blood Sugar (FBS) at each cut of point.  
The sensitivity of FBS diagnosis for the GCT diagnosis "gold standard" was determined by 
calculating how frequent the correct FBS diagnosis was made in each GCT diagnosis. The 
specificity of FBS diagnosis was determined by calculating how frequently the FBS 
diagnosis was not made when the corresponding GCT diagnosis was not present. Positive 
predictability indicated how frequently the FBS diagnosis was not made when the 
corresponding GCT diagnosis was not present. Positive predictability indicated how 
frequently the FBS diagnosis correctly reflected the GCT diagnosis. Also, the level of 
agreement between these two methods was determined at each cut-off point by the 
calculation of kappa coefficient (k). 
The Receiver Operating Characteristic (ROC) curve of a diagnostic test is a graph of the 
pairs of sensitivity and 1 minus specificity that correspond to each possible cut-off for the 
diagnostic test result (Richardson et al., 1993). This curve was used to determine the 
threshold value of FBS that correspond to the value of 7.8mmol/L by the GCT. The 
Statistical Package for the Social Sciences (SPSS) software program version 17 was used for 
all statistical analyses. 
Validity of Fasting Blood Glucose Test in Screening  




Based on the cut-off values recommended by the American Diabetic Association (ADA, 
2010) for diagnosis of GDM, the results of fasting blood sugar for 769 pregnant females 
showed that 17.2% had Impaired Fasting Tolerance (IFT) and 1.4% had provisional 
diagnosis of GDM. The corresponding results for those who responded to the GCT, are 
15.2% IGT and 1.2% provisional diagnosis of GDM (Table 1), although the results of these 
two tests were seen to be comparable, yet the agreement level, as tested by kappa, was low. 
(Table 2) 
 
% No Category 







Normal                                             [<100mg/dl(<5.6mmol/L)] 
Impaired fasting tolerance            [100-125mg/dl(5.6-6.9mmol/L)] 
Provisional diagnosis of GDM     [≥126mg/dl(7mmol/L)] 








Impaired glucose tolerance  [140-199mg/dl  (7.8-11mmol/L)] 
Provisional diagnosis of GDM  [≥ 200mg/dl ( 11.1mmol/L)] 
Table 1. Distribution of pregnant females according to their results of fasting blood glucose 
and glucose challenge tests based on the ADA classification (ADA, 2010). 
 
Glucose Challenge Test 
Fasting Blood Glucose Provisional GDM IGT Normal 
No.           % No. % No. % 
3            0.9 
2            2.7 
-         - 
47        14.3 
14        18.7 
1          25.0 
279            84.8 
59              78.7 




K = 0.054, p=0.25 
Table 2. Association between the results of Fasting blood sugar and Glucose challenge test 
among pregnant females at the National Guard Hospital. 
Figure 1 shows the scatter plot for the values and the correlation between the values 
obtained by the fasting blood glucose and those obtained by the 2hr-glucose challenge test. 
The correlation coefficient (r) was 0.25 (t-value = 5.24, p<0.0001) indicating a highly 
significant direct correlation between the values of blood sugar by the two methods. The 
linear regression equation was: y= 0.66 x + 2.98, where y is the result of the glucose 
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Based on the cut-off values recommended by the American Diabetic Association (ADA, 
2010) for diagnosis of GDM, the results of fasting blood sugar for 769 pregnant females 
showed that 17.2% had Impaired Fasting Tolerance (IFT) and 1.4% had provisional 
diagnosis of GDM. The corresponding results for those who responded to the GCT, are 
15.2% IGT and 1.2% provisional diagnosis of GDM (Table 1), although the results of these 
two tests were seen to be comparable, yet the agreement level, as tested by kappa, was low. 
(Table 2) 
 
% No Category 







Normal                                             [<100mg/dl(<5.6mmol/L)] 
Impaired fasting tolerance            [100-125mg/dl(5.6-6.9mmol/L)] 
Provisional diagnosis of GDM     [≥126mg/dl(7mmol/L)] 








Impaired glucose tolerance  [140-199mg/dl  (7.8-11mmol/L)] 
Provisional diagnosis of GDM  [≥ 200mg/dl ( 11.1mmol/L)] 
Table 1. Distribution of pregnant females according to their results of fasting blood glucose 
and glucose challenge tests based on the ADA classification (ADA, 2010). 
 
Glucose Challenge Test 
Fasting Blood Glucose Provisional GDM IGT Normal 
No.           % No. % No. % 
3            0.9 
2            2.7 
-         - 
47        14.3 
14        18.7 
1          25.0 
279            84.8 
59              78.7 




K = 0.054, p=0.25 
Table 2. Association between the results of Fasting blood sugar and Glucose challenge test 
among pregnant females at the National Guard Hospital. 
Figure 1 shows the scatter plot for the values and the correlation between the values 
obtained by the fasting blood glucose and those obtained by the 2hr-glucose challenge test. 
The correlation coefficient (r) was 0.25 (t-value = 5.24, p<0.0001) indicating a highly 
significant direct correlation between the values of blood sugar by the two methods. The 
linear regression equation was: y= 0.66 x + 2.98, where y is the result of the glucose 

































Fig. 1. Correlation between fasting blood glucose and 75g-2hr glucose challenge test. Solid 
line represents the linear regression line (y= 0.66 x + 2.98) 
Table 3 shows an example for the measurements of all terms used in evaluating the fasting 
blood glucose test based on the studied data. In this example, a measurement of 
≥5.1mmol/L by the fasting blood glucose test was considered a cut-off point at which 
subjects having that measurement or above was labeled to have pre-diabetes status by the 
FBS test result. At this particular cut-off level, it is noted that the sensitivity of the test was 
0.64, specificity was 0.53 and the false positive rate (1– specificity) was 0.21. 
 
True Pre-diabetic by 
GCT 
FBS test result 
Row total ≥5.1 mmol/L 
(Pre-diabetic) 
< 5.1 mmol/L 
(non-prediabetic) 
Pre-diabetic–yes 
(≥7.8mmol/L) 43 24 67 
Pre-diabetic - no 
(<7.8mmol/L) 161 180 341 
Column total 204 204 408 
Sensitivity = 43/67 = 0.64   Specificity = 180/341 = 0.53 
Positive predictive value = 43/204 = 0.21 False positive rate= 1 – specificity = 1 – 0.53   = 0.47 
Table 3. 2x2 classification of 408 pregnant females by "true pre-diabetes” status and by a cut-
off point ≥5.1 mmol/L for the fasting blood glucose test as one diagnostic criterion.  
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Computations for sensitivity and specificity were made for all cut-off levels along the range 
of values of the fasting blood glucose test. The resulting values for sensitivity were plotted 
against the corresponding values of (1 – specificity) to obtain the receiver operating 















Fig. 2. Receiver operating characteristic curve of fasting blood glucose measurements at the 
value of 7.8mmol/L for the glucose challenge test. The optimal threshold value of 
5.1mmol/L for fasting blood glucose test is marked with the arrow. 
As mentioned earlier, the point on the curve that was closest to the upper left hand corner 
would be the optimum trade-off level for the test. The figure shows that point 
corresponding to ≥5.1 mmol/L. At this cut-off level, the test had a sensitivity = 0.64 and a 
specificity = 0.53. The computed positive predictive value was 0.21. Thus, at this cut-off 
level, the test correctly diagnosed 64% of the true pre-diabetics, missed 36% of these pre-
diabetics, but misclassified 47% of normal ( of low risk for GDM) pregnant females as pre-
diabetics (false positives). The Area Under the Curve was reasonable (AUC=0.60). At this 
cut-off level, the level of agreement between the fasting blood glucose levels and those of 
glucose challenge test, as calculated by kappa coefficient is significant (k=0.093, p=0.011).  If 
the sensitivity is to be increased, the cut-off level should be lowered, but it will be at the 
expense of specificity. For example, at a cut of 4.7 mmol/L ( 85mg/dl) only 16% of the true 
pre-diabetics would be misclassified as normal, but on the other hand, 80% of normal 
females would be misclassified as pre-diabetics( false positives).  
4. Discussion 
GDM is an asymptomatic condition most of the time, and effectiveness of its detection has 
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diagnosis of GDM, 17.2% of the studied pregnant females had impaired fasting tolerance 
(IFT) and 1.4% had provisional diagnosis of GDM. The corresponding results for those who 
responded to the GCT are 15.2% IGT and 1.2% provisional diagnosis of GDM. These figures 
are suggestive of the necessity for screening for GDM in our community. They are 
comparable with the figures of other nearby countries (Al-Mahroos et al., 2005), but still 
higher than those of the western countries (Naylor et al., 1996; Tsutomu et al., 2002). 
Diagnostic levels for GDM remain uncertain. The guidelines present a confusing picture as 
regards screening tests for GDM. The use of a 4.7 mmol/L (85mg/dl) cut-off for fasting plasma 
glucose is suggested by some researchers, but others have suggested higher cut-offs (IDF, 
2006). Fasting glucose may not be the most appropriate measure however, and the 75g glucose 
challenge test advocated by the WHO is increasingly used internationally (IDF, 2006). 
The aim of the present study was to determine the threshold value of fasting blood glucose 
for which further testing by the 2hr-glucose challenge test is needed to confirm the pre-
diabetic status among pregnant females attending the antenatal clinics of the King Fahd 
hospital at the National Guard in Riyadh city, Saudi Arabia.. Of all pregnant females 
subjected to the fasting blood glucose testing ( n=769), only 408 subjects (53%) complied 
with the 2hr-glucose challenge test, a finding that may reflect the need for specifying the 
feasible indication for such GCT, so as not to subject all females for an unnecessary as well 
as unacceptable  test.  
The figures of the pre-diabetes by both the fasting blood glucose test (17.2%) and the GCT 
(15.2%) are nearly comparable, based on the cut-off points recommended by the American 
Diabetic Association (ADA, 2010). Correlation between the individual values of fasting 
blood glucose testing and those of 2hr-glucose challenge testing was highly significant 
(r=0.25,p<0.0001).However, the agreement between the categorical results of both tests ( in 
terms of pre-diabetes, provisional GDM, and normal) was low as calculated by the kappa 
coefficient (k=0.054,p=0.25). This finding reflect the fact that the cut-off value of 5.6mmol/L 
for fasting blood glucose test is not the threshold value for the pre-diabetes status, especially 
when we see that out of those with impaired fasting test, only 18.7 were found with IGT by 
the GCT. (Table 2)  
Thus, this suboptimal accuracy of the cut-off level of 5.6mmol/L will result in the 
misclassification of subjects. To overcome this problem to a great extent, the receiver 
operating characteristic curve analysis was used to determine the threshold value of fasting 
blood glucose. Based on the previously reported high sensitivity and specificity of the GCT 
(O’Sullivan et al., 1973), it was considered as a gold standard (in detection of the pre-diabetic 
status) against which to test the validity of different values of fasting blood glucose test.  The 
levels of sensitivity and specificity found in this study for the cut-off value of 5.1mmol/L for 
fasting blood glucose (64% and 53%) might not  suggest the use of this test, especially that in 
Brazil, examining a range of thresholds, maximum sensitivity (88%) and specificity (78%) 
was found at 4.9mmol/L (O’Sullivan et al., 1973).   
However, in the present study, at this cut-off level of 4.9mmol/L, in spite of the high 
sensitivity (82%), very low and unacceptable specificity (24%) was attained. Thus, the cut-off 
level of 5.1mmol/L could be potentially useful. At this level, of all pregnant females subjected 
to the fasting blood glucose test, only 50% would be tested by the GCT. This may result in 
better compliance to the GCT. Moreover, if women with clinical characteristics consistent with 
a high risk of GDM (marked obesity, personal history of GDM, glycosuria, or a strong family 
history of diabetes) would be considered as the target group for screening (ADA, 2006 & 
Validity of Fasting Blood Glucose Test in Screening  
for the Pre-Diabetes State Among Pregnant Females 
 
67 
Dornhorst  and Rossi, 1998), this perhaps will increase the validity of the fasting blood glucose 
threshold value of 5.1mmol/L. 
5. Conclusion 
From the collective findings of this study, and considering its limitations in terms of testing 
the validity of fasting blood glucose in defining the pre-diabetics and not the diabetics, it is 
concluded that the results may be considered preliminary and suggestive for potential 
validity of advantage of fasting blood glucose test at the specified cut-off point. This strategy 
allowed 50% of the study population to avoid the glucose challenge test altogether without 
compromising detection rates. Women with a cut-off value of fasting blood glucose below 
the threshold of 5.1mmol/L may not need to be subjected to further testing by the GCT. 
Also, a special consideration to women with high risk for GDM will improve the validity of 
this threshold, and thus, the unnecessary GCT will be avoided. 
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1. Introduction 
Diabetes is a metabolic disorder of fat, carbohydrate, and protein metabolism, characterized 
by resistance to the action of insulin, insufficient insulin secretion, or both. The two major 
classifications of diabetes mellitus (DM) are type 1 (insulin deficient) and type 2 (combined 
insulin resistance and relative deficiency in insulin secretion). They differ in clinical 
presentation, onset, etiology, and progression of disease. Two to five percent of pregnancies 
are complicated by diabetes, of which 90% are classified as gestational diabetes mellitus 
(GD) (Satman et al, 2002). GD is defined as glucose intolerance of variable severity which is 
first recognized during pregnancy, including individuals with previously undiagnosed 
diabetes as well as those in whom high glucose levels are provoked by pregnancy. This term 
should not be used for gravid women with previously diagnosed diabetes. GD has much in 
common with type 2 diabetes with similar genetic susceptibility, corresponding prevalence 
within a given population or ethnic group and similar risk factors. Both conditions can be 
considered as a mixture of insulin resistance (IR) and impaired insulin secretion. Indeed, GD 
is a predictor of future type 2 diabetes with a cumulative incidence of about 50% at 5 years. 
GD is also a predictor of the metabolic (resistance) syndrome and should probably be 
considered a cardiovascular risk factor for later life. Since its first description in the early 
1950s, GD has been one of the most controversial syndromes in the field of diabetes. 
Pregnancy is a state of insulin resistance, characterized by raised circulating insulin 
concentrations as the maternal pancreas compensates for increased peripheral demands. If 
adequate compensation does not occur, GD develops. GD is a well-established risk factor for 
adverse infant health outcomes, including fetal macrosomia, birth trauma, neonatal 
hypoglycemia, and fetal death (Cetin et al., 1997). GD can predict that the children of 
women who have GD are at an increased risk for obesity, glucose intolerance, and diabetes 
during adulthood. There is still confusion about the type of diagnostic tests and diagnostic 
criteria for GD and a screening protocol (e.g. universal versus selective screening). 
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1. Introduction 
Diabetes is a metabolic disorder of fat, carbohydrate, and protein metabolism, characterized 
by resistance to the action of insulin, insufficient insulin secretion, or both. The two major 
classifications of diabetes mellitus (DM) are type 1 (insulin deficient) and type 2 (combined 
insulin resistance and relative deficiency in insulin secretion). They differ in clinical 
presentation, onset, etiology, and progression of disease. Two to five percent of pregnancies 
are complicated by diabetes, of which 90% are classified as gestational diabetes mellitus 
(GD) (Satman et al, 2002). GD is defined as glucose intolerance of variable severity which is 
first recognized during pregnancy, including individuals with previously undiagnosed 
diabetes as well as those in whom high glucose levels are provoked by pregnancy. This term 
should not be used for gravid women with previously diagnosed diabetes. GD has much in 
common with type 2 diabetes with similar genetic susceptibility, corresponding prevalence 
within a given population or ethnic group and similar risk factors. Both conditions can be 
considered as a mixture of insulin resistance (IR) and impaired insulin secretion. Indeed, GD 
is a predictor of future type 2 diabetes with a cumulative incidence of about 50% at 5 years. 
GD is also a predictor of the metabolic (resistance) syndrome and should probably be 
considered a cardiovascular risk factor for later life. Since its first description in the early 
1950s, GD has been one of the most controversial syndromes in the field of diabetes. 
Pregnancy is a state of insulin resistance, characterized by raised circulating insulin 
concentrations as the maternal pancreas compensates for increased peripheral demands. If 
adequate compensation does not occur, GD develops. GD is a well-established risk factor for 
adverse infant health outcomes, including fetal macrosomia, birth trauma, neonatal 
hypoglycemia, and fetal death (Cetin et al., 1997). GD can predict that the children of 
women who have GD are at an increased risk for obesity, glucose intolerance, and diabetes 
during adulthood. There is still confusion about the type of diagnostic tests and diagnostic 
criteria for GD and a screening protocol (e.g. universal versus selective screening). 





population and diagnostic tests that are used and ranges from mild degrees of 
hyperglycemia to insulin-dependent diabetes (Kim et al., 2007). 
Gestational diabetes usually manifests in the latter half of pregnancy and is characterized by 
insulin levels that are insufficient to meet insulin demands.  
2. Risk factors for GD  
Risk factors for GD include obesity, family history of diabetes, age greater than 35 years of 
age, pre-diabetes detected before pregnancy, previous delivery of babies with birth weights 
greater than 4 kg, sedentary lifestyles and some ethnical groups. The frequency of GD 
significantly increases with increasing number of risk factors. However, even a combination 
of risk factors does not reliably predict the likelihood of developing GD, missing up to 50% 
of cases in population based studies (Fraser & Heller, 2007;  Jang et al., 2003) estimates that if 
age > 30 years, obesity (BMI > 27.3), family history of diabetes mellitus and glycosuria in the 
present pregnancy were included as risk factors, 56.5% of the total population had risk 
factors for GD. However, in the stated report, the prevalence of GD in Korea was 2.0%, 
Thailand - 2.0% and U.S. Caucasians - 2.3%. One large study of women with GD showed 
that an increased incidence of GD was associated with age over 35, thin or obese 
prepregnancy weight, previous stillbirth, previous spontaneous or induced abortion, 
previous low- or high-birth-weight infant and chronic hypertension (Johnstone, 1999; 
Hossein-Nezhad et al., 2007) found the age distribution and GD prevalence in 15–24 age 
group was 0.39% and 2.68% in the 35–45 age group. The authors reported 33.33% of women 
with GD who had a positive family history of diabetes, compared with 10.3% of women in 
the normal group (p < 0.0001). It is now well established that women with a family history 
of diabetes had three times higher odds for GD than women without a family history of 
diabetes. Perhaps other maternal health and lifestyle behaviors, such as levels of physical 
activity, or selective immigration, could play an important role (Scholl et al., 2002). 
Obesity in pregnancy is increasing worldwide and is associated with increased risk of 
adverse outcomes for both mother and child. Maternal obesity is also accompanied by 
alterations in glucose metabolism and by perturbations in inflammatory markers, 
adipokines and vascular dysfunction. The link between obesity and IR has been recognised 
for many years and much of this association has been attributed to disturbances in 
adipocyte function and metabolism (Huda et al. 2010). Obesity has considerable effects on 
glucose metabolism in pregnancy with a loss of the reduction in fasting glucose in early 
pregnancy and significant enhancement of peripheral and hepatic IR. All women increase 
maternal fat stores in early pregnancy irrespective of prepregnancy adiposity to meet the 
feto-placental and maternal demands of late gestation and lactation. Normal pregnancy is 
associated with marked changes in glucose metabolism and IR to facilitate provision of fuel 
substrate for the fetus. In early pregnancy insulin secretion increases, while insulin 
sensitivity is unchanged, or even slightly improved. However, as pregnancy progresses, 
insulin-mediated glucose utilization worsens by 40–60% and insulin secretion increases 
several fold in order to maintain euglycaemia in the mother. The mechanisms for this 
increased risk are multifactorial and include effects on insulin signalling similar to those 
seen in obese non-pregnant women. Women of normal weight gain around 3.8 kg of fat 
during pregnancy although there is substantial variation. In women of normal weight the 
majority of fat is accumulated centrally in the subcutaneous compartment of the trunk and 
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upper thigh. A large population-based Swedish study highlighted that an increase in BMI of 
3 kg/m2 between two consecutive pregnancies resulted in an increased risk of pre-
eclampsia, GD, gestational hypertension, caesarean delivery, stillbirth and large for 
gestation age births even if a woman has a healthy BMI during pregnancy. (Villamor & 
Cnattingius, 2006; Hossein-Nezhad et al, 2007) It reported 35% prevalence of obesity (BMI of 
more than 27) in women with GD, compared with 11.3% in normal women (p < 0.0001). Not 
only weight gained during pregnancy, but  variations in body habitus or constitution, like 
high waist-hip ratios, short stature and higher body fat percentages at given BMI levels 
could contribute as a risk factors (Davis, 2008; Mensing et al., 2002; Scholl et al., 2002)  Not 
surprisingly, obese women are 4 times more likely and severely obese women almost 9 
times more likely to develop GD than lean women. 
Pregnancy is also characterised by marked increases in plasma lipid concentrations as 
gestation advances. Plasma cholesterol and triglyceride concentrations rise by 25–50% and 
200–400% respectively. The hyperlipidaemia of pregnancy is exaggerated further in obesity 
with higher serum triglyceride and very low density lipoprotein (LDL) cholesterol 
concentrations than those observed in lean women. This is seen together with lower high 
density lipoprotein (HDL) cholesterol, although LDL cholesterol and total cholesterol 
concentrations appear similar. This pattern of dyslipidaemia is similar to that of the 
metabolic syndrome in the non-pregnant population. Some of these pathways may well 
contribute to vascular and metabolic complications in obese pregnancy.  
It is well established that people with high levels of visceral or intra-abdominal body fat are 
associated with increased risk for type 2 diabetes (Huxley et al., 2008) and impaired glucose 
tolerance even after adjustment for BMI. Recent evidence suggests that even modest fasting 
hyperglycaemia (between 4.2 and 5.6 mmol/L), currently thought to be within normal 
limits, is linearly associated with adverse pregnancy outcomes including increased birth 
weight, caesarean delivery and neonatal hypoglycaemia (Huda et al, 2010). Women with a 
history of GD are metabolically vulnerable with insufficient ß-cell reserve, and many are IR. 
Approximately 17-63% of women who are diagnosed with GD during pregnancy will 
develop it in future pregnancies, and are at a much greater risk of developing type 2 
diabetes within 5-16 years. The risk varies with the magnitude of insulin resistance, for 
example, if the patient needed insulin in pregnancy or was noted to be obese, or developed 
GD before 24 weeks gestation, the risk is greater. There is also some evidence that further 
pregnancies accelerate the rate of decline of beta cell function in women with GD. Several 
studies have reported links between GD and the subsequent risk of type 2 diabetes. Recent 
meta-analysis reports that GD corresponds to a 7.4 fold increased risk for developing type 2 
diabetes mellitus (Bellamy et al., 2009). In addition, numerous studies have reported an 
increased risk of GD in women who are overweight or obese compared with lean or normal-
weight women (Chatzi et al., 2009). GD identifies pregnancies at increased risk for adverse 
perinatal outcome. It also identifies mothers who are at increased risk of developing type 2 
DM in the future and offers the possibility of interventions and early detection. Severity of 
glucose intolerance during pregnancy, insulin requirement during pregnancy, earlier 
diagnosis during pregnancy, family history of diabetes, recurrence of GD, increasing parity, 
maternal age, prepregnancy obesity, weight gain during and after pregnancy, presence of 
islet cell antibodies, and delivery of a macrosomic infant were reportedly the key risk factors 
for type 2 DM in women with history of GD (Cho et al., 2006). One of the major 
determinants of the risk for the development of subsequent type 2 diabetes is ethnic origin. 





population and diagnostic tests that are used and ranges from mild degrees of 
hyperglycemia to insulin-dependent diabetes (Kim et al., 2007). 
Gestational diabetes usually manifests in the latter half of pregnancy and is characterized by 
insulin levels that are insufficient to meet insulin demands.  
2. Risk factors for GD  
Risk factors for GD include obesity, family history of diabetes, age greater than 35 years of 
age, pre-diabetes detected before pregnancy, previous delivery of babies with birth weights 
greater than 4 kg, sedentary lifestyles and some ethnical groups. The frequency of GD 
significantly increases with increasing number of risk factors. However, even a combination 
of risk factors does not reliably predict the likelihood of developing GD, missing up to 50% 
of cases in population based studies (Fraser & Heller, 2007;  Jang et al., 2003) estimates that if 
age > 30 years, obesity (BMI > 27.3), family history of diabetes mellitus and glycosuria in the 
present pregnancy were included as risk factors, 56.5% of the total population had risk 
factors for GD. However, in the stated report, the prevalence of GD in Korea was 2.0%, 
Thailand - 2.0% and U.S. Caucasians - 2.3%. One large study of women with GD showed 
that an increased incidence of GD was associated with age over 35, thin or obese 
prepregnancy weight, previous stillbirth, previous spontaneous or induced abortion, 
previous low- or high-birth-weight infant and chronic hypertension (Johnstone, 1999; 
Hossein-Nezhad et al., 2007) found the age distribution and GD prevalence in 15–24 age 
group was 0.39% and 2.68% in the 35–45 age group. The authors reported 33.33% of women 
with GD who had a positive family history of diabetes, compared with 10.3% of women in 
the normal group (p < 0.0001). It is now well established that women with a family history 
of diabetes had three times higher odds for GD than women without a family history of 
diabetes. Perhaps other maternal health and lifestyle behaviors, such as levels of physical 
activity, or selective immigration, could play an important role (Scholl et al., 2002). 
Obesity in pregnancy is increasing worldwide and is associated with increased risk of 
adverse outcomes for both mother and child. Maternal obesity is also accompanied by 
alterations in glucose metabolism and by perturbations in inflammatory markers, 
adipokines and vascular dysfunction. The link between obesity and IR has been recognised 
for many years and much of this association has been attributed to disturbances in 
adipocyte function and metabolism (Huda et al. 2010). Obesity has considerable effects on 
glucose metabolism in pregnancy with a loss of the reduction in fasting glucose in early 
pregnancy and significant enhancement of peripheral and hepatic IR. All women increase 
maternal fat stores in early pregnancy irrespective of prepregnancy adiposity to meet the 
feto-placental and maternal demands of late gestation and lactation. Normal pregnancy is 
associated with marked changes in glucose metabolism and IR to facilitate provision of fuel 
substrate for the fetus. In early pregnancy insulin secretion increases, while insulin 
sensitivity is unchanged, or even slightly improved. However, as pregnancy progresses, 
insulin-mediated glucose utilization worsens by 40–60% and insulin secretion increases 
several fold in order to maintain euglycaemia in the mother. The mechanisms for this 
increased risk are multifactorial and include effects on insulin signalling similar to those 
seen in obese non-pregnant women. Women of normal weight gain around 3.8 kg of fat 
during pregnancy although there is substantial variation. In women of normal weight the 
majority of fat is accumulated centrally in the subcutaneous compartment of the trunk and 
Prevalence and Risk Factors for the Development of GD in Some Eastern European  
Countries – Tendencies and Pharmacoeconomical Assessment for the Choice of Treatment 
 
71 
upper thigh. A large population-based Swedish study highlighted that an increase in BMI of 
3 kg/m2 between two consecutive pregnancies resulted in an increased risk of pre-
eclampsia, GD, gestational hypertension, caesarean delivery, stillbirth and large for 
gestation age births even if a woman has a healthy BMI during pregnancy. (Villamor & 
Cnattingius, 2006; Hossein-Nezhad et al, 2007) It reported 35% prevalence of obesity (BMI of 
more than 27) in women with GD, compared with 11.3% in normal women (p < 0.0001). Not 
only weight gained during pregnancy, but  variations in body habitus or constitution, like 
high waist-hip ratios, short stature and higher body fat percentages at given BMI levels 
could contribute as a risk factors (Davis, 2008; Mensing et al., 2002; Scholl et al., 2002)  Not 
surprisingly, obese women are 4 times more likely and severely obese women almost 9 
times more likely to develop GD than lean women. 
Pregnancy is also characterised by marked increases in plasma lipid concentrations as 
gestation advances. Plasma cholesterol and triglyceride concentrations rise by 25–50% and 
200–400% respectively. The hyperlipidaemia of pregnancy is exaggerated further in obesity 
with higher serum triglyceride and very low density lipoprotein (LDL) cholesterol 
concentrations than those observed in lean women. This is seen together with lower high 
density lipoprotein (HDL) cholesterol, although LDL cholesterol and total cholesterol 
concentrations appear similar. This pattern of dyslipidaemia is similar to that of the 
metabolic syndrome in the non-pregnant population. Some of these pathways may well 
contribute to vascular and metabolic complications in obese pregnancy.  
It is well established that people with high levels of visceral or intra-abdominal body fat are 
associated with increased risk for type 2 diabetes (Huxley et al., 2008) and impaired glucose 
tolerance even after adjustment for BMI. Recent evidence suggests that even modest fasting 
hyperglycaemia (between 4.2 and 5.6 mmol/L), currently thought to be within normal 
limits, is linearly associated with adverse pregnancy outcomes including increased birth 
weight, caesarean delivery and neonatal hypoglycaemia (Huda et al, 2010). Women with a 
history of GD are metabolically vulnerable with insufficient ß-cell reserve, and many are IR. 
Approximately 17-63% of women who are diagnosed with GD during pregnancy will 
develop it in future pregnancies, and are at a much greater risk of developing type 2 
diabetes within 5-16 years. The risk varies with the magnitude of insulin resistance, for 
example, if the patient needed insulin in pregnancy or was noted to be obese, or developed 
GD before 24 weeks gestation, the risk is greater. There is also some evidence that further 
pregnancies accelerate the rate of decline of beta cell function in women with GD. Several 
studies have reported links between GD and the subsequent risk of type 2 diabetes. Recent 
meta-analysis reports that GD corresponds to a 7.4 fold increased risk for developing type 2 
diabetes mellitus (Bellamy et al., 2009). In addition, numerous studies have reported an 
increased risk of GD in women who are overweight or obese compared with lean or normal-
weight women (Chatzi et al., 2009). GD identifies pregnancies at increased risk for adverse 
perinatal outcome. It also identifies mothers who are at increased risk of developing type 2 
DM in the future and offers the possibility of interventions and early detection. Severity of 
glucose intolerance during pregnancy, insulin requirement during pregnancy, earlier 
diagnosis during pregnancy, family history of diabetes, recurrence of GD, increasing parity, 
maternal age, prepregnancy obesity, weight gain during and after pregnancy, presence of 
islet cell antibodies, and delivery of a macrosomic infant were reportedly the key risk factors 
for type 2 DM in women with history of GD (Cho et al., 2006). One of the major 
determinants of the risk for the development of subsequent type 2 diabetes is ethnic origin. 





South or East Asian, Pacific Islands or Indigenous Australian. Women with previous GD 
have a higher prevalence of polycystic ovary syndrome (PCOS), which is a condition 
associated with IR. Similarly in a study of women with PCOS, GD developed in 20% of these 
women compared with only 9% of controls with an odds ratio of 1.9. Women with PCOS 
often attend assisted fertility clinics and should be warned of the likelihood of developing 
GD if they become pregnant (Hyer & Shehata, 2005; Metzger et al., 2010).  
Maternal diabetes during pregnancy exposes the fetus to hyperglycemia resulting in 
increased fetal insulin levels, which are associated with increased birth weight, increased 
childhood and adult obesity, and increased risk of GD and type-2 diabetes during 
childbearing age (Kim et al., 2007). 
Perinatal and maternal morbidity can be reduced by maintaining normoglycaemia in GD. 
To achieve good glycaemic control, women diagnosed with GD should monitor their blood 
glucose levels, exercise, and undergo nutrition counselling. Besides, medical treatment 
options should be incorporated in care plans. However, despite intensive treatment aiming 
at near normoglycemia, a surprisingly high risk of macrosomia and birth trauma has been 
reported among the neonates of mothers with GD. It would seem that the prevention of 
macrosomia should be the primary goal of GD management. Several studies suggest an 
increased rate of preeclampsia among women with GD, and a combination of maternal 
diabetes and pre-eclampsia is associated with poor perinatal outcome (Fan et al., 2006). 
Untreated or poorly controlled gestational diabetes can hurt the baby. It can raise the risk of 
certain pregnancy complications, like high blood pressure in the mother and having a 
larger-than-normal baby (macrosomia), which may require a C-section. Studies have shown 
that in GD the frequency of having an overweight baby is almost double, the frequency of 
having preeclampsia is almost double, and the frequency of early delivery is 40 percent 
greater. It was proven that the proper identification and management of GD are associated 
with a decrease in mortality and morbidity in infants.  
3. Testing programs 
GD is associated with maternal (pre-eclampsia, hypertension, caesarean section) and foetal 
morbidity (macrosomia, birth trauma, hypoglycaemia, hyperbilirubinemia, hypocalcemia, 
respiratory distress syndrome). Moreover, GD uncovers a pre-existing metabolic 
abnormality that may precede the development of overt diabetes mellitus. Therefore, 
prompt diagnosis of GD is essential to reduce maternal and foetal morbidity and to allow 
subsequent attempt at preventing or delaying the onset of Type 2 diabetes.  
Whether or not to screen for gestational diabetes is an issue of significant controversy. The 
ADA favors screening a woman who has risk factors for developing GD (e.g., severe obesity, 
personal history of GD or previous delivery of large-for-gestational age infant, glycosuria, 
PCOS or a strong family history of diabetes) at her first prenatal visit (American Diabetes 
Association [ADA], 2011). If test is abnormal, these individuals should be considered to 
have "overt" (not gestational) diabetes (ADA, 2010). If this screen is normal, testing should 
be repeated between weeks 24 and 28 of gestation. Pregnant women without these risk 
factors should undergo screening for GD between weeks 24 and 28 of gestation unless they 
are considered low risk. To be low risk, a woman must fulfill all the following criteria:  
 age younger than 25 years,  
 normal prepregnancy weight,  
 no known diabetes in first-degree relatives,  
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 not a member of an ethnic group with a high prevalence of GD,  
 no history of abnormal glucose tolerance,  
 no history of abnormal obstetric outcome. 
Screening for GD utilizes the oral glucose challenge test. New ADA guidelines (ADA, 2011) 
and WHO guidelines stated to perform a 75 g oral glucose tolerance test (OGTT), with 
plasma glucose measurement fasting and at 1 and 2 h at 24-28 weeks. OGTT should be 
performed in the morning after an overnight fast of at least 10 hours and after at least 3 days 
of unrestricted diet and unlimited physical activity. The patient should remain seated and 
should not smoke during the test (Johnstone, 1999). Criteria for diagnosis of GD based on 
the OGTT are summarized in Table 1. Two or more values must be met or exceeded for a 
diagnosis of diabetes to be made.  
 
Fasting ≥ 92 mg/dL (5.1 mmol/L) 
1 hour ≥ 180 mg/dL (10.0 mmol/L) 
2 hours ≥ 153 mg/dL (8.5 mmol/L) 
Table 1. Diagnosis of GD with a 75 g Glucose Load 
Results of the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study (Metzger et 
al., 2008), a large-scale (~25,000 pregnant women) multinational epidemiologic study, 
demonstrated that risk of adverse maternal, fetal, and neonatal outcomes continuously 
increased as a function of maternal glycemia at 24–28 weeks, even within ranges previously 
considered normal for pregnancy. For most complications there was no threshold for risk. 
These results have led to careful reconsideration of the diagnostic criteria for GD. The 
International Association of Diabetes and Pregnancy Study Groups (IADPSG) 
recommended that all women not known to have prior diabetes undergo a 75 g OGTT at 24–
28 weeks of gestation. This probably will significantly increase the prevalence of GD, 
however there is mounting evidence that treating even mild GD reduces morbidity for both 
mother and baby (International Diabetes Federation [IDF], 2004). Women at high risk should 
be screened as soon as feasible. If the initial screening is negative they should undergo 
retesting at 24 to 28 weeks’ gestation. 
There are two principles (selective and universal) in testing which need to be distinguished. 
First, there is selective (or at-risk) clinical need for high risk patient (obesity, a family history 
of diabetes, a history of macrosomic stillbirth, etc.). Second, there is universal screening, for 
women not clinically identified as being at particular risk. Universal screening is more 
sensitive, while selective screening is less costly. Unfortunately, the use of risk factors for 
individuals is not very effective, can result in great inconsistencies, and is a source of 
uncertainty for obstetricians and midwives. Universal screening should, at the moment, 
depend on the local prevalence of type 2 DM in the reproductive age group. Low-risk status 
requires no glucose testing, but this category is limited to those women meeting all of the 
following characteristics: age <25 years, normal weight before pregnancy, member of a 
population with a low prevalence of GD, no known diabetes in first-degree relatives, no 
history of abnormal glucose tolerance, no history of poor obstetric outcome. Where type 2 
DM is common (for example many units in the USA, Saudi Arabia and the Gulf, and certain 
ethnic minorities), then a total population screen is justified (Forsbach et al., 1997). Universal 
screening is more sensitive and more practical when a family history of diabetes cannot be 
obtained reliably (Karcaaltincaba et al., 2009). The diagnosis of GD is associated with a risk 
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screening is more sensitive and more practical when a family history of diabetes cannot be 
obtained reliably (Karcaaltincaba et al., 2009). The diagnosis of GD is associated with a risk 





population will be largely determined by those factors which predict such a risk (Fraser & 
Heller, 2007) 
Any woman diagnosed with GD should be screened for diabetes 6–12 weeks postpartum 
and should be followed up with subsequent screening for the development of diabetes or 
pre-diabetes. If the fasting plasma glucose (FPG) level is normal, then reassessment for DM 
should occur every 3 years. Family planning for subsequent pregnancies should be 
discussed, and monitoring for the development of symptoms of DM should be undertaken. 
The goal of treatment is to reduce the risks of GD for mother and child by keeping blood 
glucose levels equal to those of pregnant women who don't have such a disease. The highest 
risk of complications is established when there is an increase of the initial level of pre-
prandial blood sugar and when there is an increase of the postprandial glucose.   
Scientific evidences show that controlling glucose levels can result in less serious fetal 
complications and increased maternal quality of life and insulin administered twice daily 
during the third trimester to mothers who have even a mild degree of hyperglycemia will 
reduce fetal size, and in particular fetal adiposity. The proper management GD includes 
special meal plans and scheduled physical activity and of course - daily blood glucose 
testing. The further steps may require insulin injections. 
4. Prevalence of GD  
GD is the most common metabolic disease of pregnancy.  The prevalence of GD varies 
across the globe, as well as between racial and ethnic groups within the same country. In 
recent years there has been a reported increased trend in the prevalence of GD throughout 
the world, with huge health-care and economic costs (Bellamy et al., 2009). This is 
particularly the case in developed countries, such as the USA, the UK, Australia, China and 
New Zealand (Sinha et al., 2003; Ferrara et al., 2004; Joshy & Simmons, 2006; Metzger & 
Counstan, 1998; Fan et al., 2006; Carolan et al., 2010). The increased prevalence has been 
recently disputed, suggesting that more cases were identified through more aggressive 
universal screening. For example, Lopez-de-Andres et al. (Lopez-de-Andres et al., 2011) did 
not found increase in the prevalence of GD is Spain from 2001 to 2008. This partly coud be 
explained with the fact that with the selective approach, women at low risk for GD do not 
need to be screened and some cases could be missed. Several teams have tried to improve 
the sensitivity of selective screening by making the relevant protocols more inclusive. 
Through this ‘tinkering’, age has emerged as the most important risk factor for type 2 DM 
and, by extension, gestational diabetes. Accordingly, the lower threshold for screening has 
decreased from 30 years in earlier studies to 25 years in more recent ones.  
Approximately 8% of all pregnancies with wide-ranging differences between countries 
(ranging from 1 to 16% depending on the population studied, screening protocols and 
diagnostic criteria used) are complicated by GD (Hossein-Nezhad et al., 2007). Furthermore, 
within the same country, the prevalence of GD is strongly influenced by race and culture. 
High prevalence rates have been reported in studies from Australia (Indian-born 15%, 
Chinese 13.9%) and the United States (Zuni Indians 14.3%).  
Increasing prevalence relates to a range of factors including advanced maternal age, obesity 
and migratory patterns (Ferrara et al., 2004; Joshy & Simmons, 2006). Of particular interest 
here is the increase seen among specific ethnic groups (Joshy & Simmons, 2006, Kim et al., 
2007), which may relate to ethnic differences in maternal glucose concentrations (Scholl et 
al., 2002; Esakoff et al., 2005) and recent trends of obesity (Harris et al., 1997, Xiong et al., 
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2001, Rosenberg et al., 2003; Ben-Haroush et al., 2004). Moreover, women of non-Caucasian 
ethnicity represent a considerable portion of childbearing populations in developed 
countries, and as rates of obesity and GD grow, there is a concordant increase in the risk of 
poorer pregnancy outcomes among these groups. GD is also associated with an increased 
maternal likelihood of developing diabetes type 2 in later life, and recent research postulates 
a link between GD, childhood obesity and later onset of diabetes in the offspring (Ferrara, 
2007; Ricart et al., 2005; Carolan et al., 2010) 
USA 
In the USA more than 200,000 cases annually are complicated by GD (Bottalico, 2007). Only 
1.5–2% of Midwestern white women develop GD, while up to 15% of Native American 
women from southwestern USA have been reported to develop GD. In the Hispanic, 
African-American and Asian populations of the USA, the incidence of GD is 5–8%. Most 
women will return to normoglycemia postpartum, but 30% to 50% will develop type 2 DM 
or glucose intolerance later in life. State-, city-, hospital-level GD prevalence estimates have 
consistently shown GD rates to be higher among Asian and Pacific Islander (API) mothers 
than among white, black, or Hispanic mothers (Lawrence et al., 2008; Chu et al., 2009) found 
that among 3,108,877 births, US APIs had a substantially higher age-adjusted prevalence of 
GD (6.3%) than whites (3.8%), blacks (3.5%), or Hispanics (3.6%). 
Asia 
Oriental populations have different demographic characteristics (maternal age, height, BMI 
and frequency of obesity) to other ethnic populations and it is not clear to what extent the 
effects of age and obesity are interrelated. In Korea the life styles have changed rapidly to a 
westernized pattern characterized by sedentary occupations and consumption of refined 
food and a high-fat diet. Therefore it is reasonable to predict that the prevalence of GD in 
Korean women will increase as the prevalence of type 2 DM increases in the developing 
countries (Jang et al., 1995; 2003). The overall prevalence of GD in Korean women was 
estimated as 2.2%. The patients with GD were older, shorter and had a higher prepregnancy 
weight, BMI and parity than normal controls. The prevalence of GD in women with a single 
risk factor was 1.3% higher than that in women without risk factors (0.6%, p < 0.05), but was 
lower than that in the population at large (2.2%). However the prevalence increased to 
33.3% in patients with 4 risk factors. 
The DECODA study showed that India has a higher prevalence of diabetes than China or 
Japan (Ferrara, 2007) reported 3.8% prevalence of GD in China (20512 women screened), 
however they could not determine if there is an increase in the incidence of GD, but state 
that it is possible that absolute rate of GD has increased in China, probably due to changes 
in the lifestyle, decreased physical activity and increased incidence of obesity.  Shai et al. 
(Shai et al., 2006) found that Asian women had a higher risk of diabetes than White, 
Hispanic, or Black women. In addition, they found that weight gain increased risk of 
diabetes more for Asian than for other women. Hunsberger et al. (Hunsberger et al., 2010) 
found that, compared with women of other race/ethnicities, both high BMI and low BMI 
Asian women were at the greatest risk of having GD. Additionally, diabetes risk among 
Asians seems to increase with prolonged exposure to Western lifestyle. The Turkish 
Diabetes Epidemiology Study reported the highest prevalence of diabetes in southern 
Turkey compared with northern and central parts of Turkey (Satman et al., 2002). The 
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Di Cianni et al. (Di Cianni et al., 2003) performed a retrospective study to evaluate the 
prevalence of GD by using both the selective and the universal screening approach and the 
presence of risk factors for GD in a cohort of Italian women. From June 1st, 1995 to December 
31st, 2001, universal screening for GD was performed in 3950 women. In this analysis GD was 
significantly and independently associated to age, pre-pregnancy BMI, weight gain, height 
and family history of diabetes. The generated figures indicate that GCT was positive in 35.2% 
of cases, while the true prevalence of GD was 8.7%. When the OGTT was performed in a 
random sample of women with negative GCT, about 6.5% were found to have GD. By 
extrapolation to the whole cohort, it was then calculated that the approximate true prevalence 
of GD in the general population can be as high as 12.3%.Lopez-de-Andres et al. (Lopez-de-
Andres et al., 2011) reported the prevalence of GD is Spain from 2001 to 2008 to be 3.6%. In 
Sweden, 7817 infants (of total number 892084) were born of mothers with GD between 1992 
and 2004.  This represents an incidence of GD of 0.9% in the studied population (Ahlsson et al., 
2010). The number of adults with diabetes in the European region is expected to reach 55.2 
million. And 33.40% are from the eastern European region. 
Eastern Europe 
The prevalence of GD in Eastern Europe and especially in Bulgaria shows a very diverse 
prevalence. (IDF, 2011)  
 
Country percent  with 
diabetes 






percent  with 
diabetes 
 (20-79 years) 
2030 
population GDP nominal 
total (USD) 
1. Albania 4.8 102 800 5.1 2 986 952 12.224 billion 
2. Belarus 9.1 661 100 9.0 9 648 533 52.887 billion 
3. Bosnia and 
Herzegovina 
9.1 271 100 8.6 3 842 566 16 631 billion 
4. Bulgaria 9.0 519 500 7.8 7 351 234 44.843 billion 
5. Croatia 9.2 315 900 8.0 4 486 881 59 917 billion 
6. Estonia 9.9 97 900 9.0 1 340 021 19.123 billion 
7. Greece 8.8 754 000 7.4 11 305 118 325 088 billion 
8. Latvia 9.9 169 700 9.0 2 217 969 23 955 billion 
9. Lithuania 9.7 239 800 9.0 3 244 000 35.152 billion 
10. Macedonia 8.0 119 300 8.0 2 052 722 9470 billion 
11. Moldova 8.7 233 500 9.0 3 567 500 5 403 billlion 
12. Montenegro 8.4 35 700 8.0 620 000  
13. Romania 8.4  1 351 400 8.0 21 959 278 158 393 billion 
14. Russia 9.0 9 624 900 9.0 142 905 200 1 477 trillion 
15. Serbia  8.6 613 400 8.0 9 981 929 43.6 billion 
16. Ukraine 9.6 3 328 400 9.0  49 100 000 37.6 billion 
Table 2. The DM morbidity in Eastern European region. 
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According to the data, provided by the Diabetes Atlas, Estonia, Latvia and Ukraine are 
those eastern European countries with highest percentage of diabetes for 2010. Albania is 
the country with lowest percentage. Totally 18 438 400 is the number of the patients with 
diabetes in these sixteen countries. The mean percentage with diabetes for 2010 is 8.76. 
And the decrease for the next 20 years will be insignificant – 8.24. Of course all the eastern 
European countries are extremely diverse as the population and gross domestic product 
(GDP) are taken in mind. Russia is the richest, while Moldova, Macedonia and Albania 
are the poorest. The number of deaths attributable to diabetes (20-79 years) is 317 955. 
And there is no significant differentiation by sex 143 810 – males and 174 145 – females. A 
very interesting fact is that only five countries - Greece, Russia, Belarus, Ukraine and 
Romania have National Diabetes program according to a survey of International Diabetes 
Federation (IDF) member associations. Bulgaria for example is working in order to 
develop and implement a national diabetes program. The Bulgarian Diabetes Association 
(BDA) that is the only one national representative association for patients and diabetics in 
Bulgaria is working towards achieving this goal. It was created in 1990. On the initiative 
of the Group for parliamentary consensus to combat socially significant diseases in the 
40th National Assembly of Bulgaria and under the auspices of the National Assembly on 
2-3 February 2008 in Plovdiv, Bulgaria there was a consensus around three significant 
acts:  
1. Restriction of diabetes in Bulgaria and particularly the preparation and implementation 
of diabetic register and national program to combat diabetes should be one of the 
priorities of all institutions in Bulgaria.  
2. It is the creation of a working group of representatives of all stakeholders to draw up an 
action plan for prevention, early diagnosis and proper treatment of diabetes in Bulgaria. 
These documents must be submitted for consideration and adoption by the National 
Assembly during the autumn session of 2008.  
3. After the program and action plan, responsible institutions is imperative to take all 
necessary actions to ensure adequate funding for their practical application in the 
country. So we can conclude that Bulgaria is working towards the development of a 
National program. 
Of course not only the disease itself has to be assessed but also the complication that 
accelerates the mortality. Close to four million deaths in the 20-79 age group may be 
attributable to diabetes in 2010, accounting for 6.8% of global all-cause mortality in this age 
group. According to the literay sources - this number resembles the deaths in this age group 
from several infectious diseases. The highest number of deaths due to diabetes is expected to 
occur in countries with large populations as they have the largest numbers of people with 
diabetes like Russia.  
Another very important aspect is the health expenditures per person with diabetes in 2010. 
As it can be seen there are very big fluctuations in the Eastern European region. For example 
Greece spent 2742 USD, while Moldova – only 76 USD. In order to be precise in the 
conclusions it has to be analyzed the GDP in order to compare these expenditures. For 
Greece it is 325 088 billion USD , while for Moldova – 5 403 billlion. For Greece these mean 
health expenditures per person with diabetes are 0.0084% from the GDP of the country, 
while for Moldova – 0.014%. Bulgaria spent 0.007% from the GDP of the country for 
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Country Mean health expenditure per person with diabetes  
in 2010 (USD) 
Albania 261 
Belarus 238 












Serbia  238 
Ukraine 307 
Table 3. Mean health expenditures per person with DM in 2010 for the Eastern European 
region. 
The statistics by country for gestational diabetes shows that apporximatelly 1 in 2 014 or 
0.05% or 135 000 women get GD every year in the USA. The analysis of the data for the 




Population estimated used 
(US Census Bureau, International data 
base 2004) 
Albania 1 759 3 544 808 
Belarus 5 117 10 310 520 
Bosnia and 
Herzegovina 202 407 608 
Bulgaria 3 731 7 517 973 
Croatia 2 231 4 496 869 
Estonia 665 1 341 664 
Greece 5 284 10 647 529 
Latvia 1 144 2 306 306 
Lithuania 1 790 3 607 899 
Macedonia 1 012 2 040 085 
Romania 11 095 22 355 551 
Russia 71 457 143 974 059 
Serbia  and 
Montenegro 5 373 10 825 900 
Ukraine 23 690 47 732 079 
Table 4. Extrapolated incidence of GD (wrongdiagnosis.com, 2011) 
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These statistics are calculated extrapolations of various prevalence or incidence rates against 
the populations of a particular country or region. The statistics used for 
prevalence/incidence of GD are typically based on US, UK, Canadian or Australian 
prevalence or incidence statistics, which are then extrapolated using only the population of 
a given country. The base is that 0.05% from the population (women) will get GD annually. 
The literary data shows that the frequency of development of GD varies from 2 to 4-5 % 
from the pregnant women. Some authors even state that 9% from the pregnant women 
develop GD. In Bulgaria a pilot study shows that the frequency is even greater – 14%, but till 
today there was not perform a systematic screening. Unfortunatelly in Bulgaria there is a 
tendency for doubling the GD morbidity, because of the obesity and because of the increase 
survival rate of girls born with weight above 4 kg. 
5. St. Vincent declaration – Review and principles 
In 1989, in St. Vincent, Italy was signed the St. Vincent declaration, a joint initiative of the 
International Diabetes Federation European region and the WHO European regional office. 
It is a program for strategic action to reduce the human and economic burden of diabetes in 
Europe and has been adopted by most of the European governments. (IDF, 2004) The St. 
Vincent initiative has few target areas, which seek to improve the quality of life of people 
with diabetes and to promote education of patients so to prevent diabetes complications. 
Patient education is very important and a team approach, including physicians, pharmacists 
and nurses, is beneficial. Some of the main conclusions during the meeting were that 
“diabetes mellitus is a major and growing European health problem, a problem at all ages 
and in all countries. It currently threatens at least ten million European citizens. It is within 
the power of national governments and health departments to create conditions in which a 
major reduction in this heavy burden of disease and death can be achieved. Countries 
should give formal recognition to the diabetes problem and deploy resources for its 
solution. Plans for the prevention, identification and treatment of diabetes and particularly 
its complications should be formulated at local, national and European regional levels. 
General goals and five-year targets can be achieved by the organised activities of the 
medical services in active partnership with diabetic patients, their families, friends and 
workmates and organisations in: 
 The management of their own diabetes and education for it. 
 The planning, provision and quality audit of health care. 
 National, regional and international organisations for disseminating information about 
health maintenance. 
 Promoting and applying research. (IDF, 2004) 
The St. Vincent’s declaration outlined the following general goals for children and adults 
with diabetes: 
 sustained improvement in health experience and a life experience approaching normal 
expectation in quality and quantity. 
 prevention and cure of diabetes and its complications by intensifying research effort. 
The five-year targets that are granted in the declaration are: 
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Serbia  238 
Ukraine 307 
Table 3. Mean health expenditures per person with DM in 2010 for the Eastern European 
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These statistics are calculated extrapolations of various prevalence or incidence rates against 
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 steps for raising the awareness in the population and amongst health care professionals 
of the present opportunities and the future needs for the prevention of diabetes and its 
complications. 
 organisation training and teaching programs in diabetes management and care for 
people of all ages with diabetes, for their families, friends and working associates and 
for the health care team. 
 ensuring that care for children with diabetes is provided by individuals and teams 
specialised in the management of both diabetes and children, and that families with a 
diabetic child get the necessary social, economic and emotional support. 
 reinforcement of the existing centres of excellence in diabetes care, education and 
research.  
 promotion of independence, equity and self-sufficiency for all people with diabetes, i.e. 
children, adolescents, those in the working years of life and the elderly. 
 attempts for reducing the hindrances to the fullest possible integration of the diabetic 
citizen into society. 
 implementation of  effective measures for the prevention of costly complications: 
 
a reduce new blindness due to diabetes by one third or more. 
b reduce the number of people entering end-stage diabetic renal failure by at least 
one third. 
c reduce by one half the rate of limb amputations for diabetic gangrene. 
d cut morbidity and mortality from coronary heart disease in the diabetic by 
vigorous programmes of risk factor reduction. 
e achieve a pregnancy outcome in the diabetic woman that approximates that of 
the non-diabetic woman. 
 
 establishment of monitoring and control systems, using new information technology for 
quality assurance of diabetes health care revision and for laboratory and technical 
procedures in diabetes diagnosis, treatment and self-management. 
 promotion and granting of collaboration of European and international programmes of 
diabetes research and development through national, regional and World Health 
Organisation agencies and in active partnership with diabetes patients’ organisations. 
 taking urgent action in the spirit of the WHO programme ‘Health for All’ to establish 
joint initiative between the WHO and the International Diabetes Federation (European 
region) to initiate, accelerate and facilitate the implementation of these 
recommendations.” (IDF, 2004) 
Since 1989 further implementation and evaluation meetings have been held in Budapest 
(1992), Athens (1995), Lisbon (1997) and Istanbul (1999), where representatives of ISPAD 
have helped to formulate recommendations on behalf of children and adolescents. 
6. Pharmacoeconomical assessment of GD drug treatment. The role of the 
pharmacist for GD management 
The standard treatment of GD is insulin treatment. The metabolic control target in the GD 
treatment is blood sugar before meal under 5.8 mmo/l, postprandial blood sugar under 7.5 
mmo/l and hemoglobin HbA1-c under 6.5%. The postprandial blood glucose is of critical 
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importance for the neonatal end of the pregnancy. That is why it is very important to 
determine the cost and effectiveness of the drug treatment for women with GD. It can be 
achieved by studying the clinical effectiveness of the treatment with diet and diet + insulin 
for pregnant women with GD and determination of the ratio treatment cost/effectiveness. A 
prospective study of 50 women with gestational diabetes from Sofia, Bulgaria were studied 
from pharmacoeconomical point of view. They were divided into 2 groups: Group I (n = 30) - 
pregnant women only on a diet and Group II (n = 20) - pregnant women treated by a diet and 
insulin. The following including criteria were applied: age above 18 years, one fetus 
pregnancy, insignificant additional disease without organ damages, without infectious 
diseases, without obesity and HbA1-c under 7%. The key excluding criteria are the availability 
of diabetes before pregnancy, or prior insulin therapy, treatment with oral hypoglycemic 
drugs before pregnancy, income of drugs that have influence on the carbohydrate tolerance, 
existing obstetrics complications till the demonstration of the gestation diabetes. The diet 
treatment was with diet No 9 according to M.I. Pevzner. The diet satisfies the 
recommendations for feeding. Human insulin, in intensified insulin regimen type- bazal-
prandial, including treatment with three doses rapid acting insulin and one or two doses 
intermediate acting insulin was applied. The total costs of the treatment of a patient, on a diet 
without complications in the peripartal period is 335.02 USD and is lower in comparison with 
the total cost of the treatment of a woman treated only with insulin that is 347.42 USD. 
(p=0.04). The difference in the treatment cost is 12.40 USD. The total treatment cost of a 
pregnant woman, treated with diet with complications in the peripartal period is 363.94 USD 
and is also lower in comparison with the total cost of the treatment of a woman treated with 
insulin and with complications that is 398.90 USD (p=0,03). (Todorova et al., 2007) 
The cost-effectiveness coefficient is calculated based on the total direct medical costs, used 
for the reduction of the average 24-houred glucose under 5,8 mmol/l as for higher precision 
the calculations are proceeded with the received difference in the level of the glycated 
hemoglobin after the treatment. (Todorova et al., 2007) The over calculated CCE for 100 
women is CCE is 5141.17 USD  
CCE= 398.90 – 363.94/6,1 – 5,42 = 51.4117USD 
51.4117x 100 = 5141.17 USD 
The so calculated coefficient reflects the costs for complications that is saved by the insulin 
treatment and that should occur after an ineffective diet treatment. The interpretation of this 
coefficient shows that the spent 12.40 USD for insulin treatment for every woman in fact 
saves 51.41 USD that should be spent for the treatment of unfavorable peripartal maternal 
complications. Through the application of a model of mathematical modeling the total final 
cost for one beneficially treated woman with GD is calculated. The calculations for the two 
therapeutical alternatives are performed by the use of the probabilities for occurrence of 
effective treatment for each of them. 
The total costs of the treatment with diet is 351.69 USD  
(334.43 x 0,4) + (363.2x 0,6) = 351.69 USD 
The total cost of the treatment with insulin is 349.35 USD.  
(346.84x0,95) + (398.2x0,05) = 349.35 USD 
The applied analytical model shows that on the base of the higher per cent successfully 
treated women, the spent final costs for successfully treated woman after the treatment with 
insulin are 388,13 USD (349.32/0,9), and the final costs after the treatment with diet are 879.1 
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Table 5. “Three of decisions” of the alternatives for the treatment of GD. 
There are four clinical paths, concerning diabetes that are included in the list of the 
Bulgarian Health Insurance fund. Unfortunatelly there is no clinical path concerning DM or 
the complications of this disease that decreases the accessibility towards proper 
management of this disease. And on this base it can be explained the prospective data about 
doubling the GD morbidity. 
 
Clinical 
path No disease 
Hospital 
stay Drug treatment 
Prize 
(USD)/daily 
8 Diabetes polineuropathia  3 days 
 carbamazepine - 400-
800 mg/daily. 
 gabapentin – from 3 
times x 300 mg till 1500 
mg daily; 
 pregabalin – up to 2 х 
150 mg; 
0.23-0.46 
2.34 – 3.90 
 
3.92 
104 Decompensated DM for patients above 18 years 3 days 
 Insulin 
 Electrolities  
9.57 - once 
105 Decompensated DM for patients bellow 18 years 3 days 
 Insulin 
 Electrolities  
9.57 - once 
178 
Surgical Intervention Of 
Diabetic Foot without 
vessel reconstruction 
3 days   
Table 6. Clinical paths in Bulgaria, concerning diabetes. 
Another aspect that is innovative in the Bulgarian pharmaceutical practice, concerning the 
management of GD is the role of the pharmacist as a health-care educator in order to be 
accomplished the St. Vincent declaration aims is demonstrated. Patient education is very 
important and a team approach, including physicians, pharmacists and nurses, is 
beneficial.(38). A study that included pregnant women attending antenatal clinic with GD 
January 2009 - December 2009 demonstrated the beneficial role of patients education. The 
following including criteria are used: age above 18 years, one-fetus pregnancy, GD, 
insignificant additional disease without organ damage, without infectious diseases. The 
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study design is a pilot case-control study that includes 45 women with GD from city of 
Sofia, Bulgaria. The pregnant women were divided into two groups – Group I (n=22), that 
were educated on the proper management of their disease and were on a diet and treated 
with insulin, and Group II (n=23), that were not educated and on a diet, but treated with 
insulin on a regimen, prescribed by the physician. The assignment was based on the 
principle of random numbers through custom random number generator. The educational 
program continued 3 months. It was designed and adapted to the patients comfort, 
provided at the pharmacy they are attending. The course was presented to the 22 previously 
selected pregnant women with GD.  
The educational course included the following teaching units: 
- The essence of GD; 
- The complication of improper disease management; 
- Proper diet regimen (based on the Sample GD diet menu of the Endocrinology clinic of 
Minneapolis) and also proper drug treatment as well as hypo-and hyperglycaemia and 
physical activity for both of the groups. 
The first unit acquainted each of the women with the aim of the educational program, 
provided general concept about GD and about self-monitoring and emphasized on the 
active patient participation in the treatment. The personal information of each of the patients 
was collected, concerning the duration of the disease, the prescribed drug treatment if any, 
the frequency of the hypoglycaemic and hyperglycaemic incidents. At the end of the first 
unit, each of the patients was supplied with written materials on the essence of GD. The goal 
was to learn the seriousness of GD. 
The main topic discussed during the second teaching unit was complication of improper 
management. The educator explained the complications of GD. The educator discussed with 
every woman the effects on the fetus. 
The main topic discussed during the third teaching unit was proper diet regimen (based on 
the GD diet menu of the Endocrinology clinic of Minneapolis, USA). At the end of the session 
the patients were supplied with the Sample GD diet menu. Each of the patients was supplied 
with written materials on proper nourishing for diabetic patients and physical activity.  
The educational materials used during the program included:  
- a set of one-page written materials that illustrate the most important aspects of every 
educational lecture, provided to the patient after every session;  
- questionnaire cards for distribution among the participants as a standardized 
procedure for assessment of their knowledge acquired in the previous educational 
units;  
- individual food and activity record for the self-monitored data (food, total grams of 
carbs, comments and activities, insulin treatment);  
In the beginning and at the end of the educational process a patient satisfaction 
questionnaire was applied (Diabetes Questionnaire (IMG)). During the 3-months education 
and its end, the observed behavioural parameters performed changes. The results from the 
twice-applied questionnaire assessing the quality of life of the patients in the beginning and 
in the end of the educational programme show that the five main indices have been 
improved with on the average of 5% for the both groups, but greater for those included in 
Group I (Table 7). The greater increase was observed in the positive changes in the mood – 
7,9% for Group I and 8,2% for Group II , followed by number of days “being easy” with 6.9 
% for Group I and with 6,2% for Group II (6.7%) and possibility to perform physical 
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process affects both the physical and the psychological well-being and thus it is beneficial 
for the global patient’s quality of life.  
 
 Time period 
Variable 0 3 month 
 Group I Group II Group I Group II 
QL-positive changes in the mood  10,8% 9,9% 18,7% 18,1% 
QL-increase in days “being easy” 18,4% 17,9% 25,3% 24,1% 
QL- increase in social activity 11,1% 12,2% 14% 15,1% 
QL- increase in days being “rested” 15% 14,5% 17,4% 16,8% 
QL- increase in physical activity 13,4% 14,0% 19,2% 19,0% 
total 68,70% 68,50% 94,60% 93,10% 
mean 13,74% 13,70% 18,92% 18,62% 
Data are %. QL – “quality of life”. 
Table 7. Changes in the patients sample after the educational process 
The advanced pharmacy practitioner in diabetes management is a relatively new approach. 
The role of the pharmacist in it, integrates drug management, patients’ compliance 
assessment, blood glucose monitoring, skills training, prospective and retrospective drug 
utilization review, adverse drug reaction and toxicity screening and education of the 
patients.(Valentine et al, 2003). These skills in fact are not new for the pharmacist but their 
introduction, as systematized approach in everyday practice should correspond to the local 
circumstances. To match the context of the pharmaceutical care, defined by the APA as 
“Patient-centered, outcomes-oriented pharmacy practice that requires the pharmacist to 
work in concert with the patient to promote health, to prevent disease and to assess, 
monitor, initiate and modify medication use”, is a real challenge for the management of 
diabetes, especially for Bulgaria.(American Pharmaceutical Association [APA], 2011). 
Despite the relatively small sample size, this study shows the role of education program for 
improvement of patient’s outcomes. The results confirm the necessity of individual 
approach in the selection of therapeutic strategy for the women with GD. As the St. Vincent 
declaration assumed, the quality of life of people with diabetes has to be improved and to be 
promoted education of patients so to prevent diabetes complications. According to the St. 
Vincent declaration the aim of the treatment of GD is the achievement of child birth similar 
to the child birth by women without diabetes.(IDF, 2004) In this project are involved all 
healthcare givers, including the pharmacists in order to be achieved the goals. (Douglas et 
al., 2000; Dixon, 2002; Campbell et al., 1990; Mensing et al., 2002) The educational approach 
is a necessary step for better management of the disease in order to minimize the risk of 
maternal and fetal complications and the pharmacists are capable to perform it. The results 
obtained confirm the need for consistent patients’ education, using variety of educational 
models, as an essential part of the diabetes care that will result in improvement of patient’s 
quality of life.  
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Gestational diabetes is a subject of endless debate, uncertainty and confusion. Although it is 
a alteration during pregnancy, the true prevalence of GD remains a matter of discussion. 
The prevalence of GD in the general population is varied from 1% to 16% depending on 
both the country of origin and the nature of the indigenous population. The rate can vary 
due to differences in data collection methods, low response rates, non-random selection of 
the women, and lack of uniformity in the diagnostic criteria. More recently, the high rate of 
GD has been claimed to be an unrealistic estimation caused by universal screening, not 
carrying any specific benefit for pregnancy outcome.  
GD is considered to be a state of prediabetes. The diagnosis of GD identifies women at high 
risk of diabetes after the pregnancy. Therefore, it is important for these women who may 
develop type 2 diabetes during their life to take preventive measures as well as to prevent 
pregnancy-related complications. It is well known that raised glucose levels in women with 
GD increase both morbidity and mortality among their offspring due mainly to an increased 
incidence of congenital abnormalities and excessive fetal growth in the third trimester. 
Women with a family history of diabetes had three times higher odds for GD than women 
without a family history of diabetes. With the prevalence of type 2 diabetes increasing 
across the world, and given that the prevalence of GD is thought to shadow that of type 2 
diabetes, most populations will expect to see a rise in GD figures during the coming years. It 
is very important to establish clear policies to ensure that those at risk are reliably identified, 
appropriately treated during pregnancy and then equipped to make the necessary lifestyle 
changes to try and prevent them developing type 2 diabetes in later life.  
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1. Introduction 
It is just to remember that “Pathophysiology” refers to the study of alterations in normal 
body function (physiology and biochemistry) which result in disease. E.g. changes in the 
normal thyroid hormone level causes either hyper or hypothyroidism. Changes in insulin 
level as a decrease in its blood level or a decrease in its action will cause hyperglycemia and 
finally diabetes mellitus.  
Scientists agreed that gestational diabetes mellitus (GDM) is a condition in which women 
without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy. 
From our experience most women with GDM in the developing countries are not aware of 
the symptoms (i.e., the disease will be symptomless). While some of the women will have 
few symptoms and their GDM is most commonly diagnosed by routine blood examinations 
during pregnancy which detect inappropriate high level of glucose in their blood samples. 
GDM should be confirmed by doing fasting blood glucose and oral glucose tolerance test 
(OGTT), according to the WHO diagnostic criteria for diabetes. 
A decrease in insulin sensitivity (i.e. an increase in insulin resistance) is normally seen 
during pregnancy to spare the glucose for the fetus. This is attributed to the effects of 
placental hormones. In a few women the physiological changes during pregnancy result in 
impaired glucose tolerance which might develop diabetes mellitus (GDM). The prevalence 
of GDM ranges from 1% to 14% of all pregnancies depending on the population studied and 
the diagnostic tests used. Although the majority of women with GDM return to normal 
glucose tolerance immediately after delivery, a significant number will remain diabetic or 
continue to have impaired glucose tolerance (IGT).  
To understand how gestational diabetes occurs, it is necessary to understand the normal 
physiological metabolism of glucose during pregnancy and the physiological changes - 
mainly the endocrine changes during pregnancy in the feto-placental unit, which might 
explain the development of insulin resistance and GDM. 
1.1 Insulin 
Only about 1-2% of the pancreatic structure is endocrine tissues which are represented by the 
presence of 1-2 million islets of langerhans. These islets contain four main types of cells (A, B, 
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cells. Insulin is a 51-amino acid polypeptide (small protein) hormone consist of A and B-chains 
connected together by disulphide bridges (Ganong, 2003; Guyton & Hall, 2006). 
1.2 Insulin Receptor (IR) 
The IR is a large heterotetrameric, transmembrane glycoprotein, having a molecular weight 
of about 300,000. Each receptor consists of two alpha (α) subunit that lie outside the cell 
membrane and two beta (β) subunits that penetrate the cell membrane protruding into the 
cytoplasm connected together by disulphide bridges in a β-α- α-β configuration. IR is 
assembled from a single polypeptide pro-receptor, by dimerization, proteolytic cleavage, 
and glycosylation within the cytoplasm and Golgi apparatus, before trafficking of the 
mature receptor to the plasma membrane. These insulin receptors have also been designated 
recently as CD220 (cluster of differentiation 220) (Ganong, 2003; Guyton & Hall, 2006; Ward 
& Lawrence, 2009).   
1.3 Insulin action 
Insulin has many metabolic functions such as enhancing cellular uptake of glucose, fatty 
acids, amino acids, and potassium ions. It also has an anabolic action by increasing cellular 
formation of glycogen, lipids, and protein. These physiological functions will be reversed if 
insulin action is decreased as seen with the increase in insulin resistance during pregnancy. 
The main function of insulin concerning gestational diabetes mellitus (GDM) is its action on 
glucose and lipid metabolism. 
1.3.1 Insulin effect on lipid metabolism 
Normally insulin stimulates the synthesis and release of lipoprotein lipase from the 
endothelial cells of blood vessels causing lipolysis of triglycerides in the blood and release of 
free fatty acids (FFA). Insulin enhances the transport of FFA to the fatty cells (adipocytes) to 
be stored as lipids. Furthermore, insulin inhibits lipoprotein lipase in adipose cells 
preventing lipolysis.  
1.3.2 Insulin effect on glucose metabolism 
Insulin enhances entrance of glucose to the cells through its action on the insulin receptors. 
Insulin receptor complex will stimulates mobilization of glucose carrier protein (GLUT- 4 
transporter) from the interior of the cell to the plasma membrane which will transport 
glucose inside the cell by the process of facilitated diffusion. Furthermore, insulin-receptor 
complex will activates the storage of some glucose as glycogen while others will be 
metabolized into pyruvate and then fatty acids which are stored as triglycerides (fat) 
(Ganong, 2003; Guyton & Hall, 2006).  
1.4 Insulin-receptor interaction 
To initiate insulin effects on target cells, it first binds with and activates a membrane 
receptor protein. [4] It is the activated receptor, not the insulin that causes the subsequent 
effects. The combination of insulin with the alpha subunits will induce autophosphorylation 
of the beta subunits which will activates a local tyrosine kinase [(phosphatidylinositol 3-
kinase (PI3-K)] , which in turn begins a cascade of cell phosphorylation that increase or 
decrease the activity of enzymes, including insulin receptor substrates (IRSs). There are 
different types of IRSs (IRS-1, IRS-2, and IRS-3) which are expressed in different tissues 
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which explain the diversity of insulin action, activating or inactivating certain enzymes to 
produce the desired effect on the cellular carbohydrate, fat, and protein metabolism (Zwick 
et al., 2001; Pawson, 1995; Hans-Georg,1995;  Perz & Torlińska, 2001). 
Within seconds after insulin binds with its membrane receptors, glucose transporters are 
moved to the cell membrane to facilitate glucose entry into the cell especially to the muscle 
and adipose tissues (Guyton & Hall, 2006; Sherwood, 2010). 
2. Physiology of pregnancy 
The endocrinology of human pregnancy involves endocrine and metabolic changes that 
result from physiological alterations at the boundary between mother and fetus, known as 
the feto-placental unit (FPU), this interface is a major site of protein and steroid hormone 
production and secretion. Many of the endocrine and metabolic changes that occur during 
pregnancy can be directly attributed to hormonal signals originating from the FPU (Ganong, 
2003; Guyton & Hall, 2006; Monga & Baker, 2006).  
During early pregnancy, glucose tolerance is normal or slightly improved and peripheral 
(muscle) sensitivity to insulin and hepatic basal glucose production is normal (Catalano et 
al., 1991; Catalano et al., 1992; Catalano et al., 1993). These could be caused by the increased 
maternal estrogen and progesterone in early pregnancy which increase and promote 
pancreatic ß-cell hyperplasia (Expansion of beta-cell mass in response to pregnancy) causing 
an increased insulin release (Carr & Gabbe, 1998; Rieck & Kaestner, 2010). This explains the 
rapid increase in insulin level in early pregnancy, in response to insulin resistance. In the 
second and third trimester, the continuous increase in the feto-placental factors will decrease 
maternal insulin sensitivity, and this will stimulate mother cells to use sources of fuels 
(energy) other than glucose as free fatty acids, and this will increase supply of glucose to the 
fetus (Catalano et al., 1991; Catalano et al., 1992; Ryan & Enns, 1988). In the normal 
physiological conditions, the fetal blood glucose is 10-20% less than maternal blood glucose 
allowing the transport of glucose in the placenta to the fetal blood by the process of simple 
diffusion and facilitated transport.  Therefore, glucose is the main fuel required by the 
developing fetus, whether as a source of energy for cellular metabolism or to provide energy 
for the synthesis of protein, lipids, and glycogen. 
During pregnancy, the insulin resistance of the whole body is increased to about three times 
the resistance in the non-pregnant state.  
In general, the resistance to insulin can be characterized as pre-receptor (insulin antibodies) 
as in autoimmune diseases, receptor (decreased number of receptors on the cell surface) as 
in obesity, or post-receptor (defects in the intracellular insulin signaling pathway). In 
pregnancy, the decreased insulin sensitivity is best characterized by a post-receptor defect 
resulting in the decreased ability of insulin to bring about SLC2A4 (GLUT4) mobilization 
from the interior of the cell to the cell surface (Catalano, 2010). This could be due to increase 
in the plasma levels of one or more of the pregnancy-associated hormones (Kühl, 1991; 
Hornns, 1985).  
Although, pregnancy is associated with increase in the beta-cell mass and increase in insulin 
level throughout pregnancy but certain pregnant women are unable to up-regulate insulin 
production relative to the degree of insulin resistance, and consequently become 
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3. Diagnosis of gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance 
resulting in hyperglycemia of variable severity, with onset or first recognition during 
pregnancy. It does not exclude the possibility that unrecognized glucose intolerance may 
have antedated but has been previously unrecognized (Metzger, 1991; Definition and 
Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia World Health Organization 
[WHO], 2006). Women who become pregnant and who are known to have diabetes mellitus 
which antedates pregnancy do not have gestational diabetes but have "diabetes mellitus and 
pregnancy" and should be treated accordingly before, during, and after the pregnancy 
(WHO, 2006). 
Gestational diabetes generally has few symptoms and it is most commonly diagnosed by 
screening during pregnancy. Diagnostic tests detect inappropriately high levels of glucose in 
blood samples.  
3.1 WHO diagnostic criteria for hyperglycemia and GDM (2006)  
In the early part of pregnancy (e.g. first trimester and first half of second trimester) fasting 
and postprandial glucose concentrations are normally lower than in normal, non-pregnant 
women. Elevated fasting or postprandial plasma glucose levels at this time in pregnancy 
may well reflect the presence of diabetes which has antedated pregnancy. The occurrence of 
higher than usual plasma glucose levels at this time in pregnancy mandates careful 
management and may be an indication for carrying out an oral glucose tolerance test 
(OGTT). Nevertheless, normal glucose tolerance in the early part of pregnancy does not by 
itself establish that gestational diabetes will not develop later. 
It may be appropriate to screen pregnant women belonging to high-risk populations during the 
first trimester of pregnancy in order to detect previously undiagnosed diabetes mellitus. Formal 
systematic testing for gestational diabetes is usually done between 24 and 28 weeks of gestation. 
To determine if gestational diabetes is present in pregnant women, a standard OGTT should 
be performed after overnight fasting (8-14 hours) by giving 75 g anhydrous glucose in 250-
300 ml water. Plasma glucose is measured fasting and after 2 hours. Pregnant women who 
meet WHO criteria for diabetes mellitus or impaired glucose tolerance (IGT) are classified as 
having GDM. After the pregnancy ends, the woman should be re-classified as having either 
diabetes mellitus, or IGT, or normal glucose tolerance based on the results of a 75 g OGTT 
six weeks or more after delivery.  
The following table (table 1) summarizes the 2006 WHO recommendations for the 
diagnostic criteria for diabetes and intermediate hyperglycemia (WHO, 2006).  
 
Diabetes 
Fasting plasma glucose                  ≥7.0mmol/l (126mg/dl), or 
2–h plasma glucose *                      ≥11.1mmol/l (200mg/dl) 
Impaired Glucose Tolerance (IGT) 
Fasting plasma glucose                  <7.0mmol/l (126mg/dl) 
2–h plasma glucose*                       ≥7.8 and <11.1mmol/l  (140mg/dl and 00mg/dl) 
Impaired Fasting Glucose (IFG) 
Fasting plasma glucose                  6.1 to 6.9 mmol/L  (110mg/dl to 125 mg/dl)                        
2-h Plasma glucose*                       < 7.8 mmol/dl (140mg/dl) 
* Venous plasma 2-h after ingestion of 75gm oral glucose load (OGTT)  
Table 1. Diagnostic criteria for diabetes and intermediate hyperglycemia 
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3.2 Glycosylated hemoglobin (HbA1c) as a diagnostic test for GDM 
Since 1984, professor Alwan AAS and collaborators have adopted the measurement of 
HbA1c levels as another index for follow-up of pregnant diabetic patients, and reported a 
significant relationship between elevated levels of HbA1c late in the third trimester and feto-
maternal complications (Al-Dahwi et al., 1986; Al- Dahwi et al., 1987; Al-Dahwi et al., 1988; 
Al-Dahwi et al., 1989). Recently, the American Diabetic Association (2009) added that 
HbA1c ≥ 6.5% is another criterion for the diagnosis of diabetes (Nathan, 2009). Therefore we 
highly recommend the measurement of HbA1c during pregnancy, as an additional 
diagnostic criteria and to anticipate the maternal and fetal complications if it is abnormally 
elevated. 
4. Pathophysiology of GDM 
In the pathophysiology of GDM we have to consider two main points.  
4.1 Role of feto-placental unit in GDM. 
4.2 Role of the adipose tissue in GDM. 
4.1 The role of feto-placental unit in the development of GDM 
The past; In the last century insulin resistance and the decrease in insulin sensitivity during 
pregnancy is mainly attributed to the increase in the levels of pregnancy-associated 
hormones as estrogen, progesterone, cortisol, and placental lactogen in the maternal 
circulation (Ryan, 1988; Hornns, 1985; Ahmed & Shalayel, 1999; Polderman et al., 1994; 
Barbour et al., 2002). Normally the insulin resistance of the whole body is increased to about 
three times that seen in the non-pregnant state (Kuhl, 1998; Catalano et al., 1999). The 
increased resistance is caused by post-insulin receptor events and is probably brought about 
by the cellular effects of the increased levels of one or all of the above hormones (Davis, 
1990). As pregnancy progresses and the placenta grow larger, hormone production also 
increases and so does the level of insulin resistance. This process usually starts between 20 
and 24 weeks of pregnancy. At birth, when the placenta is delivered, the hormone 
production stops and so does the condition, strongly suggesting that these hormones cause 
GDM (Ryan & Enns, 1988; Kuhl, 1975; Buchanan & Xiang, 2005). 
4.1.1 Feto-placental unit  
The placenta synthesizes pregnenolone and progesterone from cholesterol. Some of the 
progesterone enters the fetal circulation and provides the substrate for the formation of 
cortisol and corticosterone in the fetal adrenal glands. Some of the pregnenolone  
enters the fetus and, along with pregnenolone synthesized in the fetal liver, is  
the substrate for the formation of dehydroepiandrosterone sulfate (DHEAS) and  
16-hydroxydehydroepiandrosterone sulfate (16-OHDHEAS) in the fetal adrenal. Some  
16-hydroxylation also occurs in the fetal liver. DHEAS and 16-OHDHEAS are transported 
back to the placenta, where DHEAS forms estradiol and 16-OHDHEAS forms estriol. The 
principal estrogen formed is estriol, and since fetal 16-OHDHEAS is the principal substrate 
for the estrogens, the urinary estriol excretion of the mother can be monitored as an index of 
the state of the fetus (Ganong, 2003). 
4.1.2 Diabetic action of steroid hormones (cortisol, estrogen, and progesterone) 
These hormones are increased steadily with the advance of pregnancy. The anti-insulin 
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3.2 Glycosylated hemoglobin (HbA1c) as a diagnostic test for GDM 
Since 1984, professor Alwan AAS and collaborators have adopted the measurement of 
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GDM (Ryan & Enns, 1988; Kuhl, 1975; Buchanan & Xiang, 2005). 
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the state of the fetus (Ganong, 2003). 
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Barbour et al., 2002; Barbieri, 1999; Kirwan et al., 2002; Shalayel et al., 2010). The fetus and 
the placenta interact in the formation of these steroid hormones. It has been shown that the 
increase in cortisol level during pregnancy is considered as the main hormone which cause 
decrease in glucose tolerance in normal pregnancy (Hornns, 1985; Ahmed & Shalayel, 1999). 
While others considered that estrogen and progesterone which are elevated steadily during 
pregnancy are the main hormones  which influence beta cell function in early pregnancy 
and insulin resistance especially in late pregnancy (Ryan & Enns, 1988; Polderman et al., 
1994; Glass & Kase, 1984).  
Although some scientists have considered that human chorionic gonadotropin (HCG) may 
participates in the development of insulin resistance during pregnancy as it shows higher 
level in women with GDM in comparison with normal pregnancies (Merviel et al., 2001). 
But, as we know from the normal changes during pregnancy, the main increase of HCG 
occurs during the first trimester, and this period is associated with an increase in insulin 
sensitivity and improvement of glucose tolerance. Therefore, we consider that HCG has no 
direct role as a cause of GDM.  
4.1.3 Human placental lactogen (hPL), [human chorionic somatomammotropin (hCS)]  
It is a single polypeptide chain held together by disulphide bonds. It is about 96% similar to 
human growth hormone (HGH), but has only 3% of HGH activity. Its half life is short 
(15minutes); hence its appeal as an index of placental problems (Glass & Kase, 1984). HPL, 
which is the product of the HPL-A and HPL-B genes, is secreted into both the maternal and 
fetal circulations after the sixth week of pregnancy (Handwerger & Freemark, 2000). The 
level of HPL in the maternal circulation is correlated with fetal and placental weight, 
plateauing in the last 4 weeks of pregnancy. Therefore, measurement of HPL levels is used 
as a screening test for fetal distress and neonatal asphyxia (Glass & Kase, 1984; Letchworth 
& Chard, 1972).  
4.1.3.1 Physiologicalfunction of HPL  
During pregnancy the maternal level of HPL can be altered by changing the circulating level 
of glucose. HPL is elevated with hypoglycemia and depressed with hyperglycemia (Barbour 
et al., 2002; Kuhl, 1998). The metabolic role of HPL is to mobilize lipids and free fatty acids. 
In the fed state, there is abundant glucose available, leading to increased insulin level, 
lipogenesis, and glucose utilization. This is associated with decreased gluconeogenesis, and 
a decrease in the circulating free fatty acid levels, as the free fatty acids are utilized in the 
process of lipogenesis to deposit storage packets of triglycerides (Glass & Kase, 1984; Kim & 
Feling, 1971).  
4.1.3.2 Diabetogenic action of HPL 
In the second half of pregnancy, HPL level rises approximately 10 folds. HPL stimulates 
lipolysis leading to an increase in circulating free fatty acids in order to provide a different 
fuel for the mother so that glucose and amino acids can be conserved for the fetus. The 
increase in free fatty acid levels, in turn directly interferes with insulin-directed entry of 
glucose into cells. Therefore, HPL is considered as a potent antagonist to insulin action 
during pregnancy (Glass & Kase, 1984; Mills et al., 1985). Furthermore, HPL and placental 
growth hormone act in concert in the mother to stimulate insulin-like growth factor (IGF) 
production and modulate intermediary metabolism, resulting in an increase in the 
availability of glucose and amino acids to the fetus (Handwerger & Freemark, 2000).  
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4.1.4 Placental growth hormone (PGH)    
PGH is the product of the GH-V gene specifically expressed in the syncytiotrophoblast layer 
of the human placenta. PGH (20-kDa HGH-V) differs from pituitary growth hormone by 13 
amino acids. It has high somatogenic and low lactogenic activities (Lacroix et al., 2002). PGH 
is produced by the placenta and found predominantly in the maternal circulation. It 
progressively replaces pituitary growth hormone (hGH) in the human maternal circulation 
from mid-gestation onwards, peaking towards term (Chellakooty et al., 2004). PGH appears 
to be an important potential regulator of maternal insulin resistance in human pregnancy 
and may influence fetal growth both by modifying substrate availability and through 
paracrine actions in the placental bed (McIntyre et al., 2009). 
Barbour et al (2004) demonstrated a unique mechanism of insulin resistance in non-pregnant 
transgenic mice and suggested that human placental growth hormone (hPGH) may 
contribute to the insulin resistance of normal pregnancy secondary to its effect on p85  
expression and its interference with PI 3-kinase activity in skeletal muscle.  
Nevertheless, in a recent experimental study by Vickers and Gilmour (2009), it was 
demonstrated that rats treated with HGH enhanced insulin sensitivity and suggested that 
HGH have an antidiabetic action. 
It seems that there is a controversy about the involvement of HGH with insulin resistance 
and GDM. 
In conclusion, considering the previously discussed hormones, HPL is considered as the 
main diabetogenic hormone synthesized and released from the feto-placental unit. But 
during pregnancy, there is another maternal hormone which is involved in insulin 
resistance which is prolactin. 
4.1.5 Prolactin 
Prolactin level begins to rise at 5-8 weeks of gestation, followed by a progressively increase 
in its level as pregnancy advances (Shalayel et al., 2010; Glass & Kase, 1984). The increase in 
prolactin secretion is due the increase in the size and number of maternal pituitary 
lactotrophs (Kuhl et al., 1985) and its secretion from the uterine decidual cells seems to be 
stimulated by progesterone and insulin (Ahmed & Shalayel, 1999;  Davis, 1990). 
Shalayel et al (2010) revealed that prolactin increases progressively as pregnancy advances, 
reaching a peak in the third trimester when many pregnant ladies may develop gestational 
diabetes due to the state of insulin resistance which may occur although there is no evidence 
that prolactin may be directly incorporated with the pathogenesis of glucose intolerance in 
pregnancy. A decline in insulin secretion may lead to a decline in prolactin since insulin 
stimulates both acute secretion and de novo synthesis of decidual prolactin. 
There were no significant differences in the level of plasma prolactin in normal or diabetic 
pregnancies; in fact its level might be lower in the pregnancies with GDM (Guyton & Hall, 
2006). Therefore, prolactin might have no effect on glucose intolerance during pregnancy 
(Milasinovic et al., 1997).  
4.2 The role of adipose tissue in the development of GDM 
4.2.1 Adipocytokines 
Historically, placental hormones have been considered as the primary mediators of insulin 
resistance during gestation. Over the past decade, adipose tissue has been shown to produce 
numerous factors (adipocytokines), most of them act as hormones. These adipocyte-derived 
hormones have been implicated in the regulation of maternal metabolism and gestational 
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alpha, interleukin-6, as well as the newly discovered resistin, visfatin, and apelin, are also 
known to be produced within the intrauterine environment (Catalano, 2010; Briana & 
Malamitsi-Puchner, 2009; Henry & Clarke, 2008).  
Although human placental lactogen has often been cited as the cause of the decreased insulin 
sensitivity in pregnancy, because of its production from the placenta and increasing 
concentrations with advancing gestation as described previously (Ryan & Enns, 1988), more 
recently the role of adipocytokines and elevated lipid concentrations in pregnancy have been 
correlated with the longitudinal changes in insulin sensitivity in non-pregnant women 
(Hotamisligil et al., 1994) as well as in pregnant women (Kirwan et al., 2002; Hotamisligil et al., 
1996). Evidence suggests that one or more of these adipokines (as TNF-α and leptin) could 
impair insulin signaling and cause insulin resistance (Briana & Malamitsi-Puchner, 2009; Xiang 
et al., 1999). TNF-α in specific has a potential effect in decreasing insulin sensitivity (Catalano, 
2010). While other adipocytokines might increase insulin sensitivity as adiponectin which has 
been shown to be decreased especially in late pregnancy (Al-Noaemi & Shalayel, 2009).  
4.2.1.1 Adiponectin 
Adiponectin is a novel adipocyte secreting protein hormone discovered in 1995/1996 
(Scherer et al., 1995; Nakano et al., 1996; Maeda et al., 1996; Hu et al., 1996;  Tsao et al., 2002). 
Adiponectin is abundant in the circulation of humans, with plasma levels in the microgram 
per ml range, thus accounting for approximately 0.01% of total plasma protein. 
Chen et al. (2006) reported that the human placenta produces and secretes adiponectin and 
that adiponectin and its receptors are differentially regulated by cytokines and their 
expression altered in women with gestational diabetes mellitus, suggesting that adiponectin 
may play a role in adapting energy metabolism at the materno-fetal interface.  
4.2.1.1.1 Functions of Adiponectin   
Although the physiological role of adiponectin is not yet fully determined, but it has been 
shown that there are a variety of physiological functions induced by adiponectin such as: 
4.2.1.1.1.A General functions 
i. Anti-atherosclerotic action: By inhibiting lipid-laden foam cell formation (Ouchi et al., 
2001), and inhibiting the inflammatory adipokine, tumor necrosis factor-α (TNF-α) 
(Ouchi et al., 2000).  
ii. Anti-inflammatory action: By inhibiting the phagocytic activity of macrophages and 
inhibiting the production of TNF-α by these macrophages (Yokota et al., 2000).  
iii. Anti-oxidant action: By stimulating the endothelial cells to produce nitric oxide (NO) 
(Ouchi et al., 1999). 
iv.  Anti-tumor action: There is a significant inverse association of adiponectin with 
postmenopausal endometrial and breast cancer (Mantzoros et al., 2004; Petridou et al., 
2003).  
4.2.1.1.1.B Specific anti-diabetic functions such as its actions on glucose and lipid 
metabolism 
i. Effects of adiponectin on insulin and glucose metabolism: Adiponectin has insulin-
sensitizing effects. Replenishment of a physiological dose of recombinant adiponectin to 
lipoatrophic mice significantly ameliorated insulin resistance. Moreover, insulin 
resistance in lipoatrophic mice was completely reversed by the combination of 
physiological doses of adiponectin and leptin (Hotta et al., 2000; Berg et al., 2001). In 
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addition to that, adiponectin has indirect insulin-sensitizing effect by decreasing tissue 
triglyceride (TG) content (Shulman, 2000). It is well known that tissue triglycerides 
interfere with insulin-stimulated phosphatidylinositol (PI) 3-kinase activation and 
subsequent glucose transporter 4 (GLUT-4) translocations and glucose uptake, leading 
to insulin resistance (Shulman, 2000; Godoy-Matos et al., 2010). Thus, decreased tissue 
TG content in muscle may contribute to the improved insulin signal transduction. 
Interestingly, in skeletal muscle, adiponectin increases expression of molecules 
involved in fatty acid transport such as CD36, in combustion of fatty-acid such as acyl-
coenzyme-A oxidase, and in energy dissipation such as uncoupling protein 2. These 
changes led to decreased tissue TG content in skeletal muscle whether in experimental 
animals or in human (Godoy-Matos et al., 2010; Yamauchi et al., 2001; Thamer et al., 
2002). 
ii. Effect of adiponectin on glucose metabolism: It has been reported that an acute increase 
in circulating adiponectin levels triggers a transient decrease in basal glucose levels by 
inhibiting both the expression of hepatic gluconeogenic enzymes and the rate of 
endogenous glucose production in both wild-type mice and a type 2 diabetic mouse 
model (Berg et al., 2001; Combs et al., 2001). Furthermore, Kubota et al (2002) provided 
the first direct evidence that adiponectin plays a protective role against insulin 
resistance by generating adiponectin-deficient mice. Adiponectin improves insulin 
resistance and glucose tolerance in both heterozygous (+/-) and homozygous (-/-) 
adiponectin-deficient mice.   
iii. Effects of adiponectin on lipid metabolism: Adiponectin activates AMP-Kinase (AMPK) 
and peroxisome proliferator-actvated receptor (PPAR α) in the liver and muscle, 
thereby stimulating fatty-acid oxidation and decreasing tissue TG content in the liver 
and muscle (Thamer et al., 2002; Fruebis et al., 2001; Yamauchi et al., 2003a). 
Furthermore, adiponectin decreases lipid synthesis and glucose production in the liver 
and causes a decrease in glucose and fatty acid concentration in the blood (Meier & 
Gressner, 2004; Yool et al., 2006).  
4.2.1.1.2 Adiponectin and the pathophysiology of obesity and diabetes  
Many studies have shown that plasma adiponectin concentration is negatively correlated 
with body mass index (BMI) and accordingly, lower in obese than in lean subjects (Ouchi et 
al., 1999; Hotta et al., 2000; Pena et al., 2009). Furthermore, scientists extended these finding 
by demonstrating that plasma adiponectin concentrations are inversely related to 
percentage of body fat, a direct measure of adiposity. And that is consistent across different 
ethnic groups. These results thus confirm that adiponectin is the main adipose-specific 
protein known to date that despite its excusive production in white adipose tissue, is 
negatively regulated in obesity (Hu et al., 1996; Weyer et al., 2001; Statnick et al., 2000). 
These scientific data suggest that adiponectin may have a role in the pathogenesis of obesity. 
As obesity is a predisposing factor for the development of diabetes mellitus in general and 
GDM in specific, this might explain the indirect involvement of a decreased adiponectin in 
the pathogenesis of diabetes mellitus. It has also been shown that in pregnant women there 
is a decrease in adiponectin which is associated with an increase in insulin resistance in the 
third trimester and a further decrease in women with IGT or GDM compared to pregnant 
women with normal glucose tolerance test, even after adjustment for varying degree of 
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protein known to date that despite its excusive production in white adipose tissue, is 
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These scientific data suggest that adiponectin may have a role in the pathogenesis of obesity. 
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GDM in specific, this might explain the indirect involvement of a decreased adiponectin in 
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their body fat mass compared to women with normal glucose tolerance during and after 
pregnancy (Yamauchi et al., 2003; Weyer et al., 2001; Kadowaki & Yamaushi, 2005).  
On experimental animal studies, it was shown that adiponectin causes glucose-lowering 
effects and ameliorates insulin resistance in mice (Yamauchi et al., 2003b). Thus, decreased 
plasma adiponectin concentrations (hypoadiponectinemia) could be involved in the 
pathophysiology of pregnancy-driven insulin resistance and in the pathogenesis of GDM 
and Diabetes mellitus type 2 (DM2).   
It is known that peroxisome proliferator-activated receptors (PPARs) are transcriptional 
factors involved in the regulation of insulin resistance, fat cell differentiation, and 
adipogenesis (Joosen et al., 2006; Schoonjans et al., 1996; Zeghari et al., 2000). It has been shown 
that adiponectin activates AMP-kinase and PPARγ and α which improves insulin resistance 
and reduces fasting glucose level (Tsuchida et al., 2005; Kadowaki & Yamauchi, 2005). Low 
plasma adiponectin correlates highly with insulin resistance in obesity, type 2 DM and GDM 
(Weyer et al., 2001; Worda et al., 2004; Cseh et al., 2004).  
Low adiponectin level in normal pregnancy and GDM could be due to the suppression 
effect of TNF-α and other inflammatory factors on adiponectin transcription in adipocytes 
(Bruun et al., 2003; Fasshauer et al., 2003).  These data highly support the antidiabetic effect of 
adiponectin. 
4.2.1.2 Tumor necrosis factor-α (TNF-α) 
In 1975 Carswell et al discovered the so-called tumor necrosis factor (TNF) which is released 
from macrophages and induces tumor necrosis. Increased circulating TNF-α levels have been 
associated with insulin resistance in obesity, aging, sepsis, muscle damage, and burn patients 
(Hotamisligil et al., 1996; del Aguila et al., 2000; Kirwan et al., 2001; Ling et al., 1994; Conrad et 
al., 1998). Obese animals and humans show a positive correlation between TNF-α levels and 
BMI and hyperinsulinemia (Ling et al., 1994; Clapp & Kiess, 2000; Laham et al., 1994).  
Kirwan et al (2001) reported that TNF-α is a significant predictor of insulin resistance during 
pregnancy. Together with a small additive contribution from leptin and cortisol, TNF-α 
exerted a significant influence on insulin-mediated glucose disposal. Circulating TNF-α 
showed a downward trend during early pregnancy and increased during the third trimester, 
thus mirroring insulin sensitivity changes during those periods. This observation is consistent 
with studies showing an increase in plasma TNF-α in late pregnancy (Kirwan et al., 2002; 
Clapp & Kiess, 2000; Boyd et al., 2007). TNF-α correlates inversely with insulin secretion in 
normal pregnancy and was significantly higher in GDM group (McLachlan et al., 2006).  
TNF-alpha mRNA and protein are present in human placenta and uterine cells at both early 
and late stages of gestation (Chen et al., 1991). In maternal obesity, the level of TNF-α is 
increased in the placenta compared with the non-obese pregnant women (Denison et al., 
2010). Furthermore, it has been shown that placenta and subcutaneous adipose tissues 
obtained from women with GDM release greater amount of TNF-α in response to high 
glucose compared with normal glucose. On the other hand, there was no stimulatory effect 
of high glucose on TNF-α release by tissues obtained from normal pregnant women which 
suggests that TNF-α might be involved in the pathogenesis and /or progression of GDM 
(Coughlan et al., 2001). These results could highly explain the increase in the level of TNF-α 
throughout pregnancy. The increased TNF-α levels in pregnancy fall rapidly after delivery 
(Kirwan et al., 2002; Uvena et al., 1999), which is consistent with the idea that the increase in 
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circulating TNF-α during late pregnancy is mainly due to placental secretion. These findings 
may also help to explain the rapid reversal of insulin resistance after delivery, since 
maternal levels of TNF-α decrease substantially after delivery of the placenta (Kirwan et al., 
2002; Coughlan et al., 2001). 
4.2.1.2.1 The Diabetogenic action of TNF-α 
In-vitro studies have described a direct role for TNF-α in the pathophysiology of insulin 
resistance. TNF-α downregulates insulin receptor signaling in cultured adipocytes (Catalano, 
2010), hepatocytes (Feinstein et al., 1993), and skeletal muscle (del Aguila et al., 1999). TNF-α 
activates a pathway that increases sphingomyelinase and ceramides and appears to interfere 
with insulin receptor autophosphorylation (Catalano, 2010). Also it has been shown that TNF-
α promotes serine phosphorylation of insulin receptor substrate (IRS)-1, thus impairing its 
association with the insulin receptor (Rui et al., 2001). In pregnancy, there is an evidence that 
insulin receptor and IRS-1 tyrosine phosphorylation are impaired, and serine phosphorylation 
is increased in late gestation in skeletal muscle (Friedman et al., 1999; Shao et al., 2000). 
Therefore, it seems that elevated levels of TNF-α in late gestation could attenuate insulin 
signaling, thus causing the decreased insulin sensitivity observed in pregnancy. 
Barbour et al (2007) demonstrated that in skeletal muscle there is 40% decrease in glucose 
entrance in normal pregnant women and 65% decrease in GDM compared with obese 
pregnant women. Although there is no decrease in GLUT4 protein transporter in skeletal 
muscle (Garvey et al., 1992), the GLUT4 transporters are decreased in adipose tissue (Garvey 
& Birnbaum, 1993). The increase in circulating TNF-α in women with GDM  is also 
associated with an increased TNF-α in the skeletal muscle and the  impaired insulin 
signaling persist in obese women with gestational diabetes mellitus up to one year 
postpartum (Kirwan et al., 2004). 
TNF- α is considered as one of the factors which suppress PPAR-γ (Kirwan et al., 2002). 
Furthermore, it has been shown that TNF-α downregulates PPAR-γ expression in 3T3-L1 
cells and can inhibit adipose differentiation (Zhang et al., 1996).  
Catalano et al (2002) observed a decrease in steady-state PPARγ mRNA and protein 
concentration in normal and GDM subjects during late gestation. Furthermore, it has been 
demonstrated that TNF-α decreases adiponectin gene expression in human adipocytes 
(Kappes & Loffler, 2000), and 3t3-L1 adipocytes (Fasshauer et al., 2002). Whereas 
thiazolidinediones (synthetic PPAR-gamma ligand) significantly increases the plasma 
adiponectin concentrations in insulin resistant humans and rodents without affecting their 
body weight, suggesting that the anti TNF-α will restore the adiponectin and improve the 
insulin sensitivity (Maeda et al., 2005). 
Thus the increase in TNF-α whether in subjects with normal pregnancy or with GDM might 
explain the lower level of adiponectin (insulin-sensitizing hormone). The above data highly 
suggest the involvement of TNF-α in the development of GDM. 
4.2.1.3 Resistin 
Steppan et al. (2001) showed that adipocytes secrete a unique signalling molecule, which is 
considered as a hormone and named ‘resistin’ (for resistance to insulin). Resistin is a 114-
amino acid polypeptide hormone (Doshani & Konje, 2009).  
There is a great argument about the involvement of resistin in the pathogenesis of diabetes 
mellitus. Some scientists reported the involvement of resistin in the pathogenesis of diabetes 
mellitus relying on their studies that revealed strong correlations between resistin and obesity 
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2004; Lee et al., 2005). Conversely, serum resistin levels have been found to decline with 
decreased adiposity following medical treatment (Valsamakis et al., 2004). This discovery is 
further authenticated by studies which confirmed a direct correlation between resistin levels 
and subjects with type 2DM (Steppan et al., 2001; Fujinami et al., 2004; McTernan et al., 2003). 
Nevertheless, this theory lacks support from the entire scientific community at large as an 
increasingly greater number of studies presenting contradictory evidences continue to emerge 
(Lee et al., 2003; Nagaev & Smith, 2001). Some studies found significant decreased serum 
concentrations of resistin with increased adiposity (Heilbronn et al., 2004; Way et al., 2001) 
suggesting that not only resistin is downregulated in obese subjects but that it also presents 
itself as an unlikely candidate for linking obesity to Type 2DM. Milan et al (2002) mentioned 
that a decrease of resistin mRNA after weight loss does not support the hypothesis that resistin 
may play a causative role in insulin resistance in obese rats.  
Many studies reported that in patients with type 2 diabetes or obesity, both resistin levels 
and resistin expression in fat cells are increased, correlating with hepatic, but not muscle, 
insulin resistance. In humans, the major source of resistin is the immune cells rather than the 
adipocytes, resistin being a potent inflammatory agent. Insulin inhibits resistin expression in 
adipocytes. Therefore, the elevated basal plasma resistin levels found in patients with type 2 
diabetes, despite increased insulin concentrations, may be the result of adipocyte insulin 
resistance. Resistin inhibits the phosphorylation of hepatic AMPK, decreasing β oxidation 
and increasing fatty acid esterification in triglycerides, and eventually leading to lipid 
accumulation (Maiorana et al., 2007). 
4.2.1.4 Leptin 
It was discovered as an antiobesity hormone in ob/ob mice (Zhang et al., 1994). In human 
adult, the white adipose tissue is the main source of leptin, and its circulating concentration 
is positively correlated with body mass index and fat mass (Maffei et al., 1995; Hellstrom et 
al., 2000).  
Leptin has been detected in the placenta (Masuzaki et al., 1997), and shown to be increased 
in early pregnancy, remained elevated in late pregnancy (Kirwan et al., 2002; Highman et 
al., 1998), and was highest in the more obese GDM group (Kirwan et al., 2002). The 
increased leptin during pregnancy is not proportional with the change in adipose tissue 
mass, and it return to the normal level after delivery suggesting that leptin production by 
the placenta contributes to maternal leptinemia during pregnancy (Lepercq et al., 2001).  
In vitro study on muscle, Muoio et al (1997) demonstrated that leptin attenuated both the 
antioxidative and the lipogenic effects of insulin by 50%. Cseh K et al (2002) suggested that 
the increased TNF-alpha and leptin levels may contribute to insulin resistance in GDM and 
in the third trimester of normal pregnancy. Furthermore, Qiu et al (2004) demonstrated that 
Hyperleptinemia, independent of maternal adiposity, in early pregnancy appears to be 
predictive of an increased risk of GDM later in pregnancy. Kirwan et al (2002) reported that 
leptin was increased in all women in early pregnancy, remained elevated in late pregnancy, 
and was highest in the more obese GDM group. But to adjust for the possible confounding 
effect of obesity and increased fat mass on the relationship between leptin and insulin 
sensitivity, they covaried for body fat and found that the correlation was no longer 
significant, because the increased leptin per se was not predictive of insulin sensitivity. They 
interpreted that, in addition to insulin resistance, leptin resistance may also develop in late 
pregnancy. 
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Chen et al (2010) carried out a study in which twenty women with normal pregnancy and 20 
with GDM were recruited and blood samples were taken on the day of delivery and Days 1, 
3 and 5 after delivery. Serum leptin levels were significantly higher in women with GDM 
than in the controls before delivery and decreased significantly after delivery (p < 0.001). 
After delivery there were no significant differences in serum leptin concentrations between 
women with GDM and the controls. Serum soluble leptin receptor concentrations did not 
differ neither between the two groups, nor before or after delivery. Thus, they concluded 
that Leptin may play a role in GDM through a positive correlation with insulin resistance.  
4.2.1.5 Visfatin 
Fukuhara et al (2005) isolated a newly adipocytokine, named as ‘visfatin’, which is highly 
enriched in the visceral fat of both humans and mice and whose expression level in plasma 
increases during the development of obesity. Visfatin exerted insulin-mimetic effects in 
cultured cells and lowered plasma glucose levels in mice by binding and activating the 
insulin receptors. Suggesting that visfatin's physiological role may lead to new insights into 
glucose homeostasis and/or new therapies for metabolic disorders such as diabetes. 
According to some authors, plasma concentrations of visfatin are elevated in obesity (Berndt 
et al., 2005), type 2 diabetes (Chen et al., 2006) and the increase is typically observed in GDM 
(Krzyzanowska et al., 2006; Lewandowski et al., 2007), all of which are states characterized 
by insulin resistance. There are also, however, data pointing to possible lower visfatin levels 
in obese subjects (Pagano et al., 2006), similarly, Chan et al. (2006) have reported lower 
visfatin levels in women of Chinese origin with GDM. The precise reason for these 
differences is unclear.  
Shali et al (2009) reported that maternal GDM, as well as delivery of a large-for-gestational-
age (LGA) neonate were independently associated with higher maternal plasma visfatin 
concentrations. The linkage between increased maternal circulating visfatin and the 
presence of GDM or delivery of an LGA neonate supports the hypothesis that perturbation 
of adipokines homeostasis may play a role in the pathophysiology of GDM or excess fetal 
growth. 
The current data regarding the relationship between visfatin and insulin sensitivity in 
humans are conflicting. Some authors report a lack of correlation (Berndt et al., 2005; Pagano 
et al., 2006; Zhang et al., 2010), while others observed a significant correlation (Chen et al., 
2006; Lewandowski et al., 2007). 
The role of visfatin in human physiology and pathophysiology remains to be elucidated and 
further work is needed to establish the exact function of visfatin and its mode of action on 
insulin resistance during normal pregnancy and GDM. 
4.2.1.6 Apelin 
Tatemoto et al (1998) isolated an APJ receptor ligand, designated apelin, from bovine 
stomach extracts. The preproproteins consisted of 77 amino acid residues, and the apelin 
sequence was encoded in the C-terminal regions indicating that apelin is an endogenous 
ligand for the APJ receptor.  
Apelin has been described as an adipocyte-secreted factor (adipokine), that is up-regulated 
in obesity and the expression of apelin gene in adipose tissue is reported to increase by 
insulin and TNF-α (Carpéné et al., 2007). Apelin synthesis in adipocytes is stimulated by 
insulin, and plasma apelin level markedly increases in obesity associated with insulin 
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Dray et al (2010) reported that apelin is increased in adipose tissue in different mice models 
of obesity and in the type2 diabetic patients. They reported that apelin plasma levels were 
significantly increased in type 2 diabetic patients. They suggested that apelin and APJ 
expression in mice and humans are regulated in a tissue dependent manner and according 
to the severity of insulin resistance. But, Meral et al (2010) reported that no significant 
relation was found between apelin and BMI, glucose, lipids levels, and also insulin 
sensitivity. In addition, Telejko et al (2010) reported that there is no associations between 
circulating apelin or apelin/APJ mRNA expression and GDM and no indices of insulin 
resistance were noted in their study. Furthermore, Tapan et al (2010) recently reported a 
significant decrease in plasma apelin and adiponectin levels in pubertal obese children. 
More work is needed to establish the involvement/or not of apelin and insulin resistance in 
normal pregnancy and GDM. 
5. The future 
Every now and then, there will be a new factor, hormone, adipocytokine, etc. which is 
involved in the development of insulin resistance and GDM. But the precise 
pathophysiological mechanisms which make the women unable to balance insulin needs 
and develop GDM, remain unknown. However, a number of future studies could explain 
some of these mechanisms. 
5.1 Genotyping 
Genetic variants might be involved in the defect in B-cell function and/or subcellular insulin 
signaling which contribute to the development of GDM. Therefore, we suggest a screening 
genotyping test for a significant number of pregnant women, to identify any genetic 
variants in those who develop GDM. Extending this genotyping to involve familial studies, 
to demonstrate any involvement of these genetic variants and whether they run in families. 
Any positive result will help to give a special care to those women anticipated to develop 
GDM, and thus reducing the associated maternal or fetal complications. 
5.2 Subcellular studies 
Certain studies should be done to identify the exact subcellular reactions in the normal 
insulin resistance that develop during normal pregnancy compared with those subcellular 
changes that lead to glucose intolerance and GDM. The use of radioactive substances might 
help to identify the change in phosphorylation of serine instead of tyrosine residues, or in 
any other subcellular reaction change which occurs in GDM. 
5.3 Autoimmunity 
To study certain aspects of the immune system, which could demonstrate any B-cell 
dysfunction that develops GDM and is related to autoimmunity. Furthermore, if there is any 
interference of the immune system with insulin-receptor interaction, this might contribute to 
the development of GDM. 
5.4 Environmental and diet factors 
30-40 years ago or more, it has been reported that the percent of GDM range from 1-2%, 2-
3%  then the percent increased to 1-4%, 2-7%, 5-10%.  Until recently using 1-hour glucose 
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challenge OGTT had demonstrated that up to 17% of pregnant women develop GDM. That 
means there is a significant increase in the development of GDM in these days. Could there 
be more in future? Environmental factors, changes in life style, and change of diet, such as 
decrease in using fresh diet while increase in using canned food, in addition to the use of 
high caloric diet and food with high glycemic index. All these factors, could highly 
participate in the development of GDM whether directly or indirectly by increasing the 
incidence of obesity.  
6. Conclusions 
The precise mechanisms causing GDM remain unknown. All the previously described 
maternal and feto-placental factors interact in an integrated manner in the development of 
insulin resistance and GDM. The most prominent factors, which are involved in the 
pathogenesis of GDM, are the increase in HPL and TNF-α and the decrease in adiponectin 
during pregnancy.     
Most of the women reverting to normal after delivery, will suggest that the placenta is the 
major contributing organ in the development of GDM.  
The main cause of insulin resistance during GDM is post-cellular defect manifested by a 
decreased phosphorylation of tyrosine residues in insulin receptors and insulin receptor 
substrate-1, while serine phosphorylation is increased which inhibit insulin signaling from 
activating GLUT4 translocation. 
Finally, GDM is probably produced by a complex and variable interaction of all the 
previously mentioned factors - pregnancy-induced factors, genetic, diet, environmental, 
autoimmunity, etc.  
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1. Introduction 
Gestational diabetes mellitus (GDM) usually reveals itself in the latter half of pregnancy and 
it is identified by carbohydrate intolerance of variable severity. 
The presence of GDM has implications for both the mother and the baby. Perinatal 
morbidity includes macrosomia, hypoglycemia, hyperbilirubinaemia and respiratory 
distress syndrome which lead to the subsequent complications (Hod et al., 1991). Long term 
outcomes for the offspring may include obesity and diabetes independent of genetic factors 
(Silverman et al., 1995; Van Assche et al., 1992, 2001). For the mother there is an increased 
risk of overt type 2 diabetes later in life (Mestman, 1987; O'Sullivan, 1989). Both type 2 
diabetes and gestational diabetes have common pathogenic mechanisms where pregnancy 
tends to expose disease in those women who are at risk of developing type 2 diabetes later 
in life. Similar to all forms of hyperglycemia, GDM is characterized by insulin levels that are 
inadequate to proper insulin requirement (Metzger et al.,2007).The pathogenesis of GDM 
has not been clearly defined. The most common hypothesis is that GDM is caused by 
decreasing insulin sensitivity and increasing anti-insulin hormones that are secreted by the 
placenta during pregnancy, such as human placental  lactogen, prolactin, glucocorticoid and 
progesterone (Xue-lian et al., 2008). 
It has become increasingly evident that endocrine/metabolic hormones such as leptin, 
adiponectin, resistin, proinflammatory mediators including C-reactive protein ( CRP) are 
strongly linked with abnormal carbohydrate metabolism. 
In recent times a number of first trimester studies have shown association of different 
biomarkers with the development of GDM. These include elevated serum or plasma C-
reactive protein (Wolf et al., 2003), lower sex hormone-binding globulin (Thadhani et al., 
2003), increased placental growth factor (Ong et al., 2004) and elevated leptin (Qiu et al., 
2004) and decreasing of adiponectin concentration. 
Some studies have recommended that Vitamin D deficiency could play a role in 
pathogenesis of gestational diabetes. 
This chapter will focus on the studies about the role of adipocytes mediators, 
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2. Adipocyte mediators 
It is becoming obvious that adipose tissue is not just a storage for extra energy but that it 
secretes a number of biologically active peptides as a group named adipocytokines that 
control glucose and fatty acid metabolism (Youn et al.,2004). These peptides have similar  
properties with cytokines, and so referred to as "adipocytokines“,  e.g. leptin, tumor necrosis 
factor-α(TNF-α), interleukin 6 (IL-6), adiponectin  and  resistin. These adipocytokines may 
influence activity of other tissues (Nedvidkova et al., 2005). 
2.1 Adiponectin 
2.1.1 Adiponectin structure  
Adiponectin is a 244-amino-acid-long polypeptide that regulates a number of metabolic 
processes, including glucose regulation and fatty acid catabolism. Adiponectin is exclusively 
secreted from adipose tissue into the circulation and is very plentiful in plasma relative to 
other hormones. Adiponectin concentrations ranging from 5 to 30mg/ml and  accounting 
for approximately 0.01% of total plasma protein . Females have higher levels of plasma 
concentration than males (Díez & Iglesias, 2003). 
Adiponectin was first identified in mice as a transcript overexpressed in preadipocytes 
(Lara-Castro et al.,  2007) differentiating into adipocyte (Matsuzawa et al., 2004). The human 
homologue was recognized as the most abundant transcript in adipose tissue. As opposed 
to anticipation, in spite of being produced in a fat tissue, adiponectin was found to decline 
in obesity (Díez & Iglesias, 2003; Nedvídková et al., 2005; Ukkola & Santaniemi, 2002). This 
down regulation has not been clearly described. The gene was localised to chromosome 
3p27, a region highlighted as affecting genetic vulnerability to obesity and type 2 diabetes. 
Supplementation by varying forms of adiponectin improved control of insulin, blood 
glucose and triglyceride levels in mouse models. 
Berbelin, a herbal folk medicine, has been shown to increase adiponectin expression which 
partly explains its advantageous effects on metabolic disturbances (Choi et al., 2009). 
A reduction in adiponectin expression is associated with insulin resistance in animal 
models. Administration of adiponectin has been accompanied by a reduction in plasma 
glucose and an increase in insulin sensitivity. In addition, thiazolidinediones, drugs that 
increase insulin sensitivity by stimulation of the peroxisome proliferator-activated receptor-
δ, increase plasma adiponectin and mRNA levels in mice. 
A recent study has shown that phosphorylation and Levels of the hormone are conversely 
correlated with body fat proportion in adults although the association in infants and young 
children is less clear. The hormone plays a role in the inhibition of the metabolic disturbance 
that may end in type 2 diabetes (Ukkola & Santaniemi, 2002), obesity, atherosclerosis (Díez 
& Iglesias, 2003), non-alcoholic fatty liver diseases (NAFLD) and independent risk factors 
for metabolic syndrome (Renaldi et al., 2009)., Levels of adiponectin are decreased in 
diabetics compared to non-diabetics. Weight loss significantly increases circulating levels 
(Coppola et al., 2009).  
Adiponectin automatically self-associates into larger structures. Initially, three adiponectin 
molecules bind together to form a homotrimer. The trimers continue to self-associate and 
form hexamers or dodecamers. Like the plasma concentration, the relative levels of the 
higher-order structures are sexually dimorphic, where females have increased proportions 
of the high-molecular weight forms. 
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Adiponectin exerts some of its weight reduction effects via the brain. This is similar to the 
action of leptin, but the two hormones perform complementary actions, and can have 
additive effects (Nedvídková et al., 2005). 
2.1.2 Metabolic effect of adiponectin 
Adiponectin affects glucose flux through decreasing gluconeogenesis and increasing glucose 
uptake (Díez & Iglesias, 2003; Nedvídková et al., 2005; Vasseur et al., 2003). Adiponectin has 
a role in lipid catabolism (Vasseur et al., 2003) by β-oxidation and triglyceride clearance 
(Nedvídková et al., 2005). The other metabolic effects of adiponectin are protection against 
endothelial dysfunction and improvement of insulin sensitivity and weight loss, and control 
of energy metabolism (Vasseur et al., 2006).Adiponectin has also another effects, including 
putative insulin-sensitising, anti-atherogenic and anti inflammatory characteristics (Berg et 
al., 2002; Ukkola & Santaniemi, 2002).  
Consistent with the low circulating levels of adiponectin observed in type 2 diabetes, 
adiponectin concentration is contrarily related to both insulin resistance and central 
adiposity (Arita et al., 1999; Weyer et al., 2001). Low baseline adiponectin concentration can 
predict the subsequent development of insulin resistance although elevated baseline levels 
have been shown to be protective against the succeeding development of type 2 diabetes 
(Daimon et al., 2003; Lindsay et al., 2002; Snehalatha et al., 2003; Spranger et al. , 2003). 
Recognition of gestational diabetes mellitus helps in identification of populations of young 
women at high risk of developing type 2 diabetes. Therefore, reduction in serum 
adiponectin levels in GDM may be comparable to type 2 diabetes.  
2.1.3 Adiponectin and GDM 
Some studies exhibited hypoadiponectinemia in pregnant women with gestational diabetes. 
A cross sectional study of 180 women in their third trimesters illustrated gestational diabetic 
women had more hypoadiponectinemia compared with normoglycemic controls after 
adjustment for covariates including insulin resistance. This study showed adiponectin 
concentration is an independent correlate of beta cell function in late pregnancy. 
Adiponectin was correlated with insulin secretion-sensitivity index (ISSI). ISSI was 
positively correlated with adiponectin and negatively correlated with GDM and IGT. 
Therefore, adiponectin may play a principal role in mediating insulin resistance and beta 
cell malfunction in the development of diabetes (Rentakaran et al., 2005).To determine 
whether adiponectin relate to the postpartum metabolic disturbance linking GDM with type 
2 diabetes a cohort study was done on 487 pregnant wemen in pregnancy and at 3 months 
post partum. This study demonstrated adiponectin was related to postpartum insulin 
sensitivity and  hypoadiponectinemia in pregnancy predicts postpartum insulin resistance, 
beta cell dysfunction and fasting glycaemia, and hence may be relevant to the 
pathophysiology relating GDM with type 2 diabetes (Rentakaran et al., 2010). To investigate 
level of adiponectin and metabolic factors in women with gestational diabetes a cross 
sectional study was done . The result of this study showed the level of adiponectin was 
lower in gestational diabetes and adiponectin correlates negatively with insulin resistance in 
homeostasis model assessment-insulin resistance (HOMA-IR) (Altinova et al., 2007). To 
evaluate whether adiponectin is a predictive factor for gestational diabetes mellitus (GDM) 
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Adiponectin exerts some of its weight reduction effects via the brain. This is similar to the 
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Some studies exhibited hypoadiponectinemia in pregnant women with gestational diabetes. 
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concentration is an independent correlate of beta cell function in late pregnancy. 
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positively correlated with adiponectin and negatively correlated with GDM and IGT. 
Therefore, adiponectin may play a principal role in mediating insulin resistance and beta 
cell malfunction in the development of diabetes (Rentakaran et al., 2005).To determine 
whether adiponectin relate to the postpartum metabolic disturbance linking GDM with type 
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post partum. This study demonstrated adiponectin was related to postpartum insulin 
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demonstrated that adiponectin was an independent predictor for GDM. For GDM screening, 
adiponectin was not as strong a predictor as GCT. In any case, adiponectin could be used to 
rule out pregnant women at low risk of GDM (Weerakiet et al., 2006). In a cross sectional 
study serum level of adiponectin in GDM women and impaired glucose test and normal 
pregnant women was compared. This study showed the serum adiponectin level in 
gestational diabetes was significantly lower than the impaired glucose test and control 
groups and a negative correlation between prepregnancy BMI and adiponectin 
(Soheilykhah et al., 2009). In another study, class A2 and B gestational diabetes are 
associated with a suppressed level of adiponectin (Thyfault et al., 2005 ). To investigate 
changes in serum adiponectin during pregnancy and postpartum and assess its relationship 
with insulin resistance as measured by homeostasis model assessment (HOMA-IR) a study 
was done and revealed adiponectin was lower in gestational diabetes than in control groups 
during pregnancy and a significant post reduction in adiponectin was observed in maternal 
adiponectin after delivery indicating a significant placental contribution to adiponectin 
production (Vitoratos et al., 2008). The result of the another study identified weight gain as 
the strongest factor associated with declining β cell compensation for insulin resistance in 
Hispanic women at high risk for type 2 diabetes. Such effects may be mediated through at 
least two mechanisms: alteration in adipokine levels and increasing insulin resistance (Xiang 
et al., 2010). A prospective, nested case control study showed adiponectin concentration in 
early pregnancy was significantly lower in women with GDM than controls (4.4 vs. 8.1), 
approximately 73% of women with GDM, compared with 33% of controls, had adiponectin 
concentration less than 6.4µg/ml. After adjustment for confounding, women with 
adiponectin concentration in early pregnancy, less than 6.4µg/ml, experienced a 4.6-fold 
increased risk of GDM as compared with those with higher concentrations (Williams  et al., 
2004). Postpartum follow-up showed that women developing metabolic syndrome had 
significantly lower adiponectin and resistin concentration during pregnancy. Nonetheless, 
after adjustment for age, prepregnancy BMI, logistic regression analysis did not show 
independent relation between adiponectin and resistin with development of postpartum 
metabolic syndrome (Hossein-nezhad et al., 2010 ). To evaluate plasma adiponectin levels, 
insulin resistance and glucose tolerance in women with gestational diabetes mellitus and in 
normal pregnancies adiponectin measurement were performed two times as in 28–31 weeks 
of pregnancy and at 3 months after delivery. Insulin resistance was calculated by the 
homeostasis model assessment. This study demonstrated decreased adiponectin levels in 
GDM do not normalize instantaneously following the delivery. The difference is more 
apparent in adiponectin levels than in HOMA-IR (Cavit et al., 2007). Low plasma 
adiponectin concentration was associated with GDM in another study and adiponectin 
mRNA levels in adipose tissue biopsies from GDM subjects were reduced (Ranheim et al., 
2004). Concentration of adiponectin may change before the appearance of the abnormal 
glucose level during pregnancy (Xue-lian et al., 2008). To identify potential biomarkers for 
impending gestational diabetes that appear in the plasma before impaired glucose tolerance 
a prospectively study was done and the results demonstrated a significant difference in 
insulin and adiponectin concentration at 11 weeks gestation and, compared to control 
groups, women with gestational diabetes exhibited elevated plasma insulin and reduced 
plasma adiponectin at 28 weeks gestation. Bivariate logistic regression analysis showed that 
both insulin and adiponectin were associated with subsequent development of gestational 
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diabetes. Based upon this study (Georgiou et al., 2008) the predictive threshold values for 
GDM at 11 weeks are >25µU/ml insulin and <3.5µg/ml adiponectin. This study confirmed 
the another survey (Wiliams et al., 2004) that a low blood concentration of adiponectin early 
in pregnancy is associated with increased risk of subsequent GDM. 
In summary the results of case control and prospective studies demonstrated association of 
low adiponectin and GDM. 
2.2 Leptin  
2.2.1 Leptin structure  
Leptin, a protein product of the obese (ob) gene with a 16 KDA molecular weight, is made of 
167 amino acids (Hui-lan et al., 2004 ). It is a circulating hormone that is expressed plentifully 
in the adipose tissue. Leptin is also produced by non adipose tissue  including the stomach, 
intestine and the placenta in humans (Masuzaki et al., 1997) and acts on the receptors of the 
hypothalamus to decrease food intake and increase energy consumption (Zhang et al., 1994). 
Leptin is encoded by the obesity gene. It signals to the brain when there has been enough 
eating to sustain body weight. It has been exhibited that laboratory mice have a mutation on 
the ob gene which inhibits the function of leptin causing the mice to become morbidly obese. 
In addition mutation in the gene that codes  the leptin receptor causes obesity in the mice. 
Mutations in the ob gene affect expression of leptin, which in turn can cause obesity, infertility, 
and diabetes in lab mice (Zhang et al., 1997). It is hypothesized that alteration in the human ob 
gene causes some serious cases of early-onset obesity. Other less severe kinds of human 
obesity are considered not to be caused by mutation, but by changing in regulation or 
resistance to the action of leptin (Flier et al., 1995). Diminished production of leptin or fewer 
receptors may also be responsible for those who are overweight but not obese. It seems that 
the appropriate amount of leptin has to be present in the central nervous system to leptin act 
as weight lowering in human obesity (Zhang et al., 1997). 
2.2.2 Leptin action  
Homeostatic regulation of body weight depends on the capacity of the brain to sense and 
respond to changes in peripheral energy supplies. Insulin receptors were recognized in the 
brain and concentrated in the hypothalamus. These receptors have binding and signaling 
properties like peripheral insulin receptors. Leptin and insulin enter the brain and act on 
special hypothalamic neurons to prevent food intake and alter appetite. Leptin raise energy 
expenditure by regulating of neurotransmitters. (Porter et al., 2002). The evidence shows 
that insulin and leptin also act on the hypothalamus to control glucose production from the 
liver via stimulation of the autonomic nervous system. Thus, communication between 
leptin, insulin and significant hypothalamic neurons is necessary for normal energy balance 
and glucose homeostasis, deregulation of which will lead to obesity and type 2 diabetes. 
Indeed, in many forms of obesity, hypothalamic leptin and insulin resistance develops in 
which leptin and insulin are less effective in causing anorexia and decreased body weight. 
Some studies propose that leptin also has a specific effect on the regulation of whole body 
glucose homeostasis (Al-Dahhri et al., 2002; Ceddia et al., 2002). Numerous metabolic 
studies have shown a positive association between direct and indirect measures of adiposity 
with plasma leptin concentrations. Plasma leptin concentration correlated with BMI, percent 
of body fat and plasma insulin in both overweight/obese and normal weight and decreased 
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2.2.3 Leptin and gestational diabetes 
The increased risk of GDM with increasing maternal plasma concentration of leptin is 
biologically plausible and is likely accounted for by diverse molecular and biochemical 
pathways in multiple tissue. Leptin has been shown to regulate peripheral glucose 
homeostasis through its action in skeletal muscle and its effects on hepatic gene expression 
of the gluconeogenetic enzymes and phosphoenolpyruvate carboxykinase (Rossetti et al., 
1997). In addition, leptin has been shown to directly modulate glucose handling in skeletal 
muscle by promoting fatty acid oxidation. Investigators have postulated that leptin induced 
insulin resistance may be secondary to glucose flux via the hexosamine pathway (Mueller et 
al., 1998). Although the pathophysiology of hyperleptinemia in GDM is unknown, it is clear 
that leptin has numerous actions on target tissues and is involved in regulation on several 
endocrine pathways. Although the biologic action of leptin primarily mediated through 
interactions with receptors expressed in the hypothalamus, leptin receptors are widely 
distributed across other tissues including the lungs, liver, kidney, pancreas, heart and the 
placenta (Chen et al., 1999; Hoggard et al., 1997; Kieffer et al., 1996; Schulz et al., 2000). This 
wide distribution of leptin receptors portends the peptide diverse influence on 
neuroendocrine, cardiovascular and reproductive functions. Leptin is correlated with a 
series of endocrine parameters including insulin, insulin-like growth factors, hemoglobin 
A1c and sex hormone-binding globulin 
In pregnant women with changes in maternal fat stores and glucose metabolism, leptin 
increases (Schubring et al., 2000). Maternal leptin concentration increases 2 to 3 times above 
the non-pregnant concentration with the peak around 28 weeks of gestation (Schubring et 
al., 2000). The serum leptin level relates to body weight, body mass index, fat accumulation 
of the pregnant woman, fetal growth and development and fetal fat deposits. In recent 
years, it was considered that leptin is associated in pregnancy-induced hypertension 
syndrome, fetal intrauterine growth retardation and gestational diabetes. Increasing 
maternal plasma leptin levels may result from an upregulation of adipocyte leptin synthesis 
in the presence of increasing insulin resistance and hyperinsulinemia in the second half of 
pregnancy (Laivuori et al., 2000; Rossetti et al., 1997). Investigators have shown that leptin 
directly affects whole body insulin sensitivity through regulating the efficiency of insulin-
mediated glucose metabolism by skeletal muscle (Cohen et al., 1996) and by hepatic 
regulation of gluconeogenesis (Rossetti et al., 1997). Some evidence suggests that leptin has 
an acute inhibitory effect on secretion of insulin (Ceddia et al., 2002). Large epidemiological 
studies have shown that plasma leptin concentrations were positively associated with 
insulin resistance in men and non-pregnant women (Donahue et al., 1999).  
Available data suggest a complex relation between leptin and glucose homeostasis in 
humans. Two teams of investigators have studied maternal leptin concentrations in GDM 
women and the related published results are conflicting. On the other hand, the available 
data do not explain whether the alterations in leptin concentrations are the cause or result of 
the metabolic disturbances, such as hyperglycemia, that are essential to GDM. In addition, 
the severity of any possible association of GDM risk with different concentrations of leptin 
was not assessed in either study (Festa et al., 1999; Kautzky-Willer et al., 2001). In a case-
control study reported that maternal third-trimester plasma leptin concentrations were 
higher in GDM women compared with the control group (24.9 versus 18.2 ng/mL; P=0.001) 
(Kautzky-Willer et al., 2001). Such a relation was also found in other study. (Vitoratus et al., 
2000)  Hyperleptinemia, independent of maternal adiposity, in early pregnancy appears to 
be predictive of an increased risk of GDM later in pregnancy. After adjusting for maternal 
 
The Role of Adipocyte Mediators, Inflammatory Markers and Vitamin D in Gestational Diabetes 
 
121 
prepregnancy adiposity and other confounders, women with leptin concentrations of 
31ng/ml or higher experienced a 4.7-fold increased risk of GDM as compared with women 
who had concentrations of 14.3ng/ml or lower. Each 10-ng/ml increase in the leptin 
concentration was associated with a 20% increase in GDM risk (Qiu et al., 2004). Serum 
leptin level is correlated with glucose tolerance during pregnancy (Liu et al., 2003). In a case-
control study, at 28 weeks of gestation, fasting serum concentration of leptin, insulin and 
homeostatic model assessment index were measured in three groups, GDM, IGT, and 
normal control, and compared them with each other. This study demonstrated that the 
serum leptin level was significantly higher in women with GDM than in the two other 
groups ( p = 0.03). In women with GDM and IGT, leptin was significantly positively related 
with insulin and homeostatic model assessment index (r = 0.221, p = 0.03) and (r = 0.246, p = 
0.03), respectively. (Soheilykhah et al., 2011) 
In a case-control study, noted that maternal third trimester leptin concentrations were 
significantly lower in GDM cases as compared with controls after adjusting for possible 
confounding factors such as BMI and insulin concentrations (Festa et al., 1999). 
Concentration of leptin increased before the appearance of the abnormal glucose level 
during pregnancy (Xue-lian et al., 2008). Some studies evaluated the relationship between 
leptin concentration and insulin resistance. Leptin concentration was positively associated 
with insulin level and HOMA index (Maghbooli et al., 2007). A positive and significant 
correlation between the maternal leptin and fasting insulin levels (Liu et al., 2003) and also 
has shown that leptin predicts the development of GDM independent of maternal BMI and 
other risk factors. The findings of Kautzky-Willer et al are generally consistent with the 
Different reports. (Kautzky-Willer et al., 2001 ,Lappas et al., 2005 Qiu et al., 2004). 
Several possible explanations are suggested for the disparities in the existing studies. The 
study design and the confounding factors such as the time of blood sampling (whether 
blood samples were collected before, after, or during labor) and maternal factors, including 
whether women were treated with medication or diet before blood was collected for leptin 
determination might account for differences. Moreover, variations in population 
characteristics and status of glycemic control could also account for some of the observed 
differences in the study results. 
In summary, the results of different studies from experimental, clinical, and epidemiological 
investigations suggest that leptin is an important mediator of glucose homeostasis in 
pregnancy (Qiu et al., 2004) and measurement of leptin alone, or combined with the 
assessment of other risk factors, may help identify women at risk of developing GDM. 
2.3 Resistin 
2.3.1 Resistin structure  
Insulin resistance is strongly associated with obesity, but even among obese subjects insulin 
sensitivity is different. Recently, a new adipocyte hormone, resistin, was identified, shown 
to decrease insulin-mediated glucose uptake, and shown to be increased in obese mice 
Resistin, also known as adipose tissue-specific secretory factor , is a cystein-rich protein that 
in humans is encoded by the RETN gene (Wang et al., 2002). Resistin was discovered to be 
produced and released from adipose tissue to provide endocrine functions likely involved 
in insulin resistance. This thought initially developed from studies exhibiting that serum 
resistin levels increase with obesity in several species (humans, rats, and mice) . (Yamauchi 
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in insulin resistance. This thought initially developed from studies exhibiting that serum 
resistin levels increase with obesity in several species (humans, rats, and mice) . (Yamauchi 





other tissues, including the hypothalamus, pituitary and adrenal glands, pancreas, 
gastrointestinal tract, myocytes, spleen and white blood cells  
The role of resistin in obesity and insulin resistance in humans is controversial.  
2.3.2 Resistin action 
Resistin causes insulin resistance and glucose intolerance in mice. Serum resistin levels will 
rise with increased adiposity, particularly central obesity (Degawa-Yamauchi et al., 2003; 
Vendrell et al., 2004). Conversely, serum resistin levels decrease with lowering adiposity 
following medical treatment (Valsamakis et al., 2004). The level of tissue resistin is 
decreased by insulin, cytokines such as tumour necrosis factor, α endothelin-1 and increased 
by growth and gonadal hormones, hyperglycaemia, interleukin-6 and lipopolysaccharide 
(Adeghate, 2004). Animal study exhibited that resistin gene expression and protein levels 
are regulated  in parallel with glucose and insulin during fasting and feeding Many 
researchers have shown positive correlations between resistin levels and insulin 
resistance.Thus resistin has been suggested to link obesity with type 2 diabetes (Hirosumi et 
al., 2002; Rajala et al., 2004; Silha et al., 2003; Smith et al., 2003). This discovery is further 
confirmed by studies which verified a direct correlation between resistin levels and subjects 
with type 2DM (Asensio et al., 2004; Fujinami et al., 2004; McTernan et al., 2003; Steppan et 
al., 2001). With the finding that resistin was at least in part a cause of the insulin resistance 
and T2DM, medications which specifically lead to decreased serum resistin in T2DM 
subjects were developed(Tjokroprawiro, 2006). The level of circulating resistin is decreased 
by the anti-diabetic drug  such as rosiglitazone and increased by obesity. Administration of 
the anti resistin antibody decreases blood sugar and improve insulin action in mice with diet 
induced obesity. Treatment of normal mice with recombinant resistin impairs glucose 
tolerance and decreases insulin action. Insulin stimulated glucose uptake by adipocyte is 
increased by neutralization of resistin and is reduced by resistin treatment (Steppan et al., 
2001). Because resistin is identical to a protein which had a role in allergic pulmonary 
infiltration, the effect of resistin in inflammation was studied and these researches 
demonstrated association of resistin with other physiological systems such as inflammation 
and energy homeostasis (Adeghate, 2004; Stumvoll & Häring, 2002; Vendrell et al., 2004). 
2.3.3 Resistin and gestational diabetes  
Resistin is expressed in human placenta and has been supposed to play a role in regulating 
energy metabolism in pregnancy. Resistin protein expression in placental tissue was much 
higher than that in subcutaneous adipose tissue in normal human abdomen, pregnant 
abdomen and thigh. It was indicated that resistin protein can be secreted from human 
placental tissue. Resistin might be one of the factors that lead to pregnant physiological 
insulin resistance and GDM (Yongming et al., 2006).Resistin is secreted by the placenta 
during human pregnancy (Sagawa et al., 2002) Serum resistin levels are not different among 
non-pregnant women and women in the first and second trimesters of pregnancy .Serum 
resistin  increases by the third trimester (Chen et al., 2005). Resistin is detectable at 20 weeks 
of gestation. In newborns, resistin concentrations were two to three-fold higher than those 
reported in adults regardless of sex, birth weight, pattern of growth or metabolic state of the 
mother (Yongming et al., 2006). Resistin gene expression is found in placental tissues during 
pregnancy (Yura et al., 2003) and it has been supposed that it could be involved in the 
pathogenesis of the insulin resistance state found in the second half of pregnancy and in the 
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development of gestational diabetes. Resistin levels were significantly higher in normal 
pregnant women than in nonpregnant controls and showed a negative correlation with 
gestational age. Resistin was detected in the umbilical venous blood in fetus from 20 to 41 
weeks of gestation. Detection of high levels of resistin in cord blood during gestation is 
consistent with a regulatory action of these adipokines on tissue differentiation and foetal 
growth (Cortelazzi et al., 2007). Recent reports have measured the level of resistin during 
pregnancies complicated by gestational diabetes with inconsistent results (Cortelazzi et al., 
2007, Chen et al., 2007). The result of a study showed resistin level in gestational diabetes 
was lower than normal pregnancy(Megia et al.,2008)This result inconsistent with other 
study that demonstrated  serum resistin concentration was significantly higher in women 
with GDM than in controls before delivery and the  serum levels of resistin significantly 
decreased after delivery in both the GDM group and controls.The serum level of resistin 
was different on days 1 and 3 but not by day 5 after delivery (Chen et al.,2007). The serum 
resistin levels were higher in the 1st, 2nd and 3rd trimesters of pregnancy and higher in 
GDM than in control groups and hyperresistinemia may also be associated with the 
pregnancy-induced insulin resistance (Palik et al., 2007). The discrepancy of these findings is 
unclear, but may be related to different populations of the studies, the type of study or the 
time of sampling during pregnancy. 
3. Inflammatory mediators (C-reactive protein) 
3.1 C-reactive structure and actions 
C-reactive protein (CRP) is a sensitive marker of systemic infection and is widely used in 
clinical settings (Kushner I& Rzewnicki, 1994). CRP was first detected in 1930 by Tillet and 
Frances (Tillett & Francis, 1930), who identified a substance that formed a precipitate when 
combined with polysaccharide C of streptococcus pneumonia in the sera of patients acutely 
infected with pneumococcal pneumonia. Subsequently, it was found that this reaction was 
not unique to pneumococcal pneumonia but could be found with a variety of the other acute 
infections. This was early evidence of the body’s chemical response to inflammatory states 
and led to characterization of other so called acute phase proteins (Abernathy & Avery, 
1941). CRP is normally present in low levels in serum but increase rapidly and dramatically 
in response to a variety of infectious or inflammatory conditions (Ballou & Kushner, 1992). 
Since its discovery, CRP has been studied as a screening device for occult inflammation, as a 
marker of disease activity and as a diagnostic tool (Pepys, 1981). Recently, more rapid and 
accurate methods of quantifying CRP have lead to a new interest in its value in clinical 
medicine (Palosuo et al., 1986) although low-grade inflammatory states not originated from 
infections and atherosclerosis have also been associated with an increase in CRP levels. For 
instance, obesity is linked to chronic subclinical inflammation as manifested by mild increases 
in CRP cytokines and adipocytokines and is the principal risk factor for type 2 diabetes. In 
addition, patients with increases in CRP are at risk of myocardial infarction and peripheral 
arterial disease (Engström et al., 2003; Ford, 1999; Ridker et al., 2000; Tracy et al., 1997; Yudkin 
et al., 1999). Elevated serum concentration of acute-phase proteins, exhibiting chronic 
subclinical inflammation, has been associated with insulin resistance syndrome in men and 
non-pregnant women (Festa et al., 2000; Han et al., 2002; Pradhan et al., 2002; Ridker et al., 
2003). The molecular basis for the association between the inflammation and diabetes related 





other tissues, including the hypothalamus, pituitary and adrenal glands, pancreas, 
gastrointestinal tract, myocytes, spleen and white blood cells  
The role of resistin in obesity and insulin resistance in humans is controversial.  
2.3.2 Resistin action 
Resistin causes insulin resistance and glucose intolerance in mice. Serum resistin levels will 
rise with increased adiposity, particularly central obesity (Degawa-Yamauchi et al., 2003; 
Vendrell et al., 2004). Conversely, serum resistin levels decrease with lowering adiposity 
following medical treatment (Valsamakis et al., 2004). The level of tissue resistin is 
decreased by insulin, cytokines such as tumour necrosis factor, α endothelin-1 and increased 
by growth and gonadal hormones, hyperglycaemia, interleukin-6 and lipopolysaccharide 
(Adeghate, 2004). Animal study exhibited that resistin gene expression and protein levels 
are regulated  in parallel with glucose and insulin during fasting and feeding Many 
researchers have shown positive correlations between resistin levels and insulin 
resistance.Thus resistin has been suggested to link obesity with type 2 diabetes (Hirosumi et 
al., 2002; Rajala et al., 2004; Silha et al., 2003; Smith et al., 2003). This discovery is further 
confirmed by studies which verified a direct correlation between resistin levels and subjects 
with type 2DM (Asensio et al., 2004; Fujinami et al., 2004; McTernan et al., 2003; Steppan et 
al., 2001). With the finding that resistin was at least in part a cause of the insulin resistance 
and T2DM, medications which specifically lead to decreased serum resistin in T2DM 
subjects were developed(Tjokroprawiro, 2006). The level of circulating resistin is decreased 
by the anti-diabetic drug  such as rosiglitazone and increased by obesity. Administration of 
the anti resistin antibody decreases blood sugar and improve insulin action in mice with diet 
induced obesity. Treatment of normal mice with recombinant resistin impairs glucose 
tolerance and decreases insulin action. Insulin stimulated glucose uptake by adipocyte is 
increased by neutralization of resistin and is reduced by resistin treatment (Steppan et al., 
2001). Because resistin is identical to a protein which had a role in allergic pulmonary 
infiltration, the effect of resistin in inflammation was studied and these researches 
demonstrated association of resistin with other physiological systems such as inflammation 
and energy homeostasis (Adeghate, 2004; Stumvoll & Häring, 2002; Vendrell et al., 2004). 
2.3.3 Resistin and gestational diabetes  
Resistin is expressed in human placenta and has been supposed to play a role in regulating 
energy metabolism in pregnancy. Resistin protein expression in placental tissue was much 
higher than that in subcutaneous adipose tissue in normal human abdomen, pregnant 
abdomen and thigh. It was indicated that resistin protein can be secreted from human 
placental tissue. Resistin might be one of the factors that lead to pregnant physiological 
insulin resistance and GDM (Yongming et al., 2006).Resistin is secreted by the placenta 
during human pregnancy (Sagawa et al., 2002) Serum resistin levels are not different among 
non-pregnant women and women in the first and second trimesters of pregnancy .Serum 
resistin  increases by the third trimester (Chen et al., 2005). Resistin is detectable at 20 weeks 
of gestation. In newborns, resistin concentrations were two to three-fold higher than those 
reported in adults regardless of sex, birth weight, pattern of growth or metabolic state of the 
mother (Yongming et al., 2006). Resistin gene expression is found in placental tissues during 
pregnancy (Yura et al., 2003) and it has been supposed that it could be involved in the 
pathogenesis of the insulin resistance state found in the second half of pregnancy and in the 
 
The Role of Adipocyte Mediators, Inflammatory Markers and Vitamin D in Gestational Diabetes 
 
123 
development of gestational diabetes. Resistin levels were significantly higher in normal 
pregnant women than in nonpregnant controls and showed a negative correlation with 
gestational age. Resistin was detected in the umbilical venous blood in fetus from 20 to 41 
weeks of gestation. Detection of high levels of resistin in cord blood during gestation is 
consistent with a regulatory action of these adipokines on tissue differentiation and foetal 
growth (Cortelazzi et al., 2007). Recent reports have measured the level of resistin during 
pregnancies complicated by gestational diabetes with inconsistent results (Cortelazzi et al., 
2007, Chen et al., 2007). The result of a study showed resistin level in gestational diabetes 
was lower than normal pregnancy(Megia et al.,2008)This result inconsistent with other 
study that demonstrated  serum resistin concentration was significantly higher in women 
with GDM than in controls before delivery and the  serum levels of resistin significantly 
decreased after delivery in both the GDM group and controls.The serum level of resistin 
was different on days 1 and 3 but not by day 5 after delivery (Chen et al.,2007). The serum 
resistin levels were higher in the 1st, 2nd and 3rd trimesters of pregnancy and higher in 
GDM than in control groups and hyperresistinemia may also be associated with the 
pregnancy-induced insulin resistance (Palik et al., 2007). The discrepancy of these findings is 
unclear, but may be related to different populations of the studies, the type of study or the 
time of sampling during pregnancy. 
3. Inflammatory mediators (C-reactive protein) 
3.1 C-reactive structure and actions 
C-reactive protein (CRP) is a sensitive marker of systemic infection and is widely used in 
clinical settings (Kushner I& Rzewnicki, 1994). CRP was first detected in 1930 by Tillet and 
Frances (Tillett & Francis, 1930), who identified a substance that formed a precipitate when 
combined with polysaccharide C of streptococcus pneumonia in the sera of patients acutely 
infected with pneumococcal pneumonia. Subsequently, it was found that this reaction was 
not unique to pneumococcal pneumonia but could be found with a variety of the other acute 
infections. This was early evidence of the body’s chemical response to inflammatory states 
and led to characterization of other so called acute phase proteins (Abernathy & Avery, 
1941). CRP is normally present in low levels in serum but increase rapidly and dramatically 
in response to a variety of infectious or inflammatory conditions (Ballou & Kushner, 1992). 
Since its discovery, CRP has been studied as a screening device for occult inflammation, as a 
marker of disease activity and as a diagnostic tool (Pepys, 1981). Recently, more rapid and 
accurate methods of quantifying CRP have lead to a new interest in its value in clinical 
medicine (Palosuo et al., 1986) although low-grade inflammatory states not originated from 
infections and atherosclerosis have also been associated with an increase in CRP levels. For 
instance, obesity is linked to chronic subclinical inflammation as manifested by mild increases 
in CRP cytokines and adipocytokines and is the principal risk factor for type 2 diabetes. In 
addition, patients with increases in CRP are at risk of myocardial infarction and peripheral 
arterial disease (Engström et al., 2003; Ford, 1999; Ridker et al., 2000; Tracy et al., 1997; Yudkin 
et al., 1999). Elevated serum concentration of acute-phase proteins, exhibiting chronic 
subclinical inflammation, has been associated with insulin resistance syndrome in men and 
non-pregnant women (Festa et al., 2000; Han et al., 2002; Pradhan et al., 2002; Ridker et al., 
2003). The molecular basis for the association between the inflammation and diabetes related 





insulin resistance and stimulate the acute phase inflammatory response (Fernandez-Real et al., 
2001; Kern et al., 2001; Mohamed-Ali et al., 1998; Vozarova et al., 2001).  
3.2 C-reactive protein and GDM 
Some evidence supports the theory that chronic inflammation might be a risk factor for 
developing type 2 diabetes (Freeman et al., 2002; Pradhan et al., 2001; Taniguchi et al., 2002; 
Thorand et al., 2003). Inflammation may have a role in the pathogenesis of diabetes, 
suggesting that inflammatory markers may identify patients at risk of diabetes. The issue 
was investigated in a subset of women (1584 who developed diabetes and 2193 who were 
normal after 6 years. Women with diabetes had higher median baseline level of interleukin-
6 (IL6), high sensitivity CRP and tumor necrosis factor alpha receptor 2 compared with 
control.Two markers (IL6 and CRP) were significantly associated with diabetes risk in all 
ethnic groups (Liu et al., 2007).Similar results were obtained in the women's health study 
(Pradhan et al., 2001) and the nurse health study (Hu et al., 2004). In a population –based 
study in Mexico City, serum CRP was a predictor of the metabolic syndrome and type 2 
diabetes in women but not in men (Han et al., 2002). Among middle aged men in Germany 
those with a serum CRP in the highest quartile ≥2.91ng/ml had an increased risk of type 2 
diabetes compared with men in the lowest quartile (≤0.67ng/ml) (RR 2.7,95%CI1.4-5.2) 
(Thorand et al., 2003). Epidemiological studies have shown that CRP predicts incident type 2 
diabetes and increased cardiovascular disease. In healthy middle-aged women, or young 
men, CRP levels were associated with a three–fourfold increased risk of developing diabetes 
(Buchanan,2001; kjos &Buchanan,1999). 
Very limited attention has been given to the role of inflammation in the etiology of gestational 
diabetes a condition that is biochemically and epidemiologically similar to type 2 diabetes 
(kjos & Buchanan,1999).The second and third trimesters of pregnancy represent a 
physiological type of insulin resistance (Kautzky-Willer  et  al., 1997). Insulin resistance is 
associated with dysfunction of endothelial and inflammation as well as increase production of 
cytokines by adipose tissue(Baalletshofer et al.,2000). Limited available data suggest that pro-
inflammatory cytokines may be predictive of GDM(Winkler et al., 2002; Kirwan et al., 2002). 
Some studies have measured CRP at various gestational ages in pregnant women and found 
inconsistent results regarding the association between inflammatory markers and the 
incidence of GDM and the interdependence with the degree of adiposity (Retnakaran et al., 
2003; Wolf et al., 2003,2004). The interpretation of the results was influenced by coexistence 
of hypertension, preeclampsia, and different race groups or small sample size in some 
studies. The result of a study demonstrated women with GDM had significantly higher CRP 
serum levels than normal pregnant women at 37-38 weeks of gestation but at the time of 
OGTT (24-28 weeks of pregnancy) there was not any significant difference between the two 
groups (Leipold et al. , 2005 ). This report is inconsistent with the findings of the 
Massachusetts General Hospital obstetric maternal report, where increased CRP 
concentration was shown in the first trimester (10 weeks of gestation) and the association 
between GDM and CRP depended primarily on coexisting obesity (Wolf et al., 2004). The 
result of another study demonstrated that CRP concentration is not affected by GDM until 
the end of the second trimester of pregnancy (Retnakaran et al., 2003). In the third trimester, 
however, these results suggest an up-regulation of inflammatory markers by GDM resulting 
in elevation of CRP concentration at the end of pregnancy in women with GDM. In a 
prospective nested case control study Wolf et al found that CRP concentration in the first 
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trimester predicted the development of GDM in the pregnancy. In this study risk of 
developing GDM among women in the highest CRP tertile compared with the lowest tertile 
was 3.2 (95% CI 1.2-8.8), after adjusting for age, race, smoking, parity, blood pressure and 
gestational age at CRP sampling. The risk of developing GDM among women in the highest 
compared with the lowest tertile was 3.6 (95%CI 1.2-11.4), when BMI was included in the 
model; however, the association between increased CRP and GDM was reduced (odds ratio 
for the highest compared with the lowest tertile 1.5 (95% CI 0.4-5.51). Therefore, this 
association is mediated in part by increasing BMI (Wolf et al., 2003) and pregestational 
obesity as the most prominent risk factors of GDM (Wolf et al., 2003). 
Another prospective study was done to examine the association between CRP and GDM 
risk. Women were recruited before 16 weeks gestation and were followed until delivery. 
This study demonstrated elevated CRP was associated with GDM risk. After adjustment of 
maternal prepregnancy BMI, family history of diabetes and nulliparity, women with CRP in 
the highest tertile experienced a 3.5-fold increased risk of GDM (95% CI 1.2-9.8) as compared 
with those in the lowest tertile. The association between CRP and GDM was evident when 
analyses were restricted to lean women (BMI<25kg/m2). Lean women with CRP ≥5.3mg/l 
had a 3.7-fold increased risk of GDM (95%CI 1.6-8.7) as compared with women with CRP < 
5.3mg/l. This study concluded systemic inflammation is associated with an increased risk of 
GDM and this association is independent of maternal prepregnancy adiposity (Qiu et al., 
2004). Serum CRP in gestational diabetes and pregnant control women was evaluated and 
showed CRP was positively related with fructose amine hemoglobin A1c, triglyceride and 
BMI. This study concluded CRP plays a role in pathogenesis of GDM (Li et al., 2010). The 
association of sex hormone-binding globulin, high sensitive C-reactive protein and fasting 
glucose and insulin in the late first trimester and early second trimester of pregnancy with 
the diagnosis of gestational diabetes were also evaluated. In this study sex hormone-binding 
globulin was lower and high-sensitive CRP was higher among women who subsequently 
developed gestational diabetes. Multivariate analysis suggested that sex hormone-binding 
globulin measurement was the best predictor of GDM (Smirnakis et al., 2007). A 180 healthy 
pregnant women undergoing oral glucose tolerance testing in the late second or early third 
trimester were evaluated . Based on OGTT and prepregnancy BMI, participants were 
divided to 4 groups:  (1) normal OGTT and BMI<25kg/m2; (2) normal OGTT and BMI >25; 
(3) impaired glucose tolerance, and (4) GDM. This study showed CRP level was higher in 
overweight women with normal OGTT, followed by GDM, impaired OGTT groups and lean 
normal GTT. This study demonstrated that maternal CRP are not related to GDM, but rather 
correlate significantly with prepregnancy obesity (Rentakaran et al., 2003).  
4. Vitamin D 
4.1 Vitamin D structure and actions  
Vitamin D, or calciferol, is a group of lipid soluble substance with a four-ringed cholesterol 
backbone. Human obtained Vitamin D from exposure to  Sunlight, their diet and from 
dietary supplement. Ultraviolet light convert provitamin D to vitamin D3 (cholecalciferol) in 
the skin and afterwards Vitamin D3 was bounded  by vitamin D binding proteins (DBP) and 
transported via blood to target organs for metabolism and activity. Vitamin D hydroxylate 
to form 25-hydroxy-vitamin-D (25OHD) in the liver. Hydroxylation of 25-hydroxy-vitamin-
D to 1, 25-dihydroxy-vitamin D occurs in the mitochondria of the proximal tubules of the 
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renal production of 1,25-dihydroxy-vitamin D is regulated by plasma parathyroid hormone 
and serum calcium and phosphorus levels.Vitamin D increases calcium and phosphorus 
absorption from the gut and reabsorption from the kidneys and increases plasma 
concentration of these elements. As such, the main effect of vitamin D is maintenance of 
mineral homeostasis and regulation of bone remodeling (Holick et al., 2006) . 
Vitamin D deficiency is defined when the level of 25- Hydroxyvitamin D is less than 20 
ng/ml(50 nmol/l). Level of 25-29 ng/ml can be considered to indicate a relative 
insufficiency of vitamin D and a level of 30 ng/ml or more indicate sufficient vitamin 
D.Vitamin D intoxication is observed when serum level of 25-hydroxyvitamin D are greater 
than 150 ng/ml( Dawson et al.,2005). 
Vitamin D deficiency or resistance is caused by different mechanisms including reduced of 
vitamin D access due to insufficient dietary vitamin D, fat malabsorptive disorders, and/or 
lack of photoisomerization, Impaired hydroxylation of  vitamin D by the liver and kidney to 
produce 25-OH vitamin and 1,25(OH)2-vitamin D respectively and end organ insensitivity 
to vitamin D metabolites. 
4.2 Vitamin D deficiency and diabetes 
Some human and animal studies have shown a relationship between diabetes type 1and 
vitamin D deficiency .Vitamin D deficiency make  predispose subjects to type 1 and type 2 
diabetes, and receptors for its activated form 1, 25-dihydroxy-vitamin D have been 
recognized in beta cells and immune cells. Vitamin D deficiency impairs insulin synthesis 
and secretion in humans and animal models of diabetes and some investigations suggested 
that vitamin D deficiency  has a role in the development of type 2 diabetes. Epidemiological 
studies recommended a link between vitamin D deficiency in early life and the  
subsequently onset of type 1 diabetes. In some populations, type 1 diabetes is associated 
with certain polymorphisms within the vitamin D receptor gene. In studies in non obese 
diabetic mice, pharmacological doses of 1alpha,25-dihydroxyvitamin D3, or its structural 
analogues, have been shown to delay the onset of diabetes, mainly through immune 
modulation. Vitamin D deficiency may, therefore, be included in the pathogenesis of both 
types of diabetes.(Luong et al., 2005; Mathieu et al., 2005). Vitamin D supplementation could 
improve or prevent diabetes   This effect may be due to immunomodulatory action of 
vitamin D. (Stene et al., 2000; Eva , 1999). 
There was less data about the association between vitamin D and type 2 diabetes. Some 
evidences show the role of vitamin D in insulin secretion, for example the presence of 
vitamin D receptors in β cells and the vitamin D-binding proteins in pancreatic tissue and 
the association between specific allelic variations in the vitamin D receptor and vitamin D-
binding protein genes with glucose tolerance and insulin secretion have further supported 
this hypothesis. The mechanism of action of vitamin D in type 2 diabetes is thought to be 
mediated not only through regulation of plasma calcium levels, which regulate insulin 
synthesis and secretion, but also through a direct action on pancreatic beta-cell 
function(Palomer et al.,2008).Vitamin D deficiency decreases insulin secretion without 
changing in glucagon secretion. The effects of a vitamin D deficiency on insulin and 
glucagon secretion was obtained in isolated perfused rat pancreas by radioimmunoassay of 
the secreted proteins. Throughout a 30-minute times of perfusion with glucose and arginine, 
pancreases from vitamin D-deficient rats showed a 48 percent reduction in insulin secretion 
compared to that for pancreases from vitamin D-deficient rats that had been resupplied with 
vitamin D. Vitamin D status had no effect on pancreatic glucagon secretion. This result, 
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along with the previously demonstrated presence in the pancreas of a vitamin D-dependent 
calcium-binding protein and cytosol receptor for the hormonal form of vitamin D, 1,25-
dihydroxyvitamin D3, indicates an important role for vitamin D in the endocrine 
functioning of the pancreas. The data demonstrated a positive correlation of 25(OH)D 
concentration with insulin sensitivity and a negative effect of hypovitaminosis D on 
function of ß cell. Subjects with hypovitaminosis D are at higher risk of insulin resistance 
and the metabolic syndrome.Vitamin D repletion in early stages of experimental dietary 
vitamin D deficiency and in vitamin D deficiency subjects improves glucose intolerance and 
increases insulin secretion. Some studies demonstrated that vitamin D supplementation 
increased insulin secretion in response to an oral glucose load in patients with type 2 
diabetes but not in patients with established type 2 diabetes (Chiu et al., 2004; Inomata et al., 
1986; Orwoll et al., 1994; Gedik & Akalin, 1986). Some evidence indicates that vitamin D 
increases  insulin secretion from β cells by increasing intracellular calcium concentration 
through nonselective voltage-dependent calcium channels. The main effect of vitamin D on 
insulin secretion is acquired from conversion of proinsulin to insulin. Calcium is principal 
not only for insulin exocytosis but also for cell glycolysis ( Boucher, 1998). Vitamin D also 
activates protein biosynthesis in pancreatic islets. Vitamin D deficiency reduces insulin 
secretion and action. Variation in the vitamin D receptor  or vitamin D-binding protein 
causes glucose intolerance. 
Vitamin D increases cellular glucose absorption either directly or by increasing insulin 
sensitivity. Vitamin D may directly or indirectly regulate β cell function and secretion by 
binding 1,25 dihydroxy vitamin D to β cell vitamin D receptors and controlling the balance 
between the extracellular and intracellular β cell calcium pools (Norman et al ., 1980). 
Vitamin D can promote insulin sensitivity by stimulating the expression of insulin receptors 
and enhancing insulin responsiveness for glucose transport. It also regulates extracellular 
calcium and thus establishes normal calcium inflow through cell membranes and an 
adequate intracellular cytosolic calcium pool, which is necessary for the insulin-mediated 
intracellular process in insulin responsive tissues (Draznin et al.,1988). 
4.3 Vitamin D deficiency and gestational diabetes 
Data about vitamin D as a risk factor for GDM is spare. Pregnant women with diabetes are 
known to be more vitamin D deficient compared with normal pregnant women (Bikle, 
1992). Intravenous administration of vitamin D to pregnant women with gestational 
diabetes transiently decreases fasting glucose; however, the level of insulin also decreases 
(Rudnicki & Molsted-Pedersen, 1997). Vitamin D deficiency was associated with a 2.66-fold 
increase in GDM risk and each 5 ng/ml decrease in 25-hydroxy D concentrations was 
related to a 1.29-fold increase in GDM risk (Zhang et al., 2008). Another study demonstrated 
that the serum concentration of vitamin D during 24-28 weeks of pregnancy in gestational 
diabetes was lower than normal groups (Maghbooli et al., 2007; Soheilykhah et al., 
2009).Women with GDM had a 2.66 fold increased risk of vitamin D deficiency (25-hydroxy 
D<15ng/ml) compared with control group(Soheilykhah et al.,2009). Maternal 
hypovitaminosis was reported in diabetic pregnancies in Spain and fasting glycaemia 
decreased with vitamin D supplementation (Farrant et al., 2008). Vitamin D, insulin and 
proinsulin were measured at 30 weeks gestation in another study . This study demonstrated 
that vitamin D insufficiency is common in mothers but is not associated with gestational 
diabetes. There was no association between maternal 25(OH)D and gestational diabetes.In 
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with lower 30-min glucose concentrations and higher fasting proinsulin concentrations 
(Farrant et al., 2009). Clifton-Bligh et al. showed mean serum 25(OH)D concentration  in 
pregnant women was negatively correlated with fasting plasma glucose, fasting insulin and 
insulin resistance as calculated by homeostasis model assessment. The association between 
fasting glucose and log-transformed 25OHD concentration was of borderline significance 
after accounting for ethnicity, age and body mass index in multivariate analyses. The odds 
ratio of gestational diabetes in women with 25OHD < 50 nmol/L did not reach statistical 
significance (1.92, 95% confidence interval 0.89-4.17) (Clifton-Bligh et al., 2008). 
In another study total prevalence of vitamin D deficiency (<25 nmol/L) was 70.6% in pregnant 
women. Prevalence of severe vitamin D deficiency (<12.5) in GDM patients was higher than in 
normoglycaemic pregnancies. These results show that a positive correlation of 25(OH) vitamin 
D concentrations with insulin sensitivity and vitamin D deficiency could be a confirmative 
sign of insulin resistance (Maghbooli et al., 2007). Several studies suggest that vitamin D 
supplementation in children reduces the risk of type 1 diabetes. Increasing vitamin D intake 
during pregnancy reduces the development of islet autoantibodies in offspring (Chiu et al., 
2003). In Finland, 10,366 children who were given 2000 IU of vitamin D3 per day during 
their first year of life were followed for 31 years. The risk of type 1 diabetes was reduced by 
approximately 80% (relative risk, 0.22; 95% CI, 0.05 to 0.89) ( Hypponen et al., 2001). Among 
children with vitamin D deficiency, the risk was increased by approximately 200% (relative 
risk, 3.0; 95% CI, 1.0 to 9.0). In another study, vitamin D deficiency increased insulin 
resistance, decreased insulin production, and was associated with the metabolic syndrome 
(Chiu et al., 2004). Another study demonstrated that a combined daily intake of 1200 mg of 
calcium and 800 IU of vitamin D lowered the risk of type 2 diabetes by 33% (relative risk, 
0.67; 95% CI, 0.49 to 0.90) as compared with a daily intake of less than 600 mg of calcium and 
less than 400 IU of vitamin D (Pittas et al., 2006). 4000 IU vitamin D  was administrated for 6 
months to women with vitamin D less than 50 nm/Land  median serum 25(OH)D3 
increased significantly and insulin resistance and fasting insulin decreased (Von Hurst et al., 
2010).In summary the result of different studies show high prevalence of vitamin D 
deficiency in pregnant women and most of these findings demonstrated the relationship 
between vitamin D status and glucose tolerance  in pregnancy. 
5. Conclusion 
Early diagnosis of gestational diabetes prevents maternal and fetal complications . Recently 
a number of studies illustrated association of various biomarkers with subsequent 
development of GDM . These metabolic mediators are known to be  produced in  the 
intrauterine environment . Some studies demonstrated that decreased level of adiponectin 
and increased level of leptin and resistin preceded the onset of diabetes in pregnancy.  
Some investigations  also have been shown  association between C-reactive protein and risk 
of GDM. Some researches exhibited maternal vitamin D concentration inversely related to 
fasting glucose and insulin concentration and vitamin D deficiency was associated with 
increasing risk of GDM. 
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1. Introduction 
The metabolic syndrome is a clustering of traditional cardiometabolic risk factors that include 
central obesity, dysglycemia, hypertension, hypertriglyceridemia, and reduced high-density 
lipoprotein (HDL) cholesterol. In recent years, its clinical utility, diagnostic criteria and 
underlying etiology have been the subject of continuous debate and controversy. While the 
debate continues, it remains incontrovertible that those identified with the metabolic 
syndrome are at high risk for the future development of type 2 diabetes (T2DM) and 
cardiovascular disease (CVD). In addition, an expanding body of evidence has linked the 
metabolic syndrome with several emerging non-traditional risk factors, including markers of 
hepatic fat, chronic inflammation (such as C-reactive protein (CRP)), and adipocyte 
dysregulation (such as low circulating levels of adiponectin). Interestingly, many of these 
features of the metabolic syndrome are also common to gestational diabetes mellitus (GDM). 
Indeed, GDM has also been the subject of longstanding debate throughout its history and it 
too identifies women who are at high  risk of developing T2DM and CVD in the future. 
Moreover, in recent years, GDM has been similarly linked to an array of non-traditional 
cardiometabolic risk factors, including CRP and hypoadiponectinemia. A series of studies 
have demonstrated that women with GDM are at risk of developing the metabolic syndrome 
in the years following their index pregnancy. Furthermore, emerging evidence shows that 
components of the metabolic syndrome identified in early gestation and even prior to 
pregnancy can predict the subsequent development of GDM. Taken together, these findings 
have raised the intriguing possibility that women who develop GDM may have an underlying 
latent metabolic syndrome that warrants clinical evaluation and risk factor modification.  
Though intricate and still incompletely understood, the gradual expansion of knowledge 
about inter-relationships between the metabolic syndrome, GDM and T2DM may provide 
us with opportunities to screen for and detect metabolic dysfunction at various stages of 
disease progression. In this way, GDM represents an important and early “metabolic flag” 
for an affected mother and, perhaps, her offspring. Thus, in this chapter, we explore the 
emerging relationship between GDM and the metabolic syndrome. We review the 
definitions of each condition, their limitations and controversies, and their utility and 
predictive value in identifying T2DM and CVD risk. The clinical evidence for metabolic 
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Emerging non-traditional risk factors for both metabolic syndrome and GDM will be 
described, alongside the evidence for metabolic syndrome as a consequence of GDM and as 
a potential predictive tool to detect risk for GDM before and during early pregnancy. 
Finally, we consider the concept that women who develop GDM may have a latent 
metabolic syndrome.  
2. Metabolic syndrome 
2.1 General definition and varying sets of diagnostic criteria 
The metabolic syndrome, also referred to as the insulin resistance syndrome, was initially 
proposed as a model for understanding the underlying biology and risk factors for CVD. In 
his Banting award lecture, Gerald Reaven first described ‘Syndrome X’ as the clustering of 
abnormalities related to insulin resistance (Reaven, 1988). The World Health Organization 
formally proposed the term ‘metabolic syndrome’ in 1998 (Alberti et al., 1998; DeFronzo & 
Ferrannini, 1991) to identify those at high risk for metabolic disorders and CVD. Though the 
syndrome was originally intended to identify individuals at risk for CVD, it has since 
expanded to capture those at high risk for T2DM, with which it is thought to have a stronger 
association (Ford et al., 2008). The definition of metabolic syndrome continues to evolve 
today, and is widely studied as a promising marker of cardiovascular risk. 
The syndrome is characterized by a clustering of central abdominal (visceral) obesity, 
glucose intolerance, insulin resistance, dyslipidemia and hypertension (Reaven, 1988). The 
presence of any one risk factor implies the existence of others, such that their concomitant 
occurrence collectively describes a positive dysmetabolic risk profile for CVD, or 
‘cardiometabolic risk’ (Despres et al., 2008).  
While several organizations and authoritative bodies have proposed diagnostic criteria for 
the metabolic syndrome, the most cited working definitions are those of the International 
Diabetes Federation (IDF), the World Health Organization (WHO), and the National 
Cholesterol Education Program – Adult Treatment Panel III (NCEP-ATP III) (Alberti et al., 
2005; WHO Expert Consultation, 2004; Alexander et al., 2003). These authorities have 
synthesized, analyzed and translated information gathered from a vast, globally 
representative body of research studies, in order to provide a set of diagnostic criteria with 
clinically relevant thresholds and measurements that can identify the metabolic syndrome 
and hence the risk of diabetes and CVD. Despite continued efforts, there are variations in 
the definitions, which have prompted international debate about the actual utility and 
strength of the metabolic syndrome as a diagnostic tool. Table 1 lists the criteria and 
diagnostic thresholds defined by the IDF, WHO, NCEP ATP-III, and, lastly, the recently 
published harmonized criteria (discussed in section 2.2). 
Although the ATP III and IDF definitions differ in their diagnostic threshold criteria for 
metabolic syndrome, both include the same 5 components: increased adiposity, 
hypertriglyceridemia, low levels of high density lipoprotein cholesterol (HDL-C), 
hypertension and dysglycemia. The WHO definition also includes a urine albumin to 
creatinine ratio. Meeting the dichotomous cut-off points for an abnormality in 3 or more of 
the 5 components fulfills the requirements for diagnosis according to the ATP III definition 
(Hunt et al., 2004). Though all definitions include an obesity criterion, the IDF definition 
provides ethnicity-specific values for diagnosing abdominal obesity (Reaven, 2009). 
Moreover, for diagnosing metabolic syndrome, the IDF definition requires the presence of 
increased waist circumference (WC) as a necessary prerequisite along with any 2 of the 
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other criteria. Elevated triglycerides and/or low HDL-C must fall within the prescribed 
threshold or can be applied if a person is being treated specifically for the lipid abnormality. 
In addition, the defining criteria consider those with T2DM, an elevated WC and at least 1 
other risk factor as having metabolic syndrome. The WHO requires the presence of diabetes, 
impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or insulin resistance and at 
least 2 other criteria. Among the 3 definitions, the IDF and ATP III are more commonly cited 
within the recent literature. The prevalence of metabolic syndrome in U.S. adults is 
estimated to be approximately 22% to 34% using the ATP III definition and 39% when the 
IDF criteria are applied (Ford, 2005).  
 
 NCEP-ATP III IDF WHO Harmonized IDF/AHA 
Central obesity WC >102 cm- (M) WC >88 cm- (F) 
WC >94 cm- White (M)
WC >80 cm- White (F)
WC >90cm- Asian (M)





Same as IDF cut 
points for non-
Europeans & either 
IDF or AHA criteria 
for Europeans 
Elevated 




<1.3 mmol/L- (F)  
<1.03 mmol/L- (M) 
<1.29 mmol/L- (F) 
<0.9 mmol/L- (M) 
<1.0 mmol/L- (F) 
<1.0 mmol/L- (M) 
<1.3 mmol/L- (F) 
Elevated blood 
pressure >130/85 mm Hg >130/85 mm Hg >140/90 mm Hg 
Systolic >130 and/or 
diastolic >85 mmHg 
Fasting 
hyperglycemia >6.1 mmol/L  
>5.6 mmol/L or  
diabetes or IGT  Diabetes, IFG, IGT >5.6 mmol/L 
Urine albumin: 
creatinine ratio - - > 3.4 mg/mmol - 
Table 1. Various diagnostic criteria for the metabolic syndrome 
2.2 Controversy regarding the metabolic syndrome 
The debate surrounding the metabolic syndrome stems from disagreement about its definition 
and diagnostic criteria, alongside questions related to its pathogenesis, origins, and 
applicability across populations. However, despite this ongoing debate, central obesity and 
insulin resistance have been widely postulated (Lann & LeRoith, 2007) as comprising the 
fundamental basis of the metabolic syndrome. Categorically, the syndrome is influenced by 
the complex genetic, hormonal and nutritional origins of its individual component risk factors.  
Discrepancies among the commonly used NCEP-ATP III, IDF and WHO definitions of the 
metabolic syndrome, have contributed substantially to this debate. For example, ATP III and 
WHO differ in their criteria for blood pressure, and neither definition provides specific 
guidance on how to implement these diagnostic thresholds (i.e., whether to use abnormal 
systolic vs. diastolic or both; whether to obtain measures in a particular body position; or 
whether to calculate an averaged measure). Recently, the American Heart 
Association/National Heart, Lung and Blood Institute (AHA/NHLBI) and IDF attempted to 
resolve such discrepancies with new harmonized criteria. These criteria, shown in Table 1, 
include (i) clarification of the blood pressure measurement to specify elevated levels of 
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prerequisite, such that the presence of any 3 of the 5 criteria is sufficient for diagnosis of 
metabolic syndrome (Alberti et al., 2010). The ATP III and IDF definitions differ in their 
criteria for increased fasting glucose and central obesity (using WC) (Alberti et al., 2006; 
NCEP 2001) and while obesity is measured by WC according to the ATP III and IDF 
definitions, waist-to-hip ratio is used in the WHO definition. Furthermore, urine albumin-
creatinine ratio is a criterion in the WHO definition, but is not found in the ATP III and IDF 
definitions, while several risk factors associated with insulin resistance are not considered in 
any of the definitions, including physical inactivity, family history, sex and age  (Kahn et al., 
2005).  
Further complicating the controversy is the practical observation that, despite its centrality 
to the metabolic syndrome, contrasting evidence suggests that many overweight or obese 
individuals may, by any guideline, have normal metabolic profiles (Wildman et al., 2008), 
and are not prone to future development of metabolic syndrome. Similarly, among those 
who display metabolic syndrome, not all are obese (Bruce & Hanson, 2010). Some lean 
individuals are insulin resistant and exhibit increased cardiometabolic risk. In a study of 
otherwise healthy obese individuals and insulin resistant lean individuals with a family 
history of T2DM, obesity was associated with higher insulin resistance and diastolic blood 
pressure, but conveyed no difference in other metabolic markers. In addition, within each 
BMI category, insulin resistance independently predicted metabolic syndrome, while WC 
did not. Only when age was combined with WC (but not BMI) did obesity independently 
predict metabolic syndrome, and, even so, WC was less predictive of insulin resistance at 
higher WC values (Utzschneider et al., 2010). The authors concluded that insulin sensitivity 
is a stronger predictor of metabolic syndrome than obesity, and is better than WC at 
identifying obese individuals with an otherwise healthy metabolic profile. They also 
recommended employing metabolic testing among lean individuals with a first-degree 
relative with T2DM (Utzschneider et al., 2010). Nevertheless, even when weight is 
considered, cut-points used to define obesity are not universally agreed upon and may vary 
by ethnicity (Despres et al., 2008).  
The use of different definitions of the metabolic syndrome has clouded our ability to 
compare findings across research studies. In addition, there is the question of whether the 
diagnostic criteria are too restrictive, missing those at highest risk, or, conversely, are too 
broad, resulting in an overestimation of the prevalence of  metabolic syndrome. Considering 
its inherently chronic and progressive nature, it is reasonable to infer that indicators of 
dysmetabolism, especially in younger adults, underestimate its consequences for predicting 
T2DM and CVD. Indeed, manifestation may even occur at different time-points in the 
disease trajectory, such that risk factor assessment necessitates systematic evaluation across 
a spectrum of sub-diagnostic and diagnostic ranges standardized for age.  
Another criticism of the metabolic syndrome is whether its value extends beyond that of its 
individual components. The criticism highlights both the redundancy of the classification as 
a ‘syndrome’ and the inadvertent undermining of the importance of the individual 
components. The diagnosis of metabolic syndrome, by any definition, has been studied in 
relation to the predictive value of the individual criteria. The Framingham study (Wilson et 
al., 2005) demonstrated no substantial increase in risk associated with clusters of 3 of the 5 
metabolic syndrome criteria compared with clusters of only 2 traits. In contrast, data from 
the Third National Health and Nutrition Examination Survey (Ninomiya et al., 2004) 
indicated that each of the 5 components of metabolic syndrome was an independent 
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predictor of CVD. These studies illustrate the controversy over whether a diagnosis of 
metabolic syndrome provides more useful information about CVD risk than any of its 
individual components (Reaven, 2009). Furthermore, by the current definitions, it is unclear 
whether any one risk factor is more predictive than the other, in the form of a weighted 
hierarchy. 
To address these criticisms, the American Diabetes Association (ADA) and European 
Association for the Study of Diabetes (EASD) issued a joint statement about the clinical 
utility of the metabolic syndrome; they recommended that clinicians evaluate and treat 
discrete risk factors, without diagnosing the metabolic syndrome, per se (Kahn et al., 2005). 
Specifically, rather than solely relying on diagnosis of metabolic syndrome, identification of 
one or more of its component features should prompt investigation for the presence of the 
other features. For the latter, one may also consider specific emerging risk factors not 
included in the existing definition, as outlined below. 
2.3 Metabolic syndrome and the identification of future risk of T2DM and CVD 
The IDF recommends screening for metabolic syndrome features in those with T2DM 
(Alberti et al., 2006, Alberti et al., 2005). While current recommendations are subject to 
criticism and controversy, they nevertheless provide a practical basis upon which to adopt 
management strategies. Individuals with metabolic syndrome have a 5-fold higher risk of 
developing T2DM (Alberti et al., 2010). Similarly, in a study from the UK that examined the 
prognostic impact of metabolic syndrome in T2DM, the investigators modified the ATP III 
definition to include BMI instead of WC, and found that the metabolic syndrome further 
predicted CVD incidence five years after the diagnosis of T2DM (Guzder et al., 2006).  
Showing that dysglycemia predicts metabolic syndrome necessarily identifies a predictive 
potential for T2DM as well. This is so given that metabolic syndrome -- and especially 
glucose intolerance -- is central to the development of T2DM. In the GENFIEV study, 
metabolic syndrome prevalence was 42% in those with IFG, 34% in IGT, and 74% in IFG + 
IGT (Bianchi et al., 2010). In addition, the prevalence of insulin resistance was higher in 
those with metabolic syndrome than in its absence. Hypertriglyceridemia (odds ratio [OR] 
3.38; 95% confidence interval [CI] 2.29-4.99), abdominal obesity (3.26; 95% CI 2.18-4.89), 
hyperglycemia (3.02; 95% CI 1.80-5.07) and hypertension (1.69; 95% CI 1.12-2.55) were all 
associated with insulin resistance. These findings suggest that the prevalence of the 
metabolic syndrome is high in individuals with dysglycemia, and is generally associated 
with insulin resistance (Bianchi et al., 2010). Moreover, dysglycemia and insulin resistance 
are highly predictive of T2DM. Similarly, long-term glycemic excursions will identify those 
at high risk for metabolic syndrome and T2DM. In their exploratory study, Giuffrida et al. 
(2010) investigated the relation between glycated hemoglobin (GHb), an indicator of long-
term glycemic control, and metabolic syndrome with T2DM. Each 1% increase in GHb was 
associated with metabolic syndrome (OR 1.31, 95% CI 1.18–1.45), demonstrating a strong 
relation between chronic hyperglycemia and metabolic syndrome (Giuffrida et al., 2010).  
Aboriginal Canadians have a 5-fold higher risk of T2DM compared to non-Aboriginals. 
Among the former, the metabolic syndrome can be readily identified using available clinical 
measures, and thus, may be a useful clinical tool (Reaven, 2009; Ley et al., 2009). In a 
prospective study, Ley and colleagues (2009) found that the 10-year cumulative incidence of 
T2DM in the Aboriginal Canadian population was 17.5%, with an age-dependent gradient 
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associated with metabolic syndrome (OR 1.31, 95% CI 1.18–1.45), demonstrating a strong 
relation between chronic hyperglycemia and metabolic syndrome (Giuffrida et al., 2010).  
Aboriginal Canadians have a 5-fold higher risk of T2DM compared to non-Aboriginals. 
Among the former, the metabolic syndrome can be readily identified using available clinical 
measures, and thus, may be a useful clinical tool (Reaven, 2009; Ley et al., 2009). In a 
prospective study, Ley and colleagues (2009) found that the 10-year cumulative incidence of 
T2DM in the Aboriginal Canadian population was 17.5%, with an age-dependent gradient 





The authors reported that, at baseline, metabolic syndrome had a low positive predictive 
value for future diabetes; however, the syndrome predicted incident diabetes to the same 
degree as IGT, while its high negative predictive value identified disease-free individuals at 
follow-up (Ley et al., 2009).  
In addition to identifying those at risk of T2DM, metabolic syndrome also independently 
predicts risk of CVD. In the joint statement from the ADA and the EASD (2005), the authors 
emphasized the practical use of the metabolic syndrome, focusing on its predictive value for 
CVD (Kahn et al., 2005). A meta-analysis of a series of European trials reported that 
metabolic syndrome raises the hazard ratio for CVD in women from 0.6 to 2.8 (Hu et al., 
2004). Moreover, patients with metabolic syndrome are at twice the risk of developing CVD 
over a 5-10 year period than those without the syndrome (Alberti et al., 2010). Several 
population studies have described an increased cardiovascular risk in the presence of 
metabolic syndrome (Alexander et al., 2003; Ford, 2004, 2005; Hunt et al., 2004; Isomaa et al., 
2001; McNeill et al., 2005). Alexander and colleagues (2003) used the ATP III criteria to 
assess the prevalence of coronary heart disease (CHD) among patients with the metabolic 
syndrome. They reported that those without metabolic syndrome, regardless of diabetes 
status, had a low CHD prevalence (less than 10%), while those with diabetes but not the 
metabolic syndrome exhibited no increased risk of CHD (Alexander et al., 2003). Otherwise, 
metabolic syndrome was a significant predictor of CHD (OR 2.07, 95% CI 1.66-2.59) and 
conferred a risk beyond that of diabetes alone (Alexander et al., 2003).  
In the San Antonio Heart Study, metabolic syndrome at baseline was a significant predictor 
of cardiovascular mortality over a mean follow-up of 13 years  (Hunt et al., 2004). Similarly, 
using the WHO definition, Isomaa and colleagues (2001) found that the risk for CHD and 
stroke was increased 3-fold in those with the metabolic syndrome (P < 0.001), as was 
cardiovascular mortality (P < 0.001) (Isomaa et al., 2001). In a study of individuals without 
diabetes or CVD at baseline, the ATP III– defined metabolic syndrome had an adjusted 
hazard ratio of CHD of 1.46 (95% CI, 1.23–1.74) for men and 2.05 (95% CI, 1.59–2.64) for 
women (McNeill et al., 2005).  
Ford and colleagues (2004) showed a linear association between ATP III-based metabolic 
syndrome and CVD-related mortality as well as all-cause mortality (Ford et al., 2004). A 
meta-analysis of worldwide data from studies published between 1998 and 2005, showed 
pooled relative risks (RR) of 1.27 (95% CI, 0.90–1.78) for all-cause mortality, 1.65 (95% CI, 
1.38–1.99) for CVD and 2.99 (95% CI, 1.96–4.57) for T2DM using ATP III-defined metabolic 
syndrome; in the fewer studies that used the most exact WHO definition, the pooled RRs 
were 1.37 (95% CI, 1.09–1.74) for all-cause mortality and 1.93 (95% CI, 1.39–2.67) for CVD 
(Ford, 2005). Thus, there is considerable evidence for the predictive value of the metabolic 
syndrome for identifying risk of T2DM and CVD. 
2.4 Metabolic syndrome and emerging non-traditional risk factors  
As the components of metabolic syndrome continue to be better understood, the syndrome 
appears to be a promising diagnostic and screening tool. Recent studies have identified 
chronic low-grade inflammation as a systemic consequence of obesity that is related to both 
metabolic and vascular disease. For example, the inflammatory nature of atherosclerosis 
prompted the study of inflammatory proteins, such as high-sensitivity C-reactive protein 
(CRP), as potential predictors of CVD. Indeed, epidemiological studies have shown the 
independent relation between CRP and CHD (Ridker, 1997, 1998).  
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Nakano et al, (2010) investigated the clinical significance of LDL and CRP in coronary artery 
disease (CAD) risk (Nakano et al., 2010). Among those without the metabolic syndrome, 
high CRP was not associated with a higher risk of CAD; however, those with both high CRP 
and metabolic syndrome had a doubling in their risk of CAD (Ridker et al., 2003; Sattar et 
al., 2003). Despite uncertainty regarding the utility of adding CRP to the metabolic 
syndrome definition, investigation of its potential as a predictive tool and meaningful 
addition to metabolic syndrome is advocated (Ridker et al., 2004).  
Previous studies have also examined the use of adipose tissue biomarkers, including 
adiponectin, in predicting CVD risk. Adiponectin is an adipocyte-derived polypeptide -- an 
adipokine -- that is inversely associated with obesity, insulin resistance and T2DM. As a 
protective adipokine, it inhibits gluconeogenesis and suppresses lipogenesis. Low levels of 
adiponectin result in reduced fatty acid oxidation and increased fat accumulation in the 
liver. Adipose tissue plays a central role to metabolic syndrome, and low adiponectin levels 
are associated with metabolic syndrome. In addition, the strong association between 
hypoadiponectinemia and CVD risk implicates adiponectin in the disease trajectory. 
Compared with lean controls, patients with metabolic syndrome and T2DM have lower 
circulating levels of total and  high molecular weight (HMW) adiponectin, and higher levels 
of leptin and interleukin-6 (IL-6). Decreased total and HMW adiponectin, and increased 
levels of leptin and IL-6, are characteristic of patients with metabolic syndrome and T2DM 
(Lee et al., 2009). There may also be a link between low adiponectin and fatty liver disease 
(Matsubara et al., 2004).  
Hepatic dysregulation is characterized by insulin resistance -related steatosis and oxidative 
stress (Kim & Younossi, 2008). Non-alcoholic fatty liver disease (NAFLD) -- ranging from 
simple steatosis (fatty infiltration) to inflammatory steatohepatitis (NASH), to long-term 
injury (fibrosis) -- is a strong indicator of insulin resistance in non-pregnant adults (Youssef 
& McCullough, 2002). The process of NAFLD development is in itself an extension of insulin 
resistance that reduces free fatty esterification and triglyceride storage in adipose tissue, 
subsequently resulting in the deposition of free fatty acids in non-adipose tissues, especially 
the liver (Utzschneider & Kahn, 2006). Hence, NAFLD is considered to be the principal liver 
manifestation of the metabolic syndrome (Kim & Younossi, 2008), as it requires the presence 
of insulin resistance and is closely associated with T2DM (Targher et al., 2005). In a recent 
study of adults with newly diagnosed T2DM, there was significant interplay between T2DM 
and liver injury, likely explained by NAFLD (Porepa et al., 2010). NAFLD may also be 
detected with the novel serum marker, Fetuin-A, an endogenous inhibitor of insulin 
receptor tyrosine-kinase, and a recognized “hepatokine”. Elevated plasma Fetuin-A levels 
positively predict the incidence of T2DM independent of other established risk factors (Ix et 
al., 2008; Stefan et al., 2008). In a study of 330 adults at risk for T2DM, liver fat was the 
strongest predictor of prediabetes  (Kantartzis et al., 2010) (Kantartzis et al., 2010). Among 
studied biochemical measures, serum Fetuin-A was a more significant predictor of fasting 
hyperglycemia than serum adiponectin (Kantartzis et al., 2010). In addition, individual liver 
enzymes, such as alanine aminotransferase, have varying positive associations with the 
components of the metabolic syndrome (Zhang et al., 2010).  
While hyperuricemia is prevalent among those with metabolic syndrome, its clinical utility 
remains controversial. Nonetheless, it appears to be a predictor of metabolic syndrome. One 
hypothesis is that enhanced insulin resistance due to fatty acid synthesis in the liver may be 
linked to additional purine synthesis, thereby accelerating production of uric acid. Since 
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metabolic syndrome (Matsuura et al., 1998), it follows that insulin resistance is related to 
elevated serum uric acid levels in those with metabolic syndrome (Borges et al., 2010). While 
a sex-dependent association between hyperuricemia and metabolic syndrome is apparent, 
there is no current evidence for its association with sex hormones. Sex hormone binding 
globulin (SHBG) is a liver-derived glycoprotein regulated by insulin, which inhibits its 
production in hepatocytes. Low serum SHBG levels are associated with increased insulin 
resistance and hyperinsulinemia. In a recent review Brand et al. (2011) examined 52 
observational studies and found that, for both sexes, metabolic syndrome was associated 
with low levels of SHBG (Brand et al., 2011).  
 
 
Fig. 1. Traditional & non-traditional (bolded) cardiometabolic risk factors associated with 
metabolic syndrome. 
3. Gestational Diabetes Mellitus (GDM)  
3.1 General definition and varying sets of diagnostic criteria  
GDM, defined as glucose intolerance of varying severity with first onset in late pregnancy, 
bears many of the same risk factors as T2DM, including: older maternal age, a family history 
of T2DM, non-White ethnicity, obesity, sedentary lifestyle, and previous GDM (Dornhorst et 
al., 1992; Hedderson & Ferrera, 2008; Hillier et al., 2008; Ray et al., 2001). GDM has both 
short and long-term risks for a mother and her child. Acute maternal effects include 
pregnancy-induced hypertension and increased risk of Caesarian-section, while long-term 
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consequences include increased risks of T2DM and CVD. Neonatal complications include  
fetal macrosomia and the associated risk of shoulder dystocia (Athukorala et al., 2007) which 
in turn can lead to neonatal musculoskeletal and brachial plexus injury (Christoffersson & 
Rydhstroem, 2002), while long-term sequelae are childhood obesity (Metzger, 2007), 
metabolic syndrome, and higher risk of T2DM and hypertension (Athukorala et al., 2007; 
Boney et al., 2005; Joffe et al., 1998; Leon, 1998; Metzger, 2007; Reece et al., 2009).  
Though practices vary, many countries recommend that all pregnant women be screened at 
24 to 28 weeks’ gestation with a 1- hour 50-g glucose challenge test (GCT), followed by a 
confirmatory 2-hour 75-g, or 3-hour 100-g oral glucose tolerance test (OGTT). While a 
strategy of selectively screening only women at high risk of GDM may improve the true 
positive detection rates, some women without classical risk factors for GDM will be missed, 













OGTT 3-h, 100-g 3-h, 100-g 2-h, 75-g 2-h, 75-g 
OGTT-Fasting 5.8 mmol/L 5.3 mmol/L 7.0 mmol/L 5.1 mmol/L 
OGTT-1 h 10.5 mmol/L 10.0 mmol/L - 10.0 mmol/L 
OGTT-2 h 9.2 mmol/L 8.6 mmol/L 7.8 mmol/L 8.5 mmol/L 




>2 >2 >1 >1 
Table 2. Diagnostic criteria for GDM according to commonly used definitions. 
Despite variations in diagnostic criteria, the utility of these definitions for predicting clinical 
outcomes has been demonstrated. As an example, while the ADA and WHO diagnostic 
criteria for GDM differ slightly (International Association of Diabetes and Pregnancy Study 
Group [IADPSG], 2010), the antepartum 2-hour 75g OGTT predicts adverse pregnancy 
outcomes based on both criteria: the ADA criteria resulted in an increased risk of  
macrosomia (RR 1.29, 95% CI 0.73-2.18), preeclampsia (RR 2.28, 95% CI 1.22-4.16) and 
perinatal death (RR 3.10, 95% CI 1.42-6.47) (Schmidt et al., 2001) and similar results were 
observed using the WHO criteria. Some speculate that the restrictive diagnostic criteria for 
GDM may overlook the risks faced by women with lesser degrees of dysglycemia (Ferrara et 
al., 2007; Vambergue et al., 2000). Others assert that lack of international uniformity and 
agreement of diagnostic thresholds for GDM limits their utility within clinical settings 
(Metzger & Coustan, 1998). For example, the UK guidelines recommend that only high-risk 
groups be screened (IADPSG, 2010). In Canada, screening for GDM is routinely done, but 
not in a universal manner (Wen et al., 2000). Furthermore, current guidelines do not account 
for the variable risk attributed to ethnicity, in which there are considerable differences in the 
prevalence of GDM. In a study of ethnicity and postpartum metabolism in women with 
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levels, while African-Caribbean women had a higher WC, blood pressure, and insulin levels 
(Savitz et al., 2008).  
3.2 Controversy regarding GDM 
Like the metabolic syndrome, GDM has also been the subject of controversy, especially 
surrounding the timing of screening, the choice of diagnostic test, and the defining 
thresholds on these tests for its identification. Existing guidelines used to identify GDM, and 
hence the high risk of T2DM following pregnancy, were initially adapted from criteria that 
were applied to the non-pregnant population; they were not designed to identify those at 
risk for adverse perinatal outcomes (IADPSG, 2010). Extensive research has led to 
modifications of the definition (Cutchie et al., 2006) following the original publication of the 
criteria (O’Sullivan & Mahan, 1964). Of note, these original criteria were based on the 
identification of those women at risk of developing diabetes in the years after the index 
pregnancy (O’Sullivan & Mahan, 1964). 
The clinical justification for screening for GDM currently focuses on the prevention of fetal 
macrosomia and associated obstetrical complications (Retnakaran et al., 2009c). Notably, this 
focus has resulted in a single set of diagnostic criteria used to identify women at risk for two 
different adverse outcomes (Retnakaran et al., 2009c), which effectively leads to the 
assumption that a diagnosis of GDM optimally identifies the risks of both macrosomia and 
postpartum prediabetes/diabetes. In a study designed to test this assumption, subjects 
representing the full spectrum of antepartum glucose tolerance  underwent a 3-hour OGTT, 
and the results showed that only fasting glucose emerged as a significant predictor for 
delivery of a large-for-gestational-age (LGA) infant, with an OR of 2.0 (95% CI 1.20-3.34) per 
1 mmol/L incremental increase (Retnakaran et al., 2009c). However, all three post-load 
measures were significant predictors of postpartum prediabetes/diabetes (1-h glucose: OR 
1.37, 95% CI 1.17-1.61; 2-h glucose: OR 1.55, 95% CI 1.32-1.83; 3-h glucose: OR 1.30, 95% CI 
1.10-1.53). Thus, fasting glucose values may better predict LGA risk, but post-load values 
better predict postpartum glucose intolerance (Retnakaran et al., 2009c). Clearly, an 
additional challenge to the GDM diagnostic definition includes how the results are applied. 
The prevailing consensus within the existing framework for diagnosing GDM is that 
hyperglycemia, including levels below those for overt diabetes, is associated with the 
adverse pregnancy outcomes common to GDM. In addition, most agree that screening for 
GDM at 24-28 weeks’ gestation identifies individuals in whom effective management can 
reduce glycemic excursions and minimize adverse perinatal outcomes. It remains to be 
determined, however, whether these current strategies can effectively reduce long-term 
risks of metabolic syndrome, T2DM and CVD in affected women (Nolan, 2011). Indeed, 
women who do not meet the prescribed thresholds for GDM may incur glucose-mediated 
fetal macrosomia (Mello et al., 1997; Rudge et al., 2000; Scholl et al., 2001; Sermer, et al., 
1995), and may be at  risk for T2DM and CVD (Retnakaran et al., 2008a, 2008b, 2009a, 2009b, 
2009c, 2009d, 2009e, 2010c; Shah et al., 2008). 
The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study was undertaken to 
examine the risks associated with glucose values below traditional thresholds used to 
diagnose GDM. The study findings were translated by the IADPSG, in order to harmonize 
the existing diagnostic criteria (Table 2). The practical implications of these revised criteria 
includes the universal adoption of a 2-hour, 75-g OGTT. In doing so, these 
recommendations may identify an increased number of women at lower risk for 
 
Gestational Diabetes and the Metabolic Syndrome 
 
151 
complications. How the IADPSG recommendations will impact the risk of long-term 
development of metabolic disease remains unknown at this time (IADPSG, 2010). 
3.3 GDM and the Identification of future risk of T2DM and CVD 
It is estimated that 20 to 60% of women with a history of GDM will eventually develop 
T2DM. Indeed, the relation between GDM and T2DM is well described, and the two 
conditions share a similar pathophysiology, characterized by insulin resistance of peripheral 
tissues and insufficient secretion of insulin by the pancreatic beta cells to compensate for this 
resistance (Buchanan, 2001; Buchanan & Xiang, 2005; Retnakaran et al., 2010a). Pregnancy 
itself has been described as a “stress test” for T2DM and CVD (Reece et al., 2009). It 
necessarily involves a state of severe acquired insulin resistance that is comparable to that of 
a non-pregnant person with T2DM (Bergman, 1989). Furthermore, adult offspring with 
prediabetes, born to women with previous GDM, display an 8-times higher risk of T2DM 
(Clausen et al., 2008), demonstrating the cyclical nature of diabetes (Damm, 2009) and the 
compounding effects of dysmetabolism in pregnancy. 
Since O’Sullivan’s early research illustrating high rates of IGT in the years following GDM 
(O’Sullivan, 1991), many studies have investigated the phenomena of elevated risk of T2DM 
attributed to previous GDM. In their systematic review and meta-analysis to quantify the risk 
of T2DM following GDM, Bellamy and colleagues (2009) found that women with GDM had an 
increased risk of developing T2DM compared to those women who had normoglycemic 
pregnancies (RR 7.43, 95% CI 4.79-11.51 (Bellamy et al., 2009). Epidemiological evidence shows 
that, for all populations and ethnic groups, GDM increases the risk of T2DM (Ben-Haroush et 
al., 2004). While the shared risk factors between GDM and T2DM imply a common etiology, 
the salient message is that women with a history of GDM represent a highly vulnerable group  
for the development of T2DM. This is readily evident in the 2% prevalence of T2DM following 
GDM as early as 6 weeks postpartum, with reported rates of 50-60% at 5-10 years postpartum, 
and 70% by 28 years postpartum (Kim et al, 2002; Lauenborg et al., 2004). Furthermore, at the 
population level, the health significance of GDM is apparent in the number of individuals with 
diabetes preceded by GDM. In their meta-analysis of follow-up studies of women with 
previous GDM, Cheung and Byth (2003) calculated the population-attributable risk percent 
(PAR%) for the proportion of cases of T2DM associated with prior GDM. The PAR% ranged 
from 10-31% (Cheung & Byth, 2003). These data suggest that up to one third of parous women 
with T2DM have a history of GDM. 
In addition to identifying women at risk for T2DM, GDM also has implications for future 
risk of CVD. Indeed, women with a history of GDM are at risk for sub-clinical 
atherosclerosis (Tarim et al., 2006). Studies also show an increased prevalence of 
cardiovascular risk factors in women with previous GDM (Carr et al., 2006; Lauenborg et al., 
2005; Verma et al., 2002). Shah and colleagues (2008) used large population-based 
administrative databases to examine the CVD risk in women with a history of  GDM. They 
found that, by 11.5 years after delivery, the hazard ratio for CVD in women with GDM was 
1.71 (95% CI 1.08-2.69)(Shah et al., 2008). Moreover, even mild glucose intolerance in 
pregnancy is associated with an increased risk of CVD. Compared with normoglycemic 
women who did not receive an OGTT, those who had an abnormal GCT followed by an 
OGTT that was not diagnostic of GDM still had an increased risk of CVD within 12 years of 
the index pregnancy (Retnakaran & Shah, 2009b).  
GDM likely increases the risk for developing cardiometabolic dysfunction after an affected 
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complications. How the IADPSG recommendations will impact the risk of long-term 
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previous GDM went on to develop hypertension compared to only 4% in the control group 
(Mestman, 1972). Another study demonstrated significantly higher rates of dyslipidemia, 
hypertension and mortality 26 years after GDM (O’Sullivan, 1991). Further exacerbating the 
burden of disease is family history of T2DM, which adds to the elevated risk associated with  
GDM. Carr and colleagues (2006) quantified the increased risk of CVD in women with GDM 
and a family history of T2DM, compared to women without a history of GDM (OR 1.85, 95% 
CI: 1.21-2.82) (Carr et al., 2006). It is generally recommended that women with GDM 
undergo a postpartum OGTT to detect ongoing dysglycemia. If lower thresholds for GDM 
are adopted, then more women are likely to be screened for T2DM postpartum. One hopes 
that this will offer a preventive opportunity that would otherwise be missed in these 
women.  
3.4 GDM and emerging non-traditional risk factors 
CVD is described as an inflammatory disease, with analogous findings in diabetes and 
obesity (Stern, 1995). Studies have also demonstrated the presence of inflammation in GDM, 
with high concentrations of serum CRP associated with GDM, but which are attenuated by 
further adjustment for BMI (Winzer et al., 2004; Wolf et al., 2003). In a cross-sectional study 
examining the role of maternal obesity in the association between CRP and GDM, pre-
pregnancy BMI emerged as the most important determinant of serum CRP concentration, 
independent of GDM (Retnakaran et al., 2003).  It thus emerges that obesity may mediate a 
systemic inflammatory response that underlies the relation between CRP and GDM. 
Similar to its potential as a metabolic syndrome risk factor, adiponectin is also a promising 
marker of GDM. Compared to unaffected women, those with GDM have lower levels in 
pregnancy of both total and HMW adiponectin (Retnakaran et al., 2004; Retnakaran et al., 
2007). These lower levels of total and HMW adiponectin are associated with both insulin 
resistance and pancreatic beta-cell dysfunction (Retnakaran et al., 2005; Retnakaran et al., 
2007). Furthermore, hypoadiponectinemia in pregnancy independently predicts postpartum 
metabolic dysfunction, including fasting glycemia, insulin resistance and beta-cell 
dysfunction (Retnakaran et al., 2010d). Thus, hypoadiponectinemia may play a role in the 
development of T2DM in women with a history of GDM.  
Another novel marker potentially associated with GDM is the presence of a fatty liver. In 
non-pregnant women with previous GDM who underwent MRI of the liver, those with high 
liver fat had elevated fasting serum triglyceride and insulin concentrations and lower 
whole-body insulin sensitivity than those with low liver fat on MRI (Tiikkainen et al., 2002). 
Given that NAFLD is common in T2DM, Forbes and colleagues (2011) investigated the 
prevalence and risk for NAFLD among European women with previous GDM. The 
prevalence of NAFLD was much higher in women with previous GDM (38%, 95% CI 28-47) 
than in those without GDM (17%, 95% CI 10-24)(Forbes et al., 2011). 
Limited evidence exists for the association between uric acid and GDM, although its 
predictive value in T2DM makes it a promising candidate for studies of GDM. High uric 
acid levels have been detected in women with GDM (Seghieri et al., 2003), and are 
considered a marker of preeclampsia (Barden et al., 2004).  
SHBG (Smirnakis et al., 2007) is another biochemical marker of much interest. Bartha et al. 
(2000) compared serum SHBG levels between women with and without GDM, and found 
that SHBG levels were lower in the GDM group (Bartha et al., 2000). Similarly, SHBG, in 
addition to adiponectin, was shown to be lower in women with GDM than unaffected 
controls (Nanda et al., 2011). Even when measured in early pregnancy, first-trimester SHBG 
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levels were lower among women who went on to  develop GDM compared to their peers 
(187 nmol/L vs 233 nmol/L) (Thadhani et al., 2003).  
In addition to traditional measures for GDM, these emerging risk factors are the same as 
those described for metabolic syndrome arising outside of pregnancy (Figure 2). 
Accordingly, they raise the question of whether the metabolic syndrome relates to GDM. 
 
 
Fig. 2. Traditional and non-traditional (bolded boxes) cardiometabolic risk factors associated 
with GDM. 
4. Risk of metabolic syndrome and its sequelae following GDM 
4.1 Development of metabolic syndrome after GDM 
Evidence that the metabolic syndrome both precedes and follows GDM suggests an 
increased lifetime risk of T2DM in women with prior GDM. In addition to chronic beta-cell 
dysfunction, women with GDM have chronic insulin resistance that is apparent after 
delivery. Indeed, in the decade after pregnancy, many women with previous GDM exhibit 
features of the metabolic syndrome. Considering the shared risk factors of metabolic 
syndrome and T2DM, and the similarities between GDM and T2DM, it is not surprising that 
GDM is likewise associated with metabolic syndrome. Akinci and colleagues (2010) 
collected antepartum characteristics of women who developed metabolic syndrome in their 
later years. Using the ATP III and IDF definitions for metabolic syndrome, pre-pregnancy 
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metabolic syndrome. Moreover, even a fasting glucose concentration above 5.5 mmol/L at 
the antepartum OGTT was an independent predictor  of metabolic syndrome (Akinci et al., 
2010).  Indeed,  many studies have demonstrated an increased prevalence of features of the 
metabolic syndrome following GDM. 
Egeland and Meltzer (2010) investigated the effects of GDM on future risk of metabolic and 
cardiovascular abnormalities. The prevalence of glucose intolerance at 15 years follow-up 
was 44.4% among women with prior GDM, vs. only 13.1% in those without GDM. WC at 15-
year follow-up was the strongest predictor of this difference (Egeland & Meltzer, 2010). 
Similarly, in a U.S. study, the prevalence of the metabolic syndrome was 27.2% 11 years 
after pregnancy in women with previous GDM, compared to only 8.2% in unaffected 
controls (Verma et al., 2002). Lauenborg et al. (2005) estimated the risk of metabolic 
syndrome in a Danish cohort of women 9.8 years after delivery. Women with previous 
GDM had a 3-fold higher risk of metabolic syndrome compared to non-GDM controls 
(Lauenborg et al., 2005). A similar study in Europe reported prevalences of metabolic 
syndrome of 21% and 4.6%, respectively, 8.5 years’ postpartum (Bo et al., 2004b). Indeed, 
prior gestational hyperglycemia in the absence of fulfilling the overt criteria for GDM results 
in a future risk of metabolic syndrome 2-4 times that of those with normoglycemia in 
pregnancy. This risk is 10 times higher in women with concomitant pre-pregnancy obesity 
(Bo et al., 2004a). Thus, even mild gestational hyperglycemia predicts metabolic syndrome 
(Bo et al., 2004b), and metabolic syndrome is increasingly more likely to develop over time 
following the index pregnancy (Bo et al., 2006). These studies highlight the chronic nature of 
the metabolic dysfunction associated with GDM. Furthermore, they raise the possibility that 
a diagnosis of GDM may indicate the presence of an underlying latent metabolic syndrome 
(Retnakaran et al., 2010b). 
4.2 Development of metabolic syndrome in the early postpartum after GDM 
Recent evidence implicates GDM as an early expression of metabolic syndrome (Haffner & 
Taegtmeyer, 2003). Indeed, it was recently reported that both GDM (OR 2.05, 95% CI 1.07-
3.94) and the milder state of gestational impaired glucose tolerance (GIGT) (OR 2.16, 95% CI 
1.05-4.42) independently predict postpartum metabolic syndrome by 3 months postpartum, 
even after adjustment for covariates (Retnakaran et al., 2010d). Furthermore, by 3 months 
postpartum women with GDM and GIGT also exhibit non-traditional risk factors associated 
with metabolic syndrome, including low levels of adiponectin and increased serum CRP 
(Retnakaran et al., 2010c). While many of the metabolic disturbances of pregnancy resolve 
after delivery, growing evidence supports the concept that pregnancy provides an 
opportunity to observe a pronounced expression of an otherwise subclinical metabolic 
disorder. Such metabolic disturbances, which include the metabolic syndrome component 
disorders, may indeed be apparent prior to the diagnosis of GDM.  
5. Prediction of GDM by metabolic syndrome components and associated 
risk factors 
5.1 Prediction of GDM by metabolic syndrome components in early pregnancy  
It is quite likely that the metabolic syndrome exists prior to the development of GDM. 
Indeed, GDM has even been proposed to be a component of the metabolic syndrome (Clark 
et al. 1997). In their study, Clark et al. (1997) showed that, at the time of their antepartum 
OGTT, women with GDM expressed markers of the metabolic syndrome, including low 
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serum HDL cholesterol and higher fasting plasma insulin, triglycerides, free fatty acids and 
pre-pregnancy BMI. These common features of the metabolic syndrome were each 
individually predictive of GDM, and persisted after adjustment for differences in BMI 
(Clark et al., 1997).  
In addition to conventional measures of metabolic syndrome, several non-traditional 
biomarkers have also emerged as possible predictors of GDM. As discussed earlier, low 
adiponectin is a risk factor for T2DM and an emerging risk factor for metabolic syndrome 
and GDM. Using a prospective nested case-control study design, Williams et al. (2004) 
determined whether first trimester hypoadiponectinemia predicts GDM. They found that 
73% of those with GDM had a low adiponectin level compared to 33% of controls (adjusted 
OR 4.6, 95% CI 1.8-11.6) (Williams et al., 2004). Similarly, Lain and colleagues (2008) found 
that women with low adiponectin concentrations in the first trimester were much more 
likely to be diagnosed with GDM (OR 10.2, 95% CI 1.3, 78.7) (Lain et al., 2008).  
In choosing an optimal early serum marker to predict GDM, Smirnakis and colleagues 
(2007) compared SHBG, high-sensitive CRP, and the homeostasis model of assessment of 
insulin resistance (HOMA-IR) in late first trimester and early second trimester of pregnancy 
(Smirnakis et al., 2007). Serum SHBG was lower, and serum CRP higher, in women who 
went on to develop GDM, who also had  elevated HOMA-IR in the second trimester. After 
multivariate analysis, SHBG emerged as the best predictor of GDM (Smirnakis et al., 2007). 
Alternately, Wolf et al. (2003) found that the risk of developing GDM was higher in women 
in the upper vs. lower tertiles of first-trimester CRP, after adjusting for confounders (OR 3.6, 
95% CI 1.2-11.4). Importantly, the association was attenuated when BMI was included in the 
analysis (OR 1.5, 95% CI 0.4-5.5) (Wolf et al., 2003), suggesting that obesity confounds the 
relation between inflammation and GDM.  
Qiu and colleagues (2004) found that, even after adjusting for maternal pre-pregnancy BMI 
and other confounders, women with CRP in the highest vs. lowest tertiles experienced a 3.5-
times increased risk of GDM (95% CI 1.2-9.8) (Qiu et al., 2004). Moreover,  even lean women 
had an OR for GDM of 3.7 (95% CI 1.6-8.7), suggesting that the association between elevated 
CRP and GDM may not solely depend on the presence of maternal obesity (Qiu et al., 2004). 
However, Savvidou and colleagues (2010) evaluated various first-trimester conventional 
and novel biomarkers, including adiponectin and CRP, and found only a low HDL-C and a 
high tissue plasminogen activator were significant independent predictors of GDM 
(Savvidou et al., 2010). Laughon et al (2009) reported that a first trimester concentration of 
uric acid in the highest quartile had an OR for GDM of 3.25 (95% CI 1.35-7.83), after 
adjusting for BMI and age (Laughon et al., 2009). Together, these emerging risk factors 
present an opportunity for early detection of GDM, and possibly, the identification of an 
effective tool for long-term prevention of metabolic syndrome. 
It is likely that components of metabolic syndrome exist before and after GDM. Similar to 
T2DM, where persons with IGT and IFG are at significant risk of T2DM, so too may be the 
case for metabolic syndrome in early pregnancy. Ray and colleagues (2010) coined the term 
“gestational prediabetes” to describe the absence of diabetes before pregnancy, and the 
presence of a blood glucose level (or a related marker) in early pregnancy that is higher than 
normal, but not yet high enough to meet the diagnostic criteria for GDM (Ray et al., 2010). 
Given the promising findings of using emerging biomarkers to detect dysmetabolism in 
early pregnancy and predict GDM, the next step is to identify a robust biomarker that can be 
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with metabolic syndrome, including low levels of adiponectin and increased serum CRP 
(Retnakaran et al., 2010c). While many of the metabolic disturbances of pregnancy resolve 
after delivery, growing evidence supports the concept that pregnancy provides an 
opportunity to observe a pronounced expression of an otherwise subclinical metabolic 
disorder. Such metabolic disturbances, which include the metabolic syndrome component 
disorders, may indeed be apparent prior to the diagnosis of GDM.  
5. Prediction of GDM by metabolic syndrome components and associated 
risk factors 
5.1 Prediction of GDM by metabolic syndrome components in early pregnancy  
It is quite likely that the metabolic syndrome exists prior to the development of GDM. 
Indeed, GDM has even been proposed to be a component of the metabolic syndrome (Clark 
et al. 1997). In their study, Clark et al. (1997) showed that, at the time of their antepartum 
OGTT, women with GDM expressed markers of the metabolic syndrome, including low 
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serum HDL cholesterol and higher fasting plasma insulin, triglycerides, free fatty acids and 
pre-pregnancy BMI. These common features of the metabolic syndrome were each 
individually predictive of GDM, and persisted after adjustment for differences in BMI 
(Clark et al., 1997).  
In addition to conventional measures of metabolic syndrome, several non-traditional 
biomarkers have also emerged as possible predictors of GDM. As discussed earlier, low 
adiponectin is a risk factor for T2DM and an emerging risk factor for metabolic syndrome 
and GDM. Using a prospective nested case-control study design, Williams et al. (2004) 
determined whether first trimester hypoadiponectinemia predicts GDM. They found that 
73% of those with GDM had a low adiponectin level compared to 33% of controls (adjusted 
OR 4.6, 95% CI 1.8-11.6) (Williams et al., 2004). Similarly, Lain and colleagues (2008) found 
that women with low adiponectin concentrations in the first trimester were much more 
likely to be diagnosed with GDM (OR 10.2, 95% CI 1.3, 78.7) (Lain et al., 2008).  
In choosing an optimal early serum marker to predict GDM, Smirnakis and colleagues 
(2007) compared SHBG, high-sensitive CRP, and the homeostasis model of assessment of 
insulin resistance (HOMA-IR) in late first trimester and early second trimester of pregnancy 
(Smirnakis et al., 2007). Serum SHBG was lower, and serum CRP higher, in women who 
went on to develop GDM, who also had  elevated HOMA-IR in the second trimester. After 
multivariate analysis, SHBG emerged as the best predictor of GDM (Smirnakis et al., 2007). 
Alternately, Wolf et al. (2003) found that the risk of developing GDM was higher in women 
in the upper vs. lower tertiles of first-trimester CRP, after adjusting for confounders (OR 3.6, 
95% CI 1.2-11.4). Importantly, the association was attenuated when BMI was included in the 
analysis (OR 1.5, 95% CI 0.4-5.5) (Wolf et al., 2003), suggesting that obesity confounds the 
relation between inflammation and GDM.  
Qiu and colleagues (2004) found that, even after adjusting for maternal pre-pregnancy BMI 
and other confounders, women with CRP in the highest vs. lowest tertiles experienced a 3.5-
times increased risk of GDM (95% CI 1.2-9.8) (Qiu et al., 2004). Moreover,  even lean women 
had an OR for GDM of 3.7 (95% CI 1.6-8.7), suggesting that the association between elevated 
CRP and GDM may not solely depend on the presence of maternal obesity (Qiu et al., 2004). 
However, Savvidou and colleagues (2010) evaluated various first-trimester conventional 
and novel biomarkers, including adiponectin and CRP, and found only a low HDL-C and a 
high tissue plasminogen activator were significant independent predictors of GDM 
(Savvidou et al., 2010). Laughon et al (2009) reported that a first trimester concentration of 
uric acid in the highest quartile had an OR for GDM of 3.25 (95% CI 1.35-7.83), after 
adjusting for BMI and age (Laughon et al., 2009). Together, these emerging risk factors 
present an opportunity for early detection of GDM, and possibly, the identification of an 
effective tool for long-term prevention of metabolic syndrome. 
It is likely that components of metabolic syndrome exist before and after GDM. Similar to 
T2DM, where persons with IGT and IFG are at significant risk of T2DM, so too may be the 
case for metabolic syndrome in early pregnancy. Ray and colleagues (2010) coined the term 
“gestational prediabetes” to describe the absence of diabetes before pregnancy, and the 
presence of a blood glucose level (or a related marker) in early pregnancy that is higher than 
normal, but not yet high enough to meet the diagnostic criteria for GDM (Ray et al., 2010). 
Given the promising findings of using emerging biomarkers to detect dysmetabolism in 
early pregnancy and predict GDM, the next step is to identify a robust biomarker that can be 





abnormalities likely precede pregnancy, which means that they should be detectable in early 
pregnancy as well. 
5.2 Prediction of GDM by metabolic syndrome components prior to pregnancy 
A modest body of literature exists about the existence of metabolic syndrome prior to the 
detection of GDM. Gunderson and colleagues (2009) examined pre-pregnancy 
cardiometabolic risk factors and the risk of GDM in subsequent pregnancies. They found 
that metabolic impairment often predated the onset of GDM, and that 27% of overweight 
women with one or more cardiometabolic risk factors developed GDM (Gunderson et al., 
2009). Normoglycemia with at least one metabolic risk factor (i.e., low plasma HDL-C and/or 
hyperinsulinemia) was present before pregnancy in 34% of those who developed GDM; 
among overweight women, the presence of any cardiometabolic feature was associated with 
an almost 4 times higher risk of GDM. Hedderson and Ferrara (2008) measured blood pressure 
before pregnancy and in early pregnancy, and found that women with mild hypertension in 
early pregnancy had a  small increased risk of GDM (OR 1.56, 95% CI 1.16-2.10). Those with 
frank hypertension had a 2-fold increased risk of GDM (OR 2.04, 95% CI 1.14-3.65) compared 
to normotensive women, even after adjusting for confounders. These findings were paralleled 
by mild (OR 1.44, 95 CI 0.95-2.19) and frank (OR 2.01, 95% CI 1.01-3.99) hypertension detected  
before pregnancy (Hedderson & Ferrara, 2008).  
6. Conclusions 
We have reviewed the parallels and associations between the metabolic syndrome and 
GDM. Both conditions have had multiple sets of diagnostic criteria and a history marked by 
controversies about their definition, clinical utility and significance. Both conditions identify 
a patient population that has an increased future risk of T2DM and CVD. Furthermore, both 
conditions have been associated with a similar set of emerging non-traditional risk factors. 
Consistent with these parallels, GDM predicts an increased risk of metabolic syndrome both 
in the early postpartum and in the years thereafter. Moreover, it is now becoming apparent 
that the metabolic syndrome and its associated risk factors may precede the diagnosis of 
GDM, both in early gestation and prior to the pregnancy. Taken together, these data suggest 
that GDM may represent a transient ‘unmasking’ of a latent metabolic syndrome, which 
may extend in both directions through (i) the pre-gravid state and early pregnancy, and (ii) 
the early and late postpartum. Figure 3 illustrates this lifetime continuum that may link 
metabolic syndrome, GDM, T2DM, and CVD. The chronic nature of the features of 
metabolic syndrome suggests that what we know about the temporal relation between 
metabolic syndrome, GDM, T2DM, and CVD is limited. The global burden of diabetes has 
been estimated at more than 171 million individuals with an expected increase to 366 
million by 2030 (Wild et al., 2004). The prevalence of obesity and related metabolic 
dysfunction worldwide is a vivid demonstration of the undiscriminating potential of cardio-
metabolic diseases across ethnicities and age groups. In this context, the emerging relation 
between metabolic syndrome and GDM may offer the opportunity for early detection of at-
risk individuals, long before the manifestation of overt disease. Ideally, this opportunity 
may lead to new strategies for early risk modification and ultimately disease prevention. As 
such, the emerging relation between metabolic syndrome and GDM represents an important 
area of research that may hold both clinical and public health implications. 
 




Fig. 3. Theoretical framework and conceptual model for latent metabolic syndrome 
preceding GDM. 
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1. Introduction   
Pregnancy results in a state of insulin resistance (Dahlgren, 2006) that appears to include a 
decrease in maximum insulin sensitivity or responsivity (Baban et al., 2010). This insulin 
resistance abates in the postpartum period (Kuhl, 1991). Insulin resistance is defined as the 
decrease of the biological action of insulin (Catalano, 2010; Robert, 1995), and it mainly 
presents as hyperinsulinemia (Baban et al., 2010; Robert, 1995) or decreased ability of insulin 
to regulate glucose utilization (Kim et al., 1996). 
The resistance to insulin can be characterized as pre-receptor (insulin antibodies), receptor 
(decreased number of receptors on the cell surface), or post-receptor (defects in the 
intracellular insulin signaling pathway). In pregnancy, the decreased insulin sensitivity is 
best characterized as a post-receptor defect resulting in the decreased ability of insulin to 
bring about glucose transporter (GLUT4) mobilization from the interior of the cell to the cell 
surface (Catalano, 2010). 
Most pregnant women are able to counteract the insulin resistance state by increasing their 
insulin secretion.  However, when the capacity of insulin secretion is not sufficiently large to 
meet the insulin resistance, glucose intolerance develops and the women develop 
gestational diabetes (Kuhl et al., 1985). 
Gestational diabetes mellitus (GDM) is defined as a carbohydrate intolerance of varying 
severity with onset or first recognition during the present pregnancy (Kaaja & Rönnemaa, 
2008; Damm et al., 1994; Summary and recommendation of the second international 
workshop conference of gestational diabetes, 1985; Shalayel et al., 2010). GDM has onset or 
discovery of glucose intolerance during pregnancy (Reece et al., 2009), usually in the second 
or third trimester (Shalayel et al., 2007). GDM carries long-term implications for the 
subsequent development of type 2 diabetes in the mother and increased risk for obesity and 
glucose intolerance in the offspring (Barbour et al., 2007). The world health organization 
defines diabetes in pregnancy as a fasting glucose ≥ 7.9 mmol/L or a value >11 mmol/L 2-
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Impaired Glucose Tolerance (IGT) was previously known as chemical diabetes or subclinical 
diabetes (Shalayel et al., 2007). It may be defined as an intermediate group of individuals 
whose carbohydrate metabolism does not constitute diabetes but is not entirely normal 
(Brudenell, 1993). Thus, IGT designed glucose tolerance results intermediate between 
normal glucose homeostasis and overt diabetes (Kahn et al., 2005; Bilous & Donnelly, 
2010; Burch, 1994). It is diagnosed if fasting glucose ≥ 6 but < 7.8 m mol/L or 2-hour 
glucose > 7.8 m mol/L and <11.1 mmol/L (Shalayel et al., 2010; Hope et al., 1993). About 
25% of patients with IGT eventually become diabetic (Shalayel et al., 2007). 
In fact there are significant alterations in glucose metabolism during pregnancy (Catalano, 
1994). The carbohydrate tolerance is reduced, especially in the last trimester due to reduced 
sensitivity to insulin action (Hod &, Yogev, 2007).  
Insulin resistance is defined where a normal or elevated insulin level produces an attenuated 
biological response classically this refers to impaired sensitivity to insulin mediated glucose 
disposal (Wilcox, 2005). 
The objectives of this study were to stand on the state of insulin resistance that occurs in 
pregnancy and to assess the possible role of cortisol, human placental lactogen and prolactin 
in augmentation of such state. The study also showed the effect of some maternal risk 
factors such as age, parity, previous heavy babies and first-degree family history of diabetes 
in glucose tolerance impairment in pregnancy. 
2. Subjects and methods 
The study was carried on Sudanese pregnant women in the third trimester (34.2±0.63, 
35.97±0.71 and 36.53 ±0.64 current week of gestation for the GDM, IGT and control groups 
respectively). 
2.1 Subjects 
Thirty pregnant women with the GDM,30 pregnant women with IGT and 30 pregnant 
women with a normal glucose tolerance (control group) chosen from Khartoum teaching 
hospital, Khartoum north hospital, Soba hospital, Ibrahim Malik hospital, Maternity hospital 
and Fath-Elrahman Elbasheer referral center. Oral consent was obtained from all the 
participants involved in the present study. 
All subjects overnight fasted before the test. A fasting blood sample was drawn at 6:00 
O’clock a.m. then 75 g oral glucose dissolved in 200 cc water was given for each, waiting for 
2 hours and then another blood sample was drawn from each. 
2.2 Parameters analysis 
The concentration of fasting serum c-peptide, serum cortisol, human placental lactogen and 
prolactin (2-h after 75-g glucose load) were measured with the specific radio-immunoassay.   
Insulin: the concentrations of serum insulin in the fasting sample (0 min) and in the 2-hour 
after 75 g glucose load sample were measured with the specific immunoradiometric assay 
(IRMA). 
Anti insulin antibodies (AIA): the presence of circulating anti-insulin antibodies is semi-
quantitatively estimated by determination of the binding of tracer to AIA in the serum fraction. 
Plasma levels of glucose were assayed with a glucose oxidase kit while serum levels of 
cholesterol and triacylglycerols (TAGs) were estimated by the specific enzymatic 
colorimetric methods. 
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2.3 Statistical analysis 
Data were expressed as mean, standard deviation (S.D.), standard error of mean (S.E.), and 
95% confidence interval (CI) for mean. Comparisons were made using one-way analysis of 
variance (one-way ANOVA) and the significant differences among mean values were 
indicated by Scheffe test. Data of anti-insulin antibodies (AIA) of different groups of the study 
were compared by Kruskal–Wallis one-way ANOVA. The differences among the incidence 
percentages of family history of diabetes and previous heavy babies in the different groups of 
the study were assessed by calculation of z-values and their corresponding p-values. The 
correlation coefficient (r) is used to measure the closeness of the linear relationship between 
age and 2h-plasma glucose and between parity and 2h-plasma glucose. Calculations were 
performed using Statistical Packages for Social Sciences (SPSS) program. 
3. Results 
The GDM and the IGT pregnant women were found to be significantly older than the control 
women [32.8 ±0.93 year (mean ± S.E.) and 31.1±1.1 vs. 23.9 ±0.82 respectively, p<0.0001]. 
Incidence of previous heavy babies (≥ 4.5 kg at birth) of the IGT group was significantly 
higher than that of the control group (33.3% vs 6.7%, z=2.25 and p<0.05). Also, incidence of 
previous heavy babies of the GDM group was significantly higher than that of the control 
group (46.7% vs 6.7%, z=3.2 and p<0.01). 
Percentage of first degree family history of diabetes was significantly higher in the IGT 
group when compared with that of the control group (36.7% vs 10%, z=2.1 and p < 0.05). 
Much higher significant difference was shown between the GDM group and the control 
group (53.3% vs 10%, z=3.3 and p<0.001). 
3.1 Plasma levels of glucose 
The GDM women were found to have higher mean levels of plasma glucose when 
compared with the IGT and the control pregnant women as shown in table 1 and table 2 
(p<0.0001). 
 
 Mean S.D. S.E. 95% CI 
GDM 7.59** 1.85 0.34 6.9-8.28 
IGT 5.9* 0.45 0.082 5.73-6.07 
Control 2.91 0.43 0.079 2.75-3.07 
* Significant ** Highly significant 
Table 1. Fasting plasma glucose levels (0 min) in the three studied groups (mmol/L) 
 
 Mean S.D. S.E. 95% CI 
GDM 12.35** 3.11 0.57 11.19-13.51 
IGT 7.98* 0.69 0.13 7.72-8.23 
Control 4.35 0.65 0.12 4.11-4.6 
* Significant ** Highly significant 
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3. Results 
The GDM and the IGT pregnant women were found to be significantly older than the control 
women [32.8 ±0.93 year (mean ± S.E.) and 31.1±1.1 vs. 23.9 ±0.82 respectively, p<0.0001]. 
Incidence of previous heavy babies (≥ 4.5 kg at birth) of the IGT group was significantly 
higher than that of the control group (33.3% vs 6.7%, z=2.25 and p<0.05). Also, incidence of 
previous heavy babies of the GDM group was significantly higher than that of the control 
group (46.7% vs 6.7%, z=3.2 and p<0.01). 
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3.1 Plasma levels of glucose 
The GDM women were found to have higher mean levels of plasma glucose when 
compared with the IGT and the control pregnant women as shown in table 1 and table 2 
(p<0.0001). 
 
 Mean S.D. S.E. 95% CI 
GDM 7.59** 1.85 0.34 6.9-8.28 
IGT 5.9* 0.45 0.082 5.73-6.07 
Control 2.91 0.43 0.079 2.75-3.07 
* Significant ** Highly significant 
Table 1. Fasting plasma glucose levels (0 min) in the three studied groups (mmol/L) 
 
 Mean S.D. S.E. 95% CI 
GDM 12.35** 3.11 0.57 11.19-13.51 
IGT 7.98* 0.69 0.13 7.72-8.23 
Control 4.35 0.65 0.12 4.11-4.6 
* Significant ** Highly significant 





3.2 Serum cholesterol and triacylglycerols results 
It was found that the mean levels of serum cholesterol of the IGT group and that of the 
GDM group were significantly higher than that of the control group [252.5±13.17 mg/dl 
(mean ±S.E.), 239.07±14.82 vs 195.73±8.47 respectively, F=6.22 and p<0.003]. 
Also, it was found that the mean levels of serum triacylglycerols of the GDM group and that 
of the IGT group were significant higher than that of the control group [278.47±15.90 mg/dl 
(mean ±S.E.), 259.37±11.6 vs 188.63 ±8.92 respectively, F=17.81 and p<0.0001]. 
But, there was no significant difference between the mean levels of TAGs of the GDM group 
and that of the IGT group although the serum TAGs levels were greater in the GDM group. 
3.3 Serum c-peptide results 
Fasting c-peptides mean of the IGT group was not significantly higher than that of the GDM 
and control groups [0.34±0.04 p mol/l (mean ± S.E.) vs 0.26±0.03 and 0.28±0.04 respectively, 
p>0.05]. 
3.4 Serum levels of cortisol 
There was a highly significant difference (p<0.0003) between serum level of cortisol of the 
GDM group and the IGT group from one hand and between the GDM group and the control 
group from other hand (table 3). 
 
 Mean S.D. S.E. 95% CI 
GDM 937.2** 434.8 79.38 774.9-1099.6 
IGT 794.2* 331.5 60.52 670.4-918 
Control 597.3 169.4 30.93 534-660.5 
* Significant ** Highly significant 
Table 3. Serum cortisol (nmol/l) values of the three studied group 
3.5 Serum levels of insulin 
There was no significant difference among the mean fasting serum insulin levels of the 
studied groups [12.29±0.83 MIU/ml (mean ±S.E.), 14.93±2.17 and 2.39±2.25 for the GDM, 
IGT and control groups respectively, p>0.05]. 
The men level of 2h-serum insulin of the IGT group was significantly higher than that of the 
GDM group (68±6.71 vs 36.5±3.06, p<0.002) while, it was not significantly higher than that of 
the control group (68±6.71 vs 54.88±8.15). 
3.6 Serum anti-insulin antibodies (AIA) results 
The results of AIA binding percentage to the tracer (table 4) showed significant difference 
among the three studied groups [X² (df=2) = 7.34,p<0.025]. 
 
 Mean S.D. S.E. 95%CI for 
mean 
Mean rank 
GDM 25.11** 31.01 5.66 13.53-36.69 54.25 
IGT 7.18* 2.47 0.45 6.25-8.10 46.23 
Control 6.04 1.50 0.27 5.48-6.60 36.02 
* Significant ** Highly significant 
Table 4. Percent bound results of serum AIA 
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3.7 Serum hPL results 
Although the mean HPL levels of the IGT group and that of the GDM group were higher 
than that of the control group, there were no significant differences among them 
[7.15±0.49Mg/ml (mean ± S.E.), 6.85+0.58 and 5.73±0.24, p> 0.05]. 
3.8 Serum prolactin results 
Although the control group recorded the highest levels of serum prolactin and the GDM 
recorded the lowest results, there were no significant differences among the studied groups 
[123.6±9.61 ng/dl (mean ± S.E.), 145±15 and 150.2±9.7 for the GDM, IGT and control groups 
respectively, p>0.05]. 
4. Discussion 
There is an increased frequency of gestational diabetes in oriental women and those from 
the Indian subcontinent and the Middle East (Stewart & Taylor, 1994). Pregnancy and 
diabetes mellitus aggravate each other (Potemkin, 1989). Hormonal changes occur in 
pregnancy, which profoundly affect carbohydrate metabolism. The levels of estrogen, 
progesterone, human placental lactogen, free cortisol and prolactin rise progressively as 
pregnancy advances. Of these a number, notably human placental lactogen and cortisol are 
insulin antagonists. So, insulin resistance develops in the mother as the pregnancy 
progresses, and it is most marked in the last trimester. This leads to deterioration in glucose 
tolerance (Brudenell, 1993). This explains why IGT and GDM were only discovered in the 
third trimester of gestation. 
The results showed that many maternal risk factors affect the incidence of abnormal glucose 
tolerance (IGT & GDM) in Sudanese pregnant women.  
Maternal age is an established risk factor for gestational diabetes mellitus (GDM), but there 
is no consensus on the age above which there is significantly increased risk of GDM 
(American Diabetes Association, 2004). The finding that the IGT and the GDM groups were 
significantly older than those with normal glucose tolerance (control) group, agrees with 
many previous studies that approved the direct relation between advanced maternal age 
(<35) and greater risk for incidence of GDM (Solomon et al., 1997; Cianni et al., 2003). 
Moreover, the presence of a linear relationship between the age and the 2h-plasma glucose 
ensure that there is an age related deterioration of glucose tolerance and makes the age a 
very important maternal risk factor to affect glucose intolerance incidence. 
The association between parity and diabetes seems consistent in different studies. Women 
with highest parity are frequently older and heavier. Therefore, no study that evaluates 
parity could ignore a proper age adjustment (Dode & dos Santos, 2009). Multiparity has 
been associated with GDM in some studies but not in other ones (Seghieri et al., 2005; Ben-
Haroush et al., 2004).  
Kumari et al. (2002) found that grand multiparous women with parity > 10 had greater 
gestational diabetes mellitus incidence. 
Significant higher mean parity of the IGT and the GDM groups when compared with the 
mean parity of the control (normal glucose tolerance) group as well as the existence of a 
linear relationship between parity and the 2h-plasma glucose, make the parity a very 
important maternal risk factor in impairment of glucose tolerance. This may be explained in 
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resistance to insulin (Kuhl, 1991). Parity reflects the duration of exposure to the insulin 
resistance (Peters et al., 1995). Thus, one can conclude that higher parity may lead to 
accumulation of the diabetogenic effect of pregnancy. Consequently, much more glucose 
impairment occurs. 
Genetic factors play a part in the development of diabetes although the exact mode of 
inheritance is not established (Brudenell, 1993). Recent evidence suggests that the 
gestational diabetes has a strong genetic component and is usually NIDDM. Both GDM and 
NIDDM are characterized by insulin deficiency and by insulin resistance (Dornhorst et al., 
1990). This evidence agrees with that of Csorba and Edwards (1995) who showed that the 
development of both type II and GDM is probably governed by a complex and variable 
interaction of genes and environments. Moreover, they suggest that both beta cell 
dysfunction and insulin resistance is operative in the manifestation of these disorders. This 
may explain why the incidence of first degree family history of diabetes was significantly 
higher in the GDM and in the IGT groups when compared with that of the control group. 
Therefore, family history of diabetes is a very important maternal risk factor from the 
obstetrician’s point of view (Brudenell, 1993). 
The result that the GDM and the IGT groups have incidence of previous heavy babies 
significantly higher than that of control group, make previous delivery of a large baby to be 
a very important maternal risk factor since a tendency to bear heavy babies may precede the 
development of clinical diabetes by many years (Brudenell, 1993). 
Changes in lipid metabolism occur during pregnancy. Plasma levels of triglycerides, 
cholesterol and free fatty acids rise, and there is a greater tendency to ketosis (Campbell & 
Lees, 2000). Some studies showed that total triglycerides increase with gestational time in 
pre-gestational diabetic women, GDM women and healthy control women (Montelongo et 
al., 1992). 
Every aspect of lipid metabolism is affected by pregnancy. The plasma level of free fatty 
acids falls from early to mid-pregnancy and thereafter shows a significant rise. The same is 
true for the plasma level of glycerol. This is in keeping with the accumulation of body fat 
that occurs during the anabolic phase of pregnancy (first two trimesters). In the catabolic 
phase of pregnancy (last trimester), raised free fatty acids and glycerol levels are available as 
fuel to the maternal tissues to offset the increasing diversion to the rapidly growing fetus of 
glucose and amino acids. As with free fatty, glycerol and triglycerides, plasma levels of 
cholesterol and phospholipids are increased in pregnancy (Brudenell, 1993) taking in 
account that plasma triglycerides may be a physiological contributor to infant birth weight 
(Knopp et al., 1992). Thus, one can expect more increase of these lipid substances when the 
glucose tolerance deteriorates in pregnancy. Therefore, the mean level of serum cholesterol 
and triglycerides were significantly higher in the GDM and in the IGT groups when 
compared with the control (normal glucose tolerance) group.    
The changes in lipid metabolism are mediated by hormonal changes and fit into the general 
pattern of an increase in storage of glycogen and fat in most maternal tissues during the 
metabolic first two trimesters of pregnancy, followed by the mobilization of fuel for the 
benefit of both mother and fetus in catabolic third trimester (Brudenell, 1993). 
Boden (1996) demonstrated that in early pregnancy, insulin secretion in response to glucose 
is increased, peripheral insulin sensitivity is normal or increased and glucose tolerance is 
normal or slightly enhanced. In addition, there is maternal fat accumulation. During late 
pregnancy, there is increased fetal growth and increased fetal demand for nutrients. 
Insulin Resistance in the Third Trimester of Pregnancy Suffering 
from Gestational Diabetes Mellitus or Impaired Glucose Tolerance 
 
175 
Maternal responses to these demands consist of an accelerated switch from carbohydrate to 
fat utilization that is facilitated by peripheral insulin resistance and by high blood levels of 
lipolytic hormones. In patients with GDM, insulin resistance is either comparable or greater 
than in non-diabetic pregnancy whereas insulin secretion appears to be compromised.  
Changes in hepatic and adipose metabolism alter circulating concentrations of 
triacylglycerols, fatty acids, cholesterol, and phospholipids. After an initial decrease in the 
first 8 wk of pregnancy, there is a steady increase in triacylglycerols, fatty acids, cholesterol, 
lipoproteins, and phospholipids (Butte, 2000). There is a two- to threefold increase in basal 
triglyceride and cholesterol concentrations with advancing gestation. The increases are more 
pronounced in the GDM as compared with the normal glucose tolerant pregnant woman 
(Catalano, 2010). The higher concentration of estrogen and insulin resistance are thought to 
be responsible for the hypertriglyceridemia of pregnancy (Butte, 2000). 
Thus, it is concluded that in the third trimester of pregnancy, there is a competition between 
mother and her fetus on glucose uptake. This competition will be directed towards the 
benefit of the fetus. For this reason, the pregnant women do switch to other energy source 
rather than glucose such as fat to overcome the state of insulin resistance. 
The syndrome of insulin resistance is a group of clinically diverse disorders (Catalano, 2010; 
Flier, 1992). Pregnancy induces complex changes in energy metabolism, manifested clinically 
by insulin resistance (Bedalov & Balasubramanyam, 1997). Glucose tolerance deteriorates in all 
pregnant women, but only in 2-3% of all pregnancies is the deterioration sufficiently large to 
fulfill the diagnostic criteria for gestational diabetes1. Many previous studies demonstrated 
that pregnancy result in a state of insulin resistance and women with gestational-onset 
diabetes appear to have a greater degree of insulin resistance (Ryan et al., 1985). 
Why pregnancy is capable of inducing the temporary diabetic state is still partly unknown, 
although many other studies tried to put general points to explain this state.  
Bergstrom et al. (1990) revealed that an increased fasting c-peptide reflects insulin 
resistance. In fact, insulin and c-peptide are secreted in equimolar amount. However, 
because of its longer half-life, the plasma concentration of c-peptide is higher than that of 
insulin. Within limits, c-peptides levels can serve as valuable index to insulin secretion. 
Thus, low c-peptide levels are to be expected when insulin secretion is diminished whereas 
elevated c-peptides may result from increased beta-cells activity. 
Regarding our results, the serum fasting c-peptide mean level was the highest in the IGT 
groups (0.337± 0.038 Pmol/L) when compared with the GDM group (0.262 ± 0.025) and the 
control group (0.284 ± 0.041) although the differences were not significant (P > 0.05). This 
gives prediction to the higher insulin resistance in the IGT group when compared with the 
control group. 
Most pregnant women are able to counteract the insulin resistance in pregnancy by 
increasing their insulin secretion. This also explains the highest mean levels of insulin in the 
IGT group when compared with the control group. 
Although the insulin levels, (fasting and 2h-insulin) were lower in the control group than that 
of the IGT group, the glucose tolerance kept normal. This may support the suggestion that 
during normal pregnancy, the Staub-Traugott effect i.e., improved glucose disposal after 
successive glucose load administrations occurs and appears to be caused by mechanisms other 
than enhanced insulin secretion with successive glucose loads (Lewis et al., 1993). 
However, when the capacity of insulin secretion is not sufficiently large to meet the 
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(Shalayel et al., 2010; Buchanan & Xiang, 2005). This may be due to the presence of high 
levels of insulin antagonistic hormones as hPL and cortisol (Carr & Gabbe, 1998) as well as 
high level of circulating anti-insulin antibodies which may make the pregnant women 
secrete more insulin to overcome the insulin resistance and eventually may lead to 
exhaustion of beta-cells of the pancreas. This explain the lowest mean levels of fasting c-
peptide, fasting serum insulin and 2h-serum insulin in the GDM group when compared 
with the IGT and the control groups. 
Damm et al. (1995) demonstrated that women who develop GDM have a relative insulin 
secretion deficiency, the severity of which is predictive for later development of diabetes. 
Furthermore, their relatively reduced beta-cells functions may be a significant pathogenic 
factor in relation to the high incidence of subsequent diabetes in women with GDM. This 
agrees with Paulus et al. (1995) who showed that the diagnoses of gestational diabetes 
mellitus are at a greater risk for developing diabetes in later life. 
Homko et al (2001) reported that patients with GDM during late pregnancy not only had 
severe deficiencies in insulin secretion rate (ISR) and were more insulin resistant than 
controls. In addition, the women with GDM had a major ß-cell defect that made it 
impossible for them to compensate for their increased level of insulin resistance, which 
occurred during late pregnancy.   
Our study also showed that the cortisol increases progressively as pregnancy advances and 
the mean cortisol level was significantly the highest in the GDM group when compared 
with the IGT and the control groups while its level was the lowest in the control group in 
the third trimester. This ensures the possibility role of cortisol as an insulin antagonist in the 
deterioration of the glucose tolerance in pregnancy. 
Cortisol is bound in the circulation to alpha-globulin called transcortin or corticosteroid-
binding globulin (CBG). The bound cortisol functions as circulating reservoir of hormone that 
keeps a supply of free cortisol available to the tissues. At normal levels of total plasma 
cortisol (13.5µg/dL), there is very little free cortisol in plasma, but the binding sites on CBG 
become saturated when the total plasma cortisol exceeds 20µg/dL. CBG is synthesized in 
the liver, and its production is increased by estrogen and its level is elevated during 
pregnancy. When the CBG level rises, more cortisol is bound, and initially there is a drop in 
the free cortisol level which stimulates adrenocorticotrophic hormone (ACTH) secretion. 
Therefore, more cortisol is secreted until a new equilibrium is reached at which the bound 
cortisol is elevated but the free cortisol is normal. Changes in the opposite direction occur 
when the CBG level falls. This explains why pregnant women have higher total plasma 
levels of cortisol without symptoms of glucocorticoids excess (Barrett et al., 2010). Cortisol is 
nearly totally (90%) bound to CBG up to concentrations of 25µg/dL. But, when cortisol 
concentrations rise above this level, as occurred in the IGT group (serum cortisol mean level 
= 28.57µg/dL) and in the GDM group (serum cortisol mean level = 33.71µg/dL), the 
binding capacity of CBG is exceeded and the proportion of unbound, free, cortisol rises 
greatly (Burch, 1994). This free cortisol increases glucose tolerance deterioration therefore 
confirms the dominating role of cortisol as a regulator of stress dependent insulin resistance 
(Lehrke et al., 2008). 
Human placental lactogen (hPL) is a single protein of 191 amino acids, which is encoded by 
two genes hPL/CS-A and hPL/CS-B, which are identical except for one minor difference in 
the single sequence coding region. The hPL/CS genes are clustered together with the pituitary 
growth hormone gene (hGH-N) and a variant GH gene, hGH-V, on the long arm of 
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chromosome (Davis, 1990). Human PL has only a limited homology with prolactin, but a very 
high homology with the growth hormone mRNA coding sequence, although in other species 
there is a more homology with prolactin than growth hormone. The hormone is synthesized in 
the syncytiotrophoblastic villous epithelium of the placenta and it is secreted into maternal 
blood (Davis, 1990; Strauss & Barbieri, 2009). Maternal serum hPL levels rise progressively 
from the first trimester through till term (Strauss & Barbieri, 2009) and this agrees with our 
results of serum hPL in the control group. Although, there were no significant differences 
among hPL mean level of the IGT and the GDM groups were higher than that of the control 
group. This non-significant slight increase in the IGT and the GDM groups may share in 
increasing insulin resistance in these groups when compared with control group.  
Some authors reported that pronounced fetal macrosomia may occur even with adequate 
maternal blood glucose control. The severe fetal hyperinsulinemia in this case may be 
imputed to some factor other than excessive glucose load, possibly hPL, which induces 
proliferation and enhanced function of pancreatic ß-cells. In concert with this hypothesis, 
maternal serum hPL concentrations measured in the third trimester are higher in diabetic 
pregnancies complicated by fetal macrosomia (Persson et al., 1995; Reis et al., 2002). 
The regulation of hPL secretion is not fully understood. Progesterone exerts stimulatory 
effects in early gestation, but not in late gestation. Finally the hPL/CS gene contains a 
binding site for the glucocorticoids receptor, suggesting a potential modulatory role for 
corticosteroids, and also has binding sites for a pituitary protein factor that is thought to 
regulate both prolactin and growth hormone gene expression (Davis, 1990). Furthermore, 
the very high levels of circulating estrogen that occur during pregnancy result in a parallel 
increase in the circulating levels of prolactin (Schlechte, 2007). This may explain the 
interconnection between hPL and prolactin since, it seems that prolactin, growth hormone 
and placental lactogen hormone are phylogenetically ancient hormones which in vertebrates 
have evolved from common ancestral molecules. These hormones share common effects in 
growth stimulation and lactation. Hypersomatotropism is associated with disturbance of 
glucose tolerance and insulin resistance. Hyperprolactinaemia, like hypersomatotropism, is 
associated with decreased insulin sensitivity (Foss et al., 1995). 
The present study (on control group) demonstrated that prolactin increases progressively 
from the first trimester through till third trimester. Moreover, our study revealed that there 
were no significant differences among the levels of serum prolactin in GDM, IGT, and 
control groups. This agrees with what has been mentioned by Grigorakiz et al. (2000). 
Consequently, there is no evidence that prolactin may be directly incorporated with the 
pathogenesis of glucose intolerance in pregnancy. This may agree with the study of 
Milasinović et al. (1997) who reported that there is no evidence of the functional connection 
between prolactin and glucose metabolism.  
Prolactin is found in large amounts in the amniotic fluid of humans and other primates, and 
it is now clearly established that the source of this prolactin is the placenta rather than the 
maternal or fetal pituitary. The endometrial lining of the uterus is greatly modified during 
pregnancy to form the decidua. This decidual tissue has been confirmed as the site of 
placental prolactin production by a number of different groups and the mature  
peptide hormone is immunologically indistinguishable from pituitary prolactin. 
Immunocytochemical studies have shown that the hormone is predominantly located in the 
parietal decidual cells and only very rarely in the chorionic cytotrophoblast. Amniotic fluid 
prolactin levels are very low in ectopic tubal pregnancy, confirming the role of the 
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cortisol is elevated but the free cortisol is normal. Changes in the opposite direction occur 
when the CBG level falls. This explains why pregnant women have higher total plasma 
levels of cortisol without symptoms of glucocorticoids excess (Barrett et al., 2010). Cortisol is 
nearly totally (90%) bound to CBG up to concentrations of 25µg/dL. But, when cortisol 
concentrations rise above this level, as occurred in the IGT group (serum cortisol mean level 
= 28.57µg/dL) and in the GDM group (serum cortisol mean level = 33.71µg/dL), the 
binding capacity of CBG is exceeded and the proportion of unbound, free, cortisol rises 
greatly (Burch, 1994). This free cortisol increases glucose tolerance deterioration therefore 
confirms the dominating role of cortisol as a regulator of stress dependent insulin resistance 
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Human placental lactogen (hPL) is a single protein of 191 amino acids, which is encoded by 
two genes hPL/CS-A and hPL/CS-B, which are identical except for one minor difference in 
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group. This non-significant slight increase in the IGT and the GDM groups may share in 
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imputed to some factor other than excessive glucose load, possibly hPL, which induces 
proliferation and enhanced function of pancreatic ß-cells. In concert with this hypothesis, 
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have evolved from common ancestral molecules. These hormones share common effects in 
growth stimulation and lactation. Hypersomatotropism is associated with disturbance of 
glucose tolerance and insulin resistance. Hyperprolactinaemia, like hypersomatotropism, is 
associated with decreased insulin sensitivity (Foss et al., 1995). 
The present study (on control group) demonstrated that prolactin increases progressively 
from the first trimester through till third trimester. Moreover, our study revealed that there 
were no significant differences among the levels of serum prolactin in GDM, IGT, and 
control groups. This agrees with what has been mentioned by Grigorakiz et al. (2000). 
Consequently, there is no evidence that prolactin may be directly incorporated with the 
pathogenesis of glucose intolerance in pregnancy. This may agree with the study of 
Milasinović et al. (1997) who reported that there is no evidence of the functional connection 
between prolactin and glucose metabolism.  
Prolactin is found in large amounts in the amniotic fluid of humans and other primates, and 
it is now clearly established that the source of this prolactin is the placenta rather than the 
maternal or fetal pituitary. The endometrial lining of the uterus is greatly modified during 
pregnancy to form the decidua. This decidual tissue has been confirmed as the site of 
placental prolactin production by a number of different groups and the mature  
peptide hormone is immunologically indistinguishable from pituitary prolactin. 
Immunocytochemical studies have shown that the hormone is predominantly located in the 
parietal decidual cells and only very rarely in the chorionic cytotrophoblast. Amniotic fluid 
prolactin levels are very low in ectopic tubal pregnancy, confirming the role of the 





Amniotic fluid prolactin levels rise progressively after the 14th week human gestation and 
decline somewhat during the 3rd trimester. Prolactin secretion by the deciduas appears to be 
regulated quite differently from that in the pituitary gland. The first striking difference in 
regulation is that dopamine and dopamine agonists' drugs have no inhibitory effect on 
decidual prolactin secretion or amniotic fluid prolactin levels. Estrogen exerts a strong 
stimulation on pituitary lactotrophs but appears at most to have only small effects on 
decidual prolactin production (Davis, 1990).  
The very high levels of circulating estrogen during pregnancy result in a parallel increase in 
the circulating levels of prolactin in pregnancy. The prolactin increase is to prepare the 
breasts for lactation. Prolactin levels begin to rise at 5-8 weeks of gestation and parallel the 
increase in the size and number of lactotrophs (Schlechte, 2007; Corenblum, 2008).  
Progesterone appears to stimulate decidual prolactin secretion although it has little or no 
effect on decidual cells obtained in early pregnancy. Insulin stimulates both acute secretion 
and de novo synthesis of decidual prolactin (Davis, 1990). This may explain why prolactin 
mean level was the lowest in the GDM group as the level of insulin, which stimulates 
prolactin secretion, is the lowest when compared with the other groups (IGT and the control 
groups). 
5. Conclusion   
Now, it is clear that pregnancy is diabetogenic and characterized by increased insulin 
resistance which may be explained in term of reduced insulin secretion, reduced tissue 
sensitivity to insulin and increased secretion of hormones with an anti-insulin effect such as 
human placental lactogen, free cortisol and prolactin. All these characteristics with the 
incorporation of some maternal risk factors such as age, parity, previous heavy babies and 
family history of diabetes may lead to the impairment of glucose tolerance in some pregnant 
women. Most pregnant women are able to counteract the insulin resistance in pregnancy by 
increasing their insulin secretion or by switching to other energy source rather than glucose 
such as fat particularly in the third trimester to preserve glucose to the fetus. However, 
when the capacity of insulin secretion is not sufficiently large to meet the resistance, glucose 
intolerance develops and women develop gestational diabetes. 
6. Abbreviation 
 GDM, gestational diabetes mellitus; IGT, impaired glucose tolerance; hPL, human placental 
lactogen; TAGs, triacylglycerol; NIDDM, non-insulin dependent diabetes mellitus; CBG, 
corticosteroid-binding globulin; ACTH, adrenocorticotrophic hormone. 
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1. Introduction 
When Stein and Leventhal, in 1935, observed a group of women who suffered from sterility, 
oligomenorrhoea, or amenorhhoea, hirsutism, and enlarged polycystic ovaries, the disorder 
that became known as the polycystic ovarian syndrome (PCOS) or the Stein-Leventhal 
syndrome, was diagnosed for the first time (Stein, 1958). The variability of individual 
presentation, as well as a varying collection of signs and characteristic features, with no 
single diagnostic test justify the categorization of the PCOS as a syndrome that affects not 
only reproductive health, but also the metabolic and cardiovascular systems. Although 
PCOS is one of the most common endocrinopathies in women, with an incidence of about 5-
10% throughout the reproductive age span (Metalliotakis, 2006), there are divergent 
opinions about how to define and diagnose PCOS, as well as different types of treatment 
options throughout Europe and the US (Badawy & Elnashar, 2011). The high prevalence of 
women with this endocrine disorder highlights the importance of understanding the clinical 
presentation, pathophysiology, associated disorders, and treatment options. Up to 40% of 
women of reproductive age with PCOS have Type 2 diabetes or an impaired glucose 
tolerance (Legro et al., 2005), a form of insulin resistance that occurs equally in obese, 
normal weight, and thin women with PCOS (Matalliotakis et al., 2006). PCOS has been 
associated with an increased risk for gestational diabetes mellitus (GDM), but solid evidence 
confirming PCOS as a risk factor for GDM is still missing (Toulis et al., 2009). GDM, a well-
known state of carbohydrate intolerance with a high, and rising, prevalence, causes not only 
maternal but also fetal pregnancy complications. GDM has a presentation similar to PCOS, 
and both are considered risk factors for Type 2 diabetes mellitus (Retnakaran et al., 2008). 
The aim of this review is to summarize the available evidence about the risk of impaired 
glucose tolerance and GDM in PCOS women, as well as to review the pathophysiological 
aspects. In addition, the potential beneficial influence of several PCOS-specific treatment 
options on PCOS and GDM will be discussed. 
2. Diagnostic criteria for polycystic ovary syndrome 
The National Institutes of Health (NIH) has published criteria for diagnosing PCOS, based 
on an international conference on PCOS held in 1990. Accordingly, diagnostic criteria for the 
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hyperandrogenism, where other causes have been excluded (diagnosis of exclusion) (Huang 
et al. 2010). An expanded definition can be found in the revised Rotterdam criteria, a 
consensus on diagnostic criteria of the American Society for Reproductive Medicine and the 
European Society of Human Reproduction and Embryology. At least two of three criteria 
must be present: (i) oligoamenorrhoea or amenorrhoea; (ii) hyperandrogenism 
(clinical/biochemical); and (iii) polycystic ovaries on ultrasound, defined as more than 12 
cysts of 2-9mm, or >10ml volume (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus 
Workshop Group, 2004). The revised Rotterdam criteria are considered the current standard 
diagnostic criteria. 
In 2006, the Androgen Excess Society (AES) attempted to define evidence-based guidelines 
for diagnosis and future research in a review (Azziz et al., 2006). The AES task force 
suggested that androgen excess must be considered a central feature of the disease, and that 
PCOS should be defined by the presence of hyperandrogenism (clinical and/or biochemical) 
together with signs of ovarian dysfunction (oligoovulation or anovulation and/or polycystic 
ovaries), where similar disorders have been excluded (Azziz et al., 2006). Conditions for 
exclusion must be clarified in the diagnostic procedure. Premature ovarian failure with 
oligo-/amenorrhea that might be associated with other autoimmune endocrinopathies, 
hyperprolactinoma, or Cushing's syndrome are a few clinical possibilities that merit 
attention. 
3. Pathophysiologic aspects of polycystic ovary syndrome 
The heterogeneity of the syndrome and the unclear etiology favor the theory of multiple 
underlying pathophysiologic mechanisms that have yet to be fully elucidated. A heritable 
etiology for PCOS has been investigated intensively and several associated polymorphisms 
have been identified. However, to date, none of the possible candidate genes (e.g., 
regulators of the microbiological action of insulin) could be correlated with the onset of 
PCOS (Dumesic et al., 2007). In the research field of PCOS, studies on polymorphisms 
gained on importance within the last years. Moreover, environmental factors (e.g.: lifestyle, 
nutrition) together with certain genetic mutations might lead to the individual manifestation 
of PCOS but the diversity of clinical presentations aggravates the identification of genes 
involved in the origin of PCOS. 
Although the definition of “polycystic ovary syndrome” might be ambiguous, it is 
important to emphasize that polycystic ovaries need not be present to diagnose this 
syndrome. Nevertheless, PCOS patients who demonstrate ovaries with multiple subcortical 
cysts on ultrasound and an increased proportion of primary follicles (Dumesic et al., 2007) 
have a greater rate of hyperandrogenism than women with PCOS without abnormal follicle 
development. The presence of polycystic ovaries might indicate a major clinical alteration of 
PCOS, and the presence of polycystic ovaries in childhood has been suggested as an 
indicator of a genetic predisposition (Battaglia et al., 2002). Moreover, an abnormal 
autoimmune history has been considered in PCOS, in which functional autoantibodies 
might favor the development of PCOS (Ott et al., 2010, Gleicher et al., 2007). Assuming a 
relation between insulin resistance, ovarian function, and thyroid function, elevated 
antiTPO levels have been found to influence treatment response in women with PCOS and 
infertility (Ott et al., 2010). Notably, PCOS has been called a marker for “reduced ovarian 
aging,” since serum anti-Müller hormone (AMH) levels are higher in anovulatory women 
and have been found to be elevated in women with PCOS. AMH concentrations correspond 
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to the number of antral follicles and can be correlated to the level of ovarian dysfunction in 
infertility. Thus, it is possible that the process leading to ovarian aging is delayed in PCOS, 
which might also lead to a later onset of menopause in these women (Mulders et al., 2004). 
Three hypotheses are frequently discussed in literature about how defects in primary 
cellular control mechanisms might result in PCOS: (i) an elevated luteinizing hormone (LH) 
pulse frequency and amplitude, and relatively low follicle stimulating hormone (FSH) 
serum levels (LH+/FSH-) lead to anovulation and ovarian hyperandrogenism; (ii) a defect 
in the sex steroid metabolism within the ovaries (theca cells) causes an exaggerated ovarian 
androgen secretion; and (iii) a regulatory dysfunction of the insulin pathway results in 
hyperinsulinemia and insulin resistance and contributes to the development of PCOS 
(Franks et al., 1998). These pathophysiologic mechanisms might be of special interest 
regarding the risk for GDM. Indeed, several possible insulin-mediated pathways have been 
identified that might contribute to hyperandrogenism in PCOS patients (see Figure 1). 
 
 
Fig. 1. How increased insulin levels might contribute to hyperandrogenism 
These pathophysiologic hypotheses are related in a variety of ways. Elevated hypothalamic 
gonadotropin-releasing hormone (GnRH) pulsatility influences LH secretion; consequently, 
dysfunctional pulse frequency and amplitude lead to an increased 24-hour secretion of LH. 
High LH combined with high levels of insulin result in increased ovarian androgen 
production. Hypersecretion of LH also affects oocyte development. A defect in androgen 
synthesis that results in an increased enzymatic activity involved in the synthesis of 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), and 
androstenedione leads, consequently, to an inadequate production of testosterone in ovarian 
theca cells. The synergistic interaction between LH and insulin on the ovarian theca cells 
leads to stimulation of androgen production. Several studies have provided useful 
information about a correlation between hyperandrogenism and a state of increased insulin 
resistance (Balen, 2004) (Baptiste et al., 2010). In women with PCOS, an another cause of 
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on the hepatic synthesis and secretion of the sex hormone-binding globulin (SHBG). SHBG 
levels are reduced and the blood concentrations of biologically active androgens are thus 
increased. In addition, it has been suggested that adipose tissue dysfunction also plays a 
central role in the metabolic and endocrine abnormalities observed in PCOS (Villa J et al., 
2011). 
4. Clinical manifestation of polycystic ovary syndrome 
A variety of signs and symptoms can be found in women who suffer from PCOS in which 
ovarian hyperandrogenism is considered the cardinal characteristic. The variable clinical 
presentation includes gynecological symptoms that include dysfunctional menstrual 
bleeding, such as oligo- or amenorrhea, or any kind of abnormal uterine bleeding combined 
with infrequent or absent ovulation, infertility resulting from elevated androgen levels, and 
polycystic ovaries (Dumesic et al., 2007). With regard to gynecologic malignancies, chronic 
anovulation over a long period of time is associated with a higher risk of developing 
endometrial adenocarcinoma and a higher incidence of endometrial hyperplasia, compared 
to age-matched controls (Badawy & Elnashar, 2011). Elevated serum androgen levels lead to 
androgenic disorders, such as acne, hirsutism, and alopecia androgenica, where 
hyperandrogenism is differently expressed in the PCOS phenotypes, resulting in cosmetic 
issues and psychological effects that can be burdensome and difficult to cope with. 
Last not least, PCOS has been considered to be associated with a increased risks for type II 
diabetes mellitus and GDM. When considering the association with GDM, it is notable that 
both PCOS and GDM share some common characteristic features, including obesity, 
increased insulin resistance, dyslipidemia, and other metabolic abnormalities. The common 
presence of lipid abnormalities, such as elevated serum triglyceride- and low-density 
lipoprotein levels due to negative hormonal influences on the lipid homeostasis coexist with 
obesity and increased insulin resistance. PCOS shares components with the metabolic 
syndrome characterized by a combination of insulin resistance, dyslipidemia, and 
hypertension (Boomsma et al., 2006). Although a high BMI is associated with a higher risk of 
arterial disease, an increased cardiovascular risk (up to two-fold) in women with PCOS 
cannot be completely ascribed to a higher BMI (de Groot et al., 2011). Obesity and PCOS 
show, on the one hand, an independent influence, but, on the other hand, seem to have 
additive adverse effects on insulin action. 
Up to 50% of women with PCOS suffer from an imbalance in carbohydrate homeostasis, 
central fat deposition, and increasing insulin resistance during pregnancy (Huang et al., 
2010). It has been estimated that 25–70% of women with PCOS show a rise in insulin 
resistance and have an increased risk of developing complications during pregnancy, first 
and foremost of which is GDM (Godoy-Matos et al., 2009). 
5. The risk of gestational diabetes in women with polycystic ovary syndrome 
GDM is defined as the onset or first recognition and diagnosis of glucose intolerance during 
pregnancy. The diagnostic criterion for GDM is the 75g, two-hour oral glucose tolerance test 
(OGTT). 
In fact, recent meta-analyses of pregnancy outcomes in women with PCOS demonstrated a 
significantly higher chance of developing GDM for PCOS women (odds ratios of about 2.90) 
(Boomsma et al., 2006) (Toulis et al., 2009). However, when analyzing the available evidence 
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separately, there were largely conflicting results: while most of the studies demonstrated an 
increased risk for GDM in PCOS women (odds ratios ranging from 1.15 to 22.15) (Wortsman 
et al., 1991 as cited in Boomsma et al., 2006) (Radon et al., 1999, as cited in Boomsma et al., 
2006), a few found odds ratios from 0.31 to 0.96 (Turhan et al., 2003, as cited in Boomsma et 
al., 2006) (Haakova et al., as cited in Boomsma et al., 2006). A comparison between the study 
designs revealed that the increased risks were predominantly found in cohort studies rather 
than in case-control studies. In addition, meta-analyses revealed a significant heterogeneity 
between the analyzed studies. 
Conversely, some studies did not seem to support a higher prevalence and previous history 
of PCOS in women diagnosed with GDM, when compared to pregnancies in women with 
normal glucose homeostasis (Wijeyaratne et al., 2006) (Kousta et al., 2000). Obesity, PCOS, 
and diabetes in first-degree relatives have been described as risk factors for developing 
GDM and gestational impaired glucose tolerance, especially in young women and teenage 
pregnancies (<20 years) (Karcaaltincaba et al., 2011). 
All in all, there is no solid evidence proving the increased risk for GDM in PCOS patients, 
but a trend assuming that the risk is, indeed, increased in women with PCOS, is 
recognizable. Confronted with the wide clinical and pathophysiological spectrum associated 
with the syndrome, further studies are warranted to validate the existing data.  
5.1 Diagnostic aspects  
The guidelines developed by the International Association of Diabetes and Pregnancy Study 
Groups (IADPSG) consider a screening for pre-gestational diabetes in high-risk women at 
the first prenatal visit and universal screening between the 24th and 28th week of gestation 
(Holt et al., 2011). In daily routine, an OGTT is performed in the third trimester. According 
to the diagnostic recommendations published in March 2010 by the IADPSG, fasting blood 
glucose concentrations that exceed 92 mg/dl, one-hour and two-hour glucose levels of more 
than 180 mg/dl, or 153 mg/dl measured during the OGTT, lead to the diagnosis of GDM 
(Metzger et al., 2010). Increased measurements in each of the three values raise the 
possibility of an adverse pregnancy outcome. A benefit of generalized testing to evaluate 
glycaemia levels in all pregnant women before the usual window is still a subject of 
controversy in the literature and must be decided individually (Karagiannis et al., 2010, 
Hadar et al., 2009). If increased levels of glucose are found in urine samples, or if GDM was 
present in a previous pregnancy, an OGTT in the second trimester should be performed. 
Since women who suffer from PCOS are considered to be at higher risk for developing 
GDM, it could be argued that they should undergo a more detailed and earlier screening for 
GDM. 
5.2 Pathophysiological hypotheses about the risk of gestational diabetes in women 
with polycystic ovary syndrome 
Several pathophysiologic mechanisms have been discussed that might contribute to the 
phenomenon of the increased GDM risk associated with PCOS. 
5.2.1 Genetic predisposition 
It has been hypothesized that a particular genetic background could contribute to the 
association between PCOS and GDM. In women with familial partial lipodystrophy due to 
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tissue and insulin resistance, the prevalence of PCOS and gestational diabetes was found to 
be higher than in the general population (Vantyghem et al., 2008). Moreover, mutations of 
the VNTR (variable number of tandem repeats) locus, upstream of the insulin gene (INS) 
where insulin expression is regulated, have been found in both women who suffer from 
PCOS and in women with GDM (Waterworth et al., 1997) (Lambrinoudaki et al., 2010). 
5.2.2 Preexisting insulin resistance 
In pregnancy, rising blood levels of lipolytic placental hormones lead to an elevation of free 
fatty acids that are commonly associated with the development of a dose-dependent insulin 
resistance. Affecting skeletal muscle glucose uptake, free fatty acids create a state of local 
insulin resistance and, as concentrations are elevated in late pregnancy, an increase in tissue 
insulin resistance can be observed during pregnancy (Sivan & Boden, 2003). In the presence 
of PCOS and a preexisting state of increased insulin resistance accompanying the syndrome, 
hyperglycemia seems to be induced more easily. The high pre-conception insulin resistance 
might have a deleterious additive effect on pancreatic beta cells, which are incapable of 
coping with the additive physiological insulin resistance of pregnancy (Khattab et al., 2011), 
thereby leading to an increased incidence of GDM (Toulis et al., 2009).  
5.2.3 SHBG levels 
Hyperinsulinemia stimulates in much the same way as LH-agonist ovarian testosterone 
production and decreases the serum sex hormone-binding globulin (SHBG) concentration. 
SHBG is known to have biologic functions beyond the regulation of free estrogen and 
testosterone serum levels. It has also been emphasized that low SHBG levels are associated 
with a minor glucose tolerance, thus, attributing a role to these low SHBG levels in the 
maintenance of glucose homeostasis. A possible explanation might be a modulation of the 
biologic effects of both estrogen and testosterone on liver, fat, and muscle tissue, as well as 
on other peripheral tissues (Ding et al., 2009). Furthermore, low plasma SHBG levels has 
been suggested as predictive for the risk of developing Type 2 diabetes mellitus (Ding et al., 
2009). As an early indicator of GDM risk, low preconception levels of SHBG concentrations 
have been identified as strong predictors in PCOS women, independently of obesity and 
measures of insulin resistance. One study suggested that assessment of SHBG levels before 
conception might be a useful tool to by which to identify PCOS patients at risk for GDM 
during pregnancy (Veltman-Verhulst et al., 2010). However, the pathophysiologic pathways 
of this effect are unknown. It remains unclear whether the association between GDM and 
SHBG is direct or indirect. A lower SHBG results in higher free androgens that have already 
been demonstrated to be associated with an increased GDM risk (Bartha et al., 2000). 
5.2.4 Insulin-like growth factor and insulin-like growth factor binding protein-1 
The risk for GDM has been connected to maternal plasma concentrations of insulin-like 
growth factor-1 (IGF-1) and insulin-like growth factor binding protein-1 (IGFBP-1), 
suggesting that these determinants of glucose homeostasis play a potential role in the 
pathophysiologic process and contribute to the development of GDM (Qiu et al., 2005). 
Increased serum insulin concentrations lead to an inhibition of IGFBP-1 production, 
resulting in elevated serum levels of free IGF-1. A recent meta analysis on the interaction 
between IGFBP-1 and PCOS described lower levels of IGFBP-1 in affected patients (Kelly et 
al. 2011). Notably, a lower risk for developing GDM was correlated with increased levels of 
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free IGF-1 and IGFBP-1, where higher C-peptide levels were positively associated with the 
development of GDM (Qiu et al., 2005). It should be emphasized that lower levels were 
found in obese women with/or without PCOS, compared to normal weight controls, 
suggesting that body weight has a certain influence on serum IGFBP-1 levels. The 
physiologic processes underlying the role of IGF-1 in glucose regulation are unclear. 
Infusions of IGF-1 are known to suppress glucose counter-regulatory hormones, such as 
glucagon and growth hormone (Jones & Clemmons, 1995). IGF-1 may also contribute to 
changes in insulin sensitivity and glucose uptake via direct IGF receptor-mediated effects on 
skeletal muscle (Sjogren et al., 2001). Alterations in IGFBP-1 concentrations may be due to 
variations in insulin secretion or hepatic insulin sensitivity, both known to be important 
factors in glucose regulation (Lee et al., 1997).  
5.2.5 The influence of infertility treatments 
PCOS is often accompanied by infertility that necessitates ovulation induction, using 
clomiphene citrate, gonadotropins, or even in vitro fertilization (IVF) (Boomsma et al., 2006). 
These treatment methods are known to increase the incidence of multiple pregnancies, as 
well as some negative consequences, including a rise in the risk for GDM (Schwartz et al., 
1999). Furthermore, pregnancies established after IVF carry an increased risk for maternal 
complications (Pinborg et al., 2004) (Shevell et al., 2005). However, the increased risk of 
developing GDM has been suggested to occur independently of obesity, as well as in 
populations without assisted reproductive techniques (Boomsma et al., 2006) (Toulis et al., 
2009). 
6. Therapeutic considerations 
The therapeutic challenges in the treatment of women with PCOS and GDM or impaired 
glucose tolerance arise from the diversity of recommendations and research conclusions. If 
adequately managed, the incidence of adverse perinatal outcomes in PCOS patients who 
develop GDM was found to be not significantly elevated (Li et al., 2010). Several treatment 
options exist for each of the symptoms of PCOS, and management of these patients depends 
on the individual symptoms. Clinical management of PCOS involves risk assessment for 
metabolic disorders, as diabetes and dyslipidemia, and for hypertension, cardiovascular 
complications, and liver diseases (Setji & Brown, 2007). Insulin-sensitizing drugs, such as 
metformin and/or oral contraceptives, are thought to improve the clinical features of PCOS, 
but limited data is available that assesses the true influence and safety of these drugs in this 
population (Setji & Brown, 2007). Targeting androgen symptoms, such as acne, hirsutism, 
and alopecia androgenica, estrogen-containing oral contraceptives, antiandrogens and 
topical agents are considered first-line therapy for women who do not want to conceive, as 
they effectively reduce serum androgen levels. In addition, treatment with oral 
contraceptives is associated with an improvement in the menstrual pattern. However, when 
trying to achieve pregnancy, other treatment options are offered to the patient. All of these 
might also independently influence the risk for GDM.  
6.1 Lifestyle modifications 
Addressing life-style factors before conception should be the first-line approach to reduce 
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changes in insulin sensitivity and glucose uptake via direct IGF receptor-mediated effects on 
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phenotypes of PCOS depends, to a great extent, on lifestyle and environmental factors 
(Garruti et al., 2009). Reducing weight improves the endocrine profile and has the most 
significant impact on the likelihood of ovulation and pregnancy, the most relevant 
endpoints in infertile PCOS women. Dietary composition has been considered to improve 
the initial metabolic and reproductive situation in these patients. It has been suggested that 
low fat diets be recommended to these patients to produce a decrease in hyperinsulinemia 
(Reaven, 2005). Since it has been well-established that obesity is not only associated with 
anovulation, infertility, and early miscarriage, but also with late pregnancy complications in 
women with PCOS (Badawy & Elnashar, 2011), lifestyle modifications, including dietary 
recommendations and increased exercise in order to achieve weight reduction, should be 
recommended to these patients. Bariatric surgery has also been advocated as a possible 
strategy for weight loss in PCOS women, at least in the morbidly obese, and is effective in 
restoring ovulation and improving insulin resistance. Reducing weight, along with lifestyle 
modifications that affect the patients’ behavior in a continuing way, is considered the most 
relevant therapeutic approach in women with PCOS (Hirschberg, 2009). Whether it affects 
the risk of developing GDM in subsequent pregnancies remains an open question (Escobar-
Morreale et al., 2005).  
6.2 Insulin-sensitizing drugs 
Elevated insulin resistance plays an important part in the pathophysiology of PCOS and 
GDM. Insulin-sensitizing drugs, particularly metformin, are thought to reduce androgen 
symptoms, positively influence reproductive deregulations (oligo-amenorrhoe, 
anovulation), and increase pregnancy rates in PCOS patients (Dunaif, 2008). Large placebo-
controlled trials are available only for metformin, as this is the only insulin-sensitizing drug 
with extensive clinical use in women with PCOS (De Leo et al., 2003).  
6.2.1 Metformin as a PCOS-specific therapy  
Metformin, a biguanide (see Figure 2), is a therapeutic option for restoration of ovulation in 
PCOS women. Moreover, several studies have suggested metformin as a promising 
medication in pregnancy in order to reduce the incidence of developing GDM and to 
minimize the risk for an adverse pregnancy outcome (Carlsen & Vanky, 2010). A variety of 
studies have been performed to determine the beneficial effects of metformin in PCOS, 
although the mechanisms of action–a broad spectrum of endocrine, metabolic, vascular, and 
even anti-inflammatory effects–of this drug have not been completely clarified, as yet 
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Metformin affects the hepatic glucose output and the insulin-mediated glucose consumption 
in peripheral tissues, and suppresses the free fatty acid concentrations, which results in a 
lower substrate level for gluconeogenesis. Metformin improves insulin sensitivity and 
reduces insulin blood levels by increasing peripheral glucose utilization without negatively 
influencing normal blood glucose concentrations. With regard to pregnancy, a positive 
impact on uterine vascularity and blood flow and a reduction in plasma endothelin-1 levels, 
as well as androgen and LH concentrations, have been mentioned, suggesting that 
metformin is a possible positive therapeutic drug in the prevention of pregnancy 
complications in PCOS (Khattab et al., 2011). Thus, it has been assumed that metformin 
treatment combined with a special diet reduces pregnancy complications, and also prevents 
the fetus from elevated androgen concentrations (Glueck et al., 2004a). 
Several studies have investigated a possible beneficial effect of metformin in the pregnancies 
of PCOS patients, particularly with regard to the risk of GDM. Some trials even report about 
a nine-fold (Begum et al., 2009) or ten-fold reduction (Glueck et al., 2002) of GDM after 
metformin treatment throughout pregnancy. However, the literature is controversial. The 
anticipated reduction in the prevalence of GDM after treatment with metformin during 
pregnancy could not be verified in randomized controlled trials, although metformin 
therapy had improved insulin sensitivity (Legro et al., 2007) (Fougner et al., 2008). In 
particular, recent large randomized controlled studies and meta analyses could not verify a 
relevant reduction of pregnancy complications due to metformin treatment (Vanky et al., 
2010). Thus, the general use of metformin during pregnancy in non-diabetic women with 
PCOS cannot be recommended. 
Metformin is associated with low gastrointestinal disturbances, but the available trials did not 
describe any serious adverse events. Classified as a category B drug in pregnancy, metformin 
appears to be non-teratogenic (Glueck et al., 2004b). However, results from placebo-controlled 
trials on maternal and fetal health risk have not yet been clarified. The pathogenesis of PCOS 
has been related to increased intrauterine androgen exposure; thus, the effect of therapeutic 
investigations on maternal and fetal hormone levels must be considered when treating 
pregnant women with PCOS. metformin seems to pass the placental barrier and was found to 
be present in the fetal circulation. However, androgen and estrogen levels did not seem to be 
influenced and remained within normal range (Carlsen & Vanky, 2010), whereas elevated 
SHBG levels have been reported in newborns after intrauterine metformin exposure (Vanky et 
al., 2005). The clinical relevance of these findings remains unclear. 
6.3 Other methods of ovulation induction 
With regard to pregnancy outcome, there are different possibilities of infertility treatment in 
women with PCOS and ovulatory dysfunction. Pregnancy induction by assisted 
reproductive techniques (ART) is offered if women fail to conceive spontaneously. 
Ovulation induction is based on two principles: (i) ovaries are exposed to a higher level of 
follicle stimulating hormone; and/or (ii) hormonal derangements are corrected. After 
exclusion of other causes of infertility, the fertility medication, clomiphen citrate (CC), is 
considered the first-line therapeutic approach to ovulation induction. In this approach, the 
development of a single ovulatory follicle is the main goal, since the risk for multiple 
pregnancies has to be kept as low as possible.  
Literature on the risk for GDM as it relates to CC stimulation is scarce. To date, only one 





phenotypes of PCOS depends, to a great extent, on lifestyle and environmental factors 
(Garruti et al., 2009). Reducing weight improves the endocrine profile and has the most 
significant impact on the likelihood of ovulation and pregnancy, the most relevant 
endpoints in infertile PCOS women. Dietary composition has been considered to improve 
the initial metabolic and reproductive situation in these patients. It has been suggested that 
low fat diets be recommended to these patients to produce a decrease in hyperinsulinemia 
(Reaven, 2005). Since it has been well-established that obesity is not only associated with 
anovulation, infertility, and early miscarriage, but also with late pregnancy complications in 
women with PCOS (Badawy & Elnashar, 2011), lifestyle modifications, including dietary 
recommendations and increased exercise in order to achieve weight reduction, should be 
recommended to these patients. Bariatric surgery has also been advocated as a possible 
strategy for weight loss in PCOS women, at least in the morbidly obese, and is effective in 
restoring ovulation and improving insulin resistance. Reducing weight, along with lifestyle 
modifications that affect the patients’ behavior in a continuing way, is considered the most 
relevant therapeutic approach in women with PCOS (Hirschberg, 2009). Whether it affects 
the risk of developing GDM in subsequent pregnancies remains an open question (Escobar-
Morreale et al., 2005).  
6.2 Insulin-sensitizing drugs 
Elevated insulin resistance plays an important part in the pathophysiology of PCOS and 
GDM. Insulin-sensitizing drugs, particularly metformin, are thought to reduce androgen 
symptoms, positively influence reproductive deregulations (oligo-amenorrhoe, 
anovulation), and increase pregnancy rates in PCOS patients (Dunaif, 2008). Large placebo-
controlled trials are available only for metformin, as this is the only insulin-sensitizing drug 
with extensive clinical use in women with PCOS (De Leo et al., 2003).  
6.2.1 Metformin as a PCOS-specific therapy  
Metformin, a biguanide (see Figure 2), is a therapeutic option for restoration of ovulation in 
PCOS women. Moreover, several studies have suggested metformin as a promising 
medication in pregnancy in order to reduce the incidence of developing GDM and to 
minimize the risk for an adverse pregnancy outcome (Carlsen & Vanky, 2010). A variety of 
studies have been performed to determine the beneficial effects of metformin in PCOS, 
although the mechanisms of action–a broad spectrum of endocrine, metabolic, vascular, and 
even anti-inflammatory effects–of this drug have not been completely clarified, as yet 






Fig. 2. Formula of metformin 
 
The Impact of Polycystic Ovarian Syndrome on Gestational Diabetes 
 
191 
Metformin affects the hepatic glucose output and the insulin-mediated glucose consumption 
in peripheral tissues, and suppresses the free fatty acid concentrations, which results in a 
lower substrate level for gluconeogenesis. Metformin improves insulin sensitivity and 
reduces insulin blood levels by increasing peripheral glucose utilization without negatively 
influencing normal blood glucose concentrations. With regard to pregnancy, a positive 
impact on uterine vascularity and blood flow and a reduction in plasma endothelin-1 levels, 
as well as androgen and LH concentrations, have been mentioned, suggesting that 
metformin is a possible positive therapeutic drug in the prevention of pregnancy 
complications in PCOS (Khattab et al., 2011). Thus, it has been assumed that metformin 
treatment combined with a special diet reduces pregnancy complications, and also prevents 
the fetus from elevated androgen concentrations (Glueck et al., 2004a). 
Several studies have investigated a possible beneficial effect of metformin in the pregnancies 
of PCOS patients, particularly with regard to the risk of GDM. Some trials even report about 
a nine-fold (Begum et al., 2009) or ten-fold reduction (Glueck et al., 2002) of GDM after 
metformin treatment throughout pregnancy. However, the literature is controversial. The 
anticipated reduction in the prevalence of GDM after treatment with metformin during 
pregnancy could not be verified in randomized controlled trials, although metformin 
therapy had improved insulin sensitivity (Legro et al., 2007) (Fougner et al., 2008). In 
particular, recent large randomized controlled studies and meta analyses could not verify a 
relevant reduction of pregnancy complications due to metformin treatment (Vanky et al., 
2010). Thus, the general use of metformin during pregnancy in non-diabetic women with 
PCOS cannot be recommended. 
Metformin is associated with low gastrointestinal disturbances, but the available trials did not 
describe any serious adverse events. Classified as a category B drug in pregnancy, metformin 
appears to be non-teratogenic (Glueck et al., 2004b). However, results from placebo-controlled 
trials on maternal and fetal health risk have not yet been clarified. The pathogenesis of PCOS 
has been related to increased intrauterine androgen exposure; thus, the effect of therapeutic 
investigations on maternal and fetal hormone levels must be considered when treating 
pregnant women with PCOS. metformin seems to pass the placental barrier and was found to 
be present in the fetal circulation. However, androgen and estrogen levels did not seem to be 
influenced and remained within normal range (Carlsen & Vanky, 2010), whereas elevated 
SHBG levels have been reported in newborns after intrauterine metformin exposure (Vanky et 
al., 2005). The clinical relevance of these findings remains unclear. 
6.3 Other methods of ovulation induction 
With regard to pregnancy outcome, there are different possibilities of infertility treatment in 
women with PCOS and ovulatory dysfunction. Pregnancy induction by assisted 
reproductive techniques (ART) is offered if women fail to conceive spontaneously. 
Ovulation induction is based on two principles: (i) ovaries are exposed to a higher level of 
follicle stimulating hormone; and/or (ii) hormonal derangements are corrected. After 
exclusion of other causes of infertility, the fertility medication, clomiphen citrate (CC), is 
considered the first-line therapeutic approach to ovulation induction. In this approach, the 
development of a single ovulatory follicle is the main goal, since the risk for multiple 
pregnancies has to be kept as low as possible.  
Literature on the risk for GDM as it relates to CC stimulation is scarce. To date, only one 





laparoscopic ovarian drilling in women pre-treated with metformin to those treated with 
metformin only. For all groups, there was a rate of GDM of about 30%, suggesting that 
neither CC stimulation nor laparoscopic ovarian drilling exert any effect on the risk for 
GDM (Ott et al., 2010).  
For CC-resistant anovulatory PCOS patients, second-line therapeutic approaches include 
laparoscopic ovarian drilling and gonadotropin stimulation (Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group, 2004). As mentioned above, only one trial 
has evaluated whether laparoscopic ovarian drilling would alter the risk for GDM and 
found no influence (Ott et al., 2010). Whether gonadotropin stimulation is associated with 
an increased rate of GDM remains controversial. While some studies found no difference in 
the prevalence of GDM between PCOS patients and controls (Vollenhoven et al., 2000), data 
from prospective studies suggest that medicamentous ovulation induction leads to an 
increased risk for GDM (Shevell et al., 2005). 
When all of these treatment options fail, IVF remains the last option by which to achieve 
pregnancy (Badawy & Elnashar, 2011). It has been reported that the prevalence of GDM is 
substantially increased in women after pregnancy induction via ART than in PCOS patients 
who conceive spontaneously (Bals-Pratsch et al., 2011). Proceeding on the assumption of a - 
possibly genetically determined - highly deranged insulin metabolism that may lead to this 
state of infertility where women cannot conceive spontaneously or with the help of lower-
dose stimulation protocols, the higher rate of GDM could be explained. One might raise the 
question whether the maternal endocrine status before placentation and/or after IVF 
stimulation possibly influences glucose tolerance in women with PCOS. Furthermore, 
elevated estrogen levels lead to an excessive stimulation of estrogen receptor alpha in the 
pancreatic beta cells, producing exaggerated insulin signaling that may cause an increased 
state of insulin resistance in peripheral tissues (Nadal et al., 2009).  
Moreover, IVF is known to lead to an increased risk for maternal complications, including 
GDM independently of the presence of PCOS (Pinborg et al., 2004) (Shevell et al., 2005). 
When IVF stimulation is complicated by ovarian hyperstimulation syndrome (OHSS), the 
risk for GDM increases even more (Raziel et al., 2009). Notably, PCOS is a known risk factor 
for the development of OHSS. Higher rates of GDM, but also placental abruption 
prematurity and low birth weight have been reported for pregnancies complicated by severe 
OHSS. Therefore, these pregnancies should be considered high-risk pregnancies, and 
followed/treated as such. The best option to prevent OHSS is to use mild stimulation 
protocols (Raziel et al., (2009). However, metformin has also been mentioned as leading to 
a significant reduction in OHSS rates (Khattab et al., 2006). 
7. Perinatal outcome of women with polycystic ovary syndrome and 
gestational diabetes 
Hyperglycemia negatively influences not only maternal, but also fetal health. Obesity, 
fertility treatments, and other characteristics of patients with PCOS are associated with a 
higher incidence of pregnancy complications, such as hypertension and preeclampsia 
(Boomsma et al., 2008). Compared to normal pregnancies, PCOS patients demonstrate a 
higher incidence of early pregnancy loss (Li et al., 2010). Likewise, perinatal mortality seems 
to be increased among women with PCOS, and neonatal complications are observed more 
frequently (Boomsma et al., 2006). A potential additive effect of co-existent PCOS and GDM 
on obstetrical complications advocates for a closer antenatal and intrapartal monitoring of 
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these patients (Alshammari et al., 2010). According to the Barker hypothesis, an altered 
maternal nutrition and metabolism is thought to lead both to an altered fetal nutrition and 
to changes in the endocrine and metabolic environment in which the fetus develops (de Boo 
& Harding 2006). This explains why PCOS complications might affect the fetus. 
Maternal glucose levels correlate with fetal birth weight, development of fetal macrosomia, 
fetal hyperinsulinemia, and fetal body-fat percentage (Yang et al., 2002) (Metzger et al., 
2010). Cesarean section is performed more frequently in women with GDM, as the diagnosis 
“large for gestational age” due to elevated maternal glucose levels is associated with a 
higher incidence of adverse pregnancy outcomes in spontaneous delivery (e.g., shoulder 
dystocia). PCOS also seems to correlate with a lower rate of vaginal delivery compared to 
healthy controls (Bjercke et al., 2002), although the higher incidence of Caesarean sections 
correlates with the occurrence of obesity, since women with a normal BMI and PCOS have 
an incidence of Caesarean section equal to that of age-matched controls (Boomsma et al., 
2006). 
Accordingly, the perinatal outcome of women with PCOS who develop GDM has been 
investigated intensively within the last several years. Both PCOS and associated factors, 
such as obesity or the treatment methods for fertility induction, can be considered 
responsible for the poorer pregnancy outcomes (Thatcher & Jackson, 2006, Boomsma et al., 
2008). However, with regard to the risk of macrosomia, preeclampsia, neonatal 
complications, neonatal anomalies, and death of the fetus in women with GDM and PCOS, 
compared to women with GDM alone, no significant differences have been observed (Li et 
al., 2010). Manifest obesity before pregnancy and total weight gain during pregnancy must 
be closely monitored and addressed insistently, not only to minimize the risk for GDM, but 
also to achieve better global well-being in women with PCOS. 
8. Conclusion and future research areas 
The diverse observations regarding the elevated risk of GDM in women with PCOS have 
presented scientists and clinicians with a challenge. Caution is advised when interpreting 
clinical and statistical heterogeneous studies on PCOS and pregnancy complications, as a 
variety of contradictory results are present throughout the literature. The diagnosis of PCOS 
is inconsistent, as some investigators use only ultrasound criteria alone, and others rely on 
hormonal or clinical parameters, whereas the revised Rotterdam criteria are considered the 
current valid diagnostic criteria for the diagnosis of PCOS. 
Women with PCOS who want to have children must be informed about the increased risk 
for developing GDM in their pregnancies. Metabolic findings in PCOS include increased 
insulin resistance, dyslipidemia, and elevated androgen levels - often accompanied by 
infertility and infertility treatments in order to achieve pregnancy. Confounding factors, 
such as obesity and the diverse ovulation induction treatments in infertile women with 
PCOS, can be considered potentially risk-increasing variables. Those coexisting factors, 
together with additional predisposing factors, such as a positive family history for diabetes 
mellitus, have been suggested to correlate with a generally increased risk for developing 
GDM and impaired glucose tolerance (Toulis et al., 2009). 
Comparable pathophysiological mechanisms of insulin resistance and impaired glucose 
tolerance can be found in GDM and in women with PCOS who demonstrate an increased 
tissue resistance to insulin. However, the exact pathophysiologic link between PCOS and 
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association between PCOS and GDM and shed some new light on the possible underlying 
pathomechanisms. Moreover, further investigations to evaluate a potential benefit of early 
GDM screening are warranted, particularly as GDM is a well-known risk factor for fetal and 
maternal complications (Tieu et al., 2010). 
The presence of increased glucose levels might lead to considerable pregnancy 
complications and stress on the mother and fetus. Accurate screening for GDM, together 
with regular consultations and monitoring, as well as addressing additional preventable 
stress factors, reduce the risk for developing GDM. Primary prevention can be further 
improved by lifestyle modification in women with PCOS. With regard to early diagnosis, 
screening in PCOS patients with a variety of risk factors might be justified. One might focus 
on the development of alternative markers to identify a woman at risk for developing GDM, 
in addition to the available parameters, such as fasting plasma glucose and OGTT, which 
enable clinicians to select patients at risk even before the manifestation of GDM. Thus, such 
markers as androgen levels, SHBG levels, fasting insulin levels, baseline proinsulin levels, 
and the hip-waist ratio might be of future interest. 
Metformin has been highlighted as a promising substance for reducing the risk of GDM in 
PCOS patients. However, a relevant reduction of obstetrical complications due to metformin 
treatment could not be verified in a recent randomized and controlled multicenter study 
(Vanky et al., 2010). The general use of metformin during pregnancy in non-diabetic women 
with PCOS cannot be considered a valid recommendation. 
Even with all the evidence and comparative studies, PCOS, still remains a challenging 
diagnostic and research issue, particularly with regard to its impact on GDM.  
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1. Introduction 
The incidence of type 2 diabetes mellitus (T2D) is growing worldwide. It is now established 
that interactions between the individual genetic makeup and environment contribute to the 
development of T2D. In this review, we first discuss the evidence for beta-cell dysfunction 
in IUED (in utero exposure to maternal diabetes), IUEO (in utero exposure to maternal 
overnutrition) and IUGR (in utero growth restriction) humans. We then evaluate relevant 
animal models of IUED, IUEO and IUGR focusing on the strengths and limits of each, in 
order to define critical periods and types of alterations that can lead to impaired beta-cell 
function. Finally, we discuss several potential mechanisms dissected in relevant animal 
models that begin to explain these outcomes. 
2. Perinatal risk factors for diabetes in later life: Human studies 
There are strong arguments showing that T2D is more prevalent among subjects that were 
exposed to maternal diabetes in utero (IUED). The role of maternal inheritance in T2D was 
first suggested by epidemiological studies. A higher susceptibility for diabetes is described 
in descendents from diabetic great grand mothers via the maternal line than via the paternal 
line (Dörner et al., 1984). A higher incidence of T2D and of gestational diabetes (GD) is seen 
in children of diabetic mothers as compared to those of diabetic fathers (Martin et al., 1985). 
A decreased prevalence of diabetes is seen in children from diabetic mothers, after starting a 
systematic treatment of diabetic pregnant women (Dörner et al., 1987). Especially interesting 
in this context are the studies on the Pima Indians, a population with an exceptionally high 
T2D incidence. The prevalence of impaired glucose tolerance, of T2D and of GD is much 
higher (7 fold increased) in children from mothers who had diabetes during pregnancy, than 
in children from mothers who developed diabetes only after their pregnancy. Moreover, 
paternal diabetes has a much smaller effect on the prevalence of diabetes in these offspring 
than maternal diabetes (Pettitt, 1996). 
The maternal influence in the development of T2D was reported in a majority of studies 
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higher paternal transmission (Mitchell et al., 1993; Mc Carthy et al., 1996; Viswanathan et al., 
1996; Frayling et al., 1999). The prospective Framingham Offspring Study in which all 
offspring and parents were formally tested for diabetes, demonstrated that the risk of 
impaired glucose tolerance or T2D was greater in offspring of mothers with early diabetes 
onset (before 50), suggesting the role of fetal environment (Meigs et al., 2000). However, the 
effects of fetal exposure to diabetes may be confounded by genetic factors. Mothers who had 
T2D before or during pregnancy have, by definition, early diabetes. Therefore, they may 
carry T2D susceptibility genes, which are transmitted to their offspring. To determine the 
role of the intrauterine diabetic environment per se, the prevalence of diabetes was 
compared in Pima nuclear families in which at least one sibling was born before and one 
after the mother was diagnosed with T2D. Offspring born after their mother displayed 
diabetes had a 4-fold higher risk of diabetes and a higher body mass index (BMI) than their 
full siblings born before their mother developed diabetes (Dabelea et al., 2000). These 
findings indicate that intrauterine exposure to a diabetic environment increases risk of 
obesity and T2D beyond that attributable to genetic factors, at least in Pima Indians. In 
Caucasians, offspring whose mothers had pregestational diabetes (type 1 or 2) or gestational 
diabetes had a higher frequency of impaired glucose tolerance (IGT). (Plagemann et al., 
1997). Carriers of mutations in the MODY gene hepatocyte nuclear factor 1 alpha whose 
mothers had diabetes when they were in utero, were diagnosed with diabetes 8 years earlier 
than those who inherited the mutation from the father (Stride et al. 2002). To circumvent the 
confounding effect of genes linked to early onset T2D and transmitted by the pregnant T2D 
mother, the effect of fetal exposure to T1D was evaluated in adult offspring lacking T1D 
immunological markers. A 33% prevalence of IGT was reported in offspring of T1D mothers 
compared with none in offspring of T1D fathers (control group) (Sobngwi et al., 2003). 
Altogether, these findings suggest that fetal exposure to maternal diabetes is indeed 
associated with abnormal glucose homeostasis in offspring and may participate in the excess 
of maternal transmission in T2D. 
There are some studies related to the metabolic defects associated with fetal exposure to 
maternal diabetes in human offspring. The typical feature of infants of diabetic mothers is 
fetal macrosomia and high birth weight. A correlation between high birth weight and later 
impairment of glucose tolerance therefore is expected. Among Pima Indians high birth 
weight increases the risk of developing diabetes in later life (Pettitt, 1996). In the population 
of Malta, with a high prevalence of type-2 diabetes, woman with high birth weight have an 
increased risk of developing gestational diabetes. Birth weight is significantly higher in 
mothers with a family history of diabetes from the maternal side than from the paternal 
side, and than in those with no family history of diabetes (Savona-Ventura & Chircop, 2002). 
The relation between large babies and later impaired glucose tolerance in these studies 
appears to be related to the macrosomia of babies from diabetic mothers. 
Two studies reported that IGT in offspring exposed to intrauterine diabetic environment 
resulted from decreased insulin action based on finding of a high insulin-to-glucose ratio 
during oral glucose challenge (Plagemann et al., 1997; Silverman et al., 1995). However, fetal 
exposure to maternal T1D was not associated with reduced insulin sensitivity (minimal 
model) in young offspring (Hunter et al., 2004). Offspring of T2D mothers tended to have 
decreased insulin action, but were heavier compared with offspring of healthy mothers 
(Hunter et al., 2004). In adult Pima Indians with normal glucose tolerance and who had been 
exposed to an intrauterine diabetic environment, acute insulin response to iv glucose was 
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found reduced in those offspring whose mother was diabetic before pregnancy while it 
remained normal in those whose mother developed diabetes after pregnancy (Gautier et al., 
2001). Body fat and insulin sensitivity (euglycemic hyperinsulinemic clamp) were similar in 
the two groups of subjects (Gautier et al., 2001). In the same study, acute insulin response 
was found reduced in offspring of parents (mother or father) with early onset of T2D 
(Gautier et al., 2001), suggesting that gene(s) linked to early onset diabetes is(are) associated 
with reduced insulin secretory response to glucose (Hanson et al., 1995). Offspring of T1D 
mothers had reduced insulin secretion, more pronounced in IGT subjects, but similar fat 
mass and insulin action compared with offspring of T1D fathers (Sobngwi et al., 2003). Also 
in non-diabetic offspring of mothers with young-onset T2D (diagnosed under age 50), beta-
cell function (early insulin release after oral glucose) was found decreased as compared to 
that of offspring of fathers with young-onset T2D ( Singh et al., 2006). 
Therefore human studies suggest that insulin secretion defect participates to the abnormal 
glucose tolerance observed in adult offspring exposed to maternal diabetes during fetal life. 
Importantly, they showed that insulin secretion may be reduced even in normal glucose-
tolerant offspring. Nevertheless, in children and adolescent offspring, insulin resistance 
involvement was suggested and may be related, at least in part, to their higher body weight. 
Besides IUED populations, evidence continues to mount showing that T2D is also more 
prevalent among subjects that were intrauterine growth restricted (IUGR).  The first study to 
link low birth weight to increased T2D risk was conducted in a group of men born in 
Hertfordshire, UK, who were 64 years old at the time of the study. Those men who had the 
lowest birth weight were 6 times more likely to currently have either impaired glucose 
tolerance or T2D than those men who were heaviest at birth (Hales et al., 1991). These 
findings have been reproduced in over 40 populations worldwide, including many ethnic 
groups. In some cohorts where there is a high prevalence of maternal obesity, there is also 
increased risk of diabetes at the high-birth weight end of the spectrum (U-shaped curve for 
diabetes risk distribution). This is thought to reflect the increased risk of diabetes in the 
macrosomic offspring of women with gestational diabetes (Nathanielsz et al., 2007). Some of 
the strongest evidence in support of the role for environment in underlying the relationship 
between fetal growth and T2D had come from the study of twins. Studies of adult twins in 
Denmark revealed that, in both monozygotic (identical) and dizygotic (nonidentical) twin 
pairs who were discordant for T2D, the diabetic twin had a significantly lower birth weight 
than the normoglycemic cotwin (Poulsen et al., 1997). If it is assumed that the monozygotic 
twins are genetically identical, then, the difference in birth weight must be related to the 
fetal environment. These studies thus provide strong evidence for the importance of a 
nongenetic intrauterine factor in the development of type 2 diabetes in later life. Assessing 
the impact of maternal nutrition on the health of offspring in humans is difficult. 
Investigations involving individuals conceived during conditions of famine have provided 
direct evidence of the effects exerted by maternal nutrition during gestation and lactation on 
the overall health of the adult offspring. The Dutch famine, which occurred in the western 
part of The Netherlands at the end of World War II, was a short period of famine lasting 
from December 1944 to May 1945. Prior to the onset of the famine, the affected area of The 
Netherlands consisted of a reasonably well-nourished population. The occurrence of this 
abrupt famine therefore granted researchers a unique opportunity to retrospectively study 
the effect of maternal nutrition on offspring’s glucose tolerance. Compared with individuals 
born the year before the famine, those who were in utero during the famine had higher 
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However this association was not observed in the Leningrad Siege Study (Stanner et al., 
1997). The inconsistent results might be due to differences in postnatal environmental life 
exposures. Although the Dutch population rapidly developed into a wealthy and rich 
population after the famine, the Leningrad people remained relatively poor. In a more 
recent study of a large sample of Chinese adults, a significant association was found 
between severe famine exposure during the fetal period and an increased risk of 
hyperglycemia in adulthood (Li et al., 2010). The association was stronger in subjects with a 
Western dietary pattern or higher economic status in adulthood. No consistent association 
was observed between famine exposure during childhood and hyperglycemia. These 
studies therefore provided direct evidence that poor maternal nutrition leads to increased 
susceptibility to T2D in the offspring. 
The mechanisms that underlie the association between poor maternal nutrition and T2D are 
unclear. Several studies in children and adults have shown that non-diabetic and pre-
diabetic subjects with low birth weight are insulin resistant and, thus, predisposed to 
develop T2D (Barker, 2004; Valdez et al., 1994; Bhargawa et al., 2004; Li et al., 2001; Boney et 
al., 2005; Clausen et al., 1997; Flanagan et al., 2000). Adults born small for gestational age 
showed a significantly higher percentage of body fat (Jaquet et al., 2000) and their insulin 
sensitivity adjusted for either BMI or total fat mass, was markedly decreased. In fact in was 
first  thought that the adverse effect of IUGR on glucose homeostasis is mediated through 
programming of the fetal endocrine pancreas (Hales et al., 1991), since IUGR infants have 
reduced plasma concentrations of insulin (Economides et al., 1989) and beta-cell numbers 
(Van Assche et al., 1977).  However, several studies found no impact of low birth weight on 
insulin secretion in humans (Barker, 2004; Clausen et al., 1997; Flanagan et al., 2000). To 
address this discrepancy and since insulin sensitivity per se has a profound impact on 
insulin secretion, Jensen et al. (2002) measured both insulin secretion and insulin sensitivity 
in well-matched Caucasian glucose-tolerant men either IUGR or controls. To eliminate the 
major confounders, such as ‘diabetes genes’, none of the participants had a family history of 
diabetes, hypertension and ischemic heart disease. There was no difference between the 
groups with regard to current weight, body mass index (BMI), body composition and lipid 
profile. When adjusted for insulin sensitivity, insulin secretion was found reduced by 30%. 
However insulin sensitivity was found normal in the IUGR subjects. The authors 
hypothesized that defects in insulin secretion might precede defects in insulin action and 
that when IUGR individuals accumulate body fat, they develop insulin resistance (Jensen et 
al., 2002). This is entirely consistent with the concept that despite insulin resistance being a 
crucial component of T2D in humans, the failure of beta-cell function and growth 
determines progression to the diabetic phenotype (Weir et al., 2001). Thus, decreased 
substrate availability to the IUGR fetus caused by uteroplacental insufficiency might have 
permanently impaired pancreatic beta-cell growth by neogenesis and proliferation processes 
which take place mostly during the fetal-neonatal period. This is consistent with the 
observation that pancreatic tissue taken from human fetuses with severe IUGR is 
characterized by a reduction in endocrine cell mass (Van Assche & Aerts, 1979). However 
this has not been confirmed since no difference was also found between IUGR and control 
human fetuses in insulin-positive area or islet organization during the last two months of 
pregnancy (Beringue et al., 2002). 
To summarize, what are the more common factors that confer coincident risk of T2D and 
low birth weight? Although alterations in both insulin secretion and insulin action are 
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possible, a number of points support the hypothesis that early impairment in beta-cell 
development leads to fetal growth and predispose individuals to development of T2D later 
in life. Indeed, beta-cell mass deficit has been increasingly recognized as a central cause of 
T2D over the years (Meier, 2008). The importance of beta-cell mass for T2D risk has been 
further highlighted by the results of recent genome-wide scans that have linked the 
likelihood of developing T2D to genetic defects in insulin secretion (Saxena et al., 2007; Scott 
et al., 2007; Zeggini et al., 2007). Importantly, among these T2D loci, two of them (CDKAL1 
and HHEX-IDE) which are associated with significant impairments in beta-cell function 
(Pascoe et al., 2008; Groenewoud et al., 2008), have been related to low birth weight (Freathy 
et al., 2009). In this case, the most likely explanation for the association between low birth 
weight and T2D risk seems to be a genetically determined defective development of beta-
cells leading to insufficient insulin secretion. The intrauterine insulin deficiency may then 
impair fetal growth (Terauchi et al., 2000), while insufficient insulin secretion later in life 
may confer T2D risk.  
3. Perinatal risk factors for diabetes in later life - Animal studies 
Thank to abundant studies, mostly in rodents in which the foetal environment can be 
manipulated, a substantial body of data now addresses the mechanisms involved in the 
developmental programming of glucose intolerance and T2D. 
3.1 IUED models 
In rat, maternal diabetes may be induced experimentally by streptozotocin (STZ) injection 
that selectively destroys beta-cells. Mild or severe diabetes ensue depending on the dose 
used. At birth, the progeny of mild diabetic mothers had normal weight or slight 
macrosomia and an enhanced percentage of pancreatic endocrine tissue due to hyperplasia 
and hypertrophy of the islet cells (Aerts et al., 1990 ; Reusens-Billen et al., 1984), leading to a 
higher beta-cell mass that was hyper-vascularized (Reusens & Remacle, 2001). The 
pancreatic insulin content and insulin secretion were raised in these fetuses (Kervran, et al., 
1978). On the other hand, fetuses from severe diabetic dams were small at birth and had 
decreased pancreatic weight (Aerts et al., 1997). Their beta-cells were almost degranulated, 
leading to low pancreatic insulin content and low plasma insulin (Kervran, et al., 1978). 
Similar endocrine pancreas/beta-cell alterations with low beta-cell mass have been reported 
in fetuses from spontaneous diabetic BB rats (Verhaeghe et al., 1989) or spontaneous diabetic 
GK rats (Serradas et al., 1998; Miralles & Portha, 2001). The long-term consequences have 
been evaluated in the progeny of these models. Impaired glucose tolerance was observed in 
the offspring of mild STZ diabetic rats due to lower insulin secretion in response to glucose, 
while insulin resistance was reported in the offspring of the severe STZ diabetic mothers 
(Aerts & Van Assche, 2006; Han et al., 2007; Grill et al., 1991). Glucose tolerance was also 
impaired in offspring of normal mothers receiving glucose infusion during late gestation, 
and it was associated to decreased glucose-induced insulin secretion (Ktorza et al., 1990; 
Aerts et al., 1990; Oh et al., 1988; Gauguier et al., 1991). 
The greatest difficulty in most animal models of diabetic pregnancy has been the attainment 
of a stable degree of mild hyperglycemia during gestation. Though useful, most techniques 
used to achieve models of diabetes in pregnancy have some drawbacks. Maternal glucose 
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human fetuses in insulin-positive area or islet organization during the last two months of 
pregnancy (Beringue et al., 2002). 
To summarize, what are the more common factors that confer coincident risk of T2D and 
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Impact and Mechanisms of Pancreatic Beta-Cell Mass  
Programming by Maternal Diabetes - Insight from Animal Model Studies 
 
205 
possible, a number of points support the hypothesis that early impairment in beta-cell 
development leads to fetal growth and predispose individuals to development of T2D later 
in life. Indeed, beta-cell mass deficit has been increasingly recognized as a central cause of 
T2D over the years (Meier, 2008). The importance of beta-cell mass for T2D risk has been 
further highlighted by the results of recent genome-wide scans that have linked the 
likelihood of developing T2D to genetic defects in insulin secretion (Saxena et al., 2007; Scott 
et al., 2007; Zeggini et al., 2007). Importantly, among these T2D loci, two of them (CDKAL1 
and HHEX-IDE) which are associated with significant impairments in beta-cell function 
(Pascoe et al., 2008; Groenewoud et al., 2008), have been related to low birth weight (Freathy 
et al., 2009). In this case, the most likely explanation for the association between low birth 
weight and T2D risk seems to be a genetically determined defective development of beta-
cells leading to insufficient insulin secretion. The intrauterine insulin deficiency may then 
impair fetal growth (Terauchi et al., 2000), while insufficient insulin secretion later in life 
may confer T2D risk.  
3. Perinatal risk factors for diabetes in later life - Animal studies 
Thank to abundant studies, mostly in rodents in which the foetal environment can be 
manipulated, a substantial body of data now addresses the mechanisms involved in the 
developmental programming of glucose intolerance and T2D. 
3.1 IUED models 
In rat, maternal diabetes may be induced experimentally by streptozotocin (STZ) injection 
that selectively destroys beta-cells. Mild or severe diabetes ensue depending on the dose 
used. At birth, the progeny of mild diabetic mothers had normal weight or slight 
macrosomia and an enhanced percentage of pancreatic endocrine tissue due to hyperplasia 
and hypertrophy of the islet cells (Aerts et al., 1990 ; Reusens-Billen et al., 1984), leading to a 
higher beta-cell mass that was hyper-vascularized (Reusens & Remacle, 2001). The 
pancreatic insulin content and insulin secretion were raised in these fetuses (Kervran, et al., 
1978). On the other hand, fetuses from severe diabetic dams were small at birth and had 
decreased pancreatic weight (Aerts et al., 1997). Their beta-cells were almost degranulated, 
leading to low pancreatic insulin content and low plasma insulin (Kervran, et al., 1978). 
Similar endocrine pancreas/beta-cell alterations with low beta-cell mass have been reported 
in fetuses from spontaneous diabetic BB rats (Verhaeghe et al., 1989) or spontaneous diabetic 
GK rats (Serradas et al., 1998; Miralles & Portha, 2001). The long-term consequences have 
been evaluated in the progeny of these models. Impaired glucose tolerance was observed in 
the offspring of mild STZ diabetic rats due to lower insulin secretion in response to glucose, 
while insulin resistance was reported in the offspring of the severe STZ diabetic mothers 
(Aerts & Van Assche, 2006; Han et al., 2007; Grill et al., 1991). Glucose tolerance was also 
impaired in offspring of normal mothers receiving glucose infusion during late gestation, 
and it was associated to decreased glucose-induced insulin secretion (Ktorza et al., 1990; 
Aerts et al., 1990; Oh et al., 1988; Gauguier et al., 1991). 
The greatest difficulty in most animal models of diabetic pregnancy has been the attainment 
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hyperinsulinemia, and do not mimic the relative insulin deficiency of gestational diabetes 
(Bihoreau et al., 1986). The multiple lipid and protein abnormalities associated with diabetes 
may be as important in the induction of fetal abnormalities as hyperglycemia, but they are 
not replicated by the maternal glucose infusion model. A concern of studies using STZ 
during pregnancy is the possibility that the toxin might cross the placenta and be directly 
harmful to the fetal pancreas and other fetal tissues, and thus make any analysis of the long-
term effects of hyperglycemia in utero difficult (Ryan et al., 1995). The problem may be 
circumvented by giving STZ to female neonates who will later become pregnant: this will 
result in moderate gestational hyperglycemia (Triadou et al., 1982). Finally it must be 
recognized that none of the previously mentioned models will serve directly as a model of 
human gestational diabetes. 
An ideal animal model to test the isolated impact of diabetic pregnancy would enter the 
pregnancy in a euglycemic state, become exposed to hyperglycaemic during whole 
pregnancy and return postpartum to normoglycemic environment. Such a model also 
would allow study of the long-term effects of diabetes independent of any genetic influence. 
It was recently proposed that the pregnant GK rat being transferred normal Wistar (W) rat 
embryo represents a more relevant paradigm in such a perspective (Gill-Randall et al., 2004). 
Using the GK/Par rat we have transferred W rat oocytes to diabetic GK/Par females and at 
their birth the W neonates were suckled by non-diabetic W foster mothers. Under these 
unique conditions, we have found that maternal diabetes negatively imprints the growth of 
a genetically normal (Wistar) beta-cell mass in a way as the insult is still present later at 
adult age as a decreased beta-cell population (Chavey et al., 2008; Portha et al., 2009). 
3.2 IUGR models 
Not only maternal diabetes but also intrauterine undernutrition induced by several means 
such as protein or calorie restriction, or alteration in the availability of the nutrients by 
placental insufficiency alter early islet development and provoke lasting consequences in 
rodents. 
Global restrictions (to 40-50% of normal intake) in the last week of rat pregnancy results in 
low birth weight offspring with decreased beta-cell mass. Although these animals can regain 
their body and pancreatic weights upon normal postnatal feeding, they still demonstrate a 
reduced beta-cell mass and insulin content in adulthood (Garofano et al., 1997; Bertin et al., 
2002). Extending this level of nutrient restriction during suckling results in a permanent 
reduction of beta-cell mass (Martin et al., 1997; Garofano et al., 1998) and subsequent age-
dependent loss of glucose tolerance in the offspring (Garofano et al., 1999). Underfeeding 
the rat mothers during the first two trimesters of gestation exerts no adverse effect upon 
insulin secretion and insulin action in the adult male offspring (Portha et al., 1995). 
The maternal protein restriction (5-8% as compared to 20% in normal diet) model has been 
one of the most extensively studied models of IUGR. The low-protein-fed mothers give birth 
to growth-restricted offspring (Snoeck et al., 1990; Dahri et al., 1991; Langley-Evans et al., 
1998; Desai et al., 1996; Fernandez-Twinn et al., 2005), and when suckled by their mothers 
maintained on the same low-protein diet, they remain permanently growth restricted, 
despite being weaned on a normal diet (Desai et al., 1996). Reduced placental weight and 
endocrine and metabolic abnormalities are also observed (Dahri et al., 1991; Fernandez-
Twinn et al., 2003; Ozanne et al., 1998). Despite young offspring of low-protein-fed dams 
demonstrating improved glucose tolerance (Ozanne et al., 1998; Shepherd et al., 1997), the 
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male offspring undergo an age-dependent loss in glucose tolerance, such that by 17 months 
of age they develop T2D and insulin resistance (Petry et al., 2001). Female offspring only 
develop hyperinsulinemia and impaired glucose tolerance at a much later age (21 months) 
(Fernandez-Twinn et al., 2005). Studies in this model have also demonstrated reductions in 
beta-cell mass (Snoeck et al., 1990;), skeletal muscle mass (Desai et al., 1996), central adipose 
deposit weights (Shepherd et al., 1997; Ozanne et al., 2000) and insulin signalling defects in 
muscle, adipocytes and liver (Ozanne et al., 1996; Ozanne et al., 2000; Ozanne et al., 2005). 
This IUGR model has also been associated with the development of hypertension with the 
kidney and the renin–angiotensin system as playing a role (Langley-Evans et al., 2003). 
Administration of either dexamethasone or carbenoxolone (to inhibit 11 beta-
hydroxysteroid dehydrogenase type 2) to normal pregnant rats also causes fetal growth 
retardation and the adult offspring are hypertensive and hyperglycemic, with hyperactive 
hypothalamic-pituitary-adrenal axis (Seckl, 2004). Fetal growth retardation may also result 
from experimental uteroplacental insufficiency (UPI). Fetal UPI rats have decreased levels of 
glucose, insulin, IGF1, amino acids and oxygen (Ogata et al., 1986; Simmons et al., 1992; 
Unterman et al., 1990). UPI offspring develop diabetes in later life (Simmons et al. 2001; 
Boloker et al., 2002) with a phenotype that is similar to that observed in T2D humans with 
alterations in insulin secretion and action and a failure of beta-cell function and growth 
(Holemans et al. 2003; Stoffers et al., 2003). 
3.3 IUEO models 
There are several reports on the consequences of a high fat diet (during gestation only or 
both gestation and lactation) on the adult progeny. High fat diet consumption by female rats 
malprograms the male offspring for glucose intolerance and increased body weight in 
adulthood (Srinivasan et al., 2006). Some of the observed consequences include reduced 
whole body insulin sensitivity, impaired insulin secretion and changes in the structure of 
pancreas (Guo & Jen, 1995; Taylor et al., 2005), defective mesenteric artery endothelial 
function (Khan et al., 2005), hypertension (Khan et al., 2003; Langley-Evans et al., 1996), 
alterations in renal functions (Armitage et al., 2005), increased body adiposity (Guo & Jen, 
1995; Khan et al., 2005), deranged blood lipid profile (Guo & Jen, 1995; Karnik et al., 1989; 
Khan et al., 2003), hyperleptinemia (Taylor et al., 2005), and proatherogenic lesions (Palinski 
et al., 2001). There are not many reports on fetal islet adaptations due to a high fat dietary 
modification in the dam. Cerf et al. (2005) demonstrated that feeding female rats with a high 
fat diet throughout gestation resulted in significant decreases in beta-cell volume and 
number resulting in hyperglycemia in 1-day-old newborn rat pups without changes in 
serum insulin concentrations. However, the report of fetal hyperinsulinemia in the high fat 
term rat fetus (Srinivasan et al., 2006) is not consistent with this finding.  
Also male mice whose mothers consumed a high fat diet were heavier, glucose intolerant 
and insulin resistant, and produced second-generation offspring who were insulin resistant, 
although not obese (Dunn & Bale, 2009). Whether this is a consequence of paternal in utero 
exposure or their adult sequelaes of obesity and diabetes, is unclear. It was recently reported 
that chronic high fat diet consumption in father rats induced increased body weight, 
adiposity, impaired glucose tolerance and insulin sensitivity in their offspring (Ng et al., 
2010). Relative to controls, their female offspring had an early onset of impaired insulin 
secretion and glucose tolerance that worsened with time, and normal adiposity. Among the 
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This is a proof of concept that paternal high-fat-diet exposure programs beta-cell 
dysfunction in rat F1 female offspring. This is the first report in mammals of non-genetic, 
intergenerational transmission of metabolic sequelae of a high fat diet from father to 
offspring (Ng et al., 2010). 
Among the many types of maternal metabolic stress used to produce IUGR, 
hypercholesterolemia combined to high fat diet was recently added since feeding LDL 
receptor null (LDLR-/-) mice a high fat resulted in litters with significant growth 
retardation. The LDLR-/- high fat diet offspring developed significantly larger 
atherosclerotic lesions by 90 days compared with chow diet offspring (Bhasin et al., 2009). 
Importantly, maternal hypoaminoacidemia proved to be an important antecedent in this 
hypercholesterolemic IUGR mouse (Bhasin et al., 2009) as in a protein-deficient IUGR mouse 
model (Bhasin et al., 2009) and a IUED rat model (Aerts et al., 1989). An important between 
these mechanisms may contribute to adult glucose intolerance onset, obesity, and 
atherosclerosis. In this study beta-cell mass was not investigated.  
To sum-up, it turns to be manifest that despite differences in the type, timing, and duration 
of intrauterine insult, most animal models of IUED, IUEO or IUGR have outcomes of 
impaired glucose tolerance or T2D, similar to IUED, IUEO or IUGR humans.  
4. Various early life stressors, the same target: The developing  
beta-cell mass 
As abundantly illustrated in animal models, many early life stressors such as maternal 
hyperglycaemia, undernutrition, overnutrition, hypercholesterolemia, corticosteroid 
therapy, uteroplacental insufficiency, or hypoxia, trigger a beta-cell mass adaptive response 
in the fetus. 
4.1 Critical windows for beta-cell adaptive response to early life stressors 
The development of the endocrine pancreas starts from a pool of common precursor cells 
that become progressively committed to the endocrine lineage under the control of a 
hierarchical network of transcription factors. During late fetal and early postnatal life , the 
beta cell mass is determined by the recruitment of undifferentiated precursors, as well as the 
replication and apoptosis rates of the beta cells. Obviously, any disturbance of the 
environment of the endocrine cells at a specific developmental time-point, as it occurs in a 
perturbed intra-uterine milieu, may modify the balance of controlling factors, thereby 
contributing to an adaptive beta-cell growth response which is metabolically appropriate on 
the short term. However this adaptive response may turn to be detrimental if maintained on 
the long term, as it may foster beta-cell failure and diabetes later in life. We are largely 
ignorant of when programming may be initiated during development.  
4.1.1 Pre-implantation  
An early onset for programming was indicated, as maternal low protein diet during only the 
preimplantation period of rat development (0-4 days after mating), before return to control 
diet for the remainder of the gestation, induced blastocyst abnormalities and programming 
of postnatal growth rate and hypertension (Kwong et al., 2000). More specifically it was 
shown that preimplantation embryos collected from dams after 0-4 days of maternal low 
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protein diet displayed significantly reduced cell numbers, within the inner cell mass and 
trophectoderm lineages, apparently induced by a slower rate of cellular proliferation. The 
low protein diet significantly reduced insulin and essential amino acid levels, and increased 
glucose levels within maternal serum by day 4 of development. These data indicate that the 
mildly hyperglycemic and amino acid-depleted maternal environment generated by 
undernutrition may act as an early mechanism of programming and initiate conditions of 
‘metabolic stress’, restricting early embryonic proliferation and the generation of 
appropriately sized stem-cell lineages. In chemically or genetically obtained rat diabetes 
models in which maternal serum insulin depletion and hyperglycemia are induced, 
proliferation of inner cell mass or total cell numbers within blastocysts is inhibited (Lea et 
al., 1996; Pampfer et al., 1997). Therefore the preimplantation embryo is particularly 
sensitive to metabolic modifications that may have programming consequences (Reik et al., 
1993; Dean et al., 1998), and one possibility is that the preimplantation embryo itself is 
programmed. 
4.1.2 Post-implantation 
Embryo transfer experiments may also help to dissociate the impact of the maternal 
environment into early (pre-implantation) versus late gestation (postimplantation). We 
recently found that embryos (blastocysts) from a nondiabetic Wistar strain, placed into a 
diabetic GK/Par uterus, develop a reduced beta-cell mass which remains low on the long 
term (Chavey et al., 2008). Data with rat models of prenatal undernutrition (Dumortier et al., 
2007) also illustrate that low-energy and low-protein diets that reduce the development of 
the beta-cell mass in both cases, act at different critical time-windows. The beta-cell mass is 
deficient in the low-energy pancreas because this diet reduces neogenesis, probably because 
of high glucocorticoid levels, rather than by impairing vascularisation and proliferation. 
Early gestation is thus a very sensitive period in this model. By contrast, pancreatic 
alterations take place at a later fetal stage in the low-protein model and the beta-cell mass is 
deficient in this case because this diet reduces beta-cell vascularisation and proliferation 
without altering beta-cell differentiation (Dumortier et al., 2007). 
4.1.3 Postnatal versus prenatal 
Further support for the crucial impact of prenatal nutritional environment is the recent 
report that prenatal nutrient restriction in both male and female rats led to an inappropriate 
postnatal beta-cell mass formation attributed to a decrease in the rate of beta-cell replication 
and beta-cell neogenesis (Matveyenko et al., 2010). In contrast, male and female rats exposed 
to postnatal nutrient restriction alone (with normal prenatal nutrient exposure) were 
characterized by decreased pancreatic and body weights, but a weight-adjusted beta-cell 
mass higher than control animals (Matveyenko et al., 2010). Another illustration is offered 
by observations in normal rat pups reared artificially on a high carbohydrate milk formula 
(Patel & Srinivasan, 2002): such alteration of nutrition during the suckling period only, 
induced persistent adaptation of energy metabolism in adulthood (obesity, glucose 
intolerance, impaired insulin secretion).  
4.2 Molecular mechanisms mediating the perinatal beta-cell adaptive response 
Molecular mechanisms responsible for impaired beta-cell mass formation after IUGR have 
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protein diet displayed significantly reduced cell numbers, within the inner cell mass and 
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induced persistent adaptation of energy metabolism in adulthood (obesity, glucose 
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the embryonic beta-cell progenitor pool, leading to inappropriate postnatal beta-cell 
formation. Stanger et al. (2007) demonstrated that selective genetic reduction in the size of 
Pdx1+ pancreatic progenitors during the fetal period results in impaired beta-cell formation 
during the postnatal period with consequent development of glucose intolerance during 
adulthood. Consistent with this, maternal food restriction leads to significant reduction in 
Pdx1+ and Ngn3+ (Neurogenin 3) pancreatic precursors during embryonic development in 
rats, decreased postnatal beta-cell formation, and inability to expand beta-cell mass in 
response to pregnancy (Garofano et al., 1998; Blondeau et al., 2002). Another mechanism 
proposed to explain reduced beta-cell formation after IUGR is related to prenatal 
glucocorticoid exposure. Maternal undernutrition significantly increased both fetal and 
maternal corticosterone concentrations in rats (Blondeau et al., 2001). Subsequently, 
maternal and/or fetal overexposure to glucocorticoids (via administration of 
dexamethasone) impairs both fetal and postnatal beta-cell formation in rodents and 
nonhuman primates (Blondeau et al., 2002; Bréant et al, 2006; De Vries et al., 2007; Gesina et 
al., 2004). Blondeau et al. (2001) have shown that fetal corticosterone concentrations are 
inversely correlated with fetal insulin content and postnatal beta-cell formation in rats. 
Evidence suggests that glucocorticoids can exert a direct effect on the developing fetal 
pancreas via transcriptional modulation of transcription factors involved in beta-cell 
formation and differentiation (Bréant et al., 2006). Glucocorticoid receptors are present in the 
pancreas during embryonic development of rodents and humans (Bréant et al., 2006) and 
glucocorticoids can bind to the Pdx1 promoter and thus suppress fetal endocrine cell 
differentiation (Bréant et al., 2006). Glucocorticoid treatment has been shown to significantly 
reduce fetal expression of key endocrine transcription factors such as Pdx1 and Pax6 but 
simultaneously increase expression of transcription factors that regulate development of the 
exocrine pancreas (Gesina et al., 2006).  
The UPI model of IUGR (due to bilateral uterine artery ligation) is also characterized by a 
permanent decrease in islet Pdx1 mRNA expression. This decrease has recently been shown 
to be due to progressive epigenetic silencing of the Pdx1 gene locus secondary to proximal 
promoter methylation (Stoffers et al., 2003; Park et al., 2008) and it may be responsible for 
the decreased rate of beta-cell replication and inappropriate postnatal beta-cell mass 
development (Stoffers et al., 2003; Kulkarni et al., 2004). 
It has also been demonstrated that the UPI or the low protein IUGR offspring experience 
increased oxidative stress and impaired mitochondrial function (Simmons et al., 2005). 
The mitochondrial dysfunction was not limited to just the beta-cell, as mitochondria from 
both the liver and skeletal muscle exhibit decreased oxidation of pyruvate, subsequently 
leading to the development of features commonly found in T2D (Peterside et al., 2003; 
Selak et al., 2003). Also exposure to a Western-style diet before and during pregnancy (an 
IUEO model) alters the redox state as early as preimplantation development, leading to 
mild oxidative stress associated with inflammation. The finding that administration of 
antioxidants to the dam reverses oxidative stress and completely prevents the 
development of glucose intolerance and increased adiposity in the adult offspring 
suggests that oxidative stress plays an important role in the development of adiposity in 
this case (Sen & Simmons, 2010).  
Some studies in the low protein IUGR model have demonstrated that oxidative stress is not 
limited to just mitochondrial DNA damage, but also genomic DNA, impacting on cell-cycle 
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regulation and gene expression (Chen et al., 2007). While DNA is being targeted throughout 
by ROS, there are particular regions that are known to be more sensitive to ROS-mediated 
damage, for example telomeres. Telomeres comprise GC-rich repeats and are found at the 
ends of each chromosome. They are known to shorten with each cellular division and, 
hence, can act as a mitotic clock, registering the number of replicative divisions to have 
taken place within the cell. Investigations using a low protein IUGR model have indeed 
reported a decrease in longevity in the offspring (Jennings et al., 1999; Chen et al., 2009) 
accompanied by reduction in mitochondrial antioxidant defences (Tarry-Adkins et al., 2009) 
and telomere length in islets (Tarry-Adkins et al., 2009). 
Pancreatic islet development has been shown to be influenced by a number of growth 
factors including the insulin-like growth factors, IGF-I and IGF-II whose expression in utero 
is regulated by nutrient and hormone concentrations. IUGR modify expression of both IGF 
genes in a variety of fetal tissues. In a low protein IUGR rat model with a decreased beta-cell 
mass and beta-cell replication and an increased rate of beta-cell apoptosis, gene expression 
for IGF-II but not IGF-I was found reduced in the fetal pancreas and this was (Petrik et al., 
1999). In a different IUGR model with more severe global food restriction which induced 
hyperinsulinemia and an increase in beta-cell mass in their fetuses (Alvarez et al., 1997), the 
fetal  phenotype was associated with an increase in pancreatic IGF-I expression, islet IGF-1R 
(Martn et al., 2005) and IRS-2 (Fernandez et al., 2007). In the fetal GK/Par rat exposed to 
mild hyperglycemia during gestation (a model of IUED), data from our group suggest that 
the beta-cell deficit (reduced by more than 50%) starts as early as fetal age 16 days E16 and 
reflects decreased beta-cell proliferation, a limitation of beta-cell neogenesis from precursors 
and increased apoptosis of both beta-cells and their precursors (Calderari et al., 2007). Notably, 
Pdx1 and Ngn3 expression were decreased on E18 but normally expressed on E13 (Calderari 
et al., 2007). Defective signalling through the IGF2/IGF1-R pathway may represents the 
primary instrumental anomaly since IGF2 and IGF1-R protein expressions are already 
decreased within the GK/Par pancreatic rudiment at E13, at a time when beta-cell mass (first 
wave of beta cell expansion) is in fact normal (Miralles & Portha, 2001). Low levels of 
pancreatic IGF2, associated with beta-cell mass deficiency, are maintained thereafter within the 
fetal pancreas (Serradas et al., 2002). Crossbreeding protocols between non-diabetic W and 
diabetic GK rats showed that in late gestation (E18), pancreatic IGF2 protein expression was as 
low in GKmother/GKfather and Wmother/GKfather crosses than in  GKmother/GK father 
crosses (Serradas et al., 2002). These findings rather support the hypothesis that the pancreatic 
IGF2 anomaly in the GK diabetic model is linked to a genetic determinism. This view is also 
consistent with the results of genetic analyses that linked a locus containing the gene encoding 
IGF2 to diabetes in the GK rat (Gauguier et al., 1996). The Igf2 gene is subjected to paternal 
genomic imprinting. However, because the Igf2 expression is similarly affected in fetuses, 
regardless of whether the father is W or GK (Serradas et al., 2002), we cannot conclude to a 
simple change of Igf2 gene imprinting in the GK rat. 
Finally, studies have demonstrated that the maintenance of methylated histone H3 Lys4 by 
Set7/9 a member of the SET methyltransferase family, is crucial to Pdx1 activity in beta-cell 
lines (Chakrabarti et al., 2003; Francis et al., 2005; Deering et al., 2009). This led to the 
hypothesis that Set7/9 may represent a novel chromatin-modifying protein that functions in 
part through its recruitment to target genes by cell-specific transcription factors such as 
Pdx1. Since, a role of histone methyl transferases, particularly set7, has also been 
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microvascular endothelial cells (Siebel et al., 2010), such an epigenetic change could 
potentially be involved in the deleterious effect of high glucose upon the fetal pancreas in 
the IUED models. 
5. Various early life stressors, one ultimate programming agent: Perinatal 
hyperglycemia 
As abundantly illustrated in animal models, early life stressors such as maternal  
undernutrition, overnutrition, hypercholesterolemia, corticosteroid therapy, uteroplacental 
insufficiency, or hypoxia, program metabolic adaptations that favor survival initially, but 
are ultimately detrimental to adult health. Interestingly, a crucial commonality exists 
between these models with quite different etiologies: in most of the cases, the altered 
maternal/fetal metabolism appears to be associated with a diabetogenic effect in the adult 
offspring either male or female, resulting in a permanent deficiency of the endocrine 
pancreatic function (F1). In females, the combination of a latent diabetogenic tendency (low 
insulin response) and the metabolic stress of pregnancy promotes gestational diabetes. F1 
gestational diabetes per se is an inducing factor for impaired glucose tolerance and 
gestational diabetes again in the next female generation (F2).  
Finally, the relevant message is that programming of the endocrine pancreas ultimately 
originates from hyperglycemia experienced during the fetal and/or early postnatal life, 
whatever the etiology of maternal hyperglycemia is primary (in F0 diabetic mothers) or 
secondary (in F1 diabetic mothers issued from F0 mothers exposed to undernutrition, UPI, 
or high glucocorticoid). 
6. Transgenerational inheritance of beta-cell mass programming 
While a large number of animal studies have shown the effects of undernutrition during 
foetal/perinatal development on the glucose metabolism of offspring (F1) in adulthood, 
several studies have shown that glucose metabolism is also altered in the offspring (F2) as well 
as grand offspring (F3) of fetally malnourished F1 females, even when the F1 and F2 females 
have been well nourished since weaning (Aerts & Van Assche, 2006; Benyshek et al., 2006). 
With a aim to dissect the relative parental contributions that lead to F2 offspring outcomes in 
these models of maternal (F0) undernutrition, it was recently reported that F1 males exhibit 
moderate hyperglycemia and IGT with aging and impaired glucose-stimulated insulin 
secretion and that all F2 offspring of F1 males or F1 females develop glucose intolerance 
(Jimenez-Chillaron et al., 2005). Therefore, intergenerational progression of glucose intolerance 
can derive from both the maternal and paternal lines. This is an experimental proof that 
transgenerational transmission of IGT may also occur through the paternal lineage, besides the 
more widely accepted maternal and grand maternal inheritance of diabetes (Zambrano et al., 
2005; Drake et al., 2005; Blondeau et al., 2002; Benyshek et al., 2006). 
Conceptually, transgenerational inheritance of disease risk may be mediated by nongenomic 
mechanisms, including either 1) epigenetic mechanisms (Ozanne & Constancia, 2007; Pinney 
& Simmons, 2009; Drake & Liu, 2009; Waterland & Michels, 2007) or 2) other broader 
indirect mechanisms associated with parental physiology (Gluckman et al., 2007). First, 
alterations in nutrition during development can alter epigenetic marks, thus regulating gene 
expression through DNA methylation and/or histone modifications. Interestingly, such 
epigenetic modifications may progress with aging during postnatal life, in association with 
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metabolic phenotypes, as recently observed at the Pdx1 and GLUT4 loci in UPI rats (Park et 
al., 2008; Raychaudhuri et al., 2008). If these epigenetic changes occur in the germ line, they 
can be inherited through meiosis (Chong et al., 2007), thus providing a plausible explanation 
for intergenerational effects, transmitted via either maternal or paternal lines. In addition, 
other indirect biological processes may influence phenotypes in subsequent generations. For 
example, physical constraints may alter birth size through the maternal lineage: since 
uterine size is reduced in girls that are born small and remain short, this may influence fetal 
growth and reduce weight in their progeny (Gluckman et al., 2007).  
Furthermore, maternal metabolism may also influence cross-generational phenotypes (Aerts 
& Van Assche, 2006). Maternal undernutrition during pregnancy (F0) increases risk for 
developing diabetes and obesity in her offspring (F1). When these high-risk adult F1 females 
become pregnant, the metabolic stress of pregnancy may result in hyperglycemia and/or 
overt gestational diabetes that may, in turn, contribute to defective beta-cell mass and 
increased diabetes risk in F2 offspring (Aerts & Van Assche, 2006). By this mechanism 
gestational diabetes may pass from one generation to the next one. In these last examples, 
intergenerational transmission of phenotypes would occur exclusively through the maternal 
lineage, as opposed to the epigenetic mechanisms mentioned above. Such a scenario is 
relevant to the GK/Par rat, since the GK/Par mothers are mildly hyperglycemic through 
their gestation and during the suckling period. It offers a rationale to elucidate several clues: 
1/ the initiation of pancreas programming in the F1 offspring of the first founders (F0), since 
the GK line is issued from  intercrosses between Wistar females and males with borderline 
IGT but otherwise normal basal blood glucose level (Goto et al., 1975); 2/ the progression of 
the IGT phenotype until a stable mild diabetic phenotype was reached among the 
generations (n=35) (Goto et al., 1975); 3/ the lack of attenuation of the diabetic GK 
phenotype overtime (along more than 20 years and 80 generations), since offspring of GK 
female/W male crosses were more hyperglycemic than those of W female/GK male crosses 
(Gauguier et al., 1994). 
7. Epigenetic mechanisms mediating the diabetes risk associated with beta-
cell mass programming 
Several lines of evidence indicate that epigenetic modification may be a key unifying 
mechanism mediating risk associated with a perturbed intrauterine environment. First, 
disruption of physiologic responses and functional capacity as observed in multiple tissues 
in of IUED or IUGR animals and humans, including muscle, adipose, pancreas, liver, and 
CNS may be related to histone modification and DNA methylation thereby altering related 
gene expression (Waterland & Michels, 2007).  
The preimplantation embryo is particularly sensitive to epigenetic modifications that might 
permanently alter the phenotype in the adult (Reik et al., 1993; Doherty et al., 2000). For 
example, in the agouti mouse model, folate supplementation of the maternal diet at 
conception increases DNA methylation of the agouti gene and increases longevity of the 
offspring (Cooney et al., 2002). Maternal protein restriction has been shown to alter the 
methylation status of the promoters of the glucocorticoid receptor (Lillycrop et al., 2005), 
PPARa (Lillycrop et al., 2008), and the angiotensin receptor (Bogdarina et al., 2007) with 
parallel changes in gene expression. More recent studies have shown that histone 
modifications can also be influenced by the early environment. Alterations in histone 
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metabolic phenotypes, as recently observed at the Pdx1 and GLUT4 loci in UPI rats (Park et 
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1/ the initiation of pancreas programming in the F1 offspring of the first founders (F0), since 
the GK line is issued from  intercrosses between Wistar females and males with borderline 
IGT but otherwise normal basal blood glucose level (Goto et al., 1975); 2/ the progression of 
the IGT phenotype until a stable mild diabetic phenotype was reached among the 
generations (n=35) (Goto et al., 1975); 3/ the lack of attenuation of the diabetic GK 
phenotype overtime (along more than 20 years and 80 generations), since offspring of GK 
female/W male crosses were more hyperglycemic than those of W female/GK male crosses 
(Gauguier et al., 1994). 
7. Epigenetic mechanisms mediating the diabetes risk associated with beta-
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Several lines of evidence indicate that epigenetic modification may be a key unifying 
mechanism mediating risk associated with a perturbed intrauterine environment. First, 
disruption of physiologic responses and functional capacity as observed in multiple tissues 
in of IUED or IUGR animals and humans, including muscle, adipose, pancreas, liver, and 
CNS may be related to histone modification and DNA methylation thereby altering related 
gene expression (Waterland & Michels, 2007).  
The preimplantation embryo is particularly sensitive to epigenetic modifications that might 
permanently alter the phenotype in the adult (Reik et al., 1993; Doherty et al., 2000). For 
example, in the agouti mouse model, folate supplementation of the maternal diet at 
conception increases DNA methylation of the agouti gene and increases longevity of the 
offspring (Cooney et al., 2002). Maternal protein restriction has been shown to alter the 
methylation status of the promoters of the glucocorticoid receptor (Lillycrop et al., 2005), 
PPARa (Lillycrop et al., 2008), and the angiotensin receptor (Bogdarina et al., 2007) with 
parallel changes in gene expression. More recent studies have shown that histone 
modifications can also be influenced by the early environment. Alterations in histone 





the second half of pregnancy on the programmed reduction of GLUT4 expression in the 
offspring (Raychaudhuri et al., 2008). In the case of the UPI rat model and the pancreatic 
tissue, Simmons and colleagues have reported a progressive reduction in expression of 
Pdx1, a key transcription factor regulating pancreatic development and function (Stoffers et 
al., 2003). Pdx1 expression is reduced by 50% in UPI fetuses and by 80% in adult UPI 
offspring. Notably, these changes precede the onset of beta-cell dysfunction, suggesting a 
primary pathogenic role. Since the Pdx1 promoter is a target for epigenetic modification, 
as it contains a conserved CpG islands and is associated with high levels of histone 
acetylation. Interestingly, binding of both acetylated histone H3/H4 and the transcription 
factor USF1 was found abolished in UPI fetuses (Park et al., 2008). While there was 
methylation at multiple CpGs in UPI adult offspring, no methylation was detected in UPI 
neonates, indicating that methylation was unlikely to explain Pdx1 repression early in life. 
Together, these data indicate that progressive silencing of gene expression is largely 
initiated by early epigenetic changes and is maintained thereafter even in the absence of 
further experimental insults during postnatal life. UPI also increases histone acetylation of 
the PPARalpha coactivator PGC-1 and carnitine–palmitoyltransferase I (CPT1) promoters 
in newborn and young rats, and these changes are associated with increased PGC-1 and 
CPT1 mRNAs (Fu et al., 2004). Finally, there is now little doubt that epigenetic regulation 
of gene expression also occurs in humans as a response to early nutritional insult: a recent 
study has revealed that individuals who were exposed to famine in utero during the Dutch 
Hunger Winter had altered methylation of the Igf2 gene in white blood cells in adulthood 
(Heijmans et al., 2008). 
8. Implications for human health 
Although the focus of most studies in the metabolic programming field has been on 
delineating the effects of reduced maternal nutrition, there is now a growing interest in the 
role of maternal overnutrition in the programming of diabetes risk. The worldwide 
prevalence of obesity continues to increase, in association with an increase in the risk of 
metabolic T2D. Indeed, a recent study estimated that the number of people worldwide with 
diabetes would increase from 171 million in 2000 to 366 million by 2030 if the prevalence of 
obesity remained constant (Wild et al., 2004), which has major implications for public health 
strategies worldwide (WHO, 2000). This global trend to increasing obesity is reflected in the 
increasing numbers of women who are obese during pregnancy (Kanagalingam et al., 2005). 
Given that the offspring of obese mothers have an increased risk of developing obesity and 
T2D themselves (Boney et al., 2005; Catalano, 2003; Catalano et al., 2009), the potential 
impact of the intergenerational consequences of maternal obesity is of great concern for 
public health policy makers.  
Moreover, maternal hyperglycemia per se increases the probability of adolescent obesity 
and future T2D. To what extent maternal hyperglycemia is fuelling the global rise in obesity 
and T2D is unknown, but its contribution is highly significant. The exact degree of 
hyperglycemia that has this effect and the exact timing in pregnancy at which 
hyperglycemia is impressionable on fetal programming is unknown. The need to identify 
and treat all women with gestational diabetes is very much dependent on us knowing this. 
Meanwhile, achieving rigorous glycemic control in women with diabetic pregnancy has to 
remain a major therapeutic goal. 
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Several interventions (dietary or pharmacological) to reduce the long-term sequelae of early 
life programming effects have been used in animal models. For example, the administration 
of folic acid with a low protein diet during pregnancy prevents the altered phenotype and 
epigenotype in rat offspring (Lillycrop et al., 2005), and administration of a diet rich in 
methyl donors prevents the transgenerational increase in obesity in agouti yellow mice 
(Waterland et al., 2008). Importantly, the timing of such interventions can be crucial. 
Examples include neonatal leptin treatment which reverses the programming effects of 
prenatal undernutrition (Vickers et al., 2005). In the UPI rat model, epigenetic silencing of 
the Pdx1 gene can be reversed during a critical developmental window in the neonatal 
period, using trichostatin A which inhibit HDACs (Park et al., 2008). In the same model, 
exposure to Exendin-4 in the neonatal period reversed the detrimental fetal programming 
of the beta-cell mass and prevented the development of diabetes in adulthood: this was 
closely related to restoration of pdx1 expression and beta-cell proliferation rate (Stoffers 
Diabetes 2003). A GLP-1 or Exendin-4 treatment limited to the neonatal pre-diabetic 
period was also shown to delay the installation and limit the severity of T2D in the 
GK/Par model (Tourrel et al., 2002). In such context, it is important to note that GLP1-
derived drugs that are currently used to treat patients with T2D may target chromatin 
remodelling. Treating beta-cells from the INS1 cell line or dispersed mouse islet cells with 
GLP-1 increased global acetylation of histone H3 and increased its phosphorylation in a 
concentration-dependent manner (Kim et al., 2009). Such histone modifications increased 
association with the transcription factor phospho- CREB and with cAMP-response CREB 
coactivator 2. Taken as a whole, these data may provoke optimism - that there may be a 
window for potential postnatal therapeutic interventions to prevent/modify the 
“programmed” diabetes risk. 
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1. Introduction 
Gestational Diabetes Mellitus (GDM) is glucose intolerance first diagnosed during 
pregnancy (Metzger and Coustan 1998, World Health Organization 1999). Gestational 
diabetes is a condition that complicates 3-12.% of pregnancies (Gabbe and Graves 2003, 
Omu et al 2010 ) with wide variation in the incidence of gestational diabetes reported among 
ethnic groups.This could be newly diagnosed type 1 or type 2 Diabetes Mellitus or a new 
onset of hyperglycemia secondary to metabolic changes related to pregnancy (Yogev and 
Visser 2009). The rates of Gestational diabetes mellitus are increasing with the epidemic of 
obesity worldwide. Risk factors for GDM include advanced maternal age, multiparity, and 
racial or ethnic minority status (Table 1).  
 
 Body mass index more than 30 kg/m² 
 Previous macrosomic baby weighing 4.5 kg or more 
 Previous gestational diabetes 
 Family history of diabetes (first-degree relative with diabetes) 
 Family origin with a high prevalence of diabetes: 
 South Asian (specifically women whose country of family origin is India, 
Pakistan or 
 Bangladesh) 
 Black Caribbean 
 Middle Eastern (specifically women whose country of family origin is Saudi 
Arabia, United Arab Emirates, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, 
Lebanon or Egypt) 
Reproduced from the National Institute for Health and Clinical Excellence guideline for diabetes in 
pregnancy (12) by RCOG Scientific Advisory Committee Opinion Paper 23: Diagnosis and Treatment of 
Gestational Diabetes (RCOG 2011). 
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Omu et al 2010 ) with wide variation in the incidence of gestational diabetes reported among 
ethnic groups.This could be newly diagnosed type 1 or type 2 Diabetes Mellitus or a new 
onset of hyperglycemia secondary to metabolic changes related to pregnancy (Yogev and 
Visser 2009). The rates of Gestational diabetes mellitus are increasing with the epidemic of 
obesity worldwide. Risk factors for GDM include advanced maternal age, multiparity, and 
racial or ethnic minority status (Table 1).  
 
 Body mass index more than 30 kg/m² 
 Previous macrosomic baby weighing 4.5 kg or more 
 Previous gestational diabetes 
 Family history of diabetes (first-degree relative with diabetes) 
 Family origin with a high prevalence of diabetes: 
 South Asian (specifically women whose country of family origin is India, 
Pakistan or 
 Bangladesh) 
 Black Caribbean 
 Middle Eastern (specifically women whose country of family origin is Saudi 
Arabia, United Arab Emirates, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, 
Lebanon or Egypt) 
Reproduced from the National Institute for Health and Clinical Excellence guideline for diabetes in 
pregnancy (12) by RCOG Scientific Advisory Committee Opinion Paper 23: Diagnosis and Treatment of 
Gestational Diabetes (RCOG 2011). 





There are health implications for both the mother and infant who remain at risk for 
complications such as embryopathies, spontaneous abortion and perinatal mortality and 
morbidity (Loeken 2006).  
There has been considerable controversy surrounding the screening and diagnosis, natural 
history, management and outcome of women with gestational diabetes. The 2008 NICE 
guidelines (NICE 2008) on diabetes in pregnancy detailed a screening programme targeting 
biochemical screening to women with risk factors. Women with a history of gestational 
diabetes mellitus (GDM) have an increased risk for recurrence in subsequent pregnancies, 
according to the results of a population-based, retrospective cohort study (HAPO Study 
Cooperative Research Group 2008). Oxidative stress has been implicated in the pathogenesis 
and development of complications of diabetes in pregnancy (King and Loeken 2004, Loeken 
2004, Marfella et al 2001, Morgan et al 2008, Rosen et al 2001, Wender-Ozegowska et al 
2004). The role of Butyrylcholinesterase (BuChE) in the aetiology, screening and monitoring, 
complications and future drug development of Gestational Diabetes Mellitus has become an 
interesting area of speculative research (Mahmoud et al 2003, Mohmoud etal 2006, 
Mahmoud et al 2008, Rustemeijer et al 2001, Serlin et al 2009, Sternfield et al 1997). 
2. The objective 
The objective of this chapter is to elucidate the relationship between gestational diabetes 
mellitus (GDM) and BuChE in the pathogenesis, monitoring and future drug development.  
3. Pathogenesis of GDM      
The cornerstones of development of gestational diabetes mellitus are related to modern 
lifestyle, principally, a lack of exercise and an unhealthy diet, the environment and some 
degree of genetic profile (American Diabetic Association 2003, Hollander et al 2007, Serlin et 
al 2009).  Elevated glucose in pregnancy may be caused by increased levels of diabetogenic 
factors of pregnancy such as glucocorticoids, human placental lactogen and oestrogens. 
Hyperglycaemia causes oxidative stress due to increased production of mitochondrial ROS, 
nonenzymatic glycation of proteins, and glucose autoxidation (Brownlee 2001). Elevated 
FFA can also cause oxidative stress due to increased mitochondrial uncoupling and ß-
oxidation, leading to the increased production of ROS. In addition, hyperglycemia- and FFA-
induced oxidative stress leads to the activation of stress-sensitive signaling pathways (Evans 
et al 2003). This, in turn, worsens both insulin secretion and action, leading to overt 
Gestational Diabetes Mellitus. Administration of glucocorticoids significantly decreases the 
catalytic activity of BuChE in plasma and liver regardless of sex (Vrdoljaki et al 2005). 
3.1 Hyperglycemia and oxidative stress 
The pathogenic effect of hyperglycaemia is mediated to a significant extent via increased 
production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and 
subsequent oxidative stress (King and Loeken 2004, Marfella2001, Rosen et al 2001, Wender-
Ozegowska et al 2004). ROS and RNS directly oxidize and damage DNA, proteins, and lipids 
and thus adversely affect the pancreas especially the  Langerhan cells that produce insulin. 
Similarly, there is disruption of the alpha cells that produce glucagon. The paracrine 
relationship between the pancreatic beta and alpha cells is disrupted to cause -cell 
dysfunction.  There is also growing evidence that activation of stress-sensitive pathways, such 
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as NF-kB, p38 MAPK, JNK/SAPK, and hexosamine, by elevations in glucose and possibly FFA 
levels leads to both insulin resistance and impaired insulin secretion through ß-cell 
dysfunction (Kyriakis et al 1992). Circulating serum levels of lipid peroxidation product 
malonedialdehyde (MDA) and protein oxidation markers are elevated in GDM compared to 
healthy normal pregnancy and give rise to a negatively strong correlation between MDA and 
BuChE in serum and placenta (Omu et al 2010). A third causal pathway may be through the 
induction of apoptosis of the beta cells by advanced glycation end-products. This would 
explain the varying severity of GDM among the patients.  BuChE deficiency results in delayed 
metabolism of a number of compounds of clinical significance, including glucose, thus 
contributing to the pathogenesis of diabetes mellitus.  Glucose metabolism is controlled by the 
hormone insulin produced in the pancreas. BuChE deficiency in pregnancy may be as a result 
of hereditary deficiency and haemodilution in second half of pregnancy.  
3.2 Role of estrogen receptor alpha in glucose and lipid metabolism 
The estrogen receptor ER-alpha is emerging as a key molecule involved in glucose and lipid 
metabolism. The activation of ER-alpha by physiological concentrations of E2 may play an 
important role in the adaptation of the endocrine pancreas to pregnancy. However, if ER-
alpha is over stimulated by an excess of E2 or the action of an environmental estrogen such 
as Biphenol A (Nadal et al 2009, Paloma et al 2008, Ropero et al 2008), it can result in an 
excessive insulin signaling. This may provoke insulin resistance in the liver and muscle, as 
well as beta-cell exhaustion and therefore, contribute to the development of Gestational 
Diabetes. An association between oestrogen receptor alpha and BuChE has been reported 
(Combarros et al 2007). 
3.3 Environmental factors 
The increase of endocrine-disrupting chemicals (EDCs) in the environment has been 
implicated in the aetiology of GDM (Elobeid and Allison 2008, Newbold et al 2009, Rubin 
and Sato 2009).  A connection at the epidemiologic level in humans has been recently 
proposed for dioxin, an environmental contaminant that acts through other than estrogen 
receptors (ERs) as an endocrine disruptor (Bertazzi et al 2001, Remillard et al 2002). 
3.4 Autoimmunity and Treg in GDM 
Autoimmune phenomena associated with type 1 diabetes mellitus (DM) can also be 
detected in a subgroup of women with GDM. Islet autoantibodies are present in sera from 
women with GDM with variable frequency. Distinct phenotypic and genotypic features may 
be recognised in this subset of women with GDM, which are representative of a distinct 
clinical entity. Women with previous autoimmune GDM may be candidates for potential 
immune intervention strategies (Mauricio et al 2001). Normal activity of Treg 
subpopulations are disrupted in GDM by mechanisms that threaten pregnancy and may 
contribute to other features of the disorder, with higher percentages of activated T cells than 
a matched population of healthy pregnant women. BuChE detoxifies anticholinesterases 
(AC) that are known to threaten pregnancy and one or more of these fetotoxins adversely 
impacts pregnancy outcome through a mechanism that may include Treg cells. In normal 
pregnancy, there is correlation between Treg activity and BuChE, whereas in women in 
whom adequate correlation between Treg cells and BuChE activity is not achieved 
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as NF-kB, p38 MAPK, JNK/SAPK, and hexosamine, by elevations in glucose and possibly FFA 
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failure of effective clearance of toxicants which adversely affect maternal 
immunomodulation in ways that can lead to GDM and other pregnancy-threatening 
conditions (Baccarelli et al 2002, Bertazzi et al 2001, Eskenazi et al 2004, Lappas et al 2010, 
Maussolie et al 1992,  Remillard et al 2002).  
3.5 Genetics of gestational diabetes mellitus  
There is very little published data about the genetic basis for gestational diabetes mellitus 
(GDM) (Watanabe et al 2007). However, there is evidence for clustering of type 2 diabetes 
and impaired glucose tolerance in families with a GDM (McLellan et al 1995) and evidence 
for higher prevalence of type 2 diabetes in mothers of women with GDM (Martin et al 1985).  
HLA DR3 and DR4 antigens are in higher frequency in women with GDM than in women 
with normal pregnancies. Furthermore, an association between variation in the insulin 
receptor (INSR) in Caucasian and African-American women with GDM has been reported 
(Ober et al 1989). A β-cell defect is one of the primary characteristics of GDM and β-cell 
function is a highly heritable trait(Watanabe et al 2007). 
4. Association between GDM and oxidative stress and diabetic complications 
Pregnancy is susceptible to oxidative stress and antioxidant defenses that can be altered in 
response to elevated levels of oxidative stress (Chen and Scholl 2005. Marfella et al 2001, 
Maxwell et al 1997).  
In GDM products of lipid peroxidation may be increased and antioxidant enzyme activities 
decreased and the oxygen free radicals may be involved in severe damage of cellular 
structure (Osawa andKato 2005, Twardowska-Saucha et al 1994) and pregnancy complicated 
by poor glycemic control is associated with a higher risk of embryopathies, spontaneous 
abortion and perinatal morbidity and mortality (Loeken 2006). Recently, Karacay et al (2010) 
demonstrated that plasma and serum maternal total antioxidant status (TAS) was 
decreased, while circulating levels of lipid peroxidation breakdown products (MDA) were 
increased  between 24 and 36 weeks of gestation, thus showing  that increased oxidative 
stress and reduction in antioxidant defense mechanisms may contribute to disease processes 
in GDM (Bertazzi et al 2001, Karacy et al 2010, Rustemeijer et al 2001). Carine et al (1993) 
and Zachara et al (1993) found no differences in glutathione peroxidase (GPX) levels 
between pregnant women at third trimester and non-pregnant women, but recent studies 
have demonstrated an association between GDM and impaired SOD activities and enhanced 
circulating lipid metabolite levels such as MDA (Grissa et al 2007). Catalase, the main 
regulator of hydrogen peroxide metabolism is involved in Glut 4 expression, insulin 
secretion, insulin signaling, protein tyrosine phosphatase regulation, and glucose transport 
stimulation (Goth et al 2005, Mueller et al 1997). Catalase is important in antioxidant defense 
against hydrogen peroxide and  increased risk of diabetes has been reported in hereditary 
catalase deficiency (Goth and Eaton 2000, Sindhu et al 2004). 
5. Biology of BuChE  
The enzyme cholinesterase is present in all mammals and two classes have been identified 
:acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE);  AChE exists in 
the central nervous system, platelets and the erythrocyte membrane, while BChE is more 
abundant in the serum and is synthesized by the liver (Daresh et al 2003). BuChE was 
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named “pseudocholinesterase” by Mendel and Rudney in 1943 (1943). Human plasma 
BuChE (EC 3.1.1.8) is a globular, tetrameric serine esterase with a molecular mass of ≈340 
kDa that is stable in plasma with a half-life of 12 days (Lockridge et al 1987, Ostergaard et al 
1988).  BuChE acts on hydrophilic and hydrophobic choline esters, and that it hydrolyzes a 
variety of xenobiotics as shown in Table 2. Previous studies have reported a significant 
association between the serum BuChE activity and obesity, coronary artery disease, serum 
levels of triglycerides (TG), very low-density lipoprotein, low-density lipoprotein and Apo 
lipoprotein B, type 2 diabetes mellitus and the hepatic fat content (Alcantara et al 2005, 
Cucuianau et al 1999, Randell et 2005, Sridhar et al 2005). At variance with AChE-S, BuChE 
attenuates the fibril-formation process by the aromatic W8 residue. This residue can form 
heteroaromatic complexes with soluble monomeric or low-oligomeric Aβ conformers. That 
replacement of tryptophan to a polar residue abolishes the attenuation of Aβ fibril formation 
is fully compatible with this hypothesis. AChE mRNA is 20-fold more abundant than 
BuChE mRNA. In human blood, however, BuChE, at 50 nM, is 3-fold more abundant than 
AChE (Daresh et al 2003).  
 
BuChE protein or mRNA has been found in almost every tissue of the body, showing that 
it has a function. 
1. Acetylcholine and butyrylthiocholine hydrolysis. 
2. Protection from neurotoxins 
- OP nerve agents 
- OP pesticides 
- Carbamate pesticides 
- Alzheimer drugs-donepezil and rivastigmine 
- Physostigmine in the calabar beans 
-  Cocaine from Erythroxylum coca plant 
- Solamidine from green potatoes 
- Luperzine A from the club moss 
- Anatoxina in the blue green algae. 
3. Hydrolysis of short-acting muscle relaxants 
- Succinylcholine 
4. Not clear yet 
-  Glucose and lipid metabolism   
Table 2. Functions of BuChE 
5.1 Genetics of BuChE 
The complete amino acid sequence of human serum BuChE have been described (Daresh et 
al 2003). The human butyrylcholinesterase (BuChE; EC 3.1.1.8) is encoded by a single gene 
which corresponds to the E1 locus BuCHE gene (3q26.1-q26.2) which presents four exons 
(Arpagaus et al 1993), with more than 70 already-described variants (Pantuck 1993, Souza et 
al 2005). Data from dizygotic twin pairs has shown linkage on chromosome 3 at the location 
of the BuChE gene and also on chromosome 5. BuChE is found in human plasma, either in 
homomeric viz. monomers (G1), dimers (G2), trimers (G3) and tetramers (G4), or 
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al 1989, Pantuck 1993).  The BCHE-K variant has been reported to show allelic association 
with Alzheimer disease (AD) in subjects who are also carriers of the e4 allele of 
apolipoprotein E (APOE), especially in subjects over the age of 75 years. The K variant, is 
carried on one allele by one of four persons (Rao et al 2006). As BuChE is found common to 
both Alzheimer's disease and diabetes; it may play an etiological role via influencing insulin 
resistance and lipid metabolism (Arpagaus et al 1990, Lockridge et al 1987, Rao et al 2006). 
Similarly patients with Alzheimer's disease are more vulnerable to developing impaired 
fasting glucose and type 2 diabetes mellitus (Janson et al 2004, Johansen et al 1991) 
5.2 BuChE and placental development 
In utero exposure to poisons and drugs (e.g., anticholinesterases, cocaine) is frequently 
associated with spontaneous absorption and placental malfunction. The major protein 
interacting with these compounds is butyrylcholinesterase (BuChE), which attenuates the 
effects of such xenobiotics by their hydrolysis or sequestration. Sternfeld and Associates 
(1997) studied BuChE expression during placental development. RT-PCR revealed both 
BuChE mRNA and acetylcholinesterase (AChE) mRNA throughout gestation. Maximum 
butyrylcholinesterase activity has shown in week 12. In rat placenta, BuChE activity on 
gestational day 21 reached 150% of the level on gestational day 16. BuChE detoxifies 
anticholinesterases (AC) and other toxins including free radicals that are known to threaten 
pregnancy (Hollander et al 2007, Maxwell et al 1997, Osawa and Kato 2005, Twardowska-
Saucha et al 1994).  There is evidence that Kuwaiti women experiencing disorders of 
pregnancy like preeclampsia and diabetes mellitus in pregnancy exhibited lower serum 
activity of BuChE (Mahmoud et al 2003, Mahmoud et al 2006, Mahmoud et al 2008). 
6. Clinical role of BuChE 
BuChE (BuChE; EC 3.1.1.1.8) has well-defined pharmacologic functions:  
BuChE and anaesthetic muscle relaxants: Mivacurium and succinylcholine are short-acting 
neuromuscular blocking drugs ideal for short surgical procedures as muscle relaxants used 
in anesthetic practice. The brief duration of action depends on rapid hydrolysis by plasma 
cholinesterase (Jensen et al 1991Pantuck 1993). An inherited or acquired deficiency of 
plasma BuChE can prolong the effect of mivacurium. When there is a deficiency of this 
enzyme due to the presence of one or more atypical alleles, mivacurium and succinylcholine 
are not properly metabolized and thus muscle paralysis can last for several hours (Davis et 
al 1997, Goudsouzian et al 1993, Petersen et al 1993, Savarese et al 1997). 
6.1 Factors affecting BuChE activity 
Different disease states and/or drug administrations may decrease BuChE activity.; such as 
extremes of age, pregnancy, renal and liver disease, malignancy, burns, chronic 
debility/malnutrition, myocardial infarction/cardiac failure, collagen diseases, myxedema, 
poisoning and protein energy malnutrition. Drugs that inhibit the enzyme’s activity include 
acetylcholinesterase inhibitors (neostigmine, pyridostigmine, physostigmine, and 
edrophonium), anticholinesterases (especially echothlophate), cytotoxic agents (such as 
cyclophosphamide), steroids, ester-type local anesthetics, hexafluorenium, pancuronium, 
oral contraceptives and sertraline (Klein-Schwatz and Anderson 1996, MacQueen et al 2001, 
Muller et al 2002).  
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6.2 BuChE and Organophosphatase (OP) and cocaine hydrolysis 
Another reason for continued interest in serum cholinesterase is its extraordinary sensitivity 
to organophosphate ester. Systemic administration of BuChE, at a dose sufficient to increase 
plasma BuChE levels 400-fold (5000 I.U.; i.v.), has been shown to significantly decrease 
cocaine-induced locomotor activity in rats over a 120-min session (Carmona et al 1997).  The 
identification of BuChE variants that exhibit increased cocaine hydrolysis activity provides 
treatment options for cocaine-induced conditions such as cocaine overdose and addiction 
(Arkhypova et al 2004, Lockridge et al 2005), Lynch et al 1997).   
6.3 BuChE activity and dyslipidemia and metabolic syndrome  
Serum levels of BuChE are affected by dietary fat, obesity, hyperlipidemia and diabetes 
mellitus, alcohol and many drugs are known to increase BuChE activity (Alcantara et al 
2005, Stefanello et al 2005, Vrdoljaki et al 2005). Therefore, BuChE may have a role in the 
altered lipoprotein metabolism in hypertriglyceridaemia associated with diabetes mellitus 
and insulin resistance. BuChE is synthesized in the liver, and is present in plasma and to a 
lesser extent in adipose tissue, small intestine and smooth muscle. Sridhar et al (2005) 
measured the serum level of BuChE levels in persons with type 2 diabetes mellitus and 
demonstrated a negative correlation between BuChE and serum total cholesterol and LDL 
cholesterol, thus further confirming that BuChE may be involved in lipid metabolism.  
6.4 Serum determination of BuChE 
The application of the techniques of molecular genetics has permitted precise identification 
of plasma cholinesterase variants and has resulted in the discovery of previously 
unrecognized variants. Serum BuChE activity has been determined by the method of Ellman 
et al (1961). In addition to colorimetric methods, HPLC, Electrophoresis, Immunoassay 
methods (ELIZA) and Biosensor methods have been used. 
6.5 Production of human BuChE 
Human BuChE has been obtained from human plasma by a large scale purification technique 
(Lockridge et al 2005). This procedure is severely limited by the volume of human plasma 
needed and may not be cost effective and it may not yield a sufficient amount of enzyme 
purified commercially.  Large quantities of BuChE are needed for effective prophylaxis and 
treatment of exposure. BuChE has a broad spectrum of activity, a relatively long half-life, and 
few physiological side effects. Producing recombinant BuChE (rBuChE) is an alternative to 
purification of the enzyme from human plasma. A number of studies have shown the 
feasibility of producing large quantities of BuChE in transgenic animals (goats) and transgenic 
edible plants for prophylaxis or treatment of humans exposed to OP agents (Lockridge et al 
2005, Podoly et al 2008, Protexia 2011) and cocaine overdose or addiction (Om et al 1993). 
7. Association between BuChE and oxidative stress  
Stefanello et al. (2005) investigated the effect of homocysteine administration on BuChE 
activity in the serum of rats. Acute and chronic administration of homocysteine significantly 
decreased BuChE activity but administration of vitamins A and C prevented the reduction 
of the activity.  Delwing et al (2005) observed that acute proline administration provoked a 
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demonstrated that vitamins E and C reversed the inhibition of BuChE activities provoked by 
arginine in the serum of rats, thus indicating that the reduction of BuChE activities caused 
by arginine was probably mediated by oxidative stress. In a similar fashion, Cederberg et al. 
(2001) have shown that combined treatment with vitamins E and C decreased oxidative 
stress and improved fetal outcome in experimental pregnancy. From the foregoing, BuChE 
may yet be another mechanism in the fight against oxidative stress.  
7.1 Mechanisms of the association between BuChE and oxidative stress in GDM 
In a recent report, we (Omu et al 2010) showed that BuChE activity was elevated in the serum 
and placenta in normal pregnancy as compared to diabetic cohorts (p < 0.01) and there was a 
higher activity level in gestational and type 2 diabetes on insulin (p<0.05) compared with diet 
controlled. Conversely, there was higher MDA and lower antioxidant activity in diet versus 
insulin controlled diabetes (p < 0.01). Both serum and placental BuChE activity showed a 
strong inverse correlation with MDA (r = -0.876, p < 0.001) and (r = - 0.542, p < 0.01), but strong 
positive correlation with total antioxidant activity in serum (r = 0.764, p < 0.001) and placenta 
(r = 0.642, p < 0.01). These results are therefore consistent with a mechanism in which BuChE 
acts to scavenge free radicals in the presence of oxidative stress. An interesting finding in the 
study was the higher BuChE activity in the two groups of insulin-treated diabetics compared 
with their counterparts on diet. This led to the speculation that the diabetic patients on diet 
only might not have had satisfactory glycogenic control. However, BuChE did not show any 
correlation with enzymatic antioxidants SOD and GPX (Omu et al 2010); indirectly showing 
that BuChE was not inhibiting MDA through the antioxidants pathway. While this is mere 
speculation, it has important clinical implication if the association between BuChE and 
glycemic control is confirmed by future research. HbA1c has been used for monitoring 
diabetic control of the last 3 months, maybe BuChE could be used for short term or immediate 
monitoring of glycemic control. BuChE is already a known marker of metabolic syndrome 
(Sridhar et al 2005), and its activity is high in human term placenta (Hahn et al 1993, Lappas et 
al 2010, Omu et al 2010, Simone et al 1994, Sternfield et al 1997). The lower level of placental 
BuChE activity compared with serum, shown in the study may be as a result of a high level of 
fetotoxic agents, including free radicals (oxidative stress), in the placenta that BuChE 
metabolises by hydrolysis.  
7.2 Advanced glycation end-products (AGE), reactive oxygen species (ROS) and 
BuChE  
Glycation reactions lead to the production of reactive oxygen species (ROS), which are harmful 
to cellular metabolism and cause cell damage. There are no research data of any relationship 
between AGE and BuChE activity. While it is highly speculative, BuChE may protect 
pregnancy from the effect of oxidative stress by preventing the (formation) of reactive oxygen 
species formation  by hydrolyzing and inactivating advanced glycation end products 
upstream. This hypothesis is consistent with the finding of lack of correlation between BuChE 
and SOD and GPX (Omu et al 2010). 
8. Gestational diabetes mellitus and BuChE 
Another contributor to toxicant-induced immune dysregulation as a contributor to GDM 
might be that reactive products of inflammation expressed by the maternal immune system 
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in response to paternal antigens adversely affect maternal health in ways that increase 
susceptibility to diabetes, thereby leaving women with naturally lower BuChE levels at 
greater risk for gestational and possibly Type 2 diabetes. The relationship between size of 
activated lymphocyte cohorts and BuChE activity in the RPL versus healthy cohorts  
provides additional support for the hypothesis that both immune activation and BuChE 
activity may be tied to some as-yet-unidentified systemic effector. For example, our 
observation of positive correlation between the frequency of CD3+CD16+CD56+ cells and 
BuChE activity in healthy individuals but not RPL-afflicted subjects would be expected if 
these cells which are often pathogenic, were expanded in response to environmental toxins. 
In the type 2 diabetes mellitus population serum BuChE activity has been correlated with 
insulin sensitivity (r = -0.51, P < 0.001). BuChE activity was elevated in the serum and 
placenta in normal pregnancy versus diabetic cohorts (p < 0.01) and there was a higher 
activity level in gestational and type 2 diabetes on insulin (p < 0.05) compared with diet 
controlled (Omu et al 2010, Mahmoud et al 2003, Mahmoud et al 2006, Mahmoud et al 2008, 
Rustemeijer et al 2001) 
8.1 BuChE and congenital anomalies 
BuChE may also play a significant role in congenital anomalies. Dupont et al. (1995) have 
reported that fetuses with anencephaly and open spinal bifida and gastroschisis revealed 
clearly dense band of BuChE in the amniotic fluid. A causative role for elevated free fatty 
acid (FFA) levels in the development of microvascular complications remains to be 
established, however. Increased levels of FFAs are positively correlated with both insulin 
resistance and the deterioration of ß-cell function in the context of concomitant 
hyperglycemia. These latter effects may result from oxidative stress (Evans et al 2003).  
9. Future directions and hypotheses of connection between BuChE and GDM 
There is need to explore a number of hypotheses to fully unravel the connection between 
GDM and BuChE through aggressive research efforts.  
9.1 Role of estrogen alpha receptor and BuChE in pathogenesis of gestational 
diabetes 
High levels of estrogens in the second half of pregnancy with high estrogen receptor alpha 
(ER ) lead to deterioration of glucose metabolism. Estrogens may reduce the risk of AD 
through enhancing or preserving cholinergic neurotransmission, and aromatase, the 
product of the CYP19 gene, is a critical enzyme in the peripheral synthesis of estrogens. 
There is evidence to suggest that the CYP19 and BuChE polymorphisms may interact in 
determining the risk of AD. Carriers of both the ER-a P/P genotype and the BuChE K 
variant would have decreased risk of developing AD (Conbarros et al 2007). ER alpha 
signaling activity and glucose metabolism may therefore be affected by CYP19 and BuChE 
polymorphisms. 
9.2 Advanced glycation end products hydrolysis by BuChE 
Advanced glycation end products may inhibit BuChE activities, probably as a result of the 
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in response to paternal antigens adversely affect maternal health in ways that increase 
susceptibility to diabetes, thereby leaving women with naturally lower BuChE levels at 
greater risk for gestational and possibly Type 2 diabetes. The relationship between size of 
activated lymphocyte cohorts and BuChE activity in the RPL versus healthy cohorts  
provides additional support for the hypothesis that both immune activation and BuChE 
activity may be tied to some as-yet-unidentified systemic effector. For example, our 
observation of positive correlation between the frequency of CD3+CD16+CD56+ cells and 
BuChE activity in healthy individuals but not RPL-afflicted subjects would be expected if 
these cells which are often pathogenic, were expanded in response to environmental toxins. 
In the type 2 diabetes mellitus population serum BuChE activity has been correlated with 
insulin sensitivity (r = -0.51, P < 0.001). BuChE activity was elevated in the serum and 
placenta in normal pregnancy versus diabetic cohorts (p < 0.01) and there was a higher 
activity level in gestational and type 2 diabetes on insulin (p < 0.05) compared with diet 
controlled (Omu et al 2010, Mahmoud et al 2003, Mahmoud et al 2006, Mahmoud et al 2008, 
Rustemeijer et al 2001) 
8.1 BuChE and congenital anomalies 
BuChE may also play a significant role in congenital anomalies. Dupont et al. (1995) have 
reported that fetuses with anencephaly and open spinal bifida and gastroschisis revealed 
clearly dense band of BuChE in the amniotic fluid. A causative role for elevated free fatty 
acid (FFA) levels in the development of microvascular complications remains to be 
established, however. Increased levels of FFAs are positively correlated with both insulin 
resistance and the deterioration of ß-cell function in the context of concomitant 
hyperglycemia. These latter effects may result from oxidative stress (Evans et al 2003).  
9. Future directions and hypotheses of connection between BuChE and GDM 
There is need to explore a number of hypotheses to fully unravel the connection between 
GDM and BuChE through aggressive research efforts.  
9.1 Role of estrogen alpha receptor and BuChE in pathogenesis of gestational 
diabetes 
High levels of estrogens in the second half of pregnancy with high estrogen receptor alpha 
(ER ) lead to deterioration of glucose metabolism. Estrogens may reduce the risk of AD 
through enhancing or preserving cholinergic neurotransmission, and aromatase, the 
product of the CYP19 gene, is a critical enzyme in the peripheral synthesis of estrogens. 
There is evidence to suggest that the CYP19 and BuChE polymorphisms may interact in 
determining the risk of AD. Carriers of both the ER-a P/P genotype and the BuChE K 
variant would have decreased risk of developing AD (Conbarros et al 2007). ER alpha 
signaling activity and glucose metabolism may therefore be affected by CYP19 and BuChE 
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10. Concluding remarks 
Unraveling the connection between GDM and BuChE has become a veritable area of 
research in the pathogenesis, screening, prevention and management. With the large scale 
purification of BuChE from human plasma, milk of transgenic goats and edible transgenic 
plants and its suitability for prophylactic and therapeutic protection against cocaine and 
nerve agent toxicity, the way for therapeutic use in humans, especially during complicated 
pregnancy needs urgent scientific exploration as BuChE may have an important protective 
role in normal and diabetic pregnancy by reducing oxidative stress and therefore reduce 
diabetes induced complications. Mechanisms for attenuation of the effects of oxidative stress 
by BuChE should be investigated. Heritable factors may be an underlying biological thread 
in the connection between GDM and BuChE. In addition, genetic variants of  BuChE exist, 
which may play a role in biological manifestation of individuals. Identification of such 
sequences would provide leads for further understanding of aetiological, therapeutic or 
prognostic aspects of Gestational diabetes mellitus. If future studies reveal that immune 
dysregulation is a contributor to the pathogenesis of GD or DM, characterization of the 
mechanisms will open additional avenues to development of therapeutic approaches to both 
disorders. 
11. References 
Alcantara VM, Oliveira LC, Rea RR, Suplicy HL, Chautard-Freire-Maia EA. 
Butyrylcholinesterase activity and metabolic syndrome in obese patients. Clin Chem 
Lab Med. 2005;43:285–8.  
American Diabetes Association.  Gestational diabetes mellitus.  Diabetes Care.  2003; 26: 
S103–S105. 
Arkhypova VN.,. Dzyadevychlexey S V,  Soldatkin P,  Korpan Y I. El’skaya  A V, 
Gravoueille J-M, Martelet C and Jaffrezic-Renault N. Application of enzyme field 
effect transistors for fast detection of total glycoalkaloids content in potatoes.  
Sensors and Actuators B: Chemical 2004; 103:  416-422 
Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN and Lockridge O  Structure of the 
gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry 
1990; 29:24-131. 
Baccarelli A, Mocarelli P, Patterson DG, Bonzini M, Pesatori AC, Landi MT: Immunologic 
effects of dioxin: new results from Seveso and comparison with other studies. 
Environ Health Persp 2002; 110:1169–1173. 
Bertazzi PA, Consonni PA, Bachetti S et al. Health effedts of dioxin exposure: a 20 years 
mortality study. Am J Epidemiol 2001; 153: 1031-1044  
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 
414 :813 –820.  
Carine D, Loverco G, Greko P, Capuno F, Scivaggi L. Lipid peroxidation products and 
antioxidant enzymes in red blood cells during normal and diabetic pregnancy. Eur 
J Obstet Gynaecol Reprod Biol 1993; 51: 103-109.2.  
Carmona GN, Schindler CW, Shoaib M, Jufer R, Cone EJ, Goldberg SR, Greig NH, Yu  QS 
and Gorelick DA. Attenuation of cocaine-induced locomotor activity by 
butyrylcholinesterase. Exp Clin Psychopharmacol 1998; 6:274-279. 
 
Unravelling the Connection Between Gestational Diabetes Mellitus and Butyrylcholinesterase 
 
237 
Cederberg J, Siman CM, Eriksson UJ.. Combined treatment with vitamins E and C decrease 
oxidative stress and improves fetal outcome in experimental diabetic pregnancy. 
Pediatric Research 2001; 49: 755–762. 
Chen X, Scholl TO. Oxidative stress: changes in pregnancy and with gestational diabetes  
mellitus. Curr Diab Rep. 2005; 5: 282-288. 
Combarros O, Riancho JA, Arozamena J, Mateo I, Llorca J, Infante J et al. Interaction 
between estrogen receptor-alpha and butyrylcholinesterase genes modulates 
Alzheimer's disease risk. J Neurol. 2007; 254: 1290-1292. 
Cucuianu M. Serum gamma glutamyltransferase and/or serum cholinesterase as markers of 
the metabolic syndrome. Diabetes Care. 1999;22:1381-1382.  
Darvesh S, Hopkins D A. & Geula C. Neurobiology of butyrylcholinesterase    Nature 
Reviews Neuroscience 2003; 4: 131–138. 
Davis L, Britten JJ, Morgan M. Cholinesterase. Its significance in anaesthetic practice. 
Anaesthesia. 1997;52:714   
Delwing D, Chiarani F, Wannmacher CMD, Wajner M, Wyse ATS. Effect of 
hyperprolinemia on acetylcholinesterase and butyrylcholinesterase activities in rat. 
Amino Acids 2005; .28:305–308. 
Dupont M, Vallet B, Brun A, Boulot P, Demaille J. Scanning gel densitometry of amniotic 
fluid acetylcholinesterase and butyrylcholinesterase: quantification of 'faint-
positive' bands in fetal malformations. Biol Neonate. 1995; 67: 244-247 
Ellman GL, Courtney KD, Andres V, Featherstone RM, A new and rapid colorimetric 
determination of Acetycholinesterase activity.  Bioch Pharmacol 1961; 7: 88-95 
Elobeid, M.; Allison, D. "Putative environmental-endocrine disruptors and obesity: a 
review" Current opinion in endocrinology, diabetes, and obesity 2008; 15: 403–408.  
Eskenazi B, Harley K, Bradman A, Weltzien E, Jewell NP, Barr DB, Furlong CE, Holland NT: 
Association of in utero organophosphate pesticide exposure and fetal growth and 
length of gestation in an agricultural population. Environ Health Perspect 2004; 
112:1116–1124. 
Evans J L,  Goldfine I D, Maddux B A, and Grodsky G M.Are Oxidative Stress-Activated 
Signaling Pathways Mediators of Insulin Resistance and ß-Cell Dysfunction? 
Diabetes 2003; 52 :1-8. 
Gabbe SG, Graves CR. Management of diabetes mellitus complicating pregnancy. Obstet 
Gynecol 2003; 102: 857–68.  
Góth L, Eaton JW. Hereditary catalase deficiencies and increased risk of diabetes. Lancet 
2000;356:1820-1821 
Góth L, Tóth Z, Tarnai I, Bérces M, Török  P and Bigler W N. Blood Catalase Activity in 
Gestational Diabetes Is Decreased but Not Associated with Pregnancy 
Complications Clinical Chemistry. 2005;51:2401-2404. 
Goudsouzian NG, d’Hollander AA, Viby-Mogensen J. Prolonged neuromuscular block from 
mivacurium in two patients with cholinesterase deficiency. Anesth Analg. 
1993;77:183–185. 
Grissa O, Atègbo JM, Yessoufou A, Tabka Z, Miled A, Jerbi M, Dramane KL et al. 
Antioxidant status and circulating lipids are altered in human gestational diabetes 





10. Concluding remarks 
Unraveling the connection between GDM and BuChE has become a veritable area of 
research in the pathogenesis, screening, prevention and management. With the large scale 
purification of BuChE from human plasma, milk of transgenic goats and edible transgenic 
plants and its suitability for prophylactic and therapeutic protection against cocaine and 
nerve agent toxicity, the way for therapeutic use in humans, especially during complicated 
pregnancy needs urgent scientific exploration as BuChE may have an important protective 
role in normal and diabetic pregnancy by reducing oxidative stress and therefore reduce 
diabetes induced complications. Mechanisms for attenuation of the effects of oxidative stress 
by BuChE should be investigated. Heritable factors may be an underlying biological thread 
in the connection between GDM and BuChE. In addition, genetic variants of  BuChE exist, 
which may play a role in biological manifestation of individuals. Identification of such 
sequences would provide leads for further understanding of aetiological, therapeutic or 
prognostic aspects of Gestational diabetes mellitus. If future studies reveal that immune 
dysregulation is a contributor to the pathogenesis of GD or DM, characterization of the 
mechanisms will open additional avenues to development of therapeutic approaches to both 
disorders. 
11. References 
Alcantara VM, Oliveira LC, Rea RR, Suplicy HL, Chautard-Freire-Maia EA. 
Butyrylcholinesterase activity and metabolic syndrome in obese patients. Clin Chem 
Lab Med. 2005;43:285–8.  
American Diabetes Association.  Gestational diabetes mellitus.  Diabetes Care.  2003; 26: 
S103–S105. 
Arkhypova VN.,. Dzyadevychlexey S V,  Soldatkin P,  Korpan Y I. El’skaya  A V, 
Gravoueille J-M, Martelet C and Jaffrezic-Renault N. Application of enzyme field 
effect transistors for fast detection of total glycoalkaloids content in potatoes.  
Sensors and Actuators B: Chemical 2004; 103:  416-422 
Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN and Lockridge O  Structure of the 
gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry 
1990; 29:24-131. 
Baccarelli A, Mocarelli P, Patterson DG, Bonzini M, Pesatori AC, Landi MT: Immunologic 
effects of dioxin: new results from Seveso and comparison with other studies. 
Environ Health Persp 2002; 110:1169–1173. 
Bertazzi PA, Consonni PA, Bachetti S et al. Health effedts of dioxin exposure: a 20 years 
mortality study. Am J Epidemiol 2001; 153: 1031-1044  
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 
414 :813 –820.  
Carine D, Loverco G, Greko P, Capuno F, Scivaggi L. Lipid peroxidation products and 
antioxidant enzymes in red blood cells during normal and diabetic pregnancy. Eur 
J Obstet Gynaecol Reprod Biol 1993; 51: 103-109.2.  
Carmona GN, Schindler CW, Shoaib M, Jufer R, Cone EJ, Goldberg SR, Greig NH, Yu  QS 
and Gorelick DA. Attenuation of cocaine-induced locomotor activity by 
butyrylcholinesterase. Exp Clin Psychopharmacol 1998; 6:274-279. 
 
Unravelling the Connection Between Gestational Diabetes Mellitus and Butyrylcholinesterase 
 
237 
Cederberg J, Siman CM, Eriksson UJ.. Combined treatment with vitamins E and C decrease 
oxidative stress and improves fetal outcome in experimental diabetic pregnancy. 
Pediatric Research 2001; 49: 755–762. 
Chen X, Scholl TO. Oxidative stress: changes in pregnancy and with gestational diabetes  
mellitus. Curr Diab Rep. 2005; 5: 282-288. 
Combarros O, Riancho JA, Arozamena J, Mateo I, Llorca J, Infante J et al. Interaction 
between estrogen receptor-alpha and butyrylcholinesterase genes modulates 
Alzheimer's disease risk. J Neurol. 2007; 254: 1290-1292. 
Cucuianu M. Serum gamma glutamyltransferase and/or serum cholinesterase as markers of 
the metabolic syndrome. Diabetes Care. 1999;22:1381-1382.  
Darvesh S, Hopkins D A. & Geula C. Neurobiology of butyrylcholinesterase    Nature 
Reviews Neuroscience 2003; 4: 131–138. 
Davis L, Britten JJ, Morgan M. Cholinesterase. Its significance in anaesthetic practice. 
Anaesthesia. 1997;52:714   
Delwing D, Chiarani F, Wannmacher CMD, Wajner M, Wyse ATS. Effect of 
hyperprolinemia on acetylcholinesterase and butyrylcholinesterase activities in rat. 
Amino Acids 2005; .28:305–308. 
Dupont M, Vallet B, Brun A, Boulot P, Demaille J. Scanning gel densitometry of amniotic 
fluid acetylcholinesterase and butyrylcholinesterase: quantification of 'faint-
positive' bands in fetal malformations. Biol Neonate. 1995; 67: 244-247 
Ellman GL, Courtney KD, Andres V, Featherstone RM, A new and rapid colorimetric 
determination of Acetycholinesterase activity.  Bioch Pharmacol 1961; 7: 88-95 
Elobeid, M.; Allison, D. "Putative environmental-endocrine disruptors and obesity: a 
review" Current opinion in endocrinology, diabetes, and obesity 2008; 15: 403–408.  
Eskenazi B, Harley K, Bradman A, Weltzien E, Jewell NP, Barr DB, Furlong CE, Holland NT: 
Association of in utero organophosphate pesticide exposure and fetal growth and 
length of gestation in an agricultural population. Environ Health Perspect 2004; 
112:1116–1124. 
Evans J L,  Goldfine I D, Maddux B A, and Grodsky G M.Are Oxidative Stress-Activated 
Signaling Pathways Mediators of Insulin Resistance and ß-Cell Dysfunction? 
Diabetes 2003; 52 :1-8. 
Gabbe SG, Graves CR. Management of diabetes mellitus complicating pregnancy. Obstet 
Gynecol 2003; 102: 857–68.  
Góth L, Eaton JW. Hereditary catalase deficiencies and increased risk of diabetes. Lancet 
2000;356:1820-1821 
Góth L, Tóth Z, Tarnai I, Bérces M, Török  P and Bigler W N. Blood Catalase Activity in 
Gestational Diabetes Is Decreased but Not Associated with Pregnancy 
Complications Clinical Chemistry. 2005;51:2401-2404. 
Goudsouzian NG, d’Hollander AA, Viby-Mogensen J. Prolonged neuromuscular block from 
mivacurium in two patients with cholinesterase deficiency. Anesth Analg. 
1993;77:183–185. 
Grissa O, Atègbo JM, Yessoufou A, Tabka Z, Miled A, Jerbi M, Dramane KL et al. 
Antioxidant status and circulating lipids are altered in human gestational diabetes 





Hahn T, Desoye G, Lang I, Skofitsch G. Location and activities of acetylcholinesterase and 
butyrylcholinesterase in the rat and human placenta. Anat Embryol. 1993;188: 435-
40.    
Hollander  MH, Paarlberg  KM, Huisjes  AJ.  Gestational diabetes: a review of the current 
literature and guidelines.  Obstet Gynecol Surv.  2007;62:125–136. 
HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, 
Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy 
outcomes. N Engl J Med 2008;358:1991–2002. 
Janson J, Laedtke T, Parisi JE, Brien PO, Petersen RC, Butler PC: Increased risk of type 2 
diabetes in Alzheimer disease.  Diabetes 2004, 53:474-81]. 
Jensen FS, Viby-Morgensen J, Ostergaard D. Significance of plasma cholinesterase for the 
anaesthetist. Curr Anaesth Crit Care. 1991;2:232–237. 
Johansen AE-M, Nielsen D, Andersen G, Hamid YH, Jensen DP, Glümer C, Drivsholm T, 
Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O: Large-scale studies of the 
functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes 
and insulin secretion. Diabetologia 2004, 47:1437-41.  
Karacay O, Sepici-Dincel A, Karcaaltincaba D, Sahin D, Yalvaç S, Akyol M, Kandemir O, 
Altan N. A quantitative evaluation of total antioxidant status and oxidative stress 
markers in preeclampsia and gestational diabetic patients in 24-36 weeks of 
gestation. Diabetes Res Clin Pract. 2010; 89: 231-8. 
King GL, Loeken MR.Hyperglycemia-induced oxidative stress in diabetic complications. 
Histochem Cell Biol. 2004; 122: 333-8 
Klein-Schwartz W, Anderson B. Analysis of sertraline-only overdoses. Am J Emerg Med. 
1996;14:456–458. 
Kyriakis, J.M., Banerjee, P. Nikolakaki, E., Dai, T., Rubie, E.A., Ahmad, M.F., Avruch, J. and 
Woodgett, J.R.  The stress-activated protein kinase subfamily of c-Jun kinases. 
Nature 1994, 369: 156-60.  
Lappas M, Mitton A, Permezel M. Release of Proinflammatory Cytokines and 8-Isoprostane 
from Placenta, Adipose Tissue, and Skeletal Muscle from Normal Pregnant Women 
and Women with Gestational Diabetes Mellitus. J Endocrinol. 2010; 204; 75-84. 
Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL. Complete amino 
acid sequence of human serum cholinesterase. J Biol Chem. 1987;262:549–557. 
Lockridge O, Schopfer LM, Winger G, Woods JH Large scale purification of 
butyrylcholinesterase from human plasma suitable for injection into monkeys; a 
potential new therapeutic for protection against cocaine and nerve toxicity. Journal 
of Medical Chemical, Biological and Radiological Defense. 2005; 3:1–20. 
Loeken MR. Advances in understanding the molecular causes of diabetes-induced birth 
defects. J Soc Gynecol Investig. 2006;13: 2-10. 
Lynch TJ, Mattes CE, Singh A, Bradley RM, Brady RO, Dretchen KL. Cocaine detoxification 
by human plasma butyrylcholinesterase. Toxicol Appl Pharmacol 1997;145:363–371 
MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its 
profile and use in psychiatric disorders. CNS Drug Rev. 2001;7:1–24. 
Mahmoud F, Haines D, Abul H, Omu A. Butyrylcholinesterase activity and pregnancy-
associated differences in immunologically relevant peripheral blood leukocyte 
populations. . Am J Reprod Immunol. 2003;50:77-82. 
 
Unravelling the Connection Between Gestational Diabetes Mellitus and Butyrylcholinesterase 
 
239 
Mahmoud FF, Haines DD, Abul HT, Omu AE, Abu-Donia MB. Butyrylcholinesterase 
activity in gestational diabetes: correlation with lymphocyte subpopulations in 
peripheral blood. Am J Reprod Immunol. 2006; 56:185-92. 
Mahmoud FF, Abul HT, Haines DD, Omu AE, Diejomaoh M, Wise JA, Abu Donia MB. 
Butyrylcholinesterase activity and lymphocyte subpopulations in peripheral blood 
of Kuwaiti women experiencing recurrent spontaneous abortion. Reprod Immunol. 
2008;77:186-94. 
Marfella R, Quagliaro L, Nappo F,  Ceriello A and Giugliano D. Acute hyperglycemia 
induces an oxidative stress in healthy subjects. J Clin Invest 2001; 108 : 635-636. 
Martin AO, Simpson JL, Ober C, Freinkel N: Frequency of diabetes mellitus in mothers of 
probands with gestational diabetes: possible maternal influence on the 
predisposition to gestational diabetes. Am J Obstet Gynecol 1985; 151:471–475.  
Masson P  A naturally occurring molecular form of human plasma cholinesterase is an 
albumin conjugate. Biochim Biophys Acta 1989; 988:258-266.  
Massoulie´ J, Bon S, Anselmet A, Chatel J-M, Coussen F, Duval N, Krejici E, Legay C, 
Vallette F.Biosynthesis of the molecular forms of acetylcholinesterase. In 
Multidisciplinary Approaches to Cholinesterase Functions, A Shafferman, B Velan 
(eds). New York, Plenum Press, 1992, pp 17–24. 
Mauricio D, de Leiva A. Autoimmune gestational diabetes mellitus: a distinct clinical entity? 
Diabetes Metab Res Rev 2001;17 : 422-2 
Maxwell SRJ, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GHG, Jones AF, 
Barnett AH Antioxidant status in patients with uncomplicated insulin-dependent 
and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997; 27:484–490 
McLellan JA, Barrow BA, Levy JC, Hammersley MS, Hattersley AT, Gillmer MD, Turner RC: 
Prevalence of diabetes mellitus and impaired glucose tolerance in parents of 
women with gestational diabetes. Diabetologia 1995;38: 693–698 
Mendel B. and Rudney H. Cholinesterase and pseudo-cholinesterase. Biochem. J. 1943; 37: 59-
63.  
Metzger BE, Coustan DR, the Organizing Committee. Summary and recommendations of 
the   Fourth International Workshop-Conference on Gestational Diabetes Mellitus. 
Diabetes Care 1998; 21: B161–167 
Morgan SC, Relaix F, Sandell LL, Loeken MR. Oxidative stress during diabetic pregnancy 
disrupts cardiac neural crest migration and causes outflow tract defects. Birth 
Defects Res A Clin Mol Teratol. 2008; 82: 453-63. 
Mueller S, Riedel HD, Stremmer W. Direct evidence for catalase as the predominant H2O2 
removing enzyme in human erythrocytes. Blood 1997; 90: 4973-4978.  
Müller TC, Rocha JB, Morsch VM, Neis RT, Schetinger MR. Antidepressants inhibit human 
acetylcholinesterase and butyrylcholinesterase activity. Biochim Biophys Acta. 
2002;1587:92–98   
Nadal A, Alonso-Magdalena P, Soriano S, Quesada I, Ropero AB. The pancreatic beta-cell as 
a target of estrogens and xenoestrogens: Implications for blood glucose 
homeostasis and diabetes. Mol Cell Endocrinol. 2009; 304: 63-8 
National Institute for Health and Clinical Excellence. NICE clinical guideline 63: Diabetes in 
pregnancy.Management of diabetes and its complications from pre-conception to the 





Hahn T, Desoye G, Lang I, Skofitsch G. Location and activities of acetylcholinesterase and 
butyrylcholinesterase in the rat and human placenta. Anat Embryol. 1993;188: 435-
40.    
Hollander  MH, Paarlberg  KM, Huisjes  AJ.  Gestational diabetes: a review of the current 
literature and guidelines.  Obstet Gynecol Surv.  2007;62:125–136. 
HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, 
Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy 
outcomes. N Engl J Med 2008;358:1991–2002. 
Janson J, Laedtke T, Parisi JE, Brien PO, Petersen RC, Butler PC: Increased risk of type 2 
diabetes in Alzheimer disease.  Diabetes 2004, 53:474-81]. 
Jensen FS, Viby-Morgensen J, Ostergaard D. Significance of plasma cholinesterase for the 
anaesthetist. Curr Anaesth Crit Care. 1991;2:232–237. 
Johansen AE-M, Nielsen D, Andersen G, Hamid YH, Jensen DP, Glümer C, Drivsholm T, 
Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O: Large-scale studies of the 
functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes 
and insulin secretion. Diabetologia 2004, 47:1437-41.  
Karacay O, Sepici-Dincel A, Karcaaltincaba D, Sahin D, Yalvaç S, Akyol M, Kandemir O, 
Altan N. A quantitative evaluation of total antioxidant status and oxidative stress 
markers in preeclampsia and gestational diabetic patients in 24-36 weeks of 
gestation. Diabetes Res Clin Pract. 2010; 89: 231-8. 
King GL, Loeken MR.Hyperglycemia-induced oxidative stress in diabetic complications. 
Histochem Cell Biol. 2004; 122: 333-8 
Klein-Schwartz W, Anderson B. Analysis of sertraline-only overdoses. Am J Emerg Med. 
1996;14:456–458. 
Kyriakis, J.M., Banerjee, P. Nikolakaki, E., Dai, T., Rubie, E.A., Ahmad, M.F., Avruch, J. and 
Woodgett, J.R.  The stress-activated protein kinase subfamily of c-Jun kinases. 
Nature 1994, 369: 156-60.  
Lappas M, Mitton A, Permezel M. Release of Proinflammatory Cytokines and 8-Isoprostane 
from Placenta, Adipose Tissue, and Skeletal Muscle from Normal Pregnant Women 
and Women with Gestational Diabetes Mellitus. J Endocrinol. 2010; 204; 75-84. 
Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL. Complete amino 
acid sequence of human serum cholinesterase. J Biol Chem. 1987;262:549–557. 
Lockridge O, Schopfer LM, Winger G, Woods JH Large scale purification of 
butyrylcholinesterase from human plasma suitable for injection into monkeys; a 
potential new therapeutic for protection against cocaine and nerve toxicity. Journal 
of Medical Chemical, Biological and Radiological Defense. 2005; 3:1–20. 
Loeken MR. Advances in understanding the molecular causes of diabetes-induced birth 
defects. J Soc Gynecol Investig. 2006;13: 2-10. 
Lynch TJ, Mattes CE, Singh A, Bradley RM, Brady RO, Dretchen KL. Cocaine detoxification 
by human plasma butyrylcholinesterase. Toxicol Appl Pharmacol 1997;145:363–371 
MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its 
profile and use in psychiatric disorders. CNS Drug Rev. 2001;7:1–24. 
Mahmoud F, Haines D, Abul H, Omu A. Butyrylcholinesterase activity and pregnancy-
associated differences in immunologically relevant peripheral blood leukocyte 
populations. . Am J Reprod Immunol. 2003;50:77-82. 
 
Unravelling the Connection Between Gestational Diabetes Mellitus and Butyrylcholinesterase 
 
239 
Mahmoud FF, Haines DD, Abul HT, Omu AE, Abu-Donia MB. Butyrylcholinesterase 
activity in gestational diabetes: correlation with lymphocyte subpopulations in 
peripheral blood. Am J Reprod Immunol. 2006; 56:185-92. 
Mahmoud FF, Abul HT, Haines DD, Omu AE, Diejomaoh M, Wise JA, Abu Donia MB. 
Butyrylcholinesterase activity and lymphocyte subpopulations in peripheral blood 
of Kuwaiti women experiencing recurrent spontaneous abortion. Reprod Immunol. 
2008;77:186-94. 
Marfella R, Quagliaro L, Nappo F,  Ceriello A and Giugliano D. Acute hyperglycemia 
induces an oxidative stress in healthy subjects. J Clin Invest 2001; 108 : 635-636. 
Martin AO, Simpson JL, Ober C, Freinkel N: Frequency of diabetes mellitus in mothers of 
probands with gestational diabetes: possible maternal influence on the 
predisposition to gestational diabetes. Am J Obstet Gynecol 1985; 151:471–475.  
Masson P  A naturally occurring molecular form of human plasma cholinesterase is an 
albumin conjugate. Biochim Biophys Acta 1989; 988:258-266.  
Massoulie´ J, Bon S, Anselmet A, Chatel J-M, Coussen F, Duval N, Krejici E, Legay C, 
Vallette F.Biosynthesis of the molecular forms of acetylcholinesterase. In 
Multidisciplinary Approaches to Cholinesterase Functions, A Shafferman, B Velan 
(eds). New York, Plenum Press, 1992, pp 17–24. 
Mauricio D, de Leiva A. Autoimmune gestational diabetes mellitus: a distinct clinical entity? 
Diabetes Metab Res Rev 2001;17 : 422-2 
Maxwell SRJ, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GHG, Jones AF, 
Barnett AH Antioxidant status in patients with uncomplicated insulin-dependent 
and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997; 27:484–490 
McLellan JA, Barrow BA, Levy JC, Hammersley MS, Hattersley AT, Gillmer MD, Turner RC: 
Prevalence of diabetes mellitus and impaired glucose tolerance in parents of 
women with gestational diabetes. Diabetologia 1995;38: 693–698 
Mendel B. and Rudney H. Cholinesterase and pseudo-cholinesterase. Biochem. J. 1943; 37: 59-
63.  
Metzger BE, Coustan DR, the Organizing Committee. Summary and recommendations of 
the   Fourth International Workshop-Conference on Gestational Diabetes Mellitus. 
Diabetes Care 1998; 21: B161–167 
Morgan SC, Relaix F, Sandell LL, Loeken MR. Oxidative stress during diabetic pregnancy 
disrupts cardiac neural crest migration and causes outflow tract defects. Birth 
Defects Res A Clin Mol Teratol. 2008; 82: 453-63. 
Mueller S, Riedel HD, Stremmer W. Direct evidence for catalase as the predominant H2O2 
removing enzyme in human erythrocytes. Blood 1997; 90: 4973-4978.  
Müller TC, Rocha JB, Morsch VM, Neis RT, Schetinger MR. Antidepressants inhibit human 
acetylcholinesterase and butyrylcholinesterase activity. Biochim Biophys Acta. 
2002;1587:92–98   
Nadal A, Alonso-Magdalena P, Soriano S, Quesada I, Ropero AB. The pancreatic beta-cell as 
a target of estrogens and xenoestrogens: Implications for blood glucose 
homeostasis and diabetes. Mol Cell Endocrinol. 2009; 304: 63-8 
National Institute for Health and Clinical Excellence. NICE clinical guideline 63: Diabetes in 
pregnancy.Management of diabetes and its complications from pre-conception to the 





Newbold R.; Padilla-Banks E.; Jefferson W. "Environmental estrogens and obesity". 
Molecular and cellular endocrinology 2009; 304: 84–89.  
Ober C, Xiang KS, Thisted RA, Indovina KA, Wason CJ, Dooley S: Increased risk for 
gestational diabetes mellitus associated with insulin receptor and insulin-like 
growth factor II restriction fragment length polymorphisms. Genet Epidemiol 1989; 
6:559–56.  
Om A, Ellahham S, Ornato JP, Picone C, Theogaraj J, Corretjer GP, Vetrovec GW. Medical 
complications of cocaine: Possible relationship to low plasma cholinesterase 
enzyme. Am Heart J 1993; 125:1114–1117 
Omu AE, Al-Azemi MK, Omu FE, Fatinikun T, Abraham S, George S, Mahnazhath N. 
Butyrylcholinesterase activity in women with diabetes mellitus in pregnancy: 
correlation with antioxidant activity. J Obstet Gynaecol. 2010; 30:122-6. 
Osawa T, Kato Y. Protective role of antioxidative food factors in oxidative stress caused by 
hyperglycemia. Ann N Y Acad Sci. 2005; 1043:440-51. 
Ostergaard D, Viby-Mogensen J, Hanel HK, Skovgaard LT. . Halflife of plasma 
cholinesterase. Acta Anaesthesiol Scand. 1988; 32:266–2696.  
Paloma A M, Ropero A B, Carrera M. P,. Cederroth C R,  Baquié M, Gauthier B R., Nef S, 
Stefani E and Nadal A.  Pancreatic Insulin Content Regulation by the Estrogen 
Receptor ERα. PLoS ONE. 2008; 3: e2069.  
Pantuck EJ. Plasma cholinesterase: gene and variations.  Anesth Analg. 1993 ;77:380-86. 
Petersen RS, Bailey PL, Kalameghan R, Ashwood ER. Prolonged neuromuscular block after 
mivacurium. Anesth Analg. 1993;76:194–196.  
Podoly E, Bruck T, Diamant S, Melamed-Book N, Weiss A, Huang Y, Livnah O, 
Langermann S, Wilgus H, Soreq. Human recombinant butyrylcholinesterase 
purified from the milk of transgenic goats interacts with beta-amyloid fibrils and 
suppresses their formation in vitro. Neurodegener Dis. 2008;5: 232-6. 
Protexia -Gene-Delivered Butyrylcholinesterase Is Prophylactic against the Toxicity of 
Chemical Warfare Nerve Agents and Organophosphorus Compounds J. Pharmacol. 
Exp. Ther. 2011: 337; 92-101  
Randell EW, Mathews MS, Zhang H, Seraj JS, Sun G. Relationship between serum   
butyrylcholinesterase and the metabolic syndrome. Clin Biochem. 2005;38:799–805. 
Rao A A, Sridhar G R, Thota H, Babu C S, Prasad A S, Divakar C. Alzheimer's disease and 
Type 2 diabetes mellitus: the cholinesterase connection?  Lipids in Health and Disease 
2006, 5:28-34. 
RCOG Scientific Advisory Committee Opinion Paper 23: Diagnosis and Treatment of 
Gestational Diabetes. January 2011. 
Remillard RBJ, Bunce NJ. Linking Dioxins to Diabetes: Epidemiology and Biologic 
Plausibility. Environ Health Perspect 2002; 110:853-858. 
Ropero AB, Alonso-Magdalena P, Quesada I, Nadal A. The role of estrogen receptors in the 
control of energy and glucose homeostasis. Steroids.2008.; 73; 874-79. 
Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L: The role of oxidative stress 
in  the onset and progression of diabetes and its complications: a summary of a 
Congress Series sponsored by UNESCO-MCBN, the American Diabetes 
Association, and the German Diabetes Society. Diabetes Metab Res Rev 2001;17 :189 –
212,  
 
Unravelling the Connection Between Gestational Diabetes Mellitus and Butyrylcholinesterase 
 
241 
Rubin B, Soto A. "Bisphenol A: Perinatal exposure and body weight". Molecular and cellular 
endocrinology 2009; 304: 55–62.  
Rustemeijer C, Schouten JA, Voerman HJ, Beynen AC, Donker AJM, Heines, RJ. Is 
pseudocholinesterase activity related to markers of triacylglycerol synthesis in type 
II diabetes mellitus? Clin Sci 2001;101:29-35  
Saito S, Sasaki Y, Sakai M. CD4(+)CD25 high regulatory T cells in human pregnancy. J 
Reprod Immunol. 2005; 65:111–120. 
Savarese JJ, Lien CA, Belmont MR, Wastila WB. The clinical pharmacology of new 
benzylisoquinoline-diester compounds. with special consideration of cisatracurium 
and mivacurium. Anesthetist. 1997;46:840–849 
Serlin DC and. Lash, R W. Diagnosis and Management of Gestational Diabetes Mellitus. Am 
Fam Physician. 2009 ; 80: 57-62. 
Simone C, Derewlany LO, OskampM, Johnson D, Knie B, Koren GAcetylcholinesterase and 
butyrylcholinesterase activity in the human term placenta: implications for fetal 
cocaine exposure. Journal of Laboratory and Clinical Medicine. 1994.  123: 400–406 
Sindhu RK, Koo JR, Roberts CK, Vazioori ND. Dysregulation of hepatic superoxide 
dismutase, catalase, and glutathione peroxidase in diabetes: responses to insulin 
and antioxidant therapies. Clin Exp Hypertens 2004;26:43-53 
Souza RLR, Mikami LR, Maegawa ROB and Chautard-Freire-Maia EA Four new mutations 
in the BCHE gene of butyrylcholinesterase in a Brazilian blood donor sample. Mol 
Genet Metab 2005; 84:349-353.   
Sridhar GR, Nirmala G, Apparao A, Madhavi AS, Sreelatha S, Rani J S and Vijayalakshmi P 
Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and 
bioinformatics approach. Lipids Health Dis. 2005; 4: 18-.  
Stefanello FM, Franzon R, Tagliari B, Wannmacher C, Wajner M, Wyse AT. Reduction of 
butyrylcholinesterase activity in rat serum subjected to Hyperhomocysteinemia. 
Metabolic Brain Disease 2005; 20:97–103. 
Sternfeld M, Ben-Ari S, Rachmilewitz J, Glick C, Loewenstein-Lichtenstein Y, Soreq H, 
Andres C, Zakut H, Timberg R: Normal and atypical butyrylcholinesterases in 
placental development, function, and malfunction. Cell & Mol Neurobiol 1997; 
17:315–332. 
Twardowska-Saucha K, Grzeszczak W, Lacka B, Frehlich J, Krywult D. Lipid peroxidation, 
antioxidant enzyme activity and trace element concentration in II and III trimesters 
of pregnancy in pregnant women with diabetes. Poskie Archiwum Medycyny 
Wewnetrzne j. 1994; .92: 313-21. 
Vrdoljaki A L, Bradamante V, Radi B, Peraica M, Fuchs R, Reine E. Butyrylcholinesterase  
activity and plasma lipids in dexamethasone treated rats Acta Pharm 2005; 55:  177–
185. 
Watanabe R M, Black M H, Xiang A H., Allayee H,  Lawrence J M., Buchanan T A. Genetics 
of Gestational Diabetes Mellitus and Type 2 Diabetes. Diabetes Care 2007; 30: S134-
S140  
Wender-Ozegowska E, Kozlik J, Biczysko R, Ozegowski S. Changes of Oxidative Stress          
Parameters in Diabetic Pregnancy. Free Radical Research,  2004; 38 : 795-803. 
World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its 
complications. Report of a WHO consultation. Part 1. Diagnosis and classification of 





Newbold R.; Padilla-Banks E.; Jefferson W. "Environmental estrogens and obesity". 
Molecular and cellular endocrinology 2009; 304: 84–89.  
Ober C, Xiang KS, Thisted RA, Indovina KA, Wason CJ, Dooley S: Increased risk for 
gestational diabetes mellitus associated with insulin receptor and insulin-like 
growth factor II restriction fragment length polymorphisms. Genet Epidemiol 1989; 
6:559–56.  
Om A, Ellahham S, Ornato JP, Picone C, Theogaraj J, Corretjer GP, Vetrovec GW. Medical 
complications of cocaine: Possible relationship to low plasma cholinesterase 
enzyme. Am Heart J 1993; 125:1114–1117 
Omu AE, Al-Azemi MK, Omu FE, Fatinikun T, Abraham S, George S, Mahnazhath N. 
Butyrylcholinesterase activity in women with diabetes mellitus in pregnancy: 
correlation with antioxidant activity. J Obstet Gynaecol. 2010; 30:122-6. 
Osawa T, Kato Y. Protective role of antioxidative food factors in oxidative stress caused by 
hyperglycemia. Ann N Y Acad Sci. 2005; 1043:440-51. 
Ostergaard D, Viby-Mogensen J, Hanel HK, Skovgaard LT. . Halflife of plasma 
cholinesterase. Acta Anaesthesiol Scand. 1988; 32:266–2696.  
Paloma A M, Ropero A B, Carrera M. P,. Cederroth C R,  Baquié M, Gauthier B R., Nef S, 
Stefani E and Nadal A.  Pancreatic Insulin Content Regulation by the Estrogen 
Receptor ERα. PLoS ONE. 2008; 3: e2069.  
Pantuck EJ. Plasma cholinesterase: gene and variations.  Anesth Analg. 1993 ;77:380-86. 
Petersen RS, Bailey PL, Kalameghan R, Ashwood ER. Prolonged neuromuscular block after 
mivacurium. Anesth Analg. 1993;76:194–196.  
Podoly E, Bruck T, Diamant S, Melamed-Book N, Weiss A, Huang Y, Livnah O, 
Langermann S, Wilgus H, Soreq. Human recombinant butyrylcholinesterase 
purified from the milk of transgenic goats interacts with beta-amyloid fibrils and 
suppresses their formation in vitro. Neurodegener Dis. 2008;5: 232-6. 
Protexia -Gene-Delivered Butyrylcholinesterase Is Prophylactic against the Toxicity of 
Chemical Warfare Nerve Agents and Organophosphorus Compounds J. Pharmacol. 
Exp. Ther. 2011: 337; 92-101  
Randell EW, Mathews MS, Zhang H, Seraj JS, Sun G. Relationship between serum   
butyrylcholinesterase and the metabolic syndrome. Clin Biochem. 2005;38:799–805. 
Rao A A, Sridhar G R, Thota H, Babu C S, Prasad A S, Divakar C. Alzheimer's disease and 
Type 2 diabetes mellitus: the cholinesterase connection?  Lipids in Health and Disease 
2006, 5:28-34. 
RCOG Scientific Advisory Committee Opinion Paper 23: Diagnosis and Treatment of 
Gestational Diabetes. January 2011. 
Remillard RBJ, Bunce NJ. Linking Dioxins to Diabetes: Epidemiology and Biologic 
Plausibility. Environ Health Perspect 2002; 110:853-858. 
Ropero AB, Alonso-Magdalena P, Quesada I, Nadal A. The role of estrogen receptors in the 
control of energy and glucose homeostasis. Steroids.2008.; 73; 874-79. 
Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L: The role of oxidative stress 
in  the onset and progression of diabetes and its complications: a summary of a 
Congress Series sponsored by UNESCO-MCBN, the American Diabetes 
Association, and the German Diabetes Society. Diabetes Metab Res Rev 2001;17 :189 –
212,  
 
Unravelling the Connection Between Gestational Diabetes Mellitus and Butyrylcholinesterase 
 
241 
Rubin B, Soto A. "Bisphenol A: Perinatal exposure and body weight". Molecular and cellular 
endocrinology 2009; 304: 55–62.  
Rustemeijer C, Schouten JA, Voerman HJ, Beynen AC, Donker AJM, Heines, RJ. Is 
pseudocholinesterase activity related to markers of triacylglycerol synthesis in type 
II diabetes mellitus? Clin Sci 2001;101:29-35  
Saito S, Sasaki Y, Sakai M. CD4(+)CD25 high regulatory T cells in human pregnancy. J 
Reprod Immunol. 2005; 65:111–120. 
Savarese JJ, Lien CA, Belmont MR, Wastila WB. The clinical pharmacology of new 
benzylisoquinoline-diester compounds. with special consideration of cisatracurium 
and mivacurium. Anesthetist. 1997;46:840–849 
Serlin DC and. Lash, R W. Diagnosis and Management of Gestational Diabetes Mellitus. Am 
Fam Physician. 2009 ; 80: 57-62. 
Simone C, Derewlany LO, OskampM, Johnson D, Knie B, Koren GAcetylcholinesterase and 
butyrylcholinesterase activity in the human term placenta: implications for fetal 
cocaine exposure. Journal of Laboratory and Clinical Medicine. 1994.  123: 400–406 
Sindhu RK, Koo JR, Roberts CK, Vazioori ND. Dysregulation of hepatic superoxide 
dismutase, catalase, and glutathione peroxidase in diabetes: responses to insulin 
and antioxidant therapies. Clin Exp Hypertens 2004;26:43-53 
Souza RLR, Mikami LR, Maegawa ROB and Chautard-Freire-Maia EA Four new mutations 
in the BCHE gene of butyrylcholinesterase in a Brazilian blood donor sample. Mol 
Genet Metab 2005; 84:349-353.   
Sridhar GR, Nirmala G, Apparao A, Madhavi AS, Sreelatha S, Rani J S and Vijayalakshmi P 
Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and 
bioinformatics approach. Lipids Health Dis. 2005; 4: 18-.  
Stefanello FM, Franzon R, Tagliari B, Wannmacher C, Wajner M, Wyse AT. Reduction of 
butyrylcholinesterase activity in rat serum subjected to Hyperhomocysteinemia. 
Metabolic Brain Disease 2005; 20:97–103. 
Sternfeld M, Ben-Ari S, Rachmilewitz J, Glick C, Loewenstein-Lichtenstein Y, Soreq H, 
Andres C, Zakut H, Timberg R: Normal and atypical butyrylcholinesterases in 
placental development, function, and malfunction. Cell & Mol Neurobiol 1997; 
17:315–332. 
Twardowska-Saucha K, Grzeszczak W, Lacka B, Frehlich J, Krywult D. Lipid peroxidation, 
antioxidant enzyme activity and trace element concentration in II and III trimesters 
of pregnancy in pregnant women with diabetes. Poskie Archiwum Medycyny 
Wewnetrzne j. 1994; .92: 313-21. 
Vrdoljaki A L, Bradamante V, Radi B, Peraica M, Fuchs R, Reine E. Butyrylcholinesterase  
activity and plasma lipids in dexamethasone treated rats Acta Pharm 2005; 55:  177–
185. 
Watanabe R M, Black M H, Xiang A H., Allayee H,  Lawrence J M., Buchanan T A. Genetics 
of Gestational Diabetes Mellitus and Type 2 Diabetes. Diabetes Care 2007; 30: S134-
S140  
Wender-Ozegowska E, Kozlik J, Biczysko R, Ozegowski S. Changes of Oxidative Stress          
Parameters in Diabetic Pregnancy. Free Radical Research,  2004; 38 : 795-803. 
World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its 
complications. Report of a WHO consultation. Part 1. Diagnosis and classification of 





Wyse ATS, Stefanello FM, Chiarani F, Delwing D, Wannmacher CMD, Wajner M. Arginine 
administration decreases cerebral cortex acetylcholinesterase and serum 
butyrylcholinesterase by oxidative stress induction. Neurochemical Research 2004; 
.29:385–389. 
Yogev, Y. & Visser, G. Obesity, gestational diabetes and pregnancy outcome. Seminars in 
Fetal & Neonatal Medicine 2009, 14, 77-84 
Zachara BA, Wardak C, Didkowski W, Maciage A, Marchaluk E. Changes in blood selenium 
and glutathione peroxidase concentrations and glutathione peroxidase activity in 
human pregnancy. Gynecol Obstet Invest 1993; 35: 12-17.  
13 
Gestational Hyperglycemia,  
Excessive Pregnancy Weight  
Gain and Risk of Fetal Overgrowth   
Xinhua Chen, Theresa O. Scholl,  
Robert A. Steer and T. Peter Stein  
University of Medicine and Dentistry of  
New Jersey – School of Osteopathic Medicine 
USA 
1. Introduction  
Between 1989 and 2004 the prevalence of gestational diabetes mellitus (GDM) in the US 
increased from 1.9% to 4.2% in parallel with the well documented obesity epidemic 
(Getahun et al., 2008; Mokdad et al., 2001). However, an additional 9-20% of pregnant 
women, with a milder form of glucose intolerance which does not meet the diagnostic 
criteria for GDM, may also be at risk of type 2 diabetes, cardiovascular disease and 
problems while pregnant (Stamilio et al., 2004; Mello et al., 1997; Bo et al., 2004; Nordin  
et al., 2006). 
Fetal overgrowth, defined as macrosomia (birth weight >4000g) or large-for-gestational-age 
birth (LGA, birth weight >90th percentile for a given gestational age) increases maternal 
morbidity from operative delivery and also causes serious consequences to the offspring 
including birth trauma, obesity during childhood and type 2 diabetes and metabolic 
syndrome in adult life (Boney et al., 2005; Zhang & Bowes, 1995; Langer, 2000). 
GDM and excessive pregnancy weight gain, especially in obese women are known risk 
factors for fetal overgrowth (Ray et al., 2001; Hillier et al., 2008). Although previous research 
has suggested that metabolic abnormalities are also present in pregnant women with less 
severe hyperglycemia, the clinical implications of milder maternal hyperglycemia are poorly 
described (Chen et al., 2010; Cheng et al., 2006; Nordin et al., 2006).   
The primary objective of this chapter is to use prospective data from a population of low 
income and minority women to examine (i) the influence of maternal hyperglycemia 
including GDM and less severe maternal hyperglycemia on risk of fetal overgrowth; (ii) the 
association of longitudinally measured excessive pregnancy weight gain with risk of fetal 
overgrowth (IOM, 2009); (iii) the independent contribution of gestational hyperglycemia 
and excessive pregnancy weight gain to fetal overgrowth.  
Because gestational hyperglycemia and excess weight gain during pregnancy are preventable 
risk factors, early detection and treatment of mild hyperglycemia and monitoring pregnancy 
weight gain may be important for reducing the risk of LGA, for reducing childhood and later 
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2. Maternal hyperglycemia and fetal overgrowth 
2.1 Fetal overgrowth 
Fetal growth is dependent on the capacity of mother to supply nutrients and also on the 
capacity of the placenta to transfer these nutrients to the fetus (Oken & Gillman., 2003; 
Ehrenberg et al., 2004). Maternal factors including parity, length of gestation, mother’s adult 
size, and mother’s own birth weight are strongly related to fetal growth and development 
(Langer, 2000). The prevalence of fetal overgrowth was reported as 8-16% from women 
without GDM and 15-40% from women with gestational hyperglycemia (Mello et al., 1997; 
Ostlund et al., 2003; Bo et al., 2004; Gruendhammer et al., 2003).  
2.2 GDM and fetal overgrowth 
Despite different diagnostic criteria, many studies confirmed that GDM increases the risk of 
macrosomia or LGA birth (Ricart et al., 2005; Ray et al., 2001; Ehrenberg et al., 2004). 
Maternal hyperglycemia increases fetal growth via delivery of excess maternal plasma 
glucose to the fetus, which results in fetal hyperinsulinemia and promotes fetal overgrowth 
(HAPO, 2008; Oken & Gillman., 2003). GDM women undergoing intensive diabetic care had 
similar neonatal birth weights and macrosomia rates compared to non-GDM women 
(Ogonowski et al., 2008) and a clinical trial of continuous glucose monitoring in GDM 
resulted in a significant improvement in infant birth weight with a  reduced risk of 
macrosomia (Murphy et al., 2008).  
2.3 Significance of mild gestational hyperglycemia and LGA birth 
2.3.1 Prevalence of mild gestational hyperglycemia 
Recent studies have paid more attention to pregnancy outcomes of women with gestational 
hyperglycemia less severe than overt GDM. The prevalence of mild hyperglycemia (defined 
as abnormal plasma glucose concentration during glucose challenge test with a diagnostic 
oral glucose tolerance test (OGTT) that did not meet the criteria of GDM) in women 
screened for GDM was 32% in Caucasian women (Mello et al, 1997), 25% in Mexican-
Americans (Yogev et al, 2004) and 9% in multiethnic US population where 70% were African 
American (Stamilio et al., 2004). The relatively high prevalence of less severe maternal 
hyperglycemia raises important questions about effects on the fetus since these women are 
not provided the usual diabetic care for GDM. 
2.3.2 The impact of mild gestational hyperglycemia on fetal overgrowth is 
inconsistent  
Studies suggest that an impaired maternal OGTT is associated with adverse maternal-fetal 
outcomes especially risk of macrosomia and LGA birth (Vambergue et al., 2000; Ostlund et 
al., 2003). The degree of maternal glucose intolerance was associated with a graded increase 
in the incidence of fetal macrosomia (Sermer et al., 1995). Moreover, the recent 
hyperglycemia and adverse pregnancy outcome study (HAPO) found a strong association 
of maternal glucose concentrations below levels diagnostic of diabetes with increased infant 
birth weight (HAPO, 2008), but others found no significant increase in the risk of LGA in 
mildly hyperglycemic women (Nordin et al., 2006;  Gruendhammer et al., 2003). Bo et al 
suggested that metabolic syndrome in mid-pregnancy might be an independent predictor of 
macrosomia in women with some degree of gestational hyperglycemia, including GDM and 
mild hyperglycemia without GDM (Bo et al., 2004).  
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Conflicting data on mild hyperglycemia and fetal overgrowth can be, at least in part, due to 
the different population studied and the criteria used for mild hyperglycemia. Although the 
HAPO study included multiple countries and populations and had a large sample size, it 
was focused on developing an international consensus for the diagnosis and treatment of 
carbohydrate intolerance during pregnancy, and was not designed to compare the 
difference in LGA between GDM and less severe hyperglycemic pregnancies (HAPO, 2008). 
Thus, to establish the risk of adverse fetal outcomes in relation to milder degrees of maternal 
hyperglycemia is clinically important, particularly in high risk US populations.    
2.4 The Camden study 
Camden Study is a prospective cohort study of pregnancy outcome and complications in 
young, generally healthy women residing in one of the poorest cities in the continental 
United States (Webster & Bishaw, 2006). Women with serious non-obstetric problems (e.g., 
Lupus, type 1 or 2 diabetes, seizure disorders, malignancies, acute or chronic liver disease, 
drug or alcohol abuse and psychiatric problems) were excluded from participation. The 
sample for this analysis totaled 2,373 pregnant women with live births who enrolled 
between 1996-2006.  
2.4.1 Definition of GDM and mild hyperglycemia non-GDM in Camden study 
The diagnosis of GDM was made using a two-step approach. All participants were initially 
screened by measuring the plasma glucose concentration 1h after a 50-g oral glucose challenge 
test (GCT) at 28±0.1 (mean±SE) weeks’ gestation. A diagnostic OGTT was performed on that 
subset of women exceeding the glucose threshold value (>140 mg/dl). The diagnostic criteria 
for GDM was the Carpenter/Coustan conversion as recommended by the American Diabetes 
Association (ADA) which defines GDM by two or more glucose values over the cut points of 
95,180,155,140 mg/dl at fasting, 1, 2, and 3 hours during a 100g OGTT (American Diabetes 
Association, 2000). Women with a positive GCT and fewer than two abnormal glucose values 
were identified as having an impaired GCT without GDM (impaired GCT non-GDM). All of 
patients diagnosed with GDM obtained dietary counseling and/or insulin treatment for their 
glycemic control; patients with impaired CGT non-GDM were untreated. 
We identified 2,092 women (88.1%) with normal GCT, 182 women (7.7%) with impaired 
GCT non-GDM and 99 women (4.2%) with GDM (table 1). Ethnic composition of the cohort 
was 46% Hispanic, 37.6% African American and 16.6% Caucasian plus others. When the 
maternal characteristics were rank ordered with respect to glucose tolerance status, older 
maternal age, higher pre-pregnant body mass index (BMI), obesity and prior history of 
GDM, all were found to be positively associated with maternal glycemic status (normal 
GCT, impaired GCT non-GDM or GDM) and represented a linear increasing trend in terms 
of severity (p for trend <0.001 for each). 
2.4.2 Maternal hyperglycemia and LGA birth 
LGA is defined as a neonatal birth weight greater than the 90th percentile for gestational age 
that has been adjusted for ethnicity, parity and infant sex (Zhang & Bowes, 1995). Women 
with GDM or impaired GCT without GDM had a ~2-fold increased risk for bearing an LGA 
infant as compared to women with normal GCT (table 2, model 1) after controlling for 
maternal confounding variables and using a standard which adjusted LGA for maternal 
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N (%) 2373 (100) 2092 (88.1) 182 (7.7) 99 (4.2) 
Age (yr)1 22.1±0.1 21.7±0.1 24.4±0.4 26.3±0.6 
Pre-pregnant BMI (kg/m2)1 25.7±0.1 25.4±0.1 26.6±0.5 29.8±0.8 
BMI categories1  
<18.5 146 (6.2) 141   (6.7) 5   (2.8) 0 
18.5-24.9 1157 (48.8) 1050 (50.2) 82 (45.1) 25 (25.3) 
25-29.9 587   (24.7) 503 (24.0) 50 (27.5) 34 (34.3) 
≥30 483 (20.4) 398 (19.0) 45 (24.7) 40 (40.0) 
Cigarette smoking 440 (18.5) 381(18.2) 39 (21.4) 20 (20.2) 
Ethnicity2  
Hispanic 1089 (45.9) 949 (45.4) 82 (45.0) 58 (58.6) 
African American 891(37.6) 803 (38.4) 67 (36.8) 21 (21.2) 
Caucasian & other 393 (16.6) 340 (16.3) 33 (18.1) 20 (20.2) 
Medicaid  2323 (97.9) 2047 (97.9) 178 (97.8) 98 (99.0) 
Prior GDM in multiparas1 33 (1.4) 15 (0.7) 8  (4.4) 10 (10.0) 
Primiparas2 923 (38.9) 833 (39.8) 60 (33.0) 30 (30.3) 
Data are mean ± SE or n (%). 
Normal GCT, during a glucose challenge test, glucose ≤140mg/dl; Impaired GCT non-GDM, glucose 
>140mg/dl during a glucose challenge test and non-GDM; GDM, gestational diabetes mellitus (same in 
tables 2,4,5). 
1. p for linear contrasts among groups <0.001 from ANOVA, or Mantel-Haenszel chi-square test; 
2. p for linear contrasts among groups <0.05 from Mantel-Haenszel chi-square test. 
Table 1. Characteristics of Study Participants  
for pre-pregnant BMI and net maternal weight gain (net weight gain=total weight gain- 
infant birth weight) in women with impaired GCT non-GDM (Table 2, model 2), but it was 
non-significant in women with GDM. 
 
  LGA AOR (95% CI)1 
 N Unadjusted  % Model 1
2 Model 23 
GDM 99 10.1 2.05 (1.03, 4.10) 1.52 (0.74, 3.13) 
Impaired GCT non-GDM 182 12.1 2.48 (1.50, 4.09) 2.50 (1.50, 4.14) 
Normal GCT 2092 5.3 Reference Reference 
LGA, large-for-gestational age infant; AOR, adjusted odds ratio; 95% CI, 95% confidence interval (same 
as in tables 4-5). 
1 p for linear trend <0.01. 
2 Model 1 was adjusted for age and cigarette smoking in addition to using a standard which adjusted 
LGA for maternal ethnicity, parity and fetal gender. 
3 Model 2 was adjusted for all variables in model 1 with additional adjustment for pre-pregnant BMI 
and net of weight gain (kg) during pregnancy. 
Table 2. Maternal Hyperglycemia and LGA birth 
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2.4.3 What do we learn from the Camden study? 
Complicating the interpretation of previous studies has been the inability to adjust the 
observations for important factors related to fetal growth such as pre-pregnant obesity or 
gestational weight gain, often because the data were not available (Hillier et al., 2008; 
Rosenberg et al., 2005; Aberg et al., 2001). Our study in Camden also differs because of the 
inclusion of several ethnic groups (Vambergue et al., 2000; Bo et al., 2004; Mello et al., 1997). 
With our large cohort, we had the power to control for known potential confounders that 
influence the fetal overgrowth, including pre-pregnant BMI and net gestational weight gain. 
We confirmed that untreated maternal mild hyperglycemia (impaired GCT with one 
abnormal or no abnormal glucose value at OGTT) in otherwise young and healthy  women 
in the US was associated with a 2-3 fold increased risk of delivering an LGA infant (table 2). 
These observations are consistent with previous findings from populations studied 
worldwide by the HAPO group and other studies (HAPO, 2008; Stamilio et al 2004). In 
addition, increased risk of LGA birth in GDM women (all of whom were treated by diet or 
with insulin) was associated with high maternal pre-pregnant BMI.   
3. Pregnancy weight gain and LGA birth 
3.1 Significance of optimal pregnancy weight gain and fetal growth 
To optimize gestational weight gain for both mother and fetus is critical and remains 
controversial. A large number of studies have found that excess gestational weight gain is 
associated with decreased risk of small-for-gestational age birth and with increased risk for 
LGA birth (Oken et al., 2009; Jensen et al., 2005; Hinkle et a., 2010), regardless the definition 
or the scales used for excess pregnancy weight gain (Kiel et al., 2007;  Jain et al., 2007).  
3.2 Weight gain and maternal obesity 
The independent contribution of excess gestational weight gain and maternal obesity on the 
risk of LGA or macrosomia has been extensively investigated (Jensen et al., 2005; Jain et al., 
2007), because obesity is a common problem during pregnancy (Chu et al., 2007; Sebire et 
al., 2001; Rosenberg et al., 2005). Even in women with a normal pre-pregnant BMI, a higher 
pregnancy weight gain was associated with an increased risk of LGA, while a normal 
weight gain by the 1990 The Institute of Medicine (IOM) guidelines was associated with a 
decreased risk of LGA (DeVader et al., 2007). The definition of an optimal gestational weight 
gain in obese pregnancy remains controversial (Nohr et al., 2008). Jain et al observed that 
overweight/obese women who gain weight within the IOM recommendation achieve better 
fetal outcomes (Jain et al., 2007), while others found weight gain within IOM ranges did not 
reduce the risk of LGA among the obese (Dietz et al., 2009). It was suggested that limited or 
no weight gain in more severely obese pregnant women may increase favorable neonatal 
outcomes (Kiel et al., 2007; Jensen et al., 2005). Thus, an optimal gestational weight gain may 
need to be further defined by obesity severity (Hinkle et al., 2010; Oken et al., 2009). 
3.3 What are problems in the research of weight gain during pregnancy?  
There are limited data that link excess pregnancy weight gain measured prior to screening 
for GDM and /or longitudinal gestational weight gain measures through out the pregnancy 
to adverse pregnancy outcomes. In 2009, the IOM published revised gestational weight gain 
guidelines for how much weight a woman should gain during pregnancy to optimize both 
maternal and child outcomes.  The report highlighted the importance of intervention in 
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3. Pregnancy weight gain and LGA birth 
3.1 Significance of optimal pregnancy weight gain and fetal growth 
To optimize gestational weight gain for both mother and fetus is critical and remains 
controversial. A large number of studies have found that excess gestational weight gain is 
associated with decreased risk of small-for-gestational age birth and with increased risk for 
LGA birth (Oken et al., 2009; Jensen et al., 2005; Hinkle et a., 2010), regardless the definition 
or the scales used for excess pregnancy weight gain (Kiel et al., 2007;  Jain et al., 2007).  
3.2 Weight gain and maternal obesity 
The independent contribution of excess gestational weight gain and maternal obesity on the 
risk of LGA or macrosomia has been extensively investigated (Jensen et al., 2005; Jain et al., 
2007), because obesity is a common problem during pregnancy (Chu et al., 2007; Sebire et 
al., 2001; Rosenberg et al., 2005). Even in women with a normal pre-pregnant BMI, a higher 
pregnancy weight gain was associated with an increased risk of LGA, while a normal 
weight gain by the 1990 The Institute of Medicine (IOM) guidelines was associated with a 
decreased risk of LGA (DeVader et al., 2007). The definition of an optimal gestational weight 
gain in obese pregnancy remains controversial (Nohr et al., 2008). Jain et al observed that 
overweight/obese women who gain weight within the IOM recommendation achieve better 
fetal outcomes (Jain et al., 2007), while others found weight gain within IOM ranges did not 
reduce the risk of LGA among the obese (Dietz et al., 2009). It was suggested that limited or 
no weight gain in more severely obese pregnant women may increase favorable neonatal 
outcomes (Kiel et al., 2007; Jensen et al., 2005). Thus, an optimal gestational weight gain may 
need to be further defined by obesity severity (Hinkle et al., 2010; Oken et al., 2009). 
3.3 What are problems in the research of weight gain during pregnancy?  
There are limited data that link excess pregnancy weight gain measured prior to screening 
for GDM and /or longitudinal gestational weight gain measures through out the pregnancy 
to adverse pregnancy outcomes. In 2009, the IOM published revised gestational weight gain 
guidelines for how much weight a woman should gain during pregnancy to optimize both 
maternal and child outcomes.  The report highlighted the importance of intervention in 





3.4 The US Institute of medicine new guidelines for gestational weight gain 
The new 2009 IOM guidelines are based on the WHO BMI (kg/m2) categories (WHO, 1998) 
and include the recommended total pregnancy weight gain (kg) or rates of weight gain 
during the 2nd and 3rd trimester (kg/week). Weight gain below or above the recommended 






Total weight  
gain range 
Rate of weight gain 2nd and 3rd 
trimester (mean, range)2 
  (lbs) (kg) (lbs/wk) (kg/wk) 
Under weight <18.5 28-40 12.5-18.0 1.0 (1.0-1.3) 0.51 (0.44-0.58) 
Normal weight 18.5-24.9 25-35 11.5-16.0 1.0 (0.8-1.0) 0.42 (0.35-0.50) 
Overweight 25.0-29.9 15-25 7.0-11.5 0.6 (0.5-0.7) 0.28 (0.23-0.33) 
Obese (includes 
all classes) ≥30.0 11-20 5.0-9.0 0.5 (0.4-0.6) 
0.22 (0.17-
0.27) 
1 IOM, Institute of Medicine in US. 
2 Calculations assume a 0.5-2kg (1.1-4.4 lbs) weight gain in the first trimester (based on Siega-Riz et. al., 1994; 
  Abrams et al 1995, Carmichael et al 1997). 
Table 3. New recommendations for total and rate of weight gain during pregnancy, by 
prepregnancy BMI (IOM, 2009)1 
3.5 Assessment of pregnancy weight gain  
We explored the associations between gestational weight gain assessed throughout 
pregnancy with LGA using the 2009 IOM guidelines for weight gain during pregnancy.  
Inadequate, adequate and excessive pregnancy weight gain at weeks 24, 28, 32 and at 
delivery was categorized according to IOM recommendations (table 3). Maternal obesity 
was defined as BMI ≥30 (WHO, 1998); height was measured with a stadiometer at entry. 
Gestational duration was based upon gestation from participants’ last normal menstrual 
period confirmed or modified by ultrasound.  Pregnancy weight was measured at week 12, 
24, 28, 32 and at delivery. Total gestational weight gain was computed as the difference 
between weight at delivery and recalled pre-pregnant weight. Gestational weight gain 
during the 2nd and 3rd trimester was computed as the difference between weights measured 
at each visit minuses the weight measured at week 12.  The rate of weight gain was the 
weight gain (kg) divided by gestational age (weeks).   
3.6 Excess pregnancy weight gain measured mid to late gestations and LGA birth 
The proportion of women with excess pregnancy weight gain at weeks 24, 28, and 32 was 
similar to delivery (48.5%, 52%, 54% and 50% respectively). Depending on the gestation, 21-
27% had an adequate weight gain and 22-30% had an inadequate gain throughout the four 
time points.   
Compared to women with adequate weight gain, excessive weight gain was associated with 
a 1.58-2.66 fold  increased risk of LGA birth (table 4) after controlling for all the confounding 
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variables with the exception of pre-pregnant BMI (p for trend <0.0001 for each model). 
Similar results were obtained when additional adjustment for pre-pregnant BMI. In 
addition, women with inadequate weight gain had a reduced risk of LGA birth at week 28 
and 32 (p<0.05).  
3.7 Contribution of Camden data 
These data confirmed that excess pregnancy weight gain throughout the 2ndand 3rd 
trimesters and at delivery significantly increased risk of LGA, whereas inadequate 
pregnancy weight gain reduced LGA risk. The current study has several important 
strengths. Firstly, we used the most recent IOM recommendations (2009) for the estimation 
of excess weight gain by BMI categories and the analysis models were fully adjusted for 
potential confounding, including pre-pregnant BMI. In contrast, more arbitrary criteria were 
used to define excess weight gain in previous studies (Herring et al., 2009; Rosenberg et al., 
2005), and pre-pregnant BMI either was not available or was not adjusted for in the analysis 
(Hillier et al., 2008; Rosenberg et al., 2005). Secondly, there are limited data on longitudinal 
measures of pregnancy weight gain (Herring et al., 2009; Saldana et al., 2006). We used 
multiple measures of pregnancy weight gain starting prior to the screen for GDM. The 
relationship between excess pregnancy weight gain assessed relatively early in pregnancy 
and risk of LGA could be important for preventive strategies. Total weight gain is not an 
ideal measure to evaluate in relation to fetal growth in GDM patients, because most of 
patients are treated and their weight gain is monitored after the diagnosis.   
 



















Adequate 3.5 Reference 5.1 Reference 6.1 Reference 3.6 Reference 
Inadequate 3.2 0.90 (0.47,1.71) 2.6 
0.50 
(0.27, 0.95) 2.3 
0.49 
(0.24, 0.98) 2.3 
0.62 
(0.31, 1.25) 
Excessive 8.7 2.62 (1.55, 4.43) 8.0 
1.65 
(1.05, 2.61) 7.6 
1.58 
(1.00, 2.50) 9.1 
2.66 
(1.69, 4.19) 
1 Models were adjusted for age and cigarette smoking in addition to using a standard which adjusted 
LGA for parity, ethnicity and infant gender.  
2 p for trend <0.0001 for week 24, 28, 32 and delivery respectively. 
Table 4. Excess pregnancy weight gain and LGA birth1,2 
4. Association of various degree of gestational hyperglycemia, excess 
pregnancy weight gain with LGA birth 
4.1 Does excess gestational weight gain prior to screening GDM predict risk of GDM? 
High gestational weight gain between early and mid pregnancy was positively associated 
with risk of GDM or impaired glucose tolerance (Hedderson et al., 2010; Herring et al., 
2009). In the Camden study, we found a positive association between excess weight gain 
prior to or at the time of screening for GDM (weeks 24 and 28) with increased risk for GDM 
(AOR 1.57, 95% CI 1.01, 2.44 for week 24, AOR 1.94, 95% CI 1.28, 2.95 for week 28). This 
association was not significant at week 32 or at delivery which may suggest an effect of 
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variables with the exception of pre-pregnant BMI (p for trend <0.0001 for each model). 
Similar results were obtained when additional adjustment for pre-pregnant BMI. In 
addition, women with inadequate weight gain had a reduced risk of LGA birth at week 28 
and 32 (p<0.05).  
3.7 Contribution of Camden data 
These data confirmed that excess pregnancy weight gain throughout the 2ndand 3rd 
trimesters and at delivery significantly increased risk of LGA, whereas inadequate 
pregnancy weight gain reduced LGA risk. The current study has several important 
strengths. Firstly, we used the most recent IOM recommendations (2009) for the estimation 
of excess weight gain by BMI categories and the analysis models were fully adjusted for 
potential confounding, including pre-pregnant BMI. In contrast, more arbitrary criteria were 
used to define excess weight gain in previous studies (Herring et al., 2009; Rosenberg et al., 
2005), and pre-pregnant BMI either was not available or was not adjusted for in the analysis 
(Hillier et al., 2008; Rosenberg et al., 2005). Secondly, there are limited data on longitudinal 
measures of pregnancy weight gain (Herring et al., 2009; Saldana et al., 2006). We used 
multiple measures of pregnancy weight gain starting prior to the screen for GDM. The 
relationship between excess pregnancy weight gain assessed relatively early in pregnancy 
and risk of LGA could be important for preventive strategies. Total weight gain is not an 
ideal measure to evaluate in relation to fetal growth in GDM patients, because most of 
patients are treated and their weight gain is monitored after the diagnosis.   
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4. Association of various degree of gestational hyperglycemia, excess 
pregnancy weight gain with LGA birth 
4.1 Does excess gestational weight gain prior to screening GDM predict risk of GDM? 
High gestational weight gain between early and mid pregnancy was positively associated 
with risk of GDM or impaired glucose tolerance (Hedderson et al., 2010; Herring et al., 
2009). In the Camden study, we found a positive association between excess weight gain 
prior to or at the time of screening for GDM (weeks 24 and 28) with increased risk for GDM 
(AOR 1.57, 95% CI 1.01, 2.44 for week 24, AOR 1.94, 95% CI 1.28, 2.95 for week 28). This 
association was not significant at week 32 or at delivery which may suggest an effect of 





significant association between excess weight gain and impaired GCT non-GDM (p>0.05 for 
all time points). 
4.2 The association of gestational hyperglycemia and excess weight gain with LGA 
Combined association of gestational hyperglycemia and excess weight gain on the risk of LGA 
has not been examined extensively. Hillier et al observed at GDM screening that macrosomia 
risk was increased across the spectrum of maternal glucose levels and that this relationship 
was further modified by excessive maternal weight gain (Hillier et al., 2008). A weight gain of 
40lbs or more nearly doubled the risk of fetal macrosomia among glucose intolerant women 
including those with GDM. However, results were not adjusted for pre-pregnancy BMI which 
can complicate the relationship between maternal hyperglycemia and pregnancy weight gain. 
Thus, our next goal was to examine the independent and combined contributions of 
hyperglycemia and excess weight gain on risk of LGA.  An analysis stratified by excessive 
weight gain was used to index the influence of various degrees of maternal glycemic status 
on LGA risk, using women with non-excess pregnancy weight gain (adequate and 
inadequate gain combined) and a normal GCT as the reference group.  Our results showed 
that excess weight gain (at week 24, 28, 32 or at delivery) was positively associated with a 2-
6 fold increased risks for delivering an LGA infant (table 5) regardless of whether the 
women were diagnosed with GDM, impaired GCT non-GDM or normal GCT. Furthermore, 
women with non-excess weight gain and an impaired GCT non-GDM also had a 2-3 fold 
increased risk of LGA birth during all of four time points, whereas risk of LGA was not 
increased in the GDM group with non-excess weight gain.  
 
 Weight gain at week 24 
Weight gain 
at week 28 
Weight gain 


















Excess weight gain         
GDM 11.5 4.03 (1.67, 9.73) 10.5 
3.31 
(1.39, 7.90) 11.3 
3.20 






(3.16, 11.90) 14.6 
4.97 
(2.53, 9.71) 14.1 
4.62 
(2.18, 8.31) 14.9 
6.42 
(3.20, 12.88) 
Normal GCT 7.8 2.91 (1.88, 4.48) 7.2 
2.43 
(1.58, 3.73) 6.8 
2.02 
(1.33, 3.10) 8.2 
3.58 
( 2.29, 5.60) 
Non-excess weight 
gain2         
GDM 5.6 1.64 (0.37, 7.21) 6.7 
1.69 
(0.38, 7.50) 5.9 
1.31 






(1.17, 6.59) 9.5 
2.98 
(1.31, 6.77) 9.9 
2.69 
(1.19, 6.08) 9.1 
3.79 
(1.65, 8.68) 
Normal GCT 2.8 Reference 3.1 Reference 3.6 Reference 2.5 Reference 
1  Model was adjusted for age, pre-pregnant BMI and cigarette smoking in addition to using a standard 
which adjusted LGA for maternal ethnicity, parity and fetal gender. 
2 Adequate and inadequate weight gain is combined. 
3 p for trend <0.0001. 
Table 5. Maternal hyperglycemia and LGA infant: Stratified by excess weight gain1 
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4.3 What do we learn? 
These data confirmed that hyperglycemia and excess weight gain are independently 
associated with risk of fetal overgrowth. Women with excess weight gain at any of four 
times in gestation and hyperglycemia, even a mild hyperglycemia, had a substantially 
increased risk of LGA.  Risk of LGA was not increased among gestational diabetics without 
an excessive weight gain but only among the group with impaired GCT non-GDM. Thus, 
excess pregnancy weight gain and hyperglycemia are independent risk factors for LGA.  
5. Conclusion 
By using the most updated IOM guidelines (2009) on pregnancy weight gain, we found that 
healthy, young women with mild but untreated hyperglycemia were at increased risk for 
fetal overgrowth (LGA). The risk of LGA birth in women with GDM, who are treated by 
diet or with insulin after diagnosis, was dependent on maternal pre-pregnant weight.  
Excess pregnancy weight gain assessed longitudinally through out mid to late gestation 
consistently showed strong associations with LGA risk. In addition, excess pregnancy 
weight gain and hyperglycemia appeared to be independent risk factors for LGA. The risk 
for LGA was increased still further in women with excess weight gain, even in those with 
mild hyperglycemia. Because prepregnancy obesity, mild gestational hyperglycemia, and 
excess weight gain during pregnancy are preventable risk factors, these findings suggest 
that early detection and treatment of mild hyperglycemia and monitoring pregnancy weight 
gain during early gestation are both important for reducing the risk of LGA, for reducing 
childhood and later obesity and for improving the long term risk for metabolic disease in 
the offspring.  
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excess pregnancy weight gain and hyperglycemia are independent risk factors for LGA.  
5. Conclusion 
By using the most updated IOM guidelines (2009) on pregnancy weight gain, we found that 
healthy, young women with mild but untreated hyperglycemia were at increased risk for 
fetal overgrowth (LGA). The risk of LGA birth in women with GDM, who are treated by 
diet or with insulin after diagnosis, was dependent on maternal pre-pregnant weight.  
Excess pregnancy weight gain assessed longitudinally through out mid to late gestation 
consistently showed strong associations with LGA risk. In addition, excess pregnancy 
weight gain and hyperglycemia appeared to be independent risk factors for LGA. The risk 
for LGA was increased still further in women with excess weight gain, even in those with 
mild hyperglycemia. Because prepregnancy obesity, mild gestational hyperglycemia, and 
excess weight gain during pregnancy are preventable risk factors, these findings suggest 
that early detection and treatment of mild hyperglycemia and monitoring pregnancy weight 
gain during early gestation are both important for reducing the risk of LGA, for reducing 
childhood and later obesity and for improving the long term risk for metabolic disease in 
the offspring.  
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1. Introduction 
The consequences of uncontrolled diabetes mellitus during pregnancy are severe for both 
mother and fetus. The risk of congenital malformations among infants of diabetic mothers is 
related to the quality of the diabetic control (Allen et al., 2007; American Diabetes 
Association [ADA], 2004). In diabetic pregnancy, unsatisfactory glycemic control at the 
moment of diagnosis or delivery of care was associated with an increased risk of anomalies 
(Allen et al., 2007; Schaefer-Graf at al., 2000). The most common anomalies involve the 
cardiac, musculoskeletal, and central nervous systems (Sheffield at al., 2002). Despite this 
knowledge, it has been disappointing that so few diabetic women receive preconception 
counseling, plan their pregnancies or are early referred to tertiary centers (American 
Diabetes Association [ADA], 2004; Reis at al., 2010a). Considering this reality, it is important 
to study second trimester markers of congenital cardiopathies, in order to decrease fetal 
morbidity and mortality, at birth. 
2. Congenital cardiopathies and diabetes mellitus  
If maternal hyperglycemia is present during organogenesis there is an increased risk of 
congenital anomalies and miscarriage (American Diabetes Association [ADA], 2004). 
Experimental studies suggest that hyperglycemia is the major teratogen in diabetic 
pregnancies, but other diabetes-related factors may also affect fetal outcomes (Aberg at al., 
2001; Buchanan & Kjos, 1999; Leonard et al., 1989; Ren et al., 2011). It is a fact that an 
uncontrolled diabetes mellitus in early gestation is associated with a teratogenic effect, 
causing primary cardiogenesis defects. Most types of cardiac structural lesions have been 
associated with diabetes mellitus, ranging from small septal defects to major heart disease 
(Sekhavat et al., 2010; Abu-Sulaiman & Subaih, 2004). 
The exact teratogenic mechanism of maternal diabetes is not fully defined and is likely 
multifactorial (Hornberger, 2006; Kumar et al., 2007). Diabetes mellitus affects the fetal heart 
both structurally and functionally. In late gestation, it causes a unique form of hypertrophic 
cardiomyopathy (Ren et al., 2011; Hornberger, 2006; Chaudhari et al., 2008; Russell et al., 
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1. Introduction 
The consequences of uncontrolled diabetes mellitus during pregnancy are severe for both 
mother and fetus. The risk of congenital malformations among infants of diabetic mothers is 
related to the quality of the diabetic control (Allen et al., 2007; American Diabetes 
Association [ADA], 2004). In diabetic pregnancy, unsatisfactory glycemic control at the 
moment of diagnosis or delivery of care was associated with an increased risk of anomalies 
(Allen et al., 2007; Schaefer-Graf at al., 2000). The most common anomalies involve the 
cardiac, musculoskeletal, and central nervous systems (Sheffield at al., 2002). Despite this 
knowledge, it has been disappointing that so few diabetic women receive preconception 
counseling, plan their pregnancies or are early referred to tertiary centers (American 
Diabetes Association [ADA], 2004; Reis at al., 2010a). Considering this reality, it is important 
to study second trimester markers of congenital cardiopathies, in order to decrease fetal 
morbidity and mortality, at birth. 
2. Congenital cardiopathies and diabetes mellitus  
If maternal hyperglycemia is present during organogenesis there is an increased risk of 
congenital anomalies and miscarriage (American Diabetes Association [ADA], 2004). 
Experimental studies suggest that hyperglycemia is the major teratogen in diabetic 
pregnancies, but other diabetes-related factors may also affect fetal outcomes (Aberg at al., 
2001; Buchanan & Kjos, 1999; Leonard et al., 1989; Ren et al., 2011). It is a fact that an 
uncontrolled diabetes mellitus in early gestation is associated with a teratogenic effect, 
causing primary cardiogenesis defects. Most types of cardiac structural lesions have been 
associated with diabetes mellitus, ranging from small septal defects to major heart disease 
(Sekhavat et al., 2010; Abu-Sulaiman & Subaih, 2004). 
The exact teratogenic mechanism of maternal diabetes is not fully defined and is likely 
multifactorial (Hornberger, 2006; Kumar et al., 2007). Diabetes mellitus affects the fetal heart 
both structurally and functionally. In late gestation, it causes a unique form of hypertrophic 
cardiomyopathy (Ren et al., 2011; Hornberger, 2006; Chaudhari et al., 2008; Russell et al., 





with diabetes mellitus and may contribute to the risk of fetal death in these pregnancies 
(Russell et al., 2008). Hypertrophic cardiomyopathy observed in the infant of the diabetic 
mother is characterized by thickening of the interventricular septum, and to a lesser extent 
the ventricular free walls (Hornberger, 2006).  The presence of this pathology whether is 
associated with fetal hyperinsulinaemia and general somatic growth in maternal diabetes 
(Buchanan & Kjos, 1999; Ren et al., 2011). But, the wide variety of cardiac abnormalities 
suggests a complex pathogenesis. Experimental study proposed that the down-regulation of 
genes involved in development of cardiac neural crest could contribute to the pathogenesis 
of maternal diabetes-induced congenital heart defects (Kumar et al., 2007).  
 
 
Fig. 1. Image of fetal ultrasonography: hypertrophic cardiomyopathy associated with 
Diabetes Mellitus 
3. The strategies for prevention and management of the cardiac teratogenic 
effects in diabetes mellitus 
The prevalence of pregestational diabetes among women early in their reproductive years is 
increasing. Thus, identifying women with diabetes is important because the diagnosis and 
appropriate therapy can decrease fetal and maternal morbidity (Crowtherl et al., 2005). 
Preconceptional evaluation and counseling of women with diabetes mellitus (type 1 or type 
2) is fundamental point to minimize the risk to the fetus and mother. It is known that 
pregnancies in diabetes mellitus women should be planned, but that condition was not so 
frequent (American Diabetes Association [ADA], 2004; Reis at al., 2010a; Chaudhari et al., 
2008). Unplanned pregnancy occurs in about two-thirds of women with diabetes leading to 
a persistent excess of malformations in their infants (American Diabetes Association [ADA], 
2004).  
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Given the increased risk of congenital abnormalities among infants of diabetic mothers, an 
appropriate biochemical, ultrasonographic screening process and a detailed evaluation of 
fetal cardiac structure should be offered to all pregnant women with diabetes (Allen et al., 
2007). A prenatal cardiac screening is purposed to identify defects that may require further 
evaluation and treatment, and to provide appropriate counselling to the family in a timely 
manner (American Diabetes Association [ADA], 2004; Sekhavat et al., 2010). Detailed fetal 
anatomic surveys in the early second trimester are common practice and typically include 
examination of both four-chamber and outflow tract views of the fetal heart. 
The occurrence of congenital cardiopathies at echocardiography in fetuses whose mothers 
had preexisting diabetes mellitus was investigated in our tertiary university medical center 
(Reis at al., 2010a, 2010b). The most frequent conditions were hypertrophic cardiomyopathy 
(70%), pericardial effusion (15%), followed by intermittent or persistent bradycardia (15%). 
The most frequent structural congenital cardiopathies at echocardiography was 
interventricular communication (85.7%) associated or not to another heart malformations 
(Fig. 2). Functional findings at echocardiography were significantly more frequent among 
the poorly-controlled diabetic pregnancies.  
 
 
Fig. 2. Image of fetal ultrasonography: interventricular comunication associated with 
Diabetes Mellitus  
In other reports, the malformations found in neonates, born of insulin-dependent diabetes 
mellitus gestations, included endocardial cushion defects, persistent truncus arteriosus and 
ventricular septal defects which appear to result from aberrant cardiac neural crest 
development (Sekhavat et al., 2010; Abu-Sulaiman & Subaih, 2004; Hornberger, 2006; Kumar 
et al., 2007; Russell et al., 2008). Hypertrophic cardiomyopathy was observed in 38% of 
neonates from insulin-dependent diabetes mellitus pregnant women, mainly hypertrophy of 
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4. The fructosamine level as a late marker (beyond the first trimester) for 
congenital cardiopathies 
The measurement of glycated hemoglobin (HbAlc) and serum fructosamine in order to 
assess the recent glycemic control of diabetic patients has become well established. Maternal 
HbAlc at the beginning of pregnancy and maternal age at the onset of diabetes were 
associated with congenital malformations (Aberg at al., 2001).  
Fructosamines are keto-amines formed by a non-enzymatic reaction between glucose and a 
protein (60-70% of which is glycosylated with albumin in serum), depending upon the 
severity and the duration of the hyperglycemia. Therefore, serum fructosamine directly 
reflects the dynamics of blood glucose concentration and correlates significantly with the 
mean plasma glucose levels from the preceding 1 to 3 weeks (Roberts et al., 1988; 
Weerasekera, 2000; Jenkins et al., 2007). Fructosamine testing has been available since the 
1980s. Both fructosamine and HbA1c are used primarily as monitoring tools to help 
diabetics control their blood sugar, but the A1C test is much more popular and more widely 
accepted. However, the American Diabetes Association recognizes both tests and says that 
fructosamine may be useful in situations where the A1C cannot be reliably measured 
(Goldstein et al., 2004). In addition, the measurement of fructosamine can be a helpful 
adjunct to HbA1c glycaemic control monitoring during pregnancy (Chaudry et al., 2007). 
The role of fructosamine levels as a teratogenic marker is less studied. 
Fetuses presenting a normal and abnormal echocardiography were compared using plasma 
fructosamine level means (Reis at al., 2010a).  An association between congenital 
cardiopathies at echocardiography (functional and structural including isolated 
hypertrophic cardiomiopathy) and types of diabete mellitus (insulin-depending or not), was 
evaluated. An abnormal plasma fructosamine level at 20.4±8.0 weeks of gestation was 
associated with congenital cardiopathies at echocardiography, whether or not the cardiac 
embryogenesis happened in the first trimester. The congenital cardiopathies at 
echocardiography odds ratio was 9.6 (95% CI: 2.8 – 33.7) for abnormal plasma fructosamine 
(≥2.68mmol/L) and 10.9 (95% CI: 2.7 – 45.2) when adjusted for maternal age and insulin 
usage. There was also an increased chance (3.1, 95% CI: 1.1 - 8.8) of fetal heart anomaly with 
insulin usage, but only when evaluated individually by crude odds ratio.  
In many underdeveloped countries, women do not have access or do not attend medical 
care early in pregnancy (Reis at al., 2010a, 2010b). Therefore, they are especially subject to 
the teratogenic effects of hyperglycemia.  Analyzing results of our universitary referral 
center, it was disappointing that so few diabetic women receive preconception counseling 
and plan their pregnancies (Reis at al., 2010a). Therefore, considering this reality, without 
HbA1c early values, it was important to determine the correlation between fructosamine 
maternal levels and fetal malformations.  
Based on our previous study, abnormal maternal fructosamine levels, even at the second 
trimester of pregnancy, predicts a high risk of fetal cardiac anomalies (Reis at al., 2010a). In 
this way, a fetal echocardiographic exam should be, routinely, performed in all diabetic 
mothers whose fructosamine levels are above 2.23 mmol/L  (Reis et al., 2010b).  
This recommendation was based on the significant capacity of maternal fructosamine levels to 
predict fetal heart anomaly in diabetic patients (Area Under Curve: 0.78 p-valor <0.0001), as 
shown in Fig. 3. However, different cut-off values from which fructosamine could indicate 
these malformations and they should be cautiously defined and discussed as shown in Table 1. 
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Fig. 3. Receiver–operating characteristics (ROC) curve for prediction of congenital 
cardiopathies at echocardiography for fetuses whose mothers had preexisting diabetes 
mellitus (n=65). AUC 0.78 (95% CI, 0.66–0.89), from: Reis et al., 2010 
 
Cut-off  points 
(maternal plasmatic levels of 
fructosamine ) 
Sensitivity Specificity False negative 
Positive 
Likelihood ratio 
2.23 mmol/L 88.2% 54.8% 11.8% 2.0 
2.68 mmol/L 58.8% 87.1% 41.2% 4.6 
2.90 mmol/L 44.1% 96.8% 55.9% 13.7 
Table 1. Accuracy of the maternal fructosamine levels for the prediction of fetal cardiac 
anomalies in gestations complicated by diabetes mellitus. Reference: Reis et al., 2010b 
If it is considered the cut-off value of fructosamine recommended for our local population 
(2.68mmol\L), this test will have a good specificity (87.1%) but a low sensitivity (58.8%), 
with a false negative rate of 41.2%.  Even though, for an abnormal exam, the risk of fetal 
cardiac anomaly is increased 4.6-fold.  If it is considered the cut-off value recommended by 
the manufacturer of the test  (2.90mmol/L), the exam will have a high specificity (96.8%) but 
a low sensitivity (44.1%)  with a false negative rate of 55.9%. In this case, for an abnormal 
test, the risk of fetal cardiac defects would be increased 13.7-fold. Finally considering the use 
of a cut-off  point of 2.23mmol\L, the test will show a low specificity (54.8%) but a high 
sensitivity (88.2%), with a false negative rate of 11.8%. Thus, the cut-off point of 2.23 
mmol/L is better than the other values tested, since it has the greatest sensitivity and lowest 
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Abnormal echocardiographic findings were associated with the first maternal plasma 
fructosamine levels in referral pregnancies complicated by diabetes mellitus. Hyperglycemia 
seems to be the most important determinant of these risks. Many pregnant diabetic women 
are referred at a late stage to a tertiary level of care. At this context, an abnormal plasma 
fructosamine level increases the chances of abnormalities at fetal echocardiography. It is 
possible to use a second trimester plasma fructosamine level to refer women with 
pregestational diabetes mellitus to a center of maternal-fetal medicine in order to offer them 
an appropriated assistance at birth. These findings are important for the management of 
women with diabetes mellitus and late prenatal care. 
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1. Introduction 
Diabetes mellitus complicating pregnancy is one of the most common antenatal complications 
that are associated with significant perinatal mortality and morbidity (Magee et al., 1993; Platt 
et al., 2002; Schmidt et al., 2001). Diabetic pregnancies can be divided into two categories: those 
with pre-gestational or pre-existing diabetes mellitus in which the diagnosis is made in the 
pre-pregnancy state, and those with gestational diabetes mellitus (GDM). Pre-existing diabetes 
consists of type I (insulin-dependent) diabetes mellitus (IDDM)with an incidence of around 
0.5%, and type 2 ( non-insulin-dependent) diabetes with an incidence of 2-3% ( Kapoor et al., 
2007). The incidence of gestational diabetes mellitus differs in different populations (Gunton et 
al., 2001) and ethnic groups, and was shown to be as high as 13% in Chinese populations (Ko 
et al., 2002). Effective treatment of pre-existing as well as gestational diabetes mellitus was 
shown to improve outcome and reduce perinatal mortality, as compared to untreated patients 
(Lao et al., 2001; Langer et al., 2005).   
The pathological conditions encountered in fetuses of diabetic pregnancies differ in those 
with pre-existing diabetes mellitus and those with gestational diabetes. Pre-existing 
diabetics with persistent hyperglycaemia in the perinatal period are at higher risks of 
congenital malformations (Reece et al., 2007). In addition, those women with long-standing 
pre-existing diabetes before the index pregnancy run a higher risk of having diabetic 
vasculopathy that may affect various organ-systems in the body. Involvement of the uterine 
arteries will affect the development of an effective utero-placenta blood flow, which would 
be vital in maintaining normal growth and development in the fetus. The clinical 
manifestation of fetal growth restriction (also called intrauterine growth restriction) is thus 
more common in these pregnancies. The presence of significant congenital abnormalities 
and severe fetal growth restriction resulting from such conditions are logically directly 
related to increase in perinatal mortality and morbidity. On the other hand,  gestational 
diabetes is usually only diagnosable either in a screening protocol or from clinical risk 
factors, by oral glucose tolerance test from mid trimester onwards, due to the effects of 
diabetogenic hormones from the placenta. The carbohydrate intolerance is thus short-lived 
and should last only from mid trimester to term. The hyperglycaemic states of the diabetes 
should revert to normal shortly after delivery with the removal of the placenta.  Thus, 
chronic complications such as vasculopathy in the pregnant women will not have time to 
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in gestational diabetes would stimulate fetal hyperinsulinemia, which would in turn lead to 
over-secretion of insulin-like growth factors (IGF), leading to overgrowth of the fetus 
(Kapoor et al., 2007). Thus, in contrast to pre-gestational diabetes mellitus, where 
vasculopathy is rife and the incidences of pre-eclampsia and fetal growth restriction are 
commonly encountered, GDM pregnancies pose a different category of pathophysiology 
and clinical risks. The most common fetal problems for gestational diabetes will be 
macrosomia with associated polyhydramnios, as well as increased risks of near term 
stillbirths and neonatal metabolic complications in livebirths (Sacks, 2007). Indeed, recent 
data borne out by the HAPO study has demonstrated that in maternal hyperglycaemic 
states less severe than in diabetes mellitus is also associated with increased risks of adverse 
pregnancy outcomes (HAPO Study Cooperative Research Group, 2008)  
A lot of emphasis has been put on fetal surveillance in these high-risk pregnancies in the 
attempt to optimise pregnancy outcome. There is, however, no consensus as to the best 
methods of antepartum surveillance (American College of Obstetricians & Gynecologists, 
2001). The use of Doppler studies of the umbilical artery has been demonstrated to reduce 
perinatal adverse outcome in non-diabetic pregnancies (Alfirevic et al., 1995), but its use in 
diabetic pregnancies have shown conflicting results. While umbilical artery Doppler studies 
have been shown to be more predictive of adverse outcome than cardiotocography and 
biophysical profile in diabetic pregnancies (Bracero et al., 1996), fetal compromise would 
occasionally still be observed despite normal Doppler studies (Johnstone et al., 1992). Thus, 
the precise value of Doppler studies in the monitoring of GDM pregnancies remains 
controversial.  
2. Serial growth scans for diabetic pregnancies 
The recommendations for diagnosis and treatment of GDM of the Fifth International 
Workshop-Conference on Gestational Diabetes Mellitus (Metzger et al., 2007) suggest 
consideration of fetal growth patterns to guide metabolic management of pregnant women 
with GDM. However, estimation of fetal weight, particularly at term and in fetuses with 
high neonatal weight, is not as precise as desirable (Sacks et al, 2000). Fetal overgrowth and 
accelerated growth velocity of the abdominal circumference in the third trimester is known 
to predict large for gestational age babies (Kehl et al., 1996).  Fetal overgrowth with 
macrosomia and associated polyhydramnios is associated with higher risks of near term 
stillbirth, as well as various neonatal metabolic derangements, including neonatal 
hypoglycaemia, electrolyte disturbances and neonatal jaundice. Previous randomized 
studies have demonstrated that measurement of fetal abdominal circumference throughout 
pregnancy in women with GDM is useful to identify pregnancies at high risk for fetal 
overgrowth and thus in need of more vigilant treatment including insulin therapy (Bonomo 
et al., 2004).  
Serial measurements of the fetal abdominal circumference have been used to guide 
metabolic management of pregnancies complicated by gestational diabetes mellitus. There is 
at present no consensus as to the optimal protocol for such growth scans. A recent study 
evaluated the number of sonograms needed to reliably predict the absence of fetal 
overgrowth in GDM pregnancies.  A total of 4478 ultrasound examinations were performed 
on 1914 subjects. Of 518 women with fetal abdominal circumference > 90th percentile, the 
diagnosis was detected in 73.9% with the first ultrasound examination at entry and in 13.1% 
with the second ultrasound examination. Of the fetuses, 85.9 and 86.9% of the fetuses were 
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born non-large- for- gestational- age when abdominal circumference was < 90th percentile at 
24-27 weeks and 28-32 weeks respectively; and 88% were born non-large-for-gestational-age 
when both scans showed normal growth. For those women who had no risk factors for fetal 
overgrowth, such as body mass index > 30 kg/m2, history of macrosomia, and fasting 
glucose > 100 mg/dl, the accuracy of prediction of a non-large-for-gestational-age neonate 
was 90.0, 89.5 and 95.2%. The predictive ability did not increase with more than two normal 
scans. It was concluded that the yield of sonographic diagnosis of a large fetus dropped 
markedly after the finding if a large fetal abdominal circumference < 90th percentile on tow 
sonograms, which excludes with a high reliability the risk of a large for gestational age 
newborn. The ability was enhanced in women who had no risk factors for neonatal 
macrosomia (Schaefer-Graf et al., 2011). Thus, sonographic evaluation of fetal growth 
parameters is a crucial part of ultrasound assessment of diabetic pregnancies. The 
application of Doppler examination should take into account the data from such growth 
assessment parameters.  
3. Use of Doppler studies for fetal surveillance 
Various Doppler parameters have conventionally been utilized for fetal surveillance. The 
use maternal uterine artery Doppler as a screening tool to predict subsequent development 
of pre-eclampsia and fetal growth restriction in later gestation have gained acceptance in 
recent years. Umbilical artery Doppler, middle cerebral artery Doppler, or the combination 
of the two to produce a cerebral-placental ratio, have been widely used for the assessment of 
growth restricted fetuses. Less commonly used arterial Doppler parameters include fetal 
thoracic aorta or renal arteries. Venous Doppler assessment has been extensively 
investigated in recent years, including umbilical venous waveforms, intrahepatic venous 
Doppler and ductus venosus Doppler. The following sections attempt to review the 
application of the more commonly used Doppler parameters in diabetic pregnancies.  
3.1 Maternal uterine artery 
Maternal uterine artery remodelling is the hallmark sign of successful placentation, which 
can be demonstrated by progressive alterations in Doppler waveforms derived from the 
immediate extrauterine portion of the uterine artery. Pre-pregnancy uterine arteries show 
high resistance and elastic recoil in the form of early diastolic notches and low diastolic flow 
(Schulman et al., 1986). Successful placental invasion removes intimal muscle and reduces 
vascular resistance and elastic properties, giving more rigorous diastolic flow. In 
pregnancies with normal placentation, Doppler studies show that this remodelling is rapid, 
with loss of notching by 12 weeks and low resistance indices by 20 weeks or sooner. When 
placentation is deficient, notching of waveforms remains with high resistance 
(Papageorhiou et al., 2001). Such a picture of deficient placentation strongly predicts 
maternal hypertension, including proteinuric pre-eclampsia, fetal growth restriction and 
fetal demise (Coleman et al., 2000). Uterine artery Doppler screening using high resistance, 
persistent notching, or both, identifies such risks with a sensitivity up to 85% for severe 
proteinuric pre-eclampsia and for severe fetal growth restriction (Papageorghiou et al., 
2002). However, there is so far no well established evidence of using such screening for 
adverse outcomes for either pre-existing or gestational diabetes mellitus alone.  
When uterine artery Doppler were examined in a cohort of 43 pregnancies complicated by 
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slightly higher in the presence of evident morphological vasculopathy, but could not predict 
diabetic specific fetal morbidity. It was concluded that in patients with diabetic 
vasculopathy, the uterine artery was also affected, but there was no relationship with long 
or short term parameters of glycaemic control. Based on the data, it was concluded that 
Doppler flow velocimetry of the uterine artery was a poor predictor of diabetes-specific fetal 
morbidity (Zimmermann et al., 1994).  
In another prospective survey, 24 well controlled insulin dependent pregestational diabetic 
pregnancies were compared with 25 healthy pregnant women and Doppler ultrasound was 
performed on two occasions in the third trimester separated by a one-month interval. At the 
first examination, the median pulsatility index in the fetal thoracic aorta and in the uterine 
artery was significantly lower in the diabetic group as compared to healthy controls, 
whereas umbilical and uterine pulsatility indices were similar. At the second examination at 
a more advanced gestation, a significant physiological decrease in the median pulsatility 
index of the fetal aorta and uterine artery was observed in the controls, but not in the 
diabetic group. There was no correlation between the glycosylated haemoglobin or random 
blood glucose levels and the Doppler indices. An increased incidence of neonatal morbidity 
was noted in the diabetic group. Thus, the normal physiological third trimester fall in 
resistance indices in the uteroplacental and fetal placental indices was apparently absent in 
the diabetic group, and this was associated with increased neonatal morbidity. The 
pulsatility indices were not influenced by blood glucose regulation (Grunewald et al., 1996).  
A similar retrospective study of 155 pre-gestational diabetic women between 22 weeks 
gestation and term also found that abnormal uterine artery Doppler with increased 
pulsatility index was related to pre-existing diabetic states with vasculopathy and adverse 
pregnancy outcome. There was an increased incidence of abnormal umbilical artery Doppler 
in those with abnormal uterine artery Doppler, indicating that the vasculopathy might 
influence placental perfusion and fetal well-being (Pietryga et al., 2006). Therefore, it is 
logical to expect that such screening by uterine artery Doppler will likely be effective only if 
the diabetic pregnancy is also complicated by gestational hypertension or fetal growth 
restriction. Given the higher incidence of such obstetric complications in pre-existing 
diabetes mellitus as compared to GDM, screening of diabetic pregnancies using uterine 
artery Doppler in mid trimester would probably produce a higher yield in the former group.  
3.2 Fetal umbilical artery Doppler  
The use of Doppler studies of the umbilical artery has been demonstrated to reduce 
perinatal adverse outcome in non-diabetic pregnancies (Alfirevic et al.,1995), but its use in 
diabetic pregnancies have shown conflicting results. Umbilical artery angle independent 
indices (systolic/diastolic ratio or pulsatility index) decrease with advancing gestation 
because of decreases in placenta vascular resistance, which physiologically occurs with 
advancing gestation. In pathologic conditions, such as intrauterine/ fetal growth restriction, 
the umbilical artery waveform change and the angle-independent indices become abnormal, 
giving values above their reference ranges. End-diastolic velocity may thus change from 
normal to reduced, absent or reversed. These changes represent an increased placental 
vascular resistance, and could pathologically be associated with a decrease in the number of 
placental arteries per high power field (Giles et al., 1985). The most common scenario for 
fetal growth restriction include placental insufficiency in singleton or multiple pregnancies 
from various aetiologies, which may or may not be associated with pre-eclampsia or other 
maternal conditions, or in fetuses with congenital malformations. Such a picture commonly 
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occurs in women with pre-existing diabetes mellitus with vasculopathy. In pregnancies with 
suspected fetal growth restriction, the use of umbilical artery Doppler has been 
demonstrated to reduce the number of perinatal deaths and unnecessary obstetric 
interventions. In the context of diabetic pregnancies, however, the applications of umbilical 
artery Doppler remain controversial.  
To investigate the vascular resistance by Doppler ultrasound in the umbilical artery of 53 
IDDM pregnancies longitudinally over the course of pregnancy, the resistance index of the 
Doppler waveform was correlated with the mean value of a 24 hour blood glucose profile 
and the concentrations of glycosylated haemoglobin (HbA1C), which represented 
parameters of metabolic control. Regression analysis, however, showed no significant 
correlation between vascular resistance and mean blood glucose levels or HbA1C 
concentrations (Zimmermann et al., 1992).  
In another study that included 67 normotensive women with pregnancies complicated by 
IDDM, the umbilical artery pulsatility index was compared with both pregnancy 
complications and perinatal outcome. The last umbilical pulsatility index value before 
delivery was used for analysis, and Doppler results were not used for patient management. 
Out of this cohort, 44 (66%) had pulsatility index values within the normal range between 
the 5th to 95th percentile, while 23 (34%) had abnormally high pulsatility index values. 
Among the group with pathologically abnormal umbilical pulsatility indices, analysis of the 
data revealed a significantly higher incidence of both caesarean section for acute fetal 
distress and perinatal complications. These complications include respiratory distress 
syndrome, hyperbilirubinemia, neonatal hypoglycaemia, and the need for neonatal 
intensive care unit admission. The authors concluded that in at least one third of IDDM 
patients, increased vascular resistance in the umbilical arteries were found, and these also 
suffered from higher incidences of perinatal complications (Fadda et al., 2001). 
A retrospective study of 146 patients with gestational diabetes noted that Doppler examination 
of the umbilical arteries seemed to be of little clinical value unless pregnancy was complicated 
by pre-eclampsia or intrauterine growth restriction. The study included 227 patients with 
diabetes, and umbilical artery Doppler velocimetry and glycaemic control were examined in 
the third trimester. An elevated systolic/diastolic ratio and an abnormal glycosylated 
haemoglobin level were associated with adverse pregnancy outcome, but there was no 
stratification for vascular disease or fetal growth restriction in the data (Bracero et al., 1996).  
In a prospective study of 65 well controlled diabetic pregnancies, Doppler measurements of 
uterine arteries, umbilical artery, the fetal descending thoracic aorta, and the middle cerebral 
artery (MCA) were performed together with cordocentesis for measurement of umbilical 
venous blood pH, pO2 and haematocrit. It was found that the mean umbilical venous blood 
pH was significantly lower and the haematocrit significantly higher than the appropriate 
normal mean for gestation for these diabetic pregnancies. However, the Doppler indices of 
the placental and fetal circulations were essentially normal, except in some of the cases 
complicated by pre-eclampsia or intrauterine growth restriction (Salvesen et al., 1993). It 
was thus concluded that maternal diabetes mellitus was not associated with abnormalities 
in Doppler indices of the placental or fetal circulations.  
To evaluate a random single Doppler study of the systolic/diastolic ratio of the umbilical 
artery as a predictor of perinatal outcome in diabetic pregnancies, a prospective double-
blind study was performed in 92 diabetic pregnancies between 28 and 40 weeks gestation, 
and the results were associated with perinatal outcome parameters. The sensitivity and 
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occurs in women with pre-existing diabetes mellitus with vasculopathy. In pregnancies with 
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artery as a predictor of perinatal outcome in diabetic pregnancies, a prospective double-
blind study was performed in 92 diabetic pregnancies between 28 and 40 weeks gestation, 
and the results were associated with perinatal outcome parameters. The sensitivity and 





92% respectively. The positive and negative predictive values were 54% and 86% 
respectively. The authors suggested that the systolic/diastolic ratio of the umbilical artery 
offer no advantage over other well established tests in management of diabetic pregnancies 
(Ben-Ami et al., 1995).  
In a cohort of 104 women with both type I and type II pre-existing diabetes mellitus, 
umbilical artery Doppler was performed at 28, 32, 36 and 38 weeks gestation. Overall, 22% 
had an elevated pulsatility index. If the Doppler examination was carried out within 2 
weeks of delivery, 71% with abnormal umbilical artery Doppler had adverse perinatal 
outcome (likelihood ratio 4.2). However, the sensitivity of umbilical artery Doppler to 
predict such adverse outcome was only 35%, while specificity was 94%. The positive 
Predictive value was 80% and negative predictive value was 68%. Only 30% of women with 
adverse perinatal outcome had abnormal umbilical artery Doppler measurements. The 
authors thus concluded that the performance of umbilical artery Doppler was not 
satisfactory even in this group of high risk women with pre-existing diabetes, and that it 
was not a good predictor of adverse perinatal outcome (Wong et al., 2003).  
To investigate whether complications were higher in diabetic pregnancies with cardiac 
maladaptation, fetal, uteroplacental and echocardiographic examinations were compared in 
the second and third trimester between diabetic and healthy pregnant women. Physiological 
cardiac hypertrophy was found in healthy women but was less prominent in patients with 
diabetes. While the majority of patients studied have normal Doppler results, the abnormal 
uteroplacental flow group consisted entirely of women with pregestational diabetes, 
especially IDDM patients. Neonatal complications were also more common in this 
subgroup. No relationship was found between echocardiographic findings, Doppler 
waveforms and perinatal outcome. Similar to previous studies, the findings confirmed that 
umbilical and uteroplacental Doppler were useful only in pre-existing diabetes, but not in 
GDM patients (Parlakgumus et al., 2010).  
From the above studies, it can be seen that both observational data and randomized control 
data have failed to show any consistent association between maternal diabetes and 
abnormal umbilical artery Doppler indices. It is apparent that the current evidence supports 
the use of umbilical artery Doppler only in those patients with diabetes who have 
pregnancies complicated by hypertensive diseases, fetal growth restriction, or vasculopathy. 
Umbilical Doppler studies cannot be recommended as a routine screening for fetal 
surveillance especially in patients without pre-existing diabetes mellitus (Pietryga et al., 
2006). 
3.3 Middle cerebral artery Doppler  
The middle cerebral artery (MCA) is the most studied cerebral artery because it is simple to 
sample, consistent and reproducible, and provides information on the cerebral blood flow in 
normal and growth restricted fetuses (Mari et al., 2008). In addition, the MCA can be 
sampled at an angle of near zero degrees between the ultrasound beam and the direction of 
the blood flow, so that the genuine velocity of the blood flow can be measured. In growth 
restricted foetuses, there is a redistribution of the blood flow from the fetal periphery to the 
brain, commonly known as the brain-sparing effect. In severe fetal growth restriction with 
abnormal umbilical artery, MCA Doppler is a valuable adjunct, with abnormal findings 
signifying the onset of compromise that should soon require delivery (Dubiel et al, 
2002).Overt MCA changes appear as increased diastolic velocity, and an altered cerebral-
placental ratio will thus be observed. Changes in cerebral-placental ratio may be at least 
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partly pressure-dependent, reflecting structural placental deficiencies, whereas brain-
sparing is attributed to hypoxia induced cerebrovascular dilatation (Baschat, 2003).  In those 
pregnancies over 34 weeks gestation, placental functional decline may be more dominant 
that structural decline. Thus MCA changes in brain-sparing may appear in small fetuses 
with near-normal umbilical artery Doppler (Severi et al., 2002; To et al., 2005). Such findings 
are again more likely to occur in women with pre-existing diabetes mellitus with 
vasculopathy than in those with gestational diabetes mellitus.  
Another use for examining the MCA is to detect fetal anaemia. The MCA can be insonated 
at an angle between zero and 15 degrees to measure the actual flow velocity in the vessel. 
The lowest intra- and inter-observer variability is obtained when the MCA proximal to the 
transducer is sampled near its origin from the internal carotid artery without the use of 
angle correction using a 1-2 mm sample volume (Mari et al., 2005). A peak systolic velocity 
(PSV) of 1.50 MoM in fetuses at risk of anaemia has a sensitivity for detecting anaemia of up 
to 100% (confidence interval 86-100%) in red cell alloimmunization as well as other cases of 
anaemia (Mari et al., 2000). In the context of diabetic pregnancies, maternal hyperglycemia is 
thought to cause an increase in fetal haematocrit, as cordocentesis has demonstrated a 
positive relationship between maternal hyperglycaemia and fetal polycythemia (Salvesen et 
al., 1992). Theoretically, the increase in blood viscosity due to polycythemia might be 
reflected by a corresponding decrease in blood flow velocity in the fetal circulation, which is 
opposite to the fetal anaemia model. This would be particularly prominent in affected 
macrosomic fetuses in gestational diabetes, who often suffer prolonged neonatal jaundice 
resulting from the polycythemia. However, such findings have not been consistently 
demonstrated in published reports.  
In a prospective study of 138 singleton pregnancies with GDM, umbilical artery pulsatility 
index and middle cerebral artery pulsatility index were measured serially every 4 weeks 
from the diagnosis of GDM until delivery. A total of 305 Doppler examinations were 
performed with one to four examinations for each woman. About 27% ( 38) had one or more 
abnormal pregnancy outcomes: placental abruption, pre-eclampsia, preterm delivery, small-
for-gestational-age, low Apgar scores, neonatal jaundice requiring treatment, sepsis, birth 
trauma, meconium aspiration syndrome, respiratory and neurological complications, 
However, there was extensive overlapping of the umbilical artery and MCA pulsatility 
indices,  as well as MCA PSV values between those with normal and abnormal pregnancy 
outcomes. It was thus concluded that that Doppler studies of the umbilical and cerebral 
vessels were not useful for predicting outcome in these GDM pregnancies (Leung et al., 
2004).  In another cohort of 84 GDM pregnancies, it was found that stratifying the fetuses 
into appropriate, small- and large-for-gestational-age did not give any better correlation 
between the umbilical or middle cerebral impedance indices, but did apparently show that 
the bigger fetuses had lower MCA PSV and higher mean umbilical venous flow velocity 
than the smaller fetuses (To et al, 2009). It has been proposed that the pathophysiological 
basis of altered placental vascular flow patterns in diabetic pregnancies was functional, 
related to hyperglycemia induced thromboxane/ prostacyclin ratio imbalance (Saldeen et 
al., 2002), rather than to structural abnormalities related to trophoblastic invasion during 
development of the placental vascular bed. Thus, the abnormal umbilical waveforms and 
abnormal placental-cerebral Doppler ratios that were observable in non-diabetic 
pregnancies with fetal growth restriction would not be applicable to gestational diabetic 
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partly pressure-dependent, reflecting structural placental deficiencies, whereas brain-
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pregnancies over 34 weeks gestation, placental functional decline may be more dominant 
that structural decline. Thus MCA changes in brain-sparing may appear in small fetuses 
with near-normal umbilical artery Doppler (Severi et al., 2002; To et al., 2005). Such findings 
are again more likely to occur in women with pre-existing diabetes mellitus with 
vasculopathy than in those with gestational diabetes mellitus.  
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at an angle between zero and 15 degrees to measure the actual flow velocity in the vessel. 
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transducer is sampled near its origin from the internal carotid artery without the use of 
angle correction using a 1-2 mm sample volume (Mari et al., 2005). A peak systolic velocity 
(PSV) of 1.50 MoM in fetuses at risk of anaemia has a sensitivity for detecting anaemia of up 
to 100% (confidence interval 86-100%) in red cell alloimmunization as well as other cases of 
anaemia (Mari et al., 2000). In the context of diabetic pregnancies, maternal hyperglycemia is 
thought to cause an increase in fetal haematocrit, as cordocentesis has demonstrated a 
positive relationship between maternal hyperglycaemia and fetal polycythemia (Salvesen et 
al., 1992). Theoretically, the increase in blood viscosity due to polycythemia might be 
reflected by a corresponding decrease in blood flow velocity in the fetal circulation, which is 
opposite to the fetal anaemia model. This would be particularly prominent in affected 
macrosomic fetuses in gestational diabetes, who often suffer prolonged neonatal jaundice 
resulting from the polycythemia. However, such findings have not been consistently 
demonstrated in published reports.  
In a prospective study of 138 singleton pregnancies with GDM, umbilical artery pulsatility 
index and middle cerebral artery pulsatility index were measured serially every 4 weeks 
from the diagnosis of GDM until delivery. A total of 305 Doppler examinations were 
performed with one to four examinations for each woman. About 27% ( 38) had one or more 
abnormal pregnancy outcomes: placental abruption, pre-eclampsia, preterm delivery, small-
for-gestational-age, low Apgar scores, neonatal jaundice requiring treatment, sepsis, birth 
trauma, meconium aspiration syndrome, respiratory and neurological complications, 
However, there was extensive overlapping of the umbilical artery and MCA pulsatility 
indices,  as well as MCA PSV values between those with normal and abnormal pregnancy 
outcomes. It was thus concluded that that Doppler studies of the umbilical and cerebral 
vessels were not useful for predicting outcome in these GDM pregnancies (Leung et al., 
2004).  In another cohort of 84 GDM pregnancies, it was found that stratifying the fetuses 
into appropriate, small- and large-for-gestational-age did not give any better correlation 
between the umbilical or middle cerebral impedance indices, but did apparently show that 
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basis of altered placental vascular flow patterns in diabetic pregnancies was functional, 
related to hyperglycemia induced thromboxane/ prostacyclin ratio imbalance (Saldeen et 
al., 2002), rather than to structural abnormalities related to trophoblastic invasion during 
development of the placental vascular bed. Thus, the abnormal umbilical waveforms and 
abnormal placental-cerebral Doppler ratios that were observable in non-diabetic 
pregnancies with fetal growth restriction would not be applicable to gestational diabetic 





the larger or macrosomic fetuses might be compatible with this hypothesis. In short, in the 
absence of pre-eclampsia or significant fetal growth abnormalities, the use MCA Doppler in 
diabetic pregnancies appears to have limited value.  
3.4 Umbilical Vein waveform and umbilical venous flow volume  
Arterial waveforms describe downstream resistance in critical vascular beds, in which 
disease or response to pathological conditions causes blood flow alterations. Venous 
Doppler, however, provides important cardiac data about stressed fetal circulations.  
Potential targets include the umbilical vein, inferior vena cava and the ductus venosus, 
while regional networks such as the hepatic, superior vena cava, intracranial and 
pulmonary veins have not provided clinically relevant cardiac indicators (Harman et al., 
2003). By mid second trimester, the fetal umbilical vein normally has a continuous blood 
flow pattern, but this pattern can become pulsatile in pathological conditions, such as in 
significant fetal growth restriction and in hydropic fetuses. Thus, for umbilical venous 
waveforms, it has been advocated that a qualitative assessment of continuous versus 
pulsatile blood flow is used (Mari et al., 2008). Such venous pulsations most likely represent 
severe and critical fetal myocardial dysfunction and usually only appear at very late stages 
of fetal compromise. Umbilical venous waveforms are therefore not useful as an early sign 
for assessment of fetal well being for timing delivery. 
The use of umbilical venous volume flow based on calculations of the cross-sectional area of 
the umbilical vein has been used and reported in previous studies to have a high degree of 
reproducibility (Boito et al., 2003). There have been suggestions for using the intra-
abdominal portion of the umbilical vein (Haugen et al., 2004), as the latter would be less 
mobile than a free cord loop. Empirical experience showed that the demand on technical 
expertise between the two sites were largely similar, though  the variations in the diameter 
of the intra-hepatic umbilical vein along its length could be somewhat higher than that of 
the free cord loop, and calculations of its cross-sectional diameter more complicated. In 
addition, since routine umbilical arterial Doppler would be performed on a free cord loop, it 
would be practical and convenient to extend the measurements to the adjacent vein within 
the cord segment (To & Mok, 2009). 
To evaluate whether umbilical and middle cerebral arterial Doppler indices and umbilical 
venous volume flow are reflective of maternal gestational diabetic states, and whether such 
indices would be associated with the size of the fetus, a prospective observational study was 
performed in a cohort of 84 GDM pregnancies and compared with 62 non-diabetic controls. 
It was found that the mean pulsatility index values for the umbilical artery and the mean 
total umbilical venous flow (TUVF) and TUVF per unit birth weight did not differ 
significantly between diabetic and non-diabetic pregnancies. Large-for-gestational-age 
fetuses showed higher TUVF than normal size fetuses, but the TUVF per unit birth weight 
was higher for small-gestational-age fetuses. These differences were independent of their 
diabetic status. The only significant differences between non-diabetic and diabetic 
pregnancies in the data appeared to be the difference in the diameter and the mean flow 
volume of the umbilical vein, which were again probably more likely to be related to the 
size of the fetus. It was thus concluded that umbilical venous Doppler measurements near 
term were unable to distinguish between diabetic and non-diabetic pregnancies, and that 
umbilical venous flow volume was apparently more sensitive to the size of the fetus than to 
the maternal diabetic state (To & Mok, 2009). As fetal size variations could be secondary to 
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poor maternal glycemic control, and macrosomic fetuses would demonstrate such 
measurements, it might be argued that the total umbilical venous flow would still indirectly 
reflect fetal conditions, or the presence or absence of macrosomia. However, it is obvious 
that direct measurement of fetal growth parameters would be more precise in defining fetal 
overgrowth. 
The mean total umbilical venous flow has been shown in previous studies to be related to 
the total cardiac output of the fetus, so that the larger fetus with a higher cardiac output 
would have higher flow volumes (Boito et al., 2003). It was not surprising that when 
controlled for birthweight, the mean total umbilical venous flow differences between large- 
and small-for-gestational-age fetuses were greatly attenuated. Recent data have shown that 
in growth restricted fetuses, there would be a preferential distribution of umbilical venous 
flow to the ductus venosus rather than via the fetal liver (Bellotti et al, 2004). However, 
whether such venous shunting mechanisms would be responsible for the observed higher 
mean umbilical venous flow per unit weight in small-for –gestational-age fetuses as 
compared to larger ones would require further evaluation. In diabetic pregnancies, on the 
other hand, it has been found that fetal liver volume could be associated with accelerated 
growth in these fetuses, though only marginal differences could be shown in the umbilical 
venous volume flow. Further studies to compare growth and TUVF volumes in fetuses 
within a large non-diabetic population would be of value to study the differences in 
circulatory volumes in relation to size of the fetus. 
3.5 Artioventricular valves 
The atrioventricular values (mitral and tricuspid) are characterized by two peaks – the “E” 
wave corresponding to the rapid filling of the ventricles and the “A” wave that corresponds 
to the atrial contraction. The “A” wave is taller than the “E” wave, and may reflect the 
stiffness of the fetal cardiac chambers. With advancing gestation, the E/A wave ratio 
increases. By contrast, after birth, the “E” wave will be taller than the “A” wave. In growth 
restricted fetuses, the two waves become abnormal (the E/A ratio increases) and in severe 
cases, there will be tricuspid and mitral regurgitation (Rizzo et al., 1988). Thus, in the study 
of diabetic pregnancies, such studies would be of value only if the pregnancy is complicated 
by severe fetal growth restriction.  
3.6 Ductus venosus Doppler waveforms 
The ductus venosus provides a unique combination of data, as it is the primary regulator of 
venous return in both normal and abnormal fetuses and is also a direct conduit of right 
atrial retrograde pulse waves (Harman et al., 2003). The ductus waveform is responsive to 
changes in oxygenation independent of cardiac function, and it is readily imaged because of 
its very high focal velocity on colour Doppler from early second trimester onwards. Ductus 
venosus waveforms are characterized by two peaks, the S and D, followed by a nadir, the 
atrial wave. Haemodynamically, these phases reflect the rapid chronologic change in 
pressure gradients between the umbilical vein and the right atrium. In normally grown 
fetuses, there is forward flow at the ductus venosus, and the pulsatility index for veins (S-
D/a) decreases with advancing gestation. In growth restricted fetuses, the pulsatility index 
increases, and in the most severe cases, there will be reverse flow in the atrial wave.  
Ductus venosus waveform deterioration precedes and predicts changes in biophysical 
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total umbilical venous flow (TUVF) and TUVF per unit birth weight did not differ 
significantly between diabetic and non-diabetic pregnancies. Large-for-gestational-age 
fetuses showed higher TUVF than normal size fetuses, but the TUVF per unit birth weight 
was higher for small-gestational-age fetuses. These differences were independent of their 
diabetic status. The only significant differences between non-diabetic and diabetic 
pregnancies in the data appeared to be the difference in the diameter and the mean flow 
volume of the umbilical vein, which were again probably more likely to be related to the 
size of the fetus. It was thus concluded that umbilical venous Doppler measurements near 
term were unable to distinguish between diabetic and non-diabetic pregnancies, and that 
umbilical venous flow volume was apparently more sensitive to the size of the fetus than to 
the maternal diabetic state (To & Mok, 2009). As fetal size variations could be secondary to 
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poor maternal glycemic control, and macrosomic fetuses would demonstrate such 
measurements, it might be argued that the total umbilical venous flow would still indirectly 
reflect fetal conditions, or the presence or absence of macrosomia. However, it is obvious 
that direct measurement of fetal growth parameters would be more precise in defining fetal 
overgrowth. 
The mean total umbilical venous flow has been shown in previous studies to be related to 
the total cardiac output of the fetus, so that the larger fetus with a higher cardiac output 
would have higher flow volumes (Boito et al., 2003). It was not surprising that when 
controlled for birthweight, the mean total umbilical venous flow differences between large- 
and small-for-gestational-age fetuses were greatly attenuated. Recent data have shown that 
in growth restricted fetuses, there would be a preferential distribution of umbilical venous 
flow to the ductus venosus rather than via the fetal liver (Bellotti et al, 2004). However, 
whether such venous shunting mechanisms would be responsible for the observed higher 
mean umbilical venous flow per unit weight in small-for –gestational-age fetuses as 
compared to larger ones would require further evaluation. In diabetic pregnancies, on the 
other hand, it has been found that fetal liver volume could be associated with accelerated 
growth in these fetuses, though only marginal differences could be shown in the umbilical 
venous volume flow. Further studies to compare growth and TUVF volumes in fetuses 
within a large non-diabetic population would be of value to study the differences in 
circulatory volumes in relation to size of the fetus. 
3.5 Artioventricular valves 
The atrioventricular values (mitral and tricuspid) are characterized by two peaks – the “E” 
wave corresponding to the rapid filling of the ventricles and the “A” wave that corresponds 
to the atrial contraction. The “A” wave is taller than the “E” wave, and may reflect the 
stiffness of the fetal cardiac chambers. With advancing gestation, the E/A wave ratio 
increases. By contrast, after birth, the “E” wave will be taller than the “A” wave. In growth 
restricted fetuses, the two waves become abnormal (the E/A ratio increases) and in severe 
cases, there will be tricuspid and mitral regurgitation (Rizzo et al., 1988). Thus, in the study 
of diabetic pregnancies, such studies would be of value only if the pregnancy is complicated 
by severe fetal growth restriction.  
3.6 Ductus venosus Doppler waveforms 
The ductus venosus provides a unique combination of data, as it is the primary regulator of 
venous return in both normal and abnormal fetuses and is also a direct conduit of right 
atrial retrograde pulse waves (Harman et al., 2003). The ductus waveform is responsive to 
changes in oxygenation independent of cardiac function, and it is readily imaged because of 
its very high focal velocity on colour Doppler from early second trimester onwards. Ductus 
venosus waveforms are characterized by two peaks, the S and D, followed by a nadir, the 
atrial wave. Haemodynamically, these phases reflect the rapid chronologic change in 
pressure gradients between the umbilical vein and the right atrium. In normally grown 
fetuses, there is forward flow at the ductus venosus, and the pulsatility index for veins (S-
D/a) decreases with advancing gestation. In growth restricted fetuses, the pulsatility index 
increases, and in the most severe cases, there will be reverse flow in the atrial wave.  
Ductus venosus waveform deterioration precedes and predicts changes in biophysical 





hypothesised to be the result of a volume/pressure effect, in which excess afterload is 
transmitted through the heart, and myocardial dysfunction appears as an end-stage 
compromise. A second indication of ductus venosus Doppler occurs at 12-14 weeks in 
conjunction with nuchal translucency screening and uterine artery screening. Abnormal 
retrograde atrial waves are a strong predictor of fetal cardiac abnormality, and also a good 
predictor of Down syndrome (Bilardo et al., 2001). Given the higher risks of congenital 
cardiac abnormalities in pregnancies complicated by pre-existing diabetes mellitus, ductus 
venosus screening at this gestation may have a role. There is as yet, scanty data in the 
literature that describe the use of ductus Doppler specific to diabetic pregnancies, and the 
application of ductus Doppler largely refers to that of growth restricted fetuses in general. 
To evaluate the ability of the ductus venosus Doppler to predict adverse perinatal outcome 
in pregnancies complicated by pre-existing diabetes mellitus, a prospective study that 
included 82 women with pre-existing diabetes mellitus was performed. The ductus venosus 
Doppler index was defined as abnormal if the ductus venosus peak velocity index for veins 
was equal to or greater than the 95th percentile for gestation. Abnormal ductus venosus 
index was identified in 30.5% (n=25).  Adverse perinatal outcome was identified in around 
one-third of these with abnormal indices (8/25) compared to 12.3% (5/57) with a normal 
ductus index. The sensitivity of the ductus venosus index in predicting adverse perinatal 
outcome in pre-existing diabetic pregnancies was thus 53.3% and specificity was 74.5%, with 
a positive predictive value of 32% and negative predictive value of 87.7%. The authors 
concluded that it should be useful to include ductus venosus Doppler indices as part of 
antenatal screening of pregnancies complicated by pre-existing diabetes mellitus (Wong et 
al., 2010).  
4. Practical application of Doppler studies to diabetic pregnancies 
It has thus been postulated that the degree of glycemic control would have more impact on 
the Doppler study results rather than directly related to the diabetic state (Bracero et al., 
1991). The lack of association of Doppler parameters to maternal diabetic state was 
particularly true when the pregnancy was not complicated by fetal growth restriction or 
pre-eclampsia. While higher incidences of adverse outcome in diabetic pregnancies were 
related to the occurrence of such complications or to poor glycemic control with 
macrosomia, Doppler studies have apparently only limited effectiveness in predicting 
adverse perinatal outcome in these fetuses. Summing up the available data from the 
literature, a basic protocol for the sequential use of Doppler studies in both pre-existing and 
gestational diabetic pregnancies can be proposed (Table 1). Nevertheless, the clinical 
effectiveness of such a protocol still remains to be evaluated.  
5. Summary 
Available randomized control data and observational data have failed to demonstrate any 
consistent association between maternal diabetes and abnormal umbilical arterial Doppler 
indices. Doppler measurements of other fetal vessels apart from the umbilical arteries, such 
as the fetal descending aorta and the middle cerebral artery resistance indexes, or the peak 
systolic velocity of the middle cerebral arteries have also been studied in GDM pregnancies, 
and a similar lack of predictability for adverse outcome was generally found.  The lack of 
 
 






parameters Primary endpoint 
PDM or 
GDM 






 Uterine  Notching, PI FGR PGD 
22-24 Uterine  Notching, PI FGR PGD 







PI, CRP, PSV  
PI, TUVF 
AV flow, TR, MR 
Retrograde atrial 
valves  
FGR PGD/ GDM 
PDM: pre-existing diabetes mellitus, GDM: gestational diabetes mellitus, DV: ductus venosus 
PI: pulsatility index, CRP: cerebral placental ratio, FGR: fetal growth restriction, 
PSV: peak systolic velocity, AV: atrioventricular, TR: tricuspid regurgitation, MR: mitral regurgitation 
Table 1. Sequential Doppler applications foe diabetic pregnancies 
association of Doppler parameters to maternal diabetic state was particularly true when the 
pregnancy was not complicated by fetal growth restriction or pre-eclampsia. While higher 
incidences of adverse outcome in diabetic pregnancies were related to the occurrence of 
poor glycemic control with macrosomia and polyhydramnios, conventional arterial Doppler 
indexes and cerebral /placental Doppler ratios have not been shown to be effective in 
picking up these high risk fetuses. The use of umbilical venous Doppler and venous volume 
flow based on calculations of the cross-sectional area of the umbilical vein has been reported 
in various studies to have a high degree of reproducibility. Venous volume flow 
measurements have not been found to be consistently reflective of maternal gestational 
diabetic states. Such volume flow measurements apparently reflected well the fetal growth 
and size and thus indirectly the glycemic control and the risks of perinatal complications. 
Doppler studies of other venous sites, including the intraabdominal/ intrahepatic portion of 
the umbilical vein, or the ductus venosus have also been studied with variable results. 
Whether such measurements could be used directly for monitoring fetal well being requires 
further evaluation. 
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and dietetic recommendations, findings, calculation and prescription of a correct diet 
(Distribution of: proteins, lipids and carbohydrates), in combination with counseling 
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disadvantages of the glucemyc index and how a low and moderate one allows the control of 
blood glucose. The glycemic index is defined as the area under the curve of glucose 
response after eating a recomended amount of carbohydrates from a test food after a control 
food (white bread or glucose), and these had been considered part of the control of blood 
glucose. Besides, we present the methods for collecting diet information as a complement to 
improve the follow up and the adherence to GDM. Other important aspects to discuss are 
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therapy, physical activity, benefits, risk and  the type of exercise for GDM, education, 
psychological support, insuline and drugs . The prevention and promotion should consider 
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GDM mothers have a wide range of possible complications. These recommendations should 
result in adequate weight gain for the fetus and the woman. A deficit in the weight gain is 
associated with intrauterine growth restriction for the fetus. Dietary control is defined as a 
part of the comprehensive treatment of GDM and the diets low in carbohydrates, lipids, and 
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The main goal of the dietary treatment is to maintain the maternal and fetal health and the 
diet with low carbohydrates help to the management of GDM, where the main goal is to 
achieve and to maintain blood glucose and glycated hemoglobin according to the practice 
guidelines for GDM and to avoid ketonuria. The adhesion to dietary treatment is difficult in 
most patients when they intake lower amount of carbohydrates. The findings reported in 
the control of the  GDM such as changes in weight gain,  energy intake, and macronutrients 
are part of a basic treatment to prevent complications for the fetus and the pregnant mother. 
We will review of promotion and prevention activities as part of the dietary treatment. 
Finally, we hope that this information let discuss new alternatives for GDM. 
2. Diet: Transitional changes 
Since the last century, many countries have experienced changes in health and food patterns 
that are characterized by an increasing prevalence of chronic diseases. These chronic 
diseases are the principal cause of death and commonly  happen particularly particularly in 
pregnant women and children. There are many factors that may explain these changes and 
one of the most important one to consider is the dietary habits because they explain the 
metabolic diseases (Avila A, et al., 1995; ENSANUT, 2006). As mentioned above, there are 
other factors that might explain these changes and the principal ones are the alterations in 
dietary habits that are considered important to explain the metabolic diseases (Avila A, et 
al., 1995; ENSANUT, 2006). For example, México is living an epidemiological transition that 
has occurred in recent decades. For instance, the most common causes of death in this 
transition are cardiovascular diseases, cancer, accidents and diabetes. Fifty years ago, most 
of the causes of death in the Mexican population were related to diarrhea and respiratory 
diseases. The research done at the Mexican National Institute of Nutrition supports the idea 
that the proportion of animal products in the diet of Mexicans has increased sharply. In 
addition, fast food, ,in most countries, is considered as a frequent choice for many people 
who live in the city. The epidemiological changes that have occurred in many countries are 
not homogeneous throughout the world; for instance, they vary according to geographical, 
regional and socioeconomical factors. Based on the studies carried by Romieu, et al., it is 
possible to observe the coexistence of over nutrition and under nutrition in the same 
population. In underdeveloped countries, it is possible to observe that about one-third of 
children under 5 years are stunted, and 20% of women are obese. (Romieu I, et al., 1997).  
The dynamic of the epidemiological aspects in many countries provides challenges and 
opportunities for studying dietary habits. These dietary habits can serve as the base for 
conducting studies about how the diet can modify the occurrence of chronic diseases, and 
the impact on the nutritional health can be investigated as well (Romieu I, et al., 1997; Ávila 
A, et al., 1995). Other then dietary habits, there are more factors to be considered at risk for 
developing obesity such as: excessive consumption, physical activity, sedentary and 
hereditary factors. Many countries have had an apparent economical development during 
the last decade and has contributed to the lifestyle, eating habits, customs, behaviors, etc. 
The diet of developed countries consist of cereals, legumes, fruits and vegetables. These 
changes are similar to those of the industrialized countries (high-energy diet, protein, 
animal fat and low fiber). This is the price we have had to pay for the globalization that our 
world is facing because this is the result of the free trade agreement in developed countries. 
Moreover, the powerful influence of the North American culture has affected the entire 
world. One example of this is the payment-saving culture „pay less, get more“ so it is 
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cheaper to be obese. The same phenomenon operates in fast food restaurants and 
convenience stores, among others.  
The industrialization of a city has as a consequence that some products contain raw poor 
materials disguised with flavors that result in products of low nutritional value but tasty. 
They are also well supported with good marketing strategies and are aimed especially to 
children. Another important finding is that some Latin American countries spend from 20 to 
30% of their income in food and they have the higest consumption of soft drinks in the 
world; hence, soft drinks have replaced water consumption. In additin to this, the presence 
of obesity in the family is an important factor to be considered because if both parents are 
obese then, the risk of obesity in children is 80%. Television and video games are other 
factors of great influence. In countries where the habit of reading is replaced by television 
and video games, it has been observed that there is an adjustement in children‘s behavior 
and habit consumptions of some products. For example, 85% of the commercials on TV 
promote soft drinks, desserts and fried food (Ramirez JA, et al., 2003). 
Sciences such as demography and epidemiology help to understand the phenomenology 
behind food and nutrition in a sistematic way. Where the  diet habits are related with the 
culture, traditional  habits, climate, available foods, etc. These habits do not change  
inmediately. Transitional nutrition has five phases or periods that the majority of societies 
experienced and these are (Nielsen, S & Popkin, B, 2003): 
a. Stage of "food gathering". The diet is high in carbohydrates and fiber but low in fat. This 
stage is characterized by the hunting and gathering of food. 
b.  Stage of “starvation". It occurred with the early development of agriculture when food 
was less varied and linked to periods of extreme food shortages. 
c. Stage of “increased consumption of fruits, vegetables and animal products”. Starches begin to 
be less important in the basic diet. This stage is related to the industrial and the second 
agricultural revolution.  
d. Stage of “Presence of chronic degenerative diseases”. It increases with the prevalence of 
obesity as a result of the consumption of diets high in fat, cholesterol, refined 
carbohydrates, small amounts of polyunsaturated fatty acids and fiber and physical 
inactivity. In this stage there is an increase in the population that migrate to big cities 
where home and work are located far away from traditional markets.  
e. Stage of “behavioral change”. This stage is characterized by the adoption of healthy diets, 
physical activity and the abandonment of traditional diets. Here, the consumption of 
cereals and tubers is very important. In this stage, there is a tendency to a global 
homogenization of the type of food that is consumed. Then, an intake of high energy, 
total fat, saturated fat and simple sugars is required. Moreover, physical activity 
decreases due to changes in occupational activities, transportation facilities, these 
contributed to increase the chronic diseases (diabetes mellitus, hypertension and 
atherosclerosis) related to overweight and other nutrition aspects. 
Finally, it is necessary to say that each country goes through these periods of transition at 
different times and with a different speed.  
The main characteristic of transactional nutrition is that these changes occur more rapidly in 
middle or low income countries than in the high-income ones. In low income countries, there 
is a negative impact in their economical growth due to that the fact that they spend more 
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This is done with the purpose of getting cheaper food that can be obtained faster by people. 
However, the use of this kind of food promotes the appearance of cardiovascular diseases.  
Changing of food consumption has altered in many countries because, they prefer to buy 
prepared food than to cooked it at home. As a result, the consumption of oilseeds, vegetable 
oils, fish and seafood has been decreasing but there is an increment in the consumption of 
animal fat, alcoholic beverages, meat and eggs consumption. These habits increase the costs 
and the quality of ingredients in food (Ortiz-Hernández, L, et al., 2006; Monroy-Torres R, et 
al., 2010). The changes mentioned above are part of the evidence that has been gathered 
from the population that lives in urban areas, people employ in the tertiary sectors and the 
actual role of woman (Ortiz-Hernández L, et al., 2006).  
The determinants of the are located mainly in both, the social organization and the 
technological progress of the society (Ortiz-Hernández, et al., 2006). Another determinant 
that is also important to consider is the educational level. During the periods of 1988–1994 
and, 2007-2008, the prevalence of childhood obesity in United State increased at all income 
and educational levels (CDC, 2010). 
According to diet and disease, 20 years ago, it was discovered that low birthweight was 
associated with an increased risk of adult diabetes and cardiovascular disease (CVD). A 
hypothesis was formulated with this information,wich states that that the exposure to 
undernutrition in early life increased the risk to develop these disorders in the metabolic 
programation. In order to solve the problem caused in the metabolic programation, it has 
been proposed another hypothesis that claims that it would be important  to improve the 
nutritional state from the pre gestational stage to the gestational stage and finally the 
nutritional attention to the new born to prevent common chronic diseases in the future. The 
research done with low birth weight children in many countries shows that they have 
increased CVD risk factors. The scientific findings gotten from maternal nutrition have 
contribute to understand the role of specific nutrients in the maternal diet, like low maternal 
vitamin B12 status,wich predicted the increased of adiposity and insulin resistance in 
children, especially if the mother had a folate deficiency. Both maternal undernutrition and 
gestational diabetes cause problems (glucose excess) They have also been associated with 
increased adiposity and insulin resistance in children. In underdeveloped countries, it has 
been noticed that undernutrition and overnutrition coexist. Recent intervention studies in 
developed countries have shown that CVD risk factors in the offspring can be improved by 
supplementing undernourished mothers during pregnancy. Of course, results differ 
according to the population, the intervention and the post-natal environment (Fall C., 2009). 
3. Evidence in the diet management of gestational diabetes mellitus 
Dietary therapy is the most important factor to be consider in the treatment of GDM. Therefore 
all women with GDM must receive counseling from a dietitian. Recommendations have  to be 
individualized after a dietary evaluation of each patient. The two main objectives for  the 
treatment of  GDM are to achieve normoglycemia and to provide the required nutriments for 
normal fetal growth and maternal health. A third objective that is also considered to be 
important, is to prevent excessive maternal weight gain, particularly in women who are 
overweight or have gained excess weight in pregnancy.  
Few trials have analyzed the efficacy of dietary therapy for GDM. A cluster randomized 
controlled study supports that Medical Nutrition Therapy (MNT) for GDM is recommended 
by the American Diabetes Association (ADA, 2010). The MNT is a lifestyle intervention that 
 
The Influence of Diet to Control the Metabolism in Gestational Diabetes Mellitus 
 
281 
consists of an integral component of diabetes prevention, management, and self-
management education (Goldhaber-Fiebert JD, et al., 2003).  
A recommended diet for the glucemia control in GDM must be low in carbohydrates,with a 
percentage between 35% and 50%; lipids from 30% to 40% and 20% of protein, of the total 
calories. This distribution has proved to reduce hyperglycemia and prevent macrosomia, 
when compared with diets high in carbohydrates (Franz M, et al., 2002).  
These recommendations must include a nutritional counseling because the excessive 
restriction of carbohydrates (< 120g) increases the risk of ketonuria, low birth weight and 
defective supply of glucose to the fetus impact on the neurological development (Pastor JG , 
et al, 2002; ADA, 2007;ADA, 2003, 2010; Major CA, et al, 1998). Besides the aforementioned , 
it is necessary to say that low carbohydrates diets make it difficult for patients to adher to 
the treatment.  
According to the American Diabetes Association (ADA 2010), a good diet control must, appart 
from getting glycated hemoglobin values (HbA1c) less than 6% and avoiding ketonuria 
(Standards of Medical Care in Diabetes-2008) maintain the capillary blood glucose 
concentrations in ≤95 mg/dl (Preprandial); ≤140 mg/dl (1-h postmeal); ≤120 mg/dl 2-h 
(postmeal). Regarding to plasma-referenced capillary blood glucose, the values suggested are 
≤105 mg/dl (Preprandial), ≤155 mg/dl (1-h postmeal), ≤130 mg/dl (2-h postmeal)(Standards 
of Medical Care in Diabetes-2008). With these recommendations, patients with GDM should 
have an adequate weight gain for them and the fetus as well. The weight gain recomendation 
is calculated based on prepregnancy weight or with the body mass index (BMI). A deficit in 
weight gain is associated with intrauterine growth restriction (Pastor, et al, 2002). 
Monroy-Torres R. et al. studied the influence of an individualized diet of low glycemic 
index to control GDM in woman between 24 and 26 gestational weeks. The diet was 
structured with 52% of complex carbohydrates and food of low and moderate glycemic 
index with 30% fat and 18% protein (plus 10 grams). The findings from the study were that 
the pregnant women with GDM did not have adverse effects related to blood glucose, 
glycosylated hemoglobin and weight gain. The newborns did not development macrosomia. 
The adherence observed was higher for calorie and macronutrient intake.  
3.1 Glycemic index and glycemic load 
According to Jenkins,the glycemic index (GI) is defined as the changes in blood glucose 
concentration after consuming food wich then has to be compared with standard amount of 
carbohydrate of a control food (white bread or glucose) (Jenkins DJA, 1984). The food with 
low and moderate GI has been considered as a part of a glycemic control; where the 
increased in the percentage of carbohydrates up to 60% of total calories is allowd when and 
if food of low and moderate  glicemic control is given (Fraser RB, et al, 1988). The 
consumption of processed food or food with low fiber conten increases the glycemic index 
while the GI decreases with food high in fiber, fats, proteins and it depends on the cooking 
process. Moses R et al., 2006, compared the effects of a diet of low glycemic index with a diet 
of high GI. Both diets had 55% of carbohydrates. Women with GDM who had a diet with 
high glycemic index gave as a result that they had  a newborn with high weight (large for 
gestational age) and higher ponderal index. Another important concept to discuss is the 
load Glycemic (LG) - that is the amount of carbohydrates in a specific food. The GI of food is 
not always easy to predict; for example, we could think that an ice cream has a high GI but it 
has low GI according to published charts. The reason is that an ice cream has fat and 
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consists of an integral component of diabetes prevention, management, and self-
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While the World Health Organization, the American Diabetes Association, Diabetes UK, 
and the Canadian Diabetes Association support both concepts ( IG and LG),and many other 
health professionals consider that to use GI and GL is complex because both have many 
variables that change their values and responses in the blood glucose. This is why their use 
in the clinical practice is debatable (Franz M, 2003). Other explanation is that different tables; 
with GI and LG values for different food, show different values for GI among the existing 
tables which gives as a result that their use is consider controversial specially with  new data 
has become available since the first tables were published in 2002 (Atkinson F, 2008; Foster-
Powell K, 2002). However, the most important recommendation is to follow up the advice of 
the Standards of Medical Care in Diabetes 2008: choose a variety of grains, fruits, and 
vegetables, with an emphasis on whole grains and other high-fiber foods, to work with 
dietary and behavioral changes 
3.2 Calculation and prescription of the diet 
The American Diabetes Association consensus to manage GDM recommends to take into 
account the dietary calculation (ADA 2010) to consider the value of BMI. According to the 
clinical experience the diet prescription must be individualized (Jovanovic L, 2000). The diet 
may be calculated in a range between 1700 and 2000 kcal/day. It is important to avoid diets 
with caloric content lower than 1500 Kcal because the risk of ketonuria can be increased. The 
calculation and distribution of macronutrients can be as follows: 
- Protein: 18% ( range of 10 to 20%; add 10 g, of the gestational period)  
- Fat: 30% (of these 7% saturated), range of 25 to 40% and reducing the intake of trans fat 
lowers LDL cholesterol 
- Complex carbohydrates: 52% (range of 40 to 60%) 
The American Diabetes Association (ADA, 2004) recommends to add 25 kcal per kilogram 
during pregnancy. A strategy to evaluate the adherence to energy consumption is to 
monitor weight gain which should not exceed 400 grams per week from the second 
trimester of pregnancy. 
According to the table 1, ,we can see how the range of carbohydrates varies between 40% 
and 55% or more of the total calories. The American Diabetes Association of the United 
States recommends that all pregnant women with overweight and / or GDM should receive 
a diet with 35-40 grams of carbohydrates ( simple carbohydrates), from food with low 
glycemic index. However, a consumption of carbohydrates less than 40% is risky because it 
results in ketonuria (ADA, 2010). 
 
Variables ADA 2010 Euglycemic diets 
*BMI: 80 -120 % 35 Kcal / Kg (ideal weight ) 30 Kcal / Kg (ideal weight ) 
*BMI: 121 –150% 35 Kcal / Kg (ideal weight ) 24 Kcal / Kg (ideal weight ) 
*BMI: >= 151 % 35 Kcal / Kg (ideal weight ) 12 Kcal / Kg (ideal weight ) 
Protein requirement 20 % of total calories 20 % of total calories 
Fat intake < 25 % of total calories >= 40 % of total calories 
Saturated fat intake <7% of total calories  
Carbohydrates requirements > 55 % of total calories < 40 % of total calories 
Cholesterol Requirements 300 mg/d < 800 mg / d 
* Relationship of BMI based on the percentage of body fat 
Table 1. Comparison of diets recommended in GDM 
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We can observe in table 1 that the range of carbohydrates varies from less than 40% to over 
55%. The American Diabetes Association of the United States recommends that all pregnant 
women with overweight and/or GDM must receive a diet with 35-40% of carbohydrates and 
food with low GI. The percentage of calories, that depends on carbohydrates , is reduced, a 
20% of proteins and 30% of fat is recommended. This is done to keep the balance of 
macronutrients. In fact, it is advisable that the distribution to be similar to a normal diet but it 
is importan to have considered the quality of food and macronutrients (ADA 2004; 2010). It is 
important to control the intake of carbohydrates because they are  the first nutrient that affects 
the postprandial glucose levels in addition to breakfast carbohydrate load.  
During pregnancy, hormone levels of placental lactogen, cortisol, progesterone and 
prolactine increase and this affects the insuline to lower blood glucose levels. Therefore, 
breakfast carbohydrate load of 15 to 30 g is recommended. The total daily carbohydrates 
and calorie intake should be individualized according to glucose control. When a dietitian 
designs a meal plan, carbohydrates intake should be distributed during the day in a three 
time meal and two or three small meals (snacks) (Sheard, N.F., et al., 2004).  For example, a 
diet of 2000 calories where the carbohydrates can represent a 40% of total calories; that in 
grams is equivalent to 200 grams, the total calories should be distributed during day as 
follow: 
• Breakfast 7.5- 10%(15- 20g) 
• Snack 10% (between breakfast and lunch) 
• Lunch 35% 
• Snack 15% (between lunch and dinner) 
• Dinner 20% 
• Evening Snack 10% 
The minimum amount of carbohydrates required to prevent the starvation activation systems 
(ketosis) of fasting is between 100 and 150 grams per day. According to the Food and 
Nutrition Board in 2002, 130 grams per day of carbohydrate is enough to satisfy the glucose 
requirement of the brain (FNB, 2005). Moreover, this recommendation should provide a list of 
food of low and moderate glycemic index (≤ 55 and from 59 to 69, respectively). Each country 
has different patterns of food exchange that are based on the consumer habits and customs of 
each population. For example, Mexico has the Mexican Food System Equivalents (Marvan L, et 
al., 2008), it is a educational system that is provided to patients with GDM to explain the 
amount of food intake from different food groups. To understand better the amounts and real 
food portions, the dietitians often used food replicas. Based on what it was meal times 
explained above, food should be distributed depending on the glucose control in six or seven 
meals (three main meals and three or four snacks) (Jovanovic L, 2000, Monroy-Torres R, et al., 
2008). Dietary and nutritional advice, lifestyle counseling and restriced food should be 
provided to patients in a written list. Adding proteins and fat to the meal plan for woman with 
GDM will not raise the postmeal glucose levels and to satisfy the woman´s hunger during the 
day (Monroy-Torres R, et al., 2008). 
The methods to collect dietary information vary in their accurancy and ease use. The 24-
hour recall is one of the easiest methods to collect information from the patient´s intake. It 
consists of obtaining information from food and fluid intake from a previous day ( 24 hours) 
and it is based on the assumption that the intake described is typical of a daily intake. 





While the World Health Organization, the American Diabetes Association, Diabetes UK, 
and the Canadian Diabetes Association support both concepts ( IG and LG),and many other 
health professionals consider that to use GI and GL is complex because both have many 
variables that change their values and responses in the blood glucose. This is why their use 
in the clinical practice is debatable (Franz M, 2003). Other explanation is that different tables; 
with GI and LG values for different food, show different values for GI among the existing 
tables which gives as a result that their use is consider controversial specially with  new data 
has become available since the first tables were published in 2002 (Atkinson F, 2008; Foster-
Powell K, 2002). However, the most important recommendation is to follow up the advice of 
the Standards of Medical Care in Diabetes 2008: choose a variety of grains, fruits, and 
vegetables, with an emphasis on whole grains and other high-fiber foods, to work with 
dietary and behavioral changes 
3.2 Calculation and prescription of the diet 
The American Diabetes Association consensus to manage GDM recommends to take into 
account the dietary calculation (ADA 2010) to consider the value of BMI. According to the 
clinical experience the diet prescription must be individualized (Jovanovic L, 2000). The diet 
may be calculated in a range between 1700 and 2000 kcal/day. It is important to avoid diets 
with caloric content lower than 1500 Kcal because the risk of ketonuria can be increased. The 
calculation and distribution of macronutrients can be as follows: 
- Protein: 18% ( range of 10 to 20%; add 10 g, of the gestational period)  
- Fat: 30% (of these 7% saturated), range of 25 to 40% and reducing the intake of trans fat 
lowers LDL cholesterol 
- Complex carbohydrates: 52% (range of 40 to 60%) 
The American Diabetes Association (ADA, 2004) recommends to add 25 kcal per kilogram 
during pregnancy. A strategy to evaluate the adherence to energy consumption is to 
monitor weight gain which should not exceed 400 grams per week from the second 
trimester of pregnancy. 
According to the table 1, ,we can see how the range of carbohydrates varies between 40% 
and 55% or more of the total calories. The American Diabetes Association of the United 
States recommends that all pregnant women with overweight and / or GDM should receive 
a diet with 35-40 grams of carbohydrates ( simple carbohydrates), from food with low 
glycemic index. However, a consumption of carbohydrates less than 40% is risky because it 
results in ketonuria (ADA, 2010). 
 
Variables ADA 2010 Euglycemic diets 
*BMI: 80 -120 % 35 Kcal / Kg (ideal weight ) 30 Kcal / Kg (ideal weight ) 
*BMI: 121 –150% 35 Kcal / Kg (ideal weight ) 24 Kcal / Kg (ideal weight ) 
*BMI: >= 151 % 35 Kcal / Kg (ideal weight ) 12 Kcal / Kg (ideal weight ) 
Protein requirement 20 % of total calories 20 % of total calories 
Fat intake < 25 % of total calories >= 40 % of total calories 
Saturated fat intake <7% of total calories  
Carbohydrates requirements > 55 % of total calories < 40 % of total calories 
Cholesterol Requirements 300 mg/d < 800 mg / d 
* Relationship of BMI based on the percentage of body fat 
Table 1. Comparison of diets recommended in GDM 
 
The Influence of Diet to Control the Metabolism in Gestational Diabetes Mellitus 
 
283 
We can observe in table 1 that the range of carbohydrates varies from less than 40% to over 
55%. The American Diabetes Association of the United States recommends that all pregnant 
women with overweight and/or GDM must receive a diet with 35-40% of carbohydrates and 
food with low GI. The percentage of calories, that depends on carbohydrates , is reduced, a 
20% of proteins and 30% of fat is recommended. This is done to keep the balance of 
macronutrients. In fact, it is advisable that the distribution to be similar to a normal diet but it 
is importan to have considered the quality of food and macronutrients (ADA 2004; 2010). It is 
important to control the intake of carbohydrates because they are  the first nutrient that affects 
the postprandial glucose levels in addition to breakfast carbohydrate load.  
During pregnancy, hormone levels of placental lactogen, cortisol, progesterone and 
prolactine increase and this affects the insuline to lower blood glucose levels. Therefore, 
breakfast carbohydrate load of 15 to 30 g is recommended. The total daily carbohydrates 
and calorie intake should be individualized according to glucose control. When a dietitian 
designs a meal plan, carbohydrates intake should be distributed during the day in a three 
time meal and two or three small meals (snacks) (Sheard, N.F., et al., 2004).  For example, a 
diet of 2000 calories where the carbohydrates can represent a 40% of total calories; that in 
grams is equivalent to 200 grams, the total calories should be distributed during day as 
follow: 
• Breakfast 7.5- 10%(15- 20g) 
• Snack 10% (between breakfast and lunch) 
• Lunch 35% 
• Snack 15% (between lunch and dinner) 
• Dinner 20% 
• Evening Snack 10% 
The minimum amount of carbohydrates required to prevent the starvation activation systems 
(ketosis) of fasting is between 100 and 150 grams per day. According to the Food and 
Nutrition Board in 2002, 130 grams per day of carbohydrate is enough to satisfy the glucose 
requirement of the brain (FNB, 2005). Moreover, this recommendation should provide a list of 
food of low and moderate glycemic index (≤ 55 and from 59 to 69, respectively). Each country 
has different patterns of food exchange that are based on the consumer habits and customs of 
each population. For example, Mexico has the Mexican Food System Equivalents (Marvan L, et 
al., 2008), it is a educational system that is provided to patients with GDM to explain the 
amount of food intake from different food groups. To understand better the amounts and real 
food portions, the dietitians often used food replicas. Based on what it was meal times 
explained above, food should be distributed depending on the glucose control in six or seven 
meals (three main meals and three or four snacks) (Jovanovic L, 2000, Monroy-Torres R, et al., 
2008). Dietary and nutritional advice, lifestyle counseling and restriced food should be 
provided to patients in a written list. Adding proteins and fat to the meal plan for woman with 
GDM will not raise the postmeal glucose levels and to satisfy the woman´s hunger during the 
day (Monroy-Torres R, et al., 2008). 
The methods to collect dietary information vary in their accurancy and ease use. The 24-
hour recall is one of the easiest methods to collect information from the patient´s intake. It 
consists of obtaining information from food and fluid intake from a previous day ( 24 hours) 
and it is based on the assumption that the intake described is typical of a daily intake. 





recall the eaten food or not to estimate the amount of food eaten. On the other hand, the 
method offers the advantage of analizing the average consumption of energy, carbohydrates, 
fats and proteins from the diet. This allows to analyze to the amount of food and the adhesion 
to the diet from the beginning and to follow it up. Another method is the Food-frequency- 
questionnaire that is often used in combination with the 24-hour recall. The food-frequency- 
questionnaire provides a list of food or food group where the patient can have different 
options to answer like: rarely, never, frecuently, occasionally, daily, weekly and monthly. The 
Food-frequency- questionnaire is only recommended to use only at the beginning and the end 
of  GDM treatment and this method is useful to evaluate changes in the eating habits and to 
analize the diet of patients within the next parameters: adequate, complete, balanced, enough and 
varied - these define a recommended diet. A diet is recommended for GDM when it has all 
these parameters: a) Enough: means to cover the energy requirements according to the 
individual characteristics like age, weight, physical activity and physiological conditions, b) 
balanced: means to intake nutrients based on references amounts (52% of complex 
carbohydrates, protein in 18%, fat in 30%); c) Complete: means to include at least three food 
groups at every meal and, d) varied: means to include different types of food within the same 
group, in a day (Marvan L, et al., 2008). Food records and postmeal monitoring of blood 
glucose can help to identify food that is less tolerated and to let individual nutrition and food 
recommendations changes (Sheard, N.F., et al., 2004). 
If the modification of the food plan alone does not prove to achieve and mantain 
normoglicemya, then insuline therapy is needed. To achieve the goals with the use of 
insulin, women must eat the corrcect amounts of carbohydrates and they must eat at regular 
meal times (ADA, 2010), all above information is important to avoid unnecessary 
hypoglycemia risk. Exchange lists or counting carbohydrates are the methods that help 
patients with GDM select and decide themselves what to eat according their glucose levels 
and their insulin therapy. Since insulin is the therapy of choice for most diabetic women, 
several authors suggest to apply the method of carbohydrate counting or exchange lists 
during the first nutrition interview. In table 2, you can see the recommendations of a dietary 
treatment in combination with insulin that depend on the response to the glycemic control 
(Standards of Medical Care in Diabetes-2008). 
 
 
Preconception stage First strategy Second strategy 
Normal Diet Diet + Insulin 
GDM controlled with insulin Diet + Insulin  
GDM controlled 
hypoglycemic drugs Diet +Insulin Diet+ Insulin 
GDM controlled with diet Strict Diet Diet+ Insulin 
 
Adapted: Monroy-Torres-Sanchez Naves R & J, 2011 
Table 2. Recommendations of dietary treatment in combination with insulin in GDM 
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The ADA (2010) mentions that all women should receive individualized counseling to 
provide adequate calories and nutrients during pregnancy. This counseling must help 
achieve the goal and maintain the blood glucose (fasting 105 mg/dl , 1 hr 155 mg/dl , and 2 
hrs 130 mg/dl ) and glycated hemoglobin (HbA1c )in 6%. For obese women, the treatment 
must be a 30%–33% of caloric restriction, it means near to 25 cal/kg per day is 
recommended, wich should be calculated with the current weight. Carbohydrate should be 
restricted to 35%–40% of calories. There are also data that support the use of low 
carbohydrate diets in pregnancy, and for carbohydrates to be low, the glycemic index. In a 
nonrandomized study, there was evidence that women with GDM on a diet comprising less 
than 42% carbohydrate, had lower post-prandial glucose levels, were less likely to require 
insulin, and had a lower incidence of large for gestational age. A small study with 
randomized pregnant women with low GI or high GI diets found that the former resulted in 
lower glucose levels, a blunting of the pregnancy associated rise in insulin resistance, and 
lower birthweight. In another study of GI, women assigned to a low GI diet during 
pregnancy gave birth to infants who were lighter and had a lower incidence of large for 
gestational age, compared to women given a high GI diet. Additional dietary measures are 
usually based upon the general recommendations for diabetes mellitus. A reduction in 
simple carbohydrates and fat intake is advisable. Emphasis is given to spreading the dietary 
intake over six meals daily, with three main meals and three snacks in order to avoid large 
carbohydrate loads at any time. Except for saccharin, which can cross the placenta and is 
therefore not recommended, other noncaloric sweeteners may be used in moderation 
(Moses, R., et al, 2006). 
4. Preventive and promotional strategies 
Medical nutrition therapy (MNT), including: 
• Education 
• Diet 
• Physical activity 
• Where justified, Insulin 
• Psychological support to improve acceptance and adherence to disease treatment 
We must consider that if GDM is not diagnosed at the early stage, mother‘ dietary habits 
and overall health in this period will have consequences in the short, medium and long term 
effecting the child as well. Regarding to the educational intervention, patients with GDM 
should know: 
• What is GDM? 
• The importance of metabolic control and risk of ketonuria 
• Characteristics of recommended diet plan 
• Self-monitoring techniques 
• Goals of the blood glucose control 
• Types of insulin, application techniques (where insulin is required) 
• Importance of early intervention, monitoring and control postpartum 
• Prevention of future type 2 diabetes mellitus 
Weight loss is not recommended during pregnancy, even though the woman is obese. For 
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• Physical activity 
• Where justified, Insulin 
• Psychological support to improve acceptance and adherence to disease treatment 
We must consider that if GDM is not diagnosed at the early stage, mother‘ dietary habits 
and overall health in this period will have consequences in the short, medium and long term 
effecting the child as well. Regarding to the educational intervention, patients with GDM 
should know: 
• What is GDM? 
• The importance of metabolic control and risk of ketonuria 
• Characteristics of recommended diet plan 
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• Goals of the blood glucose control 
• Types of insulin, application techniques (where insulin is required) 
• Importance of early intervention, monitoring and control postpartum 
• Prevention of future type 2 diabetes mellitus 
Weight loss is not recommended during pregnancy, even though the woman is obese. For 





according to the start value of BMI except in the adolescent woman , where the weight 
increment must be higher. 
The objectives of a diet plan are: 
• Get optimal metabolic control and to prevent hypoglycemia 
• Adequate weight gain during pregnancy 
Some studies recommend energy consumption between 1800 and 2200 kcal, bearing in mind 
that weight gain should be among the lower ranks. In adolescents, low weight or great 
complexion is recommended to increase energy requirements. 
The exercise is useful to help control metabolism. The type of exercise for pregnant women 
is with the work that can be done with the upper extremities. However it is contraindicated 
in the following cases: 
• Increased uterine contractions 
• Multiple pregnancy 
• During hyperglycemia and hypoglycemia 
• history of stroke or arrhythmia 
• Hypertension 
4.1 Physical activity 
Currently more pregnant women want to have their pregnancy in natural and  
healthy conditions. Exercising in pregnant women is controversial as to the changes 
presented in their body and the hormonal levels. A long time ago, pregnancy was 
experienced as an illness, and had several myths related to it, including the exercise. The 
scientific arguments to restrict physical activity during pregnancy suggest that exercise 
causes an increment in maternal body temperature and therefore in the fetus too, with 
increased release of catecholamines, decreased circulating glucose and decreased blood flow 
to the placenta. However, there are other scientific studies that show the benefits of a 
regular physical activity during pregnancy to maintain health. When it is a normal 
pregnancy is recommended that pregnant women continue to perform normal physical 
effort. 
For athletes, it is recommended to decrease the intensity, especially during the second 
trimester of pregnancy and especially during the last month. Pregnancy increases the 
elasticity of the ligaments by the effect of hormones released during pregnancy. For this 
reason, it is advisable to practice sports that do not require jumping, excessive stretching 
and to use appropriate footwear. Some reported benefits of regular moderate physical 
activity during pregnancy are (Artal, R. & Toole, M.O ., 2003): 
- Helps improve fitness and body image of pregnant women, contributing to increased 
weight. 
- Maintains cardiovascular function. 
- Improved glycemic control. 
- Promotes the welfare state joins mother and a better mood by providing psychological 
benefits. 
- Decreases stress and anxiety. 
- Provides better labor 
- Promotes weight recovery after childbirth.  
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In people with type 2 diabetes, there is a lot of evidence that suggests that regular physical 
activity improves insulin sensitivity, weight loss, thereby improves glucose control. Several 
studies have examined whether regular exercise is also beneficial in the management of 
GDM, for example, Jovanovic L, (Jovanovic L, 2000) randomized 19 women with GDM to a 
regime of diet alone, or diet with 20 minutes of supervised aerobic training three days per 
week for six weeks. This modest amount of physical activity resulted in lower fasting 
glucose levels, lower glucose responses to a glucose challenge, and a lower HbA1c . Another 
study randomized 29 women with GDM to 30 minutes of exercise (70% of maximal heart 
rate) of three to four times per week. In this case the glucose levels did not improve in those 
who exercised. The action might be through the activation of AMPK, a kinase that is 
activated during exercise, it is possible that exercise may act through the same molecular 
cellular pathway and therefore there are not additive effects of these two treatment 
regimens (Hardie DG, 2004). 
Another study found that women with a prepregnancy value BMI of 25 and who were in 
the exercise program were less likely to require insulin. Therefore, it seems reasonable to 
recommend that when there is not medical or obstetric contraindication, women with GDM 
should maintain a sensible level of light and moderate intensity if there is physical activity 
during the pregnancy. The above studies provide enough evidence that moderate physical 
activity such as walking between 20 and 30 minutes each day, or three to four times per 
week, through this they can achieve the glycemic control. The diet should provide with 
adequate nutrition for pregnancy. Carbohydrates should be distributed throughout the day 
over main meals and snacks. Limiting carbohydrates at 40% of the total caloric intake and 
having a higher proportion of carbohydrates of lower glycaemic index decreases 
postprandial glucose levels and reduces the need for insulin therapy (Smith, C.S. & Van 
Andel, R., 2001; Artal, R. & Toole, M.O ., 2003). 
There is not enough evidence to support dietary or drug treatment in patients  
with gestational diabetes. Gestational diabetes and impaired glucose tolerance are 
associated with macrosomia and may be associated with an increased risk for 
cesarean delivery, shoulder dystocia, and birth trauma. Although preexisting diabetes has 
been shown to increase the risk of poor perinatal outcomes, it is not clear that  
data relating to preexisting diabetes can be extrapolated to patients with gestational 
diabetes. 
Tuffnell and colleagues (Olwan N, 2009)researched the Cochrane Pregnancy and 
Childbirth Group trials register, the Cochrane Central Register of Controlled Trials, and 
bibliographies of relevant articles. They identified three studies of 223 women with 
impaired glucose tolerance; none of these studies was a randomized controlled trial 
comparing management strategies. Intensive management of gestational diabetes is time-
consuming and resource-intensive. Overall, the evidence is insufficient to support the 
therapy for gestational diabetes. However, universal screening is the standard of care in 
most communities. When faced with abnormal results, most family physicians will opt to 
follow the consensus opinion of our specialist colleagues. For example, a study that 
analyzed the higher egg and cholesterol intakes found that they are associated with 
increased risk of type 2 diabetes mellitus. It was also observed that the higher egg and 
cholesterol intakes before and during pregnancy are associated with an increased risk of 
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Several lines of evidence indicate that realistic modifications of diet and lifestyle can 
prevent diabetes type 2. Some of the main determinants include lack of physical activity, 
hours of TV watching, low quality and energy dense diets, and high caloric sweetener 
intake. Caloric beverages have been recognized as an important source of energy and 
have been associated with an increased risk of overweight. (Schulze MB, 2005; Ludwig 
DS, 2001). 
Lifestyle modification, to increase exercise and to modify diet habits are an effective way of 
to prevent and to delay the onset of type 2 diabetes in the future in women with GDM. One 
important aspect of combating the epidemics of obesity and type 2 diabetes has been 
through dietary strategies. Recently, very-low-carbohydrate diets have gained much 
popularity. Recently the effects of a diet lower in carbohydrates and higher in protein has 
been evaluated in obese and over-weight  patients with type 2 diabetes  for analyze the 
changes in blood glucose levels and in the insulin resistance. Because glucose is the major 
insulin secretagogue carbohydrate, its reduction would be expected to be beneficial in type 2 
diabetes and the use of such diets. Although, as noted above, official recommendations 
generally continue to suggest low fat and high carbohydrate intake (Arora & McFarlane , 
2005; Fioster GD, 2003) . 
Efforts to change diets, physical activity patterns, and other aspects of lifestyle have 
traditionally attempted to educate individuals through schools, health care providers, 
worksites, and general media. These efforts will continue to play an important role, but they 
can be strongly reinforced by policy and environmental changes. 
5. Conclusion  
The control and prevention of GDM must be the principal goal. The dietary treatment must 
be based on the design and prescription of diets according to cultural habits, economical 
aspects and the diet must be accessible. The family, the health team and the society should 
be into the treatment of the GDM, mainly the prevention of diabetes mellitus type 2. To 
achieve this goal the authors suggest:  
- To evaluate the best evidence in the dietary management of patients with GDM and to 
design programs that involve motivation. 
- To monitor weight gain in pregnant women according to prepegnancy BMI and 
considering the biochemical markers, including glucose and glycated hemoglobin in 
order to adapt and correctly identify the nutritional treatment. 
- To monitor not only fasting glucose, but the postprandial 
- To increase surveillance and to monitor at intervals of 3 to 4 weeks in each 
appointment, for increasing the adherence to the diet. 
- To perform several scientific studies to identify other factors that support control of the  
GDM. 
Finally, it is important to consider the economical and social influence (Wilson C, 2003). 
Pregnant women usually modify their food intake according to the influence of their 
nutritional orientation . The full costs to achieve a behavioral change and the policies are 
complex and difficult to estimate. The efforts to reduce the increment of diabetes mellitus 
type 2, is screening pregnant women. In sum, the benefits will be for the fetus growth and 
health for both 
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1. Introduction 
The expectation of treatment goals in the management of gestational diabetes are the most 
stringent and precise for control of diabetes in adults (American Diabetes Association, 2011; 
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2008). It is 
well accepted that the achievement of these goals requires an effective collaboration 
between a well-trained physician, a nurse educator and a qualified dietician experienced in 
working with pregnancy and, most importantly the woman with gestational diabetes 
(Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2008; 
Murphy, et al., 2010; Jacqueminet S, 2010; Kim, 2010; Kjos S, 1999). The more involved the 
woman becomes in her own treatment plan, the more likely that she will succeed (Meltzer S. 
J., 2010). 
2. Never underestimate the value of a well-planned, balanced diet 
Once a diagnosis of gestational diabetes has been made, the initial step is always an 
assessment of the woman’s present diet and the introduction of changes which would 
optimize her glucose control. Without an understanding and application of the concepts of 
medical nutrition therapy, further attempts at controlling glucose will always be limited. 
Individual dietary counselling with a trained dietician is preferable, whenever possible 
(Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2008; 
International Diabetes Federation Writing Group, 2009).  
The major concepts of the diet consist of identifying fast and more slowly absorbed 
carbohydrate sources: fruits and vegetables, starchy foods such as bread, pastas, rice, 
noodles, grains, and milk and milk products as the major carbohydrate in the diet. In any 
one meal, optimally there is a small portion of fruits and/or vegetables which will be 
absorbed quickly, a portion of starches/grains which will be absorbed more slowly, 
accompanied by a portion of protein and a small portion of fat. The mix of two forms of 
carbohydrate absorbed over different time periods, as well as the presence of fat and protein 
which, apart from being essential nutrients, slow further the absorption of glucose from the 
gut permits a more gradual and slower rise of glucose post-meal. This makes glucose much 
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in Figure 1. Additionally, use of foods with low glycemic index (higher in fibre and 
producing a lower post-ingestion glucose elevation) has been shown to be of help in 
minimizing effects of excess glucose in the pregnancy (Grant, Wolever, O'Connor, 
Nissenbaum, & Josse, 2011; Tzanetakou, Mikhailidis, & Perrea, 2011; Thomas D, 2009). 
Foetal growth, particularly asymmetric growth with increased central fat patterning relates 
to the effectiveness of glucose control of post-meal elevations and in general terms, excess 
post-prandial hyperglycaemia has negative effects on maternal and foetal well-being 
(Standl, Schnell, & Ceriello, 2011; Parretti, et al., 2001; DeVeciana, et al., 1995). 
In gestational diabetes, as with early type 2 diabetes, the first phase of insulin release is 
impaired (Ornoy, 2011; Catalano, Kirwan, Haugel-de Mouzon, & King, 2003), thus more 
concentrated forms of carbohydrate (sugar added to coffee, juices, candies, cakes etc.) will be 
absorbed too quickly for the slow insulin response, allowing the glucose to go up quickly to 
above normal levels which may then affect the baby. The stimulation of insulin release can 
occur in response to certain amino acids. There may still be an intact protein-stimulated 
insulin release response even if the glucose-stimulated insulin release is compromised 
which can help avoid elevated glucose values (Catalano, Kirwan, Haugel-de Mouzon, & 
King, 2003). These concepts are relatively simple to understand and when explained to the 
woman with GDM helps her to understand the basis of her dietary efforts and concerns. 
Providing an explanation to the woman with visual tools suggesting the relative absorption 
times and how different foods work will make it easier for her to understand what she is 





Fig. 1.  
Insulin Use in Gestational Diabetes – Pragmatic  






Fig. 2.  
Author’s statement: Sara J. Meltzer, MD, FRCPC, FACP 
Figure 1 and 2 were developed by the author for use in clinical work teaching women with 
gestational diabetes the basic concepts of diet and are included here for those who may find 
them helpful. 
To be sure that the diet has been effectively instituted – using food diaries and encouraging 
measuring and weighing can be very helpful to help the women understand successes and 
problems with her choices of foods in her normal environment (Burke, Wang, & Sevick, 
2011). Unfortunately, some women will limit their food choices dramatically leaving out 
foods typical of their normal diet in an effort to reach glucose targets. Since it is important 
for the woman to understand how to incorporate the foods normally present in her diet 
including ethnically diverse foods while she has the help and time of a dietician’s advice 
and can see the effects on her glycemic control with frequent testing, excessive limitation of 
her food choices should be discouraged. The effectiveness of long-term dietary adjustments 
to decrease insulin need is more likely if she understands the effects of her preferred foods 
on her glucose control. Since the mother is often in charge of family meal-planning and 
cooking, her application of learned knowledge should help her avoid future diabetes and 
reduce the risks to her offspring whose eating habits develop at home (Ratner, et al., 2008; 
Tuomilehto, et al., 2001; Verier-Mine, 2010; Diabetes Prevention Program Research Group, 
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Pre-pregnancy BMI and actual weight gain are potentially modifiable risk factors so 
attention to both weight control pre-pregnancy and rate and total amount of weight gain in 
the pregnancy are important (Hutcheon, Platt, Meltzer, & Egeland, 2006; Radesky, Oken, 
Rifas-Shirman, Kleinman, Rich-Edwards, & Gillman, 2008). Recommended weight gain is 
often based on the Institute of Medicine recommendations, relate to pre-pregnancy BMI and 
intake will often be 25-30 kcal/kg (Institute of Medicine and National Research Council 
Committee to Re-examine IOM Pregnancy Weight Guidelines, 2009).  
3. Teach self-monitoring and establish glucose targets 
Another important facet of achieving glucose control will be to determine if the glucose 
values are appropriately controlled at various times of the day. In this situation, use of 
self-blood glucose monitoring (SBGM) is very effective. Avoiding starvation is also 
important so many centres will routinely test at some point for urine ketonuria to 
determine if the women are receiving adequate calories for their needs. The basic concepts 
of testing are easy to convey and ideally a qualified diabetes educator or pharmacist 
would review techniques in the use of the meter and lancet device chosen. In situations 
where this is not available, peer-to peer teaching may be equally effective.  It is valuable 
to verify the accuracy of the woman’s technique and device by asking her to do a 
comparative test against the laboratory value, ideally in a fasting state which provides a 
better comparator than in post-meal values which are in a state of flux and may differ in 
the capillary and venous system physiologically. This is important to clarify since the 
glucose targets required are within the normal range and many meters may have a small 
degree of consistent error which, if known, can be considered in defining her at-home 
meter glucose targets. 
The usefulness of the testing is markedly enhanced if the woman is instructed on how to use 
this information to adjust her therapy (Hawkins J. S., Casey, Lo, Moss, McIntyre, & Leveno, 
2009). The more pragmatic and useful the testing, the more likely compliance with 
management will be. Thus self-blood glucose monitoring is often done before breakfast and 
at 60-90 minutes after meals, since studies suggest that this is the highest level of glucose 
seen in the post-meal phase for the majority of women (Jovanovic L. G., 2008). The peak 
post-prandial glucose level in obese women tends to be higher and later - more around 90 
minutes after the meal (Ben-Haroush, Yogev, Chen, Rosenn, Hod, & Langer, 2004). In many 
parts of the world, the post-meal test timing recommended may be closer to 120 minutes or 
2 hours. Health providers must be aware that only testing before or after main meals may 
miss other parts of the day with significant increases in glucose so random testing at other 
times may also need to be suggested (Montaner, Ripolles, Pamies, & Corcoy, 2011)(29).  
In most national guidelines, the goal of therapy is to achieve values which fall into the 
normal range, thus under 5.1 or 5.3 mmol/L (92-95mg/dl) fasting, under 7.8mmol/L 
(140mg/dl) at 1h post load, and under 6.7mmol/L (120mg/dl) at 2h post-load (American 
Diabetes Association, 2011; Canadian Diabetes Association Clinical Practice Guidelines 
Expert Committee, 2008). It must be realized that these numbers indicate the mean plus two 
standard deviations above the mean… the actual mean is lower…usually between 3.8 – 4.4 
mmol/L in the fasting state and rarely above 6.5mmol/L at any point after the meal 
(Gillmer, Beard, Brooke, & Oakley, 1975; Parretti, et al., 2001; Rowan, Gao, Hague, & 
McIntyre, 2010; Yogev, Ben-Haroush, Chen, Rosenn, Hod, & Langer, 2004). Depending on 
the reliability of the individual, her meter accuracy and the evaluation of the pregnancy in 
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terms of weight gain, macrosomia and relative risks for the offspring, lower achieved values 
are often possible and near-normal values can often be reached using the right insulin 
protocol and self-adjustment of insulin by the patient.  There is no proven value of running 
blood glucose values at the top end of normal (or near the abnormal range) rather than the 
middle, so going for truly normal would appear to make sense if hypoglycemia does not 
occur. In a study of a Pima Indian cohort, diabetes conveyed excess offspring risk of obesity 
and glucose intolerance independent of genetic factors and other studies have explored the 
role of diet type and intake quantity in future offspring risks (Dabalea, et al., 2000; Reusens 
& Remacle, 2001). In fact, results of glucose targets achieved by any means in the MiG’s 
study (metformin in gestational diabetes) suggest that outcomes are optimal in terms of 
appropriate fetal weight for dates with values closer to the mean of normal (Rowan, Gao, 
Hague, & McIntyre, 2010) and a long-term follow-up study (15 years) attaining similar 
lower mean values led to a very low incidence (1%) of teenage offspring glucose intolerance 
(Egeland & Meltzer, 2010). In the HAPO study, there was an association with maternal post-
load glucose and clinical neonatal hypoglycemia; for the one hour glucose value (adjusted 
OR, 1.13; 95%CI; 1.03-1.26) and a weak association for the two hour glucose value (adjusted 
OR, 1.13; 95% CI 1.00-1.12) (HAPO Study Cooperative Research Group., 2009).  Even within 
normal ranges, maternal glucose values have been linked to offspring insulin sensitivity and 
beta cell function (Reusens & Remacle, 2001; Bush, Chandler-Laney, Rouse, Granger, Oster, 
& Gower, 2011). In obese women particularly, achievement of the optimal glucose targets 
improves fetal outcomes (Langer, Yogev, Xenakis, & Brustman, 2005). 
4. Physical activity should be encouraged unless precluded for obstetric 
reasons… 
The effectiveness of a physically active lifestyle has been shown to help prevent the 
development of type 2 diabetes in those at risk such as women diagnosed with gestational 
diabetes (Ratner, et al., 2008; Sanz, Gautier, & Hanaire, 2010).  Most guidelines recommend 
some form of regular exercise in pregnancy although only a few studies address this issue in 
detail (American Diabetes Association, 2011; Canadian Diabetes Association Clinical 
Practice Guidelines Expert Committee, 2008; Division of Nutrition PA, and Obesity, Centers 
for Disease Control; ACOG Committee Opinion, 2002; Bung, Artal, Khodiguian, & Kjos, 
1991; Artal, Lockwood, & Brown, 2010). At the very least, encouraging women to walk after 
meals often for a total of 30 minutes per day is the recommendation and this can improve 
glucose results and will help the women understand during pregnancy how effective small 
amounts of exercise can be on glucose control. Care must be used in women with evidence 
of pre-term labour or any previous suggestions of cervical incompetence; however this is the 
minority of women with gestational diabetes. 
5. Insulin adjustment algorithms with the patient self-adjusting are easy to 
teach and effective… 
Initiation of insulin, if needed, is no longer a reason to hospitalize a patient. Insulin is often 
needed in about 10-50% of women, depending on the population and the criteria used for 
diagnosis (Langer, Berkus, Brustman, Anyaegbunum, & Mazze, 1991). Once the effect of diet 
on initial testing has been evaluated and if the woman’s glucose values exceed the upper limits 
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role of diet type and intake quantity in future offspring risks (Dabalea, et al., 2000; Reusens 
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teach and effective… 
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Consideration of the degree of macrosomia seen on ultrasound, particularly if increased 
abdominal girth is seen in the foetus may be used as a moderating factor in the need for 
initiation of insulin and potentially in the target glucose values aimed for (Buchanan, et al., 
1998)(44). The HAPO study showed a clear correlation with macrosomia and the glucose 
values attained on the oral glucose tolerance test result at 28-32 weeks [fasting glucose 
adjusted OR, 1.38; 95% CI:1.32-1.44, one-hour adjusted OR, 1.46  ; 95% CI 1.39-1.53, two-hour 
adjusted OR, 1. 38 ; 95% CI: 1.32-1.44] (HAPO Study Cooperative Research Group, Metger BE; 
Lowe LR; Dyer AR et al, 2008). If there is no evidence of macrosomia on ultrasound and the 
initial A1c is below a pregnancy normal mean of 5.3%, it may be possible to accept slightly 
higher glucose values and still obtain a good foetal outcome.  
The use of insulin pens has greatly simplified the teaching of insulin injection; however it is 
also relatively easy to teach injections using insulin syringes in a short teaching session, 
possibly in small groups. It is important that any woman being initiated on insulin (or any 
oral agent which is a secretogogue for that matter) be taught how to recognize and treat a 
hypoglycemic episode. The use of written and picture educational material often available 
from insulin producing companies will facilitate the educational essentials that must be 
explained. The concept of site use and rotation is another issue which should be addressed 
by the teaching nurse.  
There have been studies using both metformin and glyburide as oral agents for the 
management of gestational diabetes showing reasonably comparative composite outcomes. 
There were 46% of the women in the metformin study who still required insulin and there 
was inadequate power in the glyburide randomized trial to determine macrosomia and 
neonatal hypoglycemia outcomes (Rowan, Hague, Gao, Battin, Moore, & and MiG Trial 
Investigators, 2008; Langer, Conway, Berkis, Xenakis, & Gonzales, 2000). At present in most 
countries, it remains “off-label” and most guidelines do not suggest its routine use or only if 
for some reason insulin cannot be used (American Diabetes Association, 2011; Canadian 
Diabetes Association Clinical Practice Guidelines Expert Committee, 2008; Jacqueminet S, 
2010). For these reasons, it will not be addressed in detail in this chapter. 
In terms of the actual insulin prescription, the concept of using a famous train robber’s 
recommendation - Sutton’s law “Go where the money is!” can be very helpful. In other words, 
pick the part of the day which is most abnormal from the point of view of glucose control. In 
general, improvement to absolutely normal of the fasting glucose value will facilitate the 
release of insulin by the woman and improve glucose much of the day (Pennartz, Schenker, 
Menge, Schmidt, Nauck, & Meier, 2011). In the majority of cases, bedtime insulin is the most 
effective first step although the women from South East Asia and Asia may have post-meal 
glucose which tends to be higher and may have normal fasting glucose values.  
If the fasting glucose is the value which is above range, initiation of intermediate insulin at 
bedtime (neutral protamine Hagedorn or NPH in human or pork form) at a low dose should 
be done (can be as low as 2 units in a very nervous woman who is not too obese, but the 
usual starting dose would be 8 – 10 units minimum or 0.1 units/kg).  In many clinics, the 
women return on a regular basis for adjustment of their insulin doses. As insulin needs 
increase progressively in response to placental growth and production of anti-insulin 
hormones, this often means that the initial period after adjustment is well controlled but 
over the two weeks the glucose control may deteriorate. It is very easy to have the women 
do the progressive adjustment of her own insulin based on her morning blood glucose (and 
thus her body’s response to the insulin given); she can then increase the dose by specified 
increments until she achieves the desired range. The increments are largest for high glucose 
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values (as much as 6 units at once) and gradually reduce to as little as 1 unit more insulin for 
the evening dose as the target range is reached (See Figure 3a).  In someone who is markedly 
obese or may have evidence of acanthosis nigricans, often an initial dose may be 0.1-0.2 
units/kg administered at bedtime again with an increase in dose the following day if the 
fasting glucose has not achieved the desired range. An important part of the algorithm is a 
glucose value below which she MUST REDUCE her evening dose of NPH. This avoids 
hypoglycaemia before it happens and discourages overzealous increases in insulin dosages. 
Our experience has been very effective and safe using the value of 4.2mmol/L below which 
a woman will reduce that night’s dose as this glucose value is far away from the values of 
3.2 or 2.8mmol/L which would be felt as a hypoglycemic reaction and require treatment 
(Snyder, Gray-Donald, & Koski, 1994; Meltzer, Snyder, Penrod, Nudi, & Morin, 2010).  
In situations where women have markedly elevated fasting and post-meal glucose levels, an 
overall dose of 0.5 – 0.7u/kg can be used in the proportion of about 40% as bedtime NPH 
insulin and the remainder split over the day with a bit more at breakfast and less at lunch ie. 
25% - 15% - 20% of the total calculated dose given as regular or rapid-acting insulin prior to 
breakfast, lunch and dinner respectively. 
On very rare occasions likely explaining the lack of literature related to it, women develop a 
local allergy to NPH at the injection site with swelling and redness developing up to 12 
hours after the last injection of NPH at that site and lasting for about one to two days. In 
virtually every situation where this has been seen and is deemed intolerable by the woman, 
switching to regular human insulin as a 10pm injection and retesting glucose at 0400 to 
adjust the 10 pm dose as well as adding a 0400h injection of human (preferably) or pork 
regular insulin which will be adjusted based on the pre-breakfast result will often correct the 
allergy problem and continue to effectively control the glucose.  Usually the dose can be 
reduced from the previous insulin dose and given as one third at 2200h and about one third 
or a bit less at 0400h. Subsequent self-adjustment protocols can still be used with an added 
time of 0400h and will allow for safe correction of insulin to optimal doses. Unfortunately, 
this approach does interfere with the woman’s sleep. The use of detemir or glargine insulin 
may be alternatives; however it has yet to be reported in this situation. 
If the fasting glucose is normal and the post-meal is the glucose which is elevated (often 
related to ethnic differences), the insulin administered will be regular insulin or a rapid-
acting analogue administered prior to the meal (See Figure 3b). If Regular insulin is used, 
the time it should be taken before the meal is often 20-30 minutes, which is why the rapid-
acting analogues are often preferred, as they can be take much closer to the meal (0-15 
minutes) and still effectively control the post-prandial 60-90 minute peak (Pettitt, Ospina, 
Kolaczynski, & Jovanovic, 2003). The effectiveness of the dose is evaluated by the woman 
using her post-meal glucose value for that meal and the following day, the dosage for that 
meal will be adjusted up or down in order to achieve the desired values. Since at meals, 
occasionally, even the “best” patient may change her food from the recommended meal 
plan, it is often appropriate to wait for 2 abnormal values before increasing the dose, 
however only one value lower than the desired goal requires that the dose be reduced the 
following day. Allowing the woman to be responsible for the gradual and persistent 
adjustments of insulin dose regularly seen in GDM as the placenta continues to grow and 
her insulin needs rise can facilitate her care. Occasional additional tests in relation to snacks 
or prior to meals may be necessary to determine glucose control is always good (Montaner, 
Ripolles, Pamies, & Corcoy, 2011). Visits may be further apart because the woman is making 
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has been useful in women whose understanding of the language may be limited so that 
even women not easily able to read and write have been able to make use of this protocol 
(Figure 3c). Occasionally, there are women who feel much too insecure to adjust, or simply 
cannot seem to understand the algorithm. In cases like these, the medical team (diabetes 
nurse educator and physician) will, of necessity, need to make the adjustments and thus, 
likely require more frequent visits. This is the exception rather than the rule. 
Thus, the patient can continue to adjust her insulin appropriately, gradually increasing the 
insulin doses until between 34-37 weeks, where some decrease in insulin requirements is 
often seen as the baby is now bigger and eats more, so siphons off glucose most obviously 
overnight when the patient is not eating but the baby still is. In addition, the placenta is no 
longer growing and may be aging, so the placental hormones which have been increasing 
insulin resistance are gradually decreasing. In fact, an early or dramatic fall in insulin 
requirements may be an early manifestation of a placental problem and may help alert the 
health professionals.  
 
 
Fig. 3.  
6. Approaching the finish line – what to do for labour and delivery 
There are few papers determining the effectiveness of specific protocols for use in labour 
where the protocols specifics are detailed (Palmer & Inturissi, 1992; Ramanathan, Khoo, & 
Arismendy, 1991; Leparcq, et al., 2008; Jovanovic & Petersen, 1983; Hawkins & Casey, 2007). 
In 1983, using a Biostator®, Jovanovic and Peterson determined that the average hourly 
need for glucose to cover the needs of labour was 2.55 mg/kg/min (Jovanovic & Petersen, 
1983). When translated into the approximate hourly rate for a 70kg woman, this would 
mean 9.45g/hour as an infusion rate. This would require very large amounts of fluids or 
perhaps a central line to provide such glucose-intense amounts in a normal clinical setting. 
The majority of the recommended and detailed protocols have been used in type 1 diabetic 
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patients. In the diabetes and pregnancy clinics today, many of the patients have type 2 
diabetes with significantly more insulin resistance and a high total daily dose (TDD). 
Additionally, many women with gestational diabetes picked up in pregnancy may have 
glucose abnormalities outside of pregnancy and significant underlying insulin resistance. 
The majority of protocols presume that the hourly needs for insulin are always the same in 
labour; however, it may be more appropriate to use a gradually adjusting protocol based on 
insulin need in patients with type 2 or gestational diabetes. 
For these reasons, we have developed a protocol based on the patient’s total daily dose to 
provide the initial insulin infusion rate. As a compromise for fluid use, not only for glucose 
provision, but potentially for oxytocin induction or other fluids needed for obstetric reasons, 
the protocol developed provides 5g/h of glucose in the form of dextrose 10% at 50 ml/hour 
beginning on the morning of induction or Caesarean section, or when the patient arrives in 
labour. Since labour is a significant activity, the obstetricians are encouraged to provide a 
consistent amount of at least 5g of glucose to be delivered per hour to avoid fatigue and 
ketosis. If the glucose value exceeds 4.5mmol/L (81mg/dl), an insulin infusion is begun.  
For women with gestational diabetes, an insulin infusion protocol is not provided if the total 
daily dose is less than 30 units per day. If above 30 units, the total number of units taken in 
the day is divided in half (since about half of the insulin she takes will be to cover meals) 
and the remaining insulin dose is divided by 24 to permit the determination of a starting 
dose in units per hour.  
The insulin dose is adjusted hourly keeping the amount glucose infused stable and realizing 
that insulin requirements usually fall in labour. If there is a fall of glucose to under 
4.0mmol/L (72mg/dl), the dose is reduced quickly, below 3.5mmol/L (63mg/dl)…even 
more and at 3.0mmol/L, the insulin is stopped – glucose in the form of 50% dextrose is 
given to provide 10 gm of immediate glucose (i.e. 20 ml.) and repeated every 10 minutes 
until the glucose rises above 4.5mmol/L (81mg/dl). If the glucose rises, the dose is increased 
incrementally until a steady state is reached. In our hospital protocol, we aim for a glucose 
between 4.0 – 5.5mmol/L (72 – 100 mg/dl) during labour using this protocol, with success 
and minimal hypoglycaemia, however this is due to intensive in-house review of the 
protocol on a regular basis and consistency over 20 years. The entire protocol is pre-printed 
in the clinic prior to labour using dosages at about 36-37 weeks and the women is given a 
copy to present on arrival in the delivery room.  
As part of a quality assessment program, we retrospectively evaluated the effectiveness of 
this protocol for labour and delivery in use 20 years in our institution for glucose control in 
women with type 1, type 2 and gestational diabetes. Ethical approval of the assessment and 
chart review was obtained from the McGill University Health Center Ethics Board. Women 
who delivered for the years 2004-2006 and were treated with an insulin dose ≥ 30units/day 
prior to labour and managed with an intra-partum protocol were included. Patients were 
excluded if they did not receive the insulin protocol due to precipitated labor of urgent CS 
or if the chart was missing vital maternal or neonatal data. 
The protocol includes a glucose infusion of 5g/h as 10% dextrose in water and an insulin 
infusion using ½ of the TDD/24 as the initial hourly rate was begun if CBGM was 
≥4.5mmol/L and adjusted to maintain glucose between 4.5-5.5mmol/L. At placental 
delivery, insulin is held and glucose increased to 10g/h until glucose goes above 
5.5mmol/L. A total of 80 women were evaluated in 86 pregnancies. Of those, 31(39%) had 
type 1 DM with mean BMI 21.7, 9 with microvascular complications, mean duration of DM 
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T3 5.3%. The mean FPG by trimester of T1 7.0, 6.0, 5.6 mmol/L respectively; mean 1hPC T1 
7.3 T2 6.2  T3 6.0  mmol/L and insulin was administered in 90% of labours. The 49(61%) 
women with type 2 DM had a mean BMI of 33kg/m2, a mean duration of DM of 3.3years, 2 
with microvascular complications, and 76% had Caesarian sections. The mean A1C by 
trimester was T1 8.5%, T2 7% and T3 6.7%. The mean FPG by trimester was: T1 7.7, T2 6.3, 
T3 5.5mmol/L, and the mean 1hPC T1 9.6, T2 7.0, T3 7.2 mmol/L and insulin infusion was 
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Mean insulin dose in labour was 1.73units/h for DM1, 2.2unit/h in DM2. Maternal 
hypoglycemia (CBG <3.3 mmol/L) occurred in 16% of labour occurring equally in DM1 or 
DM2, however there were only 4 episodes of maternal hypoglycemia <2.5mmol/L. Mean 
glucose achieved overall was 5.8mmol/L (6.1mmol/L for DM1; 5.6mmol/L for DM2). Of 
the 863 CBG readings, there were 31% between 4.5-5.5mmol/L, 24% lower, and 43% higher 
with 9% ≥7mmol/l (See Figure 5). Neonatal hypoglycaemic events (BS ≤2.2mmol/L 
occurred in 32 neonates (37% - 46% in DM1 offspring, 40% in DM2 offspring (p=0.047) and 
4(12%) in babies whose mother did not receive maternal IV insulin. No significant 
relationship was seen between glucose control in labour, nor in any trimester in labour and 
neonatal hypoglycemia. The results of the glucose control can be seen in Figure 6. The 
findings suggest that this relatively simple protocol which can be prepared by house-staff 
based on total daily dose was able to safely control both DM1 and DM2 /gestational 
diabetic women with minimal hypo or hyper-glycemic risk for mother or offspring. The 
degree of glucose control in labour did not appear to relate to the risk of hypoglycemia in 
the neonate in this sample size. (Figure 5) 
Once the baby has been delivered, the needs for insulin fall faster than the insulin is 
metabolized, so the women is at risk of hypoglycaemia in the first 1-2 hours after delivery. 
Thus, the protocol emphasizes stopping the insulin at delivery and increasing the glucose 
infusion to 10g/hour immediately after the delivery of the baby and for the next 2 hours. If 
the glucose remains above 5.5mmol/L, the infusion rate can be reduced to 5g an hour again 
or discontinued and the woman would be allowed to eat if she underwent a vaginal 
delivery. As most women with gestational diabetes have normal glucose post-partum, this 
can be checked with capillary blood glucose monitoring (CBGM) the following day pre and 
post breakfast. If there is evidence of abnormal glucose intolerance (particularly in someone 
who may have had type 2 diabetes only diagnosed in pregnancy) in the initial post-partum 
period, depending on its severity, the woman may be instructed to continue with medical 
nutrition therapy and testing and re-assess in 1 month, or she may require some form of 
therapy with oral agents or insulin on leaving the hospital.  
If her glucose appears normal prior to discharge, she should undergo an OGTT at 6 weeks to 
6 months post-partum (or before she next conceives) to verify her glucose tolerance status – 
the actual timing varies related to guidelines established in various countries and related to 
the ethnic risks present in that country (Canadian Diabetes Association Clinical Practice 
Guidelines Expert Committee, 2008; Reinblatt, Morin, & Meltzer, 2006; McClean, Farrar, 
Kelly, Tuffnell, & Whitelaw, 2010). Initial post-partum testing within the first year is most 
effective if an oral glucose tolerance test is done; however, of those with any abnormality, 
further regular follow-up is likely adequate with a fasting plasma glucose and potentially an 
A1C (Lee, Mak, Lao, & Chung, 2011; Kim, Herman, & Vijan, 2007). Many women with GDM 
will have evidence of some form of dysglycemia or impaired glucose tolerance which would 
be amenable to preventive therapy. Additionally, even for women who tested normal, they 
must be reminded that their long term risks of developing diabetes remain elevated as does 
their cardiovascular risks (Egeland & Meltzer, 2010; Bellamy, Casas, Hingorani, & Williams, 
2009; Ratnakaran, Qi, Connelly, Sermer, Hanley, & Zinman, 2010). It should not be forgotten 
that the presence of gestational diabetes in the mother appears to confer future risk for the 
offspring in terms of obesity and glucose intolerance (Nolan, Damm, & Prentki, 2011; 
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Fig. 5. Glucose values achieved in labour with insulin adjustment protocol and incidence of 
neonatal hypoglycemia. 
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Fig. 6. Mean capillary blood glucose in labour in women with type 1 or type 2 DM  
In the appendix there are copies of the insulin adjustment algorithm, document sheets for 
management in English and French and in-hospital insulin algorithms for day by day 
management and for insulin in  labour protocol. 
7. Conclusion  
Management of gestational diabetes can be very rewarding.  This chapter has tried to raise 
the important issue that implication of the woman enthusiastically in her own self-care can 
facilitate care and become a tool to sensitize her to her future role in the family lifestyle 
choices. 
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9. Appendix 1  
Insulin adjustment protocol in English 
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11. Appendix 3 
Insulin adjustment protocol for use in hospital 
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1. Introduction 
Gestational diabetes mellitus is commonly defined as hyperglycemia with onset or first 
recognition during pregnancy. However, this definition of gestational diabetes does not 
exclude pregnant women with undiagnosed pre-existing diabetes that now accounts around 
1% of diabetes mellitus cases in pregnancy. Prompt identification of pre-existing diabetes, if 
compared with women with gestational diabetes mellitus, is essential, for the reason that 
women with pre-existing diabetes are at risk of giving birth to infants with serious 
malformations, and adverse pregnancy outcomes are increased in this cluster, too. These 
include serious injury at birth, increased probability of cesarean delivery, and increased 
incidence of newborn admission in intensive care unit. 
The incidence of gestational diabetes is unfortunately increasing, it accounts for 90% of cases 
of diabetes mellitus in pregnancy, and it has strong association with adverse pregnancy 
outcomes. Risk factors connected to gestational diabetes mellitus include older age, family 
history and previous history of gestational diabetes mellitus, obesity, polycystic ovary 
syndrome and high blood pressure (American Diabetes Association, 2009; Hedderson and 
Ferrara, 2008). If untreated, it may lead to diverse complications, such as fetal 
hyperinsulinemia, increased weight at birth, higher rates of cesarian deliveries, shoulder 
dystocia, more neonatal hypoglycemia, and is associated with concomitant preeclampsia in 
pregnant women. Therefore, given that gestational diabetes may have long-term 
pathological consequences for both mother and the child, it is important that it is recognized 
and correctly managed. 
Treatment of gestational diabetes is aimed to maintain euglycemia and it involves regular 
glucose monitoring, dietary modification, life style changes, exercise, and, when necessary, 
pharmacotherapy. Insulin therapy is the first choice of treatment, although glyburide and 
metformin may be indicated, too. In women receiving pharmacotherapy scheduled 
monitoring of fetal well-being with antenatal tests should be pursued. 
2. Non-pharmacological treatment 
Self-monitoring of blood glucose is considered to be essential during pregnancy. This is 
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mild gestational diabetes positively correlates with reduced rate of fetal overgrowth and 
gestational weight gain (Hawkins, 2010). Moreover, taking into account that excessive 
gestational weight gain correlates with postpartum weight retention, regular monitoring of 
blood glucose during pregnancy might certainly have long-term benefits (Siega-Riz et al., 
2009). Common fasting, preprandial and postprandial glucose tests are all recommended in 
order to attain adequate glycemic targets and reduce overall rate of large-for-gestational-age 
infant births (Aschwald et al., 2009; Jovanovic, 2008; Riskin-Mashiah et al., 2009). The 
frequency and timing of home glucose monitoring for gaining and maintaining target 
glucose levels should be individualized. Generally, the monitoring of blood glucose level is 
performed in the fasting state, and 1–2 hours after meals, too. Taking into account the 
increased risk of nocturnal hypoglycemia that may be present during the course of 
pregnancy; in pregnant women receiving insulin night testing or even continuous glucose 
monitoring might be suggested (McLachlan et al., 2007). 
It is recommended that women diagnosed with gestational diabetes should have expert 
dietitian counseling to ensure that medical nutrition therapy supports euglycemia, adequate 
nutritional intake and controlled weight gain. Dietary recommendations should be 
individualized for each patient. Moderate carbohydrate restriction and proper distribution 
of daily meals should be emphasized. Namely, six meals per day are recommendable, 
including three major meals and three smaller ones - snacks. As a result, it has been shown 
that restriction of carbohydrates to 35–40% will decrease maternal glucose levels and 
improve maternal and fetal outcomes (Major et al., 1998). For pregnant women with body 
mass index >30 kg/m2, a 30–33% calorie restriction is expected to reduce hyperglycemia and 
plasma triglycerides (Moore, 2010). Moreover, fetal-based strategy to govern maternal 
glucose control may notably improve outcomes for the fetus given that increased fetal 
abdominal circumference on an ultrasound (conducted between 28-34 weeks) has been 
found to be connected to increased insulin in amniotic fluid, thus directly revealing poor 
maternal glycemic control. Assessing the fetal response to maternal gestational diabetes 
mellitus by ultrasound measurement of fetal abdominal circumference starting in the second 
and early third trimesters and repeated every 2– 4 weeks can provide useful information (in 
combination with maternal self-monitoring of blood glucose levels) to guide management 
decisions (Metzger et al., 2007). 
Individually adjusted physical activity should be promoted, especially in overweight or 
obese women who are often insulin resistant and at risk for preeclampsia. Thus, the amount 
of physical activity consisting of 20 minutes aerobic training three days weekly for six 
weeks, has been shown to result in lower fasting glucose levels, lower glucose responses to a 
glucose challenge, and a lower glycated hemoglobin - HbA1c (Jovanovic-Peterson et al., 
1989).  Avery et al. (1997) have also observed improved glucose levels in women who 
exercised 30 minutes 3-4 times per week. The delay in requirement of insulin was reported 
in another study involving resistance training three times per week (Brankston et al., 2004). 
Exercises may not be advisable if obstetrical contraindications exist, or in cases in which 
physical activity actually worsens glycemic control.   
3. Pharmacological treatment 
Insulin is the first-line pharmacological intervention for gestational diabetes and it should be 
initiated in women diagnosed with gestational diabetes or impaired glucose tolerance who 
did not achieve glycemic control within two weeks by the sole application of individualized 
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nutrition plan. During pregnancy, the main objective of insulin therapy will be to attain 
glucose levels similar to those before pregnancy. If indicated, at the beginning small doses of 
insulin are to be administered, and then insulin doses should be gradually increased. This 
should be accompanied by the appropriate administration intervals until target glucose 
levels are attained. Taking into account that insulin resistance rises during the whole 
pregnancy period, the insulin regimens must be continuously monitored, reviewed and 
modified. This is particularly significant during the third trimester of pregnancy when the 
required dosage of insulin usually increases. Hypoglycemia prevention measurements 
should be clearly explained to all pregnant women on insulin therapy. Sill, insulin therapy is 
considered to be effective and safe, and it is regarded as the gold standard of 
pharmacotherapy for gestational diabetes. It has been well determined that the use of 
insulin to achieve glycemic targets reduces fetal and maternal morbidities. In this way, daily 
glucose control and diet that were associated with insulin treatment and additional obstetric 
interventions have been confirmed to reduce the incidence of shoulder dystocia and 
macrosomia (Horvath et al., 2010).   
A diversity of protocols can be used, but multiple injections are considered to be the most 
effective. The majority insulin protocols include intermediate-acting insulins, such as 
isophane, and short-acting insulins, such as regular recombinant, as well the insulin 
analogues aspart and lispro. Although isophane is the intermediate-acting insulin of the first 
choice for women with gestational diabetes, evidences also support the use of short-acting 
insulin analogues in women who require pharmacological treatment of gestational diabetes. 
Moreover, the use of insulin analogs in pregnancy presents the potential benefits of more 
closely mimicking biological pancreatic insulin secretion compared to regular insulin 
(Klieger et al., 2008).  
Insulin lispro is insulin analog with fast absorption rate and a short duration of action that 
improves postprandial glucose levels and reduces hypoglycemic episodes when injected 
immediately prior to meals (Anderson et al., 1997). In the study conducted by Jovanovic et 
al., (1999) it was of interest to compare the immunologic response to insulin lispro with that 
to regular human insulin, thereby assuring its safety for use in women with gestational 
diabetes, and to verify that it is effective. Anti-insulin antibody levels were similar in the 
two groups. Insulin lispro was not detectable in the cord blood. During a meal test, areas 
under the curve for glucose, insulin, and C-peptide were significantly lower in the lispro 
group. Mean fasting and postprandial glucose concentrations and end point HbA1c were 
similar in the two groups but the lispro group demonstrated fewer hypoglycemic episodes. 
Accordingly, in women with gestational diabetes mellitus, the use of insulin lispro enabled 
the attainment of near-normal glucose levels at the one hour post-prandial time point and 
was associated with normal anthropometric characteristics; whereas use of regular insulin 
was not able to blunt the one hour peak post-prandial response to a near-normal extent and 
resulted in infants with a tendency toward the disproportionate growth (Mecacci et al., 
2003). Bhattacharyya et al. (2001) reported no increase in adverse outcome using lispro 
insulin in diabetic pregnancies, in either gestational or pre-gestational diabetes. Likewise, 
there was no difference in respect to congenital anomalies of gestational diabetic groups, 
which used either insulin lispro or regular human insulin (Aydin et al., 2008).  
In consideration to insulin aspart use, it has been demonstrated that effective postprandial 
glycemic control in women with gestational diabetes mellitus who required insulin was 
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nutrition plan. During pregnancy, the main objective of insulin therapy will be to attain 
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immediately prior to meals (Anderson et al., 1997). In the study conducted by Jovanovic et 
al., (1999) it was of interest to compare the immunologic response to insulin lispro with that 
to regular human insulin, thereby assuring its safety for use in women with gestational 
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two groups. Insulin lispro was not detectable in the cord blood. During a meal test, areas 
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similar in the two groups but the lispro group demonstrated fewer hypoglycemic episodes. 
Accordingly, in women with gestational diabetes mellitus, the use of insulin lispro enabled 
the attainment of near-normal glucose levels at the one hour post-prandial time point and 
was associated with normal anthropometric characteristics; whereas use of regular insulin 
was not able to blunt the one hour peak post-prandial response to a near-normal extent and 
resulted in infants with a tendency toward the disproportionate growth (Mecacci et al., 
2003). Bhattacharyya et al. (2001) reported no increase in adverse outcome using lispro 
insulin in diabetic pregnancies, in either gestational or pre-gestational diabetes. Likewise, 
there was no difference in respect to congenital anomalies of gestational diabetic groups, 
which used either insulin lispro or regular human insulin (Aydin et al., 2008).  
In consideration to insulin aspart use, it has been demonstrated that effective postprandial 
glycemic control in women with gestational diabetes mellitus who required insulin was 





endogenous insulin secretion (Pettitt et al., 2003). In particular, the peak insulin 
concentration was higher and the peak glucose and C-peptide concentrations were lower 
with both insulin preparations than with no exogenous insulin. Moreover, glucose areas 
under the curve above baseline were significantly lower with insulin aspart, but not with 
regular insulin, than with no insulin. In another randomized, parallel, open-label, 
controlled, multicenter and multinational study of type 1 diabetes pregnancy the fetal 
outcome using insulin aspart was comparable with human insulin, with a tendency toward 
fewer fetal losses and preterm deliveries (Hod at al., 2008). In another study, insulin aspart 
was more effective than regular human isulin in decreasing postprandial glucose 
concentrations (Pettitt et al., 2007). The authors of this investigation found out that duration 
of insulin aspart injection 5 min before a meal rather than 30 min prior to meals offered a 
more convenient therapy for subjects with gestational diabetes mellitus. Moreover, overall 
safety and effectiveness of insulin aspart were comparable to regular human insulin in 
pregnant women with gestational diabetes mellitus. 
Glyburide and metformin are oral antidiabetics that may be considered as second line 
agents in cases of gestational diabetes with poor glycemic control with insulin, or in women 
who refuse insulin. This is supported by the fact that when compared with insulin, 
administration of oral hypoglycemic agents was not associated with risk of neonatal 
hypoglycemia, caesarean section, or large-for-gestational-age babies births (Dhulkotia et al., 
2010). No significant differences were found in maternal fasting or postprandial glycemic 
control, too. It appears that glyburide may be preferred, as metformin use is more likely to 
need supplemental insulin for glycemic control and in addition metformin crosses the 
placenta with possible long-term effects. It has been estimated that fetal levels of metformin 
may reach approximately half of maternal levels (Vanky et al., 2005). 
The sulfonylurea glyburide is safe and effective at controlling glucose levels in majority of 
pregnant women with gestational diabetes mellitus. The study of Langer et al. (2005) was 
aimed to investigate the association between glyburide dose, degree of severity in 
gestational diabetes mellitus, level of glycemic control, and pregnancy outcome in insulin- 
and glyburide-treated patients. It has been reported that glyburide and insulin were equally 
efficient for treatment of gestational diabetes mellitus in all levels of disease severity. In 
earlier investigation it was also demonstrated that there were no significant differences 
between the glyburide and insulin groups in the percentage of infants who were large for 
gestational age, who had macrosomia, who had lung complications, who had 
hypoglycemia, who were admitted to a neonatal intensive care unit; or who had fetal 
anomalies (Langer et al., 2000). Glyburide is regarded as a pharmacologically active 
substance that minimally crosses placenta, as supported by different in vitro and in vivo 
investigations that demonstrated very low transplacental transport of glyburide to the fetal 
circulation. This is due to high plasma protein binding, short half-life, as well as its active 
transport from the fetus to the mother (Bertini et al., 2005; Koren 2001; Kraemer et al., 2006). 
In the study aimed to identify placental transporters potentially involved in limiting the 
transplacental transfer of glyburide to the fetus it was demonstrated that glyburide is 
preferentially transported by the breast cancer resistance protein pump and multidrug 
resistance-associated protein 3, that are highly expressed in placental tissues and limit the 
passage of therapeutic or toxic xenobiotics to the fetus (Gedeon et al., 2006).  Unfortunately, 
poor clinical response to glyburide has been reported in women with higher fasting and 
postprandial glucose values on their oral glucose tolerance test or in the group of diabetic 
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women on diet therapy. Other identified predictors of glyburide treatment failure were 
advanced maternal age, earlier diagnosis of gestational diabetes mellitus, higher gravidity 
or higher parity (Kahn et al., 2006). Otherwise, glyburide can be recommended for women 
in whom insulin cannot be used. In that way, it has been confirmed that this oral 
hypoglycemic can be used safely and effectively during the second and the third trimester of 
pregnancy without increasing maternal or fetal complications when compared with insulin 
(Langer et al., 2000). Glyburide has been shown to be safe in breastfeeding, too (Feig et al., 
2005). However, it has to be emphasized that in some investigations a glyburide-related 
increased risk of preeclampsia, macrosomia, neonatal hypoglycemia, admission to a 
neonatal intensive care unit; as well a need for phototherapy have been reported (Jacobson 
et al., 2005; Ramos et al., 2007). 
The second oral antidiabetic drug used in gestational diabetes mellitus, as a monotherapy or 
with supplemental insulin, is metformin, a biguanide. It lowers blood glucose levels by 
decreasing hepatic gluconeogenesis, increasing peripheral glucose disposal and reducing 
intestinal glucose absorption (Hundal & Inzucchi, 2003). In average, up to half the women 
using metformin may require supplemental insulin. It has been demonstrated that women 
requiring supplemental insulin had a higher body mass index and had higher baseline 
glucose levels (Rowan et al. 2008). If compared to insulin, metformin was not associated 
with increased perinatal complications except of higher incidence of perinatal mortality if 
administered during the third trimester (Hellmuth et al., 2000). Although it may appear that 
metformin is safe alternative to insulin therapy, it does cross the placenta (Vanky et al., 
2005) and scientific data are still not conclusive enough to recommend the standard use of 
metformin during pregnancy beyond the first trimester. Data that are more recent suggested 
that in women with gestational diabetes mellitus, not controlled with diet and exercise, who 
were then randomized to the metformin or the insulin arm, metformin has been shown to be 
an effective alternative to insulin in the treatment of gestational diabetes mellitus (Moore et 
al., 2007). This was substantiated by findings showing that difference in the rate of cesarean 
delivery was not statistically significant between the two groups, neither the neonatal 
statistics involving birth weight, Apgar score at 5 minutes, respiratory distress syndrome, 
hyperbilirubinemia, neonatal hypoglycemia or neonatal intensive care unit admission. 
Likewise, in investigation of Rowan et al. (2008) women with gestational diabetes mellitus at 
20 to 33 weeks of gestation were randomly assigned to open treatment with metformin 
(with supplemental insulin if required) or insulin. The primary outcome was a composite of 
neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute 
Apgar score less than 7, or prematurity. The rate of the primary composite outcome was 
comparable between the group assigned to metformin and the insulin group, suggesting 
that in women with gestational diabetes mellitus, metformin (alone or with supplemental 
insulin) was not associated with increased perinatal complications as compared with 
insulin. The retrospective data of Tertti et al. (2008) have been also indicative for the 
assumption that metformin was effective in controlling gestational diabetes and was not 
associated with a higher risk of maternal or neonatal complications compared with insulin. 
Namely, there were no differences between the metformin-treated group and the other two 
investigated groups (women treated with insulin and women with no pharmacological 
treatment) in terms of maternal outcomes (total weight gain during pregnancy or after the 
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hypertension, pre-eclampsia etc.). In this investigation, no differences between the 
metformin-treated group and the other two groups were observed in relation to mean birth 
weights, prevalence of macrosomia, or gestational weeks at delivery. Finally, there were no 
differences between the groups in relation to other neonatal outcomes (small for gestational 
age, Apgar scores, umbilical artery pH or base excess, etc.). This drug is contraindicated in 
the case of preeclampsia, intrauterine growth restriction or placental insufficiency. 
Moreover, given that metformin crosses placenta, it could increase insulin sensitivity in the 
fetus, thus probably affecting growth and fetal hepatic glucose production. 
4. Postpartum considerations 
After delivery, it is fundamental that women receive the appropriate postpartum 
counseling, testing, and follow-up. In a long-term view, most women with gestational 
diabetes do not require insulin therapy following delivery. Nevertheless, glucose levels 
should be regularly checked after discharge, since it has been confirmed that the progression 
of gestational diabetes mellitus to type 2 diabetes increased steeply within the first 5 years 
after delivery and appeared to plateau after 10 years (Kim et al., 2002). It has been 
determined that progressive beta-cell failure to compensate for the ongoing insulin 
resistance correlates with progression from gestational diabetes mellitus to type 2 diabetes. 
Insulin resistance that presents as a high serum insulin concentrations in association with 
blood glucose concentrations that are normal or high, results from defects in insulin 
responsiveness in muscle, fat and liver. Therefore, screening for diabetes at regular intervals 
should be of paramount importance. In addition, among women with a family history of 
type 2 diabetes, those with prior gestational diabetes mellitus were even more likely not 
only to have cardiovascular disease risk factors, including metabolic syndrome and type 2 
diabetes, but also to have experienced cardiovascular disease events, which occurred at a 
younger age (Carr et al., 2006). Moreover, the development of metabolic syndrome in 
children with increasing age is known to be related to maternal gestational diabetes 
mellitus, maternal glycemia in the third trimester, maternal obesity, neonatal macrosomia, 
and childhood obesity (Vohr  & Boney, 2008). Consequently, post partum evaluation and 
management of reversible cardiovascular risk factors such as smoking, obesity, 
hypertension, and hyperlipidemia should be undertaken (Cheung, 2009).  
It is confirmed that a good predictor of early postpartum development of diabetes is 
elevated fasting plasma glucose during pregnancy and, in women having positive tests to 
specific autoantibodies [anti-glutamic acid decarboxylase (anti-GAD); anti-protein tyrosine 
phosphatase ICA 512 (anti–IA-2)], higher incidence of diabetes by six months postpartum 
has been shown, too. In addition, it should be pointed out that some women with 
gestational diabetes mellitus, especially lean ones under 30 years of age who required 
insulin during pregnancy, could progress to type 1 diabetes. Therefore, women diagnosed 
with gestational diabetes should be screened for diabetes 6 to 12 weeks postpartum and 
should have subsequent screening for the development of diabetes or prediabetes 
(American Diabetes Association, 2009). An oral glucose tolerance test at three-year intervals 
has been also shown to be a beneficial approach for screening. 
All women with gestational diabetes should be encouraged on a healthy lifestyle and in 
order to prevent diabetes and cardiovascular complications education on lifestyle 
modification should start in pregnancy and continue postpartum. In that way, usual 
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recommendations to promote postpartum weight adjustments and decrease the incidence of 
type 2 diabetes include breastfeeding, exercising at a moderate intensity, and modifications 
of nutrition for specific weight-loss objectives (National Collaborating Centre for Women’s 
and Children’s Health, 2008). It has been determined that breastfeeding itself promotes 
weight loss for the mother, decreases possibility of maternal progression to type 2 diabetes, 
reduces insulin resistance in mothers and decreases likelihood of obesity in the child. 
Children born to mothers who had poor glycemic control should undergo regular 
evaluations of height, weight and blood glucose concentration, as well as monitoring for 
appropriate physical activity and diet to minimize the likelihood of obesity (Elchalal, 2004). 
5. Conclusion 
The incidence of gestational diabetes is increasing and this pathological condition has strong 
association with adverse pregnancy outcomes. If untreated, gestational diabetes may lead to 
diverse complications, such as fetal hyperinsulinemia, increased weight at birth, higher rates 
of cesarian deliveries, shoulder dystocia, neonatal hypoglycemia, and it is also associated 
with concomitant preeclampsia in pregnant women. Therefore, given that gestational 
diabetes may have long-term pathological consequences for both mother and the child, it is 
important that it is recognized and correctly managed. Moreover, preconceptional screening 
and medical informing of women with diabetes type 1 or 2 would be significant in order to 
reduce risk to the fetus and mother connected to gestational diabetes. Treatment of 
gestational diabetes is aimed to maintain euglycemia and it should involve regular glucose 
monitoring, dietary modification, life style changes, exercise, and, when necessary, 
pharmacotherapy. Insulin therapy is the first choice of treatment, although glyburide and 
metformin could be indicated, too. In a long-term view, in order to prevent development of 
diabetes later in life, as well as different cardiovascular complications, an adequate 
education on lifestyle modifications should start in pregnancy and continue postpartum. 
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1. Introduction 
During pregnancy, 5-14% of women are diagnosed with gestational diabetes mellitus 
(GDM) and the incidence has been increasing (Jovanovic & Pettitt, 2001; Paglia & Coustan, 
2011). While insulin treatment is still the “gold standard” therapy for controlling maternal 
glycemia, the increasing use of oral anti-diabetic agents such as glyburide and metformin 
has begun to change standard care (Maymone et al., 2011). Anti-diabetic drugs are often 
titrated over a prolonged period of time to achieve glycemic control. Prolonged 
hyperglycemia increases the likelihood of adverse fetal/neonatal and maternal outcomes. 
Thus, quickly achieving glycemic control during pregnancy can significantly reduce the 
occurrence of certain adverse perinatal and maternal outcomes (Karakash & Einstein, 2011).  
Glyburide is a second generation oral sulfonylurea (Feldman, 1985). Glyburide lowers blood 
sugar levels by stimulating the pancreas to secrete insulin and by helping the body use 
insulin efficiently. Considerable data in the literature suggest that glyburide may be a safe 
alternative to insulin for the treatment of GDM due to its similar efficacy to insulin and its 
low fetal distribution (Nicholson & Baptiste-Roberts, 2011; Maymone et al., 2011). 
Physiological and biochemical changes that occur during pregnancy alter the 
pharmacokinetics of glyburide, thus affecting the safety and efficacy of the drug for both the 
mother and the fetus. Understanding pregnancy-induced changes in the disposition of 
glyburide (including fetal exposure) will be important for optimizing dosage guidelines 
during pregnancy. In this chapter, current knowledge on the safety and efficacy of glyburide 
for the treatment of GDM, pregnancy-related effects on maternal disposition as well as 
placental transport and metabolism of the drug will be summarized. 
2. Gestational diabetes mellitus and treatment options 
The American College of Obstetricians and Gynecologists (ACOG) committee on practice 
defines GDM as “carbohydrate intolerance that begins or is first recognized during 
pregnancy” (2001). Similar to type II diabetes mellitus, GDM is the result of an inability to 
compensate for the degree of insulin resistance. Insulin resistance is normal to some extent 
during pregnancy as a means of ensuring that glucose is freely available to the developing 
fetus; however, in women predisposed to diabetes, the degree of insulin resistance can be so 
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Properly treating GDM is of great concern as the condition complicates 5-14% of 
pregnancies. If untreated, GDM presents a danger to both the mother and baby, particularly 
the risk of hypertension, preeclampsia, urinary tract infections, cesarean delivery and 
development of type II diabetes mellitus later in life in mothers, as well as macrosomia, 
neonatal hypoglycemia, childhood obesity and type II diabetes mellitus in the offspring 
(2002; 2009; 2010; Paglia & Coustan, 2011). Diet therapy is the first line of treatment for GDM 
and is adequate for controlling glucose concentrations in the majority of patients. Those 
failing diet therapy are managed with the addition of pharmacotherapy (Landon et al., 
2007). The American Diabetes Association (ADA) suggests that women with GDM should 
seek nutritional counseling by a dietician in order to individualize diet therapy by patient 
height and weight (2001). To prevent ketonuria, which can hinder the cognitive 
development of children ages 3 – 9, the ACOG recommends caloric restrictions that are not 
to exceed 33% of current diet (2001). 
There are two general options of pharmacotherapy for the treatment of GDM. Traditionally, 
insulin therapy has been the “gold standard” for the management of GDM, when diet 
therapy and exercise fail to achieve maternal glycemic control. Pregnant women have 
difficulty adhering to insulin therapy regimens because of the challenges with route of 
administration and schedule. Therefore, oral hypoglycemic agents such as glyburide and 
metformin are being increasingly used to treat GDM, and have been shown to have similar 
efficacy and safety as insulin, as well as lower cost and easier route of administration 
(Maymone et al., 2011; Nicholson & Baptiste-Roberts, 2011). The safety of insulin for use in 
pregnancy has been well established without the risk of transfer across the placenta. The 
FDA has not approved the use of glyburide or metformin for the treatment of women with 
GDM. This chapter will focus its discussion on glyburide. 
3. Glyburide and its clinical pharmacokinetics 
Glyburide is a second generation oral sulfonylurea, and its chemical structure is shown in 
Figure 1. Glyburide is indicated as an adjunct to diet therapy and serves to lower blood 
glucose levels in patients with type II diabetes mellitus (Feldman, 1985). Glyburide exerts its 
pharmacological effect by stimulating insulin secretion from pancreatic β-islet cells. It 
inhibits ATP-sensitive potassium channels on the surface of pancreatic β-islet cells, leading 
to cellular membrane depolarization. Depolarization at the cellular membrane prompts 
voltage-gated calcium channels to open, increasing the intracellular calcium concentration, 
which stimulates the release of insulin into the portal vein. Glyburide is administered in 
1.25, 2.5 or 5 mg tablets. The FDA approved dosage range is 1.25 mg up to 20 mg per day. 
When higher dosages of glyburide are required, patients are typically switched to insulin.  
Glyburide is a small lipophilic molecule (LogP = 4.8, MW = 494 Da) that is highly bound to 
plasma proteins (99.8% plasma protein binding). Glyburide is well absorbed with an oral 
bioavailability of approximately 95% for micronized tablets (Jonsson et al., 1994). It exhibits 
biphasic elimination kinetics with an initial distribution half-life (T1/2α) of roughly 30 min 
and a terminal elimination half-life (T1/2β) of approximately 10 hours (Feldman, 1985; 
Jonsson et al., 1994). Thus, the overall elimination half-life of glyburide is approximately 4 
hours. Glyburide has a small volume of distribution (0.2 L/kg), despite its lipophilic nature, 
and has negligible renal clearance.  
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Glyburide is extensively metabolized in the liver with a low hepatic extraction ratio. One 
enzyme involved in glyburide metabolism is CYP2C9, which is highly polymorphic. The 
CYP2C9 variant, CYP2C9*3, exhibits lower catalytic activity than wild-type CYP2C9*1 
(Cavallari & Limdi, 2009). Kirchheriner et al. showed that the oral clearance of glyburide 
in the CYP2C9*3/*3 subjects (n = 3) was ~40% of that in CYP2C9*1/*1 subjects (n = 4) 
(Kirchheiner et al., 2002). Niemi et al. reported that the area under plasma concentration-
time curve (plasma AUC) of glyburide in subjects heterozygous for CYP2C9*3 
(CYP2C9*1/*3 or CYP2C9*2/*3, n = 2) was 280% of that in the CYP2C9*1/*1 subjects (n = 
5) (Niemi et al., 2002). Yin et al. demonstrated that the oral plasma AUC of glyburide in 
CYP2C9*1/*3 subjects (n = 6) of the Chinese population was higher by ~100% as 
compared with that in the CYP2C9*1/*1 subjects (n = 12) (Yin et al., 2005). These clinical 
studies appear to suggest that CYP2C9 contributes significantly to glyburide metabolism 
in vivo.  
On the other hand, in vitro studies using human liver microsomes have shown that CYP3A4 
contributes greater than 50% of glyburide metabolism, while CYP2C9 contributes a much 
smaller percentage (Naritomi et al., 2004; Zharikova et al., 2009; Zhou et al., 2010a). 
Additionally, Lilja et al. showed that oral administration of clarithromycin, an inhibitor of 
CYP3A but not CYP2C9, significantly increased Cmax and the plasma AUC of glyburide 
(Lilja et al., 2007). The epidemiological study (Schelleman et al., 2010) and case reports 
(Bussing & Gende, 2002; Leiba et al., 2004) all indicated that the concomitant use of 
glyburide with clarithromycin was associated with severe hypoglycemia. Thus, CYP3A also 
appears to contribute to glyburide metabolism in vivo. It is possible that glyburide is 
metabolized in vivo through the joint actions of hepatic CYP3A and CYP2C9.  
In vitro metabolism studies using human liver microsomes or recombinant systems 
revealed that, besides CYP3A4 and CYP2C9, glyburide was also metabolized by other 
cytochrome P450 enzymes such as CYP3A5, CYP2C8 and CYP2C19, but to a much lesser 
extent (Naritomi et al., 2004; Zharikova et al., 2009; Zhou et al., 2010a). Zharikova et al. 
determined five metabolites of glyburide formed in human liver microsomes: M1 (4-trans-
hydrocyclohexyl glyburide), M2a (4-cis-hydrocyclohexyl glyburide), M2b (3-cis-
hydrocyclohexyl glyburide), M3 (3-trans-hydrocyclohexyl glyburide), M4 (2-trans-
hydrocyclohexyl glyburide) and M5 (ethylene-hydroxylated glyburide) (Zharikova et al., 
2009; Zharikova et al., 2007). The chemical structures of these glyburide metabolites are 
shown in Figure 1. CYP3A4 catalyzes the formation of M1-M5. CYP2C9 catalyzes the 
formation of M1-M3. CYP2C8 catalyzes the formation of M1, M2b, M3 and M4. CYP2C19 
catalyzes the formation of M2a, M2b and M3 (Zharikova et al., 2009; Zharikova et al., 
2007). The two major metabolites of glyburide, M1 and M2b, which account for 
approximately half of all the metabolites formed in vitro by human liver microsomes 
(Zharikova et al., 2007), are excreted into the bile and urine (~50% each) (Feldman, 1985). 
M1 and M2b are not likely to contribute significantly to hypoglycemic action in humans 
since they are only weakly active (1/400th and 1/40th as active, respectively, as glyburide 
in preclinical models, as described in the FDA labeling). However, there were also studies 
indicating that M1 and M2b retain 75% and 50%, respectively, of the hypoglycemic 
activity of glyburide in humans (Rydberg et al., 1994). The systemic exposure of M1 is 
only 2 – 4% of that of glyburide (Zheng et al., 2009). The pharmacological activity of other 
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Fig. 1. The chemical structures of glyburide and its metabolites. M1, 4-trans-hydrocyclohexyl 
glyburide; M2a, 4-cis-hydrocyclohexyl glyburide; M2b, 3-cis-hydrocyclohexyl glyburide; M3, 
3-trans-hydrocyclohexyl glyburide; M4, 2-trans-hydrocyclohexyl glyburide; and M5, 
ethylene-hydroxylated glyburide.  
4. The efficacy and safety of glyburide during pregnancy 
Although glyburide is not currently approved by the FDA to treat GDM, the 
pathophysiology of GDM is similar to type II diabetes mellitus and consequently, glyburide 
has been increasingly prescribed to women with GDM. There are obvious benefits to using 
oral hypoglycemic agents such as glyburide and metformin rather than insulin.  Oral agents 
are less expensive, easier to administer and demonstrate improved patient compliance as 
compared to insulin. Clinical studies have been conducted to compare the efficacy and 
safety of such oral agents with those of insulin for the treatment of GDM. In this section, the 
results of clinical studies comparing the efficacy and safety of glyburide versus insulin will 
be summarized. 
4.1 Clinical efficacy during pregnancy  
There are several randomized controlled clinical trials that examined the efficacy of 
glyburide during pregnancy (Langer et al., 2000; Anjalakshi et al., 2007; Bertini et al., 2005; 
Ogunyemi et al., 2007). Langer et al. performed the largest clinical study that compared the 
efficacy of glyburide to insulin for the treatment of GDM (Langer et al., 2000). This group 
randomly assigned 404 women with GDM into two treatment groups (insulin or glyburide), 
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and showed no statistically significant difference in fasting, preprandial, 2-hour 
postprandial and mean blood glucose concentrations between the glyburide and insulin 
groups (~106 mg/dL, 105 mg/dL, 130 mg/dL, and 115 mg/dL, respectively). Langer 
concluded that glyburide was as effective as insulin for the treatment of GDM and therefore 
can be used as a clinically effective alternative to insulin therapy. These authors reported 
eight women in the glyburide group (4%) who required insulin therapy. These authors also 
performed a subsequent analysis of the data from this clinical study to determine if the 
severity of GDM was linked to the dosage of glyburide required to achieve adequate 
glycemic control (Langer et al., 2000). It was found that glyburide doses were increased and 
the success rate of glyburide therapy decreased as disease severity increased. At each level 
of disease severity, there was no difference in maternal and neonatal outcomes between the 
insulin and glyburide groups.  
Two smaller clinical studies also compared the efficacy of glyburide and insulin in the 
treatment of GDM, and no difference was observed in fasting and 2-hour postprandial 
blood glucose concentrations (Anjalakshi et al., 2007; Bertini et al., 2005). In contrast, 
Ogunyemi et al. reported significantly higher fasting and 2-hour postprandial blood glucose 
concentrations in patients receiving glyburide than in patients receiving insulin (Ogunyemi 
et al., 2007). Bertini et al. found that glucose control was not achieved in 5 patients in the 
glyburide group (20.8% failure rate) who had to switch to insulin therapy, despite 
similarities in maternal demographics across groups (age, weight and parity) (Bertini et al., 
2005). Since the sample size of this randomized-controlled trial was relatively small, this 
may not accurately reflect the true failure rate of glyburide therapy.  
In addition, retrospective studies have been conducted to assess the efficacy of glyburide. 
Jacobson et al. performed a retrospective study of 584 women with GDM who had failed 
diet therapy and were treated with glyburide or insulin between the years of 1999-2002 
(Jacobson et al., 2005). Patients from both groups were similar in age and nulliparity; 
however, women in the insulin group weighed more on average and had a higher mean 
fasting blood glucose level (105.4 versus 102.4 mg/dL). Women in the glyburide group had 
significantly lower post-treatment fasting and postprandial blood glucose levels. The failure 
rate of glyburide was reported to be 12%. The glyburide group did experience a higher rate 
of preeclampsia (12% versus 6%), despite controlling for body mass index and ethnicity. 
Jacobson et al. observed no statistical difference in neonatal outcomes such as birth weight 
and macrosomia, as well as incidence of cesarean delivery between groups. Ramos et al. 
retrospectively examined the effectiveness of glyburide (n = 44) versus insulin (n = 78) in 
women with GDM who had a 50 g 3-hour oral glucose challenge test of ≥200 mg/dL and a 
pretreatment fasting plasma glucose level of ≥105 mg/dL (Ramos et al., 2007). There were 
no significant differences between the two groups with respect to blood glucose levels. The 
failure rate of glyburide was 16%. There were no significant differences in fetal outcomes 
between the two treatment groups; however, the incidence of neonatal hypoglycemia was 
higher in glyburide-treated women (34% versus 15%, respectively) (Ramos et al., 2007). It is 
worth noting that retrospective studies were often not adequately powered and were 
without adequate controls. Therefore, making general conclusions regarding the efficacy of 
glyburide is difficult.  
To predict the treatment failure rate for glyburide in women with GDM, Kahn et al. 
conducted a prospective cohort study (n = 75) which demonstrated that fasting blood 
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failure rates (Kahn et al., 2006). The authors also reported that women who were older, had 
more than one child and were diagnosed with GDM earlier in their pregnancy were more 
likely to fail glyburide therapy.  On the other hand, Rochon et al. suggested that only higher 
mean blood glucose levels (≥ 200 mg/dL in the 50 g 1-hour oral glucose challenge test) were 
indicators of glyburide failure (Rochon et al., 2006). 
4.2 Maternal and neonatal safety 
Several studies have been conducted to investigate the adverse effects of glyburide versus 
insulin (Anjalakshi et al., 2007; Bertini et al., 2005; Langer et al., 2000; Ogunyemi et al., 2007; 
Yogev et al., 2004). Among these studies, Langer et al. conducted the largest randomized 
controlled trial with 404 pregnant women to receive glyburide or insulin, and found a 
significantly higher percentage of women with a blood glucose level <40 mg/dL in the insulin 
group compared with the glyburide group (20% versus 4%) (Langer et al., 2000). Yogev et al. 
demonstrated that 19 of 30 insulin-treated patients with GDM (63%) experienced 
asymptomatic hypoglycemia versus 7 of 25 (28%) glyburide-treated patients (Yogev et al., 
2004). On the other hand, in the study with 97 pregnant women, Ogunyemi et al. did not 
report a significant difference in hypoglycemia between the insulin and glyburide groups (31% 
verse 38%, respectively) (Ogunyemi et al., 2007). Other studies reported no hypoglycemic 
events (Anjalakshi et al., 2007; Bertini et al., 2005). Although the results varied, possibly due to 
difference in definition of hypoglycemia, these studies appear to support the notion that 
glyburide therapy generally causes fewer hypoglycemic events than insulin therapy. Langer et 
al. also showed no difference in the incidence of preeclampsia among women treated with 
insulin or glyburide (Langer et al., 2000). Bertini et al. found no significant difference in 
changes in maternal weight of women treated with insulin as compared to glyburide (Bertini 
et al., 2005). Likewise, no significant differences were reported in the percentage of women 
with cesarean delivery in the insulin group compared with the glyburide group (Anjalakshi et 
al., 2007; Bertini et al., 2005; Langer et al., 2000; Ogunyemi et al., 2007).         
Various clinical studies have also analyzed the effects of glyburide and insulin on neonatal 
adverse outcomes. In an earlier study, Coetzee and Jackson treated over 600 pregnant women 
suffering from GDM or type II diabetes mellitus with glyburide/metformin combination 
therapy (Coetzee and Jackson, 1985). Patients were classified as new diabetics, known 
diabetics or untreated diabetics. The untreated diabetic group was made up of pregnant 
women with type II diabetes mellitus or GDM who were not seen in the clinic until term. Each 
class of patients was further organized into four treatment groups: (1) diet therapy, (2) diet 
plus metformin therapy, (3) diet plus glyburide therapy, (4) diet plus metformin/glyburide 
combination therapy, and (5) treatment group (4) with the addition of insulin therapy due to 
inadequate glucose control (Coetzee and Jackson, 1985). Metformin therapy appeared to be the 
safest (0 still births, 1 neonatal death, and 33 per 1,000 perinatal morbidities, i.e. large for 
gestational age, low birthweight, hypoglycemia, jaundice and congenital abnormalities), 
followed by glyburide (1 still birth, 0 neonatal deaths, and 43 per 1,000 perinatal morbidities) 
and the emergency insulin group (1 still birth, 4 neonatal deaths, and 59 per 1,000 perinatal 
morbidities). In women with newly diagnosed GDM, insulin therapy appeared to be the safest 
(no adverse birth outcomes), followed by metformin (1 neonatal death and 16 per 1,000 
perinatal morbidities) and glyburide (1 still birth and 42 per 1,000 perinatal morbidities). The 
authors also reported a decrease in perinatal morbidities among the glyburide group 
compared with the diet therapy group as well as zero cases of serious neonatal hypoglycemia.    
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Bertini et al. found just the opposite to be true in a clinical study with 70 patients diagnosed 
with GDM (Bertini et al., 2005). Patients were placed on insulin therapy (n = 27), glyburide 
therapy (n = 24) or acarbose therapy (n = 19). The authors reported that neonatal 
hypoglycemia was observed in 8 newborns, 6 of which were from the glyburide group. 
Likewise, in the study with 97 women (n = 49 in the insulin group and n = 48 in the 
glyburide group), Ogunyemi et al. reported that 28% of infants in the glyburide group 
experienced an episode of hypoglycemia versus 13% in the insulin group, and the difference 
was statistically significant (Ogunyemi et al., 2007). In contrast, Langer et al. showed no 
difference in the incidence rate of hypoglycemia for infants between the insulin and 
glyburide treatment groups (Langer et al., 2000). Bertini et al. also demonstrated that a 
significantly higher percentage of fetuses were large for gestational age (LGA) infants in the 
glyburide group compared with the insulin group (25% versus 3.7%, respectively) (Bertini et 
al., 2005); however, Langer et al. reported comparable incidence rates of LGA between the 
two groups (n = 404) (Langer et al., 2000). All the clinical studies consistently reported 
higher average infant birth weights in the glyburide group than the insulin group, but the 
difference was small (an average of ~100 g) and not statistically significant (Anjalakshi et al., 
2007; Bertini et al., 2005; Langer et al., 2000; Ogunyemi et al., 2007). Few congenital 
malformations or anomalies were reported in either group. It is worth noting that the study 
by Langer et al. investigated significantly more subjects than any other study, and hence the 
results obtained could be more adequately powered and reliable. 
Overall, in women with GDM, glyburide achieved similar efficacy of glycemic control as 
insulin therapy. The maternal and neonatal safety of glyburide does not substantially differ 
from insulin therapy. However, it should be noted that, at present, there is no long-term 
safety data for infants whose mothers were treated with glyburide. Thus, further studies are 
needed to assess the long-term effects of maternal glyburide administration on child and 
adolescent development (neurologic and behavioral) as well as the incidence rate of type II 
diabetes mellitus and obesity.  
5. Pregnancy-induced pharmacokinetic changes of glyburide  
Physiological and biochemical changes that occur in pregnancy may affect the 
pharmacokinetics of drugs, namely absorption, distribution, metabolism and elimination 
(Anderson, 2005; Klieger et al., 2009; Loebstein et al., 1997). Such changes include, among 
others, changes in volume of distribution of drugs and plasma protein binding (Loebstein et 
al., 1997; Mendenhall, 1970), induction or down-regulation of cytochrome P450 enzyme 
expression and activity (Hebert et al., 2008; Tracy et al., 2005), and increase in renal blood 
flow and glomerular filtration (Dunlop & Davison, 1987). The effects of such pregnancy-
induced pharmacokinetic changes may be such that a dosage adjustment is required to 
accommodate increased potency of a drug or decreased efficacy. However, the balance of 
treating the mother and protecting the fetus may likely present challenges specifically for 
drug compounds that require increased dosages in order to be effective during pregnancy. 
Glyburide is such a case.   
5.1 Clinical pharmacokinetic studies 
To evaluate pregnancy-induced changes in the pharmacokinetics of glyburide, Hebert et al. 
compared parameter estimates for steady-state pharmacokinetics of glyburide in pregnant 
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(Hebert et al., 2009). Dose-normalized steady-state plasma concentrations of glyburide were 
approximately one-half in pregnant women with GDM as compared with those in non-
pregnant women with type II diabetes mellitus, consistent with a 2-fold increase in apparent 
oral clearance of glyburide during pregnancy. Modeling and simulations of this data 
demonstrate that pregnant women with GDM require much higher dosages of glyburide to 
achieve comparable concentrations as non-pregnant women. Whether higher dosages will 
be required during pregnancy to achieve glycemic control still needs further study.  
5.2 In vivo animal studies 
In vivo pharmacokinetic studies in pregnant mice have been performed to investigate the 
mechanism of pregnancy-induced increase in the apparent oral clearance of glyburide 
(Zhou et al., 2010b). Several groups have shown that CYP3A is a major enzyme responsible 
for the in vitro metabolism of glyburide (Naritomi et al., 2004; Zharikova et al., 2009; Zhou et 
al., 2010a). It has also been well established that hepatic CYP3A activity is significantly 
induced by pregnancy (Hebert et al., 2008; Tracy et al., 2005). Therefore, it has been 
hypothesized that pregnancy induces the activity of hepatic CYP3A, resulting in an increase 
in the oral clearance of glyburide (Zhou et al., 2010b). Since it has been shown that the levels 
of hepatic Cyp3a content in pregnant mice and its activity measured using testosterone as 
the probe substrate are significantly increased compared with those in non-pregnant mouse 
controls (Mathias et al., 2006; Zhang et al., 2008), the pregnant mouse was used as the animal 
model to test this hypothesis (Zhou et al., 2010b). Upon characterization, the 
pharmacokinetics of glyburide indeed demonstrated a two-fold increase in its hepatic 
clearance in pregnant mice on gestation day 15 compared to non-pregnant mice, a 
magnitude of change similar to that observed in the human clinical study, but with no 
changes in plasma protein binding (Zhou et al., 2010b). 
To investigate the mechanism of this pharmacokinetic change in pregnant mice, Zhou et al. 
further determined glyburide depletion in mouse hepatic S-9 fractions and found the half-
life of glyburide depletion to be markedly shorter in S-9 fractions from pregnant mice 
compared to non-pregnant mice. Glyburide depletion was also inhibited to a large extent by 
the Cyp3a inhibitor, ketoconazole, suggesting that the increase in hepatic clearance of 
glyburide during pregnancy may be due to an increase in the activity of hepatic Cyp3a 
(Zhou et al., 2010b). These studies support the notion that CYP3A plays a significant role in 
the clearance of glyburide in pregnancy. This finding has significant clinical implications. 
For example, significant drug-drug interactions may occur with glyburide and CYP3A 
inducers or inhibitors (Lilja et al., 2007).    
5.3 Placental transport of glyburide 
Hebert et al. have also shown that glyburide concentrations are measurable in umbilical 
cord blood at the time of delivery, suggesting that glyburide crosses the placenta and thus 
may pose adverse effects on the developing fetus (Hebert et al., 2009). The average umbilical 
cord to maternal plasma concentration ratio of glyburide was 0.7 ± 0.4 (Hebert et al., 2009). 
This less than unity ratio indicates that glyburide does not cross the placental barrier 
entirely by passive diffusion, even though it is highly lipophilic (LogP = 4.8). Many ATP-
binding cassette (ABC) efflux transporters such as P-glycoprotein (P-gp), breast cancer 
resistance protein (BCRP), and multidrug resistance proteins (MRPs) are highly expressed 
on the apical membrane of placental syncytiotrophoblasts facing maternal blood, where they 
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protect the fetus by expelling drugs, xenobiotics, and metabolites from the fetal 
compartment to the maternal circulation (Behravan & Piquette-Miller, 2007; Ceckova-
Novotna et al., 2006; Mao, 2008; Ni & Mao, 2010). Glyburide has been shown to be a 
substrate of such ABC efflux transporters. Thus, it is likely that ABC efflux transporters in 
the placenta play an important role in limiting fetal exposure to glyburide.               
To test this hypothesis, Gedeon et al. examined the role of P-gp, BCRP and MRPs in the 
efflux of glyburide using stable cell lines expressing these transporters in the presence or 
absence of selective inhibitors (Gedeon et al., 2006). Their results suggested that glyburide 
was preferentially transported by BCRP and MRP3, but not by P-gp, MRP1 or MRP2. 
Likewise, Gedeon et al. demonstrated that inhibition of P-gp or MRP1 did not affect 
accumulation of [3H]-glyburide in inside-out brush border human placental membrane 
vesicles; however, inhibition of BCRP did (Gedeon et al., 2008b). Using the dually perfused 
human placental cotyledon model, Gedeon et al. further showed that the rate of transfer of 
glyburide across the placenta in the presence of indomethacin (an inhibitor of MRP1, MRP2 
or MRP3) was not different from the rate of transfer in the absence of inhibitor (Gedeon et 
al., 2008a), suggesting that MRP1, 2, or 3 may be only minimally involved in the transport of 
glyburide across the human placenta. On the other hand, the role of BCRP in the transfer of 
glyburide across the human placenta was confirmed in a similar human placental perfusion 
study (Pollex et al., 2008). In contrast, Hemauer et al showed that MRP1 appears to play a 
greater role in the efflux of glyburide than P-gp or BCRP (Hemauer et al., 2010). Using 
inside-out brush border membrane vesicles isolated from human term placentas in the 
presence or absence of selective inhibitors (verapamil for P-gp, Ko143 for BCRP, and 
indomethacin for MRP1), Hemauer et al. determined the relative contribution of P-gp, 
BCRP, and MRP1 to the uptake of glyburide into the inside-out membrane vesicles to be 9 ± 
5%, 25 ± 5%, and 43 ± 4%, respectively (Hemauer et al., 2010).  
Zhou et al. confirmed that glyburide is a substrate for human BCRP and mouse Bcrp1 using 
Madin Darby canine kidney (MDCK) cell transwell transport experiments (Zhou et al., 
2008). Zhou et al. also characterized glyburide disposition in wild-type and Bcrp1-/- 
pregnant mice to elucidate the role of Bcrp1 in limiting glyburide transfer across the 
placenta to the fetal compartment. The results showed that the maternal plasma 
concentration-time profiles remained the same between wild-type and knockout mice; 
however, the fetal area under the concentration-time curve (AUC) of glyburide in Bcrp1-/- 
pregnant mice was two times greater than that in wild-type mice (Zhou et al., 2008). It is 
worth noting that the amount of glyburide entering the fetus only accounts for a small 
fraction of the total amount of glyburide in the body (Zhou et al., 2008). These results 
confirm that BCRP and Bcrp1 are important determinants of fetal exposure to glyburide 
(Zhou et al., 2008). All these in vitro, ex vivo, and in vivo studies suggest that ABC efflux 
transporters, particularly BCRP, are important in protecting the fetus from exposure to 
glyburide. Thus, if a drug known to be a BCRP inhibitor is co-administered with glyburide, 
fetal exposure to glyburide may be increased through inhibition of placental BCRP.  
5.4 Placental metabolism of glyburide 
The placenta may also protect the fetus by metabolizing drugs or xenobiotics ingested by the 
mother. Human term placentas have been used in several studies to characterize placental 
metabolism of glyburide (Jain et al., 2008; Zharikova et al., 2009; Zharikova et al., 2007). 
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metabolite  (ethylene-hydroxylated glyburide), and the rest to other metabolites (Zharikova 
et al., 2007). When compared to human liver microsomes; however, the total Vmax for all 
metabolites was much lower for placental microsomes (13 ± 0.8 pmol/min/mg protein) than 
human liver microsomes (213 ± 37 pmol/min/mg protein). Although the relative 
contribution of placental drug-metabolizing enzymes to the overall disposition of glyburide 
may in fact be minimal, the formation of M5 in such close proximity to the fetus could have 
clinical implications for fetal metabolite exposure. However, at this time, the 
pharmacological activity of M5 is unknown. Zharikova et al. further identified CYP19 to be 
the major drug-metabolizing enzyme responsible for the biotransformation of glyburide to 
M5 in the human placenta (Zharikova et al., 2009). The intrinsic clearance of CYP19 for 
glyburide was 0.02 µL/min/pmol CYP and only represented 1.8% of the overall intrinsic 
clearance of human liver microsomes for glyburide.  
Jain et al. studied glyburide metabolism using placental microsomes isolated from human 
term placentas from women with uncomplicated pregnancies, women with GDM on diet 
therapy, or women with GDM on glyburide (Jain et al., 2008). They found that placental 
microsomes from uncomplicated pregnancies showed higher M1 and M2 metabolite 
formation rates compared to placentas from women with GDM on diet therapy or on diet 
therapy plus glyburide. However, there was no difference in glyburide metabolism between 
placentas from diet therapy and diet therapy plus glyburide (Jain et al., 2008). The 
differences in placental microsomal metabolite formation may reflect the effects of GDM on 
the placenta. Histologic abnormalities in the placenta are more common in women with 
GDM than non-diabetic controls (Daskalakis et al., 2008). 
Based upon the results obtained so far, the placenta appears to play a very minor role in 
determining maternal disposition of glyburide, but may play a significant role in controlling 
fetal exposure to the drug and metabolites. Very limited data is available in this regard, and 
the role of placental metabolism in controlling fetal drug exposure warrants further 
investigation.    
6. Conclusions 
Although insulin therapy has been the “gold standard” for the treatment of GDM, the 
increasing use of oral anti-diabetic agents such as glyburide and metformin has begun to 
change the standard of care. Glyburide is a second generation sulfonylurea. Clinical studies 
demonstrate that glyburide is a safe alternative to insulin therapy for the treatment of GDM 
due to its similar efficacy to insulin, relatively low fetal exposure, lower cost and ease of 
administration. The pharmacokinetic properties of glyburide resulting in low fetal exposure 
include: high plasma protein binding, a relatively short elimination half-life, and efflux 
transport by ABC transporters such as BCRP in the placenta. Glyburide is also metabolized 
in the placenta by CYP19, which may limit fetal exposure to the parent compound but 
simultaneously expose the fetus to metabolites. However, it is reassuring that the currently 
used glyburide dosage range for pregnant women with GDM has comparable maternal, 
fetal and neonatal outcomes as insulin therapy.  
In addition to the concern of fetal exposure, physiological changes that occur during 
pregnancy may alter the pharmacokinetics of glyburide, thus affecting the safety and 
efficacy of the drug for both the mother and the fetus. Indeed, a recent clinical study has 
demonstrated that the apparent oral clearance of glyburide is increased two-fold in 
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pregnant women with gestational diabetes as compared to non-pregnant women with type 
II diabetes mellitus (Hebert et al., 2009). This finding implies the need for further evaluation 
and dosage optimization for glyburide during pregnancy. The mechanism of such a change 
in glyburide disposition during pregnancy has not been fully understood, but is likely 
related to increased expression and activity of cytochrome P450 enzymes in the liver, such 
as CYP2C9 and CYP3A.  
In summary, glyburide has been increasingly used for the treatment of GDM with similar 
safety and efficacy to insulin therapy. The mechanistic understanding of pregnancy-induced 
changes in the disposition of this drug (including fetal exposure) will be important for 
optimizing dosage guidelines for glyburide during pregnancy.  
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glyburide was 0.02 µL/min/pmol CYP and only represented 1.8% of the overall intrinsic 
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used glyburide dosage range for pregnant women with GDM has comparable maternal, 
fetal and neonatal outcomes as insulin therapy.  
In addition to the concern of fetal exposure, physiological changes that occur during 
pregnancy may alter the pharmacokinetics of glyburide, thus affecting the safety and 
efficacy of the drug for both the mother and the fetus. Indeed, a recent clinical study has 
demonstrated that the apparent oral clearance of glyburide is increased two-fold in 
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pregnant women with gestational diabetes as compared to non-pregnant women with type 
II diabetes mellitus (Hebert et al., 2009). This finding implies the need for further evaluation 
and dosage optimization for glyburide during pregnancy. The mechanism of such a change 
in glyburide disposition during pregnancy has not been fully understood, but is likely 
related to increased expression and activity of cytochrome P450 enzymes in the liver, such 
as CYP2C9 and CYP3A.  
In summary, glyburide has been increasingly used for the treatment of GDM with similar 
safety and efficacy to insulin therapy. The mechanistic understanding of pregnancy-induced 
changes in the disposition of this drug (including fetal exposure) will be important for 
optimizing dosage guidelines for glyburide during pregnancy.  
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1. Introduction 
1.1 Obesity and type 2 diabetes prevalence are increasing among women of child-
bearing age 
There has been a significant increase over the past few decades in the the prevalence of 
women of child-bearing age who are overweight (body mass index, BMI ≥ 25 kg/m2) or 
obese (BMI ≥ 30 kg/m2). Women of childbearing age are at an increased risk for obesity 
(Villamor & Cnattingius, 2006) and type 2 diabetes (Lipscombe & Hux, 2007) because of 
excessive weight gain during pregnancy and weight retention after delivery (Rooney et al., 
2005). Data from the 2007-2008 “National Health and Nutrition Examination Survey” 
(NHANES) showed that 60% and 34% of  American women aged 20-39 years were 
overweight or obese, respectively (Flegal et al., 2010). Abdominal obesity (i.e. waist 
circumference ≥ 88 cm; (Lean et al., 1995)), a risk factor for many chronic diseases (Després, 
2001) also increased and reached 51.3% in 2007-2008 (Ford et al., 2010). Data from the 
“Pregnancy Risk Assessment Monitoring System” in nine states indicated that pre-
pregnancy obesity increased from 13% to 22% between 1993 and 2002 (Kim et al., 2007). 
Worldwide population estimates of pre-pregnancy overweight is approximately 34% 
(Callaway et al., 2006; LaCoursiere et al., 2005) and that of pre-pregnancy obesity is 25% 
(Chu et al., 2009), which may be an underestimation. This escalating problem may 
contribute to the obesity and diabetes epidemics, as overweight women who gain 10% or 
more of their pre-pregnancy body mass are at higher risk for complications such as 
gestational diabetes mellitus (GDM; (Carducci et al., 1999)) and pregnancy-induced 
hypertension (Pole & Dodds, 1999). Additionally, higher recurrence of GDM has been 
associated with greater pre-pregnancy weight, BMI and excessive pregnancy weight gain 
(Foster-Powell & Cheung, 1998). 
1.2 Women of child-bearing age are inactive, particularly overweight and obese 
women 
Low levels of physical activity may be contributing to the obesity and type 2 diabetes 
epidemics in women of child-bearing age. Physical activity levels may be evaluated using 
different tools but pedometers and accelerometers provide an accurate and objective 
method of measuring walking and other ambulatory activities. Physical activity levels based 
on step counts have been defined: <5,000 steps per day = sedentary, 5,000-7,499 steps per 
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1. Introduction 
1.1 Obesity and type 2 diabetes prevalence are increasing among women of child-
bearing age 
There has been a significant increase over the past few decades in the the prevalence of 
women of child-bearing age who are overweight (body mass index, BMI ≥ 25 kg/m2) or 
obese (BMI ≥ 30 kg/m2). Women of childbearing age are at an increased risk for obesity 
(Villamor & Cnattingius, 2006) and type 2 diabetes (Lipscombe & Hux, 2007) because of 
excessive weight gain during pregnancy and weight retention after delivery (Rooney et al., 
2005). Data from the 2007-2008 “National Health and Nutrition Examination Survey” 
(NHANES) showed that 60% and 34% of  American women aged 20-39 years were 
overweight or obese, respectively (Flegal et al., 2010). Abdominal obesity (i.e. waist 
circumference ≥ 88 cm; (Lean et al., 1995)), a risk factor for many chronic diseases (Després, 
2001) also increased and reached 51.3% in 2007-2008 (Ford et al., 2010). Data from the 
“Pregnancy Risk Assessment Monitoring System” in nine states indicated that pre-
pregnancy obesity increased from 13% to 22% between 1993 and 2002 (Kim et al., 2007). 
Worldwide population estimates of pre-pregnancy overweight is approximately 34% 
(Callaway et al., 2006; LaCoursiere et al., 2005) and that of pre-pregnancy obesity is 25% 
(Chu et al., 2009), which may be an underestimation. This escalating problem may 
contribute to the obesity and diabetes epidemics, as overweight women who gain 10% or 
more of their pre-pregnancy body mass are at higher risk for complications such as 
gestational diabetes mellitus (GDM; (Carducci et al., 1999)) and pregnancy-induced 
hypertension (Pole & Dodds, 1999). Additionally, higher recurrence of GDM has been 
associated with greater pre-pregnancy weight, BMI and excessive pregnancy weight gain 
(Foster-Powell & Cheung, 1998). 
1.2 Women of child-bearing age are inactive, particularly overweight and obese 
women 
Low levels of physical activity may be contributing to the obesity and type 2 diabetes 
epidemics in women of child-bearing age. Physical activity levels may be evaluated using 
different tools but pedometers and accelerometers provide an accurate and objective 
method of measuring walking and other ambulatory activities. Physical activity levels based 
on step counts have been defined: <5,000 steps per day = sedentary, 5,000-7,499 steps per 





12,500= highly active (Tudor-Locke et al., 2008). Pedometer data from the “American On the 
Move” study showed that women aged 18-39 years took approximately 5500 steps per day 
(Bassett et al., 2010). Similar results were found by Tudor-Locke et al. using accelerometer 
data from the 2005-2006 NHANES (Tudor-Locke et al., 2010). They reported that women 
took approximately 5,800 steps per day (Tudor-Locke et al., 2010). Interestingly, the authors 
also reported that normal weight women took more steps per day compared to overweight 
and obese women (6,486, 5,069 and 5,782, respectively). In Canada, accelerometer results 
from the 2007-2008 “Canadian Health Measures Survey” showed that women aged 20-39 
years took nearly 9,000 steps per day. Again, obese women were less active compared to 
normal weight women. Noteworthy, studies conducted on populations that have a lower 
prevalence of overweight and obesity, like Japan and Australia, reported higher steps per 
day (Inoue et al., 2006; McCormack et al., 2003). Achievement of public health 
recommendation (i.e ≥ 30 minutes of moderate-to-vigorous physical activity per day, 
accumulated in bouts lasting at least 10 minutes, on at least 5 out of 7 days (Canadian 
Society for Exercise Physiology & ParticipACTION, 2010; WHO, 2010)) were also examined 
using accelerometers. Results showed that less than 5% of women of child-bearing age meet 
these recommendations (Colley et al., 2011; Troiano et al., 2008; Tudor-Locke et al., 2010). 
Taken together, these findings showed that women of child-bearing age are inactive and 
suggested that being sedentary, and the prevalence of physical inactivity, may be 
contributing to the obesity  and diabetes epidemics. 
1.3 Maternal obesity is associated with impaired glucose metabolism  
Entering pregnancy overweight or obese are closely linked to numerous unfavourable 
pregnancy outcomes, such as the development of impaired glucose tolerance (IGT) or GDM 
(Catalano & Ehrenberg, 2006; Chu et al., 2007; Davies et al., 2010; Nelson et al., 2009). 
Women who are obese prior to pregnancy are more likely to develop IGT as compared to 
normal weight women (Saldana et al., 2006; Tovar et al., 2009). Similarly, the risk of 
developing GDM has been shown to increase with increasing BMI: overweight and obese 
women have 2.14 (95% CI 1.82-2.53) and 3.56 (95% CI 3.05-4.21) times the risk of developing 
GDM compared to normal weight women (Chu et al., 2007). GDM prevalence rates are 0.7% 
in normal weight, 2.3% in overweight, 4.8% in obese and 5.5% in extremely obese (BMI ≥ 35 
kg/m2) women (Kim et al., 2010). More than 70% of women with GDM have a BMI of 25 
kg/m2 or higher (Kim et al., 2010). Similarly, maternal abdominal adiposity in early 
pregnancy has been associated with a positive glucose challenge test (i.e. glucose levels ≥ 7.8 
mmol/L) and an increased risk of GDM (Brisson et al., 2010; Martin et al., 2009).  
1.4 Excessive gestational weight gain is associated with impaired glucose 
metabolism 
Another risk factor for developing IGT and GDM is excessive gestational weight gain 
(GWG). A cohort study revealed a positive relationship between weight gain in excess of the 
Institute of Medicine (IOM) guidelines (IOM, 1990) and the development of IGT, although 
these findings were limited to Hispanic women with a pre-pregnancy BMI ≥ 35 kg/m2 
(Tovar et al., 2009). Saldana et al. found in the “Pregnancy, Infection and Nutrition” (PIN) 
cohort a two-fold increased risk of IGT among overweight women who gained excessive 
weight up to the end of the second trimester (Saldana et al., 2006). Data from the “Project 
Viva” showed similar findings, with women in the highest quartile of GWG (i.e. 12.9 kg to 
 
Exercise Guidelines for Women with Gestational Diabetes 
 
341 
29.1 kg) being at increased risk for IGT, compared to those women in the lowest quartile of 
GWG (i.e -9.4 kg to 7.9 kg), independent of pre-pregnancy BMI (Herring et al., 2009). Finally, 
Kieffer et al. showed an estimated 2% increase in risk of GDM associated with each pound 
of maternal weight gained after adjusting for pre-pregnancy BMI (Kieffer et al., 2001). 
Excessive GWG, especially during the first trimester of pregnancy, has been found to be 
associated with an increased risk of GDM (Hedderson et al., 2010; Morisset et al., 2011), 
suggesting that timing of excessive GWG may be important and may be related to different 
patterns of metabolic change affecting glucose metabolism regulation.  
Data from the 2006 “Maternity Experiences Survey”, conducted in Canada, showed that 52% 
of Canadian women gained more than the recommended weight in pregnancy (Lowell & 
Miller, 2010). Moreover, the survey showed that women with a higher pre-pregnancy BMI 
were more likely than normal weight and underweight women to gain more weight than 
recommended. Fifty-five percent of overweight and obese women gained more weight than 
recommended, compared with 41% of those who were in the normal range and 26% of those 
who were underweight (Lowell & Miller, 2010). Previous studies reported similar findings, 
that is, overweight and obese women are more likely to exceed their target weight gain 
(Caulfield et al., 1996; Tovar et al., 2009; Saldana et al., 2006; Stuebe et al., 2009). Avoidance 
of excessive GWG may therefore constitute an opportunity for the prevention of impaired 
glucose metabolism during pregnancy.  
1.5 Insulin resistance, the link between overweight/obesity, excessive gestational 
weight gain and impaired glucose metabolism 
The underlying mechanism linking pre-pregnancy overweight/obesity to IGT or GDM is 
insulin resistance, coupled with an inadequate insulin response due to pancreatic beta-cell 
dysfunction (Buchanan & Xiang, 2005). Althought overweight and obese women present a 
similar 50% decrease in insulin sensitivity over the period of gestation, they are more insulin 
resistant than normal weight women throughout pregnancy (Catalano, 2010). Positive 
correlations have been reported between maternal body weight, BMI, fat mass and insulin 
resistance (Ahlsson et al., 2010). Maternal fat mass explained 36% of the variation in insulin 
resistance, and insulin resistance accounted for 62% of the variation in glucose production 
(Ahlsson et al., 2010). Adipose tissue is an active organ that secretes numerous factors 
involved in the development of insulin resistance, such as free fatty acids, leptin, 
adiponectin, interleukin-6 (IL-6), plasminogen activator inhibitor-1 (PAI-1), tumor necrosis 
factor-α (TNF-α), resistin, retinol binding protein 4, visfatin, etc. (Rasouli & Kern, 2008). In 
obese non-pregnant individuals, adipose tissue releases increased amounts of these factors, 
except adiponectin, which may explain the link between obesity, insulin resistance and type 
2 diabetes (Kahn et al., 2006). In pregnant women, it has been reported that mean levels of 
adiponectin declined, and PAI-1 increased as BMI increments increased (Lowe et al., 2010). 
Recent studies have focused on the role of adipokines during normal pregnancy and 
pregnancy complicated by GDM and showed that the pattern of change in maternal 
circulating adipokine levels may be involved in the pathophysiology of GDM (Briana & 
Malamitsi-Puchner, 2009).  
Excessive GWG may also further enhance normal pregnancy-induced insulin resistance and 
be linked to impaired glucose metabolism. Maternal adipose tissue represents 30% of GWG 
(IOM, 1990) but the proportion of GWG attributed to adipose tissue is more important in 
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excessive GWG has been associated with GDM risk (Hedderson et al., 2010; Morisset et al., 
2011). It is therefore possible that rapid GWG in early pregnancy results in an increased 
release of “diabetogenic” factors, exacerbating earlier pregnancy-induced insulin resistance 
and thereby leading to IGT or GDM in women having beta-cell defects.  
In summary, an increased number of women of child-bearing age are overweight or obese 
and physically inactive and these women will likely start their pregnancy overweight or 
obese and sedentary. These factors have been associated with an increased risk for excessive 
GWG, a deterioration in insulin resistance beyond that induced by pregnancy and impaired 
glucose metabolism. Therefore, any intervention that helps to limit excessive gestational 
weight gain and attenuate pregnancy-induced insulin resistance may be successful in 
preventing impaired glucose metabolism. 
2. Physical activity is part of a healthy pregnancy 
A minimal amount of physical activity must be maintained to achieve health benefits during 
pregnancy. Physical inactivity and a sedentary lifestyle may put the mother and fetus at risk 
for disease through altered maternal pregnancy adaptations (Mottola 2008). In fact, women 
who were the most active before pregnancy (Chu et al. 2007) and throughout pregnancy 
(Dye et al. 1997), had the lowest prevelence of GDM. If GDM and IGT can be prevented, 
overall rates of obesity and type 2 diabetes, especially in at risk population groups may also 
be decreased.   
2.1 Maternal physical activity is associated with reduced risk of impaired glucose 
metabolism 
Pregnancy-induced insulin resistance develops at the skeletal muscle level (Buchanan & 
Xiang, 2005). Investigators have demonstrated that exercise increases the rate of glucose 
uptake into the skeletal muscle, a process that is regulated by the translocation of the 
glucose transport protein GLUT-4 (Goodyear & Kahn, 1998; Hayashi et al., 1997; Ryder et 
al., 2001). Regular exercise in non pregnant individuals results in numerous beneficial 
adaptations in skeletal muscle, including increases in GLUT-4 expression, which contributes 
to an increased responsiveness of muscle glucose uptake to insulin (i.e. increased muscle 
insulin sensitivity) (Goodyear & Kahn, 1998; Hayashi et al., 1997; Ryder et al., 2001). This 
may explain the observed link between level of physical activity and improvement in 
glucose homeostasis and insulin sensitivity (Goodyear & Kahn, 1998; Koivisto et al., 1986), 
and a risk reduction of 50% for type 2 diabetes mellitus (T2DM) in at risk individuals 
(Madden et al., 2008; Yates et al., 2007). These physiological and molecular mechanisms 
underlying the beneficial effects of exercise may also be present in pregnant women since 
successful reduction in the risk of developing IGT and GDM have been reported in women 
who were active either before and/or during pregnancy (Tobias et al., 2010).  
In the “Nurse Health Study II”, women in the highest quintile of physical activity before 
pregnancy, specifically vigorous activity, had a 20% risk reduction for the development of 
GDM compared with inactive women (Zhang et al., 2006). In women not performing 
vigorous activity, brisk walking was also significantly associated with a reduced risk. 
Similarly, physical activity before pregnancy, particularly vigorous activity, was associated 
with a 44% risk reduction of GDM and a 24% risk reduction of any antepartum IGT in 
women participating in “Project Viva” (Oken et al., 2006). Women who reported physical 
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activity both before and during pregnancy presented a greater risk reduction in both GDM 
and IGT (51% and 30%, respectively) compared with women reporting no activities in both 
time periods (Oken et al., 2006). Dempsey et al. reported that women who participated in 
any physical activity during the year before getting pregnant experienced a 56% risk 
reduction in GDM compared with inactive women, but those who engaged in physical 
activity during both time periods experienced a 69% reduced risk (Dempsey et al., 2004b). It 
has also been shown that pre-gravid physical activity (vigorous activity) was associated 
with a reduced risk of IGT in pregnancy, an effect likely mediated by enhanced insulin 
sensitivity (Retnakaran et al., 2009).   
Similar results were found when investigating the effect of physical activity during 
pregnancy. Dye et al. reported that exercise during pregnancy (i.e. 30 minutes of exercise 
once or more per week) was associated with reduced rates of GDM, but only among women 
with a pre-pregnancy BMI>33 kg/m2 (Dye et al., 1997). A study including only Latina 
women showed that those in the lowest quartile of sports or exercise in mid-pregnancy had 
a two-fold increased risk of IGT as compared with women in the highest quartile 
(Gollenberg et al., 2010). Similar association was found with total sedentary behaviours (a 
composite score of TV watching, sitting at work and sport or exercise reverse scores) 
(Gollenberg et al., 2010). A case-control study reported that women who participated in any 
recreational physical activity during the first 20 weeks of pregnancy experienced a 48% 
reduction in GDM risk, as compared with inactive women (Dempsey et al., 2004a). It has 
also been shown that women who were previously inactive but became active during 
pregnancy had a 57% risk reduction in GDM compared to those who remained inactive (Liu 
et al., 2008). Finally, a prospective study reported that increased physical activity during 
pregnancy was associated with decreased fasting insulin concentrations (Liu et al., 2010), 
suggesting that being active during pregnancy may prevent impaired glucose metabolism 
through attenuation of pregnancy-induced insulin resistance.   
2.2 Maternal physical activity is associated with preventing excessive gestational 
weight gain 
Another mechanism through which physical activity may prevent impaired glucose 
metabolism is by limiting excessive GWG. Prospective data from the “Project Viva” showed 
that 30 minutes per day of walking, vigorous physical activity or total physical activity 
during pregnancy were inversely associated with the risk of excessive GWG (Stuebe et al., 
2009). Similar findings were found by Olson et al. who found that decreased physical 
activity was associated with excessive GWG (Olson & Strawderman, 2003). Lifestyle 
intervention studies also showed successful results with respect to the prevention of 
excessive GWG. Two reports  using meta-analyses of intervention trials showed that 
exercise programs, combined with or without nutrition counselling, helps to limit GWG 
(Streuling et al., 2010a; Streuling et al., 2010b). Interventions that combined exercise and 
dietary counseling were found to be more successful in limiting GWG, with an average 
reduction of GWG of 1.2 kg (p=0.01) found in the intervention groups compared to the 
control groups (Streuling et al., 2010b). Three studies found significant lower GWG in the 
exercise plus nutrition intervention group compared with the control groups (Asbee et al., 
2009; Claesson et al., 2008; Shirazian et al., 2010), 3 studies found a non significant trend in 
lower GWG in the intervention group compared with the control group (Gray-Donald et al., 
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that 30 minutes per day of walking, vigorous physical activity or total physical activity 
during pregnancy were inversely associated with the risk of excessive GWG (Stuebe et al., 
2009). Similar findings were found by Olson et al. who found that decreased physical 
activity was associated with excessive GWG (Olson & Strawderman, 2003). Lifestyle 
intervention studies also showed successful results with respect to the prevention of 
excessive GWG. Two reports  using meta-analyses of intervention trials showed that 
exercise programs, combined with or without nutrition counselling, helps to limit GWG 
(Streuling et al., 2010a; Streuling et al., 2010b). Interventions that combined exercise and 
dietary counseling were found to be more successful in limiting GWG, with an average 
reduction of GWG of 1.2 kg (p=0.01) found in the intervention groups compared to the 
control groups (Streuling et al., 2010b). Three studies found significant lower GWG in the 
exercise plus nutrition intervention group compared with the control groups (Asbee et al., 
2009; Claesson et al., 2008; Shirazian et al., 2010), 3 studies found a non significant trend in 
lower GWG in the intervention group compared with the control group (Gray-Donald et al., 





al., 2006; Kinnunen et al., 2007; Polley et al., 2002). Findings from intervention studies using 
only exercise were less consistent than findings from intervention studies combining 
exercise and nutrition. Seven trials reported a trend for less GWG in the exercise group 
(Barakat et al., 2009; Cavalcante et al., 2009; Clapp et al., 2000; Ong et al., 2009; Santos et al., 
2005; Sedaghati et al., 2007; Yeo, 2009) which was significant in only one of these trials 
(Sedaghati et al., 2007). Five trials reported that women in the exercise group did not gain 
significantly less weight than women in the control group (Collings et al., 1983; Garshasbi & 
Faghih Zadeh, 2005; Hopkins et al., 2010; Marquez-Sterling et al., 2000; Prevedel et al., 2003). 
An average reduction in GWG of 0.6 kg (p=0.03) was found in the exercise intervention 
groups compared to the control groups (Streuling et al., 2010a). A single arm intervention 
study, combining exercise and diet, reported that 56% of obese women kept their GWG to ≤ 
6 kg (study weight goal) and no cases of reduced glucose tolerance were observed 
(Lindholm et al., 2010). Finally, a recent study conducted in our laboratory showed that 
excessive GWG was prevented in 80% of overweight and obese women using a Nutrition 
and Exercise Lifestyle Intervention Program (NELIP) (Mottola et al., 2010).  
In summary, the prevailing literature clearly indicates that physical activity before and/or 
during pregnancy has a protective effect against excessive GWG and impaired glucose 
metabolism. Results from intervention studies suggest that in order to be the most 
successful in limiting GWG, and thus in helping to prevent impaired glucose metabolism, 
lifestyle interventions should promote both regular physical activity and healthy eating 
habits. Promoting a healthy lifestyle during pregnancy, especially in overweight and obese 
women, becomes increasingly important in the context of the prevention of impaired 
glucose metabolism. 
2.3 Guidelines for physical activity during pregnancy 
Active promotion of physical activity for pregnant women is strongly recommended by 
professionnal societies, such as the American College of Obstetricians and Gynecologists 
(ACOG, 2002), the Royal College of Obstetricians and Gynaecologists (RCOG, 2006), the 
Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Canadian Society of 
Exercise Physiologists (CSEP) (Davies et al., 2003). The ACOG suggested that “in the 
absence of either medical or obstetric contraindications, 30 minutes or more of moderate 
exercise a day on most, if not all, days of the week is recommended for pregnant women” 
(ACOG, 2002). The recent opinion statement from the SOGC (Davies et al., 2010) on obesity 
during pregnancy strongly suggests that regular exercise during pregnancy may help to 
reduce the risk of medical complications associated with maternal obesity. However, all 
pregnant women should be medically prescreened and consult their health care provider 
before engaging in an exercise program. In 2008, the Unites States government released 
physical activity guidelines for Americans, including recommendations specifically for 
pregnant women to attain at least 150 minutes of moderate intensity aerobic activity per 
week if not already highly active or doing vigorous intensity activity. Healthy pregnant 
women who engaged in vigorous aerobic activity or are highly active prior to pregnancy are 
encouraged to continue physical activity (U.S Department of Health and Human Services 
2008). Finally, the joint SOGC/CSEP Clinical Practice Guidelines encourage women to 
exercise if they have no contraindications (Davies et al., 2003). The SOGC/CSEP Clinical 
Practice Guidelines provide detailed recommendations about the frequency, intensity, time 
and type of exercise, following the FITT principle for exercise prescription. Women should 
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exercise 3 to 4 times per week, starting with 15 minutes of aerobic activity at a target heart 
rate intensity and increasing time slowly to a maximum of 30 minutes per exercise session. 
All aerobic activity should be preceded by 10- to 15-minutes of warm-up and followed by 
10- to 15-minutes of cool-down. Appropriate exercise intensity may be monitored by using 
target heart-rate zones, the Borg-scale (rating of perceived exertion, RPE) or the “talk test” 
(Davies et al., 2003). Heart-rate zones that are provided in the guidelines correspond to 
moderate-intensity exercise (i.e. 60-80% of maximal aerobic capacity, VO2 max). Aerobic 
exercise in which large muscle groups are used, including walking, stationary cycling, aqua 
exercise, or low-impact aerobics are recommended for low risk pregnant women (Davies et 
al. 2003). 
Overweight and obese women can participate in exercise, if they have no contraindications 
to being physically active. Twenty medically pre-screened obese and 20 normal weight 
pregnant women participated in a graded treadmill exercise test to volitional fatigue to 
examine the impact of obesity on the ventilatory response to weight-bearing exercise during 
pregnancy (Davenport et al., 2009). We concluded that exercise ventilatory response is 
increased during pregnancy but is not affected further by obesity during graded treadmill 
exercise (Davenport et al., 2009). This is important in that there is no apparent ventilatory 
limitation to submaximal weight-bearing exercise representing daily living activities such as 
walking, in pregnant obese women, which lends support to the feasibility of exercise 
prescription in this population group (Mottola, 2009). Target heart rate zones developed for 
normal weight pregnant women may be too difficult for overweight and obese women to 
obtain, and thus we developed and validated target heart rate zones for medically pre-
screened overweight and obese women at a much lower intensity but high enough to achieve 
aerobic benefits (Davenport et al. 2008a). The intensity is approximately 20-39% heart rate 
reserve (HRR), and at a normal walking pace which may help with compliance in this 
population group. 
Currently, there are no step recommendations for pregnant women but those that have been 
defined for adults (Tudor-Locke et al., 2008) may be used for pregnant women. As walking is 
the most reported activity during pregnancy (Evenson et al., 2004; Evenson & Wen, 2010; 
Mottola & Campbell, 2003; Petersen et al., 2005), providing step recommendations to pregnant 
women may encourage them to be more active. Previous studies conducted in our laboratory 
showed that pregnant women took more than 10,000 steps per day when a 40-minute walk 
was added to their usual daily activities (Davenport et al., 2008b; Mottola et al., 2010).    
2.4 Are pregnant women meeting the physical activity guidelines? 
Although maternal physical activity has clear health benefits on pregnancy outcomes, and 
professional societies strongly recommend active promotion of physical activity for 
pregnant women, most women remain inactive during pregnancy. In Canada, only 30% of 
pregnant women meet the adult step recommendations of 10,000 steps per day (Cohen et al., 
2010). Data from large cohort studies, such as the “Behavioral Risk Factor Surveillance 
System” (BRFSS), NHANES and PIN showed that the majority of women do not meet the 
recommendations for physical activity during pregnancy, based on information collected by 
interviews or questionnaires (Borodulin et al., 2008; Evenson et al., 2004; Evenson & Wen, 
2010; Petersen et al., 2005). The guidelines from the ACOG and from the Center for 
Controlled Disease (CDC)/American College of Sports Medicine (ACSM) both suggest 30 
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on the type of activity, as guidelines for ACOG include only exercise and guidelines from 
CDC/ACSM include any type of physical activity. If the recommendations for physical 
activity were based on the ACOG guidelines, only 3% of pregnant women meet the 
recommendations (Borodulin et al., 2008). If the recommendations for physical activity were 
based on the CDC/ACSM guidelines, approximately 15% of pregnant women meet the 
recommendations (Borodulin et al., 2008; Evenson et al., 2004; Evenson & Wen, 2010; 
Petersen et al., 2005). In Spain, 20% of women comply with ACOG criteria whereas 70% 
comply with CDC/ACSM criteria (Amezcua-Prieto et al., 2010).  
In summary, most women are physically inactive during pregnancy. This may be 
contributing to excessive GWG given that women who are meeting the recommendations 
for exercise during pregnancy are more likely to achieve appropriate GWG (Cohen et al., 
2010). Moreover, given the clear association between physical inactivity during the perinatal 
period and risk for impaired glucose metabolism, physical inactivity may be contributing to 
the 10 to 100% increase in GDM prevalence observed in several race/ethnic groups during 
the past 20 years (Dabelea et al., 2005; Ferrara, 2007; Getahun et al., 2008). 
3. Exercise as an adjunctive therapy for gestational diabetes mellitus 
management 
3.1 Conventional management of gestational diabetes mellitus 
The primary management for women with GDM is control of energy intake, usually 
referred to as medical nutrition therapy (MNT) (Metzger, 2006). As a dietary intervention, 
the goals of MNT are to provide adequate nutrition for the mother and fetus, provide 
sufficient calories for appropriate maternal weight gain, maintain normoglycemia, and 
avoid ketosis (Franz et al., 2002). The dietary plan suggested by a registered dietitian usually 
includes eating smaller meals more often, more choices of complex carbohydrates with a 
low glycemic index, and the elimination of high glycemic foods, including carbonated 
beverages, sweets, and cake (CDA, 2008). Self-capillary glucose monitoring using a 
glucometer may be recommended up to seven times per day. The goal of monitoring is to 
maintain glucose concentrations in acceptable ranges. The Canadian Diabetes Association 
(CDA) recommends maintaining the following capillary blood glucose values: pre-prandial 
glucose < 5.3 mmol/L, 1-hour post-prandial glucose < 7.8 mmol/L, and 2-hour post-
prandial glucose < 6.7 mmol/L. The Fifth International Workshop-Conference on 
Gestational Diabetes Mellitus guidelines are the same (Metzger et al., 2007). If after 2 weeks 
of MNT, failure to control capillary glucose concentrations will progress to management of 
glycemia by insulin injections. It is imperative that maternal blood glucose be maintained 
below these values, either with MNT plus insulin injections or MNT and lifestyle changes. 
The type and amount of insulin injected is beyond the scope of this article but depends on 
medical intervention and management (Metzger et al., 2007).  
3.2 Exercise/lifestyle management for women with gestational diabetes mellitus 
Exercise has long been accepted as an adjunctive intervention in the management of 
diabetes in non pregnant individuals (ADA, 2011; CDA, 2008; Colberg et al., 2010). In type 2 
diabetic individuals, exercise has been reported to improve insulin sensitivity and insulin-
stimulated muscle glucose uptake (Kennedy et al., 1999), to have a positive effect on 
glycemic control and to decrease cardiovascular risk (Kavookjian et al., 2007). However, 
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there is still controversy regarding the benefits of exercise in improving glycemic control in 
GDM women, despite endorsements by professionnal organisations. The ACOG (ACOG, 
2001) suggests that “women with GDM who lead an active lifestyle should be encouraged to 
continue a program of exercise approved for pregnancy.” The American Diabetes 
Association (ADA) (ADA, 2004) suggests that “women without medical or obstetrical 
contraindications be encouraged to start or continue a program of moderate exercise as part 
of treatment for GDM.” The CDA (CDA, 2008) suggests that “physical activity should be 
encouraged, with the frequency, type, duration and intensity tailored to individual obstetric 
risk.” The recommendation from the Fifth International Workshop-Conference on GDM 
suggests “planned physical activity of 30 minutes/day is recommended … Advising GDM 
patients to walk briskly or do arm exercises while seated in a chair for at least 10 minutes 
after each meal accomplishes this goal” (Metzger et al., 2007).  
Evidence-based studies determining the frequency, intensity, time, and type of activity are 
needed to provide the best possible outcomes for women with GDM. When exercise was 
evaluated for controlling blood glucose concentrations or for delaying or preventing insulin 
therapy, the results were discordant. In the recent ACSM/ADA joint position statement, level 
of evidence concerning the effect of physical activity to control GDM was non-existent for the 
ADA, and weak for the ACSM (Colberg et al., 2010). These mixed results could be due to the 
non-randomization of the subject pool, the different anthropometric characteristics of the 
women, small sample sizes, lack of well-controlled or reported exercise intensity, the 
differences in exercise modalities, or questionable compliance to the exercise program. 
Consequently, because of lack of consistent evidence regarding the benefits of exercise in 
improving glycemic control in GDM women, exercise remains an adjunctive therapy.  
The acute effect of exercise on glucose excursion has been evaluated by several authors 
(Table 1). Avery and Walker (2001) reported that a single 30-minute bout of exercise on a 
cycle ergometer at 35% or 55% of maximum oxygen consumption (VO2 max) improved 
glucose excursion compared with rest in women with GDM (Avery & Walker, 2001). Garcia-
Patterson et al. found similar results, showing that light postprandial walking at 2.5 km/h 
decreased glucose excursion in GDM women (Garcia-Patterson et al., 2001). Lesser et al. 
(1996) determined the effects of a single bout of stationary cycling for 30 minutes at 60% VO2 
max, comparing six GDM women to five normal glycemic pregnant women. The effects of a 
mixed meal 14 hours after the exercise bout were examined. In contrast to the above studies, 
no improvement in glucose excursion due to the exercise was found in the GDM women. 
This could be due to a mixed meal being used in the acute experiment and because 
measurements occurred 14 hours after the exercise bout. 
The chronic effect of exercise for controlling blood glucose concentrations has also been 
investigated (Table 2). A 6-week arm ergometry exercise program was successful in 
normalizing fasted and 1-h plasma glucose concentrations and glycosylated hemoglobin 
(HbA1c) in GDM women randomized to diet therapy plus exercise compared with diet 
therapy alone (Jovanovic-Peterson et al., 1991). The exercise program consisted of 20 
minutes of arm ergometry, three times per week, at an intensity less than or equal to 50% 
VO2 max. The results of this study gave rise to the recommendation of arm exercise for GDM 
women mentioned above. In contrast to the above studies, Bung et al. (Bung et al., 1991) 
randomized GDM women into a group with diet and insulin therapy or diet and exercise. 
The exercise program consisted of stationary cycle ergometry (50% VO2 max) for 45 minutes 
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glycemic control were found between groups, the authors suggested that exercise may 
provide avoidance of insulin therapy through an increase in insulin sensitivity. In another 
study, GDM women were randomized to a partial home-based exercise program (70% of 
estimated maximal heart rate) and compared with GDM women with no structured exercise 
program (Avery et al., 1997). Although the exercise program improved the cardiorespiratory 
fitness of the GDM women, glucose  excursion was not different compared with the women 
with no structured exercise program (Avery et al., 1997). More recently, Artal et al. (2007) 
randomized obese GDM women into MNT plus exercise (60% VO2 max) or MNT alone. 
Results showed that the MNT plus exercise group limited GWG and had no adverse 
pregnancy outcomes. The authors concluded that placing obese women with GDM on a 
lifestyle intervention strategy of weight gain restriction may optimize pregnancy outcomes 
and impact future weight management behaviors. Using a different exercise modality, de 
Barros et al. (de Barros et al., 2010) randomized GDM women into a resistance exercise 
program (elastic band) group or MNT alone group. A reduction in the number of patients 
who required insulin was obseved in the exercise group compared with the MNT group. 
Furthermore, the percentage of time spent within the proposed target glucose range was 
higher in the exercise group compared with the MNT group. 
In a 2004 retrospective chart review from London, Canada, assessing conventional 
management of women diagnosed with GDM, Davenport et al. (2005) showed that by 30 
weeks of pregnancy, 62% of these women  required insulin therapy (after trying 
conventional management for 2 weeks after diagnoses). Of this cohort, women with a pre-
pregnancy BMI of 25 kg/m2 or greater were 2.6 times more likely to require insulin therapy 
than those women with a BMI below 25 kg/m2 . The average pre-pregnancy BMI of women 
requiring insulin therapy was 30.6 ± 6.4 kg/m2. This high incidence of insulin therapy in 
women with a BMI of 25 kg/m2 or greater may indicate the need for intensive therapy to 
delay or prevent insulin usage. In women with an early GDM diagnosis (at 16 to 20 weeks of 
gestation) who followed a structured walking program (30% HRR), 3–4 times per week in 
addition to conventional management, only 50% required insulin therapy (Davenport et al., 
2005). In another study evaluating 30 GDM women, 10 following conventional management 
plus a low-intensity walking program (30% HRR, 3–4 times per week) matched by insulin 
useage to 20 women following conventional management alone, we reported lower mean 
capillary glucose concentrations at the end of pregnancy (fasting and 1h after meals) in the 
exercising group (Davenport et al., 2008b). The lower glucose concentrations were achieved 
while requiring fewer units of insulin per kg per day. Using a different exercise modality, 
Brankston et al. (Brankston et al., 2004) randomized GDM women to a group with diet alone 
or a group of diet plus circuit-type resistance training. The number of women requiring 
insulin was not different between groups. However, they found that within the diet plus 
exercise group, 30% of the women who exercised 2-3 times per week were prescribed insulin 
therapy compared to 67% of those who exercised <2 per week. Moreover, a subgroup 
analysis that examined only overweight and obese women showed a lower incidence of 
insulin use, a lower prescription of insulin and a longer delay from diagnosis to the 
initiation of insulin therapy in the diet plus exercise group.  
Taken together, the above results are very encouraging. However, future lifestyle 
intervention programs are required to confirm these promising results and to determine the 
frequency, intensity, time, and type of activity that are needed to provide the best possible 
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15-minute bouts with 5-minute rests between each, for a total of 45 minutes. The joint 
SOGC/CSEP Clinical Practice Guidelines (Davies et al., 2003) provides detailed 
recommendations regarding frequency, intensity, time, and type of activity for healthy 
pregnant women. The same recommendations may be used for pregnant women with 
GDM, except that the intensity of exercise might be adapted and that precaution should be 
taken, especially for women using insulin. The SOGC/CSEP Clinical Practice Guidelines 
provides heart-rate zones corresponding to exercise of moderate intensity (i.e. 60-80% of 
VO2 max). However, this intensity may be too high for pregnant women with GDM who are 
overweight or obese and possibly sedentary. The ACSM suggested that previously 
sedentary overweight and obese pregnant women should initiate an aerobic exercise 
program at an intensity equivalent to 20% to 39% of reserve aerobic capacity (VO2 reserve) 
(ACSM, 2005). These developed and validated target heart-rate zones based on age, 
equivalent to 20% to 39% VO2 reserve are 102 to 124 beats per minute (bpm) for overweight 
and obese women 20 to 29 years of age and 101 to 120 bpm for those aged 30 to 39 years 
(Davenport et al., 2008a).  
Interestingly, lower-intensity aerobic exercise seems to be more efficient in term of glycemic 
control than moderate-intensity exercise for pregnant women. Indeed, all intervention 
studies that used lower-intensity aerobic exercise (i.e. ≤60% VO2 max) were successful in 
controlling blood glucose concentrations and/or limiting/preventing insulin therapy (Artal 
et al., 2007; Bung et al., 1991; Davenport et al., 2008b; Jovanovic-Peterson et al., 1991) 
whereas the only study that used moderate-intensity aerobic exercise (i.e. 70% VO2 max) was 
not succesfull (Avery et al., 1997). Mottola et al. (1998b) investigated low-risk pregnant 
women and showed that mild exercise (30% HRR) on a stationary bike was better at 
promoting glucose tolerance in response to an oral glucose load after exercise than moderate 
intensity exercise (70% HRR) in late gestational women. Biopsies of the vastus lateralis 
muscle in these late pregnant women showed that total  GLUT4 (glucose transporters 
sensitive to insulin) was elevated in the mild exercise–trained women (starting at 16–20 
weeks gestation until delivery) compared with moderately trained women (Mottola et al., 
1998a). Subsequently, when nutritional intake was controlled during pregnancy (to ~ 8350 
kJ/day, with 200 g of carbohydrate/day), the combination of nutritional control and mild 
exercise (30% HRR on a stair climber) was better than mild exercise alone in controlling 
blood glucose concentrations and preventing excessive weight gain during pregnancy. This 
effect remained at 2 months postpartum (Mottola et al., 1999). 
The above studies provided groundwork for development of a Nutrition and Exercise 
Lifestyle Intervention Program (NELIP), in which a mild walking program (30% HRR) was 
combined with nutritional control (8350 kJ/day; 200 g of carbohydrate/day) for women at 
risk for GDM (Sopper et al., 2004). Preliminary results are encouraging, in that women at 
risk for GDM did not develop this disease while on NELIP (N = 23), excessive weight gain 
was prevented, and normal glucose tolerance remained at 2 months postpartum (Batada et 
al., 2003). In addition, pregnant women at risk for GDM on NELIP maintained an insulin 
sensitivity index similar to those at low risk for GDM, and none developed GDM (Mottola et 
al., 2005b). It is suggested that overweight women at risk for GDM can be given a NELIP at 
16 weeks of pregnancy to maintain insulin sensitivity and glucose excursion and to prevent 
excessive weight gain and GDM. Assessment of HbA 1c in these women also showed values 
well below the diabetic range (Mottola et al., 2005a). Studies conducted by our lab suggest 
that mild exercise, regardless of modality (bike, stair climber, or walking), may be a key 
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factor—in combination with nutritional control—in helping women at risk for GDM and 
those women diagnosed with GDM, regulate blood glucose concentrations and prevent 
excessive weight gain during pregnancy.  
4. Summary and recommendations 
Obesity and type 2 diabetes are reaching epidemic proportions in society today and women 
of childbearing age are at risk for developing these diseases because of excessive weight 
gain during pregnancy and weight retention after birth. If modifiable risk factors for 
developing diabetes during pregnancy, such as preventing excessive weight gain and 
preserving glucose tolerance, can be reduced by incorporating physical activity, then 
exercise can be used as a powerful tool to reduce the diabetes and obesity epidemics in 
successive generations. Unfortuately, researchers have not be able to suggest an evidence-
based program with guidelines for frequency, intensity, time and type of activity (FITT 
principal for exercise presciption) that would produce the best possible outcomes for 
women with GDM. Although preliminary results are encouraging, exercise is still 
considered an adjunctive therapy, and the true effectiveness of a specific exercise program 
in controlling glucose excursion and reducing the incidence of insulin therapy remains 
untapped.  
Based on the literature reviewed, it is suggested that in using the FITT principal of exercise 
prescription, women who are at risk for or who have been diagnosed with GDM, should 
engage in activity at a frequency of 3-4 times per week, for at least 25 minutes each session, 
at a mild intensity (walking pace), building to 40 minutes, would be sufficient to provide 
health benefits. In addition, it is suggested that if pedometers are available, 10,000 steps per 
day may also regulate glucose metabolism. If women with GDM are overweight or obese, a 
target heart rate of 102-124 beats per minute (20 to 29 years of age) and 101 to 120 beats per 
minute (30 to 39 years of age) may also be used to monitor intensity. Continuing research is 
necessary in this important field especially if new stringent cut-offs for diagnoses of GDM 
are adopted as guidelines, as they will cause a higher prevalance of GDM, increasing the 
cost of medical care. Prevention of GDM by adoption of a healthy lifestyle and active living 
may be key. 
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1. Introduction 
Gestational Diabetes Mellitus (GDM) bring repercussions not only during pregnancy and 
delivery, but also in the future, with implications for Public Health. Nonetheless, after 
delivery, there is a tendency of the health team and medical institutions to relax the care 
given to women with GDM, probably due to the fact that their blood glucose values usually 
return rapidly to their normal level, wasting in this way the opportunity of preserving the 
health status of these relatively young group of women with a high risk of cardiovascular 
events, greatly due to the subsequent development of type 2 diabetes (Bentley-Lewis, 2009; 
Shah et al., 2008). In recent years an increase in the prevalence of GDM in different 
populations and ethnic groups has been observed (Dabelea et al., 2005; Hunt & Schuller, 
2007). Being GDM, very frequently, a diabetes precursor, a large number of fertile women 
will be increasingly subjected to a higher risk of developing it in a variable time, generally 
during middle age. This implies a long period of potential risk for chronic micro and 
macroangiophatic complications, with implied high social and economical costs. 
Women with GDM constitute an excellent target for applying diabetes preventive measures 
and its comorbidities. In this sense, a continuous and prolonged post-partum follow-up is 
recommended with two main objectives: to implement non-pharmacological and 
pharmacological preventive measures, whose efficiency has  been shown in some studies 
(Buchanan et al., 2002; Ratner et al., 2008), and also to carry out early detection of diabetes 
and other cardiovascular risk factors by guidelines that unfortunately, vary from one 
organization to another (Asociación Latinoamericana de Diabetes (ALAD), 2008: Metzger et 
al., 2007: National Institute for Health and Clinical Excellence (NICE), 2008), partly 
explaining low compliance rates and short duration of follow-ups, even in developed 
countries (Blatt et al., 2011; Dinh et al., 2003; Ferrara et al., 2009; Kim et al., 2007a). Moreover, 
maternal breastfeeding stimulus and the most adequate contraceptive method are included 
(Kim, 2009, 2010; Kitzmiller et al., 2007). More recently, the association between GDM with 
periodontal disease has been demonstrated, therefore it was considered pertinent to include 
oral health measures (Friedlander et al., 2007; Novak et al., 2006).  
During pregnancy, women with GDM require education under the premise that glucose 
intolerance is not always transitory, but that at any time after delivery it can become 
permanent, in order to increase awareness of the importance of postpartum follow-up, 
during which educational strategies aimed at correcting knowledge deficits on healthy life-
styles are studied in-depth (Rivas et al., 2010a); moreover, to overcome difficulties found in 
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seems essential to incorporate profound changes in the quality of life of the population that 
favor individual life-style changes. However, for a postpartum follow-up program to be 
successful, it is also important to amend existing weaknesses regarding knowledge and 
motivation of the interdisciplinary team responsible for health care in this area (Almario et 
al., 2008; Clark et al., 2003), and also, to provide health care services with easy access for all 
women with previous GDM (Kim et al., 2007a). 
This chapter will expound on focusing the future risks of women with GDM, as well as the 
basic aspects regarding early detection and prevention of diabetes and other cardiovascular 
risk factors. 
2. Maternal risks 
Maternal GDM repercussions in the future include an increased risk of developing GDM in 
subsequent pregnancies (Moses, 1997a), type 2 diabetes (Kim et al., 2002) and other 
cardiovascular risk factors such as obesity (Yun et al., 2007), dyslipidemia (Meyer-Seifer, 
1996) and hypertension (Gonçalves et al., 2005), which show up isolated or grouped in the 
Metabolic Syndrome (Madarász et al., 2008). Generally, they are accompanied by some 
degree of vascular, fibrinolytic and inflammatory dysfunction (Farhan et al., 2006¸ Heitritter, 
2005). Furthermore, the risk of other clinical conditions like polycystic ovary (PCO) (Kousta 
et al., 2000), periodontal disease (Xiong et al., 2006) and depression (34 Kozhimannil et al., 
2009) is increased (Table 1). 
 
• GDM in subsequent pregnancies  
• Type 1 diabetes  
• Type 2 diabetes 
• Metabolic Syndrome   
• Vascular abnormalities  
• Cardiovascular Disease 
• Polycystic ovaries  
• Periodontal Disease 
• Depression 
Table 1. Maternal Risks in women with Previous GDM 
2.1 GDM in subsequent pregnancies 
GDM recurrence occurs due to an abnormal glucose tolerance state that aggravates 
primarily due to physiological demands and hormonal changes of pregnancy itself, but may 
also show the presence of type 2 diabetes, that was not diagnosed between pregnancies, 
since a postpartum diabetes screening was not carried out. 
GDM recurrence rates in subsequent pregnancies show contradictory results, varying in 
different studies according to the population studied, GDM diagnostic criteria used, 
diabetes postpartum screenings and the exclusion or not of the preexisting diabetes 
proportion. In a review, it was found that they ranged from 30 and 84%, being White 
women rates <40% and in other ethnic groups that include African-American, Latin-
American an Asian women >50%, constituting ethnic group different from Caucasian, the 
most consistent predictor of GDM recurrence (Kim et al., 2007b).Other associations have 
been reported with GDM recurrence such as fat intake (Moses et al., 1997b), pre-pregnancy 
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maternal weight (Macneill et al., 2001) and the presence of impaired fasting glucose (IFG) or 
impaired glucose tolerance (IGT) in two-month postpartum screenings (Kwak et al., 2008).  
GDM risk in a second pregnancy has been found nearly ten-folds higher among women 
with previous GDM than in women without this family history, 41.3% and 4.2%, 
respectively. The risk increases with the number of previous GDM episodes and thus, with 
the third pregnancy, GDM recurrence was more marked when GDM had been diagnosed 
during the two previous pregnancies (Getahun et al., 2010).  
A new GDM pregnancy is not associated itself to a risk increase of type 2 diabetes in women 
with GDM history (Russel et al., 2008). Nonetheless, the absence of recurrent GDM in a 
subsequent pregnancy may show a decrease in the risk of developing type 2 diabetes   
(Retnakaran et al., 2011). 
2.2 Diabetes  
There is strong evidence proving that women with GDM show a high risk of developing 
diabetes through their lives (Damm et al., 2003). Even though the highest frequency 
corresponds to type 2 diabetes, type 1 diabetes may also occur, whose proportion will vary 
depending on the population studied (Järvelä et al., 2006). 
2.2.1 Type 1 diabetes  
For many decades GDM has been acknowledged as a heterogeneous alteration, where 
autoimmunity against beta cells constitutes the pathogenic basis in a small group of 
patients, who show a higher risk of developing type 1 diabetes during pregnancy or after 
delivery (Mauricio et al., 1996).  
In women with GDM, the determination of different specific antibodies against pancreatic 
beta cells, like antibodies to islet cells (ICA), glutamic acid decarboxilase antibodies 
(GADA), tyrosine phosphatase tyrosine (IA-2A), and most recently, GAD 65, proven pre-
clinical markers of type 1 diabetes (Mitchell et al., 2000; Murgia et al., 2008), has allowed to 
know that autoimmune GDM corresponds to 10% of GDM cases in Caucasian women and 
contributes to a peculiar and complex pre-diabetic state, with a high risk for progressing to 
type 1 diabetes and to a latent autoimmune diabetes of adulthood (LADA) (de Leiva et al., 
2007; Lapolla et al., 2009). The risk increases with the number of antibodies present 
(Füchtenbusch et al., 1997), and is higher during the first postpartum years (Nilsson et al., 
2007). In studies carried out on women with GDM that show positive antibodies, it was 
found that they were younger, showed lower body mass index (BMI), less proportion of 
family members with diabetes, less abdominal circumference, and lower levels of plasmatic 
insulin than in those women without antibodies. Moreover, they had gained less weight 
during pregnancy and had required insulin treatment in a higher proportion (Bo et al., 
2003). Non-Caucasian women with GDM have been less studied looking for autoimmune 
markers, being found in some cases, similar GADA incidence than in Caucasian women 
(Kousta et al., 2001), while in other studies, lower incidences have been obtained, but 
resulting likewise, the presence of antibodies against beta cells, an indicator of future type 1 
diabetes, even at early stages after delivery (Yu et al, 2009).  
The presence of antibodies in women with GDM shows immune-mediated pancreas 
destruction that causes a deficit in insulin secretion and development of type 1 diabetes. 
Therefore, the importance of making a type 1 diabetes diagnose as soon as possible, to apply 
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an adequate metabolic control that lowers the risk of poor pregnancy results (Wucher et al., 
2011) and of micro-vascular maternal complications in the future. Thus, in high risk 
populations of women with GDM, type 1 diabetes screenings must be carried out, looking 
for antibodies against beta cells. 
2.2.2 Type 2 diabetes 
Numerous epidemiological data suggest an association between GDM and type 2 diabetes, 
showing correspondence in both prevalences in a given population. These two disorders 
share metabolic aspects, risk factors and genetic susceptibility (Ben-Haroush et al., 2004).  
Physiopathological changes that occur in GDM, insulin resistance and the relative insulin 
deficiency due to the pancreatic beta cells deterioration, are similar to processes that occur in 
other pre-diabetic states of type 2 diabetes (Harlev & Wiznitzer, 2010) and they persist after 
pregnancy (Kousta et al., 2003). GDM and type 2 diabetes also have in common risk factors 
like BMI increase, family history of diabetes, increased age, Asian and African ethnic origin 
(Kim et al., 2002). Likewise, evidence has been gathered regarding that GDM susceptibility, as 
well as type 2 diabetes, has a genetic component where pregnancy could act as an 
environmental stressor that catalyses progression to a diabetic state in women with genetic 
predisposition. It is possible that both conditions are multigenic diseases in whose etiology 
interact variations of multiple genes with environmental factors, but no definite conclusions 
can yet be established, since the study on GDM genetics is on its initial stages and also because 
most researches have been carried out on a small group of White ethnic women (Robitaille & 
Grant, 2008), finding in some of them, that alleles associated to an increase of developing type 
2 diabetes, are elevated in women with previous GDM (Lauenborg et al., 2009). 
Cumulative incidence of type 2 diabetes varies widely in different reports, with a range of 
2.6 to 70% in studies that examined women between 6 weeks postpartum to 28 years 
postpartum (Kim et al., 2002. During the first months, glucose tolerance abnormalities in 
women with previous GDM were already found, showing diabetes prevalence rates  < 10% 
in White ethnic women (Pallardo et al., 1999; Feig et al., 2008) and ~10%, or higher in other 
ethnic groups (Kjos et al., 1990; Lin et al., 2005; Rivas et al., 2007). These rates most probably 
include women with type 2 diabetes, whose diagnosis had been unnoticed before 
pregnancy, being impossible to exclude them, due to the GDM definition used worldwide.  
Progress to diabetes is strong during the first years after delivery, with an annual rate of 5-
10%, reaching ~50% in five years, followed by a slower progression, and appearing a 
plateau after ten years (Kim et al., 2002; Wollitzer & Jovanovic, 2007). However, more recent 
studies show that postpartum risk of diabetes in women with DGM increases linearly 
through  the follow-up period, without indication of decrease after five years or plateau 
evidence of the incidence at ten years postpartum (Feig et al., 2008; Chodick  et al.,2010).  
It has been estimated that in women with GDM, the risk of developing type 2 diabetes along 
their lives is almost eight-fold higher than in those women who have not developed it 
(Chodick et al., 2010; Bellamy et al., 2009). In the well-known study Diabetes Prevention 
Program (DPP), women with GDM history showed a 74% increased hazard for developing 
diabetes than women without this history (17.1%/year compared to 9.8%/year, 
respectively) (Ratner et al., 2008) and, in Australia, it was found that 20-30% of women with 
type 2 diabetes refer previous GDM (Cheung & Byth, 2003). 
Several maternal risk factors have been associated to the conversion rate to diabetes, 
resulting highly predictive at short and long-term the oral glucose tolerance test (OGTT) 
 
Gestational Diabetes Mellitus After Delivery 
 
367 
values during pregnancy, mainly, fasting plasma glucose (FPG) (Kim et al., 2002; Golden et 
al., 2009) and in lower proportion, 2-hour glucose values (Golden et al., 2009; Åberg et al., 
2002), area under OGTT curve (Golden et al., 2009; Weijers et al., 2006) and the number of 
OGTT abnormal values (Chodick et al., 2010). It has also been found that insulin therapy 
during pregnancy predicts future maternal diabetes (Chodick et al., 2010; Catalano et al., 
1991) and it is known that weight gain before, during and after pregnancy increases and 
accelerates the development of type 2 diabetes in women with previous GDM (Metzger et 
al,. 1993; Baptiste-Roberts et al., 2009; Xiang et al 2010). 
Other risk factors of type 2 diabetes in women with DGM have been reported, among them, 
age, non-Caucasian ethnicity, early GDM onset (Sinha et al,. 2003), length of postpartum 
period, deterioration of beta cell function and use of progestin-only contraception (Xiang et al 
2010, Xiang et al 2006a). A series of modifiable factors like low physical activity, low fruit and 
vegetable consumption, tobacco habits, low educational instruction, and low family income 
have also been found associated to the risk of type 2 diabetes in women with GDM history 
(Yun S et al., 2007). There is less knowledge on other risk factors of diabetes described in recent 
years in women with GDM, such as alteration of some inflammatory and fibrinolytic 
dysfunction markers, among them adiponectin decrease (Retnakaran et al. 2010), increase in C-
reactive protein (CRP) (Di Benedetto et al., 2005), homocysteine (Cho et al., 2005) and 
plasminogen activator inhibitor type 1 (PAI-1) (Morimitsu et al., 2007), among others. 
2.3 Metabolic syndrome and its components 
GDM is a marker for future development of type 2 diabetes and Metabolic Syndrome in the 
mother, currently acknowledging pregnancy as a window that reveals future metabolic and 
cardiovascular risks for the mother (Sattar & Greer 2002). 
Glucose tolerance abnormalities in postpartum have been associated to other components of 
the Metabolic Syndrome.  General obesity (Vohr & Boney, 2008), visceral obesity (Albareda 
et al,. 2005) and increases in body fat content, particularly visceral fat (Lim et al., 2007), are 
more frequent in women with GDM history compared to those in control groups. Also there 
is a higher risk of high blood pressure (Gonçalves  et al., 2005; Wender-Ozegowska  et al., 
2007) and impairment of lipid profile like high triglycerides and LDL-cholesterol values and 
low HDL-cholesterol values, even though some results are not always consistent (Wender-
Ozegowska et al., 2007; Meyers-Seifer & Vohr, 1996; Rivas et al., 2010b). Frequently, varying 
abnormalities are found both in insulin sensitivity as well as in the secretion function of 
pancreatic beta cells (Tura et al., 2008). 
The prevalence of the Metabolic Syndrome, regardless of the diagnostic criteria used, is 
three-fold higher in women with previous GDM than in women without this history and 
increases seven-fold in obese women (Lauenborg et al., 2005).  Pre-pregnancy obesity, OGTT 
fasting plasma glucose during index pregnancy and postpartum weight gain are predictors 
of developing Metabolic Syndrome (Akinci et al., 2010). 
2.4 Vascular abnormalities  
As in other high risk type 2 diabetes groups, in women with previous GDM, apart from 
abdominal obesity and insulin resistance, vascular abnormalities including impaired 
vascular reactivity, increased levels of some markers of endothelial activation, 
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Among the reported vascular abnormalities are increase of peripheral vascular resistance 
(Heitritter et al., 2005) and impaired endothelium-dependent vasodilation, assessed at the 
brachial artery by high resolution ultrasound (Anastasiou etal., 1998), but this finding was 
not found in another study (Hannemann et al., 2002). On the other hand, serum adiponectin 
levels, an adipokine with known vascular effects, have been found to be lower in women 
with GDM during pregnancy and postpartum (Heitritter et al., 2005; Vitoratos et al., 2008a; 
Costacou et al., 2008). On the contrary, PAI-1 has been found elevated, considered as an 
expression of fibrinolytic dysfunction (Farhan et al., 2006), and of markers of low-grade sub-
clinical inflammation, Interleukin-1beta (IL-1β) has also been found elevated (Vitoratos et 
al., 2008b), whereas CRP shows contradictory results, since in some studies higher values 
have been obtained in women with previous GDM than in women with normoglycemic 
pregnancies (Heitritter et al., 2005; Di Cianni et al., 2007), no differences have been shown in 
other studies (Thomann et al., 2008) and in some, it is only significant the increase of CRP 
when diabetes has already been developed (Kim et al., 2008).  
2.5 Cardiovascular disease (CVD) 
As it has been described previously, women with previous GDM show in higher proportion, 
compared to women in control groups, numerous cardiovascular risk factors such as 
abdominal obesity, insulin resistance, abnormal glucose tolerance, dyslipidemia, high blood 
pressure values, Metabolic Syndrome, impairments of endothelial dysfunction and 
inflammation markers. For this reason, it has been proposed that these women have higher 
long-term probabilities of developing CVD (Bentley-Lewis, 2009), showing in an incidence 
research review that GDM history increases the risk of CVD about 1.7 folds (Verier-Mine, 
2010). This topic is of vital importance since CVD, and particularly, coronary artery disease, 
constitute one of the main causes of mortality and disability in different countries, thus its 
prevention and early identification in this group of young women may contribute to 
improve health indicators.  
2.6 Polycystic ovaries 
The prevalence of PCO has been found elevated in women with previous GDM, showing 
that both pathologies have common associations like obesity and insulin resistance (Kousta 
et al., 2000; Koivunen et al., 2001). 
2.7 Periodontal disease 
Women with GDM have shown higher frequency and severity of periodontal disease during 
pregnancy and postpartum than women without GDM, after controlling for age, income, 
smoking, dental calculus (Novak et al., 2006). The prevalence of periodontal disease in 
women with previous GDM is lower than in non-pregnant women with type 1 and 2 
diabetes, but higher than in non-diabetic women and without GDM family history (Xiong et 
al., 2006). A higher risk of dental caries also seems to exist (Friedlander et al., 2007).   
2.8 Stress, anxiety and depression 
Pregnancy generally represents an increase in stress and anxiety in all women, therefore, 
when GDM develops, considered as a high risk pregnancy demanding comprehensive 
treatment measures and monitoring of metabolic control, stress levels may increase even 
more (York et al., 1996). However, there are very few studies on this topic. On the other 
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hand, an association between diabetes during pregnancy and prenatal depression in low-
income women has been found (Kozhimannil et al., 2009), showing the importance of 
psycho-social aspects. 
3. Detection and prevention of diabetes and other cardiovascular risk factors 
Care for women with GDM is extended after delivery in order to assess at an early stage 
their new metabolic status, and more importantly, to take individual and collective 
measures that contribute to prevent or at least, retard the progression to diabetes and other 
cardiovascular risk factors. Thus, it is necessary that health services provide postpartum 
follow-up programs and motivate women with GDM to attend the activities programmed. 
Moreover, it is fundamental that the environment surrounding such women promotes life-
style changes that not only favor them, but also their family and the rest of the population.  
3.1 Postpartum follow-up of women with GDM 
For many years the importance of postpartum follow-up of women with GDM has been 
emphasized (Beischer et al., 1997). More recent findings suggest that it should be extended 
to women with any abnormal glucose homeostasis level during pregnancy (Retnakaran et 
al., 2008). Such a follow-up includes the aspects shown in Table 2. 
 
• Diabetes screening  
• Detection of cardiovascular risk factors     
• Education 
• Incentive and facilities for  breastfeeding   
• Appropriate family planning and contraception  
• Oral health measures 
• Life-style changes   
• Pharmacologic  intervention 
Table 2.  Postpartum Follow-up of women with GDM 
3.1.1 Diabetes screening 
During the immediate post-partum period of patients with GDM, glucose tests are run to 
detect those few cases where hyperglycemia persists, which mainly correspond to women 
whose type 2 diabetes had not been detected before pregnancy. The diabetes diagnose is 
confirmed if FPG is > 126 mg/dl (7.0 mmol/l) or if hyperglycemia symptoms and a random 
plasma glucose > 200 mg/dl (11.1 mmol/l) are present (American Diabetes Association 
(ADA), 2011). 
All those women not diagnosed with diabetes are programmed for a diabetes screening 
between weeks six and twelve of postpartum, due to a high incidence of glucose tolerance 
abnormalities already detected at that time and also because these results allow identifying 
women with high risks of developing diabetes during the next fifteen years (Kjos et al., 
1995). If diabetes screening is not possible at this time, it must be emphasized in the 
following weeks.  Diabetes screening is carried out with a 75g- 2h- OGTT, of higher 
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et al., 2007b). If the results are not compatible with diabetes diagnose, whether they are 
normal or indicators of IGT, or IFG, the test is repeated the following year and then, 
annually or every three years, according to the different international scientific associations 
since regarding periodicity of screening, no current criteria uniformity exists (Metzger et al., 
2007, American College of Obstetricians and Gynecologists (ACOG), 2009, Asociación 
Latinoamericana de Diabetes (ALAD), 2008). It is possible that HbA1c will be recommended 
in the future for postpartum diabetes screening in women with GDM, but studies on this 
test have not yet been published. 
3.1.2 Detection and treatment of cardiovascular risk factors 
Every time diabetes screenings are carried out, for detecting hypertension, obesity and 
dyslipidemias, women with previous GDM are determined for blood pressure, abdominal 
circumference, body mass index and triglyceride plasma levels, cholesterol, HDL-c and 
LDL-c. Determination of insulin levels, insulin-sensitivity indices, markers of endothelial 
activation, fibrinolysis/coagulation and low grade subclinical inflammation, and other 
specialized tests are optional in the clinical practice and are reserved in most cases, for 
research purposes. If the presence of any cardiovascular risk factor is confirmed, the 
corresponding therapeutic measures are prescribed.  
3.1.3 Education 
Education, initiated during pregnancy, constitutes the basis for GDM management. It is 
imparted in theoretical-practical sessions individually or in groups, whose content and 
strategies take into account the socio-economical and cultural characteristics of the enrolled 
women. At the postpartum stage, it is directed basically to imparting knowledge on future 
maternal risks and on their off-spring, as well as to the life-style changes that contribute to 
prevent or retard diabetes development and its co-morbidities.  It has been found that 
knowledge on these topics is limited in women with GDM, but increases after participating 
in an educational program imparted by specialized health personnel (Rivas et al., 2010a). 
3.1.4 Breastfeeding incentive and facilities 
As other women, women with GDM must be actively stimulated for exclusively 
breastfeeding for the longest period during the first year of their child (Metzger et al., 2007). 
But in this case, it is paramount to contribute in reducing subsequent risks of obesity and 
glucose tolerance abnormalities. Even though there is currently no definite conclusion on 
this (Gouveri et al., 2011), many studies show beneficial results of breastfeeding in women 
with GDM (Kjos et al., 1993; Gunderson et al., 2010). 
3.1.5 Appropriate family planning and contraception 
In women with GDM postpartum contraception is recommended (Metzger et al., 2007) in 
order to prevent a future unplanned pregnancy, with a high risk of developing once more 
GDM and where teratogenic effects of non-diagnosed diabetes may also be present. There is 
a wide option of contraceptive methods (Kim, 2009; Kim, 2010; Damm et al., 2007) that in 
general differ little from the ones used by other women. However, it is important to choose 
a contraceptive method that does not increase maternal risk of glucose intolerance, 
metabolic syndrome and CVD, as it occurs with barrier methods, the lactation amenorrhea 
method during the first six months and intrauterine devices (IUD), both copper and 
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levonorgestrel-releasing IUD, which possess known advantages and limitations. Low-dose 
combination oral contraceptives, with ethinyl estradiol and a progestin, may also be used, 
but they are not recommended for women that have other cardiovascular risk factors like 
hypertension. Even though family history of GDM does not mean contraindication of any 
method, progestin-only pills should be avoided in women who are breastfeeding, since in a 
study carried out on Latin-women it was found that it was associated to an increase of 
diabetes risk, assuming that breastfeeding may be a relatively progestagenic state (Kjos et 
al., 1998). Neither long-acting progestin methods like depot medroxyprogesterone acetate 
nor medroxyprogesterone, may be suggested as a first option since they may have major 
effects on the hydrocarbonated metabolism, as it was proven in Navajo women (Kim et al., 
2001). In parous women refraining from another pregnancy, surgical sterilization is a good 
option, particularly in those delivering by cesarean section, since sterilization may be 
practiced during surgical procedures. 
3.1.6 Oral health measures 
It is important that oral health measures proposed to the population in general for 
prevention of caries and periodontal disease, are rigorously adopted by women with 
previous GDM, who moreover, should visit at least annually the dentist in order to carry 
out an early diagnose of these complications when they arise and to apply the required 
therapeutic measures. The dentist will be on the alert to detect if progression to diabetes has 
occurred, contributing with this pathology screening (Friedlander et al., 2007). 
3.1.7 Life-style changes  
Childbearing years constitute one of the stages in the life of a woman more prone to weight 
gain. Thus, life-style changes make up the building blocks for the prevention of diabetes and 
other cardiovascular risk factors in women with GDM. Providing preventive care leading to 
reach and maintain an adequate weight, that include strategies on the aspects shown on 
Table 3, would result extremely beneficial for the health of this vulnerable population group 
and also cost-effective (Kapustin, 2008). Even though specific studies on this aspect are 
scarce and show limitations, it has been found that intensive intervention on life-style 
changes in women with previous GDM, reduced to a 50% diabetes incidence (Ratner et al., 
2008). Undoubtedly, there is a need to study in depth this topic.  
  
• Healthy nutrition  
• Physical activity 
• Non-smoking 
• Low to Moderate alcohol consume 
• Adequate stress management 
Table 3. Life-style changes in women with previous GDM 
3.1.7.1 Healthy nutrition 
In general, nutritional recommendations for women with a high risk of developing type 2 
diabetes tend to reduce the consumption of processed foods with high content of sugars, salt 
and trans fats, favoring the consumption of fresh foods like whole grains, legumes, 
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3.1.7.1 Healthy nutrition 
In general, nutritional recommendations for women with a high risk of developing type 2 
diabetes tend to reduce the consumption of processed foods with high content of sugars, salt 
and trans fats, favoring the consumption of fresh foods like whole grains, legumes, 





fatty acids; in other words, foods with low levels of cholesterol and saturated fats but rich in 
fiber, micronutrients and antioxidants (Melanson, 2008). Daily calorie intake is tailored by 
nutritionists, according to the characteristics of each woman, so they guarantee weight loss 
if recommended and at the same time, an adequate nutrition. It is fundamental to provide 
education on calorie count, food portions, food selection and preparation, reading and 
interpreting labels, since self-monitoring of intake may help them to incorporate the food 
plan in their life-styles and adopt these new behavior patterns (Case et al., 2006).  Uniform 
nutritional recommendations in women with a GDM history are needed. 
3.1.7.2 Physical activity 
Increasing physical activity is paramount in the daily routine of women with previous 
GDM, if there is no contraindication for this after a thorough medical evaluation. The goal is 
to reach a program of aerobic exercises like walking, swimming, dancing, bike riding for 30 
minutes five or more days a week, beginning gradually from 5-10 minutes daily in 
sedentary women. Before and after exercising, stretching exercises must be done for 5-10 
minutes. If this is complemented with strength training using light weights or elastic bands, 
weight loss is increased and muscle tone is improved, having a favorable effect on the 
glucose metabolism (Case et al., 2006).  
3.1.7.3 Non-smoking 
Quitting smoking is recommended in women with previous GDM     (Verier-Mine, 2010), in 
spite of the lack of studies assessing the effects of tobacco in this group with a high risk of 
diabetes and cardiovascular disease. Nonetheless, it has been found that smoking increases 
the risk of diabetes in women, without discerning if they have this family history or not 
(Rimm et al., 1993). 
3.1.7.4 Light to moderate alcohol consumption 
Light to moderate alcohol consumption has been found associated with a minor risk of 
developing type 2 diabetes in middle-aged women and this benefit does not seem to persist 
when alcohol consumption increases (Wannamethee et al., 2003). It is not known if this 
result may be generalized to women with previous GDM, but it results sensible to avoid a 
high level of alcohol consumption due to the possible weight gain and the potential increase 
of type 2 diabetes risk.  
3.1.7.5 Adequate stress management 
Learning and the use of periodic tools to allow managing stress adequately may contribute 
to the goal of keeping healthy women with GDM history. The presence of symptoms of 
depression or excessive anxiety is an indication for assessment and treatment by specialized 
Mental Health professionals, according to each case. 
3.1.8 Pharmacologic intervention 
The use of pharmacologic agents has been explored for preventing or retarding diabetes in 
women with previous GDM. Studies with troglitazone (Buchanan et al., 2002) and 
pioglitazone (Xiang et al., 2006b) have been carried out, demonstrating effectiveness in both 
cases in overweight women. Nonetheless, the former has been discontinued for its 
hepatotoxic effects, and the use of the latter is limited since its prescription is not authorized 
for prevention, due to its safety profile regarding future cardiovascular and osteoporosis 
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disease, and its cost (Verier-Mine, 2010; Kim, 2009: Kim, 2010). When metphormine was 
used in a study, the risk of type 2 diabetes was half reduced in women with overweight and 
obesity (Ratner et al., 2008). Therefore, further research will provide more insight for its 
prescription in clinical practice in combination with a healthy life-style, particularly in obese 
women with glucose intolerance after a GDM pregnancy.  
As shown, an adequate postpartum follow-up program for women with GDM comprises a 
wide range of health-care, clinical-metabolic, gynecological, nutritional, educational, 
psycho-social, physical training, and odontological activities, among others, carried out by 
an interdisciplinary team, in order to prevent or retard progression to diabetes and other 
cardiovascular risk factors, and if this is not attained, to confirm its diagnose as soon as 
possible. 
Unfortunately worldwide, postpartum follow-ups of women with GDM are low. In the 
United States during the first postpartum months, FPG measurements were ordered on 
60.5% women and only completed by 34% (Dinh et al., 2003). In a long cohort of women 
with GDM, 42% were not tested for FPG, the test was not ordered in 21% of them and none 
were tested for OGTT (Dietz et al., 2008). Only 37% were tested for FPG or OGTT with a 
mean of ~ 14 months of postpartum (Smirmakis et al., 2005). In Canada, it has been shown 
that physicians do not order postpartum OGTT, in spite of counting on a publication with 
guidelines based on expert opinions on the subject (Clark et al., 2003). At a Venezuelan 
hospital, in a follow-up program, a 66.19% OGTT adherence after a postpartum period of 
4.04 years + 2.68 was met, with only 17.98% attendance to all basic education sessions (Rivas 
et al., 2010c). Achieving favorable changes in life-styles of women with GDM has resulted 
even more difficult to attain (Stage et al., 2004; Smith et al., 2005), and progression to 
diabetes continues increasing.   
3.2 Changes in quality of life of the population 
Individual approach directed to inform women with GDM on the need of reclassifying their 
metabolic status after delivery, results insufficient for making possible the prevention of 
diabetes and other cardiovascular risk factors. The need to reinforce knowledge and 
motivation in the health care team is evident, as well as the access to health care in this area. 
Moreover, there is a need for stronger research and confrontation on the social determinants 
that make difficult for GDM women, adherence to postpartum follow-up and the adoption of 
healthy life-styles (Hjaltested & Conroy, 2010). Structural measures targeted to the population 
in general, like the ones shown in Table 4, would undoubtedly result in greater benefit. 
 
• Increasing  production, distribution and marketing of fresh foods   
• Promoting the creation and use of public transportation, bicycle lanes, walking lanes  
• Promoting the creation and use  of public sport courts and parks 
• Promoting and protecting breastfeeding 
• Regulating production, distribution and marketing of processed foods rich in trans 
fats, saturated fats, salt  and refined sugars 
• Regulating publicity through communication media of this kind of foods  
• Promoting smoke-free environments 
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After delivery, women with GDM have a high risk of developing diabetes, metabolic 
syndrome, CVD and other clinical disorders that imply a decrease in the quality of life and 
high health-care costs. Thus, over several decades early detection of diabetes and other 
cardiovascular risk factors has been emphasized. For those women who do not show this, it 
is very important to apply strategies directed towards primary prevention like healthy life-
style changes and possible pharmacological intervention, even though further research on 
these results is needed. To meet both objectives, it is paramount to carry out, on one hand, 
life-long postpartum follow-up in women with GDM, and also, to research social 
determinants that affect compliance to these preventive programs and to put into practice 
collective measures that create favorable conditions for its adherence. 
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Gestational diabetes mellitus is defined as hyperglycemia with onset or first 
recognition during pregnancy. The incidence of gestational diabetes is still 
increasing and this pathological condition has strong association with adverse 
pregnancy outcomes. Since gestational diabetes can have long-term pathological 
consequences for both mother and the child, it is important that it is promptly 
recognized and adequately managed. Treatment of gestational diabetes is aimed 
to maintain euglycemia and it should involve regular glucose monitoring, dietary 
modifications, life style changes, appropriate physical activity, and when necessary, 
pharmacotherapy. Adequate glycemic control throughout the pregnancy can notably 
reduce the occurrence of specific adverse perinatal and maternal outcomes. In a long-
term prospect, in order to prevent development of diabetes later in life, as well to avoid 
associated complications, an adequate education on lifestyle modifications should start 
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